



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 167382**

**TO: Terra Gibbs**  
**Location: REM-2D10/2C18**  
**Art Unit: 1635**  
**Thursday, October 06, 2005**  
**Case Serial Number: 10/633843**

**From: Barb O'Bryen**  
**Location: Biotech-Chem Library**  
**Remsen 1a69**  
**Phone: 571-272-2518**

*BOB*  
**barbara.obryen@uspto.gov**

### **Search Notes**

**THIS PAGE BLANK (USPTO)**



167382

From: Gibbs, Terra  
Sent: Friday, September 30, 2005 9:57 AM  
To: STIC-Biotech/ChemLib  
Subject: Sequence search request...

I have another request for a score over length search:  
I need a length limited nucleotide sequence search of SEQ ID NO:3 of USSN 10/633,843 where the returns are rank ordered based on the score over length/ratio. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio.

Terra Cotta Gibbs, Ph.D.  
Art Unit 1635  
Remsen Building 2D10  
Mailbox 2C18  
571-272-0758

RECEIVED  
SEP 30 2005  
STIC/BIOTECH DIVISION  
(STIC)

\*\*\*\*\*

Searcher: \_\_\_\_\_  
Searcher Phone: \_\_\_\_\_  
Date Searcher Picked up: \_\_\_\_\_  
Date completed: \_\_\_\_\_  
Searcher Prep Time: \_\_\_\_\_  
Online Time: \_\_\_\_\_

\*\*\*\*\*

Type of Search  
NA# \_\_\_\_\_ AA# \_\_\_\_\_  
S/L: \_\_\_\_\_ Oligomer: \_\_\_\_\_  
Encode/Transl: \_\_\_\_\_  
Structure #: \_\_\_\_\_ Text: \_\_\_\_\_  
Inventor: \_\_\_\_\_ Litigation: \_\_\_\_\_

\*\*\*\*\*

Vendors and cost where applicable  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
QUESTEL/ORBIT: \_\_\_\_\_  
LEXIS/NEXIS: \_\_\_\_\_  
SEQUENCE SYSTEM: \_\_\_\_\_  
WWW/Internet: \_\_\_\_\_  
Other (Specify): \_\_\_\_\_

**THIS PAGE BLANK (USPTO)**

## SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 6, 2005, 10:38:15 ; Search time 0.001 Seconds  
(without alignments)  
218.500 Million cell updates/sec

Title: US-10-633-843-3-COPY  
Perfect score: 874  
Sequence: 1 ctgcagcgctctgggtttcc.....tattaaagaatccaaattc 874

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 125 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 5 summaries

Database : estdb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	42.4	4.9	48	1	N79542
C 2	36	4.1	44	1	H41186
C 3	14.8	1.7	19	1	AZ610584
C 4	11.8	1.4	44	1	H41186
C 5	10.8	1.2	14	1	AJ590269

ALIGNMENTS

RESULT 1  
N79542/c  
LOCUS  
DEFINITION  
2b09h12.s1 Soares fetal lung NBHL19W Homo sapiens cDNA clone  
IMAGE:301607 3' similar to gb:X02317 SUPEROXIDE DISMUTASE (HUMAN);  
mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

RESULT 2  
H41186  
LOCUS  
DEFINITION  
Yn88b11.r1 Soares adult brain N2bSHB55Y Homo sapiens cDNA clone  
IMAGE:175485 5' similar to gb:X02317 SUPEROXIDE DISMUTASE (HUMAN);  
mRNA sequence.

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL ; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
Trace considered overall poor quality

Seq primer: m13 -40 forward  
High quality sequence stop: 1.  
Location/Qualifiers

FEATURES

source

1. .48

/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:1246531"  
/db\_xref="taxon:9606"  
/clone="IMAGE:301607"  
/dev\_stage="19 weeks"  
/lab\_host="DH10B (ampicillin resistant)"  
/clone\_lib="Soares fetal lung NBHL19W"  
/note="Organ: lung; Vector: pT73D (Pharmacia) with a  
modified polylinker; Site\_1: Not I; Site\_2: Eco RI; 1st  
strand cDNA was primed with a Not I - oligo(dT) primer  
[5'-TGTTACCAATCTGAAGTGGAGCGCGCAATTTTTTTTTTTT-3'],  
double-stranded cDNA was size selected, ligated to Eco RI  
adapters (Pharmacia), digested with Not I and cloned into  
the Not I and Eco RI sites of a modified pT73 vector  
(Pharmacia). Library went through one round of  
normalization to a Cot = 5. Library constructed by Bento  
Soares and M.Fatima Bonaldo. This library was constructed  
from the same fetus as the fetal heart library, Soares  
fetal heart NBHL19W."

Query Match 4.9%; Score 42.4; DB 1; Length 48;  
Best Local Similarity 89.6%; Pred. No. 0.18;  
Matches 43; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 533 TTCCCTTGATGCTGAGCGCCCTTAACCTCATCTGTTATCCCTGCT 580  
DB 48 TTCCCTTGATGCTGAGCGCCCTTNACNCACTGTTTCTGCT 1

RESULT 2

H41186

LOCUS

DEFINITION

Yn88b11.r1 Soares adult brain N2bSHB55Y Homo sapiens cDNA clone  
IMAGE:175485 5' similar to gb:X02317 SUPEROXIDE DISMUTASE (HUMAN);  
mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1995)

Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

Insert Size: 1582

High quality sequence starts: 1

High quality sequence stops: 1

Source: IMAGE Consortium, LLNL

This clone is available royalty-free through LLNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.  
Trace considered overall poor quality  
Insert Length: 1582 Std Error: 0.00  
Seq primer: M13Rpl  
High quality sequence stop: 1.

Location/Qualifiers  
1. .44

FEATURES  
source

```
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3837520"
/db_xref="taxon:9606"
/clone="IMAGE:175485"
/sex="Male"
/dev_stage="55-year old"
/lab_host="PH10B (ampicillin resistant)"
/clone_lib="Soares adult brain N2b5HB55Y"
/note="Organ: brain; Vector: p77T3D (Pharmacacia) with a
modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
strand cDNA was primed with a Not I - oligo(dT) primer [5',
TGTTACCAATCTGAATGGGAGCGCGCTTTTTTTTTTTTTTTT 3'],
double-stranded cDNA was size selected, ligated to Eco RI
adapters (Pharmacacia), digested with Not I and cloned into
the Not I and Eco RI sites of a modified p77T3 vector
(Pharmacacia). Library went through one round of
normalization to a Cot = 53. Library constructed by Bento
Soares and M.Fatima Bonaldo. The adult brain RNA was
provided by Dr. Donald H. Gilden. Tissue was acquired
17-18 hours after death which occurred in consequence of a
ruptured aortic aneurysm. RNA was prepared from a pool of
tissues representing the following areas of the brain:
frontal, parietal, temporal and occipital cortex from the
left and right hemispheres, subcortical white matter,
basal ganglia, thalamus, cerebellum, midbrain, pons and
medulla."
```

Query Match 4.1%; Score 36; DB 1; Length 44;

Best Local Similarity 88.6%; Pred. No. 0.33;

Matches 39; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 323 AATGTGACTGCTGACAAAGATGGTGGCGGATGTGTCTATTGA 366

Db 1 ATATTACTGCTGACAAATATAGTGGCTATGTCTATTGA 44

RESULT 3

AZ610584/c

LOCUS

DEFINITION 19 bp DNA linear GSS 13-DEC-2000  
1M0435P20 Mouse 10kb plasmid UUGC1M library Mus musculus genomic

clone UUGC1M0435P20 R, genomic survey sequence.

ACCESSION AZ610584

VERSION AZ610584.1

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 19)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Becorn,T., Duval,B., Hamill,C.,

Islam,M., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

Niederhauser,A. and Wright,D.,Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

CONTACT: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0435 row: P column: 20  
Seq primer: CACACAGGAACAGCTATGACC  
Class: plasmid ends

High quality sequence stop: 19.

Location/Qualifiers

FEATURES  
source

```
1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0435P20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 Kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PWD42 [gi|4732114|gb|AF129072.1], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
```

Query Match 1.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 4.1;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 AGCAGAACGAAAGTAATG 146

Db 19 AGCAGACGGAAGAAATG 2

RESULT 4

H41186/c

LOCUS

DEFINITION

H41186 44 bp mRNA linear EST 31-JUL-1995  
Yn88b11.r1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone  
IMAGE:175485 5' similar to gb:X02317 SUPEROXIDE DISMUTASE (HUMAN); ,  
mRNA sequence.

ACCESSION H41186

VERSION H41186.1

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1 (bases 1 to 44)

AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,

Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,

Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,

Trevaaskis,E., Waterston,R., Williamson,A., Wohlmann,P. and

Wilson,R.

The WashU-Merck EST Project

Unpublished (1995)

CONTACT: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

Insert Size: 1582

High quality sequence starts: 1

High quality sequence stops: 1



**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 6, 2005, 10:39:53 ; Search time 3 Seconds  
(without alignments)  
3.794 Million cell updates/sec

Title: US-10-633-843-3-COPY  
Perfect score: 874  
Sequence: 1 ctgcgcgcgtctgggtttcc.....tattaaagaatccaaattc 874

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 363 seqs, 6512 residues

Total number of hits satisfying chosen parameters: 726

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 363 summaries

Database : gedb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	28	3.2	28	1	AR090891
2	28	3.2	28	1	AR090892
3	28	3.2	28	1	AR197926
4	28	3.2	28	1	AR197927
5	28	3.2	28	1	AR260080
6	28	3.2	28	1	AR260081
7	27.4	3.1	29	1	E06744
8	27	3.1	27	1	AX473368
9	24	2.7	24	1	AR061116
10	24	2.7	24	1	AR064690
11	24	2.7	24	1	AR528355
12	23	2.6	23	1	AX473370
13	23	2.6	23	1	AX473371
14	23	2.6	23	1	AX710079
15	23	2.6	23	1	AX710080
16	22.6	2.6	30	1	BD143416
17	22	2.5	29	1	AR017558
18	21.8	2.5	25	1	A06400
19	21.8	2.5	25	1	AR364465
20	21	2.4	21	1	BD144206
21	20.4	2.3	22	1	BD144209
22	20	2.3	21	1	AR061103
23	20	2.3	21	1	AR064682
24	20	2.3	21	1	I04213
25	20	2.3	21	1	I06878
26	20	2.3	21	1	AR528347
27	19.8	2.3	23	1	BD174099
28	19	2.2	19	1	BD144208
29	17.2	2.0	22	1	A06401
30	17.2	2.0	22	1	ACCSSION:BD172232
31	17.2	2.0	22	1	BD172551
32	17.2	2.0	22	1	BD172870
33	17.2	2.0	22	1	ACCSSION:BD173189

C 34	17.2	2.0	22	1	BD175223
C 35	17.2	2.0	22	1	BD260461
C 36	17.2	2.0	22	1	AR364466
C 37	17.2	2.0	22	1	AR410601
C 38	17.2	2.0	22	1	AR438965
C 39	17.2	2.0	22	1	AR472985
C 40	17.2	2.0	22	1	AR526971
C 41	17.2	2.0	22	1	AR566004
C 42	17.2	2.0	22	1	AX076912
C 43	17.2	2.0	22	1	AX098397
C 44	17.2	2.0	22	1	BD075372
C 45	17.2	2.0	22	1	AX697416
C 46	17	1.9	17	1	AX671956
C 47	17	1.9	17	1	AX730213
C 48	17	1.9	17	1	AX733558
C 49	17	1.9	17	1	AX736487
C 50	17	1.9	17	1	AX739220
C 51	17	1.9	17	1	BD174097
C 52	17	1.9	17	1	AR061105
C 53	17	1.9	21	1	AR064684
C 54	17	1.9	21	1	AR528349
C 55	17	1.9	21	1	AR338227
C 56	16.8	1.9	20	1	AR061108
C 57	16.8	1.9	21	1	AR064687
C 58	16.8	1.9	21	1	AR268352
C 59	16.8	1.9	21	1	I04212
C 60	16	1.8	16	1	I06877
C 61	16	1.8	16	1	AX081870
C 62	16	1.8	17	1	AX737712
C 63	16	1.8	17	1	AX737721
C 64	16	1.8	17	1	AX737721
C 65	16	1.8	18	1	AX738471
C 66	16	1.8	19	1	AR225282
C 67	15.8	1.8	20	1	I73106
C 68	15.8	1.8	20	1	AR305282
C 69	15.8	1.8	20	1	AR309386
C 70	15.8	1.8	20	1	AR350302
C 71	15.8	1.8	20	1	BD061259
C 72	15.8	1.8	21	1	BD061259
C 73	15.6	1.8	17	1	AX707589
C 74	15.6	1.8	17	1	AX707589
C 75	15.4	1.8	17	1	BD255580
C 76	15.4	1.8	17	1	BD255581
C 77	15.4	1.8	17	1	I06872
C 78	15.2	1.7	20	1	AR121018
C 79	15.2	1.7	20	1	BD272639
C 80	15.2	1.7	20	1	CO871960
C 81	15.2	1.7	20	1	CO871961
C 82	15.2	1.7	20	1	CO871987
C 83	15.2	1.7	20	1	CO871990
C 84	15.2	1.7	20	1	E27497
C 85	15.2	1.7	20	1	AR531387
C 86	15.2	1.7	20	1	AX167893
C 87	15	1.7	15	1	CO821402
C 88	15	1.7	15	1	CO821408
C 89	15	1.7	17	1	AX081871
C 90	15	1.7	17	1	AX706658
C 91	15	1.7	17	1	AX707588
C 92	15	1.7	17	1	AX732679
C 93	15	1.7	17	1	AR199396
C 94	14.8	1.7	19	1	BD195707
C 95	14.8	1.7	19	1	AR282800
C 96	14.8	1.7	19	1	AX129356
C 97	14.4	1.6	17	1	A16196
C 98	14.4	1.6	17	1	A16242
C 99	14.4	1.6	17	1	BD203207
C 100	14.4	1.6	17	1	BD255579
C 101	14.4	1.6	17	1	BD255582
C 102	14.4	1.6	17	1	BD257636
C 103	14.4	1.6	17	1	I23680
C 104	14.4	1.6	17	1	I23682
C 105	14.4	1.6	17	1	AR433547
C 106	14.4	1.6	17	1	ACCSSION:AR433549

GenBank/EMBL

c 107	14.4	1.6	17	1	AX216792	ACCESSION:AX216792	180	13.8	1.6	18	1	AX796133	ACCESSION:AX796133
c 108	14.4	1.6	17	1	AX216884	ACCESSION:AX216884	c 181	13.8	1.6	18	1	BD014805	ACCESSION:BD014805
c 109	14.4	1.6	17	1	AX701183	ACCESSION:AX701183	182	13.4	1.5	15	1	CQ821404	ACCESSION:CQ821404
c 110	14.4	1.6	17	1	AX706656	ACCESSION:AX706656	183	13.4	1.5	15	1	CQ821409	ACCESSION:CQ821409
c 111	14.4	1.6	17	1	AX706657	ACCESSION:AX706657	c 184	13.4	1.5	16	1	BD178695	ACCESSION:BD178695
c 112	14.4	1.6	17	1	AX707586	ACCESSION:AX707586	c 185	13.4	1.5	16	1	AR328540	ACCESSION:AR328540
113	14.4	1.6	17	1	AX707587	ACCESSION:AX707587	c 186	13.4	1.5	16	1	AX600643	ACCESSION:AX600643
114	14.4	1.6	17	1	AX731809	ACCESSION:AX731809	c 187	13.4	1.5	17	1	BD255583	ACCESSION:BD255583
115	14.4	1.6	17	1	AX733720	ACCESSION:AX733720	188	13.4	1.5	17	1	AR188790	ACCESSION:AR188790
116	14.4	1.6	17	1	AX735175	ACCESSION:AX735175	189	13.4	1.5	17	1	AR188791	ACCESSION:AR188791
117	14.4	1.6	17	1	AX761994	ACCESSION:AX761994	c 190	13.4	1.5	17	1	AR192144	ACCESSION:AR192144
c 118	14.4	1.6	18	1	CQ784352	ACCESSION:CQ784352	c 191	13.4	1.5	17	1	AR192145	ACCESSION:AR192145
c 119	14.4	1.6	19	1	E31531	ACCESSION:E31531	192	13.4	1.5	17	1	AR324643	ACCESSION:AR324643
c 120	14.4	1.6	19	1	AX130329	ACCESSION:AX130329	193	13.4	1.5	17	1	AR324644	ACCESSION:AR324644
121	14	1.6	17	1	AR046169	ACCESSION:AR046169	c 194	13.4	1.5	17	1	AR326022	ACCESSION:AR326022
122	14	1.6	17	1	AR046171	ACCESSION:AR046171	c 195	13.4	1.5	17	1	AR326023	ACCESSION:AR326023
123	14	1.6	17	1	AR046173	ACCESSION:AR046173	c 196	13.4	1.5	17	1	AX214956	ACCESSION:AX214956
124	14	1.6	17	1	I53221	ACCESSION:I53221	c 197	13.4	1.5	17	1	AX265895	ACCESSION:AX265895
125	14	1.6	17	1	I53223	ACCESSION:I53223	c 198	13.4	1.5	17	1	AX265896	ACCESSION:AX265896
126	14	1.6	17	1	I53225	ACCESSION:I53225	199	13.4	1.5	17	1	AX728909	ACCESSION:AX728909
c 127	14	1.6	17	1	AX215042	ACCESSION:AX215042	200	13.4	1.5	17	1	AX729782	ACCESSION:AX729782
c 128	14	1.6	17	1	AX215907	ACCESSION:AX215907	201	13.4	1.5	17	1	AX732168	ACCESSION:AX732168
c 129	14	1.6	17	1	AX216554	ACCESSION:AX216554	c 202	13.4	1.5	17	1	AX732908	ACCESSION:AX732908
130	13.8	1.6	17	1	BD257133	ACCESSION:BD257133	203	13.4	1.5	17	1	AX737665	ACCESSION:AX737665
131	13.8	1.6	17	1	BD257134	ACCESSION:BD257134	204	13.4	1.5	17	1	AX761865	ACCESSION:AX761865
132	13.8	1.6	17	1	BD257135	ACCESSION:BD257135	205	13	1.5	13	1	BD263834	ACCESSION:BD263834
133	13.8	1.6	17	1	CQ624220	ACCESSION:CQ624220	206	13	1.5	13	1	BD263836	ACCESSION:BD263836
c 134	13.8	1.6	17	1	I06874	ACCESSION:I06874	207	13	1.5	13	1	BD263838	ACCESSION:BD263838
c 135	13.8	1.6	17	1	AR190462	ACCESSION:AR190462	208	13	1.5	13	1	BD263840	ACCESSION:BD263840
c 136	13.8	1.6	17	1	AR325385	ACCESSION:AR325385	209	13	1.5	13	1	AX048320	ACCESSION:AX048320
c 137	13.8	1.6	17	1	AR327698	ACCESSION:AR327698	210	13	1.5	13	1	AX048322	ACCESSION:AX048322
138	13.8	1.6	17	1	AR329394	ACCESSION:AR329394	211	13	1.5	13	1	AX048324	ACCESSION:AX048324
139	13.8	1.6	17	1	AR465283	ACCESSION:AR465283	212	13	1.5	13	1	AX048326	ACCESSION:AX048326
c 140	13.8	1.6	17	1	AX081872	ACCESSION:AX081872	c 213	13	1.5	16	1	CQ786469	ACCESSION:CQ786469
c 141	13.8	1.6	17	1	AX215655	ACCESSION:AX215655	214	13	1.5	16	1	AR329602	ACCESSION:AR329602
142	13.8	1.6	17	1	AX265751	ACCESSION:AX265751	215	13	1.5	17	1	AR186415	ACCESSION:AR186415
c 143	13.8	1.6	17	1	AX265752	ACCESSION:AX265752	216	13	1.5	17	1	AR323046	ACCESSION:AR323046
144	13.8	1.6	17	1	AX691936	ACCESSION:AX691936	217	13	1.5	17	1	AR327316	ACCESSION:AR327316
c 145	13.8	1.6	17	1	AX782232	ACCESSION:AX782232	218	13	1.5	17	1	AR328890	ACCESSION:AR328890
c 146	13.8	1.6	18	1	AR175662	ACCESSION:AR175662	219	13	1.5	17	1	AR328891	ACCESSION:AR328891
c 147	13.8	1.6	18	1	I30650	ACCESSION:I30650	c 220	13	1.5	17	1	AX215041	ACCESSION:AX215041
c 148	13.8	1.6	18	1	I30651	ACCESSION:I30651	c 221	13	1.5	17	1	AX215043	ACCESSION:AX215043
c 149	13.8	1.6	18	1	I30652	ACCESSION:I30652	c 222	13	1.5	17	1	AX215043	ACCESSION:AX215043
c 150	13.8	1.6	18	1	I30653	ACCESSION:I30653	223	12.8	1.5	16	1	AR10669	ACCESSION:AR10669
c 151	13.8	1.6	18	1	I30654	ACCESSION:I30654	224	12.8	1.5	16	1	CQ821403	ACCESSION:CQ821403
c 152	13.8	1.6	18	1	I30655	ACCESSION:I30655	c 225	12.8	1.5	16	1	AR328567	ACCESSION:AR328567
c 153	13.8	1.6	18	1	I30656	ACCESSION:I30656	226	12.8	1.5	16	1	AR328701	ACCESSION:AR328701
c 154	13.8	1.6	18	1	I30657	ACCESSION:I30657	227	12.8	1.5	16	1	AX040892	ACCESSION:AX040892
c 155	13.8	1.6	18	1	I30658	ACCESSION:I30658	c 228	12.8	1.5	17	1	AR8539	ACCESSION:AR8539
c 156	13.8	1.6	18	1	I30659	ACCESSION:I30659	c 229	12.8	1.5	17	1	AR90506	ACCESSION:AR90506
c 157	13.8	1.6	18	1	I30660	ACCESSION:I30660	230	12.8	1.5	17	1	AR110572	ACCESSION:AR110572
c 158	13.8	1.6	18	1	I30661	ACCESSION:I30661	231	12.8	1.5	17	1	AR151792	ACCESSION:AR151792
c 159	13.8	1.6	18	1	I30662	ACCESSION:I30662	c 232	12.8	1.5	17	1	BD141639	ACCESSION:BD141639
c 160	13.8	1.6	18	1	I46109	ACCESSION:I46109	c 233	12.8	1.5	17	1	BD142773	ACCESSION:BD142773
c 161	13.8	1.6	18	1	I46110	ACCESSION:I46110	234	12.8	1.5	17	1	BD200757	ACCESSION:BD200757
c 162	13.8	1.6	18	1	I46111	ACCESSION:I46111	c 235	12.8	1.5	17	1	BD201590	ACCESSION:BD201590
c 163	13.8	1.6	18	1	I46112	ACCESSION:I46112	c 236	12.8	1.5	17	1	BD201591	ACCESSION:BD201591
c 164	13.8	1.6	18	1	I46113	ACCESSION:I46113	237	12.8	1.5	17	1	BD232934	ACCESSION:BD232934
c 165	13.8	1.6	18	1	I46114	ACCESSION:I46114	238	12.8	1.5	17	1	BD233095	ACCESSION:BD233095
c 166	13.8	1.6	18	1	I46115	ACCESSION:I46115	c 239	12.8	1.5	17	1	BD241523	ACCESSION:BD241523
c 167	13.8	1.6	18	1	I46116	ACCESSION:I46116	c 240	12.8	1.5	17	1	BD256491	ACCESSION:BD256491
c 168	13.8	1.6	18	1	I46117	ACCESSION:I46117	c 241	12.8	1.5	17	1	BD256939	ACCESSION:BD256939
c 169	13.8	1.6	18	1	I46118	ACCESSION:I46118	242	12.8	1.5	17	1	BD257132	ACCESSION:BD257132
c 170	13.8	1.6	18	1	I46119	ACCESSION:I46119	243	12.8	1.5	17	1	BD257552	ACCESSION:BD257552
c 171	13.8	1.6	18	1	I46120	ACCESSION:I46120	c 244	12.8	1.5	17	1	BD258550	ACCESSION:BD258550
c 172	13.8	1.6	18	1	I46121	ACCESSION:I46121	c 245	12.8	1.5	17	1	BD258551	ACCESSION:BD258551
c 173	13.8	1.6	18	1	AR195238	ACCESSION:AR195238	246	12.8	1.5	17	1	CQ616850	ACCESSION:CQ616850
c 174	13.8	1.6	18	1	AR222320	ACCESSION:AR222320	247	12.8	1.5	17	1	CQ616851	ACCESSION:CQ616851
c 175	13.8	1.6	18	1	AR241439	ACCESSION:AR241439	248	12.8	1.5	17	1	CQ617968	ACCESSION:CQ617968
c 176	13.8	1.6	18	1	AX003146	ACCESSION:AX003146	249	12.8	1.5	17	1	CQ617969	ACCESSION:CQ617969
c 177	13.8	1.6	18	1	AX132972	ACCESSION:AX132972	250	12.8	1.5	17	1	CQ622481	ACCESSION:CQ622481
178	13.8	1.6	18	1	AX599241	ACCESSION:AX599241	251	12.8	1.5	17	1	CQ622482	ACCESSION:CQ622482
179	13.8	1.6	18	1	AX767687	ACCESSION:AX767687	c 252	12.8	1.5	17	1	CQ623027	ACCESSION:CQ623027



```
LOCUS AR090892 28 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 1012 from patent US 5994076.
ACCESSION AR090892
VERSION AR090892.1 GI:10017647
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 1012 30-NOV-1999;
FEATURES
source
1..28
/mol_type="unassigned DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 5
LOCUS AR260080 28 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 1011 from patent US 6489455.
ACCESSION AR260080
VERSION AR260080.1 GI:27310591
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1011 03-DEC-2002;
FEATURES
source
1..28
/mol_type="unassigned DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 3
LOCUS AR197926 28 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1011 from patent US 6352829.
ACCESSION AR197926
VERSION AR197926.1 GI:20247775
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 1011 05-MAR-2002;
FEATURES
source
1..28
/mol_type="unassigned DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 AGTGCAGGGCATCATCAATTCGAGCAG 133
Db 1 AGTGCAGGGCATCATCAATTCGAGCAG 28

RESULT 4
LOCUS AR197927/c 28 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1012 from patent US 6352829.
ACCESSION AR197927
VERSION AR197927.1 GI:20247776
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 1012 05-MAR-2002;
FEATURES
source
1..28
/mol_type="unassigned DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 AGTGCAGGGCATCATCAATTCGAGCAG 133
Db 1 AGTGCAGGGCATCATCAATTCGAGCAG 28

RESULT 6
LOCUS AR260081/c 28 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 1012 from patent US 6489455.
ACCESSION AR260081
VERSION AR260081.1 GI:27310592
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1012 03-DEC-2002;
FEATURES
source
1..28
/mol_type="unassigned DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 AGTGCAGGGCATCATCAATTCGAGCAG 133
Db 1 AGTGCAGGGCATCATCAATTCGAGCAG 28

RESULT 7
LOCUS E06744 29 bp RNA linear PAT 29-SEP-1997
DEFINITION CDNA fragment.
ACCESSION E06744
VERSION E06744.1 GI:2174926
KEYWORDS JP 1994046860-A/2.
SOURCE Homo sapiens (human)
```

```
Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 5
LOCUS AR260080 28 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 1011 from patent US 6489455.
ACCESSION AR260080
VERSION AR260080.1 GI:27310591
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1011 03-DEC-2002;
FEATURES
source
1..28
/mol_type="genomic DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 AGTGCAGGGCATCATCAATTCGAGCAG 133
Db 1 AGTGCAGGGCATCATCAATTCGAGCAG 28

RESULT 6
LOCUS AR260081/c 28 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 1012 from patent US 6489455.
ACCESSION AR260081
VERSION AR260081.1 GI:27310592
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 28)
Unclassified.
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1012 03-DEC-2002;
FEATURES
source
1..28
/mol_type="genomic DNA"

Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 6.9;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 7
LOCUS E06744 29 bp RNA linear PAT 29-SEP-1997
DEFINITION CDNA fragment.
ACCESSION E06744
VERSION E06744.1 GI:2174926
KEYWORDS JP 1994046860-A/2.
SOURCE Homo sapiens (human)
```

```

ORGANISM      Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 29)
AUTHORS      Sukenaga,Y., Morino,T., Morita,M., Seiya,K. and Nakamura,T.
TITLE        NEW DNA CAPABLE OF CODING HUMAN SOD AND MICROORGANISM HAVING THE
JOURNAL      Patent: JP 1994045860-A 2 22-FEB-1994;
NIPPON KAYAKU CO LTD
COMMENT
OS      Homo sapiens
PN      JP 1994045860-A/2
PD      22-FEB-1994
PF      25-SEP-1992 JP 199279193
PI      SUKENAGA YOSHIKAZU, MORINO TOMIO, MORITA MAKOTO, SEYA KENJI,
PT      NAKAMURA TSUNERO
PC      C12N1/53,C12N1/21//C12N9/02,(C12N1/21,C12R1:19),(C12N9/02, PC
C12R1:19);
CC      strandedness: Double;
CC      topology: Linear;
CC      hypothetical: No;
CC      anti-sense: No;
CC      *source: tissue_type=placenta;
FH      Key      Location/Qualifiers
FT      5'UTR      1..29.
              Location/Qualifiers
              1..29
              /organism="Homo sapiens"
              /mol_type="genomic RNA"
              /db_xref="taxon:9606"

Query Match      3.1%; Score 27.4; DB 1; Length 29;
Best Local Similarity 96.6%; Pred. No. 8.5;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      39 AGGACCTCGCGCGCTAGCGAGTTATG 67
Db      1 AGGACCAGCGCGCTAGCGAGTTATG 29

RESULT 8
AX473368/c
LOCUS      27 bp DNA linear PAT 09-AUG-2002
DEFINITION      Sequence 1 from Patent WO0203979.
ACCESSION      AX473368
VERSION        AX473368.1 GI:22207996
KEYWORDS      synthetic construct
SOURCE        other sequences; artificial sequences.
ORGANISM
REFERENCE
1
AUTHORS      Huang,P., Plunkett,W.K. and Feng,L.
TITLE        Cancer therapeutics involving the administration of
2-methoxyestradiol and an agent that increases intracellular
superoxide anion
JOURNAL      Patent: WO 0203979-A 1 17-JAN-2002;
Board of Regents, The University of Texas System (US)
FEATURES
source
1..27
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic Primer"

Query Match      3.1%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      61 AGTTATGGCGACGAAGGCCGTGTGCGT 87
Db      27 AGTTATGGCGACGAAGGCCGTGTGCGT 1

RESULT 9
ORGANISM      Homo sapiens
24 bp DNA linear PAT 29-SEP-1999
AR061116
Sequence 18 from patent US 5843641.
AR061116
VERSION        AR061116.1 GI:5988807
KEYWORDS      Unknown.
SOURCE        Unclassified.
ORGANISM      Brown,R., Horvitz,H.Robert. and Rosen,D.R.
REFERENCE      Methods for the diagnosis, of familial amyotrophic lateral
AUTHORS      sclerosis
TITLE        Patent: US 5843641-A 18 01-DEC-1998;
JOURNAL      Location/Qualifiers
FEATURES      1..24
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      556 CCCTTAACATCATCTGTTATCCTGC 579
Db      24 CCCTTAACATCATCTGTTATCCTGC 1

RESULT 10
AR064690/c
LOCUS      24 bp DNA linear PAT 29-SEP-1999
DEFINITION      Sequence 13 from patent US 5849290.
ACCESSION      AR064690
VERSION        AR064690.1 GI:5994906
KEYWORDS      Unknown.
SOURCE        Unclassified.
ORGANISM      Brown,R., Horvitz,H.Robert. and Rosen,D.R.
REFERENCE      Compounds and methods for the diagnosis, treatment and prevention
AUTHORS      of diseases of cell death
TITLE        Patent: US 5849290-A 13 15-DEC-1998;
JOURNAL      Location/Qualifiers
FEATURES      1..24
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      556 CCCTTAACATCATCTGTTATCCTGC 579
Db      24 CCCTTAACATCATCTGTTATCCTGC 1

RESULT 11
AR528355/c
LOCUS      24 bp DNA linear PAT 08-OCT-2004
DEFINITION      Sequence 13 from patent US 6723893.
ACCESSION      AR528355
VERSION        AR528355.1 GI:53916383
KEYWORDS      Unknown.
SOURCE        Unclassified.
ORGANISM      Brown,R., Horvitz,H.R. and Rosen,D.R.
REFERENCE      Mice having a mutant SOD-1-encoding transgene
AUTHORS      Patent: US 6723893-A 13 20-APR-2004;
JOURNAL      Location/Qualifiers
FEATURES      1..24
              /organism="unknown"
              /mol_type="unassigned DNA"

```

```
/organism="unknown"
/mol_type="genomic DNA"

Query Match      2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 556 CCCTTAACATCATCTGTTATCCTGC 579
Db 24 CCCTTAACATCATCTGTTATCCTGC 1

RESULT 12
LOCUS AX473370 23 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 3 from Patent WO0203979.
ACCESSION AX473370
VERSION AX473370.1 GI:22207998
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Huang, P., Plunkett, W. K. and Feng, L.
TITLE Cancer therapeutics involving the administration of
2-methoxyestradiol and an agent that increases intracellular
superoxide anion
JOURNAL Patent: WO 0203979-A 3 17-JAN-2002;
Board of Regents, The University of Texas System (US)
FEATURES
source 1..23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic Primer"

Query Match      2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 ACGAAGCCGCTGCGCTGCTGAA 93
Db 1 ACGAAGCCGCTGCGCTGCTGAA 23

RESULT 13
LOCUS AX473371/c 23 bp DNA linear PAT 09-AUG-2002
DEFINITION Sequence 4 from Patent WO0203979.
ACCESSION AX473371
VERSION AX473371.1 GI:22207999
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Huang, P., Plunkett, W. K. and Feng, L.
TITLE Cancer therapeutics involving the administration of
2-methoxyestradiol and an agent that increases intracellular
superoxide anion
JOURNAL Patent: WO 0203979-A 4 17-JAN-2002;
Board of Regents, The University of Texas System (US)
FEATURES
source 1..23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic Primer"

Query Match      2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CTGGAAGTCGTTTGGCTTGCTGTGT 508
Db 23 CTGGAAGTCGTTTGGCTTGCTGTGT 1

RESULT 14
LOCUS AX710079 23 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 5 from Patent WO03016527.
ACCESSION AX710079
VERSION AX710079.1 GI:29786676
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Pincemall, J., Piette, J. and Marechal, D.
TITLE Process for the detection of oxidative stress and kit for its
implementation
JOURNAL Patent: WO 03016527-A 5 27-FEB-2003;
Probiox SA (BE)
FEATURES
source 1..23
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGCACAAAGAT 343
Db 1 GCAATGTGACTGCTGCACAAAGAT 23

RESULT 15
LOCUS AX710080/c 23 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 6 from Patent WO03016527.
ACCESSION AX710080
VERSION AX710080.1 GI:29786677
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Pincemall, J., Piette, J. and Marechal, D.
TITLE Process for the detection of oxidative stress and kit for its
implementation
JOURNAL Patent: WO 03016527-A 6 27-FEB-2003;
Probiox SA (BE)
FEATURES
source 1..23
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 383 CTCTCAGGAGACCATTTGCATCAT 405
Db 23 CTCTCAGGAGACCATTTGCATCAT 1

RESULT 16
LOCUS BD143416 30 bp DNA linear PAT 17-JAN-2003
DEFINITION Oligonucleotide sequence for early diagnosis of graft versus host
```

```

disease.
BD143416
ACCESSION BD143416.1 GI:27849174
VERSION BD143416.1 GI:27849174
KEYWORDS JP 2002125679-A/168.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 30)
AUTHORS Tokunaga,K., Suyama,A., Wakui,M., Kurata,K. and Morimoto,N.
TITLE Oligonucleotide sequence for early diagnosis of graft versus host
JOURNAL disease
Patent: JP 2002125679-A 168 08-MAY-2002;
COMMENT OLYMPUS OPTICAL CO LTD
OS JP 2002125679-A/168
PD 08-MAY-2002
PF 24-OCT-2000 JP 2000324400
PI KATSUSHI TOKUNAGA,AKIRA SUYAMA,MASATOSHI WAKUI,KENICHI KURATA,
PI NORUHIKO MORIMOTO
PC C12N15/09,C12M1/00,C12Q1/68,C12N15/00 CC
Oligonucleotide sequence specific to the
sequence of accession
CC number
CC m35725 (GenBank) Location/Qualifiers
FH Key 1. .30
FT source Location/Qualifiers
FT source Location/Qualifiers
/organism='Artificial Sequence'.
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 2.6%; Score 22.6; DB 1; Length 30;
Best Local Similarity 86.2%; Pred. No. 33;
Matches 25; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 510 TAATTGGATCGCCCAATAAATTCCT 538
| | | | | | | | | | | | | | | | | | | | | |
Db 1 TGATTGGATTGGCAGTAACATTCCT 29
| | | | | | | | | | | | | | | | | | | | | |

RESULT 17
AR017558/c
LOCUS AR017558 29 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 2 from patent US 5780024.
ACCESSION AR017558
VERSION AR017558.1 GI:3973161
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 29)
AUTHORS Brown,R.H., Fishman,P.S., Francis,J.W. and Hosler,B.A.
TITLE Superoxide dismutase/tetanus toxin fragment C hybrid protein
JOURNAL Patent: US 5780024-A 2 14-JUL-1998;
FEATURES Location/Qualifiers
source 1. .29
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.5%; Score 22; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 777 ATGGGTATTAACTGTGCAGAA 798
| | | | | | | | | | | | | | | | | | | | | |
Db 29 ATGGGTATTAACTGTGCAGAA 8
| | | | | | | | | | | | | | | | | | | | | |

RESULT 18
A06400/c
LOCUS A06400 25 bp DNA linear PAT 18-JUN-1993

```

```

DEFINITION Oligonucleotide primer.
ACCESSION A06400
VERSION A06400.1 GI:412849
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 25)
AUTHORS
JOURNAL Patent: WO 900605-A 8 25-JAN-1990;
FEATURES Location/Qualifiers
source 1. .25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 2.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 33;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 418 GGTGGTCCATGAAAAGCAGATGAC 442
| | | | | | | | | | | | | | | | | | | | | |
Db 25 GGTGGTTCATGAAAGAGCAGATGAC 1
| | | | | | | | | | | | | | | | | | | | | |

RESULT 19
AR364465/c
LOCUS AR364465 25 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 19 from patent US 5290690.
ACCESSION AR364465
VERSION AR364465.1 GI:34427112
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Mrabet,N., Lasters,I., Stanssens,P., Matthysens,G., Wodak,S. and
Quax,W.J.
TITLE Methods and means for controlling the stability of proteins
JOURNAL Patent: US 5290690-A 19 01-MAR-1994;
FEATURES Location/Qualifiers
source 1. .25
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 33;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 418 GGTGGTCCATGAAAAGCAGATGAC 442
| | | | | | | | | | | | | | | | | | | | | |
Db 25 GGTGGTTCATGAAAGAGCAGATGAC 1
| | | | | | | | | | | | | | | | | | | | | |

RESULT 20
BD144206/c
LOCUS BD144206 21 bp DNA linear PAT 17-JAN-2003
DEFINITION ALS model rat.
ACCESSION BD144206
VERSION BD144206.1 GI:27849964
KEYWORDS JP 2002142610-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Aoki,M., Itoyama,Y., Miyoshi,I. and Kasai,N.
TITLE ALS model rat
JOURNAL Patent: JP 2002142610-A 2 21-MAY-2002;
COMMENT OS TOHOKU TECHNO ARCH CO LTD
OS Artificial Sequence
PN JP 2002142610-A/2
PD 21-MAY-2002
PF 07-NOV-2000 JP 2000339567

```







```

FEATURES             Location/Qualifiers
     source            1..19
                        /organism="synthetic construct"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32630"

Query Match
Best Local Similarity 2.2%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GTCGTAGGCCCTTAACCTC 565
Db 19 GTCGTAGGCCCTTAACCTC 1

RESULT 29
A06401/c
LOCUS             A06401             22 bp      DNA      linear      PAT 18-JUN-1993
DEFINITION       Oligonucleotide primer.
ACCESSION        A06401
VERSION          A06401.1  GI:412850
KEYWORDS         .
SOURCE            synthetic construct
ORGANISM          other sequences; artificial sequences.
REFERENCE        1 (bases 1 to 22)
AUTHORS          .
JOURNAL          Patent: WO 900605-A 9 25-JAN-1990;
FEATURES             Location/Qualifiers
     source            1..22
                        /organism="synthetic construct"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:32630"

Query Match
Best Local Similarity 2.0%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 GACTTGGCGCAAGGTGGAAATG 461
Db 22 GACTTGGCGCGGTGGAAATG 1

RESULT 30
BD172232/c
LOCUS             BD172232             22 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION       Secreted and transmembrane polypeptides and nucleic acids encoding
                        the same.
ACCESSION        BD172232
VERSION          BD172232.1  GI:28413530
KEYWORDS         JP 2002223786-A/5.
SOURCE            synthetic construct
ORGANISM          other sequences; artificial sequences.
REFERENCE        1 (bases 1 to 22)
AUTHORS          Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
                        Yuan,J.
TITLE            Secreted and transmembrane polypeptides and nucleic acids encoding
                        the same
JOURNAL          Patent: JP 2002223786-A 5 13-AUG-2002;
COMMENT          GENENTECH INC
OS               Artificial Sequence
PN               JP 2002223786-A/5
PD               13-AUG-2002
PF               18-DEC-2001  JP 2001385135
PR               17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059123 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
18-SEP-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR

FEATURES             Location/Qualifiers
     source            1..22
                        /organism="synthetic construct"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32630"

Query Match
Best Local Similarity 2.0%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGCAGACTTA 768
Db 22 GACCTGTATTTGTCGCGACTTA 1

RESULT 31
BD172551/c
LOCUS             BD172551             22 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION       Secreted and transmembrane polypeptides and nucleic acids encoding
                        the same.
ACCESSION        BD172551
VERSION          BD172551.1  GI:28413853
KEYWORDS         JP 2002238586-A/5.
SOURCE            synthetic construct
ORGANISM          other sequences; artificial sequences.
REFERENCE        1 (bases 1 to 22)
AUTHORS          Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
                        Yuan,J.
TITLE            Secreted and transmembrane polypeptides and nucleic acids encoding
                        the same
JOURNAL          Patent: JP 2002238586-A 5 27-AUG-2002;
COMMENT          GENENTECH INC
OS               Artificial Sequence
PN               JP 2002238586-A/5
PD               27-AUG-2002
PF               18-DEC-2001  JP 2001385205
PR               17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059123,17-SEP-1997 US 60/059121 PR
17-SEP-1997 US 60/059113,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
18-SEP-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR

```



```

17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,31-OCT-1997 US 60/064248 PR
31-OCT-1997 US 60/064809,31-OCT-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, C07K14/435, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02, C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19),
PC (C12N5/10, C12R1:91), C12N15/00, C12N5/00, (C12N5/00, C12R1:91) CC
Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1. .22
/organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1. .22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 94;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768
||||| | | | | | | | | |
Db 22 GACCTGTATGTGCGGACTTA 1

RESULT 34
BD175223/c
LOCUS
DEFINITION
Secretory and transmembrane polypeptide and nucleic acid encoding
the same.
BD175223
BD175223.1 GI:29120919
KEYWORDS
JP 2002253280-A/5.
SOURCE
synthetic construct
ORGANISM
other sequences: artificial sequences.
REFERENCE
1 (bases 1 to 22)
AUTHORS
Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and
Yuan, J.
TITLE
Secretory and transmembrane polypeptide and nucleic acid encoding
the same
JOURNAL
Patent: JP 2002253280-A 5 10-SEP-2002;
GENENTECH INC
COMMENT
OS Artificial Sequence
PN JP 2002253280-A/5
PD 10-SEP-2002
PF 18-DEC-2001 JP 2001385319
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR

```

```

17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,31-OCT-1997 US 60/064248 PR
31-OCT-1997 US 60/064809,31-OCT-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09, A61K45/00, A61P1/12, A61P13/12, A61P17/00, A61P17/06, PC
A61P25/00,
PC A61P25/16, A61P25/28, A61P31/12, A61P35/00, C07K14/47, C07K16/18,
PC C07K19/00,
PC C12N1/19, C12N1/21, C12N5/10, A61K38/00, A61K39/395, A61K39/395,
PC A61P43/00, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), (C12N5/10,
PC C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), (C12N5/10,
PC C12R1:91),
PC C12N15/00, A61K37/02, (C12N5/00, C12R1:91) CC
Description of Artificial Sequence: Synthetic FH Key
Location/Qualifiers
FT source 1. .22
/organism='Artificial Sequence'.
FEATURES
source
Location/Qualifiers
1. .22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 94;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768
||||| | | | | | | | | |
Db 22 GACCTGTATGTGCGGACTTA 1

RESULT 35
BD260461/c
LOCUS
DEFINITION
Methods and compositions for inhibiting neoplastic cell growth.
ACCESSION
BD260461
VERSION
BD260461.1 GI:33070231
KEYWORDS
JP 2002527452-A/3.
SOURCE
synthetic construct
ORGANISM
other sequences: artificial sequences.
REFERENCE
1 (bases 1 to 22)
AUTHORS
Wood, W.I. and Yuan, J.
TITLE
Methods and compositions for inhibiting neoplastic cell growth
JOURNAL
Patent: JP 2002527452-A 3 27-AUG-2002;
GENENTECH INC
COMMENT
OS Artificial Sequence
PN JP 2002527452-A/3
PD 27-AUG-2002
PF 05-OCT-1999 JP 2000575898

```

Stewart,T.A., Tumas,D., Williams,P.M. and Wood,W.I.  
 Secreted and transmembrane polypeptides and nucleic acids encoding  
 the same  
 JOURNAL Patent: US 6635469-A 7 21-OCT-2003;  
 FEATURES Location/Qualifiers  
 source 1..22  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 94;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTGCCAGACTTA 768  
 ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATGTGCCGACTTA 1

RESULT 38  
 AR438965/c  
 LOCUS AR438965 22 bp DNA linear PAT 20-FEB-2004  
 DEFINITION Sequence 7 from patent US 6664376.  
 ACCESSION AR438965  
 VERSION AR438965.1 GI:42664814  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 22)  
 AUTHORS Ashkenazi,A., Botstein,D., Desnoyers,L., Eaton,D.L., Ferrara,N.,  
 Fliszaroff,E., Fong,S., Gao,W.-Q., Gerber,H., Gerritsen,M.E.,  
 Goddard,A., Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Hillan,K.J.,  
 Kljavin,I.J., Mather,J.P., Pan,J., Paoni,N.F., Roy,M.A.,  
 Stewart,T.A., Tumas,D., Williams,P.M. and Wood,W.I.  
 TITLE Secreted and transmembrane polypeptides and nucleic acids encoding  
 the same  
 JOURNAL Patent: US 6664376-A 7 16-DEC-2003;  
 FEATURES Location/Qualifiers  
 source 1..22  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 94;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTGCCAGACTTA 768  
 ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATGTGCCGACTTA 1

RESULT 39  
 AR472985/c  
 LOCUS AR472985 22 bp DNA linear PAT 20-FEB-2004  
 DEFINITION Sequence 7 from patent US 6686451.  
 ACCESSION AR472985  
 VERSION AR472985.1 GI:42708360  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 22)  
 AUTHORS Desnoyers,L., Goddard,A., Godowski,P.J., Gurney,A.L., Mather,J.P.,  
 Williams,P.M. and Wood,W.I.  
 TITLE Secreted and transmembrane polypeptides and nucleic acids encoding  
 the same  
 JOURNAL Patent: US 6686451-A 7 03-FEB-2004;  
 FEATURES Location/Qualifiers  
 source 1..22  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 2.0%; Score 17.2; DB 1; Length 22;

RESULT 42		
AX076912/c		
LOCUS	AX076912	22 bp
	DNA	linear
		PAT 22-FEB-2001

**AUTHORS** Ashkenazi, A.J., Botstein, D., Desnovers, L., Eaton, D.L., Ferrara, N., Filvaroff, E., Fong, S., Gao, W.Q., Gerber, H., Gerritsen, M.E., Goddard, A., Godowski, P.J., Grimaldi, C.J., Gurney, A.L., Hillan, K.J., Kijavini, I.J., Mather, J.P., Pan, J., Paoni, N.F., Roy, M.A., Stewart, T.A., Tumas, D., Williams, P.M. and Wood, W.I.

**TITLE** Secreted and transmembrane polypeptides and nucleic acids encoding the same

**JOURNAL** Patent: WO 0104311-A 7 18-JAN-2001; Genentech Inc. (US)

**FEATURES**  
 source  
 Location/Qualifiers  
 1..22  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Synthetic Oligonucleotide Probe"

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 94;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

**QY** 747 GACCTGTATTTGCCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
**Db** 22 GACCTGTAATGTCGCGACTTA 1

**RESULT 45**  
**BD075372/c**  
**LOCUS** BD075372 22 bp DNA linear PAT 27-AUG-2002  
**DEFINITION** Secretory and transmembrane polypeptide and nucleic acid encoding the same.  
**ACCESSION** BD075372  
**VERSION** BD075372.1 GI:22620975  
**KEYWORDS** JP 2001516580-A/5.  
**SOURCE** synthetic construct  
**ORGANISM** other sequences; artificial sequences.

**REFERENCE** 1 (bases 1 to 22)  
**AUTHORS** Wood, W.I., Gurney, A.L., Goddard, A., Penica, D., Chen, J. and Yuan, J.  
**TITLE** Secretory and transmembrane polypeptide and nucleic acid encoding the same

**JOURNAL** Patent: JP 2001516580-A 5 02-OCT-2001; GENENTECH INC

**COMMENT**  
**OS** Artificial Sequence  
**FN** JP 2001516580-A/5  
**PD** 02-OCT-2001  
**PF** 16-SEP-1998 JP 2000511867  
 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR  
 17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR  
 17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR  
 18-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR  
 18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR  
 17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR  
 21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR  
 24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR  
 24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR  
 24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR  
 27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR  
 28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR  
 28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR  
 28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR  
 29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR  
 29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR  
 29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063735 PR  
 29-OCT-1997 US 60/064103, 31-OCT-1997 US 60/063870 PR  
 03-NOV-1997 US 60/064248, 07-NOV-1997 US 60/064809 PR  
 12-NOV-1997 US 60/065186, 17-NOV-1997 US 60/065846 PR  
 18-NOV-1997 US 60/065893, 21-NOV-1997 US 60/066120 PR  
 21-NOV-1997 US 60/066364, 24-NOV-1997 US 60/066772 PR  
 24-NOV-1997 US 60/066466, 24-NOV-1997 US 60/066770 PR  
 24-NOV-1997 US 60/066511, 24-NOV-1997 US 60/066453 PR  
 25-NOV-1997 US 60/066840

**PI** WILLIAM I WOOD, AUSTIN L GURNEY, AUDLEY GODDARD, DIANE PENICA, PI  
 JEAN CHEN,

---

**PI** JEAN YUAN  
**PC** C12N15/09, C07K14/47, C07K16/18, C07K16/28, C07K19/00,  
**PC** C12N1/19,  
**PC** C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/02, C12P21/08, PC  
 C12R1/91,  
**PC** C12N15/00, C12N5/00  
**CC** Description of Artificial Sequence: Synthetic FH Key  
**FT** Location/Qualifiers  
 source  
 1..22  
 /organism="Artificial Sequence".

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 94;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

**QY** 747 GACCTGTATTTGCCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
**Db** 22 GACCTGTAATGTCGCGACTTA 1

**RESULT 46**  
**AX671956**  
**LOCUS** AX671956 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 401 from Patent WO03004526.  
**ACCESSION** AX671956  
**VERSION** AX671956.1 GI:29330304  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

**REFERENCE** 1  
**AUTHORS** Telerman, A., Anson, R. and Tuijnder, M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and their use as  
 medicines

**JOURNAL** Patent: WO 03004526-A 401 16-JAN-2003;  
 Molecular Engines Laboratories (FR)

**FEATURES**  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 1.9%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 73;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

**QY** 690 GATCACTTGGAGATT 706  
 ||||| ||||| ||||| ||||| |||||  
**Db** 1 GATCACTTGGAGATT 17

**RESULT 47**  
**AX673655**  
**LOCUS** AX673655 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 2100 from Patent WO03004526.  
**ACCESSION** AX673655  
**VERSION** AX673655.1 GI:29332003  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

**REFERENCE** 1  
**AUTHORS** Telerman, A., Anson, R. and Tuijnder, M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and their use as

```

medicines
JOURNAL Patent: WO 03004526-A 2100 16-JAN-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 GATCGCCCAATAACAT 533
Db 1 GATCGCCCAATAACAT 17

RESULT 48
AX730213/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1847 from Patent WO03025175.
DEFINITION AX730213
ACCESSION AX730213.1 GI:30509556
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 1847 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 363 TTGAAGATTCTGTGATC 379
Db 17 TTGAAGATTCTGTGATC 1

RESULT 49
AX733568 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 5202 from Patent WO03025175.
DEFINITION AX733568
ACCESSION AX733568
VERSION AX733568.1 GI:30512911
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5202 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

medicines
JOURNAL Patent: WO 03004526-A 2100 16-JAN-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 GATCACTTGGAGATT 706
Db 1 GATCACTTGGAGATT 17

RESULT 50
AX736487 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2077 from Patent WO03025177.
DEFINITION AX736487
ACCESSION AX736487
VERSION AX736487.1 GI:30515775
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2077 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 GATCACTTGGAGATT 706
Db 1 GATCACTTGGAGATT 17

RESULT 51
AX739220 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 4810 from Patent WO03025177.
DEFINITION AX739220
ACCESSION AX739220
VERSION AX739220.1 GI:30518517
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4810 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 GATCGCCCAATAACAT 533
Db 1 GATCGCCCAATAACAT 533

```



```
|||||
1 GATCGCCCAATAACAT 17

Db
RESULT 52
BD174097
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD174097
19 bp DNA linear PAT 18-FEB-2003
Method of treating disease in association with decrease in the
expression of AOP-1 gene or AOP-1 and remedies for the disease.
BD174097
BD174097.1 GI:28415432
WO 02064169-A/10.
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 19)
Hattori,F., Sugimura,K. and Furuya,M.
Method of treating disease in association with decrease in the
expression of AOP-1 gene or AOP-1 and remedies for the disease
Patent: WO 02064169-A 10 22-AUG-2002;
SUNTORY LTD,SUNTORY BIOMEDICAL RESEARCH LTD,FUMIYUKI HATTORI,
KEIJIRO SUGIMURA,MAYUMI FURUYA
OS Artificial Sequence
PN WO 02064169-A/10
PD 22-AUG-2002
PF 18-FEB-2002 WO 2002JP001358
PR 16-FEB-2001 JP 01P 041003
PI FUMIYUKI HATTORI,KEIJIRO SUGIMURA,MAYUMI FURUYA PC
A61K48/00,A61K31/711,A61K38/17,A61P9/02,A61P29/00, PC
A61P19/02,
PC A61P25/00,A61P13/12,G01N33/15,G01N33/50//C12N15/12 CC
Method of treating disease in association
with decrease in the
expression
CC of AOP-1 gene or AOP-1 and remedies for the disease FH Key
Location/Qualifiers
FT source 1..19
FT /organism='Artificial Sequence'.

FEATURES
source
1..19
Location/Qualifiers
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match 1.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 292 GGATGAAGAGGCATG 308
|||||
3 GGATGAAGAGGCATG 19

Db
RESULT 53
AR061105/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR061105
21 bp DNA linear PAT 29-SEP-1999
Sequence 7 from patent US 5843641.
AR061105
AR061105.1 GI:5988796
Unknown.
Unclassified.
1 (bases 1 to 21)
Brown,R., Horvitz,H.Robert. and Rosen,D.R.
Methods for the diagnosis, of familial amyotrophic lateral
sclerosis
Patent: US 5843641-A 7 01-DEC-1998;
Location/Qualifiers
1..21
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 1.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
|||||
21 GGAGATAATACAGCAGG 5

Db
RESULT 54
AR064684/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR064684
21 bp DNA linear PAT 29-SEP-1999
Sequence 7 from patent US 5849290.
AR064684
AR064684.1 GI:5994900
Unknown.
Unclassified.
1 (bases 1 to 21)
Brown,R., Horvitz,H.Robert. and Rosen,D.R.
Compounds and methods for the diagnosis, treatment and prevention
of diseases of cell death
Patent: US 5849290-A 7 15-DEC-1998;
Location/Qualifiers
1..21
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 1.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
|||||
21 GGAGATAATACAGCAGG 5

Db
RESULT 55
AR528349/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR528349
21 bp DNA linear PAT 08-OCT-2004
Sequence 7 from patent US 6723893.
AR528349
AR528349.1 GI:53916377
Unknown.
Unclassified.
1 (bases 1 to 21)
Brown,R., Horvitz,H.R. and Rosen,D.R.
Mice having a mutant SOD-1-encoding transgene
Patent: US 6723893-A 7 20-APR-2004;
Location/Qualifiers
1..21
/organism='unknown'
/mol_type='genomic DNA'

Query Match 1.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
|||||
21 GGAGATAATACAGCAGG 5

Db
RESULT 56
AR338227/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS

AR338227
20 bp DNA linear PAT 17-AUG-2003
Sequence 48 from patent US 6569618.
AR338227
AR338227.1 GI:33724978
Unknown.
Unclassified.
1 (bases 1 to 21)
Brown,R., Horvitz,H.Robert. and Rosen,D.R.
Methods for the diagnosis, of familial amyotrophic lateral
sclerosis
Patent: US 5843641-A 7 01-DEC-1998;
Location/Qualifiers
1..21
/organism='unknown'
/mol_type='unassigned DNA'
```

```

SOURCE      Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Yasue,H. and Yoshimura,M.
TITLE        Diagnosis of diseases associated with coronary twitching
JOURNAL      Patent: US 659618-A 48 27-MAY-2003;
FEATURES     Location/Qualifiers
             1..20
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 93;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 168 GCATTAAAGGACTGACTGAA 187
Db 20 GCCTAAAGGACTGCCTGAA 1

RESULT 57
LOCUS      AR061108      21 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 10 from patent US 5843641.
ACCESSION  AR061108
VERSION     AR061108.1 GI:5988799
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 21)
AUTHORS      Brown,R., Horvitz,H.Robert. and Rosen,D.R.
TITLE        Methods for the diagnosis, of familial amyotrophic lateral
JOURNAL      sclerosis
FEATURES     Patent: US 5843641-A 10 01-DEC-1998;
             Location/Qualifiers
             1..21
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 99;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGAGGCATGTTGGAGACT 317
Db 2 ATATAGGCATGTTGGAGACT 21

RESULT 58
LOCUS      AR064687      21 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 10 from patent US 5848290.
ACCESSION  AR064687
VERSION     AR064687.1 GI:5994903
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 21)
AUTHORS      Brown,R., Horvitz,H.Robert. and Rosen,D.R.
TITLE        Compounds and methods for the diagnosis, treatment and prevention
JOURNAL      of diseases of cell death
FEATURES     Patent: US 5849290-A 10 15-DEC-1998;
             Location/Qualifiers
             1..21
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 99;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

SOURCE      Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Hallelwell,R.A. and Mullenbach,G.T.
TITLE        Superoxide dismutase cloning and expression in microorganisms
JOURNAL      Patent: EP 0138111-A1 8 24-APR-1985;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 157 GGTGTGGGGAGCACTT 172
Db 16 GGTGTGGGGAGCACTT 1

RESULT 61
LOCUS      I06877/c      16 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION Sequence 8 from Patent EP 0340805.
ACCESSION  I06877
VERSION     I06877.1 GI:589854
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 16)

SOURCE      Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 21)
AUTHORS      Brown,R., Horvitz,H.R. and Rosen,D.R.
TITLE        Mice having a mutant SOD-1-encoding transgene
JOURNAL      Patent: US 6723893-A 10 20-APR-2004;
FEATURES     Location/Qualifiers
             1..21
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      1.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 99;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGAGGCATGTTGGAGACT 317
Db 2 ATATAGGCATGTTGGAGACT 21

RESULT 59
LOCUS      AR528352      21 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 10 from patent US 6723893.
ACCESSION  AR528352
VERSION     AR528352.1 GI:53916380
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 21)
AUTHORS      Brown,R., Horvitz,H.R. and Rosen,D.R.
TITLE        Mice having a mutant SOD-1-encoding transgene
JOURNAL      Patent: US 6723893-A 10 20-APR-2004;
FEATURES     Location/Qualifiers
             1..21
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      1.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 99;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGAGGCATGTTGGAGACT 317
Db 2 ATATAGGCATGTTGGAGACT 21

RESULT 60
LOCUS      I04212/c      16 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION Sequence 8 from Patent EP 0138111.
ACCESSION  I04212
VERSION     I04212.1 GI:591829
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Hallelwell,R.A. and Mullenbach,G.T.
TITLE        Superoxide dismutase cloning and expression in microorganisms
JOURNAL      Patent: EP 0138111-A1 8 24-APR-1985;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 157 GGTGTGGGGAGCACTT 172
Db 16 GGTGTGGGGAGCACTT 1

RESULT 61
LOCUS      I06877/c      16 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION Sequence 8 from Patent EP 0340805.
ACCESSION  I06877
VERSION     I06877.1 GI:589854
KEYWORDS   .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 16)
```

AUTHORS Hallelwell, R.A. and Mullenbach, G.T.  
 TITLE Superoxide dismutase and expression in microorganisms  
 JOURNAL Patent: EP 0340805-A1 8 08-NOV-1989;  
 FEATURES Location/Qualifiers  
 source  
 1. .16  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 88;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 157 GGTGTGGGAAGCATT 172  
 |||||  
 Db 16 GGTGTGGGAAGCATT 1

RESULT 62  
 AX081870/c  
 LOCUS AX081870 17 bp DNA linear PAT 27-FEB-2001  
 DEFINITION Sequence 114 from Patent WO0109183.  
 ACCESSION AX081870  
 VERSION AX081870.1 GI:13170677  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.

REFERENCE 1  
 AUTHORS Brinkmann, U., Hoffmeyer, S., Eichelbaum, M. and Roots, I.  
 TITLE Polymorphisms in the human mdr-1 gene and their use in diagnostic  
 and therapeutic applications  
 JOURNAL Patent: WO 0109183-A 114 08-FEB-2001;  
 EPIDAUROS AG Biotechnologie Aktiengesellschaft (DE)  
 FEATURES Location/Qualifiers  
 source  
 1. .17  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="synthetic"

Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 95;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336  
 |||||  
 Db 16 GCAATGTGACTGCTGA 1

RESULT 63  
 AX737712  
 LOCUS AX737712 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 3302 from Patent WO03025177.  
 ACCESSION AX737712  
 VERSION AX737712.1 GI:30517000  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and the use  
 thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 3302 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 95;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 GATCACTTGGAGATT 705  
 |||||  
 Db 1 GATCACTTGGAGATT 16

RESULT 64  
 AX737721  
 LOCUS AX737721 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 3311 from Patent WO03025177.  
 ACCESSION AX737721  
 VERSION AX737721.1 GI:30517009  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and the use  
 thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 3311 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 95;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 GATCGCCCAATAACA 532  
 |||||  
 Db 1 GATCGCCCAATAACA 16

RESULT 65  
 AX378471/c  
 LOCUS AX378471 18 bp DNA linear PAT 18-MAR-2002  
 DEFINITION Sequence 260 from Patent WO0206525.  
 ACCESSION AX378471  
 VERSION AX378471.1 GI:19574324  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Cohen, D., Blumenfeld, M., Chumakov, I., Abderrahim, H. and Bihain, B.  
 TITLE Obesity associated biallelic marker maps  
 JOURNAL Patent: WO 0206525-A 260 24-JAN-2002;  
 GENSET (FR)  
 FEATURES Location/Qualifiers  
 source  
 1. .18  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

primer\_bind  
 1. .18  
 /note="upstream amplification primer 99-32162 for SEQ 89"

Query Match 1.8%; Score 16; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 1e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 TGAAGGTGTGGGAAG 168  
 |||||  
 Db 16 TGAAGGTGTGGGAAG 1

```
RESULT 66
AR225282
LOCUS AR225282 19 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 27 from patent US 6441273.
ACCESSION AR225282
VERSION AR225282.1 GI:23334504
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 19)
AUTHORS Aldwinckle,H.S. and Gaitan,A.L.
TITLE Constitutive and inducible promoters from coffee plants
JOURNAL Patent: US 6441273-A 27 27-AUG-2002;
FEATURES
source
1. .19
/moi_type="genomic DNA"

Query Match 1.8%; Score 16; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 195 ATGGATTCCATGTTTCATG 212
||||| ||||| ||||| |||||
Db 1 ATGGNTTCCATGTCATG 18

RESULT 67
I73106/c
LOCUS I73106 20 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 2 from patent US 5686072.
ACCESSION I73106
VERSION I73106.1 GI:3009245
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Uhr,J.W., Vitetta,E.S. and Scheuermann,R.H.
TITLE Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JOURNAL Patent: US 5686072-A 2 11-NOV-1997;
FEATURES
source
1. .20
/moi_type="unassigned DNA"

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 ACTGAAGGCGCTGCATGGAT 200
||||| ||||| ||||| |||||
Db 20 ACTGAAGCGCTGCAGGAT 2

RESULT 68
AR305282/c
LOCUS AR305282 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 236 from patent US 6545137.
ACCESSION AR305282
VERSION AR305282.1 GI:31694592
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.

TITLE Receptor
JOURNAL Patent: US 6545137-A 236 08-APR-2003;
FEATURES
source
1. .20
/moi_type="genomic DNA"

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAAT 460
||||| ||||| ||||| |||||
Db 20 CTTGGGCAGAGTGGATAT 2

RESULT 69
AR309386/c
LOCUS AR309386 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 236 from patent US 6555654.
ACCESSION AR309386
VERSION AR309386.1 GI:31701391
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.

TITLE LDL-receptor
JOURNAL Patent: US 6555654-A 236 29-APR-2003;
FEATURES
source
1. .20
/moi_type="genomic DNA"

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAAT 460
||||| ||||| ||||| |||||
Db 20 CTTGGGCAGAGTGGATAT 2

RESULT 70
AR350302
LOCUS AR350302 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 79 from patent US 6586245.
ACCESSION AR350302
VERSION AR350302.1 GI:33751273
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F., Baker,B.F., Wyatt,J. and Davis,S.E.
TITLE Antisense modulation of CD40 ligand expression
JOURNAL Patent: US 6586245-A 79 01-JUL-2003;
FEATURES
source
1. .20
/moi_type="genomic DNA"

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGAC 394
||||| ||||| ||||| |||||
Db 2 GATCTCACTGTGAGGACAC 20
```

CC	Strandedness	Topology	Linear	Length	DB 1	DB 2	DB 3	DB 4	DB 5	DB 6	DB 7	DB 8	DB 9	DB 10	DB 11	DB 12	DB 13	DB 14	DB 15	DB 16	DB 17	DB 18	DB 19	DB 20	DB 21	DB 22	DB 23	DB 24	DB 25	DB 26	DB 27	DB 28	DB 29	DB 30	DB 31	DB 32	DB 33	DB 34	DB 35	DB 36	DB 37	DB 38	DB 39	DB 40	DB 41	DB 42	DB 43	DB 44	DB 45	DB 46	DB 47	DB 48	DB 49	DB 50	DB 51	DB 52	DB 53	DB 54	DB 55	DB 56	DB 57	DB 58	DB 59	DB 60	DB 61	DB 62	DB 63	DB 64	DB 65	DB 66	DB 67	DB 68	DB 69	DB 70	DB 71	DB 72	DB 73	DB 74	DB 75	DB 76	DB 77	DB 78	DB 79	DB 80	DB 81	DB 82	DB 83	DB 84	DB 85	DB 86	DB 87	DB 88	DB 89	DB 90	DB 91	DB 92	DB 93	DB 94	DB 95	DB 96	DB 97	DB 98	DB 99	DB 100	DB 101	DB 102	DB 103	DB 104	DB 105	DB 106	DB 107	DB 108	DB 109	DB 110	DB 111	DB 112	DB 113	DB 114	DB 115	DB 116	DB 117	DB 118	DB 119	DB 120	DB 121	DB 122	DB 123	DB 124	DB 125	DB 126	DB 127	DB 128	DB 129	DB 130	DB 131	DB 132	DB 133	DB 134	DB 135	DB 136	DB 137	DB 138	DB 139	DB 140	DB 141	DB 142	DB 143	DB 144	DB 145	DB 146	DB 147	DB 148	DB 149	DB 150	DB 151	DB 152	DB 153	DB 154	DB 155	DB 156	DB 157	DB 158	DB 159	DB 160	DB 161	DB 162	DB 163	DB 164	DB 165	DB 166	DB 167	DB 168	DB 169	DB 170	DB 171	DB 172	DB 173	DB 174	DB 175	DB 176	DB 177	DB 178	DB 179	DB 180	DB 181	DB 182	DB 183	DB 184	DB 185	DB 186	DB 187	DB 188	DB 189	DB 190	DB 191	DB 192	DB 193	DB 194	DB 195	DB 196	DB 197	DB 198	DB 199	DB 200	DB 201	DB 202	DB 203	DB 204	DB 205	DB 206	DB 207	DB 208	DB 209	DB 210	DB 211	DB 212	DB 213	DB 214	DB 215	DB 216	DB 217	DB 218	DB 219	DB 220	DB 221	DB 222	DB 223	DB 224	DB 225	DB 226	DB 227	DB 228	DB 229	DB 230	DB 231	DB 232	DB 233	DB 234	DB 235	DB 236	DB 237	DB 238	DB 239	DB 240	DB 241	DB 242	DB 243	DB 244	DB 245	DB 246	DB 247	DB 248	DB 249	DB 250	DB 251	DB 252	DB 253	DB 254	DB 255	DB 256	DB 257	DB 258	DB 259	DB 260	DB 261	DB 262	DB 263	DB 264	DB 265	DB 266	DB 267	DB 268	DB 269	DB 270	DB 271	DB 272	DB 273	DB 274	DB 275	DB 276	DB 277	DB 278	DB 279	DB 280	DB 281	DB 282	DB 283	DB 284	DB 285	DB 286	DB 287	DB 288	DB 289	DB 290	DB 291	DB 292	DB 293	DB 294	DB 295	DB 296	DB 297	DB 298	DB 299	DB 300	DB 301	DB 302	DB 303	DB 304	DB 305	DB 306	DB 307	DB 308	DB 309	DB 310	DB 311	DB 312	DB 313	DB 314	DB 315	DB 316	DB 317	DB 318	DB 319	DB 320	DB 321	DB 322	DB 323	DB 324	DB 325	DB 326	DB 327	DB 328	DB 329	DB 330	DB 331	DB 332	DB 333	DB 334	DB 335	DB 336	DB 337	DB 338	DB 339	DB 340	DB 341	DB 342	DB 343	DB 344	DB 345	DB 346	DB 347	DB 348	DB 349	DB 350	DB 351	DB 352	DB 353	DB 354	DB 355	DB 356	DB 357	DB 358	DB 359	DB 360	DB 361	DB 362	DB 363	DB 364	DB 365	DB 366	DB 367	DB 368	DB 369	DB 370	DB 371	DB 372	DB 373	DB 374	DB 375	DB 376	DB 377	DB 378</
----	--------------	----------	--------	--------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	----------

```
/note="t=a or g"

Query Match          1.8%; Score 15.6; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
      |||||:|||||
      2 GCAATGTRACTGCTGA 17

RESULT 75
BD255580/c
LOCUS          17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION     Regulation of repressor genes using nucleic acid molecules.
ACCESSION      BD255580
VERSION        BD255580.1 GI:33065350
KEYWORDS       JP 2002541795-A/3373.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 3373 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Eukaryote
                PN JP 2002541795-A/3373
                PD 10-DEC-2000
                PF 11-APR-2000 JP 2000611654
                PR 12-APR-1999 US 60/129390
                PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
                C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
                C12P21/02,
                PC
                C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
                C12R1:91),
                PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
                PC A61K37/02,
                PC (C12N5/00,C12R1:91)
                CC Regulation of repressor genes using nucleic acid molecules FH
                Key source Location/Qualifiers
                FT source 1..17
                FT Location/Qualifiers
                   1..17
                   /organism='Eukaryote'.
                   /organism='unidentified'
                   /mol_type='genomic DNA'
                   /db_xref='taxon:32644'

QUERY MATCH          1.8%; Score 15.4; DB 1; Length 17;
BEST LOCAL SIMILARITY 94.1%; Pred. No. 1.1e+02;
MATCHES 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 AATGAAGAAAGTACAAAG 475
      |||||:|||||
      17 AATGAAGAAATACAAAG 1

RESULT 77
I06872/c
LOCUS          17 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION     Sequence 3 from Patent EP 0340805.
ACCESSION      I06872
VERSION        I06872.1 GI:589849
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Hallowell,R.A. and Mullenbach,G.T.
TITLE          Superoxide dismutase and expression in microorganisms
JOURNAL        Patent: EP 0340805-A1 3 08-NOV-1989;
FEATURES       Location/Qualifiers
                source
                   1..17
                   /organism='unknown'
                   /mol_type='unassigned DNA'

Query Match          1.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 122 AATTTGAGCAGAGGA 138
      |||||:|||||
      17 AACTTCGAGCAGAGGA 1

RESULT 78
AR121018
LOCUS          20 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION     Sequence 39 from patent US 6159694.
ACCESSION      AR121018
VERSION        AR121018
KEYWORDS       AR121018.1 GI:14104594
SOURCE         .
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 20)

Query Match          1.8%; Score 15.6; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
      |||||:|||||
      2 GCAATGTRACTGCTGA 17

RESULT 75
BD255580/c
LOCUS          17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION     Regulation of repressor genes using nucleic acid molecules.
ACCESSION      BD255580
VERSION        BD255580.1 GI:33065350
KEYWORDS       JP 2002541795-A/3373.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 3373 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Eukaryote
                PN JP 2002541795-A/3373
                PD 10-DEC-2000
                PF 11-APR-2000 JP 2000611654
                PR 12-APR-1999 US 60/129390
                PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
                C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
                C12P21/02,
                PC
                C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
                C12R1:91),
                PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
                PC A61K37/02,
                PC (C12N5/00,C12R1:91)
                CC Regulation of repressor genes using nucleic acid molecules FH
                Key source Location/Qualifiers
                FT source 1..17
                FT Location/Qualifiers
                   1..17
                   /organism='Eukaryote'.
                   /organism='unidentified'
                   /mol_type='genomic DNA'
                   /db_xref='taxon:32644'

QUERY MATCH          1.8%; Score 15.4; DB 1; Length 17;
BEST LOCAL SIMILARITY 94.1%; Pred. No. 1.1e+02;
MATCHES 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 459 ATGAAGAAAGTACAAAG 475
      |||||:|||||
      17 ATGAAGAAATACAAAG 1

RESULT 76
BD255581/c
LOCUS          17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION     Regulation of repressor genes using nucleic acid molecules.
ACCESSION      BD255581
VERSION        BD255581.1 GI:33065351
KEYWORDS       JP 2002541795-A/3374.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 3374 10-DEC-2002;
```

```

AUTHORS      Karras,J.G.
TITLE        Antisense modulation of stat3 expression
JOURNAL      Patent: US 6159694-A 39 12-DEC-2000;
FEATURES     Location/Qualifiers
source       1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 200 TTCCATGTTTCATGAGTTTG 219
|||||
Db 1 TTCCATGTTTCATCATTTG 20

RESULT 79
BD272639      20 bp DNA linear PAT 17-JUL-2003
LOCUS         Antisense oligonucleotide modulation of STAT3 expression.
DEFINITION    Antisense oligonucleotide modulation of STAT3 expression.
ACCESSION     BD272639
VERSION       BD272639.1 GI:33082407
KEYWORDS      JP 2002541784-A/39.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     Karras,J.G.
AUTHORS       Antisense oligonucleotide modulation of STAT3 expression
TITLE         ISIS PHARMACEUTICALS INC
JOURNAL       OS Artificial Sequence
COMMENT       PN JP 2002541784-A/39
PD 10-DEC-2002
PF 06-APR-2000 JP 2000611544
PR 08-APR-1999 US 09/288461
PI JAMES G KARRAS
PC C12N15/09,A61K31/711,A61K48/00,A61P29/00,A61P35/00,
PC A61P37/02,
PC A61P43/00,C12N5/06,C12Q1/02,C12N15/00,C12N5/00 CC Antisense
oligonucleotide
FH Key Location/Qualifiers
FT source 1..20
/mol_type="genomic DNA"
/db_xref="taxon:32630"

FEATURES
source       1..20
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 200 TTCCATGTTTCATGAGTTTG 219
|||||
Db 1 TTCCATGTTTCATCATTTG 20

RESULT 80
CQ871960      20 bp DNA linear PAT 27-SEP-2004
LOCUS         Sequence 37 from Patent WO2004078940.
DEFINITION    Sequence 37 from Patent WO2004078940.
ACCESSION     CQ871960
VERSION       CQ871960.1 GI:52745967
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Thompson,J.E. and Taylor,C.

USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSIONOF
EIF-5A1
Patent: WO 2004078940-A 39 12-DEC-2000;
Senesco Technologies, Inc. (US)
Location/Qualifiers
source       1..20
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCGCTAGC 59
|||||
Db 1 GGACCTTGGCGTGGCGGTGC 20

RESULT 81
CQ871961/c    20 bp DNA linear PAT 27-SEP-2004
LOCUS         Sequence 38 from Patent WO2004078940.
DEFINITION    Sequence 38 from Patent WO2004078940.
ACCESSION     CQ871961
VERSION       CQ871961.1 GI:52745968
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Thompson,J.E. and Taylor,C.
TITLE         USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSIONOF
EIF-5A1
Patent: WO 2004078940-A 38 16-SEP-2004;
Senesco Technologies, Inc. (US)
Location/Qualifiers
source       1..20
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCGCTAGC 59
|||||
Db 1 GGACCTTGGCGTGGCGGTGC 20

RESULT 82
CQ871987      20 bp DNA linear PAT 27-SEP-2004
LOCUS         Sequence 64 from Patent WO2004078940.
DEFINITION    Sequence 64 from Patent WO2004078940.
ACCESSION     CQ871987
VERSION       CQ871987.1 GI:52745993
KEYWORDS      synthetic construct
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1
AUTHORS       Thompson,J.E. and Taylor,C.
TITLE         USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSIONOF
EIF-5A1
Patent: WO 2004078940-A 64 16-SEP-2004;
Senesco Technologies, Inc. (US)
Location/Qualifiers
source       1..20
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Synthetic
```

PR TSUYOSHI SHIMONISHI, SATOSHI KANEKO, SATORU NIRASAWA, PI  
KIYOSHI HAYASHI,  
PI KAZUTOMO HARAGUCHI  
PC C12N15/09, C12N1/21, C12N9/36// (C12N15/09, C12R1:465), (C12N15/09,  
PC C12R1:19),  
PC (C12N1/21, C12R1:19), (C12N9/36, C12R1:465), C12N15/00, (C12N15/00,  
PC C12R1:465),  
PC (C12R1:465),

```

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
/note="Designed oligonucleotide primer for PCR"
/ad_xref="taxon:32630"

```



```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 295 TGAAGAGCGCATGTTGGAG 314
Db 20 TGTAGAGGGCATGTTGGAG 1

RESULT 87
CQ821402
LOCUS CQ821402 15 bp DNA linear PAT 14-JUN-2004
DEFINITION Sequence 8 from Patent WO2004038019.
ACCESSION CQ821402
VERSION CQ821402.1 GI:48716051
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Beeson,D., Wood,M. and Abdelgany,A.
AUTHORS Dnazyme cleaving mutant polynucleotides
TITLE Patent: WO 2004038019-A 8 06-MAY-2004;
JOURNAL ISIS INNOVATION LIMITED (GB)
FEATURES
Location/Qualifiers
source
1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 95 GCGGACGGCCAGTG 109
Db 1 GCGGACGGCCAGTG 15

RESULT 88
CQ821408
LOCUS CQ821408 15 bp DNA linear PAT 14-JUN-2004
DEFINITION Sequence 14 from Patent WO2004038019.
ACCESSION CQ821408
VERSION CQ821408.1 GI:48716057
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Beeson,D., Wood,M. and Abdelgany,A.
AUTHORS Dnazyme cleaving mutant polynucleotides
TITLE Patent: WO 2004038019-A 14 06-MAY-2004;
JOURNAL ISIS INNOVATION LIMITED (GB)
FEATURES
Location/Qualifiers
source
1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 437 GATGACTTGGGCAA 451
Db 1 GATGACTTGGGCAA 15

RESULT 89
AX081871/c
LOCUS AX081871 17 bp DNA linear PAT 27-FEB-2001
DEFINITION Sequence 115 from Patent WO0109183.

```

```

ACCESSION AX081871
VERSION AX081871.1 GI:13170678
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1 Brinkmann,U., Hoffmeyer,S., Eichelbaum,M. and Roots,I.
AUTHORS Polymorphisms in the human mdr-1 gene and their use in diagnostic
TITLE and therapeutic applications
JOURNAL Patent: WO 0109183-A 115 08-FEB-2001;
EPIDAUROS AG Biotechnologie Aktiengesellschaft (DE)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="y=c or t"

Query Match 1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGCTG 335
Db 17 GTGCAATGTGACTGCTG 1

RESULT 90
AX706658/c
LOCUS AX706658 17 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 355 from Patent WO03013534.
ACCESSION AX706658
VERSION AX706658.1 GI:29563081
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Heinrich,G. and Kerb,R.
AUTHORS Methods for the treatment of cancer with irinotecan based on CYP3A5
TITLE Patent: WO 03013534-A 355 20-FEB-2003;
JOURNAL Epidauros Biotechnologie AG (DE)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
misc_feature 8
/note="y=c or t"

Query Match 1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGCTG 335
Db 17 GTGCAATGTGACTGCTG 1

RESULT 91
AX707588/c
LOCUS AX707588 17 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 355 from Patent WO03013536.
ACCESSION AX707588
VERSION AX707588.1 GI:29563761
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1

```

AUTHORS Heinrich,G. and Kerb,R.  
 TITLE Methods for treatment of cancer using irinotecan based on UGT1A1  
 JOURNAL Patent: WO 03013336-A 355 20-FEB-2003,  
 Epidauros Biotechnologie AG (DE)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 misc\_feature 8  
 /note="y=c or t"

Query Match 1.7%; Score 15; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGCTG 335  
 | | | | | | | | | | | | | | | | | | | | |  
 Db 17 GTGCAATGTRACTGCTG 1

RESULT 92  
 AX732679  
 LOCUS AX732679 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 4313 from Patent WO03025175.  
 ACCESSION AX732679  
 VERSION AX732679.1 GI:30512022  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 JOURNAL Patent: WO 03025175-A 4313 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 1.7%; Score 15; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 811 TCAAGCCTGTGAATA 825  
 | | | | | | | | | | | | | | | | | | | | |  
 Db 3 TCAAGCCTGTGAATA 17

RESULT 93  
 AR199396  
 LOCUS AR199396 20 bp DNA linear PAT 20-APR-2002  
 DEFINITION Sequence 17 from patent US 6355434.  
 ACCESSION AR199396  
 VERSION AR199396.1 GI:20249470  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Drazen,J.M., In,K.-H., Asano,K., Beier,D. and Grobholz,J.  
 TITLE 5-Lipoxygenase gene polymorphisms and their use in classifying  
 patients  
 JOURNAL Patent: US 6355434-A 17 12-MAR-2002;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 1.7%; Score 15; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 ACGCTGGAAGTCGTT 497  
 | | | | | | | | | | | | | | | | | | | | |  
 Db 3 ACGCTGGAAGTCGTT 17

RESULT 94  
 BD195707/c  
 LOCUS BD195707 19 bp DNA linear PAT 17-JUL-2003  
 DEFINITION In vivo use of recombinagenic oligonucleobases to correct genetic  
 lesions in hepatocytes.  
 ACCESSION BD195707  
 VERSION BD195707.1 GI:33005477  
 KEYWORDS JP 2002511851-A/5.  
 SOURCE unidentified  
 ORGANISM unidentified  
 unclassified.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Of,R.O.T.U., Steer,C.J., Kren,B.T. and Opadhyay,P.T.B.  
 TITLE In vivo use of recombinagenic oligonucleobases to correct genetic  
 lesions in hepatocytes  
 JOURNAL Patent: JP 2002511851-A 5 16-APR-2002;  
 REGENTS OF THE UNIVERSITY OF MINNESOTA, CLIFFORD J STEER, BETSY T  
 KREN, PARAMITA T BANDY OPADHYAY  
 COMMENT OS Unidentified  
 PN JP 2002511851-A/5  
 PD 16-APR-2002 JP 1998547429  
 PF 30-APR-1998 JP 1998547429  
 PR 30-APR-1997 US 60/045288,05-AUG-1997 US 60/054837 PR  
 10-NOV-1997 US 60/064996  
 PI REGENTS OF THE UNIVERSITY OF MINNESOTA, CLIFFORD J STEER, BETSY  
 T KREN,  
 PI PARAMITA T BANDY OPADHYAY  
 PC Cl2Q1/68,A61K48/00,C07H21/04  
 CC Strandedness: Single;  
 CC Topology: Linear;  
 CC In vivo use of recombinagenic oligonucleobases to correct  
 genetic lesions  
 CC in hepatocytes  
 FH key Location/Qualifiers  
 FT source 1..19  
 /organism='Unidentified'.  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.5e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGCTGGC 54  
 | | | | | | | | | | | | | | | | | | | | |  
 Db 19 CCAGGACCTCGCGGAGGC 2

RESULT 95  
 AR282800/c  
 LOCUS AR282800 19 bp DNA linear PAT 10-APR-2003  
 DEFINITION Sequence 31 from patent US 6524613.  
 ACCESSION AR282800  
 VERSION AR282800.1 GI:29719584  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Steer,C.J., Kren,B.T., Bandyopadhyay,P. and Roy-Chowdhury,J.

```

TITLE      Hepatocellular chimeraplasty
JOURNAL    Patent: US 6524613-A 31 25-FEB-2003;
FEATURES   Location/Qualifiers
           source
           1..19
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      1.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  37  CCAGGACCTCGGCGTGGC 54
      |||||
Db   19  CCAGGACCTGGCGGAGGC 2

RESULT 96
AX129356/c
LOCUS      AX129356              19 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 574 from Patent WO0130362.
ACCESSION  AX129356
VERSION     AX129356.1 GI:14135661
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Robbins,J.M. and Tritz,R.
TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
          diseases
JOURNAL   Patent: WO 0130362-A 574 03-MAY-2001;
          IMMUSOL, INC. (US)
FEATURES   Location/Qualifiers
           source
           1..19
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"
           /note="Cdk6 ribozyme binding site"

Query Match      1.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  452  GGTGGAAATGAAGAAAGT 469
      |||||
Db   19  GGTGTGAATCAAGAAAGT 2

RESULT 97
AX16196/c
LOCUS      AX16196              17 bp      DNA      linear      PAT 14-JUN-1994
DEFINITION Oligonucleotide primer pair 2, second.
ACCESSION  AX16196
VERSION     AX16196.1 GI:583046
KEYWORDS   .
SOURCE     synthetic construct
            other sequences; artificial sequences.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Rossau,Rudi. and Van Heuverswijn,Hugo.
TITLE     Hybridization probes derived from the spacer region between the 16S
          and 23S rRNA genes for the detection of non-viral microorganisms
JOURNAL   Patent: EP 0452596-A 4 23-OCT-1991;
          N.V. INNOGENETICS S.A.
FEATURES   Location/Qualifiers
           source
           1..17
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  67  GCGGACGAAGGCGCGTG 82
      |||||
Db   16  GCGGACGAAGGCGCGTG 1

RESULT 98
AX16242/c
LOCUS      AX16242              17 bp      DNA      linear      PAT 14-JUN-1994
DEFINITION Oligonucleotide primer AP23.
ACCESSION  AX16242
VERSION     AX16242.1 GI:583092
KEYWORDS   .
SOURCE     synthetic construct
            other sequences; artificial sequences.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Rossau,Rudi. and Van Heuverswijn,Hugo.
TITLE     Hybridization probes derived from the spacer region between the 16S
          and 23S rRNA genes for the detection of non-viral microorganisms
JOURNAL   Patent: EP 0452596-A 50 23-OCT-1991;
          N.V. INNOGENETICS S.A.
FEATURES   Location/Qualifiers
           source
           1..17
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"

Query Match      1.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  67  GCGGACGAAGGCGCGTG 82
      |||||
Db   16  GCGGACGAAGGCGCGTG 1

RESULT 99
BD203207/c
LOCUS      BD203207              17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
          molecule participating in vasculogenic response.
ACCESSION  BD203207
VERSION     BD203207.1 GI:33012977
KEYWORDS   JP 2002509721-A/6233.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE     Method and reagent for treating diseases or conditions concerning
          molecule participating in vasculogenic response
JOURNAL   Patent: JP 2002509721-A 6233 02-APR-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Homo sapiens (human)
           EN JP 2002509721-A/6233
           PD 02-APR-2002
           PF 24-MAR-1999 JP 2000541291
           PR 27-MAR-1998 US 60/079678
           PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
           PI JAMES A MCSWIGGEN
           PC
           C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
           A61P29/00,
           PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
           C12N5/00
           CC Method and reagent for treating diseases or conditions CC
           concerning molecule
           CC participating in vasculogenic response
           FH Key
           FT source
           1..17

```

```
FT          Location/Qualifiers
source      1..17
            /organism='Homo sapiens (human)'
            /organism='Homo sapiens'
            /mol_type='genomic RNA'
            /db_xref='taxon:9606'

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 676 AGAACTGATTATGA 691
Db      |||||
16 AGAAACTGATTCTGA 1

RESULT 100
BD255579/c
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD255579
VERSION     BD255579.1 GI:33065349
KEYWORDS   JP 2002541795-A/3372.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 3372 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
          PN JP 2002541795-A/3372
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
          C12R1:91),
          PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC A61K37/02,
          PC (C12N5/00,C12R1:91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key Location/Qualifiers
          FT source 1..17
          FT /organism='Eukaryote'.

FEATURES
source      1..17
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 AATGAAGAAAGTACAA 473
Db      |||||
16 AATGAAGAAATACAA 1

RESULT 102
BD257636
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD257636
VERSION     BD257636.1 GI:33067406
KEYWORDS   JP 2002541795-A/5429.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 5429 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
          PN JP 2002541795-A/5429
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
          C12R1:91),
          PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC A61K37/02,
          PC (C12N5/00,C12R1:91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key Location/Qualifiers
          FT source 1..17
          FT /organism='Eukaryote'.

FEATURES
source      1..17
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 461 GAAGAAAGTACAAGA 476
Db      |||||
17 GAAGAAATACAAGA 2

RESULT 101
BD255582/c
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD255582
VERSION     BD255582.1 GI:33065352
KEYWORDS   JP 2002541795-A/3375.
SOURCE     unidentified
ORGANISM   unclassified
```

```
unclassified.
1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 3375 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
          PN JP 2002541795-A/3375
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
          C12R1:91),
          PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC A61K37/02,
          PC (C12N5/00,C12R1:91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key Location/Qualifiers
          FT source 1..17
          FT /organism='Eukaryote'.

FEATURES
source      1..17
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 AATGAAGAAAGTACAA 473
Db      |||||
16 AATGAAGAAATACAA 1

RESULT 102
BD257636
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD257636
VERSION     BD257636.1 GI:33067406
KEYWORDS   JP 2002541795-A/5429.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 5429 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
          PN JP 2002541795-A/5429
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
          C12R1:91),
          PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC A61K37/02,
          PC (C12N5/00,C12R1:91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key Location/Qualifiers
          FT source 1..17
          FT /organism='Eukaryote'.

FEATURES
source      1..17
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 AATGAAGAAAGTACAA 473
Db      |||||
16 AATGAAGAAATACAA 1

RESULT 102
BD257636
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD257636
VERSION     BD257636.1 GI:33067406
KEYWORDS   JP 2002541795-A/5429.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE     Regulation of repressor genes using nucleic acid molecules
JOURNAL   Patent: JP 2002541795-A 5429 10-DEC-2002;
          RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
          PN JP 2002541795-A/5429
          PD 10-DEC-2002
          PF 11-APR-2000 JP 2000611654
          PR 12-APR-1999 US 60/129390
          PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
          C12R1:91),
          PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC A61K37/02,
          PC (C12N5/00,C12R1:91)
          CC Regulation of repressor genes using nucleic acid molecules FH
          Key Location/Qualifiers
          FT source 1..17
          FT /organism='Eukaryote'.

FEATURES
source      1..17
            /organism='unidentified'
            /mol_type='genomic DNA'
            /db_xref='taxon:32644'
```

```
source 1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 AGGAAAGTAATGGACC 150
|||||
Db 1 AGGAAACTAATGGACC 16

RESULT 103
123680/c
LOCUS 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 102 from patent US 5536638.
ACCESSION 123680
VERSION 123680.1 GI:1603550
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rossau,R. and Van Heuverswyn,H.
TITLE Hybridization probes derived from the spacer region between the 16S
and 23S rRNA genes for the detection of Neisseria gonorrhoeae
JOURNAL Patent: US 5536638-A 102 16-JUL-1996;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82
|||||
Db 16 GCGACGAGGCGGTG 1

RESULT 104
123682/c
LOCUS 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 104 from patent US 5536638.
ACCESSION 123682
VERSION 123682.1 GI:1603552
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rossau,R. and Van Heuverswyn,H.
TITLE Hybridization probes derived from the spacer region between the 16S
and 23S rRNA genes for the detection of Neisseria gonorrhoeae
JOURNAL Patent: US 5536638-A 104 16-JUL-1996;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82
|||||
Db 16 GCGACGAGGCGGTG 1

RESULT 105
123682/c
LOCUS 17 bp DNA linear PAT 07-SEP-2001
DEFINITION Sequence 2234 from Patent WO0159103.
ACCESSION AX216792
VERSION AX216792.1 GI:15526853
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2234 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
```

---

```
AR433547/c
LOCUS 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 102 from patent US 6656689.
ACCESSION AR433547
VERSION AR433547.1 GI:40196383
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rossau,R. and Van Heuverswyn,H.
TITLE Hybridization probes derived from the spacer region between the 16S
and 23S rRNA genes for the detection of non-viral microorganisms
JOURNAL Patent: US 6656689-A 102 02-DEC-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82
|||||
Db 16 GCGACGAGGCGGTG 1

RESULT 106
AR433549/c
LOCUS 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 104 from patent US 6656689.
ACCESSION AR433549
VERSION AR433549.1 GI:40196385
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rossau,R. and Van Heuverswyn,H.
TITLE Hybridization probes derived from the spacer region between the 16S
and 23S rRNA genes for the detection of non-viral microorganisms
JOURNAL Patent: US 6656689-A 104 02-DEC-2003;
FEATURES
source Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.6%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82
|||||
Db 16 GCGACGAGGCGGTG 1

RESULT 107
AX216792/c
LOCUS 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2234 from Patent WO0159103.
ACCESSION AX216792
VERSION AX216792.1 GI:15526853
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2234 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
```

```

McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
  source
    1..17
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Nucleic Acid"

Query Match
  1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 857 TTAAGAAGATCCAAAT 872
Db 17 TTAAGAAGATCCAAAT 2

RESULT 108
AX216884
LOCUS AX216884 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2326 from Patent WO0159103.
ACCESSION AX216884
VERSION AX216884.1 GI:15526945
KEYWORDS
  .
SOURCE synthetic construct
  ORGANISM synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
  Blatt, L., McSwiggen, J. and Chowrira, B.M.
  Method and reagent for the modulation and diagnosis of cd20 and
  nogo gene expression
  Patent: WO 0159103-A 2326 16-AUG-2001;
  RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
  McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
  source
    1..17
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Nucleic Acid"

Query Match
  1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 822 AATAAAACCCGTAT 837
Db 1 AATAAAACCCGTAT 16

RESULT 109
AX701183/c
LOCUS AX701183 17 bp DNA linear PAT 03-APR-2003
DEFINITION Sequence 19 from Patent WO03012097.
ACCESSION AX701183
VERSION AX701183.1 GI:29536953
KEYWORDS
  .
SOURCE synthetic construct
  ORGANISM synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
  Price, G.B. and Zannis-Hadjopoulos, M.
  Methods of inhibiting dna replication
  Patent: WO 03012097-A 19 13-FEB-2003;
  Price, Gerald B. (CA) ; Zannis-Hadjopoulos, Maria (CA)
FEATURES
  source
    1..17
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="Synthetic oligonucleotide"

Query Match
  1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 822 AATAAAACCCGTAT 837
Db 1 AATAAAACCCGTAT 16

RESULT 110
AX706656/c
LOCUS AX706656 17 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 353 from Patent WO03013534.
ACCESSION AX706656
VERSION AX706656.1 GI:29563079
KEYWORDS
  .
SOURCE Homo sapiens (human)
  ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  Heinrich, G. and Kerb, R.
  Methods for the treatment of cancer with irinotecan based on CYP3A5
  Patent: WO 03013534-A 353 20-FEB-2003;
  Epidauros Biotechnologie AG (DE)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
Db 16 GCAATGTGACTGCTGA 1

RESULT 111
AX706657
LOCUS AX706657 17 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 354 from Patent WO03013534.
ACCESSION AX706657
VERSION AX706657.1 GI:29563080
KEYWORDS
  .
SOURCE Homo sapiens (human)
  ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Heinrich, G. and Kerb, R.
  Methods for the treatment of cancer with irinotecan based on CYP3A5
  Patent: WO 03013534-A 354 20-FEB-2003;
  Epidauros Biotechnologie AG (DE)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
Db 16 GCAATGTGACTGCTGA 1

RESULT 112
AX707586/c
LOCUS AX707586 17 bp DNA linear PAT 04-APR-2003

```

```

DEFINITION Sequence 353 from Patent WO03013536.
ACCESSION AX707586
VERSION AX707586.1 GI:29563759
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Heinrich, G. and Korb, R.
TITLE Methods for treatment of cancer using irinotecan based on UG1A1
JOURNAL Patent: WO 03013536-A 353 20-FEB-2003;
Epidaurus Biotechnologie AG (DE)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTAAGTCTGA 336
DB 16 GCAATGTAAGTCTGA 1

RESULT 113
AX707587
LOCUS AX707587 17 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 354 from Patent WO03013536.
ACCESSION AX707587
VERSION AX707587.1 GI:29563760
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Heinrich, G. and Korb, R.
TITLE Methods for treatment of cancer using irinotecan based on UG1A1
JOURNAL Patent: WO 03013536-A 354 20-FEB-2003;
Epidaurus Biotechnologie AG (DE)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTAAGTCTGA 336
DB 2 GCAATGTAAGTCTGA 17

RESULT 114
AX731809
LOCUS AX731809 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3443 from Patent WO03025175.
ACCESSION AX731809
VERSION AX731809.1 GI:30511152
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3443 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTAAGTCTGA 336
DB 2 GCAATGTAAGTCTGA 17

RESULT 115
AX733720
LOCUS AX733720 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5354 from Patent WO03025175.
ACCESSION AX733720
VERSION AX733720.1 GI:30513063
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5354 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTGTAAAT 635
DB 2 ATCTTAAAGTGTAT 17

RESULT 116
AX735175
LOCUS AX735175 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 765 from Patent WO03025177.
ACCESSION AX735175
VERSION AX735175.1 GI:30514452
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 765 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"

```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 ATCCTCTATCCAGAAA 276
Db 2 ATCCTATATCCAGAAA 17

RESULT 117
LOCUS AX7611994 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5315 from Patent WO03040369.
ACCESSION AX7611994
VERSION AX7611994.1 GI:32256610
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Molecular Engines Laboratories (FR)
PATENT: WO 03040369-A 5315 15-MAY-2003;
FEATURES
source
1..17
Location/Qualifiers
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTGTAT 635
Db 2 ATCTTAAAGTGTAT 17

RESULT 118
LOCUS CO784352/c 18 bp DNA linear PAT 17-MAR-2004
DEFINITION Sequence 8 from Patent WO2004016317.
ACCESSION CO784352
VERSION CO784352.1 GI:45538840
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Touw,I.P., Delwel,H.R., Lowenberg,B. and Valk,P.J.
TITLE Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
JOURNAL Patent: WO 2004016317-A 8 26-FEB-2004;
Erasmus University Medical Center Rotterdam (NL)
FEATURES
source
1..18
Location/Qualifiers
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer pUTR3"

Query Match      1.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 444 TGGGCAAGGTGGAAA 459
Db 19 TGGGCACGGTGGAAA 4

RESULT 120
LOCUS AX130329/c 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 1547 from Patent WO0130362.
ACCESSION AX130329
VERSION AX130329.1 GI:14136634
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 1547 03-MAY-2001;
IMMOSOL, INC. (US)
FEATURES
source
1..19
Location/Qualifiers
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 TCACCTCTCAGGAGACC 395
Db 16 TCACCTCTGAGGAGACC 1

RESULT 119
LOCUS E31531/c 19 bp DNA linear PAT 18-JUN-2001
DEFINITION Novel protein and DNA thereof.
ACCESSION E31531
VERSION E31531.1 GI:13021563
KEYWORDS JP 1999266870-A/13.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 19)
AUTHORS Yusuke,N. and Mayumi,T.
TITLE Novel protein and DNA thereof
JOURNAL Patent: JP 1999266870-A 13 05-OCT-1999;
YUSUKE NAKAMURA,TAKEDA CHEM IND LTD
COMMENT OS Unidentified
PN JP 1999266870-A/13
PD 05-OCT-1999
PF 25-MAR-1998 JP 1998078127
PR
PI YUSUKE NAKAMURA,MAYUMI TAMARI
PC C12N15/09,A61K38/45,A61K48/00,C07K16/40,C12N1/21,C12N9/12, PC C12Q1/48,
PC G01N33/53//A01K67/027,(C12N1/21,C12R1:19),(C12N9/12,C12R1:19),
PC C12N15/00,
PC A61K37/52
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..19
FT /organism='Unidentified'.
FT Location/Qualifiers
1..19
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match      1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 444 TGGGCAAGGTGGAAA 459
Db 19 TGGGCACGGTGGAAA 4

RESULT 120
LOCUS AX130329/c 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 1547 from Patent WO0130362.
ACCESSION AX130329
VERSION AX130329.1 GI:14136634
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 1547 03-MAY-2001;
IMMOSOL, INC. (US)
FEATURES
source
1..19
Location/Qualifiers
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
```







COMMENT  
RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
FN JP 2002541795-A/4926  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
FT /organism='Eukaryote'.

FEATURES  
source Location/Qualifiers  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 1..6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 776 GATGGGTATTAACTTGT 792  
|||||  
Db 1 GATGGGTATTAAACATG 17

RESULT 131  
BD257134  
LOCUS 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Regulation of repressor genes using nucleic acid molecules.  
ACCESSION BD257134  
VERSION BD257134.1 GI:33066904  
KEYWORDS JP 2002541795-A/4927.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 4927 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC

COMMENT  
OS Eukaryote  
FN JP 2002541795-A/4927  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
FT /organism='Eukaryote'.

FEATURES  
source Location/Qualifiers  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 1..6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 777 ATGGGTATTAAACTTGT 793  
|||||  
Db 1 ATGGGTATTAAACATGT 17

## RESULT 132

BD257135  
LOCUS 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Regulation of repressor genes using nucleic acid molecules.  
ACCESSION BD257135  
VERSION BD257135.1 GI:33066905  
KEYWORDS JP 2002541795-A/4928.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 4928 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC

COMMENT  
OS Eukaryote  
FN JP 2002541795-A/4928  
PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PR 12-APR-1999 US 60/129390  
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
FT /organism='Eukaryote'.

FEATURES  
source Location/Qualifiers  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 1..6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 778 TGGGTATTAACTTGT 794  
|||||  
Db 1 TGGGTATTAAACATGTC 17

## RESULT 133

CO624220  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 8960 from Patent WO0192524.  
ACCESSION CO624220  
VERSION CO624220.1 GI:41674438  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8960 06-DEC-2001;

```

      Aecomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCGCTGCATGGA 199
Db 1 CTGAAGGCGCGACATGGA 17

RESULT 134
LOCUS I06874 17 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 5 from Patent EP 0340805.
ACCESSION I06874
VERSION I06874.1 GI:589851
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Halliwell,R.A. and Mullenbach,G.T.
TITLE Superoxide dismutase and expression in microorganisms
JOURNAL Patent: EP 0340805-A1 5 08-NOV-1989;
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 GACCATTCATCATCTGG 408
Db 17 GACCACTGCATCATCTGG 1

RESULT 135
LOCUS AR190462/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5950 from patent US 6346398.
ACCESSION AR190462
VERSION AR190462.1 GI:20236427
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5950 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 TGTAGTCTGAGGCCCT 559
Db 17 TGCAGTCTGAGGTCCCT 1

      Aecomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCGCTGCATGGA 199
Db 1 CTGAAGGCGCGACATGGA 17

RESULT 136
LOCUS AR325385/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2787 from patent US 6566127.
ACCESSION AR325385
VERSION AR325385.1 GI:33711193
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2787 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="unknown"
                    /mol_type="unassigned RNA"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 TGTAGTCTGAGGCCCT 559
Db 17 TGCAGTCTGAGGTCCCT 1

      Aecomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 GACCATTCATCATCTGG 408
Db 17 GACCACTGCATCATCTGG 1

RESULT 137
LOCUS AR327698 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5100 from patent US 6566127.
ACCESSION AR327698
VERSION AR327698.1 GI:33713506
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5100 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1..17
                    /organism="unknown"
                    /mol_type="unassigned RNA"

     Query Match     1.6%; Score 13.8; DB 1; Length 17;
     Best Local Similarity 88.2%; Pred. No. 1.7e+02;
     Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 ACCAGTGCAGTCTCTCA 255
Db 17 ATCAGTGCAGTCTCTCA 1

RESULT 138
LOCUS AR329394 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6796 from patent US 6566127.
ACCESSION AR329394
VERSION AR329394.1 GI:33715202
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6796 20-MAY-2003;
```

```

FEATURES             Location/Qualifiers
     source
     1..17
/mol_type="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 642 ACTTTTCAGAGTGTCT 658
|| ||||| |||||
Db 1 ACCTTTTCAGAGTGTCT 17

RESULT 139
AR465283
LOCUS             17 bp DNA linear PAT 20-FEB-2004
DEFINITION       Sequence 8960 from patent US 6686188.
ACCESSION        AR465283
VERSION          AR465283.1 GI:42700340
KEYWORDS
SOURCE           Unknown.
ORGANISM         Unknown.
REFERENCE        1 (bases 1 to 17)
AUTHORS         Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE           Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL          Patent: US 6686188-A 8960 03-FEB-2004;
FEATURES
     source
     1..17
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCGCTGCATGGA 199
||||||| |||||
Db 1 CTGAAGGCGCGACATGGA 17

RESULT 140
AX081872/c
LOCUS             17 bp DNA linear PAT 27-FEB-2001
DEFINITION       Sequence 116 from Patent WO0109183.
ACCESSION        AX081872
VERSION          AX081872.1 GI:13170679
KEYWORDS
SOURCE           synthetic construct
ORGANISM         other sequences; artificial sequences.
REFERENCE        1
AUTHORS         Brinkmann, U., Hoffmeyer, S., Eichelbaum, M. and Roots, I.
TITLE           Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
JOURNAL          Patent: WO 0109183-A 116 08-FEB-2001;
EPIDAUROS AG Biotechnologie Aktiengesellschaft (DE)
FEATURES
     source
     1..17
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="synthetic"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 319 GCGCATGTGACTGTGCTG 335
| ||||| |||||

FEATURES             Location/Qualifiers
     source
     1..17
/mol_type="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 AGAAACTGATTTATGAT 692
||||||| |||||
Db 1 AGATACTCATTTATGAT 17

RESULT 141
AX215655/c
LOCUS             17 bp RNA linear PAT 07-SEP-2001
DEFINITION       Sequence 1097 from Patent WO0159103.
ACCESSION        AX215655
VERSION          AX215655.1 GI:15525698
KEYWORDS
SOURCE           synthetic construct
ORGANISM         other sequences; artificial sequences.
REFERENCE        1
AUTHORS         Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE           Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL          Patent: WO 0159103-A 1097 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
     Location/Qualifiers
     1..17
/mol_type="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Nucleic Acid"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 730 AAAATGCTGTGTTTCAAT 746
||||||| |||||
Db 17 AAAATGTTTGTGCAAT 1

RESULT 142
AX265751
LOCUS             17 bp DNA linear PAT 26-OCT-2001
DEFINITION       Sequence 3142 from Patent WO0173002.
ACCESSION        AX265751
VERSION          AX265751.1 GI:16514550
KEYWORDS
SOURCE           Homo sapiens (human)
ORGANISM         Homo sapiens
REFERENCE        1
AUTHORS         Knies, E.B., Gamper, H.B. and Rice, M.C.
TITLE           Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL          Patent: WO 0173002-A 3142 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
     Location/Qualifiers
     1..17
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 AGAAACTGATTTATGAT 692
||||||| |||||
Db 1 AGATACTCATTTATGAT 17

RESULT 143
AX265752/c
LOCUS             17 bp DNA linear PAT 26-OCT-2001
DEFINITION       Sequence 3143 from Patent WO0173002.
ACCESSION        AX265752
VERSION          AX265752

```

JOURNAL	Patent: WO 03050284-A 563 19-JUN-2003;					
FEATURES	Amer sham Biosci ences (SV) Corp. (US)					
source	1. .17 Location/Qualifiers					
	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"					
Query Match	1.6%; Score 13.8; DB 1; Length 17;					
Best Local Similarity	88.2%; Pred. No. 1.7e+02;					
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	635 TTCTGTGACTTTTTCAG 651 					
Db	17 TTCTGAGACTTTTTCAG 1 					
RESULT 146	PAT 17-DEC-2001					
ARL175662/c						
LOCUS	ARL175662 18 bp DNA linear					
DEFINITION	Sequence 62 from patent US 6309853.					
ACCESSION	ARL175662					
VERSION	ARL175662.1 GI:17916961					
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 18)					
AUTHORS	Friedman,J.M., Zhang,Y. and Proenca,R.					
TITLE	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof					
JOURNAL	Patent: US 6309853-A 62 30-OCT-2001;					
FEATURES	Location/Qualifiers					
source	1. .18 /organism="unknown" /mol_type="unassigned DNA"					
Query Match	1.6%; Score 13.8; DB 1; Length 18;					
Best Local Similarity	88.2%; Pred. No. 1.8e+02;					
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	452 GGTTGGAAATGAAGAAG 468 					
Db	18 GGTTGGAAATGTAGATC 2 					
RESULT 147	PAT 06-FEB-1997					
I30650/c						
LOCUS	I30650 18 bp DNA linear					
DEFINITION	Sequence 88 from patent US 5580971.					
ACCESSION	I30650					
VERSION	I30650.1 GI:1821441					
KEYWORDS						
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	Unclassified.					
AUTHORS	1 (bases 1 to 18)					
TITLE	Mitsuhashi,M.					
JOURNAL	Fungal detection system based on rRNA probes					
FEATURES	Patent: US 5580971-A 88 03-DEC-1996; Location/Qualifiers					
source	1. .18 /organism="unknown" /mol_type="unassigned DNA"					
Query Match	1.6%; Score 13.8; DB 1; Length 18;					
Best Local Similarity	88.2%; Pred. No. 1.8e+02;					
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	432 AAGCAGATGACTTGCGC 448 					
Db	17 AAGCTGATGACTTGCGC 1 					

```
RESULT 148
I30651/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 89 from patent US 5580971.
ACCESSION  I30651
VERSION     I30651.1  GI:1821442
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 89 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 89 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

RESULT 149
I30652/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 90 from patent US 5580971.
ACCESSION  I30652
VERSION     I30652.1  GI:1821443
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 90 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

RESULT 150
I30653/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 91 from patent US 5580971.
ACCESSION  I30653
VERSION     I30653.1  GI:1821444
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 91 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1
```

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

RESULT 151
I30654/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 92 from patent US 5580971.
ACCESSION  I30654
VERSION     I30654.1  GI:1821445
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 92 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

RESULT 152
I30655/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 93 from patent US 5580971.
ACCESSION  I30655
VERSION     I30655.1  GI:1821446
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Mitsuhashi,M.
TITLE     Fungal detection system based on rRNA probes
JOURNAL   Patent: US 5580971-A 93 03-DEC-1996;
FEATURES   Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AACGAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGGC 1

RESULT 153
I30656/c
LOCUS      18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 94 from patent US 5580971.
ACCESSION  I30656
```

```
VERSION      I30656.1  GI:1821447
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Mitsuhashi,M.
TITLE        Fungal detection system based on rRNA probes
JOURNAL      Patent: US 5580971-A 94 03-DEC-1996;
FEATURES     Location/Qualifiers
              source
              1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AAGCAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGC 1

RESULT 154
I30657/c
LOCUS      I30657
DEFINITION Sequence 95 from patent US 5580971.
ACCESSION  I30657
VERSION     I30657.1  GI:1821448
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Mitsuhashi,M.
TITLE       Fungal detection system based on rRNA probes
JOURNAL     Patent: US 5580971-A 95 03-DEC-1996;
FEATURES    Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AAGCAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGC 1

RESULT 155
I30658/c
LOCUS      I30658
DEFINITION Sequence 96 from patent US 5580971.
ACCESSION  I30658
VERSION     I30658.1  GI:1821449
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Mitsuhashi,M.
TITLE       Fungal detection system based on rRNA probes
JOURNAL     Patent: US 5580971-A 96 03-DEC-1996;
FEATURES    Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AAGCAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGC 1

RESULT 156
I30659/c
LOCUS      I30659
DEFINITION Sequence 97 from patent US 5580971.
ACCESSION  I30659
VERSION     I30659.1  GI:1821450
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Mitsuhashi,M.
TITLE       Fungal detection system based on rRNA probes
JOURNAL     Patent: US 5580971-A 97 03-DEC-1996;
FEATURES    Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AAGCAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGC 1

RESULT 157
I30660/c
LOCUS      I30660
DEFINITION Sequence 98 from patent US 5580971.
ACCESSION  I30660
VERSION     I30660.1  GI:1821451
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Mitsuhashi,M.
TITLE       Fungal detection system based on rRNA probes
JOURNAL     Patent: US 5580971-A 98 03-DEC-1996;
FEATURES    Location/Qualifiers
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      432 AAGCAGATGACTTGGGC 448
Db      17 AAGCTGATGACTTGGC 1

RESULT 158
I30661/c
LOCUS      I30661
DEFINITION Sequence 99 from patent US 5580971.
ACCESSION  I30661
VERSION     I30661.1  GI:1821452
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
```



```
AUTHORS Mitsuhashi,M.
TITLE Fungal detection system based on rRNA probes
JOURNAL Patent: US 5580971-A 99 03-DEC-1996;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGGC 1

RESULT 159
I30662/c
LOCUS 130662 18 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 100 from patent US 5580971.
ACCESSION I30662
VERSION I30662.1 GI:1821453
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M.
TITLE Fungal detection system based on rRNA probes
JOURNAL Patent: US 5580971-A 100 03-DEC-1996;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGGC 1

RESULT 160
I46109/c
LOCUS 146109 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 88 from patent US 5639612.
ACCESSION I46109
VERSION I46109.1 GI:2470074
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 88 17-JUN-1997;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGGC 1

RESULT 161
I46110/c
LOCUS 146110 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 89 from patent US 5639612.
ACCESSION I46110
VERSION I46110.1 GI:2470075
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 89 17-JUN-1997;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGGC 1

RESULT 162
I46111/c
LOCUS 146111 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 90 from patent US 5639612.
ACCESSION I46111
VERSION I46111.1 GI:2470076
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 90 17-JUN-1997;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGGC 1

RESULT 163
I46112/c
LOCUS 146112 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 91 from patent US 5639612.
ACCESSION I46112
VERSION I46112.1 GI:2470077
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
```

```
JOURNAL Patent: US 5639612-A 91 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 164
I46113/c
LOCUS I46113 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 92 from patent US 5639612.
ACCESSION I46113
VERSION I46113.1 GI:2470078
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 92 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 165
I46114/c
LOCUS I46114 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 93 from patent US 5639612.
ACCESSION I46114
VERSION I46114.1 GI:2470079
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 93 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

JOURNAL Patent: US 5639612-A 91 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 166
I46115/c
LOCUS I46115 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 94 from patent US 5639612.
ACCESSION I46115
VERSION I46115.1 GI:2470080
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 94 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 167
I46116/c
LOCUS I46116 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 95 from patent US 5639612.
ACCESSION I46116
VERSION I46116.1 GI:2470081
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 95 17-JUN-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
||||| ||||| ||||| ||||| |||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 168
I46117/c
LOCUS I46117 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 96 from patent US 5639612.
ACCESSION I46117
VERSION I46117.1 GI:2470082
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Mitsuhashi,M. and Cooper,A.
TITLE Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL Patent: US 5639612-A 96 17-JUN-1997;
```

FEATURES  
source Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 169  
I46118/c  
LOCUS I46118 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 97 from patent US 5639612.  
ACCESSION I46118  
VERSION I46118.1 GI:2470083  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 97 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 170  
I46119/c  
LOCUS I46119 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 98 from patent US 5639612.  
ACCESSION I46119  
VERSION I46119.1 GI:2470084  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 98 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 171  
I46121/c  
LOCUS I46121 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 100 from patent US 5639612.  
ACCESSION I46121  
VERSION I46121.1 GI:2470086  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 100 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 172  
I46121/c  
LOCUS I46121 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 100 from patent US 5639612.  
ACCESSION I46121  
VERSION I46121.1 GI:2470086  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 100 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 173  
AR195238/c  
LOCUS AR195238 18 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 62 from patent US 6350730.  
ACCESSION AR195238  
VERSION AR195238.1 GI:20244675  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.  
TITLE OB polypeptides and modified forms as modulators of body weight  
JOURNAL Patent: US 6350730-A 62 26-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

I46120/c  
LOCUS I46120 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 99 from patent US 5639612.  
ACCESSION I46120  
VERSION I46120.1 GI:2470085  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 99 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 172  
I46121/c  
LOCUS I46121 18 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 100 from patent US 5639612.  
ACCESSION I46121  
VERSION I46121.1 GI:2470086  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Mitsuhashi,M. and Cooper,A.  
TITLE Method for detecting polynucleotides with immobilized polynucleotide probes identified based on T.sub.m  
JOURNAL Patent: US 5639612-A 100 17-JUN-1997;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 173  
AR195238/c  
LOCUS AR195238 18 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 62 from patent US 6350730.  
ACCESSION AR195238  
VERSION AR195238.1 GI:20244675  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Friedman,J.M., Zhang,Y. and Proenca,R.  
TITLE OB polypeptides and modified forms as modulators of body weight  
JOURNAL Patent: US 6350730-A 62 26-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAAATGAAGAAG 468
DB 18 GGTGGAAATGTAGATG 2

RESULT 174
AX003146/c
LOCUS      18 bp      DNA      linear      PAT 26-SEP-2002
DEFINITION Sequence 62 from patent US 6429290.
ACCESSION  AR222320
VERSION     AR222320.1 GI:23329805
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Friedman,J.M., Zhang,Y. and Proenca,R.
TITLE     OB polypeptides, modified forms and derivatives
JOURNAL   Patent: US 6429290-A 62 06-AUG-2002;
FEATURES   Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAAATGAAGAAG 468
DB 18 GGTGGAAATGTAGATG 2

RESULT 175
AR241439/c
LOCUS      18 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 62 from patent US 6471956.
ACCESSION  AR241439
VERSION     AR241439.1 GI:27287129
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Friedman,J.M., Zhang,Y. and Proenca,R.
TITLE     Ob polypeptides, modified forms and compositions thereto
JOURNAL   Patent: US 6471956-A 62 29-OCT-2002;
FEATURES   Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAAATGAAGAAG 468
DB 18 GGTGGAAATGTAGATG 2

RESULT 176
AX003146/c
LOCUS      18 bp      DNA      linear      PAT 24-AUG-2000
DEFINITION Sequence 7 from Patent WO932659.
ACCESSION  AX003146

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAAATGAAGAAG 468
DB 18 GGTGGAAATGTAGATG 2

RESULT 177
AX003146/c
LOCUS      18 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 4190 from Patent WO0130362.
ACCESSION  AX132972
VERSION     AX132972.1 GI:14139282
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Robbins,J.M. and Tritz,R.
TITLE     Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL   Patent: WO 0130362-A 4190 03-MAY-2001;
FEATURES   Location/Qualifiers
            source
            1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            /note="Hammerhead ribozyme recognition site for cdc 2 kinase"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 22 TTGCAGTCCTCGGAACC 38
DB 18 TTGCAGTACTAGGAACC 2

RESULT 178
AX599241
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2003
DEFINITION Sequence 581 from Patent WO0207272.
ACCESSION  AX599241
VERSION     AX599241.1 GI:28399383
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAAATGAAGAAG 468
DB 18 GGTGGAAATGTAGATG 2

RESULT 179
AX003146/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2003
DEFINITION Sequence 581 from Patent WO0207272.
ACCESSION  AX599241
VERSION     AX599241.1 GI:28399383
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
```

```

Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
Felet,C. and Ziebart,H.
Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
Patent: WO 02077272-A 581 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
    source
        1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Detection oligonucleotide for RB1"
Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 487 TCGAAGTCGTTGGCTT 503
DB 2 TCGAAGCGTTGGATT 18
RESULT 179
AX767687
LOCUS AX767687 18 bp DNA linear PAT 02-JUL-2003
DEFINITION Sequence 335 from Patent WO03044226.
ACCESSION AX767687
VERSION AX767687.1 GI:32436292
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Burger,M., Caldwell,C., Genc,B., Becker,E., Maier,S. and
Nimmrich,I.
TITLE Method and nucleic acids for the analysis of a lymphoid cell
proliferative disorder
JOURNAL Patent: WO 03044226-A 335 30-MAY-2003;
Epigenomics AG (DE)
FEATURES
    source
        1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Detection oligonucleotide for RB1"
Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 487 TCGAAGTCGTTGGCTT 503
DB 2 TCGAAGCGTTGGATT 18
RESULT 180
AX796133
LOCUS AX796133 18 bp DNA linear PAT 04-OCT-2003
DEFINITION Sequence 476 from Patent WO03052135.
ACCESSION AX796133
VERSION AX796133.1 GI:37516799
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Burger,M., Field,J.K., Genc,B., Lloglou,T., Lipscher,E., Maier,S.
and Nimmrich,I.
TITLE Method and nucleic acids for the analysis of a lung cell
proliferative disorder
JOURNAL Patent: WO 03052135-A 476 26-JUN-2003;
Epigenomics AG (DE)
FEATURES
    Location/Qualifiers

```

```

    source
        1..18
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Detection oligonucleotide for RB1"
Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 487 TCGAAGTCGTTGGCTT 503
DB 2 TCGAAGCGTTGGATT 18
RESULT 181
BD014805/c
LOCUS BD014805 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Modulator of weight, corresponding nucleic acid and protein, and
diagnosis and remedy utilization thereof.
ACCESSION BD014805
VERSION BD014805.1 GI:22555612
KEYWORDS JP 2001157591-A/46.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Friedmann,J.M., Zhang,Y., Proenca,R., Maffei,M., Halaas,J.L.,
Kajiwarra,K. and Burley,S.K.
TITLE Modulator of weight, corresponding nucleic acid and protein, and
diagnosis and remedy utilization thereof
JOURNAL Patent: JP 2001157591-A 46 12-JUN-2001;
THE ROCKEFELLER UNIVERSITY
COMMENT
OS Homo sapiens (human)
PN JP 2001157591-A/46
PD 12-JUN-2001
PF 29-SEP-2000 JP 2000301496
PR 30-NOV-1994 US 08/347563,10-MAY-1995 US 08/438431 PR
07-JUN-1995 US 08/483211
PI JEFFRY M FRIEDMAN,YIYING ZHANG,RICARDO PROENCA,MARGHERITA PI
MAFFEI,
PI JEFFRY L HALAAS,KETAN KAJIWARA,STEPHEN K BURLEY PC
C12N15/09,A61K31/711,A61K38/00,A61K39/395,A61K45/00,A61K48/00, PC
A61P3/04,
PC A61P3/06,A61P3/10,A61P9/12,C07K14/47,C07K16/18,C12N1/19,C12N1/
21,C12N5/10.
PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68//C12N1/19,C12R1/72, PC
(C12N1/19,C12R1:85), (C12N1/19,C12R1:19), (C12N1/19,C12R1:07), PC
(C12N1/21,C12R1:465), (C12N1/21,C12R1:38), (C12N5/10,C12R1:91), PC
(C12P21/02,C12R1:19), C12N15/00,A61K37/02, C12N5/00,C12N5/00, PC
(C12N5/00,C12R1:91)
CC Strandedness: Single;
CC Topology: Linear;
CC PCR primer swss2588 specific in sequence tag site FH Key
CC Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
    source
        1..18
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
Query Match
Best Local Similarity 1.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 452 GGTGGAATGGAAGAAG 468
DB 18 GGTGGAATGTAAGATG 2
FEATURES
    Location/Qualifiers

```

```
RESULT 182
CQ821404
LOCUS CQ821404 15 bp DNA linear PAT 14-JUN-2004
DEFINITION Sequence 10 from Patent WO2004038019.
ACCESSION CQ821404
VERSION CQ821404.1 GI:48716053
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Beeson,D., Wood,M. and Abdelgany,A.
TITLE Dnazyme cleaving mutant polynucleotides
JOURNAL Patent: WO 2004038019-A 10 06-MAY-2004;
ISIS INNOVATION LIMITED (GB)
FEATURES
source
1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 95 GCGCAGCGCCCAAGTG 109
Db 1 GCGCAGCGCCCAAGTG 15
RESULT 183
CQ821409
LOCUS CQ821409 15 bp DNA linear PAT 14-JUN-2004
DEFINITION Sequence 15 from Patent WO2004038019.
ACCESSION CQ821409
VERSION CQ821409.1 GI:48716058
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Beeson,D., Wood,M. and Abdelgany,A.
TITLE Dnazyme cleaving mutant polynucleotides
JOURNAL Patent: WO 2004038019-A 15 06-MAY-2004;
ISIS INNOVATION LIMITED (GB)
FEATURES
source
1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 437 GATGACTCGGCCAAA 451
Db 1 GATGACTCGGCCAAA 15
RESULT 184
BD178695/c
LOCUS BD178695/c 16 bp DNA linear PAT 16-APR-2003
DEFINITION Gene panel for genes involving liver regeneration.
ACCESSION BD178695
VERSION BD178695.1 GI:30015962
KEYWORDS WO 02077222-A/33.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 16)
REFERENCE
```

```
AUTHORS Yokoya,F., Okutsu,T., Mori,M., Yoshiyuki, Takahara, Fukuda,H.,
Aburatani,H. and Sonaka,I.
TITLE Gene panel for genes involving liver regeneration
JOURNAL Patent: WO 02077222-A 33 03-OCT-2002;
AJINOMOTO CO INC,FUMIHIKO YOKOYA,TOMOHIISA OKUTSU,MAIKO MORI,
YOSHIYUKI TAKAHARA,HISAO FUKUDA,HIROYUKI ABURATANI,ICHIRO SONAKA
OS Artificial Sequence
PN WO 02077222-A/33
PD 03-OCT-2002
PF 13-MAR-2002 WO 2002JP002372
PR 13-MAR-2001 JP 01P 070940
PI FUMIHIKO YOKOYA,TOMOHIISA OKUTSU,MAIKO MORI,YOSHIYUKI PI
TAKAHARA,HISAO FUKUDA,
PI HIROYUKI ABURATANI,ICHIRO SONAKA
PC GI2N15/09,GI2Q1/68,GI0N33/15,GI0N33/50,GI0N37/00 CC
Description of Artificial Sequence: primer
FH Key Location/Qualifiers
FT source
1..16
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 310 TGGACACTTGGGCAA 324
Db 15 TGGACACTTGGGCAA 1
RESULT 185
AR328540/c
LOCUS AR328540 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5942 from patent US 6566127.
ACCESSION AR328540
VERSION AR328540.1 GI:33714348
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5942 20-MAY-2003;
FEATURES
source
1..16
Location/Qualifiers
1..16
/mol_type="unknown"
/mol_type="unassigned RNA"
Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 241 CAGTGCAGGTCTCTCA 255
Db 16 CAGTGCAGGTCTCTCA 2
RESULT 186
AX600643
LOCUS AX600643 16 bp DNA linear PAT 17-FEB-2003
DEFINITION Sequence 2 from Patent WO2092853.
ACCESSION AX600643
VERSION AX600643.1 GI:28400597
KEYWORDS Bacillus cereus
SOURCE Bacillus cereus
ORGANISM Bacillus cereus
Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus; Bacillus
```

```
cereus group.
REFERENCE
1 Breen,A.W. and Singleton,F.L.
  AUTHORS Detection of spore forming bacteria
  TITLE Patent: WO 02092853-A 2 21-NOV-2002;
  JOURNAL HERCULES INCORPORATED (US)
  FEATURES Location/Qualifiers
  source
    1..16
      /organism="Bacillus cereus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:1396"
  Query Match
    Best Local Similarity 1.5%; Score 13.4; DB 1; Length 16;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 429 AAAAAGCAGTGACT 443
Db 2 AAAAAGCAGTGACT 16
RESULT 187
BD255583/C 17 bp DNA linear PAT 17-JUL-2003
LOCUS Regulation of repressor genes using nucleic acid molecules.
DEFINITION BD255583
ACCESSION BD255583
VERSION JP 2002541795-A/3376.
KEYWORDS unidentifed
SOURCE unclassified.
ORGANISM 1 (bases 1 to 17)
REFERENCE Blatt,L., Zwick,M., Pavco,P. and McSwiggen,J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
TITLE Patent: JP 2002541795-A 3376 10-DEC-2002;
JOURNAL RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/3376
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
FT /organism="Eukaryote".
FEATURES
source
  1..17
    Location/Qualifiers
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
  Query Match
    Best Local Similarity 1.5%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 458 AATGAAGAAAGTACA 472
Db 15 AATGAAGAAATACA 1
RESULT 188
AR188790 17 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 4278 from patent US 6346398.
DEFINITION
```

```
ACCESSION AR188790 17 bp DNA linear PAT 20-APR-2002
VERSION AR188790.1 GI:20234755
KEYWORDS
SOURCE Unknown.
ORGANISM 1 (bases 1 to 17)
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
FEATURES Patent: US 6346398-A 4278 12-FEB-2002;
source Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
  Query Match
    Best Local Similarity 1.5%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 642 ACTTTTTCAGAGTTG 656
Db 3 ACGTTTTCAGAGTTG 17
RESULT 189
AR188791 17 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 4279 from patent US 6346398.
DEFINITION AR188791
ACCESSION AR188791
VERSION AR188791.1 GI:20234756
KEYWORDS
SOURCE Unknown.
ORGANISM 1 (bases 1 to 17)
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
FEATURES Patent: US 6346398-A 4279 12-FEB-2002;
source Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
  Query Match
    Best Local Similarity 1.5%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 642 ACTTTTTCAGAGTTG 656
Db 2 ACGTTTTCAGAGTTG 16
RESULT 190
AR192144/C 17 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 7632 from patent US 6346398.
DEFINITION AR192144
ACCESSION AR192144
VERSION AR192144.1 GI:20238109
KEYWORDS
SOURCE Unknown.
ORGANISM 1 (bases 1 to 17)
REFERENCE Unclassified.
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL related to levels of vascular endothelial growth factor receptor
FEATURES Patent: US 6346398-A 7632 12-FEB-2002;
source Location/Qualifiers
  1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
```

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266  
 ||||| ||||| |||||  
 Db 17 CTCACCTGTAATCCTC 3

RESULT 191  
 AR192145/c  
 LOCUS AR192145 17 bp DNA linear PAT 20-APR-2002  
 DEFINITION Sequence 7633 from patent US 6346398.  
 ACCESSION AR192145  
 VERSION AR192145.1 GI:20238110  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6346398-A 7633 12-FEB-2002;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266  
 ||||| ||||| |||||  
 Db 16 CTCACCTGTAATCCTC 2

RESULT 192  
 AR324643  
 LOCUS AR324643 17 bp RNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 2045 from patent US 6566127.  
 ACCESSION AR324643  
 VERSION AR324643.1 GI:33710451  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6566127-A 2045 20-MAY-2003;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTG 656  
 ||||| ||||| |||||  
 Db 3 ACGTTTTCAGAGTTG 17

RESULT 193  
 AR324644  
 LOCUS AR324644 17 bp RNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 2046 from patent US 6566127.  
 ACCESSION AR324644

VERSION AR324644.1 GI:33710452  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6566127-A 2046 20-MAY-2003;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTG 656  
 ||||| ||||| |||||  
 Db 2 ACGTTTTCAGAGTTG 16

RESULT 194  
 AR326022/c  
 LOCUS AR326022 17 bp RNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 3424 from patent US 6566127.  
 ACCESSION AR326022  
 VERSION AR326022.1 GI:33711830  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6566127-A 3424 20-MAY-2003;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266  
 ||||| ||||| |||||  
 Db 17 CTCACCTGTAATCCTC 3

RESULT 195  
 AR326023/c  
 LOCUS AR326023 17 bp RNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 3425 from patent US 6566127.  
 ACCESSION AR326023  
 VERSION AR326023.1 GI:33711831  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6566127-A 3425 20-MAY-2003;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"



```

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTAAATCCTC 266
DB 16 CTCACCTGTAATCCTC 2

RESULT 196
AX214956/c
LOCUS AX214956 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 398 from Patent WO0159103.
ACCESSION AX214956
VERSION AX214956.1 GI:15524999
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 398 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="Nucleic Acid"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 857 TTAAAGAAATCCAAA 871
DB 15 TTAAAGAAATCCAAA 1

RESULT 197
AX265895/c
LOCUS AX265895 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3286 from Patent WO0173002.
ACCESSION AX265895
VERSION AX265895.1 GI:16514694
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 3286 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 TATTAAGAAATCCCA 869
DB 1 TATTAAGAAATCCCA 15

RESULT 198
AX265896/c
LOCUS AX265896 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3287 from Patent WO0173002.
ACCESSION AX265896
VERSION AX265896.1 GI:16514695
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 3287 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 TATTAAGAAATCCCA 869
DB 17 TATTAAGAAATCCCA 3

RESULT 199
AX728909/c
LOCUS AX728909 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 543 from Patent WO03025175.
ACCESSION AX728909
VERSION AX728909.1 GI:30508252
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
JOURNAL reversion, apoptosis and/or virus resistance and their use as
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 210 ATCAGTTTGGAGATA 224
DB 2 ATCAGTTTGGAGATA 16

RESULT 200
AX729782/c
LOCUS AX729782 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1416 from Patent WO03025175.
ACCESSION AX729782
VERSION AX729782.1 GI:30509125
KEYWORDS

```

```

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 1416 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            1..17
            Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      801 TCTTTGTCATTCAAG 815
Db      3 TCTTTGTCATTAAAG 17

RESULT 201
AX732168      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      AX732168
DEFINITION      Sequence 3802 from Patent WO03025175.
ACCESSION      AX732168
VERSION        AX732168.1 GI:30511511
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Telerman,A., Amson,R. and Tuijnder,M.
TITLE         Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL      Patent: WO 03025175-A 3802 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES     source
            1..17
            Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      690 GATCACTTGGAGAT 704
Db      1 GATCACTTGGAAAT 15

RESULT 202
AX732908/c    17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      AX732908
DEFINITION      Sequence 4542 from Patent WO03025175.
ACCESSION      AX732908
VERSION        AX732908.1 GI:30512251
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Telerman,A., Amson,R. and Tuijnder,M.
TITLE         Sequences involved in phenomena of tumour suppression, tumour

```

```

            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL      Patent: WO 03025175-A 4542 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES     source
            1..17
            Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      628 AGTGTAATTGTGTGA 642
Db      17 AGTGTAATGTGTGA 3

RESULT 203
AX737665      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      AX737665
DEFINITION      Sequence 3255 from Patent WO03025177.
ACCESSION      AX737665
VERSION        AX737665.1 GI:30516953
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Telerman,A., Amson,R. and Tuijnder,M.
TITLE         Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL      Patent: WO 03025177-A 3255 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES     source
            1..17
            Location/Qualifiers
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      801 TCTTTGTCATTCAAG 815
Db      3 TCTTTGTCATTAAAG 17

RESULT 204
AX761865      17 bp      DNA      linear      PAT 25-JUN-2003
LOCUS      AX761865
DEFINITION      Sequence 5186 from Patent WO03040369.
ACCESSION      AX761865
VERSION        AX761865.1 GI:32256481
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Telerman,A., Amson,R. and Tuijnder,M.
TITLE         Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL      Patent: WO 03040369-A 5186 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES     source
            1..17
            Location/Qualifiers
            /organism="Homo sapiens"

```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGG 390
DB 1 GATCTCACTCTGAGG 15

RESULT 205
BD263834
LOCUS Adeno-associated virus-delivered ribozyme compositions and methods
DEFINITION 13 bp RNA linear PAT 17-JUL-2003
of use.
ACCESSION BD263834
VERSION BD263834.1 GI:33073602
KEYWORDS JP 2002542805-A/56.
SOURCE synthetic construct
ORGANISM
other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 13)
AUTHORS Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
Burger,C.
TITLE Adeno-associated virus-delivered ribozyme compositions and methods
of use
JOURNAL Patent: JP 2002542805-A 56 17-DEC-2002;
UNIVERSITY OF FLORIDA
COMMENT OS Artificial Sequence
PN JP 2002542805-A/56
PD 17-DEC-2002
PF 28-APR-2000 JP 2000615402
PR 30-APR-1999 US 60/131942
PI ALFRED S LEWIN,NICHOLAS MUZYCZKA,WILLIAM W HAUSWIRTH PI
,CHRISTIAN TESCHENDORF,
PC CORINNA BURGER
PC C12N15/09,A01K67/027,C12N9/00,C12Q1/68,C12N15/00 CC
Description of Artificial Sequence: SYNTHETIC PEPTIDE FH Key
Location/Qualifiers
FT source 1..13
FT Location/Qualifiers
1..13
/organism="Artificial Sequence".
FEATURES
source
1..13
/organism="synthetic construct"
/mol_type="genomic RNA"
/db_xref="taxon:32630"

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 354 ATGTGCTCTATTGA 366
DB 1 ATGTGCTCTATTGA 13

RESULT 207
BD263838
LOCUS Adeno-associated virus-delivered ribozyme compositions and methods
DEFINITION 13 bp RNA linear PAT 17-JUL-2003
of use.
ACCESSION BD263838
VERSION BD263838.1 GI:33073606
KEYWORDS JP 2002542805-A/60.
SOURCE synthetic construct
ORGANISM
other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 13)
AUTHORS Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
Burger,C.
TITLE Adeno-associated virus-delivered ribozyme compositions and methods
of use
JOURNAL Patent: JP 2002542805-A 60 17-DEC-2002;
UNIVERSITY OF FLORIDA
COMMENT OS Artificial Sequence
PN JP 2002542805-A/60
PD 17-DEC-2002
PF 28-APR-2000 JP 2000615402
PR 30-APR-1999 US 60/131942
PI ALFRED S LEWIN,NICHOLAS MUZYCZKA,WILLIAM W HAUSWIRTH PI
,CHRISTIAN TESCHENDORF,
PC CORINNA BURGER
PC C12N15/09,A01K67/027,C12N9/00,C12Q1/68,C12N15/00 CC
Description of Artificial Sequence: SYNTHETIC PEPTIDE FH Key
Location/Qualifiers
FT source 1..13
FT Location/Qualifiers
1..13
/organism="Artificial Sequence".
FEATURES
source
1..13
/organism="synthetic construct"
/mol_type="genomic RNA"
/db_xref="taxon:32630"

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245 GCAGGTCCTCACT 257
DB 1 GCAGGTCCTCACT 13

RESULT 206
BD263836
LOCUS Adeno-associated virus-delivered ribozyme compositions and methods
DEFINITION 13 bp RNA linear PAT 17-JUL-2003
of use.
ACCESSION BD263836
VERSION BD263836.1 GI:33073604
KEYWORDS JP 2002542805-A/58.
SOURCE synthetic construct
ORGANISM
other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 13)
AUTHORS Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
Burger,C.
TITLE Adeno-associated virus-delivered ribozyme compositions and methods
of use.
JOURNAL Patent: JP 2002542805-A 58 17-DEC-2002;
UNIVERSITY OF FLORIDA
COMMENT OS Artificial Sequence
PN JP 2002542805-A/58
PD 17-DEC-2002
PF 28-APR-2000 JP 2000615402
PR 30-APR-1999 US 60/131942
PI ALFRED S LEWIN,NICHOLAS MUZYCZKA,WILLIAM W HAUSWIRTH PI
,CHRISTIAN TESCHENDORF,
PC CORINNA BURGER
PC C12N15/09,A01K67/027,C12N9/00,C12Q1/68,C12N15/00 CC
Description of Artificial Sequence: SYNTHETIC PEPTIDE FH Key
Location/Qualifiers
FT source 1..13
FT Location/Qualifiers
1..13
/organism="Artificial Sequence".
FEATURES
source
1..13
/organism="synthetic construct"
/mol_type="genomic RNA"
/db_xref="taxon:32630"

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGTGTCCTCATGAA 430
```

```

Db          1  GGTGGTCCCATGAA 13
|||||
Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 208
BD263840    13 bp  RNA  linear  PAT 17-JUL-2003
LOCUS      Adeno-associated virus-delivered ribozyme compositions and methods
DEFINITION
ACCESSION  BD263840.1 GI:33073608
VERSION    JP 2002542805-A/62.
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1 (bases 1 to 13)
AUTHORS   Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
          Burger,C.
TITLE      Adeno-associated virus-delivered ribozyme compositions and methods
          of use
JOURNAL    Patent: JP 2002542805-A 62 17-DEC-2002;
COMMENT    UNIVERSITY OF FLORIDA
OS         Artificial Sequence
PN         JP 2002542805-A/62
PD         17-DEC-2002
PF         28-APR-2000 JP 2000615402
PR         30-APR-1999 US 60/131942
PI         ALFRED S LEWIN,NICHOLAS MUZYCZKA,WILLIAM W HAUSWIRTH PI
          CHRISTIAN TESCHENDORF,
          PI CORINNA BURGER
PC         C12N15/09,A01K67/027,C12N9/00,C12Q1/68,C12N15/00 CC
          Description of Artificial Sequence: SYNTHETIC PEPTIDE FH  Key
          Location/Qualifiers
FT         source 1..13
FT         Location/Qualifiers
          1..13
          /organism="Artificial Sequence".

Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 488  GGAAGTCGTTGG 500
|||||
Db          1  GGAAGTCGTTGG 13
|||||

RESULT 209
AX048320    13 bp  RNA  linear  PAT 15-DEC-2000
LOCUS      Sequence 56 from Patent WO0066780.
DEFINITION
ACCESSION  AX048320
VERSION    AX048320.1 GI:11877085
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS   Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
          Burger,C.
TITLE      Adeno-associated virus-delivered ribozyme compositions and methods
          of use
JOURNAL    Patent: WO 0066780-A 56 09-NOV-2000;
          University of Florida (US)
          Location/Qualifiers
          1..13
          /organism="synthetic construct"
          /mol_type="unassigned RNA"
          /db_xref="taxon:32630"
          /note="SYNTHETIC PEPTIDE"

Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418  GGTGGTCCCATGAA 430
|||||
Db          1  GGTGGTCCCATGAA 13
|||||
Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 245  GCAGGTCCTCACT 257
|||||
Db          1  GCAGGTCCTCACT 13
|||||

RESULT 210
AX048322    13 bp  RNA  linear  PAT 15-DEC-2000
LOCUS      Sequence 58 from Patent WO0066780.
DEFINITION
ACCESSION  AX048322
VERSION    AX048322.1 GI:11877087
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS   Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
          Burger,C.
TITLE      Adeno-associated virus-delivered ribozyme compositions and methods
          of use
JOURNAL    Patent: WO 0066780-A 58 09-NOV-2000;
          University of Florida (US)
          Location/Qualifiers
          1..13
          /organism="synthetic construct"
          /mol_type="unassigned RNA"
          /db_xref="taxon:32630"
          /note="SYNTHETIC PEPTIDE"

Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 354  ATGTGTCATTGA 366
|||||
Db          1  ATGTGTCATTGA 13
|||||

RESULT 211
AX048324    13 bp  RNA  linear  PAT 15-DEC-2000
LOCUS      Sequence 60 from Patent WO0066780.
DEFINITION
ACCESSION  AX048324
VERSION    AX048324.1 GI:11877089
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS   Lewin,A.S., Muzyczka,N., Hauswirth,W.W., Teschendorf,C. and
          Burger,C.
TITLE      Adeno-associated virus-delivered ribozyme compositions and methods
          of use
JOURNAL    Patent: WO 0066780-A 60 09-NOV-2000;
          University of Florida (US)
          Location/Qualifiers
          1..13
          /organism="synthetic construct"
          /mol_type="unassigned RNA"
          /db_xref="taxon:32630"
          /note="SYNTHETIC PEPTIDE"

Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418  GGTGGTCCCATGAA 430
|||||
Db          1  GGTGGTCCCATGAA 13
|||||
Query Match 1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```



```
Best Local Similarity 100.0%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 0;

QY 691 ATCACTTGAAGA 703
Db 3 ATCACTTGAAGA 15

RESULT 217
AR327316 LOCUS 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4718 from patent US 6566127.
ACCESSION AR327316
VERSION AR327316.1 GI:33713124
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4718 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
Db 4 ATCACTTGAAGA 16

RESULT 218
AR328890 LOCUS 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6292 from patent US 6566127.
ACCESSION AR328890
VERSION AR328890.1 GI:33714698
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6292 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
Db 4 ATCACTTGAAGA 16

RESULT 219
AR328891 LOCUS 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6293 from patent US 6566127.
ACCESSION AR328891
VERSION AR328891.1 GI:33714699
KEYWORDS
```

```
Unknown.
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6293 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCCATGAAAAA 433
Db 4 GGTCCATGAAAAA 16

RESULT 220
AX215041 LOCUS 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 483 from Patent WO0159103.
ACCESSION AX215041
VERSION AX215041.1 GI:15525084
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 483 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 675 GAGAACTGATT 687
Db 17 GAGAACTGATT 5

RESULT 221
AX215043 LOCUS 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 485 from Patent WO0159103.
ACCESSION AX215043
VERSION AX215043.1 GI:15525086
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 485 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
Location/Qualifiers
```

```
source 1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 TGAGAAACTGATT 686
DB 13 TGAGAAACTGATT 1

RESULT 222
AX726716/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4403 from Patent WO03025176.
ACCESSION AX726716
VERSION AX726716.1 GI:30506059
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4403 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 681 CTGATTATGATC 693
DB 13 CTGATTATGATC 1

RESULT 223
A10669
LOCUS 16 bp DNA linear PAT 02-DEC-1993
DEFINITION Oligonucleotide (H6).
ACCESSION A10669
VERSION A10669.1 GI:490795
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 16)
AUTHORS Ueda,I., Niwa,M., Saito,Y., Sato,S., Ono,H. and Kitaguchi,T.
TITLE Process for production of gamma-interferon
JOURNAL Patent: EP 0176916-A 54 09-APR-1986;
FUJISAWA PHARMACEUTICAL CO., LTD
FEATURES
source 1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

source 1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 TGAGAAACTGATT 686
DB 13 TGAGAAACTGATT 1

RESULT 222
AX726716/c
LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4403 from Patent WO03025176.
ACCESSION AX726716
VERSION AX726716.1 GI:30506059
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4403 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 681 CTGATTATGATC 693
DB 13 CTGATTATGATC 1

RESULT 223
A10669
LOCUS 16 bp DNA linear PAT 02-DEC-1993
DEFINITION Oligonucleotide (H6).
ACCESSION A10669
VERSION A10669.1 GI:490795
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 16)
AUTHORS Ueda,I., Niwa,M., Saito,Y., Sato,S., Ono,H. and Kitaguchi,T.
TITLE Process for production of gamma-interferon
JOURNAL Patent: EP 0176916-A 54 09-APR-1986;
FUJISAWA PHARMACEUTICAL CO., LTD
FEATURES
source 1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 ATCACTTGGAGATT 706
DB 1 ATCACTTGGAGATT 16

RESULT 224
CQ821403
LOCUS 16 bp DNA linear PAT 14-JUN-2004
DEFINITION Sequence 9 from Patent WO2004038019.
ACCESSION CQ821403
VERSION CQ821403.1 GI:48716052
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Beeson,D., Wood,M. and Abdelgany,A.
TITLE Dnzyme cleaving mutant polynucleotides
JOURNAL Patent: WO 2004038019-A 9 06-MAY-2004;
ISIS INNOVATION LIMITED (GB)
FEATURES
source 1. .16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 94 GGGCGACGGCCCGAGTG 109
DB 1 GGGCGACGGCCCGAGTG 16

RESULT 225
AR328567/c
LOCUS 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5969 from patent US 6566127.
ACCESSION AR328567
VERSION AR328567.1 GI:33714375
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Bacobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5969 20-MAY-2003;
FEATURES
source 1. .16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 638 TGTGACTTTTTCAGAG 653
DB 16 TGTGACTTTTTCAGTG 1

RESULT 226
AR328701
LOCUS 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6103 from patent US 6566127.
ACCESSION AR328701
VERSION AR328701.1 GI:33714509
KEYWORDS Unknown.
SOURCE Unknown.
```

```
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 16)
AUTHORS
Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE
Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL
Patent: US 6566127-A 6103 20-MAY-2003;
FEATURES
Location/Qualifiers
1..16
source
/organism="unknown"
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 CCATGAAAGAGCAGAT 439
Db 1 CCATGAAATGCAAT 16

RESULT 227
AX040892
LOCUS
AX040892 16 bp DNA linear PAT 23-NOV-2000
DEFINITION
Sequence 37 from Patent WO0065090.
ACCESSION
AX040892
VERSION
AX040892.1 GI:11340514
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
Lok S. and Whitmore,T.E.
TITLE
The insulin receptor-related receptor gene sequence for diagnosis
of human obesity and diabetic disorders
JOURNAL
Patent: WO 0065090-A 37 02-NOV-2000;
ZymoGenetics, Inc. (US)
FEATURES
Location/Qualifiers
1..16
source
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 380 TCATCTCAGGAGACC 395
Db 1 TTACTCTCAGGAGGCC 16

RESULT 228
A88539/c
LOCUS
A88539 17 bp DNA linear PAT 22-JAN-2000
DEFINITION
Sequence 687 from Patent WO9833904.
ACCESSION
A88539
VERSION
A88539.1 GI:6737109
KEYWORDS
unidentified
SOURCE
unidentified
ORGANISM
unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Brysch,W. and Schlingensiepen,K.
TITLE
AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL
Patent: WO 9833904-A 687 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
Location/Qualifiers
1..17
source
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGTGG 53
Db 1 CCNGGACATCGCGTGG 17

RESULT 231
AR151792
LOCUS
AR151792 17 bp DNA linear PAT 08-AUG-2001
DEFINITION
Sequence 52 from patent US 6232109.

ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Kikuchi,Y., Kiyokawa,S., Shimada,Y., Ohbayashi,M., Shimada,R. and
Okinaka,Y.
TITLE
Plant genes encoding flavonoid-3', 5'-hydroxylase
JOURNAL
Patent: US 6114601-A 52 05-SEP-2000;
FEATURES
Location/Qualifiers
1..17
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 730 AAAATGTCGTGTTCAA 745
Db 16 AAAATGTTTATTTCAA 1

RESULT 229
A90506/c
LOCUS
A90506 17 bp DNA linear PAT 22-JAN-2000
DEFINITION
Sequence 687 from Patent EP0856579.
ACCESSION
A90506
VERSION
A90506.1 GI:6739020
KEYWORDS
unidentified
SOURCE
unidentified
ORGANISM
unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Brysch,W.D. and Schlingensiepen,K.D.
TITLE
An antisense oligonucleotide preparation method
JOURNAL
Patent: EP 0856579-A 687 05-AUG-1998;
BIOGNOSTIK GES (DE)
FEATURES
Location/Qualifiers
1..17
source
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 730 AAAATGTCGTGTTCAA 745
Db 16 AAAATGTTTATTTCAA 1

RESULT 230
AR110572
LOCUS
AR110572 17 bp DNA linear PAT 14-FEB-2001
DEFINITION
Sequence 52 from patent US 6114601.
ACCESSION
AR110572
VERSION
AR110572.1 GI:12826848
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Kikuchi,Y., Kiyokawa,S., Shimada,Y., Ohbayashi,M., Shimada,R. and
Okinaka,Y.
TITLE
Plant genes encoding flavonoid-3', 5'-hydroxylase
JOURNAL
Patent: US 6114601-A 52 05-SEP-2000;
FEATURES
Location/Qualifiers
1..17
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 730 AAAATGTCGTGTTCAA 745
Db 16 AAAATGTTTATTTCAA 1

RESULT 231
AR151792
LOCUS
AR151792 17 bp DNA linear PAT 08-AUG-2001
DEFINITION
Sequence 52 from patent US 6232109.
```



```
ACCESSION AR151792
VERSION    AR151792.1 GI:15117842
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Kikuchi,Y., Kiyokawa,S., Shimada,Y., Ohbayashi,M., Shimada,R. and
           Okinaka,Y.
TITLE      Plant genes
JOURNAL    Patent: US 6232109-A 52 15-MAY-2001;
FEATURES   Location/Qualifiers
           source
             1..17
             /organism="unknown"
             /mol_type="unassigned DNA"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGTGG 53
Db 1 CCGGACATCGCGTGG 17

RESULT 232
BD141639/c
LOCUS
DEFINITION p53-Dependent novel apoptosis-associated protein and method of
           screening apoptosis controller.
ACCESSION BD141639
VERSION    BD141639.1 GI:23236584
KEYWORDS   WO 0212496-A/17.
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1 (bases 1 to 17)
AUTHORS    Nakamura,Y. and Arakawa,H.
TITLE      p53-Dependent novel apoptosis-associated protein and method of
           screening apoptosis controller
JOURNAL    Patent: WO 0212496-A 17 14-FEB-2002;
           JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO,
           CENTER FOR ADVANCED SCIENCE AND TECHNOLOGY INCUBATION LTD, YUSUKE
           NAKAMURA, HIROFUMI ARAKAWA
COMMENT    OS Artificial Sequence
           PN WO 0212496-A/17
           PD 14-FEB-2002
           PF 02-AUG-2001 WO 2001JP006666
           PR 03-AUG-2000 JP 00P 240399
           PI YUSUKE NAKAMURA,HIROFUMI ARAKAWA
           PC C12N15/12.C07K14/47.C07K16/18.C12P21/02.C12Q1/68.G01N33/50. PC
           G01N33/15.
           PC A61K45/00.A61K48/00.A61K38/17.A61P43/00.A61P35/00 CC
           Description of Artificial Sequence:Artificially Synthesized CC
Primer Sequence
FH Key Location/Qualifiers
FT source 1..17
   /organism="Artificial Sequence".
   /organism="synthetic construct"
   /mol_type="genomic DNA"
   /db_xref="taxon:32630"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 431 AAAGCAGACTGCTGG 446
Db 16 AAAGCAGAGACTGG 1

ACCESSION AR151792
VERSION    AR151792.1 GI:15117842
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Kikuchi,Y., Kiyokawa,S., Shimada,Y., Ohbayashi,M., Shimada,R. and
           Okinaka,Y.
TITLE      Plant genes
JOURNAL    Patent: US 6232109-A 52 15-MAY-2001;
FEATURES   Location/Qualifiers
           source
             1..17
             /organism="unknown"
             /mol_type="unassigned DNA"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGTGG 53
Db 1 CCGGACATCGCGTGG 17

RESULT 233
BD142773/c
LOCUS
DEFINITION Thermostable ribonuclease H.
ACCESSION BD142773
VERSION    BD142773.1 GI:23237718
KEYWORDS   WO 0222831-A/55.
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1 (bases 1 to 17)
AUTHORS    Umori,T., Sato,Y., Kovama,N., Hirano,R., Takakura,H., Kobori,H.,
           Hashimoto,Y., Asada,K. and Kato,I.
TITLE      Thermostable ribonuclease H
JOURNAL    Patent: WO 0222831-A 55 21-MAR-2002;
           TAKARA SHUZO CO LTD,TAKASHI UEMORI,YOSHIMI SATO,NOBUTO KOYAMA, RYO
           HIRANO, HIKARU TAKAKURA,HIROSHI KOBORI,YUJI HASHIMOTO,KIYOZO ASADA,
           IKUNOSHIN KATO
COMMENT    OS Artificial Sequence
           PN WO 0222831-A/55
           PD 21-MAR-2002
           PF 13-SEP-2001 WO 2001JP007930
           PR 14-SEP-2000 JP 00P 280785.07-MAR-2001 JP 01P 064074 PI
           TAKASHI UEMORI,YOSHIMI SATO,NOBUTO KOYAMA,RYO HIRANO,HIKARU PI
           TAKAKURA.
           PI HIROSHI KOBORI,YUJI HASHIMOTO,KIYOZO ASADA,IKUNOSHIN KATO PC
           C12N15/55.C12N9/22.C12N1/21
           CC Designed chimeric oligonucleotide primer as VT2-IP18N1 for CC
           amplifying a
           CC VFN1 from hemorhagic Escherichia coli 0-157. CC
           'Nucleotides 15 to 17 are ribonucleotides-other nucleotides CC
           are
           CC deoxyribonucleotides'
           FH Key Location/Qualifiers
           FT source 1..17
             /organism='Artificial Sequence'.
             /organism='synthetic construct'
             /mol_type='genomic DNA'
             /db_xref="taxon:32630"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836
Db 16 GAAGAAACCCAGTA 1

RESULT 234
BD200757/c
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response.
ACCESSION BD200757
VERSION    BD200757.1 GI:33010527
KEYWORDS   JP 2002509721-A/3783.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE      Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response
JOURNAL    Patent: JP 2002509721-A 3783 02-APR-2002;
           RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Homo sapiens (human)
           PN JP 2002509721-A/3783
           PD 02-APR-2002
           PF 24-MAR-1999 JP 2000541291
```

```
RESULT 233
BD142773/c
LOCUS
DEFINITION Thermostable ribonuclease H.
ACCESSION BD142773
VERSION    BD142773.1 GI:23237718
KEYWORDS   WO 0222831-A/55.
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1 (bases 1 to 17)
AUTHORS    Umori,T., Sato,Y., Kovama,N., Hirano,R., Takakura,H., Kobori,H.,
           Hashimoto,Y., Asada,K. and Kato,I.
TITLE      Thermostable ribonuclease H
JOURNAL    Patent: WO 0222831-A 55 21-MAR-2002;
           TAKARA SHUZO CO LTD,TAKASHI UEMORI,YOSHIMI SATO,NOBUTO KOYAMA, RYO
           HIRANO, HIKARU TAKAKURA,HIROSHI KOBORI,YUJI HASHIMOTO,KIYOZO ASADA,
           IKUNOSHIN KATO
COMMENT    OS Artificial Sequence
           PN WO 0222831-A/55
           PD 21-MAR-2002
           PF 13-SEP-2001 WO 2001JP007930
           PR 14-SEP-2000 JP 00P 280785.07-MAR-2001 JP 01P 064074 PI
           TAKASHI UEMORI,YOSHIMI SATO,NOBUTO KOYAMA,RYO HIRANO,HIKARU PI
           TAKAKURA.
           PI HIROSHI KOBORI,YUJI HASHIMOTO,KIYOZO ASADA,IKUNOSHIN KATO PC
           C12N15/55.C12N9/22.C12N1/21
           CC Designed chimeric oligonucleotide primer as VT2-IP18N1 for CC
           amplifying a
           CC VFN1 from hemorhagic Escherichia coli 0-157. CC
           'Nucleotides 15 to 17 are ribonucleotides-other nucleotides CC
           are
           CC deoxyribonucleotides'
           FH Key Location/Qualifiers
           FT source 1..17
             /organism='Artificial Sequence'.
             /organism='synthetic construct'
             /mol_type='genomic DNA'
             /db_xref="taxon:32630"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836
Db 16 GAAGAAACCCAGTA 1

RESULT 234
BD200757/c
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response.
ACCESSION BD200757
VERSION    BD200757.1 GI:33010527
KEYWORDS   JP 2002509721-A/3783.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE      Method and reagent for treating diseases or conditions concerning
           molecule participating in vasculogenic response
JOURNAL    Patent: JP 2002509721-A 3783 02-APR-2002;
           RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Homo sapiens (human)
           PN JP 2002509721-A/3783
           PD 02-APR-2002
           PF 24-MAR-1999 JP 2000541291
```

```

PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 437 GATGACTTGGCAAAG 452
Db 2 GATGACTTGGGAAG 17

RESULT 235
BD201590/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
ACCESSION
BD201590.1 GI:33011360
VERSION
JP 2002509721-A/4616.
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4616 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4616
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 437 GATGACTTGGCAAAG 452
Db 2 GATGACTTGGGAAG 17

RESULT 235
BD201590/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
ACCESSION
BD201590.1 GI:33011360
VERSION
JP 2002509721-A/4616.
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4616 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4616
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AAACATTAAACACTGT 618
Db 17 AGACTTTAAACACTGT 2

RESULT 236
BD201591/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD201591.1 GI:33011361
VERSION
JP 2002509721-A/4617.
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4617 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4617
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AAACATTAAACACTGT 618
Db 16 AGACTTTAAACACTGT 1

RESULT 237
BD232934
LOCUS
DEFINITION
Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION
BD232934.1 GI:33042704
VERSION
JP 2002518065-A/30.
KEYWORDS
Aids-associated retrovirus
SOURCE
Aids-associated retrovirus
ORGANISM
Viruses; Retroid viruses; Retroviridae.
REFERENCE
1 (bases 1 to 17)
Stuyver,L.
AUTHORS
Patent of detecting mutation selected by drug in HIV protease gene
TITLE
Patent: JP 2002518065-A 30 25-JUN-2002;
JOURNAL
INNOGENETICS NV

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AAACATTAAACACTGT 618
Db 17 AGACTTTAAACACTGT 2

RESULT 236
BD201591/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD201591.1 GI:33011361
VERSION
JP 2002509721-A/4617.
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4617 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4617
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FEATURES
source
1..17
Location/Qualifiers
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AAACATTAAACACTGT 618
Db 16 AGACTTTAAACACTGT 1

RESULT 237
BD232934
LOCUS
DEFINITION
Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION
BD232934.1 GI:33042704
VERSION
JP 2002518065-A/30.
KEYWORDS
Aids-associated retrovirus
SOURCE
Aids-associated retrovirus
ORGANISM
Viruses; Retroid viruses; Retroviridae.
REFERENCE
1 (bases 1 to 17)
Stuyver,L.
AUTHORS
Patent of detecting mutation selected by drug in HIV protease gene
TITLE
Patent: JP 2002518065-A 30 25-JUN-2002;
JOURNAL
INNOGENETICS NV

```

```

COMMENT      OS      Aids-associated retrovirus
              PN      JP 2002518065-A/30
              PD      25-JUN-2002
              PR      22-JUN-1999 JP 2000556068
              PF      24-JUN-1998 EP 98870143.9
              PI      LIEVEN STUYVER
              PC      C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
              CC      Method of detecting mutation selected by drug in HIV protease
              CF      gene
              FH      Key      Location/Qualifiers
              FT      source      1..17
              FT      Location/Qualifiers
              FT      /organism='Aids-associated retrovirus'.
              FT      /organism="Aids-associated retrovirus"
              FT      /mol_type="genomic DNA"
              FT      /db_xref="taxon:11966"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      218 GGAGATAATACAGCAG 233
          |||||
Db      2 GCAGATAATACAGTAG 17

RESULT 238
BD233095      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Method of detecting mutation selected by drug in HIV protease gene.
DEFINITION      BD233095
ACCESSION      BD233095
VERSION      BD233095.1 GI:33042865
KEYWORDS      JP 2002518065-A/191.
SOURCE      Aids-associated retrovirus
ORGANISM      Aids-associated retrovirus
              Viruses; Retroviridae.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stuyver,L.
TITLE      Method of detecting mutation selected by drug in HIV protease gene
JOURNAL      INNOCENTICS NV

COMMENT      OS      Aids-associated retrovirus
              PN      JP 2002518065-A/191
              PD      25-JUN-2002
              PR      22-JUN-1999 JP 2000556068
              PF      24-JUN-1998 EP 98870143.9
              PI      LIEVEN STUYVER
              PC      C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
              CC      Method of detecting mutation selected by drug in HIV protease
              CF      gene
              FH      Key      Location/Qualifiers
              FT      source      1..17
              FT      Location/Qualifiers
              FT      /organism='Aids-associated retrovirus'.
              FT      /organism="Aids-associated retrovirus"
              FT      /mol_type="genomic DNA"
              FT      /db_xref="taxon:11966"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712 GTTTTATAAAGTCAG 727
          |||||
Db      1 GTTTTATCAAGTCAG 16

RESULT 239
BD241523/c
LOCUS      Method of detecting mutation selected by drug in HIV protease gene.
DEFINITION      BD241523/c
ACCESSION      BD241523/c
VERSION      BD241523/c.1 GI:33051293
KEYWORDS      JP 2002525127-A/470.
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
TITLE      Methods and products related to genotyping and DNA analysis
JOURNAL      Patent: JP 2002525127-A 470 13-AUG-2002;
              MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT      OS      Homo sapiens (human)
              PN      JP 2002525127-A/470
              PD      13-AUG-2002
              PR      24-SEP-1999 JP 2000572407
              PF      25-SEP-1998 US 60/101757
              PI      JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
              PC      C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
              CC      G01N37/00,
              CC      C12N15/00
              CC      Methods and products related to genotyping and DNA analysis FH
              Key      Location/Qualifiers
              FT      source      1..17
              FT      /organism='Homo sapiens (human)'.
              FT      Location/Qualifiers
              FT      1..17
              FT      /organism="Homo sapiens"
              FT      /mol_type="genomic DNA"
              FT      /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      428 GAAAGACGAGTCACT 443
          |||||
Db      17 GAGAAAGCAGAGGACT 2

RESULT 240
BD256491/c
LOCUS      Regulation of repressor genes using nucleic acid molecules.
DEFINITION      BD256491
ACCESSION      BD256491
VERSION      BD256491.1 GI:33066261
KEYWORDS      JP 2002541795-A/4284.
SOURCE      unidentified
ORGANISM      unclassified.
              1 (bases 1 to 17)
REFERENCE      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
AUTHORS      Regulation of repressor genes using nucleic acid molecules
TITLE      Patent: JP 2002541795-A 4284 10-DEC-2002;
JOURNAL      RIBOZYME PHARMACEUTICALS INC
COMMENT      OS      Eukaryote
              PN      JP 2002541795-A/4284
              PD      10-DEC-2002
              PR      11-APR-2000 JP 2000611654
              PR      12-APR-1999 US 60/129390
              PI      LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
              PC      C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
              CC      C12P21/02,
              CC      C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
              CC      C12R1:91),
              CC      (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
              CC      A61K37/02,
              CC      (C12N5/00,C12R1:91)
              CC      Regulation of repressor genes using nucleic acid molecules FH
              Key      Location/Qualifiers
              FT      source      1..17
              FT      /organism='Eukaryote'.
              FT      FT

```





```

VERSION      CQ616851.1  GI:41667069
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
             Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 1591 06-DEC-2001;
             Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match
Best Local Similarity  1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  290 AAGGATGAAGAGGCG 305
      ||||| |||||
Db   1 AAGGATGCAGAAAGGC 16

RESULT 248
CQ617968
LOCUS      CQ617968             17 bp  DNA          linear    PAT 02-FEB-2004
DEFINITION Sequence 2708 from Patent WO0192524.
ACCESSION  CQ617968
VERSION     CQ617968.1  GI:41668186
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2708 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match
Best Local Similarity  1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  206 GTTCATGAGTTGGAG 221
      ||||| |||||
Db   2 GTTCATGAGGTTTGAG 17

RESULT 249
CQ617969
LOCUS      CQ617969             17 bp  DNA          linear    PAT 02-FEB-2004
DEFINITION Sequence 2709 from Patent WO0192524.
ACCESSION  CQ617969
VERSION     CQ617969.1  GI:41668187
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.

```

```

TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2709 06-DEC-2001;
             Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match
Best Local Similarity  1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  206 GTTCATGAGTTGGAG 221
      ||||| |||||
Db   1 GTTCATGAGGTTTGAG 16

RESULT 250
CQ622481
LOCUS      CQ622481             17 bp  DNA          linear    PAT 02-FEB-2004
DEFINITION Sequence 7221 from Patent WO0192524.
ACCESSION  CQ622481
VERSION     CQ622481.1  GI:41672699
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7221 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match
Best Local Similarity  1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  337 CAAGATGCTGTGGCC 352
      ||||| |||||
Db   2 CAAGTGATGTGGCC 17

RESULT 251
CQ622482
LOCUS      CQ622482             17 bp  DNA          linear    PAT 02-FEB-2004
DEFINITION Sequence 7222 from Patent WO0192524.
ACCESSION  CQ622482
VERSION     CQ622482.1  GI:41672700
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7222 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

```

```
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAAGATGGTGGCC 352
    ||||| |||||
Db 1 CAAAGTGATGTGCC 16

RESULT 252
CQ623027/c
LOCUS      17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7767 from Patent WO0192524.
ACCESSION CQ623027
VERSION   CQ623027.1 GI:41673245
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7767 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCTCTGCTAGCT 584
    ||||| |||||
Db 17 TGTTCCTGCTGGCT 2

RESULT 255
CQ623242/c
LOCUS      17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7982 from Patent WO0192524.
ACCESSION CQ623242
VERSION   CQ623242.1 GI:41673460
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7982 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCTCTGCTAGCT 584
    ||||| |||||
Db 16 TGTTCCTGCTGGCT 1

RESULT 256
CQ623419
LOCUS      17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8159 from Patent WO0192524.
ACCESSION CQ623419
VERSION   CQ623419.1 GI:41673637
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
```

```
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CCGACACTGGTGTC 424
    ||||| |||||
Db 17 CCGACACTGGTGTC 2

RESULT 253
CQ623028/c
LOCUS      17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7768 from Patent WO0192524.
ACCESSION CQ623028
VERSION   CQ623028.1 GI:41673246
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
           Shannon, M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7768 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CCGACACTGGTGTC 424
    ||||| |||||
Db 16 CCGACACTGGTGTC 1
```

```
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8159 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 AGGATGAAGAGAGGCA 306
    |||||
    2 AGTATGAAGAAGCA 17

Db

RESULT 257
CQ623420      17 bp      DNA      linear      PAT 02-FEB-2004
LOCUS
DEFINITION    Sequence 8160 from Patent WO0192524.
ACCESSION     CQ623420
VERSION       CQ623420.1 GI:41673638
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8160 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 AGGATGAAGAGAGGCA 306
    |||||
    1 AGTATGAAGAAGCA 16

Db

RESULT 258
CQ624219      17 bp      DNA      linear      PAT 02-FEB-2004
LOCUS
DEFINITION    Sequence 8959 from Patent WO0192524.
ACCESSION     CQ624219
VERSION       CQ624219.1 GI:41674437
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8959 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
```

```
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCGTCATGG 198
    |||||
    2 CTGAAGGCGCATGG 17

Db

RESULT 259
CQ624221      17 bp      DNA      linear      PAT 02-FEB-2004
LOCUS
DEFINITION    Sequence 8961 from Patent WO0192524.
ACCESSION     CQ624221
VERSION       CQ624221.1 GI:41674439
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8961 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 TGAAGGCGTCATGGA 199
    |||||
    1 TGAAGGCGCATGGA 16

Db

RESULT 260
CQ625473/c     17 bp      DNA      linear      PAT 02-FEB-2004
LOCUS
DEFINITION    Sequence 10213 from Patent WO0192524.
ACCESSION     CQ625473
VERSION       CQ625473.1 GI:41675691
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 10213 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 TGAAGGCGCATGGA 199
    |||||
    1 TGAAGGCGCATGGA 16

Db

RESULT 260
CQ625473/c     17 bp      DNA      linear      PAT 02-FEB-2004
LOCUS
DEFINITION    Sequence 10213 from Patent WO0192524.
ACCESSION     CQ625473
VERSION       CQ625473.1 GI:41675691
KEYWORDS      .
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 10213 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```



QY 6 GCCTCTGGGCTTTCCG 21  
Db 17 GTGCTCTGGGCTTTCCG 2

RESULT 261  
CO625474/c  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 10214 from Patent WO0192524.  
ACCESSION CO625474  
VERSION CO625474.1 GI:41675692  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 10214 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCCTCTGGGCTTTCCG 21  
Db 16 GTGCTCTGGGCTTTCCG 1

RESULT 262  
AR187195  
LOCUS 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 2683 from patent US 6346398.  
ACCESSION AR187195  
VERSION AR187195.1 GI:20233160  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2683 12-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 396 ATTCATCATTTGGCCG 411  
Db 2 AGTGATCTTTGGCCG 17

RESULT 263  
AR189873/c  
LOCUS 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5361 from patent US 6346398.  
ACCESSION AR189873  
VERSION AR189873.1 GI:20235838  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 5361 12-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 790 TTGTCAGATATGCTTT 805  
Db 16 TTGTCAGATATGCTTT 1

RESULT 264  
AR191786/c  
LOCUS 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7274 from patent US 6346398.  
ACCESSION AR191786  
VERSION AR191786.1 GI:20237751  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7274 12-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 TGCTCTATTGAAGATTC 372  
Db 17 TGTAGATTGAAGATTC 2

RESULT 265  
AR192428  
LOCUS 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7916 from patent US 6346398.  
ACCESSION AR192428  
VERSION AR192428.1 GI:20238393  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7916 12-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 TGCTCTATTGAAGATTC 372  
Db 17 TGTAGATTGAAGATTC 2

RESULT 265  
AR192428  
LOCUS 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 7916 from patent US 6346398.  
ACCESSION AR192428  
VERSION AR192428.1 GI:20238393  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7916 12-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 663 AGTACTGTAGTGAGA 678
Db 2 AGTTCTCTAGTGAGA 17

RESULT 266
LOCUS AR323805 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1207 from patent US 6566127.
ACCESSION AR323805
VERSION AR323805.1 GI:33709613
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1207 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 396 ATTGCATCTTGGCCG 411
Db 2 AGTGCATCTTGGCCG 17

RESULT 267
LOCUS AR324861/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2263 from patent US 6566127.
ACCESSION AR324861
VERSION AR324861.1 GI:33710669
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2263 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 790 TTGTCAGATTTCCTTT 805
Db 16 TTGTCAGATTTCCTTT 1

RESULT 268
LOCUS AR325681/c 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3083 from patent US 6566127.
ACCESSION AR325681
VERSION AR325681.1 GI:33711489
KEYWORDS
SOURCE

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3083 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 TGCTATTGAAGATTC 372
Db 17 TGTAGATTGAAGATTC 2

RESULT 269
LOCUS AR326297 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3699 from patent US 6566127.
ACCESSION AR326297
VERSION AR326297.1 GI:33712105
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3699 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 663 AGTACCTGTAGTGAGA 678
Db 2 AGTTCTCTAGTGAGA 17

RESULT 270
LOCUS AR327132 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4534 from patent US 6566127.
ACCESSION AR327132
VERSION AR327132.1 GI:33712940
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4534 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 663 AGTACCTGTAGTGAGA 678
Db 2 AGTTCTCTAGTGAGA 17

RESULT 270
LOCUS AR327132 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4534 from patent US 6566127.
ACCESSION AR327132
VERSION AR327132.1 GI:33712940
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4534 20-MAY-2003;
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 766 TTAAATCAGATGGG 781
Db 2 TTATATCAGATGTG 17

RESULT 271
AR328136 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 5538 from patent US 6566127.
DEFINITION AR328136
ACCESSION AR328136
VERSION AR328136.1 GI:33713944
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5538 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TAAAAACCCGTGTGG 839
Db 1 TAAAAACCCAGTCTGG 16

RESULT 274
AR402378/c 17 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 718 from patent US 6623962.
DEFINITION AR402378
ACCESSION AR402378
VERSION AR402378.1 GI:40149828
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 718 23-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 114 GCATCATCAATTTCGA 129
Db 17 GCATTATCAATTTCAA 2

RESULT 275
AR457913 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 1590 from patent US 6686188.
DEFINITION AR457913
ACCESSION AR457913
VERSION AR457913.1 GI:42692970
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.B.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1590 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TAAAAACCCGTGTGG 839
Db 2 TAAAAACCCAGTCTGG 17

RESULT 273
AR328865 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6267 from patent US 6566127.
DEFINITION AR328865
ACCESSION AR328865
VERSION AR328865.1 GI:33714673
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
```

---

```
QY 766 TTAAATCAGATGGG 781
Db 2 TTATATCAGATGTG 17

RESULT 271
AR328136 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 5538 from patent US 6566127.
DEFINITION AR328136
ACCESSION AR328136
VERSION AR328136.1 GI:33713944
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5538 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 396 ATGTCATCTTGGCCG 411
Db 1 AGTGCATCTTGGCCG 16

RESULT 272
AR328864 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6266 from patent US 6566127.
DEFINITION AR328864
ACCESSION AR328864
VERSION AR328864.1 GI:33714672
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6266 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TAAAAACCCGTGTGG 839
Db 2 TAAAAACCCAGTCTGG 17

RESULT 273
AR328865 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6267 from patent US 6566127.
DEFINITION AR328865
ACCESSION AR328865
VERSION AR328865.1 GI:33714673
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
```

```
QY 290 AAGGATGAAGAGAGGC 305
Db 2 AAGGATGCAGAAAGGC 17

RESULT 276
AR457914
LOCUS AR457914 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1591 from patent US 6686188.
ACCESSION AR457914
VERSION AR457914.1 GI:42692971
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1591 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 290 AAGGATGAAGAGAGGC 305
Db 1 AAGGATGCAGAAAGGC 16

RESULT 277
AR459031
LOCUS AR459031 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2708 from patent US 6686188.
ACCESSION AR459031
VERSION AR459031.1 GI:42694088
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2708 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 290 AAGGATGAAGAGAGGC 305
Db 1 AAGGATGCAGAAAGGC 16

RESULT 278
AR459032
LOCUS AR459032 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2709 from patent US 6686188.
ACCESSION AR459032
VERSION AR459032.1 GI:42694089
KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2709 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTGGAG 221
Db 2 GTTCATGAGTTGGAG 17

RESULT 279
AR463544
LOCUS AR463544 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7221 from patent US 6686188.
ACCESSION AR463544
VERSION AR463544.1 GI:42698601
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7221 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTGGAG 221
Db 1 GTTCATGAGTTGGAG 16

RESULT 280
AR463545
LOCUS AR463545 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7222 from patent US 6686188.
ACCESSION AR463545
VERSION AR463545.1 GI:42698602
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7222 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAGATGGTGGGCC 352
Db 2 CAAGATGGTGGGCC 17
```

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAGATGGTGGCC 352  
|||||  
Db 1 CAAGGTGATGGCC 16

RESULT 281  
AR464090/c  
LOCUS AR464090 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 7767 from patent US 6686188.  
ACCESSION AR464090  
VERSION AR464090.1 GI:42699147  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 7767 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CCGCACACTGGTGTC 424  
|||||  
Db 17 CCGGACACTGGTGTC 2

RESULT 282  
AR464091/c  
LOCUS AR464091 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 7768 from patent US 6686188.  
ACCESSION AR464091  
VERSION AR464091.1 GI:42699148  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 7768 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CCGCACACTGGTGTC 424  
|||||  
Db 16 CCGGACACTGGTGTC 1

RESULT 283  
AR464304/c  
LOCUS AR464304 17 bp DNA linear PAT 20-FEB-2004

DEFINITION Sequence 7981 from patent US 6686188.  
ACCESSION AR464304  
VERSION AR464304.1 GI:42699361  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 7981 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCCTGCTAGCT 584  
|||||  
Db 17 TGTTCCTGCTGGCT 2

RESULT 284  
AR464305/c  
LOCUS AR464305 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 7982 from patent US 6686188.  
ACCESSION AR464305  
VERSION AR464305.1 GI:42699362  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 7982 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCCTGCTAGCT 584  
|||||  
Db 16 TGTTCCTGCTGGCT 1

RESULT 285  
AR464482  
LOCUS AR464482 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8159 from patent US 6686188.  
ACCESSION AR464482  
VERSION AR464482.1 GI:42699539  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8159 03-FEB-2004;

```
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 AGGATGAAGAGGCA 306
Db 2 AGTATGAAGAGCA 17

RESULT 286
AR464483
LOCUS AR464483 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8160 from patent US 6686188.
ACCESSION AR464483
VERSION AR464483.1 GI:42699540
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8160 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 291 AGGATGAAGAGGCA 306
Db 1 AGTATGAAGAGCA 16

RESULT 287
AR465282
LOCUS AR465282 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8959 from patent US 6686188.
ACCESSION AR465282
VERSION AR465282.1 GI:42700339
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8959 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCCTGCATGG 198
Db 2 CTGAAGGCCGACATGG 17

RESULT 288
AR465284
LOCUS AR465284 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8961 from patent US 6686188.
ACCESSION AR465284
VERSION AR465284.1 GI:42700341
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8961 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 TGAAGCCCTGCATGGA 199
Db 1 TGAAGGCCGACATGGA 16

RESULT 289
AR466536/c
LOCUS AR466536 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10213 from patent US 6686188.
ACCESSION AR466536
VERSION AR466536.1 GI:42701593
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10213 03-FEB-2004;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCGTCTGGGGTTCCG 21
Db 17 GTGTCTGGGGCTTCG 2

RESULT 290
AR466537/c
LOCUS AR466537 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10214 from patent US 6686188.
ACCESSION AR466537
VERSION AR466537.1 GI:42701594
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
```

Shannon, M.E.  
 Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
 Patent: US 6686188-A 10214 03-FEB-2004;  
 JOURNAL  
 FEATURES  
 source  
 1. .17  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match  
 Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCGTCTGGGGTTCCG 21  
 DB 16 GTGCTGGGGCTCCG 1

RESULT 291  
 AR483024/c  
 LOCUS  
 DEFINITION  
 Sequence 470 from patent US 6703228.  
 ACCESSION  
 AR483024  
 VERSION  
 AR483024.1 GI:47245547  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 Unknown.  
 Unclassified.  
 REFERENCE  
 1 (bases 1 to 17)  
 AUTHORS  
 Landers, J., Jordan, B., Houman, D.E. and Charest, A.  
 TITLE  
 Methods and products related to genotyping and DNA analysis  
 JOURNAL  
 Patent: US 6703228-A 470 09-MAR-2004;  
 FEATURES  
 Location/Qualifiers  
 1. .17  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match  
 Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 428 GAAAGACGAGTCACT 443  
 DB 17 GAGAAGACGAGACT 2

RESULT 292  
 AX007488  
 LOCUS  
 DEFINITION  
 Sequence 30 from Patent WO9967428.  
 ACCESSION  
 AX007488  
 VERSION  
 AX007488.1 GI:9995185  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 Aids-associated retrovirus  
 Aids-associated retrovirus  
 Viruses; Retroid viruses; Retroviridae.  
 REFERENCE  
 1  
 AUTHORS  
 Stuyver, L.  
 TITLE  
 Method for detection of drug-selected mutations in the hiv protease gene  
 JOURNAL  
 Patent: WO 9967428-A 30 29-DEC-1999;  
 INNOGENETICS NV (BE); STUYVER LIEVEN (BE)  
 FEATURES  
 Location/Qualifiers  
 1. .17  
 /organism="Aids-associated retrovirus"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:11966"

Query Match  
 Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAG 233

Db 2 GCAGATAATACAGTAG 17 .  
 RESULT 293  
 AX007649  
 LOCUS  
 DEFINITION  
 Sequence 191 from Patent WO9967428.  
 ACCESSION  
 AX007649  
 VERSION  
 AX007649.1 GI:9995346  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 Aids-associated retrovirus  
 Aids-associated retrovirus  
 Viruses; Retroid viruses; Retroviridae.  
 REFERENCE  
 1  
 AUTHORS  
 Stuyver, L.  
 TITLE  
 Method for detection of drug-selected mutations in the hiv protease gene  
 JOURNAL  
 Patent: WO 9967428-A 191 29-DEC-1999;  
 INNOGENETICS NV (BE); STUYVER LIEVEN (BE)  
 FEATURES  
 Location/Qualifiers  
 1. .17  
 /organism="Aids-associated retrovirus"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:11966"

Query Match  
 Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 712 GTTTTATAAACTCAG 727  
 DB 1 GTTTTATAAACTCAG 16

RESULT 294  
 AX215885/c  
 LOCUS  
 DEFINITION  
 Sequence 1327 from Patent WO0159103.  
 ACCESSION  
 AX215885  
 VERSION  
 AX215885.1 GI:15525928  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 synthetic construct  
 synthetic construct  
 other sequences; artificial sequences.  
 REFERENCE  
 1  
 AUTHORS  
 Blatt, L., McSwiggen, J. and Chowrira, B.M.  
 TITLE  
 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
 JOURNAL  
 Patent: WO 0159103-A 1327 16-AUG-2001;  
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)  
 FEATURES  
 Location/Qualifiers  
 1. .17  
 /organism="synthetic construct"  
 /mol\_type="unassigned RNA"  
 /db\_xref="taxon:32630"  
 /note="Nucleic Acid"

Query Match  
 Best Local Similarity 1.5%; Score 12.8; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 112 GGGCATCATCAATTTC 127  
 DB 16 GGGCATTAGCAATTTC 1

RESULT 295  
 AX216724/c  
 LOCUS  
 DEFINITION  
 Sequence 2166 from Patent WO0159103.  
 ACCESSION  
 AX216724

VERSION AX216724.1 GI:15526785  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
JOURNAL nogo gene expression  
PATENT: WO 0159103-A 2166 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 732 AATGCTGTTTCAATG 747  
||||| ||||| |||||  
Db 17 AATGTTTGTGCAATG 2

RESULT 296  
AX262632  
LOCUS AX262632 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 23 from Patent WO0173002.  
ACCESSION AX262632  
VERSION AX262632.1 GI:16511431  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
PATENT: WO 0173002-A 23 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 852 GCCTATTAAAGAATC 867  
||||| ||||| |||||  
Db 1 GGCTATCAAGAGATC 16

RESULT 297  
AX262633/c  
LOCUS AX262633/c 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 24 from Patent WO0173002.  
ACCESSION AX262633  
VERSION AX262633.1 GI:16511432  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.

TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
PATENT: WO 0173002-A 24 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 852 GCCTATTAAAGAATC 867  
||||| ||||| |||||  
Db 17 GGCTATCAAGAGATC 2

RESULT 298  
AX264260/c  
LOCUS AX264260 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1651 from Patent WO0173002.  
ACCESSION AX264260  
VERSION AX264260.1 GI:16513059  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
PATENT: WO 0173002-A 1651 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 728 TTAATAATGCTGTTTC 743  
||||| ||||| |||||  
Db 16 TGAATAATGACTGTTTC 1

RESULT 299  
AX264261  
LOCUS AX264261 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1652 from Patent WO0173002.  
ACCESSION AX264261  
VERSION AX264261.1 GI:16513060  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
PATENT: WO 0173002-A 1652 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"



```

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 728 TTAATAATGCTGTGTTTC 743
Db 2 TGAATAATGACTGTTTC 17

RESULT 300
AX499465/c
LOCUS AX266427 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3818 from Patent WO0173002.
ACCESSION AX266427
VERSION AX266427.1 GI:16515226
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec,E.B., Gamper,H.B. and Rice,M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3818 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 GGCATGTTGGAGACTT 318
Db 17 GCCATGTTGCAGACTT 2

RESULT 301
AX266428
LOCUS AX266428 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3819 from Patent WO0173002.
ACCESSION AX266428
VERSION AX266428.1 GI:16515227
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec,E.B., Gamper,H.B. and Rice,M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3819 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 GGCATGTTGGAGACTT 318
Db 1 GCCATGTTGCAGACTT 16

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 728 TTAATAATGCTGTGTTTC 743
Db 2 TGAATAATGACTGTTTC 17

RESULT 302
AX499465/c
LOCUS AX499465 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 772 from Patent EPI229046.
ACCESSION AX499465
VERSION AX499465.1 GI:23381758
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Zhan,J.
AUTHORS Human testis expressed patched like protein
TITLE Patent: EP 1229046-A 772 07-AUG-2002;
JOURNAL Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 TGACTTTGGCGAAAGGT 454
Db 17 TGACTTCTGCAAGGT 2

RESULT 303
AX499466/c
LOCUS AX499466 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 773 from Patent EPI229046.
ACCESSION AX499466
VERSION AX499466.1 GI:23381759
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Zhan,J.
AUTHORS Human testis expressed patched like protein
TITLE Patent: EP 1229046-A 773 07-AUG-2002;
JOURNAL Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 TGACTTTGGCGAAAGGT 454
Db 16 TGACTTCTGCAAGGT 1

RESULT 304
AX499489
LOCUS AX499489 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 796 from Patent EPI229046.
ACCESSION AX499489
VERSION AX499489.1 GI:23381782
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan, J.
TITLE        Human testis expressed patched like protein
JOURNAL      Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 98 GACGGCCAGTCGAGG 113
DB 2 GACGGCGCGTCGAGG 17

RESULT 305
AX499490
LOCUS          AX499490                17 bp    DNA          linear    PAT 27-SEP-2002
DEFINITION     Sequence 797 from Patent EP1229046.
ACCESSION      AX499490
VERSION        AX499490.1 GI:23381783
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Zhan, J.
TITLE          Human testis expressed patched like protein
JOURNAL        Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 98 GACGGCCAGTCGAGG 113
DB 2 GACGGCGCGTCGAGG 17

RESULT 305
AX499490
LOCUS          AX499490                17 bp    DNA          linear    PAT 27-SEP-2002
DEFINITION     Sequence 797 from Patent EP1229046.
ACCESSION      AX499490
VERSION        AX499490.1 GI:23381783
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Zhan, J.
TITLE          Human testis expressed patched like protein
JOURNAL        Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 98 GACGGCCAGTCGAGG 113
DB 1 GACGGCGCGTCGAGG 16

RESULT 306
AX502741/c
LOCUS          AX502741                17 bp    DNA          linear    PAT 27-SEP-2002
DEFINITION     Sequence 4048 from Patent EP1229046.
ACCESSION      AX502741
VERSION        AX502741.1 GI:23385034
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Zhan, J.
TITLE          Human testis expressed patched like protein
JOURNAL        Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 98 GACGGCCAGTCGAGG 113
DB 1 GACGGCGCGTCGAGG 16

RESULT 306
AX502741/c
LOCUS          AX502741                17 bp    DNA          linear    PAT 27-SEP-2002
DEFINITION     Sequence 4048 from Patent EP1229046.
ACCESSION      AX502741
VERSION        AX502741.1 GI:23385034
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Zhan, J.
TITLE          Human testis expressed patched like protein
JOURNAL        Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Zhan, J.
TITLE        Human testis expressed patched like protein
JOURNAL      Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836
DB 17 GAAAGAAAACCCCTGTA 2

RESULT 307
AX502742/c
LOCUS          AX502742                17 bp    DNA          linear    PAT 27-SEP-2002
DEFINITION     Sequence 4049 from Patent EP1229046.
ACCESSION      AX502742
VERSION        AX502742.1 GI:23385035
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Zhan, J.
TITLE          Human testis expressed patched like protein
JOURNAL        Patent: EP 1229046-A 4049 07-AUG-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836
DB 16 GAAAGAAAACCCCTGTA 1

RESULT 308
AX532554/c
LOCUS          AX532554                17 bp    DNA          linear    PAT 22-NOV-2002
DEFINITION     Sequence 2063 from Patent EP1239051.
ACCESSION      AX532554
VERSION        AX532554.1 GI:25256871
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens
REFERENCE      1
AUTHORS        Shannon, M.
TITLE          Human posh-like protein 1
JOURNAL        Patent: EP 1239051-A 2063 11-SEP-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 ATTTCTTTGTCATCCA 813
DB 17 ATTTCTTTGTCATCCA 2

RESULT 309
```

```
AX532555/c
LOCUS AX532555 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 2064 from Patent EP1239051.
ACCESSION AX532555
VERSION AX532555.1 GI:252556873
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 2064 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 798 ATTCTTGTCTCAATCA 813
Db 16 ATTCTTGTCTTCCA 1

RESULT 310
LOCUS AX579511/c 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1349 from Patent WO0211674.
ACCESSION AX579511
VERSION AX579511.1 GI:27648713
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clea-1)
JOURNAL Patent: WO 0211674-A 1349 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 641 GACTTTTTCAGAGTTG 656
Db 17 GACTTCTCAGAGTTG 2

RESULT 311
LOCUS AX635776 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 2915 from Patent EP1260586.
ACCESSION AX635776
VERSION AX635776.1 GI:28471390
KEYWORDS
SOURCE unidentified
ORGANISM unidentified

unclassified.
1
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Nodak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Weedler,D., Thompson,J.D., Tracz,D., Ueman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 2915 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 GTGATCTCACTCTCAG 389
Db 1 GGTCTTCACTCTCAG 16

RESULT 312
LOCUS AX673256/c 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1701 from Patent WO03004526.
ACCESSION AX673256
VERSION AX673256.1 GI:29331604
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1701 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 AAACGTGATTATGATC 693
Db 16 AAAATGATTAGGATC 1

RESULT 313
LOCUS AX674510 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2955 from Patent WO03004526.
ACCESSION AX674510
VERSION AX674510.1 GI:29332858
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
```

reversion, apoptosis and/or resistance to viruses and their use as medicines

JOURNAL Patent: WO 03004526-A 2955 16-JAN-2003;  
Molecular Engines Laboratories (FR)

## FEATURES

source

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 747 GACCTGTATTGCGCA 762

Db 1 GATCTGTCTTTTGCCA 16

## RESULT 314

AX688284

LOCUS AX688284 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1016 from Patent EP1281758.

ACCESSION AX688284  
VERSION AX688284.1 GI:29410984

KEYWORDS

SOURCE Homo sapiens (human)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

AUTHORS

TITLE

Shannon, M., Gu, Y. and Nguyen, C.T.  
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

mdz12

Patent: EP 1281758-A 1016 05-FEB-2003;

Aeomica, Inc. (US)

## FEATURES

source

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 AGGTGTGGGAGCAT 171

Db 2 AGGTTTGGGAGCCT 17

## RESULT 315

AX688285

LOCUS AX688285 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1017 from Patent EP1281758.

ACCESSION AX688285  
VERSION AX688285.1 GI:29410985

KEYWORDS

SOURCE Homo sapiens (human)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

AUTHORS

TITLE

Shannon, M., Gu, Y. and Nguyen, C.T.  
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

mdz12

Patent: EP 1281758-A 1017 05-FEB-2003;

Aeomica, Inc. (US)

## FEATURES

source

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 156 AGGTGTGGGAGCAT 171

Db 1 AGGTTTGGGAGCCT 16

## RESULT 316

AX691935

LOCUS AX691935 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 4667 from Patent EP1281758.

ACCESSION

AX691935

VERSION AX691935.1 GI:29414876

KEYWORDS

SOURCE Homo sapiens (human)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

AUTHORS

TITLE

Shannon, M., Gu, Y. and Nguyen, C.T.  
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

mdz12

Patent: EP 1281758-A 4667 05-FEB-2003;

Aeomica, Inc. (US)

## FEATURES

source

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 CTGAGGCCCTTAAC 564

Db 2 CTGAGGCCCTCAGCT 17

## RESULT 317

AX691937

LOCUS AX691937 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 4669 from Patent EP1281758.

ACCESSION

AX691937

VERSION AX691937.1 GI:29414878

KEYWORDS

SOURCE Homo sapiens (human)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

AUTHORS

TITLE

Shannon, M., Gu, Y. and Nguyen, C.T.  
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

mdz12

Patent: EP 1281758-A 4669 05-FEB-2003;

Aeomica, Inc. (US)

## FEATURES

source

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 TGAGGCCCTTAATC 565

Db 1 TGAGGCCCTCAGCTC 16

```
RESULT 318
AX725440/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 3127 from Patent WO03025176.
ACCESSION  AX725440
VERSION     AX725440.1 GI:30504783
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 3127 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      424 CCATGAAAGGAGAT 439
Db      17 CCTTGAAGAAATCAGAT 2

RESULT 319
AX728278/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5965 from Patent WO03025176.
ACCESSION  AX728278
VERSION     AX728278.1 GI:30507621
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 5965 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      424 CCATGAAAGGAGAT 439
Db      17 CCTTGAAGAAATCAGAT 2

RESULT 320
AX729524
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 1158 from Patent WO03025175.
ACCESSION  AX729524
VERSION     AX729524.1 GI:30508867
```

```
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 1158 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      261 ATCCTCTATCCAGAAA 276
Db      2 ATCCTATATCTAGAAA 17

RESULT 321
AX729894/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 1528 from Patent WO03025175.
ACCESSION  AX729894
VERSION     AX729894.1 GI:30509237
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 1528 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      670 GTATGTGAGAACTGAT 685
Db      17 GTTGTGAAGAACTGAT 2

RESULT 322
AX732441/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 4075 from Patent WO03025175.
ACCESSION  AX732441
VERSION     AX732441.1 GI:30511784
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
```

TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 4075 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 236 TGTACAGTGCAGTC 251  
|||||  
Db 16 TGTACAGTGCAGATC 1

RESULT 323  
AX732552/C  
LOCUS AX732552 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4186 from Patent WO03025175.  
ACCESSION AX732552  
VERSION AX732552.1 GI:30511895  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 4186 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 185 GAAGGCTGCATGGAT 200  
|||||  
Db 17 GAAGGCTGGTGGAT 2

RESULT 324  
AX733805/C  
LOCUS AX733805 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5439 from Patent WO03025175.  
ACCESSION AX733805  
VERSION AX733805.1 GI:30513148  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 5439 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17

/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 505 TGGTGTAAATGGGATC 520  
|||||  
Db 16 TGGTGTAACTGGGATC 1

RESULT 325  
AX733950  
LOCUS AX733950 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5584 from Patent WO03025175.  
ACCESSION AX733950  
VERSION AX733950.1 GI:30513293  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 5584 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGA 391  
|||||  
Db 1 GATCTCCTCTCAGGA 16

RESULT 326  
AX735466  
LOCUS AX735466 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 1056 from Patent WO03025177.  
ACCESSION AX735466  
VERSION AX735466.1 GI:30514743  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 1056 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 2.1e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY 690 GATCACTTGAAGATT 705
Db 1 GATCACTTAGAAATT 16

RESULT 327
AX736213/C
LOCUS AX736213 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1803 from Patent WO03025177.
ACCESSION AX736213
VERSION AX736213.1 GI:30515490
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1803 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 AAACGATTTATGATC 693
Db 16 AAACGATTTGATC 1

RESULT 328
AX736475
LOCUS AX736475 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2065 from Patent WO03025177.
ACCESSION AX736475
VERSION AX736475.1 GI:30515763
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2065 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 GATCACTTGAAGATT 705
Db 1 GATCGCTTAGAAGATT 16

RESULT 329
AX737257
LOCUS AX737257 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2847 from Patent WO03025177.
ACCESSION AX737257
VERSION AX737257.1 GI:30516545
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2847 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 170 ATTAAGGAGCTGACTG 185
Db 2 ATCCAAGGAGCTGACTG 17

RESULT 330
AX737808
LOCUS AX737808 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3398 from Patent WO03025177.
ACCESSION AX737808
VERSION AX737808.1 GI:30517096
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telerman,A., Anson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3398 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 595 ATCCTGATTAACATTA 610
Db 2 ATCCTGTAATATTA 17

RESULT 331
AX738774/C
LOCUS AX738774 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4364 from Patent WO03025177.
ACCESSION AX738774
VERSION AX738774.1 GI:30518064
KEYWORDS
SOURCE Homo sapiens (human)
```





```

/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 595 ATCCTGATAAATTA 610
    ||||| ||||| |||||
Db 2 ATCCTGCTAAATTA 17

RESULT 336
AX759535
LOCUS      17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2856 from Patent WO03040369.
ACCESSION AX759535
VERSION    AX759535.1 GI:32254151
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Teleman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL    Patent: WO 03040369-A 2856 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 690 GATCACTTGAAGATT 705
    ||||| ||||| |||||
Db 1 GATCACTTAGAAAATT 16

RESULT 337
AX759882/c
LOCUS      17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3203 from Patent WO03040369.
ACCESSION AX759882
VERSION    AX759882.1 GI:32254498
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Teleman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL    Patent: WO 03040369-A 3203 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 185 GAAGGCTGCATGGAT 200
    ||||| ||||| |||||
Db 17 GAAGGCTGCGTGGAT 2

/db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 595 ATCCTGATAAATTA 610
    ||||| ||||| |||||
Db 2 ATCCTGCTAAATTA 17

RESULT 336
AX759535
LOCUS      17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2856 from Patent WO03040369.
ACCESSION AX759535
VERSION    AX759535.1 GI:32254151
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Teleman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL    Patent: WO 03040369-A 2856 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 690 GATCACTTGAAGATT 705
    ||||| ||||| |||||
Db 1 GATCACTTAGAAAATT 16

RESULT 337
AX759882/c
LOCUS      17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3203 from Patent WO03040369.
ACCESSION AX759882
VERSION    AX759882.1 GI:32254498
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Teleman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL    Patent: WO 03040369-A 3203 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 185 GAAGGCTGCATGGAT 200
    ||||| ||||| |||||
Db 17 GAAGGCTGCGTGGAT 2

```

```

VERSION      AX782230.1  GI:32950079
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 561 19-JUN-2003;
              Amersham Biosciences (SV) Corp. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      638  TGTGACTTTTTCAGAG 653
           ||| ||||| |||||
Db       16  TGAGACTTTTCAGG 1

RESULT 341
AX782231/c
LOCUS       AX782231                17 bp    DNA    linear    PAT 17-JUL-2003
DEFINITION  Sequence 562 from Patent WO03050284.
ACCESSION   AX782231
VERSION     AX782231.1  GI:32950080
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 562 19-JUN-2003;
              Amersham Biosciences (SV) Corp. (US)
FEATURES     source
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      636  TGTGACTTTTTCAG 651
           ||| ||||| |||||
Db       17  TCTGAGACTTTTTCAG 2

RESULT 342
AX782233/c
LOCUS       AX782233                17 bp    DNA    linear    PAT 17-JUL-2003
DEFINITION  Sequence 564 from Patent WO03050284.
ACCESSION   AX782233
VERSION     AX782233.1  GI:32950082
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 564 19-JUN-2003;
              Amersham Biosciences (SV) Corp. (US)

```

```

FEATURES     source
              Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      635  TTGTGACTTTTTCAC 650
           ||| ||||| |||||
Db       16  TCTGAGACTTTTTCAC 1

RESULT 343
BD066052/c
LOCUS       BD066052                17 bp    DNA    linear    PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066052
VERSION     BD066052.1  GI:22611655
KEYWORDS    JP 2001511000-A/687.
SOURCE      unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Schlingsiepen,K.H. and Brysch,W.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: JP 2001511000-A 687 07-AUG-2001;
              BIOGNOSTIK GSELSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT      OS Unknown
              PN JP 2001511000-A/687
              PD 07-AUG-2001
              PF 30-JAN-1998  JP 1998532533
              PR 31-JAN-1997  EP 97101531.8
              PI KARL HERMANN SCHLINGSIEPEN,WOLFGANG BRYSCH
              PC C12N15/11,C07H21/04,A61K31/70
              CC An antisense oligonucleotide preparation method FH Key
              Location/Qualifiers
              FT source
              1..17
              /organism='Unknown'.
FEATURES     source
              Location/Qualifiers
              1..17
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      730  AAAATGTCGTGTTCAA 745
           ||||| |||||
Db       16  AAAATGTTTATTTCAA 1

RESULT 344
BD067878/c
LOCUS       BD067878                17 bp    RNA    linear    PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
              to levels of epidermal growth factor receptors.
ACCESSION   BD067878
VERSION     BD067878.1  GI:22613481
KEYWORDS    JP 2001511003-A/718.
SOURCE      unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE        Enzymatic nucleic acid treatment of diseases or conditions related
              to levels of epidermal growth factor receptors
JOURNAL      Patent: JP 2001511003-A 718 07-AUG-2001;
              RIBOZYME PHARMACEUTICALS INC,ASTON UNIV

```

```

COMMENT      OS      Unidentified
PN      JP 2001511003-A/718
PD      07-AUG-2001
PF      14-JAN-1998 JP 1998532913
PR      31-JAN-1997 US 60/036476, 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA PELL, JAMES A MCSWIGGEN PC
C12N9/00, C07K14/71
CC      Strandedness: Single;
CC      Topology: Linear;
CC      Enzymatic nucleic acid treatment of diseases or conditions CC
      related to
CC      levels of epidermal growth factor receptors
FH      Key      Location/Qualifiers
FT      source  1..17
FT      /organism='Unidentified'.
FEATURES
source
1..17      Location/Qualifiers
1..17      /organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      114 GCATCATCAATTTCGA 129
DB      17 GCATTATCAATTTCAA 2
|||||
RESULT 345
BD104610/c
LOCUS      BD104610      17 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION      Kit and method for determining HLA type.
ACCESSION      BD104610
VERSION      BD104610.1 GI:22650184
KEYWORDS      WO 0192572-A/714.
SOURCE      synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.
TITLE      Kit and method for determining HLA type
JOURNAL      Patent: WO 0192572-A 714 06-DEC-2001;
      NISSHINO INDUSTRIES INC, SYSTEM RESEARCH INC, HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA
COMMENT      OS      Artificial Sequence
PN      WO 0192572-A/714
PD      06-DEC-2001
PF      01-JUN-2001 WO 2001JP004662
PR      01-JUN-2000 JP 00P 164798
PI      HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI PI MATSUMURA, MICHIO NISHIDA
FH      Key      Location/Qualifiers
FT      source  1..17
FT      /organism='Artificial Sequence'.
FEATURES
source
1..17      Location/Qualifiers
1..17      /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      104 CCAGTCGAGGCATCA 119
|||||

```

```

DB      17 CCAGTACTGGGCATCA 2
RESULT 346
CQ821410
LOCUS      CQ821410      14 bp      DNA      linear      PAT 14-JUN-2004
DEFINITION      Sequence 16 from Patent WO2004038019.
ACCESSION      CQ821410
VERSION      CQ821410.1 GI:48716059
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS      Beeson,D., Wood,M. and Abdelgany,A.
TITLE      Dnazyme cleaving mutant polynucleotides
JOURNAL      Patent: WO 2004038019-A 16 06-MAY-2004;
      ISIS INNOVATION LIMITED (GB)
FEATURES
source
1..14      Location/Qualifiers
1..14      /organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match      1.4%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. NO. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      437 GATGACTTGGCAA 450
DB      1 GATGACTCGGGCAA 14
|||||
RESULT 347
AX081113
LOCUS      AX081113      14 bp      DNA      linear      PAT 27-FEB-2001
DEFINITION      Sequence 13 from Patent WO0109385.
ACCESSION      AX081113
VERSION      AX081113.1 GI:13170025
KEYWORDS      synthetic construct
SOURCE      synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Lukhtanov,E.A., Podymnagin,M.A. and Hedgpeth,J.
TITLE      Attachment of oligonucleotides to solid supports through schiff base type linkages for capture and detection of nucleic acids
JOURNAL      Patent: WO 0109385-A 13 08-FEB-2001;
      Epoch Pharmaceuticals, Inc. (US)
FEATURES
source
1..14      Location/Qualifiers
1..14      /organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/Note="probe-5' Ald"
Query Match      1.4%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. NO. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      496 TTGCGCTTGTGTG 509
DB      1 TTGCGCTGTGTG 14
|||||
RESULT 348
C135229/c
LOCUS      C135229      15 bp      DNA      linear      PAT 13-MAY-1997
DEFINITION      Sequence 197 from patent US 5599706.
ACCESSION      C135229
VERSION      C135229.1 GI:2088197
KEYWORDS

```

SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	Unknown. Unclassified. 1 (bases 1 to 15) Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R. Ribozymes targeted to apo(a) mRNA Patent: US 5599706-A 197 04-FEB-1997; Location/Qualifiers 1..15 /organism="unknown" /mol_type="unassigned DNA"									
	Query Match	1.4%;	Score 12.4;	DB 1;	Length 15;					
	Best Local Similarity	92.9%;	Pred. No. 2.1e+02;							
	Matches	13;	Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
	QY	703	ATTGTATAGTTT	716						
	Db	15	ATTGGATAGTTT	2						
	RESULT 349									
	LOCUS	AX085048	Sequence 225 from Patent WO0113117.	15 bp	DNA	linear	PAT 09-MAR-2001			
	ACCESSION	AX085048								
	VERSION	AX085048.1	GI:13275196							
SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	synthetic construct other sequences; artificial sequences. Herath,H.M. Proteins, genes and their use for diagnosis and treatment of breast cancer Patent: WO 0113117-A 225 22-FEB-2001; Oxford GlycoSciences (UK) Limited (GB) Location/Qualifiers 1..15 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Probe"									
	Query Match	1.4%;	Score 12.4;	DB 1;	Length 15;					
	Best Local Similarity	92.9%;	Pred. No. 2.1e+02;							
	Matches	13;	Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
	QY	84	GCGTGCTGAAGGC	97						
	Db	2	GCGTGCTGAGGC	15						
	RESULT 350									
	LOCUS	A35583	Synthetic human IFN-alpha 2 gene oligo.	16 bp	DNA	linear	PAT 02-DEC-1996			
	ACCESSION	A35583								
	VERSION	A35583.1	GI:1926965							
SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	synthetic construct synthetic construct other sequences; artificial sequences. 1 (bases 1 to 16) Cambie,R. and Edge,M.D. Analogous interferon polypeptides, process for their preparation and pharmaceutical compositions containing them Patent: EP 0194006-A 28 10-SEP-1986; IMPERIAL CHEMICAL INDUSTRIES PLC Location/Qualifiers 1..16 /organism="synthetic construct" /mol_type="unassigned DNA"									
	Query Match	1.4%;	Score 12.4;	DB 1;	Length 16;					
	Best Local Similarity	92.9%;	Pred. No. 2.2e+02;							
	Matches	13;	Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
	QY	362	ATTGAAGATTCTGT	375						
	Db	15	ATTGAGATTCTGT	2						
	RESULT 353									
	LOCUS	AX099234	Sequence 18 from Patent WO0120031.	16 bp	DNA	linear	PAT 02-APR-2001			
	DEFINITION	AX099234								
	ACCESSION	AX099234								
SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	Unassigned. Unclassified. 1 (bases 1 to 16) Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6566127-A 5681 20-MAY-2003; Location/Qualifiers 1..16 /organism="unknown" /mol_type="unassigned RNA"									
	Query Match	1.4%;	Score 12.4;	DB 1;	Length 16;					
	Best Local Similarity	92.9%;	Pred. No. 2.2e+02;							
	Matches	13;	Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
	QY	473	AAGACAGGAACGC	486						
	Db	16	AAGACAGGAACGC	3						
	RESULT 351									
	LOCUS	AR235510	Sequence 9 from patent US 6461810.	16 bp	DNA	linear	PAT 20-DEC-2002			
	ACCESSION	AR235510								
	VERSION	AR235510.1	GI:27278731							
SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	Unknown. Unclassified. 1 (bases 1 to 16) Presco,J.R. and Johnson,M.D. Triplex in-situ hybridization Patent: US 6461810-A 9 08-OCT-2002; Location/Qualifiers 1..16 /organism="unknown" /mol_type="genomic DNA"									
	Query Match	1.4%;	Score 12.4;	DB 1;	Length 16;					
	Best Local Similarity	92.9%;	Pred. No. 2.2e+02;							
	Matches	13;	Conservative	0;	Mismatches 1;	Indels	0;	Gaps	0;	
	QY	799	TTTCTTTGTCATTC	812						
	Db	3	TTTCTTTTCATTC	16						
	RESULT 352									
	LOCUS	AR328279	Sequence 5681 from patent US 6566127.	16 bp	RNA	linear	PAT 17-AUG-2003			
	DEFINITION	AR328279								
	ACCESSION	AR328279.1	GI:33714087							

```

VERSION  AX099234.1  GI:13538411
SOURCE    synthetic construct
ORGANISM  synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS   Hasegawa,K.K., Kikuchi,Y.K., Nakano,H.K., Molloy,H. and Chiano,M.
TITLE      Polymorphisms in a kiocho gene
JOURNAL    Patent: WO 0120031-A 18 22-MAR-2001;
            KYOWA HAKKO KOGYO CO., LTD. (JP)
FEATURES  Location/Qualifiers
            1..16
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="PCR Primer 14 (Example 2)"

Query Match      1.4%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 GGCCTCAGTCGAGG 114
Db 2 GGCCTCAGTCGAGG 15

RESULT 354
AX590960/c
LOCUS      AX590960
DEFINITION Sequence 400 from Patent WO02086113.
ACCESSION  AX590960
VERSION     AX590960.1  GI:27949510
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS   Cookson,W.O., Moffat,M.P., Allen,M. and Lench,N.
TITLE      Enzyme and snp marker for disease
JOURNAL    Patent: WO 02086113-A 400 31-OCT-2002;
            Isis Innovation Limited (GB)
FEATURES  Location/Qualifiers
            1..16
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Primer"

Query Match      1.4%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 134 AAGGAAGTAATGG 147
Db 14 AAGGAAGCAATGG 1

RESULT 355
CQ828340/c
LOCUS      CQ828340
DEFINITION Sequence 58 from Patent WO2004053120.
ACCESSION  CQ828340
VERSION     CQ828340.1  GI:49731823
KEYWORDS   Rattus norvegicus (Norway rat)
SOURCE     Rattus norvegicus
ORGANISM   Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1
AUTHORS   Weihe,E., Bieller,A. and Schaefer,M.K.
TITLE      Regulatory elements in the 5' region of the vrl gene
JOURNAL    Patent: WO 2004053120-A 58 24-JUN-2004;

```

```

FEATURES  Location/Qualifiers
            1..14
            /organism="Rattus norvegicus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:10116"
            /note="v$CEBFB 01"

Query Match      1.4%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 ATTGCATCATTTG 407
Db 12 ATTGCATCATTTG 1

RESULT 356
AR133678/c
LOCUS      AR133678
DEFINITION Sequence 2103 from patent US 6194150.
ACCESSION  AR133678
VERSION     AR133678.1  GI:14122583
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE      Nucleic acid based inhibition of CD40
JOURNAL    Patent: US 6194150-A 2103 27-FEB-2001;
            Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 AAAGCAGATGAC 442
Db 14 AAAGCAGATGAC 3

RESULT 357
I39110
LOCUS      I39110
DEFINITION Sequence 148 from patent US 5616488.
ACCESSION  I39110
VERSION     I39110.1  GI:2083590
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS   Sullivan,S., Draper,K.G., McSwiggen,J. and Stinchcomb,D.T.
TITLE      IL-5 targeted ribozymes
JOURNAL    Patent: US 5616488-A 148 01-APR-1997;
            Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 AAAATGTCGTGT 741
Db 1 AAAATGTCGTGT 12

```

```

RESULT 358
I80907/c
LOCUS      15 bp      DNA      linear      PAT 10-JUN-1998
DEFINITION Sequence 24 from patent US 5709997.
ACCESSION  I80907
VERSION     I80907.1  GI:3209197
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Marshall,R.L., Jou,C., Simons,J.N., Leary,T.P., Muerhoff,A.Scott.,
          Desai,S.M. and Mushahwar,I.K.
TITLE     Nucleic acid detection of hepatitis GB virus
JOURNAL   Patent: US 5709997-A 24 20-JAN-1998;
FEATURES   Location/Qualifiers
            source
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  90  TGAAGGGCGACG 101
Db    |||||
13  TGAAGGGCGACG 2

RESULT 359
AX377090
LOCUS      15 bp      DNA      linear      PAT 18-MAR-2002
DEFINITION Sequence 11 from Patent WO0212561.
ACCESSION  AX377090
VERSION     AX377090.1  GI:19573381
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Kazemi,A., Messer,C. and Tanguay,D.A.
TITLE     Haplotypes of the origl gene
JOURNAL   Patent: WO 0212561-A 11 14-FEB-2002;
          Genaisance Pharmaceuticals, Inc. (US)
FEATURES   Location/Qualifiers
            source
            1..15
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY  611 AACACTGTAATCTT 624
Db    |||||:||||
1  AACACTGKAATATT 14

RESULT 360
AX635353
LOCUS      15 bp      RNA      linear      PAT 21-FEB-2003
DEFINITION Sequence 2492 from Patent EP1260586.
ACCESSION  AX635353
VERSION     AX635353.1  GI:28470967
KEYWORDS   .
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE  1
AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
          Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,

Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 2492 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
            source
            1..15
            /organism="unidentified"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32644"

Query Match      1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  730 AAAATGTCTGTT 741
Db    |||||
1  AAAATGTCTGTT 12

RESULT 361
AR029842
LOCUS      16 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 31 from patent US 5861244.
ACCESSION  AR029842
VERSION     AR029842.1  GI:5943056
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 16)
AUTHORS   Wang,C.-G. and Hepburn,A.G.
TITLE     Genetic sequence assay using DNA triple strand formation
JOURNAL   Patent: US 5861244-A 31 19-JAN-1999;
          Location/Qualifiers
FEATURES   Location/Qualifiers
            source
            1..16
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.4%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  456 GAAATGAAGAAA 467
Db    |||||
5  GAAATGAAGAAA 16

RESULT 362
AR329561/c
LOCUS      16 bp      RNA      linear      PAT 17-AUG-2003
DEFINITION Sequence 6963 from patent US 6566127.
ACCESSION  AR329561
VERSION     AR329561.1  GI:33715369
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 16)
AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6566127-A 6963 20-MAY-2003;
          Location/Qualifiers
FEATURES   Location/Qualifiers
            source
            1..16
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      1.4%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 93 AGGGCGACGGCC 104  
Db 15 AGGGCGACGGCC 4

RESULT 363  
BD104793/C  
LOCUS BD104793 16 bp DNA linear PAT 27-AUG-2002  
DEFINITION Kit and method for determining HLA type.  
ACCESSION BD104793  
VERSION BD104793.1 GI:22650367  
KEYWORDS WO 0192572-A/897.  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.  
TITLE Kit and method for determining HLA type  
JOURNAL Patent: WO 0192572-A 897 06-DEC-2001;  
NISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO NISHIDA  
COMMENT OS Artificial Sequence  
PN WO 0192572-A/897  
PD 06-DEC-2001  
PF 01-JUN-2001 WO 2001JP004662  
PR 01-JUN-2000 JP 00P 164798  
PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI MATSUMURA,  
PI SHOGO MORIYA,MICHIO NISHIDA  
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53  
CC Description of Artificial Sequence:capture  
FH Key Location/Qualifiers  
FT source 1..16  
FT /organism='Artificial Sequence'.  
FEATURES  
source  
1..16  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 1.4%; Score 12; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 825 AAAAACCCCTGTA 836  
Db 12 AAAAACCCCTGTA 1

Search completed: October 6, 2005, 10:39:58  
Job time : 4 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 6, 2005, 10:41:23 ; Search time 2 Seconds  
(without alignments)  
2.994 Million cell updates/sec

Title: US-10-633-843-3-COPY  
Perfect score: 874  
Sequence: 1 ctgcagctctgtgggtttcc.....tattaaagaatccaatttc 874

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 188 seqs, 3426 residues

Total number of hits satisfying chosen parameters: 376

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 194 summaries

Database : issdb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	28	3.2	28	1	US-08-859-998-1011
2	28	3.2	28	1	US-08-859-998-1012
3	28	3.2	28	1	US-09-225-928-1011
4	28	3.2	28	1	US-09-225-928-1012
5	28	3.2	28	1	US-09-225-201B-1011
6	28	3.2	28	1	US-09-225-201B-1012
7	24	2.7	24	1	US-08-023-980B-18
8	24	2.7	24	1	US-08-486-953A-13
9	24	2.7	24	1	US-08-204-052-13
10	22	2.5	29	1	US-08-668-381A-2
11	21.8	2.5	25	1	5290690-19
12	21.8	2.5	25	1	5290690-19
13	20	2.3	21	1	US-08-023-980B-5
14	20	2.3	21	1	US-08-486-953A-5
15	20	2.3	21	1	US-08-204-052-5
16	17.2	2.0	22	1	US-09-307-794A-7
17	17.2	2.0	22	1	US-09-505-125A-7
18	17.2	2.0	22	1	US-09-505-125A-7
19	17.2	2.0	22	1	US-09-505-125A-7
20	17.2	2.0	22	1	US-09-505-125A-7
21	17.2	2.0	22	1	US-09-505-125A-7
22	17.2	2.0	22	1	US-09-505-125A-7
23	17.2	2.0	22	1	US-09-505-125A-7
24	17.2	2.0	22	1	US-09-505-125A-7
25	17.2	2.0	22	1	US-09-505-125A-7
26	17.2	2.0	22	1	US-09-505-125A-7
27	17.2	2.0	22	1	US-09-505-125A-7
28	17.2	2.0	22	1	US-09-505-125A-7
29	17.2	2.0	22	1	US-09-505-125A-7
30	16.8	1.9	20	1	US-09-068-506-48
31	16.8	1.9	21	1	US-08-023-980B-10
32	16.8	1.9	21	1	US-08-486-953A-10
33	16.8	1.9	21	1	US-08-204-052-10

34	16	1.8	19	1	US-09-545-686-27	Sequence 27, Appl
35	15.8	1.8	20	1	US-08-202-042-2	Sequence 2, Appl
36	15.8	1.8	20	1	US-09-060-299-236	Sequence 236, App
37	15.8	1.8	20	1	US-09-402-923A-236	Sequence 236, App
38	15.8	1.8	20	1	US-09-909-595-79	Sequence 79, Appl
39	15.2	1.7	20	1	US-09-040-285A-4	Sequence 4, Appl
40	15.2	1.7	20	1	US-09-288-461-39	Sequence 39, Appl
41	15.2	1.7	20	1	US-09-758-881-39	Sequence 39, Appl
42	15	1.7	20	1	US-08-846-020A-17	Sequence 17, Appl
43	15	1.7	20	1	US-09-617-871-17	Sequence 17, Appl
44	14.8	1.7	19	1	US-09-108-006C-31	Sequence 31, Appl
45	14.8	1.7	19	1	US-09-696-791-574	Sequence 574, App
46	14.4	1.6	17	1	US-08-412-614-102	Sequence 102, App
47	14.4	1.6	17	1	US-08-412-614-104	Sequence 104, App
48	14.4	1.6	17	1	US-08-635-761-102	Sequence 102, App
49	14.4	1.6	17	1	US-08-635-761-104	Sequence 104, App
50	14.4	1.6	17	1	US-09-312-520-102	Sequence 102, App
51	14.4	1.6	17	1	US-09-312-520-104	Sequence 104, App
52	14.4	1.6	17	1	US-09-863-086-102	Sequence 102, App
53	14.4	1.6	17	1	US-09-863-086-104	Sequence 104, App
54	14.4	1.6	17	1	US-09-696-791-1547	Sequence 1547, App
55	14	1.6	17	1	US-08-373-124A-962	Sequence 962, App
56	14	1.6	17	1	US-08-373-124A-964	Sequence 964, App
57	14	1.6	17	1	US-08-373-124A-966	Sequence 966, App
58	14	1.6	17	1	US-08-435-628-962	Sequence 962, App
59	14	1.6	17	1	US-08-435-628-964	Sequence 964, App
60	14	1.6	17	1	US-08-435-628-966	Sequence 966, App
61	13.8	1.6	17	1	US-08-584-040-5950	Sequence 5950, App
62	13.8	1.6	17	1	US-09-371-772B-2787	Sequence 2787, App
63	13.8	1.6	17	1	US-09-371-772B-2787	Sequence 2787, App
64	13.8	1.6	17	1	US-09-371-772B-2787	Sequence 2787, App
65	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
66	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
67	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
68	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
69	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
70	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
71	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
72	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
73	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
74	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
75	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
76	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
77	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
78	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
79	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
80	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
81	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
82	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
83	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
84	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
85	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
86	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
87	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
88	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
89	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
90	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
91	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
92	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
93	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
94	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
95	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
96	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
97	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
98	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
99	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
100	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
101	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
102	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
103	13.8	1.6	17	1	US-09-866-108A-8960	Sequence 8960, App
104	13.4	1.5	17	1	US-09-866-108A-8960	Sequence 8960, App
105	13.4	1.5	17	1	US-09-866-108A-8960	Sequence 8960, App
106	13.4	1.5	17	1	US-09-866-108A-8960	Sequence 8960, App



```
Db      1 AGTGCAGGCATCATCAATTCGAGCAG 28
|||||
RESULT 2
US-08-859-998-1012/c
; Sequence 1012, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1012:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; FILING DATE:
; APPLICATION NUMBER:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1012:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
US-08-859-998-1012
Query Match      3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      376 GATCTCACTCTCAGGAGACCATTCGATC 403
|||||
Db      28 GATCTCACTCTCAGGAGACCATTCGATC 1
|||||
RESULT 3
US-09-225-928-1011
; Sequence 1011, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>

QY      106 AGTGAGGGCATCATCAATTCGAGCAG 133
|||||
Db      1 AGTGAGGGCATCATCAATTCGAGCAG 28
|||||
RESULT 4
US-09-225-928-1012/c
; Sequence 1012, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
```

```
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/859,998
/ FILING DATE: 21-MAY-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Field, Bret E.
/ REGISTRATION NUMBER: 37,620
/ REFERENCE/DOCKET NUMBER: 09096/002001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-322-5070
/ TELEFAX: 415-854-0875
/ INFORMATION FOR SEQ ID NO: 1011:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 28 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ FEATURE:
/ OTHER INFORMATION: oligonucleotide primer
/ SEQUENCE DESCRIPTION: SEQ ID NO: 1011:
US-09-225-928-1012
Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 5
US-09-225-201B-1011
/ Sequence 1011, Application US/09225201B
/ Patent No. 6489455
/ GENERAL INFORMATION:
/ APPLICANT: Chenchik, Alex
/ Johhadze, George
/ Bibilashvilli, Robert
/ TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
/ EXPRESSION
/ NUMBER OF SEQUENCES: 1375
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson, P.C.
/ STREET: 2200 Sand Hill Road, Suite 100
/ CITY: Menlo Park
/ STATE: CA
/ COUNTRY: US
/ ZIP: 94025
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: Windows95
/ SOFTWARE: FastSeq for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/225,201B
/ FILING DATE: 05-Jan-1999
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/859,998
/ FILING DATE: 21-MAY-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Field, Bret E.
/ REGISTRATION NUMBER: 37,620
/ REFERENCE/DOCKET NUMBER: 09096/002001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-322-5070
/ TELEFAX: 415-854-0875
/ INFORMATION FOR SEQ ID NO: 1011:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 28 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ FEATURE:
/ OTHER INFORMATION: oligonucleotide primer
/ SEQUENCE DESCRIPTION: SEQ ID NO: 1012:
US-09-225-928-1012
Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 6
US-09-225-201B-1012/C
/ Sequence 1012, Application US/09225201B
/ Patent No. 6489455
/ GENERAL INFORMATION:
/ APPLICANT: Chenchik, Alex
/ Johhadze, George
/ Bibilashvilli, Robert
/ TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
/ EXPRESSION
/ NUMBER OF SEQUENCES: 1375
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson, P.C.
/ STREET: 2200 Sand Hill Road, Suite 100
/ CITY: Menlo Park
/ STATE: CA
/ COUNTRY: US
/ ZIP: 94025
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: Windows95
/ SOFTWARE: FastSeq for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/225,201B
/ FILING DATE: 05-Jan-1999
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/859,998
/ FILING DATE: 21-MAY-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Field, Bret E.
/ REGISTRATION NUMBER: 37,620
/ REFERENCE/DOCKET NUMBER: 09096/002001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-322-5070
/ TELEFAX: 415-854-0875
/ INFORMATION FOR SEQ ID NO: 1012:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 28 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ FEATURE:
/ OTHER INFORMATION: oligonucleotide primer
/ SEQUENCE DESCRIPTION: SEQ ID NO: 1012:
US-09-225-201B-1012
Query Match 3.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1
```

```
RESULT 7
US-08-023-980B-18/c
; Sequence 18, Application US/08023980B
; Patent No. 5843641
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 585 Commercial Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-1024
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/023,980B
; FILING DATE: 26-FEB-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/177001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/723-4123
; TELEFAX: 617/723-8962
; TELEX:
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-023-980B-18

Query Match 2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 556 CCCTTAACCTCATCTGTTATCTCTGC 579
DB 24 CCCTTAACCTCATCTGTTATCTCTGC 1

RESULT 8
US-08-486-953A-13/c
; Sequence 13, Application US/08486953A
; Patent No. 5849290
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 176 Federal Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/204,052
; FILING DATE: 28-FEB-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/023,980
; FILING DATE: 26-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
```

```
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: FastSeq
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,953A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/204,052
; FILING DATE: 28-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/428-0200
; TELEFAX: 617/428-7045
; TELEX:
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-486-953A-13

Query Match 2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 556 CCCTTAACCTCATCTGTTATCTCTGC 579
DB 24 CCCTTAACCTCATCTGTTATCTCTGC 1

RESULT 9
US-08-204-052-13/c
; Sequence 13, Application US/08204052
; Patent No. 6723893
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/204,052
; FILING DATE: 28-FEB-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/023,980
; FILING DATE: 26-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
```

```
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-204-052-13

Query Match          2.7%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 556 CCCTTAACCTCATCTGTTATCCTGC 579
Db 24 CCCTTAACCTCATCTGTTATCCTGC 1

RESULT 10
US-08-668-381A-2/c
; Sequence 2, Application US/08668381A
; Patent No. 5780024
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert H.
; APPLICANT: Fishman, Paul S.
; APPLICANT: Francis, Jonathan W.
; APPLICANT: Hoeler, Betsy A.
; TITLE OF INVENTION: SUPEROXIDE DISMUTASE/TETANUS TOXIN
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/668,381A
; FILING DATE: 21-JUN-1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,473
; FILING DATE: 23-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,164
; REFERENCE/DOCKET NUMBER: 00786/269001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-668-381A-2

Query Match          2.5%; Score 22; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 777 ATGGGTATTAAACTTGTCAGAA 798
```

---

```
Db 29 ATGGGTATTAAACTTGTCAGAA 8

RESULT 11
5290690-19/c
; Patent No. 5290690
; APPLICANT: MRABET, NADIR; LASTERS, IGNACE; STANSSENS, PATRICK
; MATTHYSSENS, GASTON; WODAK, SHOSHANA; QUAX, WILHELMUS J.
; TITLE OF INVENTION: METHODS AND MEANS FOR CONTROLLING THE
; STABILITY OF PROTEINS
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/398,706
; FILING DATE: 25-AUG-1989
; SEQ ID NO: 19:
; LENGTH: 25
5290690-19

Query Match          2.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 9.7;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 418 GGTGTCCTCATGAAAAGCAGATGAC 442
Db 25 GGTGTCCTCATGAAAAGCAGATGAC 1

RESULT 12
5290690-19/c
; Patent No. 5290690
; APPLICANT: MRABET, NADIR; LASTERS, IGNACE; STANSSENS, PATRICK
; MATTHYSSENS, GASTON; WODAK, SHOSHANA; QUAX, WILHELMUS J.
; TITLE OF INVENTION: METHODS AND MEANS FOR CONTROLLING THE
; STABILITY OF PROTEINS
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/398,706
; FILING DATE: 25-AUG-1989
; SEQ ID NO: 19:
; LENGTH: 25
5290690-19

Query Match          2.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 9.7;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 418 GGTGTCCTCATGAAAAGCAGATGAC 442
Db 25 GGTGTCCTCATGAAAAGCAGATGAC 1

RESULT 13
US-08-023-980B-5/c
; Sequence 5, Application US/08023980B
; Patent No. 5843641
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 585 Commercial Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-1024
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICANT: Brown, Robert  
;; FILING DATE: 26-FEB-1993  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Clark, Paul T.  
;; REGISTRATION NUMBER: 30,162  
;; REFERENCE/DOCKET NUMBER: 00786/177001  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 617/723-4123  
;; TELEFAX: 617/723-8962  
;; TELEX:  
;; INFORMATION FOR SEQ ID NO: 5:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 21 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA  
US-08-023-980B-5

Query Match 2.3%; Score 20; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 118 CATCAATTCGAGCAGAAGG 137  
|||||  
Db 21 CATCAATTCGAGCAGAAGG 2

RESULT 14  
US-08-486-953A-5/c  
;; Sequence 5, Application US/08486953A  
;; Patent No. 5849290  
;; GENERAL INFORMATION:  
;; APPLICANT: Brown, Robert  
;; APPLICANT: Horvitz, H. Robert  
;; APPLICANT: Rosen, Daniel R.  
;; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
;; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
;; NUMBER OF SEQUENCES: 53  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESS: Clark & Elbing LLP  
;; STREET: 176 Federal Street  
;; CITY: Boston  
;; STATE: MA  
;; COUNTRY: USA  
;; ZIP: 02110  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: FastSeq  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/486,953A  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 424  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/204,052  
;; FILING DATE: 28-FEB-1994  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Clark, Paul T.  
;; REGISTRATION NUMBER: 30,162  
;; REFERENCE/DOCKET NUMBER: 00786/223002  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 617/428-0200  
;; TELEFAX: 617/428-7045  
;; TELEX:  
;; INFORMATION FOR SEQ ID NO: 5:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 21 base pairs

;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA  
US-08-486-953A-5  
Query Match 2.3%; Score 20; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 118 CATCAATTCGAGCAGAAGG 137  
|||||  
Db 21 CATCAATTCGAGCAGAAGG 2

RESULT 15  
US-08-204-052-5/c  
;; Sequence 5, Application US/08204052  
;; Patent No. 6723893  
;; GENERAL INFORMATION:  
;; APPLICANT: Brown, Robert  
;; APPLICANT: Horvitz, H. Robert  
;; APPLICANT: Rosen, Daniel R.  
;; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
;; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
;; NUMBER OF SEQUENCES: 53  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESS: Fish & Richardson P.C.  
;; STREET: 225 Franklin Street  
;; CITY: Boston  
;; STATE: MA  
;; COUNTRY: USA  
;; ZIP: 02110-2804  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/204,052  
;; FILING DATE: 28-FEB-1994  
;; CLASSIFICATION: 800  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/023,980  
;; FILING DATE: 26-FEB-1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Clark, Paul T.  
;; REGISTRATION NUMBER: 30,162  
;; REFERENCE/DOCKET NUMBER: 00786/223001  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 617/542-5070  
;; TELEFAX: 617/542-8906  
;; TELEX: 200154  
;; INFORMATION FOR SEQ ID NO: 5:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 21 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA  
US-08-204-052-5

Query Match 2.3%; Score 20; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 118 CATCAATTCGAGCAGAAGG 137  
|||||  
Db 21 CATCAATTCGAGCAGAAGG 2

RESULT 16  
US-09-907-794A-7/c







```

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,700
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-700-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768
DB 22 GACCTGTAATGTGCCGACTTA 1

RESULT 20
US-09-603A-7/c
; Sequence 7, Application US/09903603A
; Patent No. 6767995
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter

```

```

; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: GNE.161822C12
; CURRENT APPLICATION NUMBER: US/09/903,603A
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-903-603A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768
DB 22 GACCTGTAATGTGCCGACTTA 1

```

```
RESULT 21
US-09-904-920A-7/c
; Sequence 7, Application US/09904920A
; Patent No. 6806352
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,920A
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-920A-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768
Db 22 GACCTGTATGTGCCGACTTA 1

RESULT 22
US-09-909-064-7/c
; Sequence 7, Application US/09909064
; Patent No. 6818449
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/909,064
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
```

```

; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/000219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-909-064-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGACACTTA 768
|||||
Db 22 GACCTGTAATGTCGCGACTTA 1

RESULT 23
US-09-905-381A-7/c
; Sequence 7, Application US/09905381A
; Patent No. 6818746
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paooni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,381A
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28

```

```

; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/000219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-381A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGACACTTA 768
|||||
Db 22 GACCTGTAATGTCGCGACTTA 1

RESULT 24
US-09-906-618-7/c
; Sequence 7, Application US/09906618
; Patent No. 6828146
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paooni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel

```

```
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,618
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO: 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
; US-09-906-618-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTAATGTCGCGACTTA 768
DB 22 GACCTGTAATGTCGCGACTTA 1

RESULT 25
5290690-20/c
; Patent No. 5290690
; APPLICANT: MRABET, NADIR; LASTERS, IGNACE; STANSSENS, PATRICK
; MATTHYSSENS, GASTON; WODAK, SHOSHANA; QUAX, WILHELMUS J.
; TITLE OF INVENTION: METHODS AND MEANS FOR CONTROLLING THE
; STABILITY OF PROTEINS
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/398,706
; FILING DATE: 25-AUG-1999
; SEQ ID NO: 20:
; LENGTH: 22
; US-09-906-618-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 GACTTGGCGCAAGGTGGAATG 461
DB 22 GACTTGGCGCGCGGTGGAATG 1

RESULT 27
US-08-023-980B-7/c
; Sequence 7, Application US/08023980B
; Patent No. 5843641
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 585 Commercial Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-1024
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/023,980B
; FILING DATE: 26-FEB-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/177001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/723-4123
; TELEFAX: 617/723-8962
; TELEX:
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
```

```
5290690-20
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 GACTTGGCGCAAGGTGGAATG 461
DB 22 GACTTGGCGCGCGGTGGAATG 1

RESULT 26
5290690-20/c
; Patent No. 5290690
; APPLICANT: MRABET, NADIR; LASTERS, IGNACE; STANSSENS, PATRICK
; MATTHYSSENS, GASTON; WODAK, SHOSHANA; QUAX, WILHELMUS J.
; TITLE OF INVENTION: METHODS AND MEANS FOR CONTROLLING THE
; STABILITY OF PROTEINS
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/398,706
; FILING DATE: 25-AUG-1999
; SEQ ID NO: 20:
; LENGTH: 22
; 5290690-20

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 35;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 GACTTGGCGCAAGGTGGAATG 461
DB 22 GACTTGGCGCGCGGTGGAATG 1

RESULT 27
US-08-023-980B-7/c
; Sequence 7, Application US/08023980B
; Patent No. 5843641
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 585 Commercial Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-1024
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/023,980B
; FILING DATE: 26-FEB-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/177001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/723-4123
; TELEFAX: 617/723-8962
; TELEX:
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
```

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-023-980B-7

Query Match 1.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
Db 21 GGAGATAATACAGCAGG 5

RESULT 28
US-08-486-953A-7/c
; Sequence 7, Application US/08486953A
; Patent No. 5849290
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 176 Federal Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: FastSeq
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,953A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/204,052
; FILING DATE: 28-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223002
; TELEPHONE: 617/428-0200
; TELEFAX: 617/428-7045
; TELEX:
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-486-953A-7

Query Match 1.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
Db 21 GGAGATAATACAGCAGG 5

RESULT 29
US-08-204-052-7/c
; Sequence 7, Application US/08204052
; Patent No. 6723893
; GENERAL INFORMATION:
; APPLICANT: Brown, Robert
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Rosen, Daniel R.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,
; TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/204,052
; FILING DATE: 28-FEB-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/023,980
; FILING DATE: 26-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-204-052-7

Query Match 1.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAGG 234
Db 21 GGAGATAATACAGCAGG 5

RESULT 30
US-09-068-506-48/c
; Sequence 48, Application US/09068506A
; Patent No. 6569618
; GENERAL INFORMATION:
; APPLICANT: YASUE, Hirofumi
; APPLICANT: YOSHIMURA, Kumamoto
; TITLE OF INVENTION: DIAGNOSIS OF DISEASES ASSOCIATED WITH CORONARY
; ARTERY DISEASE
; FILE REFERENCE: 0032-245P
; CURRENT APPLICATION NUMBER: US/09/068,506A
; CURRENT FILING DATE: 1998-07-10
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: Primers  
US-09-068-506-48

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 33;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 168 GCATTAAAGGACTGACTGAA 187  
||| ||||| ||||| |||||  
Db 20 GCCTAAAGGACTGCCTGAA 1

RESULT 31  
US-08-023-980B-10  
; Sequence 10, Application US/08023980B  
; Patent No. 5843641  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 45  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Clark & Elbing LLP  
; STREET: 585 Commercial Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02109-1024  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/023,980B  
; FILING DATE: 26-FEB-1993  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162  
; REFERENCE/DOCKET NUMBER: 00786/177001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/723-4123  
; TELEFAX: 617/723-8962  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 21 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-023-980B-10

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 32  
US-08-486-953A-10  
; Sequence 10, Application US/08486953A  
; Patent No. 5849290  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/486,953A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/204,052  
; FILING DATE: 28-FEB-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162  
; REFERENCE/DOCKET NUMBER: 00786/223002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/428-0200  
; TELEFAX: 617/428-7045  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 21 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-486-953A-10

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 33  
US-08-204-052-10  
; Sequence 10, Application US/08204052  
; Patent No. 6723893  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 34  
US-08-486-953A-10  
; Sequence 10, Application US/08486953A  
; Patent No. 5849290  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Clark & Elbing LLP  
; STREET: 176 Federal Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: FastSeq  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/486,953A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/204,052  
; FILING DATE: 28-FEB-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162  
; REFERENCE/DOCKET NUMBER: 00786/223002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/428-0200  
; TELEFAX: 617/428-7045  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 21 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-486-953A-10

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 35  
US-08-204-052-10  
; Sequence 10, Application US/08204052  
; Patent No. 6723893  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/204,052  
; FILING DATE: 28-FEB-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162  
; REFERENCE/DOCKET NUMBER: 00786/223002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/428-0200  
; TELEFAX: 617/428-7045  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 21 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-204-052-10

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 36  
US-08-486-953A-10  
; Sequence 10, Application US/08486953A  
; Patent No. 5849290  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 37  
US-08-204-052-10  
; Sequence 10, Application US/08204052  
; Patent No. 6723893  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 38  
US-08-486-953A-10  
; Sequence 10, Application US/08486953A  
; Patent No. 5849290  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

RESULT 39  
US-08-204-052-10  
; Sequence 10, Application US/08204052  
; Patent No. 6723893  
; GENERAL INFORMATION:  
; APPLICANT: Brown, Robert  
; APPLICANT: Horvitz, H. Robert  
; APPLICANT: Rosen, Daniel R.  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DIAGNOSIS,  
; TITLE OF INVENTION: TREATMENT AND PREVENTION OF DISEASES OF CELL DEATH  
; NUMBER OF SEQUENCES: 53  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

Query Match 1.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 37;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGCATGTTGGAGACT 317  
||| ||||| ||||| |||||  
Db 2 ATATAGGCGCATGTTGGAGACT 21

```

; APPLICATION NUMBER: US/08/204,052
; FILING DATE: 28-FEB-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/023,980
; FILING DATE: 26-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/223001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-204-052-10

Query Match 1.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred.No.37;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGGCGATGTTGGAGACT 317
DB 2 ATATAGCATGTTGGAGACT 21

RESULT 34
US-09-545-686-27
; Sequence 27, Application US/09545686
; Patent No. 6441273
; GENERAL INFORMATION:
; APPLICANT: Aldwinckle, Herbert S.
; APPLICANT: Gaitan, Alvaro L.
; TITLE OF INVENTION: CONSTITUTIVE AND INDUCIBLE PROMOTERS FROM COFFEE PLANTS
; FILE REFERENCE: 19603/3261
; CURRENT APPLICATION NUMBER: US/09/545,686
; CURRENT FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 60/180,934
; PRIOR FILING DATE: 2000-02-08
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; NAME/KEY: unsure
; LOCATION: (5)
; OTHER INFORMATION: N at any position in this sequence is either A, C,
; OTHER INFORMATION: G, or T.
; US-09-545-686-27

Query Match 1.8%; Score 16; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No.39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 195 ATGGATTCCTGTTTCATG 212
DB 1 ATGGTTCCCATGTCATG 18

RESULT 35
US-08-202-042-2/c
; Sequence 2, Application US/08202042
; Patent No. 5686072

```



```
;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICANT: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 236:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-060-299-236

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 46;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAAAT 460
Db 20 CTTGGGCAGAGTGGATAT 2

RESULT 37
US-09-402-923A-236/c
; Sequence 236, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; Hees, John W
; Caakey, Charles T
; Cox, Roger D
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R
; Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
```

```
;
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 236:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 236:
; US-09-402-923A-236

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 46;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAAAT 460
Db 20 CTTGGGCAGAGTGGATAT 2

RESULT 38
US-09-909-595-79
; Sequence 79, Application US/09909595
; Patent No. 6586245
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brenda F. Baker
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Scott E. Davis
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 LIGAND EXPRESSION
; FILE REFERENCE: RTS-0223
; CURRENT APPLICATION NUMBER: US/09/909,595
; CURRENT FILING DATE: 2001-07-18
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-909-595-79

Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 46;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGAC 394
Db 2 GATCTCACTCTCAGGAGAC 20

RESULT 39
US-09-040-285A-4/c
; Sequence 4, Application US/09040285A
; Patent No. 6013502
; GENERAL INFORMATION:
; APPLICANT: SHIMONISHI, TSUYOSHI
; APPLICANT: KANEKO, SATOSHI
; APPLICANT: NIRASAWA, SAIORU
; APPLICANT: HAYASHI, KIYOSHI
; APPLICANT: HARAGUCHI, KAZUTOMO
; TITLE OF INVENTION: GENE OF CELL WALL LYTIC ENZYME, AND
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MATER & NEUSTADT,  
ADDRESSEE: P.C.  
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR  
CITY: ARLINGTON  
STATE: VA  
COUNTRY: USA  
ZIP: 22202

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/040,285A  
FILING DATE: 18-MAR-1998

CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: JP 343630/1997

FILING DATE: 12-JAN-1997

ATTORNEY/AGENT INFORMATION:

NAME: OBLON, NORMAN F.

REGISTRATION NUMBER: 24,618

REFERENCE/DOCKET NUMBER: 8361-0004-0X

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-413-3000

TELEFAX: 703-413-2220

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: /desc = "prepared from amino acid

DESCRIPTION: sequence)"

ORIGINAL SOURCE:

ORGANISM: Streptomyces rutgersensis

STRAIN: H-46

INDIVIDUAL ISOLATE: Enzyme produced by Streptomyces

INDIVIDUAL ISOLATE: rutgersensis

US-09-040-285A-4

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 70.0%; Pred. No. 56;  
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 521 GCCCAATAACATTCCTTG 540

Db 20 GCCCARTCSACRTTSCCYTG 1

RESULT 40  
US-09-288-461-39  
Sequence 39, Application US/09288461  
Patent No. 6159694  
GENERAL INFORMATION:

APPLICANT: Karras, James G.

TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3

FILE REFERENCE: ISPH-0338

CURRENT FILING DATE: 1999-04-08

NUMBER OF SEQ ID NOS: 107

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 39

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Synthetic Sequence

US-09-288-461-39

Query Match 1.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 56;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 200 TTCCATGTTTCATGAGTTTGG 219

Db 1 TTCCATGTTTCATCACTTTTG 20

RESULT 41  
US-09-758-881-39  
Sequence 39, Application US/09758881  
Patent No. 6727064  
GENERAL INFORMATION:

APPLICANT: Karras, James G

TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3

FILE REFERENCE: ISPH-0532

CURRENT APPLICATION NUMBER: US/09/758,881

CURRENT FILING DATE: 2001-01-11

PRIOR APPLICATION NUMBER: PCT/US00/09054

PRIOR FILING DATE: 2000-04-06

PRIOR APPLICATION NUMBER: 09/288,461

PRIOR FILING DATE: 1999-04-08

NUMBER OF SEQ ID NOS: 152

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 39

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

US-09-758-881-39

Query Match 1.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 56;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 200 TTCCATGTTTCATGAGTTTGG 219

Db 1 TTCCATGTTTCATCACTTTTG 20

RESULT 42  
US-08-846-020A-17  
Sequence 17, Application US/08846020A  
Patent No. 6090547  
GENERAL INFORMATION:

APPLICANT: Drzen M.D., Jeffrey M.

APPLICANT: In M.D., Kwang-Ho

APPLICANT: Asano M.D., Koichiro

APPLICANT: Beier, David

APPLICANT: Grobholz, James

TITLE OF INVENTION: 5-Lipoxygenase Gene Sequence

TITLE OF INVENTION: Polymorphisms and Their Use in Classifying Patients

NUMBER OF SEQUENCES: 43

CORRESPONDENCE ADDRESS:

ADDRESSEE: CHOATE, HALL & STEWART

STREET: 53 State Street

CITY: Boston

STATE: MA

COUNTRY: USA

ZIP: 02109-2891

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/846,020A

FILING DATE:

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Jarrell Ph.D., Brenda H.

```
;
; REGISTRATION NUMBER: 39,223
; REFERENCE/DOCKET NUMBER: 0092662-0012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 248-5000
; TELEFAX: (617) 248-5000
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
; IMMEDIATE SOURCE:
; CLONE: Exon 1 antisense primer
US-08-846-020A-17

Query Match 1.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 ACGCTGGAAGTCGTT 497
Db 3 ACGCTGGAAGTCGTT 17

RESULT 43
US-09-617-871-17
; Sequence 17, Application US/09617871
; Patent No. 6355434
; GENERAL INFORMATION:
; APPLICANT: Drzen M.D., Jeffrey M.
; APPLICANT: In M.D., Kwang-Ho
; APPLICANT: Asano M.D., Koichiro
; APPLICANT: Beier, David
; APPLICANT: Grobholz, James
; TITLE OF INVENTION: 5-Lipoxygenase Gene Sequence
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSER: CHOATE, HALL & STEWART
; STREET: 53 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2891
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/617,871
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,020
; FILING DATE:
; TELECOMMUNICATION INFORMATION:
; NAME: Jarrell Ph.D., Brenda H.
; REGISTRATION NUMBER: 39,223
; REFERENCE/DOCKET NUMBER: 0092662-0012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 248-5000
; TELEFAX: (617) 248-4000
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"

; IMMEDIATE SOURCE:
; CLONE: Exon 1 antisense primer
US-09-617-871-17

Query Match 1.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 60;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 ACGCTGGAAGTCGTT 497
Db 3 ACGCTGGAAGTCGTT 17

RESULT 44
US-09-108-006C-31/c
; Sequence 31, Application US/09108006C
; Patent No. 6524613
; GENERAL INFORMATION:
; APPLICANT: Steer, Clifford J.
; Kren, Betsy T.
; Bandyopadhyay, Paramita
; Roy-Chowdhury, Jayanta
; TITLE OF INVENTION: Hepatocellular Chimeraplasty
; NUMBER OF SEQUENCES: 62
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kimeragen, Inc.
; STREET: 300 Pheasant Run
; CITY: Newtown
; STATE: PA
; COUNTRY: USA
; ZIP: 18940
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/108,006C
; FILING DATE: 30-Jun-1992
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/054,288
; FILING DATE: 30-APR-1997
; APPLICATION NUMBER: 60/054,837
; FILING DATE: 05-AUG-1997
; APPLICATION NUMBER: 60/064,996
; FILING DATE: 10-NOV-1997
; APPLICATION NUMBER: 60/074,497
; FILING DATE: 12-FEB-1998
; APPLICATION NUMBER: PCT US 98/08834
; FILING DATE: 30-APR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Friebe, Thomas
; REGISTRATION NUMBER: 29258
; REFERENCE/DOCKET NUMBER: 7991-015-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-504-4444
; TELEFAX: 215-504-4545
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-108-006C-31

Query Match 1.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 37 CCAGGACCTCGCGTGGC 54  
 |||||  
 Db 19 CCAGGACCTCGCGGAGGC 2

RESULT 45  
 US-09-696-791-574/c  
 ; Sequence 574, Application US/09696791  
 ; Patent No. 6770633  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Robbins, Joan M.  
 ; APPLICANT: Tritsch, Richard  
 ; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
 ; FILE REFERENCE: 480124.407  
 ; CURRENT APPLICATION NUMBER: US/09/696,791  
 ; CURRENT FILING DATE: 2000-10-25  
 ; NUMBER OF SEQ ID NOS: 4523  
 ; SOFTWARE: Patentin Ver. 2.0  
 ; SEQ ID NO 574  
 ; LENGTH: 19  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; OTHER INFORMATION: Cdk6 ribozyme binding site  
 US-09-696-791-574

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 58;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAGT 469  
 |||||  
 Db 19 GGTGTGAATGAGAAAGT 2

RESULT 46  
 US-08-412-614-102/c  
 ; Sequence 102, Application US/08412614  
 ; Patent No. 5536638  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Rossau, Rudi  
 ; APPLICANT: Van Heuverswyn, Hugo  
 ; TITLE OF INVENTION: Hybridization Probes Derived from the  
 ; TITLE OF INVENTION: Spacer Region Between the 16S and 23S rRNA Genes for the  
 ; TITLE OF INVENTION: Detection of No. 5536638-Viral Microorganisms  
 ; NUMBER OF SEQUENCES: 104  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Merchant & Gould  
 ; STREET: 3100 No. 5536638west Center  
 ; CITY: Minneapolis  
 ; STATE: MN  
 ; COUNTRY: USA  
 ; ZIP: 55402-4131  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette 3.5 inch, 1.44 mb capacity  
 ; COMPUTER: IBM PC compatible (Compaq Deskpro 286e)  
 ; OPERATING SYSTEM: MS-DOS  
 ; SOFTWARE: Wordperfect Version #5.1  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/412,614  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/965,394  
 ; FILING DATE: 17-DEC-1992  
 ; APPLICATION NUMBER: PCT/EP91/00743  
 ; FILING DATE: 18-APR-1991  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: GB/90901054.3  
 ; FILING DATE: 18-APR-1990  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Hillson, Randall A.  
 ; REGISTRATION NUMBER: 31,838  
 ; REFERENCE/DOCKET NUMBER: 8076.75-USWO  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 612-332-5300  
 ; TELEFAX: 612-332-9081  
 ; INFORMATION FOR SEQ ID NO: 104:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 17 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 US-08-412-614-104

; REGISTRATION NUMBER: 31,838  
 ; REFERENCE/DOCKET NUMBER: 8076.75-USWO  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 612-332-5300  
 ; TELEFAX: 612-332-9081  
 ; INFORMATION FOR SEQ ID NO: 102:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 17 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 US-08-412-614-102

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 52;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGCAGCAAGCCGTG 82  
 |||||  
 Db 16 GCGCAGCAAGCCGTG 1

RESULT 47  
 US-08-412-614-104/c  
 ; Sequence 104, Application US/08412614  
 ; Patent No. 5536638  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Rossau, Rudi  
 ; APPLICANT: Van Heuverswyn, Hugo  
 ; TITLE OF INVENTION: Hybridization Probes Derived from the  
 ; TITLE OF INVENTION: Spacer Region Between the 16S and 23S rRNA Genes for the  
 ; TITLE OF INVENTION: Detection of No. 5536638-Viral Microorganisms  
 ; NUMBER OF SEQUENCES: 104  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Merchant & Gould  
 ; STREET: 3100 No. 5536638west Center  
 ; CITY: Minneapolis  
 ; STATE: MN  
 ; COUNTRY: USA  
 ; ZIP: 55402-4131  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Diskette 3.5 inch, 1.44 mb capacity  
 ; COMPUTER: IBM PC compatible (Compaq Deskpro 286e)  
 ; OPERATING SYSTEM: MS-DOS  
 ; SOFTWARE: Wordperfect Version #5.1  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/412,614  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/965,394  
 ; FILING DATE: 17-DEC-1992  
 ; APPLICATION NUMBER: PCT/EP91/00743  
 ; FILING DATE: 18-APR-1991  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: GB/90901054.3  
 ; FILING DATE: 18-APR-1990  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Hillson, Randall A.  
 ; REGISTRATION NUMBER: 31,838  
 ; REFERENCE/DOCKET NUMBER: 8076.75-USWO  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 612-332-5300  
 ; TELEFAX: 612-332-9081  
 ; INFORMATION FOR SEQ ID NO: 104:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 17 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 US-08-412-614-104

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 67 GCGACGAGGCGGTG 82  
DB 16 GCGACGAGGCGGTG 1

RESULT 48  
US-08-635-761-102/c  
; Sequence 102, Application US/08635761  
; Patent No. 5945282  
; GENERAL INFORMATION:  
; APPLICANT: Rossau, Rudi  
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER REGION BE  
; NUMBER OF SEQUENCES: 104  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
; STREET: 3100 No. 5945282west Center, 90 S. 7th Street  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: U.S.A.  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/635,761  
; FILING DATE: 19-APR-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/965,394  
; FILING DATE: 17-DEC-1992  
; APPLICATION NUMBER: 08/412,614  
; FILING DATE: 29-MAR-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hillson, Randall A  
; REGISTRATION NUMBER: 31,838  
; REFERENCE/DOCKET NUMBER: 8076.75USC1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612/332-5300  
; TELEFAX: 612/332/9081  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 102:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: Genomic DNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE:  
; ORIGINAL SOURCE:  
US-08-635-761-102

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82  
DB 16 GCGACGAGGCGGTG 1

RESULT 49  
US-08-635-761-104/c  
; Sequence 104, Application US/08635761  
; Patent No. 5945282

; GENERAL INFORMATION:  
; APPLICANT: Rossau, Rudi  
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER REGION BE  
; NUMBER OF SEQUENCES: 104  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
; STREET: 3100 No. 5945282west Center, 90 S. 7th Street  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: U.S.A.  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSEQ Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/635,761  
; FILING DATE: 19-APR-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/965,394  
; FILING DATE: 17-DEC-1992  
; APPLICATION NUMBER: 08/412,614  
; FILING DATE: 29-MAR-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hillson, Randall A  
; REGISTRATION NUMBER: 31,838  
; REFERENCE/DOCKET NUMBER: 8076.75USC1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 612/332-5300  
; TELEFAX: 612/332/9081  
; TELEX:

; INFORMATION FOR SEQ ID NO: 104:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: both  
; TOPOLOGY: both  
; MOLECULE TYPE: Genomic DNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; FRAGMENT TYPE:  
; ORIGINAL SOURCE:  
US-08-635-761-104

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGACGAGGCGGTG 82  
DB 16 GCGACGAGGCGGTG 1

RESULT 50  
US-09-312-520-102/c  
; Sequence 102, Application US/09312520  
; Patent No. 6277577  
; GENERAL INFORMATION:  
; APPLICANT: Rossau, Rudi  
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER REGION BE  
; NUMBER OF SEQUENCES: 104  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
; STREET: 3100 No. 6277577west Center, 90 S. 7th Street  
; CITY: Minneapolis  
; STATE: MN  
; COUNTRY: U.S.A.  
; ZIP: 55402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/312,520  
FILING DATE: 19-APR-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/965,394  
FILING DATE: 17-DEC-1992  
APPLICATION NUMBER: 08/412,614  
FILING DATE: 29-MAR-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Hillson, Randall A  
REGISTRATION NUMBER: 31,838  
REFERENCE/DOCKET NUMBER: 8076.75USC1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/332-5300  
TELEFAX: 612/332/9081  
TELEX:  
INFORMATION FOR SEQ ID NO: 102:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE:  
ORIGINAL SOURCE:  
US-09-312-520-102

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 67 GCGCAGCAAGGCCGTG 82  
|||||  
Db 16 GCGCAGCAAGGCCGTG 1

RESULT 51  
US-09-312-520-104/c  
Sequence 104, Application US/09312520  
Patent No. 6277577  
GENERAL INFORMATION:  
APPLICANT: Rossau, Rudi  
TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER REGION BE  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
STREET: 3100 No. 6277577west Center, 90 S. 7th Street  
CITY: Minneapolis  
STATE: MN  
COUNTRY: U.S.A.  
ZIP: 55402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/312,520  
FILING DATE: 19-APR-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/965,394  
FILING DATE: 17-DEC-1992  
APPLICATION NUMBER: 08/412,614  
FILING DATE: 29-MAR-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Hillson, Randall A  
REGISTRATION NUMBER: 31,838

REFERENCE/DOCKET NUMBER: 8076.75USC1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/332-5300  
TELEFAX: 612/332/9081  
TELEX:  
INFORMATION FOR SEQ ID NO: 104:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: both  
TOPOLOGY: both  
MOLECULE TYPE: Genomic DNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE:  
ORIGINAL SOURCE:  
US-09-312-520-104

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 52;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 67 GCGCAGCAAGGCCGTG 82  
|||||  
Db 16 GCGCAGCAAGGCCGTG 1

RESULT 52  
US-09-863-086-102/c  
Sequence 102, Application US/09863086  
Patent No. 6656689  
GENERAL INFORMATION:  
APPLICANT: Rossau, Rudi  
TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER  
REGION BETWEEN THE 16S A  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt  
STREET: 3100 No. 6656689west Center, 90 S. 7th Street  
CITY: Minneapolis  
STATE: MN  
COUNTRY: U.S.A.  
ZIP: 55402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/863,086  
FILING DATE: 22-May-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 09/312,520  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 08/412,614  
FILING DATE: 29-MAR-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Hillson, Randall A  
REGISTRATION NUMBER: 31,838  
REFERENCE/DOCKET NUMBER: 8076.75USC1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/332-5300  
TELEFAX: 612/332/9081  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 102:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
HYPOTHETICAL: NO

```
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 102:
US-09-863-086-102

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      67 GCGACGAGGCGGTG 82
Db      16 GCGACGAGGCGGTG 1

RESULT 53
US-09-863-086-104/c
; Sequence 104, Application US/09863086
; Patent No. 665689
; GENERAL INFORMATION:
; APPLICANT: Robsau, Rudi
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER
; REGION BETWEEN THE 16S A
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 No. 6656689west Center, 90 S. 7th Street
; CITY: Minneapolis
; STATE: MN
; COUNTRY: U.S.A.
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,086
; FILING DATE: 22-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/312,520
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 29-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Hillson, Randall A
; REGISTRATION NUMBER: 31,838
; REFERENCE/DOCKET NUMBER: 8076.75USC1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/332-5300
; TELEFAX: 612/332/9081
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: both
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 104:
US-09-863-086-104

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      67 GCGACGAGGCGGTG 82
Db      16 GCGACGAGGCGGTG 1
```

```
Db      16 GCGACGAGGCGGTG 1

RESULT 54
US-09-696-791-1547/c
; Sequence 1547, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1547
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A2 ribozyme binding site
US-09-696-791-1547

Query Match      1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      673 GTGAGAAACTGATTTA 688
Db      16 GTAGAAACTGATTTA 1

RESULT 55
US-08-373-124A-962
; Sequence 962, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 962:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-962

```

```

Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 60;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 709 ATAGTTTATAAAA 722
Db 3 AUAUUUUUAAAAA 16

```

```

RESULT 56
US-08-373-124A-964
; Sequence 964, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 964:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-964

```

```

Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 60;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 709 ATAGTTTATAAAA 722
Db 2 AUAUUUUUAAAAA 15

```

```

RESULT 57
US-08-373-124A-966
; Sequence 966, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 966:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-966

```

```

Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 60;

```



Matches	8	Conservative	6	Mismatches	0	Indels	0	Gaps	0
---------	---	--------------	---	------------	---	--------	---	------	---

**Oy**      709 ATAGTTTATAAAA 722  
          |::|::|::|::|  
**Dd**      1 AUAUUUUUAAAAA 14

```

RESULT 58
US-08-435-628-962
; Sequence 962, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
;

```

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 57.1%; Pred. No. 60;  
Matches 8; Conservative 6; Mismatches 0; Indels

**Qy** 709 ATAGTTTATAAAA 722  
|||:::|||  
**Dd** 3 AUAGUUUUAUAAAA 16

Matches	8	Conservative	6	Mismatches	0	Indels	0	Gaps	0
---------	---	--------------	---	------------	---	--------	---	------	---

US-08-435-628-964  
; Sequence 964, Application US/08435628  
; Patent No. 5817796

Query Match	1.6%	Score 14;	DB 1;	Length 17;
Best Local Similarity	57.1%;	Pred. No. 60;		
Matches	8;	Conservative	6;	Mismatches
				0;
				Indels
				0;
				Gaps
				0;

Qy . . 709 ATAGTTTATAAAA 722  
||:||:||:  
Db 2 AUAGUUUUAUAAAA 15

RESULT 60  
 US-08-435-628-966  
 ; Sequence 966, Application US/08435628  
 ; Patent No. 5817796  
 ; GENERAL INFORMATION:

```

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 966:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-966

Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 60;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 709 ATAGTTTATAAAA 722
Db 1 AUAUUUUUAAAAA 14

RESULT 61
US-08-584-040-5950/c
; Sequence 5950, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR

```

```

; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2086
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5950:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5950

Query Match 1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 543 TGTAGTCTGAGGCCCT 559
Db 17 TGCAGTCTGAGTCCCT 1

RESULT 62
US-09-371-772B-2787/c
; Sequence 2787, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2787
; LENGTH: 17

```

```
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-6796

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 TGTAGTCTGAGCCCT 559
Db 17 TGCAGTCTGAGGTCCT 1

RESULT 63
US-09-371-772B-5100/c
; Sequence 5100, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5100
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5100

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 ACCAGTGCAGGTCCTCA 255
Db 17 ATCAGTGCAGGTCCTCA 1

RESULT 64
US-09-371-772B-6796
; Sequence 6796, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6796
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-09-371-772B-6796

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 64;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTCCT 658
Db 1 ACGUUUCAGAGUUGGU 17

RESULT 65
US-09-866-108A-8960
; Sequence 8960, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8960

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCTGCATGGA 199
Db 1 CTGAAGGCGGACATGGA 17

RESULT 66
US-09-685-664B-2787/c
; Sequence 2787, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2787
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2787

Query Match 1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 TGTAGTCTGAGGCCCT 559
Db 17 TCGAGTCTGAGGTCCCT 1

RESULT 67
US-08-379-081B-88/c
; Sequence 88, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YSAL16S
US-08-379-081B-89

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 69
US-08-379-081B-90/c
; Sequence 90, Application US/08379081B
; Patent No. 5580971
```

```
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YSASRSUA
US-08-379-081B-88

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 68
US-08-379-081B-89/c
; Sequence 89, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YSAL16S
US-08-379-081B-89

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 69
US-08-379-081B-90/c
; Sequence 90, Application US/08379081B
; Patent No. 5580971
```

```

; GENERAL INFORMATION:
; APPLICANT: MITSURASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESSES:
; ADDRESSES: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida lusitanae
; IMMEDIATE SOURCE:
; CLONE: YSASRRNA
; US-08-379-081B-90

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 71
US-08-379-081B-92/c
; Sequence 92, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSURASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSES: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; APPLICATION NUMBER: US/08/379,081B

; GENERAL INFORMATION:
; APPLICANT: MITSURASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESSES:
; ADDRESSES: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
```

```
; ORIGINAL SOURCE:
; ORGANISM: Candida kefyr
; IMMEDIATE SOURCE:
; CLONE: YSASRSUB
US-08-379-081B-92

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTGGGC 448
DB 17 AAGCTGATGACTTGGC 1

RESULT 72
US-08-379-081B-93/c
; Sequence 93, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida krusei
; IMMEDIATE SOURCE:
; CLONE: YSASRSUD
US-08-379-081B-94

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTGGGC 448
DB 17 AAGCTGATGACTTGGC 1

RESULT 74
US-08-379-081B-95/c
; Sequence 95, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/08/379,081B  
FILING DATE:  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: ALTMAN, DANIEL E  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 95:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida tropicalis  
IMMEDIATE SOURCE:  
CLONE: YSASRRNAB  
US-08-379-081B-95

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGC 1

RESULT 75  
US-08-379-081B-96/c  
Sequence 96, Application US/08379081B  
Patent No. 5580971  
GENERAL INFORMATION:  
APPLICANT: MITSUHASHI, MASATO  
TITLE OF INVENTION: FUNGAL DETECTION SYSTEM  
NUMBER OF SEQUENCES: 407  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
STREET: 620 NEWPORT CENTER DRIVE  
CITY: NEWPORT BEACH  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,081B  
FILING DATE:  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: ALTMAN, DANIEL E  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 96:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO

ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida tropicalis  
IMMEDIATE SOURCE:  
CLONE: YSASRSUG  
US-08-379-081B-96

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGC 1

RESULT 76  
US-08-379-081B-97/c  
Sequence 97, Application US/08379081B  
Patent No. 5580971  
GENERAL INFORMATION:  
APPLICANT: MITSUHASHI, MASATO  
TITLE OF INVENTION: FUNGAL DETECTION SYSTEM  
NUMBER OF SEQUENCES: 407  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
STREET: 620 NEWPORT CENTER DRIVE  
CITY: NEWPORT BEACH  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,081B  
FILING DATE:  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: ALTMAN, DANIEL E  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida viswanathii  
IMMEDIATE SOURCE:  
CLONE: YSASRSUH  
US-08-379-081B-97

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
|||||  
Db 17 AAGCTGATGACTTGGC 1

RESULT 77  
US-08-379-081B-98/c

```

; Sequence 98, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida parapsilosis
; IMMEDIATE SOURCE:
; CLONE: YSASRSUF
; US-08-379-081B-98

```

```

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 432 AAGCAGATGACTTGGGC 448
DB 17 AAGCTGATGACTTGGC 1

```

```

RESULT 78
US-08-379-081B-99/c
; Sequence 99, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida guilliermondii
; IMMEDIATE SOURCE:
; CLONE: YSASRSUC
; US-08-379-081B-99

```

```

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 432 AAGCAGATGACTTGGGC 448
DB 17 AAGCTGATGACTTGGC 1

```

```

RESULT 79
US-08-379-081B-100/c
; Sequence 100, Application US/08379081B
; Patent No. 5580971
; GENERAL INFORMATION:
; APPLICANT: MITSUHASHI, MASATO
; TITLE OF INVENTION: FUNGAL DETECTION SYSTEM
; NUMBER OF SEQUENCES: 407
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 NEWPORT CENTER DRIVE
; CITY: NEWPORT BEACH
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,081B
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: ALTMAN, DANIEL E
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 100:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA

```



```

; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida glabrata
; IMMEDIATE SOURCE:
; CLONE: YS5CRRNAS
US-08-379-081B-100

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
|||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 80
US-08-379-078-88/c
; Sequence 88, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YS4RSUA
US-08-379-078-88

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
|||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 81
US-08-379-078-89/c
; Sequence 89, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YSAL16S
US-08-379-078-89

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
|||||
Db 17 AAGCTGATGACTTGGGC 1

RESULT 82
US-08-379-078-90/c
; Sequence 90, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Candida albicans
; IMMEDIATE SOURCE:
; CLONE: YS4RSUA
US-08-379-078-88

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448
|||||
Db 17 AAGCTGATGACTTGGGC 1
```

STREET: 620 Newport Center Drive 16th Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,078  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/974,406  
FILING DATE: 12-NOV-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 90:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida lusitanae  
IMMEDIATE SOURCE:  
CLONE: YSASRRNAA  
US-08-379-078-90

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 83  
US-08-379-078-91/c  
Sequence 91, Application US/08379078  
Patent No. 5639612  
GENERAL INFORMATION:  
APPLICANT: Mitsuhashi, Masato  
APPLICANT: Cooper, Allan  
TITLE OF INVENTION: Gene Detection System  
NUMBER OF SEQUENCES: 726  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
STREET: 620 Newport Center Drive 16th Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,078  
FILING DATE:  
CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/974,406  
FILING DATE: 12-NOV-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 91:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida lusitanae  
IMMEDIATE SOURCE:  
CLONE: YSASRSUE  
US-08-379-078-91

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
Db 17 AAGCTGATGACTTGGCG 1

RESULT 84  
US-08-379-078-92/c  
Sequence 92, Application US/08379078  
Patent No. 5639612  
GENERAL INFORMATION:  
APPLICANT: Mitsuhashi, Masato  
APPLICANT: Cooper, Allan  
TITLE OF INVENTION: Gene Detection System  
NUMBER OF SEQUENCES: 726  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
STREET: 620 Newport Center Drive 16th Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,078  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/974,406  
FILING DATE: 12-NOV-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 92:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid

;  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA to rRNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Candida kefyr  
; IMMEDIATE SOURCE:  
; CLONE: YSASRSUB  
; US-08-379-078--92

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
Db 17 AAGCTGATGACTTGGC 1

RESULT 85  
US-08-379-078-93/c  
; Sequence 93, Application US/08379078  
; Patent No. 5639612  
; GENERAL INFORMATION:  
; APPLICANT: Mitsuhashi, Masato  
; APPLICANT: Cooper, Allan  
; TITLE OF INVENTION: Gene Detection System  
; NUMBER OF SEQUENCES: 726  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
; STREET: 620 Newport Center Drive 16th Floor  
; CITY: Newport Beach  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 92660  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/379,078  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/974,406  
; FILING DATE: 12-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Altman, Daniel E.  
; REGISTRATION NUMBER: 34,115  
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
; TELEPHONE: 714-760-0404  
; TELEFAX: 714-760-9502  
; INFORMATION FOR SEQ ID NO: 93:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA to rRNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Candida krusei  
; IMMEDIATE SOURCE:  
; CLONE: YSASRRAC  
; US-08-379-078--93

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
Db 17 AAGCTGATGACTTGGC 1

RESULT 86  
US-08-379-078-94/c  
; Sequence 94, Application US/08379078  
; Patent No. 5639612  
; GENERAL INFORMATION:  
; APPLICANT: Mitsuhashi, Masato  
; APPLICANT: Cooper, Allan  
; TITLE OF INVENTION: Gene Detection System  
; NUMBER OF SEQUENCES: 726  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
; STREET: 620 Newport Center Drive 16th Floor  
; CITY: Newport Beach  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 92660  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/379,078  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/974,406  
; FILING DATE: 12-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Altman, Daniel E.  
; REGISTRATION NUMBER: 34,115  
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
; TELEPHONE: 714-760-0404  
; TELEFAX: 714-760-9502  
; INFORMATION FOR SEQ ID NO: 94:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA to rRNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Candida krusei  
; IMMEDIATE SOURCE:  
; CLONE: YSASRSUD  
; US-08-379-078--94

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGGC 448  
Db 17 AAGCTGATGACTTGGC 1

RESULT 87  
US-08-379-078-95/c  
; Sequence 95, Application US/08379078  
; Patent No. 5639612  
; GENERAL INFORMATION:  
; APPLICANT: Mitsuhashi, Masato  
; APPLICANT: Cooper, Allan  
; TITLE OF INVENTION: Gene Detection System



```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORGANISM: Candida viswanathii
; IMMEDIATE SOURCE:
; CLONE: YSARSUH
US-08-379-078-97

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 90
US-08-379-078-98/c
; Sequence 98, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORGANISM: Candida parapsilosis
; IMMEDIATE SOURCE:
; CLONE: YSARSUF
US-08-379-078-98

```

```

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 91
US-08-379-078-99/c
; Sequence 99, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to rRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORGANISM: Candida guilliermondii
; IMMEDIATE SOURCE:
; CLONE: YSARSUC
US-08-379-078-99

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AACGATGACTTGGGC 448
Db 17 AAGCTGATGACTTGGC 1

RESULT 92
US-08-379-078-100/c
; Sequence 100, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:

```

APPLICANT: Mitsubishi, Masato  
APPLICANT: Cooper, Allan  
TITLE OF INVENTION: Gene Detection System  
NUMBER OF SEQUENCES: 726  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBE, MARTENS, OLSON AND BEAR  
STREET: 620 Newport Center Drive 16th Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,078  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/974,406  
FILING DATE: 12-NOV-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 100:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA to rRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Candida glabrata  
IMMEDIATE SOURCE:  
CLONE: Y55CHRNAS  
US-08-379-078-100

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 432 AAGCAGATGACTTGGC 448  
Db 17 AAGCTGATGACTTGGC 1

RESULT 93  
US-08-485-942A-62/c  
Sequence 62, Application US/08485942A  
Patent No. 6048837  
GENERAL INFORMATION:  
APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA,  
APPLICANT: MARGHERITA WAFPEI, JEFFREY HALAAS, KETAN GAJIWALA, AND STEPHEN K. BURLE  
TITLE OF INVENTION: OB POLYPEPTIDE AS MODULATORS OF BODY WEIGHT (AS  
TITLE OF INVENTION: AMENDED)  
NUMBER OF SEQUENCES: 99  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Klauber & Jackson  
STREET: 411 Hackensack Avenue  
CITY: Hackensack  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 07601  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/485,942A  
FILING DATE: JUNE 7, 1995  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/438,431  
FILING DATE: May 10, 1995  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/347,563  
FILING DATE: No. 6048837ember 30, 1994  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/292,345  
FILING DATE: August 17, 1994  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Jackson Esq., David A.  
REGISTRATION NUMBER: 26,742  
REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2F  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201 487-5800  
TELEFAX: 201 343-1684  
TELEX: 133521  
INFORMATION FOR SEQ ID NO: 62:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (primer)  
DESCRIPTION: sequence tagged-site specific PCR primer sWSS25588  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Human  
US-08-485-942A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAG 468  
Db 18 GGTGGAATGTAGATG 2

RESULT 94  
US-09-344-579-8  
Sequence 8, Application US/09344579  
Patent No. 6054316  
GENERAL INFORMATION:  
APPLICANT: Brenda F. Baker  
APPLICANT: Lex M. Cowser  
TITLE OF INVENTION: ANTISENSE MODULATION OF ETS-2 EXPRESSION  
FILE REFERENCE: RTS-0063  
CURRENT APPLICATION NUMBER: US/09/344,579  
CURRENT FILING DATE: 1999-06-25  
NUMBER OF SEQ ID NOS: 47  
SEQ ID NO 8  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-344-579-8

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 98 GACGGCCAGTGCAGG 114  
|||  
Db 2 GACGGCCAGTGCAGG 18

RESULT 95  
 US-08-488-214A-62/c  
 ; Sequence 62, Application US/08488214A  
 ; Patent No. 6124439  
 ; GENERAL INFORMATION:  
 ; APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENZA,  
 ; APPLICANT: MARGHERITA MAPPEL, JEFFREY HALAAS, KETAN GAJIWALA, AND STEPHEN K. BURLE  
 ; TITLE OF INVENTION: OB POLYPEPTIDE ANTIBODIES AND METHOD OF MAKING  
 ; TITLE OF INVENTION: (AS AMENDED)  
 ; NUMBER OF SEQUENCES: 99  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Klauber & Jackson  
 ; STREET: 411 Hackensack Avenue  
 ; CITY: Hackensack  
 ; STATE: New Jersey  
 ; COUNTRY: USA  
 ; ZIP: 07601  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/488,214A  
 ; FILING DATE: JUNE 7, 1995  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/438,431  
 ; FILING DATE: May 10, 1995  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/347,563  
 ; FILING DATE: No. 6124439ember 30, 1994  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/292,345  
 ; FILING DATE: August 17, 1994  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Jackson Esq., David A.  
 ; REGISTRATION NUMBER: 26,742  
 ; REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2D  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 201 487-5800  
 ; TELEFAX: 201 343-1684  
 ; TELEX: 133521  
 ; INFORMATION FOR SEQ ID NO: 62:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 18 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (primer)  
 ; DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588  
 ; HYPOTHETICAL: NO  
 ; ANTI-SENSE: NO  
 ; ORIGINAL SOURCE:  
 ; ORGANISM: Human  
 ; US-08-488-214A-62

RESULT 96  
 US-08-488-208A-62/c  
 ; Sequence 62, Application US/08488208A  
 ; Patent No. 6124448  
 ; GENERAL INFORMATION:  
 ; APPLICANT: THE ROCKEFELLER UNIVERSITY  
 ; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING  
 ; TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC  
 ; TITLE OF INVENTION: USES THEREOF  
 ; NUMBER OF SEQUENCES: 98  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Klauber & Jackson  
 ; STREET: 411 Hackensack Avenue  
 ; CITY: Hackensack  
 ; STATE: New Jersey  
 ; COUNTRY: USA  
 ; ZIP: 07601  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/488,208A  
 ; FILING DATE: 07-JUN-1995  
 ; CLASSIFICATION: 514  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/485,943  
 ; FILING DATE: June 7, 1995  
 ; APPLICATION NUMBER: 08/438,431  
 ; FILING DATE: May 10, 1995  
 ; CLASSIFICATION: 514  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/347,563  
 ; FILING DATE: No. 6124448ember 30, 1994  
 ; CLASSIFICATION: 514  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 08/292,345  
 ; FILING DATE: August 17, 1994  
 ; CLASSIFICATION: 514  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Jackson Esq., David A.  
 ; REGISTRATION NUMBER: 26,742  
 ; REFERENCE/DOCKET NUMBER: 600-1-087 CIP21  
 ; TELEPHONE: 201 487-5800  
 ; TELEFAX: 201 343-1684  
 ; TELEX: 133521  
 ; INFORMATION FOR SEQ ID NO: 62:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 18 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (primer)  
 ; DESCRIPTION: sequence tagged-site specific PCR primer sWS52588  
 ; HYPOTHETICAL: NO  
 ; ANTI-SENSE: NO  
 ; ORIGINAL SOURCE:  
 ; ORGANISM: Human  
 ; US-08-488-208A-62

```

RESULT 97
US-08-483-211A-62/c
; Sequence 62, Application US/08483211A
; Patent No. 6309853
; GENERAL INFORMATION:
; APPLICANT: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING
; TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC
; TITLE OF INVENTION: USES THEREOF
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,211A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/485,943
; FILING DATE: June 7, 1995
; APPLICATION NUMBER: 08/438,431
; FILING DATE: May 10, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/347,563
; FILING DATE: No. 6309853ember 30, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/292,345
; FILING DATE: August 17, 1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP2I
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 62:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; SEQUENCE DESCRIPTION: SEQ ID NO: 62:
US-08-483-211A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAG 468
DB 18 GGTGGAATGAGAAAG 2

RESULT 98
US-08-483-211A-62/c
; Sequence 62, Application US/08483211A
; Patent No. 6309853
; GENERAL INFORMATION:
; APPLICANT: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING
; TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC
; TITLE OF INVENTION: USES THEREOF
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,211A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/485,943
; FILING DATE: June 7, 1995
; APPLICATION NUMBER: 08/438,431
; FILING DATE: May 10, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/347,563
; FILING DATE: No. 6309853ember 30, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/292,345
; FILING DATE: August 17, 1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP2I
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 62:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; SEQUENCE DESCRIPTION: SEQ ID NO: 62:
US-08-483-211A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAG 468
DB 18 GGTGGAATGAGAAAG 2

RESULT 99
US-08-438-431A-62/c
; Sequence 62, Application US/08438431A
; Patent No. 6429290
; GENERAL INFORMATION:
; APPLICANT: JEFFERY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA, MARGHERITA MAFFEI,
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PR
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue

```

```

; Sequence 62, Application US/08488223A
; Patent No. 6350730
; GENERAL INFORMATION:
; APPLICANT: THE ROCKEFELLER UNIVERSITY
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC
; TITLE OF INVENTION: ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES TH
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,223A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/485,943
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/347,563
; FILING DATE: No. 6350730ember 30, 1994
; APPLICATION NUMBER: 08/292,345
; FILING DATE: August 17, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP2I
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 62:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; SEQUENCE DESCRIPTION: SEQ ID NO: 62:
US-08-488-223A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAG 468
DB 18 GGTGGAATGAGAAAG 2

RESULT 99
US-08-438-431A-62/c
; Sequence 62, Application US/08438431A
; Patent No. 6429290
; GENERAL INFORMATION:
; APPLICANT: JEFFERY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA, MARGHERITA MAFFEI,
; TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PR
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue

```



CITY: Hackensack  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 07601  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/438,431A  
FILING DATE: May 10, 1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/347,563  
FILING DATE: No. 6429290ember 30, 1994  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/292,345  
FILING DATE: August 17, 1994  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Jackson Esq., David A.  
REGISTRATION NUMBER: 26,742  
REFERENCE/DOCKET NUMBER: 600-1-087 CIP1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201 487-5800  
TELEFAX: 201 343-1684  
TELEX: 133521  
INFORMATION FOR SEQ ID NO: 62:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (primer)  
DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Human  
US-08-438-431A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAG 468  
Db 18 GGTGGAATGTAGAATG 2

RESULT 100  
US-08-488-225A-62/c  
Sequence 62, Application US/08488225A  
Patent No. 6471956  
GENERAL INFORMATION:  
APPLICANT: THE ROCKEFELLER UNIVERSITY  
TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING  
TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USE  
NUMBER OF SEQUENCES: 98  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Klauber & Jackson  
STREET: 411 Hackensack Avenue  
CITY: Hackensack  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 07601  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/488,225A  
FILING DATE: June 7, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/483,211  
FILING DATE: June 7, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/438,431  
FILING DATE: May 10, 1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/347,563  
FILING DATE: No. 6471956ember 30, 1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/292,345  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Jackson Esq., David A.  
REGISTRATION NUMBER: 26,742  
REFERENCE/DOCKET NUMBER: 600-1-087 CIP2J  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201 487-5800  
TELEFAX: 201 343-1684  
TELEX: 133521  
INFORMATION FOR SEQ ID NO: 62:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (primer)  
DESCRIPTION: sequence tagged-site specific PCR primer  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Human  
US-08-488-225A-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAG 468  
Db 18 GGTGGAATGTAGAATG 2

RESULT 101  
US-09-696-791-4190/c  
Sequence 4190, Application US/09696791  
Patent No. 6770633  
GENERAL INFORMATION:  
APPLICANT: Robbins, Joan M.  
APPLICANT: Tritz, Richard  
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
TITLE OF INVENTION: SKIN AND EYE DISEASES  
FILE REFERENCE: 480124.407  
CURRENT APPLICATION NUMBER: US/09/696,791  
CURRENT FILING DATE: 2000-10-25  
NUMBER OF SEQ ID NOS: 4523  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 4190  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase  
US-09-696-791-4190

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 22 TTGCAGTCTCTCGAACC 38  
||||| ||| |||||  
DB 18 TTGCAGTACTAGGAACC 2

RESULT 102  
US-09-599-002-7/c  
; Sequence 7, Application US/09599002  
; Patent No. 6797465  
; GENERAL INFORMATION:  
; APPLICANT: MYHR, Kjell-Morten  
; APPLICANT: NYLAND, Harold I.  
; APPLICANT: VEDELER, Christian A.  
; TITLE OF INVENTION: METHOD FOR DISEASE DIAGNOSIS BASED ON FC RECEPTOR GENOTYPING  
; FILE REFERENCE: Q59836  
; CURRENT APPLICATION NUMBER: US/09/599,002  
; CURRENT FILING DATE: 2000-06-22  
; PRIOR APPLICATION NUMBER: PCT/GB98/03872  
; PRIOR FILING DATE: 1998-12-22  
; PRIOR APPLICATION NUMBER: GB 9727055.7  
; PRIOR FILING DATE: 1997-12-22  
; PRIOR APPLICATION NUMBER: GB 9802207.2  
; PRIOR FILING DATE: 1998-02-02  
; NUMBER OF SEQ ID NOS: 10  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Human  
US-09-599-002-7

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 71;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 229 AGCAGCGCTGACCAATG 245  
||||| ||| ||||| |||||  
DB 17 AGCAGCGCTGACCAATG 1

RESULT 103  
US-09-371-772B-5942/c  
; Sequence 5942, Application US/09371772B  
; Patent No. 6586127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH800.876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5942  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5942

Query Match 1.5%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 64;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 241 CAGTCAGGTCCTCA 255  
||||| ||| |||||  
DB 16 CAGTCAGGTCCTCA 2

RESULT 104  
US-08-584-040-4278  
; Sequence 4278, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2086  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 4278:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-4278

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 53.3%; Pred. No. 72;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTG 656  
||:|:|:|:|:|:|  
DB 3 ACGUUUCAGAGUUG 17

RESULT 105  
US-08-584-040-4279  
; Sequence 4279, Application US/08584040  
; Patent No. 6346398

```

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4279:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4279

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 72;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTG 656
DB 2 ACGUUUUCAGAGUUG 16

RESULT 106
US-08-584-040-7632/c
; Sequence 7632, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7632:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7632

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266
DB 17 CTCACCTGTAACTCCTC 3

RESULT 107
US-08-584-040-7633/c
; Sequence 7633 Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```

; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7633:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7633
```

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 72;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 252 CTCACCTTTAATCCTC 266
      ||||| ||||| |||||
Db 16 CTCACCTGTAATCCTC 2
```

```

RESULT 108
US-09-371-772B-2045
; Sequence 2045, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2045
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2045
```

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 53.3%; Pred. No. 72;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

```
QY 642 ACTTTTTCAGAGTTG 656
      || :||| |||||
Db 3 ACGUUUCAGAGUUG 17
```

```

RESULT 109
US-09-371-772B-2046
; Sequence 2046, Application US/09371772B
; Patent No. 6566127
```

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2046
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2046
```

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 53.3%; Pred. No. 72;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

```
QY 642 ACTTTTTCAGAGTTG 656
      || :||| |||||
Db 2 ACGUUUCAGAGUUG 16
```

```

RESULT 110
US-09-371-772B-3424/c
; Sequence 3424, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3424
```

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 72;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 252 CTCACCTTTAATCCTC 266
      ||||| ||||| |||||
Db 17 CTCACCTGTAATCCTC 3
```

```

RESULT 111
US-09-371-772B-3425/c
; Sequence 3425, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

LIFE: KNA  
 ORGANISM: Homo sapiens  
 S-09-685-664B-2046  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 53.3%;  
 Matches 8; Conservative 6; Pident. No. 72;  
 Mismatches 1; Indels

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

**GENERAL INFORMATION:**

Sequence 3424, Application US/09685664B  
Patent No. 6818447  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: MCSwiggan, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH800-876-K (400/021)  
CURRENT APPLICATION NUMBER: US/09/685,664B  
CURRENT FILING DATE: 2000-10-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
PRIOR APPLICATION NUMBER: US 09/371,772  
PRIOR FILING DATE: 1999-08-10  
NUMBER OF SEQ ID NOS: 8231  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3424  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Mus musculus  
US-09-685-664B-3424

TYPE: RNA  
ORGANISM: Mus musculus  
3-09-685-664B-3424

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. NO. 72;  
Matches 14; Conservative 1; Indels

US-09-685-664B-2046  
; Sequence 2046, Application US/09685664B  
; Patent No. 6818447

RESULT 115

```
US-09-685-664B-3425/c
; Sequence 3425, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3425
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3425

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 72;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266
DB 16 CTCACCTGAATCCTC 2

RESULT 116
US-09-371-772B-7004
; Sequence 7004, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7004
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7004

Query Match 1.5%; Score 13; DB 1; Length 16;
Best Local Similarity 84.6%; Pred. No. 73;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCATGAAAAA 433
DB 4 GGUCCAUGAAAAA 16
```

```
RESULT 117
US-08-584-040-1903
; Sequence 1903, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA: US/08/584,040
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1903:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1903

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 82;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
DB 3 AUCACUUGGAAGA 15

RESULT 118
US-09-371-772B-448
; Sequence 448, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; PRIOR FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 448  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-448

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 76.9%; Pred. No. 82;  
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
QY 691 ATCACTTGAAGA 703  
Db 3 AUCACUUGGAAGA 15  
:-:|:|:|:|:|:|

RESULT 119  
US-09-371-772B-4718  
; Sequence 4718, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; PRIOR FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4718  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-4718

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 76.9%; Pred. No. 82;  
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;  
QY 691 ATCACTTGAAGA 703  
Db 4 AUCACUUGGAAGA 16  
:-:|:|:|:|:|:|

RESULT 120  
US-09-371-772B-6292  
; Sequence 6292, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6292  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-6292

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 82;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 421 GGTCCATGAAAA 433  
Db 5 GGUCCAUGAAAA 17  
:-:|:|:|:|:|:|

RESULT 121  
US-09-371-772B-6293  
; Sequence 6293, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6293  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-6293

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 82;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 421 GGTCCATGAAAA 433  
Db 4 GGUCCAUGAAAA 16  
:-:|:|:|:|:|:|

RESULT 122  
US-09-685-664B-448  
; Sequence 448, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B

```
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 448
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-448

Query Match          1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 82;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATCACTTGGAAGA 703
      1:||||:|||||
      3 AUCACUGGAAGA 15

Db

RESULT 123
US-09-371-772B-5969/c
; Sequence 5969, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5969
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5969

Query Match          1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 78;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      638 TGTGACATTTTCAGAG 653
      16 TGTGACATTTTCAGTG 1

Db

RESULT 124
US-09-371-772B-6103
; Sequence 6103, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
```

```
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6103
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6103

Query Match          1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 78;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      424 CCATGAAAAAGCAGAT 439
      1:|||||
      1 CCAUGAAAAUGCAAAU 16

Db

RESULT 125
US-08-985-162-718/c
; Sequence 718, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 718:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-718
```



```
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 114 GCATCATCAATTTCGA 129
DB 17 GCATTATCAATTTCAA 2

RESULT 126
US-08-606-505B-52
; Sequence 52, Application US/08606505B
; Patent No. 6114601
; GENERAL INFORMATION:
; APPLICANT: KIKUCHI, Yasuhiro
; APPLICANT: KIKAWA, Shigeto
; APPLICANT: SHIMADA, Yukihisa
; APPLICANT: OHBAYASHI, Masaya
; APPLICANT: SHIMADA, Ritsuko
; APPLICANT: OKINAKA, Yasushi
; TITLE OF INVENTION: NOVEL PLANT GENES
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
; COMPUTER: IBM PS/V
; OPERATING SYSTEM: MS-DOS Ver3.30
; SOFTWARE: PATENT AID Ver1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/606,505B
; FILING DATE: 23-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP44963/92
; FILING DATE: 02-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-218-2100
; TELEFAX: 212-218-2200
; INFORMATION FOR SEQ ID NO: 52 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: Synthetic DNA
; US-08-606-505B-52

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGGTGG 53
DB 1 CCNGGACATCGCGGTGG 17

RESULT 127
US-09-616-990-52
; Sequence 52, Application US/09616990
; Patent No. 6232109
; GENERAL INFORMATION:
; APPLICANT: KIKUCHI, Yasuhiro
; APPLICANT: KIKAWA, Shigeto
; APPLICANT: SHIMADA, Yukihisa
```

```
; OHBAYASHI, Masaya
; SHIMADA, Ritsuko
; OKINAKA, Yasushi
; TITLE OF INVENTION: NOVEL PLANT GENES
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
; COMPUTER: IBM PS/V
; OPERATING SYSTEM: MS-DOS Ver3.30
; SOFTWARE: PATENT AID Ver1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/616,990
; FILING DATE: 14-JUL-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP44963/92
; FILING DATE: 02-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-218-2100
; TELEFAX: 212-218-2200
; INFORMATION FOR SEQ ID NO: 52 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: Synthetic DNA
; US-09-616-990-52

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGGTGG 53
DB 1 CCNGGACATCGCGGTGG 17

RESULT 128
US-08-584-040-2683
; Sequence 2683, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
```

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2683:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-2683

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 396 ATTGCATTCATGGCCG 411  
Db 2 AGUGCAUUCUUGGCCG 17

RESULT 129  
US-08-584-040-5361/c  
; Sequence 5361, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995

ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 5361:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-5361

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 790 TTGTCAGAAATTTCTTT 805  
Db 16 TTGTCAGTATGTCITT 1

RESULT 130  
US-08-584-040-7274/c  
; Sequence 7274, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 7274:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid

STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-7274

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 TGTCTATTGAAGATTC 372  
Db 17 TGTAGATTGAAGATTC 2

## RESULT 131

US-08-584-040-7916  
Sequence 7916, Application US/08584040  
Patent No. 6346398

## GENERAL INFORMATION:

APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
TITLE OF INVENTION: GROWTH FACTOR  
NUMBER OF SEQUENCES: 8502

## CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

## COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510

## INFORMATION FOR SEQ ID NO: 7916:

SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

US-08-584-040-7916

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 663 AGTACCTGTAGTGAGA 678  
Db 2 AGUUCUCCUAGUGAGA 17

## RESULT 132

US-09-371-772B-1207  
Sequence 1207, Application US/09371772B  
Patent No. 6566127

## GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1207  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens

US-09-371-772B-1207

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 396 ATTGCATCATGGCCG 411  
Db 2 AGUGCAUCUUGGCCG 17

## RESULT 133

US-09-371-772B-2263/c  
Sequence 2263, Application US/09371772B  
Patent No. 6566127

## GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 2263  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Mus sp.

US-09-371-772B-2263

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 790 TTGTCAGATTCTTT 805  
Db 16 TTGTCAGTATGCTTT 1

## RESULT 134

US-09-371-772B-3083/c  
; Sequence 3083, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3083  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3083

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 TGTCTATTGAAGATTC 372  
||| |||||  
Db 17 TGTAGATTGAAGATTC 2

## RESULT 135

US-09-371-772B-3699  
; Sequence 3699, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3699  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3699

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 663 AGTACCTGTAGTACG 678  
||: ||: ||: |||  
Db 2 AGUUCUCUAGUGAGA 17

## RESULT 136

US-09-371-772B-4534  
; Sequence 4534, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4534  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-4534

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 766 TTAATCAGATGGG 781  
::: |||||  
Db 2 UUAUACAGAGUG 17

## RESULT 137

US-09-371-772B-5538  
; Sequence 5538, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5538  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5538

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 88;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 396 ATTGCATTCGCGC 411  
|: ||: ||: |||  
Db 1 AGUGCAUCUUGGCG 16

## RESULT 138

US-09-371-772B-6266

; Sequence 6266, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Akhtar, Saghir  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00.876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6266  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-6266

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 88;  
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 824 TAAAAACCCCTGTATGG 839  
Db 2 UAAAAACCCAGUCUGG 17

## RESULT 139

US-09-371-772B-6267  
; Sequence 6267, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00.876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6267  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-6267

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 88;  
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 824 TAAAAACCCCTGTATGG 839  
Db 1 UAAAAACCCAGUCUGG 16

## RESULT 140

US-09-401-063-718/c  
; Sequence 718, Application US/09401063

; Patent No. 6523962  
; GENERAL INFORMATION:  
; APPLICANT: Akhtar, Saghir  
; APPLICANT: Fell, Patricia  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT  
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
; TITLE OF INVENTION: FACTOR RECEPTORS  
; NUMBER OF SEQUENCES: 1877  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ for Windows 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/401,063  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/985,162  
; FILING DATE: 04 December 1997  
; APPLICATION NUMBER: 60/036,476  
; FILING DATE: 31 January 1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 230/107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 718:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-401-063-718

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 114 GCATCATCAATTTCGA 129  
Db 17 GCATTATCAATTTCAA 2

## RESULT 141

US-09-866-108A-1590  
; Sequence 1590, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David R.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A

```
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1590

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 290 AAGGTGAGAGAGGC 305
DB 2 AAGGTGCGAAGGC 17

RESULT 142
US-09-866-108A-1591
; Sequence 1591, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2708
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2708

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 290 AAGGTGAGAGAGGC 305
DB 2 AAGGTGCGAAGGC 17

RESULT 143
US-09-866-108A-2708
; Sequence 2708, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2708
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2708

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTGGAG 221
```

```
; CURRENT FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1591
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1591

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 290 AAGGTGAGAGAGGC 305
DB 1 AAGGTGCGAAGGC 16

RESULT 143
US-09-866-108A-2708
; Sequence 2708, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2708
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2708

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTGGAG 221
```

```
Db      2 GTTCATGAGGTTTGAG 17
|||||
RESULT 144
US-09-866-108A-2709, Application US/09866108A
; Sequence 2709, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2709
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2709

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      206 GTTCATGAGTTTGAG 221
|||||
Db      1 GTTCATGAGGTTTGAG 16
|||||
RESULT 145
US-09-866-108A-7221
; Sequence 7221, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      206 GTTCATGAGTTTGAG 221
|||||
Db      1 GTTCATGAGGTTTGAG 16
|||||
RESULT 146
US-09-866-108A-7222
; Sequence 7222, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2709
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2709

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      337 CAAGATGGTGTGGCC 352
|||||
Db      2 CAAGGTGATGTGGCC 17
|||||
RESULT 146
US-09-866-108A-7222
; Sequence 7222, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7221
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7221
```

; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aecomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 7222  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-7222

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 337 CAAAGTGTGTGGCC 352  
Db 1 CAAAGTGTGTGGCC 16

RESULT 147  
US-09-866-108A-7767/c  
; Sequence 7767, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AECOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aecomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 7767  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-7767

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 409 CCGCACACTGGTGTC 424  
Db 17 CCGCACACTGGTGTC 2

RESULT 148  
US-09-866-108A-7768/c  
; Sequence 7768, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AECOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aecomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 7768  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-7768

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 409 CCGCACACTGGTGTC 424  
Db 16 CCGCACACTGGTGTC 1

RESULT 149  
US-09-866-108A-7981/c  
; Sequence 7981, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE



FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 7981  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-7981

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCTCTGCTAGCT 584  
DB 17 TGTATCTCTGCTGGCT 2

RESULT 150  
US-09-866-108A-7982/c  
Sequence 7982, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 7982  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-7982

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 569 TGTATCTCTGCTAGCT 584  
DB 16 TGTATCTCTGCTGGCT 1

RESULT 151  
US-09-866-108A-8159  
Sequence 8159, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8159  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8159

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 88;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8959

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      183 CTGAAGGCGCTGCATGG 198
Db      2 CTGAAGGCGGACATGG 17
      |||||
RESULT 154
US-09-866-108A-8961
; Sequence 8961, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

QY      291 AGGATGAAGAGGCA 306
Db      1 AGTATGAAGAAGCA 16
      |||||
RESULT 153
US-09-866-108A-8959
; Sequence 8959, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8160
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8160

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      291 AGGATGAAGAGGCA 306
Db      1 AGTATGAAGAAGCA 16
      |||||
RESULT 153
US-09-866-108A-8959
; Sequence 8959, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8961
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8961

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 TGAAGGCGCATGGA 199
      |||||
Db 1 TGAAGGCGCATGGA 16

RESULT 155
US-09-866-108A-10213/c
; Sequence 10213, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10214
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10214

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCGTCGTGGGCTTCCG 21
      |||||
Db 16 GTGTCGTGGGCTTCCG 1

RESULT 157
US-09-404-912-470/c
; Sequence 470, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; Genotyping and DNA Analysis
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCGTCGTGGGCTTCCG 21
      |||||
Db 17 GTGTCGTGGGCTTCCG 2

RESULT 156
US-09-866-108A-10214/c
; Sequence 10214, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10214
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10214

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GCGTCGTGGGCTTCCG 21
      |||||
Db 16 GTGTCGTGGGCTTCCG 1

RESULT 157
US-09-404-912-470/c
; Sequence 470, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; Genotyping and DNA Analysis
```

```
; FILE REFERENCE: M0656/7045 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 470
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-470
```

```
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 428 GAAAGACGATGACT 443
Db 17 GAGAAAGCAGAGACT 2
```

```
RESULT 158
US-09-720-435A-30
; Sequence 30, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; CURRENT FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-30
```

```
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 218 GCAGATAATACAGCAG 233
Db 2 GCAGATAATACAGTAG 17
```

```
RESULT 159
US-09-720-435A-191
; Sequence 191, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; CURRENT FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 191
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-191
```

```
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 712 GTTTTATAAACTCAG 727
Db 1 GTTTTATCAAGTCAG 16
```

```
RESULT 160
US-09-685-664B-1207
; Sequence 1207, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1207
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1207
```

```
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 88;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 396 ATTGCATCATTCGCGC 411
Db 2 AGUGCAUCUUGGCGC 17
```

```
RESULT 161
US-09-685-664B-2263/C
; Sequence 2263, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
```



Best Local Similarity 92.9%; Pred. No. 78;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 703 ATTTGTATAGTTT 716  
| | | | | | | | | |  
Db 15 ATTTGGATAGTTT 2

## RESULT 165

US-08-363-240A-144/c  
; Sequence 144, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry  
; APPLICANT: McSwiggen, James  
; APPLICANT: Bisgaier, Charles  
; APPLICANT: Pape, Michael  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: PREVENTION, INHIBITION OF  
; TITLE OF INVENTION: PROGRESSION AND REGRESSION  
; TITLE OF INVENTION: OF VASCULAR DISEASES  
; NUMBER OF SEQUENCES: 1243  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:

ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 144:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-144

Query Match 1.4%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 78;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 693 CACTTGGAGATTT 706  
| | | | | | | | | |  
Db 15 CTCCTTGAAGATTT 2

## RESULT 166

US-08-363-240A-145/c  
; Sequence 145, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry

APPLICANT: McSwiggen, James  
APPLICANT: Bisgaier, Charles  
APPLICANT: Pape, Michael  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
TITLE OF INVENTION: PREVENTION, INHIBITION OF  
TITLE OF INVENTION: PROGRESSION AND REGRESSION  
TITLE OF INVENTION: OF VASCULAR DISEASES  
NUMBER OF SEQUENCES: 1243  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:

ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 145:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-145

Query Match 1.4%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 78;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 693 CACTTGGAGATTT 706  
| | | | | | | | | |  
Db 14 CTCCTTGAAGATTT 1

## RESULT 167

US-08-774-310-197/c  
; Sequence 197, Application US/08774310  
; Patent No. 5877022  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Daniel T.  
; APPLICANT: McSwiggen, James  
; APPLICANT: Newton, Roger S.  
; APPLICANT: Ramharack, Randy  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES  
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF  
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY  
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN  
; NUMBER OF SEQUENCES: 392  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles

STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/774,310  
FILING DATE: December 23, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/311,760  
FILING DATE: September 23, 1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 223/229  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 197:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-774-310-197

Query Match 1.4%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 78;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ATTTGTATGTTT 716  
||||| |||||||  
Db 15 ATTTGGATGTTT 2

RESULT 168  
US-09-531-000-9  
Sequence 9, Application US/09531000  
Patent No. 6461810  
GENERAL INFORMATION:  
APPLICANT: JOHNSON, Marion D.  
APPLICANT: FRESKO, Jacques R.  
TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION  
FILE REFERENCE: 2448-103  
CURRENT APPLICATION NUMBER: US/09/531,000  
CURRENT FILING DATE: 2000-09-08  
PRIOR APPLICATION NUMBER: PCT/US98/23765  
PRIOR FILING DATE: 1998-11-10  
PRIOR APPLICATION NUMBER: 60/064,997  
PRIOR FILING DATE: 1997-11-10  
NUMBER OF SEQ ID NOS: 77  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 9  
LENGTH: 16  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Target  
OTHER INFORMATION: sequences  
US-09-531-000-9

Query Match 1.4%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 88;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 799 TTTCCTTTCATTC 812  
||||| |||||||  
Db 3 TTTCCTTTCATTC 16

RESULT 169  
US-09-371-772B-5681/C  
Sequence 5681, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R-  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5681  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5681

Query Match 1.4%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 88;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 362 ATTGAAGATTCGT 375  
||||| |||||||  
Db 15 ATTGCAGATTCGT 2

RESULT 170  
US-08-319-492B-148  
Sequence 148, Application US/08319492B  
Patent No. 5616488  
GENERAL INFORMATION:  
APPLICANT: Sullivan, Sean M.  
APPLICANT: Draper, Kenneth G.  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES  
TITLE OF INVENTION: OF IL-5  
NUMBER OF SEQUENCES: 751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/319,492B  
FILING DATE: October 7, 1994  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
TWO

```

; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 148:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-319-492B-148

```

```

Query Match 1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 58.3%; Pred. No. 88;
Matches 7; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 730 AAAATGCTCTGTT 741
Db 1 AAAAUGUCUGUU 12

```

```

RESULT 171
US-08-363-240A-143/c
; Sequence 143, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 143:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-143
Query Match 1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 695 CTTGAGAGATT 706
Db 15 CTTGAGAGATT 4

```

```

RESULT 172
US-08-635-309-24/c
; Sequence 24, Application US/08635309
; Patent No. 5709997
; GENERAL INFORMATION:
; APPLICANT: Ronald L. Marshall
; APPLICANT: Cynthia Jou
; APPLICANT: John N. Simons
; APPLICANT: Thomas P. Leary
; APPLICANT: A. Scott Muerhoff
; APPLICANT: Suresh M. Desai
; APPLICANT: Isa K. Mushahwar
; TITLE OF INVENTION: NUCLEIC ACID DETECTION OF HEPATITIS GB VIRUS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release 1.0, Version 1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/635,309
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Priscilla E. Porembski
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 5792.US.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708/937-0378
; TELEFAX: 708/938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: synthetic DNA
US-08-635-309-24

```

```

Query Match 1.4%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 90 TGAAGGGCGACG 101
Db 13 TGAAGGGCGACG 2

```

```

RESULT 173
US-08-585-684B-2103/c
; Sequence 2103, Application US/08585684B
; Patent No. 5877021

```



GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/585,684B  
FILING DATE: January 16, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/000,951  
FILING DATE: July 7, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2103:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-585-684B-2103

Query Match 1.4%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 AAAGCAGATGAC 442  
| | | | | | | | | |  
Db 14 AAAGCAGATGAC 3

RESULT 174  
US-09-038-073-2103/c  
Sequence 2103, Application US/09038073  
Patent No. 6194150  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/038,073  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/585,684  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2103:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-038-073-2103

Query Match 1.4%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 88;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 AAAGCAGATGAC 442  
| | | | | | | | | |  
Db 14 AAAGCAGATGAC 3

RESULT 175  
US-08-173-489C-31  
Sequence 31, Application US/08173489C  
Patent No. 5861244  
GENERAL INFORMATION:  
APPLICANT: WANG, C. -G.  
APPLICANT: HEPBURN, A. G.  
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.  
NUMBER OF SEQUENCES: 365  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
STREET: 510 EAST 73RD STREET,  
CITY: NEW YORK  
STATE: NEW YORK  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44Mb storage  
COMPUTER: IBM PC/XT/AT  
OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: Wordperfect Version 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 31:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: double stranded  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
DESCRIPTION: dystrophin gene (Accession # M18533,  
DESCRIPTION: M17154, M18026) nucleotides 4480 to 4495  
HYPOTHETICAL: No  
ANTI-SENSE: No  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
POSITION IN GENOME:  
CHROMOSOME/SEGMENT: X-chromosome  
MAP POSITION: Xp21.3-p21.1  
PUBLICATION INFORMATION:  
AUTHORS: Koenig, M, Hoffman, E P, Monaco, A P, Feener, C J,  
AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.  
TITLE: Complete cloning of the  
TITLE: preliminary genomic organization of the DMD  
TITLE: gene in normal and affected individuals  
JOURNAL: Cell  
VOLUME: 50  
PAGES: 509-517  
DATE: 1987  
AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,  
AUTHORS: Kunkel, L M.  
TITLE: Conservation of the Duchenne  
TITLE: muscular dystrophy gene in mice and humans  
JOURNAL: Science  
VOLUME: 238  
PAGES: 347-350  
DATE: 1987  
AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.  
TITLE: The complete sequence of  
TITLE: dystrophin predicts a rod-shaped cytoskeletal  
TITLE: protein  
JOURNAL: Cell  
VOLUME: 53  
PAGES: 219-228  
DATE: 1988  
RELEVANT RESIDUES IN SEQ ID NO: 31 :FROM 1 TO 16  
US-08-173-489C-31.

Query Match 1.4%; Score 12; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 456 GAAATGAAGAAA 467  
|||  
Db 5 GAAATGAAGAAA 16

RESULT 176  
US-09-371-772B-6963/c  
Sequence 6963, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 6963  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-6963

Query Match 1.4%; Score 12; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 AGGCGCAGCGCC 104  
|||  
Db 15 AGGCGCAGCGCC 4

RESULT 177  
US-08-373-124A-962/c  
Sequence 962, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
TITLE OF INVENTION: CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 962:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-373-124A-962

Query Match 1.4%; Score 12; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;

QY 713 TTTTATAAACT 724  
 Db 16 TTTTATAAACT 5

## RESULT 178

US-08-373-124A-964/c  
 ; Sequence 964, Application US/08373124A  
 ; Patent No. 5646042  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Stinchcomb, Dan T.  
 ; APPLICANT: Draper, Kenneth  
 ; APPLICANT: McSwiggen, James  
 ; APPLICANT: Jarvis, Thale  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
 ; TREATMENT OF RESTENOSIS AND  
 ; CANCER USING RIBOZYMES  
 ; NUMBER OF SEQUENCES: 2627  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Lyon & Lyon  
 ; STREET: 633 West Fifth Street  
 ; CITY: Suite 4700  
 ; STATE: Los Angeles  
 ; CITY: California  
 ; COUNTRY: U.S.A.  
 ; ZIP: 90071

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 MEDIUM TYPE: storage  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: IBM P.C. DOS 5.0  
 SOFTWARE: Word Perfect 5.1  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/373,124A  
 FILING DATE: January 13, 1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 08/245,466  
 FILING DATE: May 18, 1994

REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 209/035  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (213) 489-1600  
 TELEFAX: (213) 955-0440  
 TELEX: 67-3510  
 INFORMATION FOR SEQ ID NO: 964:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

US-08-373-124A-964  
 Query Match 1.4%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Mismatches 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 TTTTATAAACT 724  
 Db 15 TTTTATAAACT 4

## RESULT 179

US-08-435-628-962/c  
 ; Sequence 962, Application US/08435628  
 ; Patent No. 5817796  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Stinchcomb, Dan T.  
 ; APPLICANT: Draper, Kenneth  
 ; APPLICANT: McSwiggen, James  
 ; APPLICANT: Jarvis, Thale  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR

US-08-373-124A-966/c  
 ; Sequence 966, Application US/08373124A  
 ; Patent No. 5646042  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Stinchcomb, Dan T.  
 ; APPLICANT: Draper, Kenneth  
 ; APPLICANT: McSwiggen, James  
 ; APPLICANT: Jarvis, Thale  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
 ; TREATMENT OF RESTENOSIS AND  
 ; CANCER USING RIBOZYMES  
 ; NUMBER OF SEQUENCES: 2627  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Lyon & Lyon  
 ; STREET: 633 West Fifth Street  
 ; CITY: Suite 4700  
 ; STATE: Los Angeles  
 ; CITY: California  
 ; COUNTRY: U.S.A.  
 ; ZIP: 90071

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 MEDIUM TYPE: storage  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: IBM P.C. DOS 5.0  
 SOFTWARE: Word Perfect 5.1  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/373,124A  
 FILING DATE: January 13, 1995  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 08/245,466  
 FILING DATE: May 18, 1994

REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 209/035  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (213) 489-1600  
 TELEFAX: (213) 955-0440  
 TELEX: 67-3510  
 INFORMATION FOR SEQ ID NO: 966:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

US-08-373-124A-966  
 Query Match 1.4%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Mismatches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 TTTTATAAACT 724  
 Db 14 TTTTATAAACT 3

## RESULT 180

US-08-435-628-962/c  
 ; Sequence 962, Application US/08435628  
 ; Patent No. 5817796  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Stinchcomb, Dan T.  
 ; APPLICANT: Draper, Kenneth  
 ; APPLICANT: McSwiggen, James  
 ; APPLICANT: Jarvis, Thale  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR

;; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
;; NUMBER OF SEQUENCES: 2627  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071

;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
;; MEDIUM TYPE: storage  
;; COMPUTER: IBM Compatible  
;; OPERATING SYSTEM: IBM P.C. DOS 5.0  
;; SOFTWARE: Word Perfect 5.1  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/435,628  
;; FILING DATE: 05-MAY-1995  
;; CLASSIFICATION: 514

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/373,124  
;; FILING DATE: January 13, 1995  
;; APPLICATION NUMBER: 08/245,466  
;; FILING DATE: May 18, 1994  
;; APPLICATION NUMBER: 08/192,943  
;; FILING DATE: February 7, 1994  
;; APPLICATION NUMBER: 07/987,132  
;; FILING DATE: December 7, 1992  
;; APPLICATION NUMBER: 07/936,422  
;; FILING DATE: August 26, 1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 209/035  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510

;; INFORMATION FOR SEQ ID NO: 962:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
US-08-435-628-962

Query Match 1.4%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 713 TTTTATAAACT 724  
|||  
Db 16 TTTTATAAACT 5

RESULT 181

US-08-435-628-964/c  
; Sequence 964, Application US/08435628  
; Patent No. 5817796

;; GENERAL INFORMATION:  
;; APPLICANT: Stinchcomb, Dan T.  
;; APPLICANT: Draper, Kenneth  
;; APPLICANT: McSwiggen, James  
;; APPLICANT: Jarvis, Thale  
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
;; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
;; TITLE OF INVENTION: CANCER USING RIBOZYMES  
;; NUMBER OF SEQUENCES: 2627  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street

;; STREET: Suite 4700  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
;; MEDIUM TYPE: storage  
;; COMPUTER: IBM Compatible  
;; OPERATING SYSTEM: IBM P.C. DOS 5.0  
;; SOFTWARE: Word Perfect 5.1  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/435,628  
;; FILING DATE: 05-MAY-1995  
;; CLASSIFICATION: 514

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/373,124  
;; FILING DATE: January 13, 1995  
;; APPLICATION NUMBER: 08/245,466  
;; FILING DATE: May 18, 1994  
;; APPLICATION NUMBER: 08/192,943  
;; FILING DATE: February 7, 1994  
;; APPLICATION NUMBER: 07/987,132  
;; FILING DATE: December 7, 1992  
;; APPLICATION NUMBER: 07/936,422  
;; FILING DATE: August 26, 1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 209/035  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510

;; INFORMATION FOR SEQ ID NO: 964:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
US-08-435-628-964

Query Match 1.4%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 713 TTTTATAAACT 724  
|||  
Db 15 TTTTATAAACT 4

RESULT 182

US-08-435-628-966/c  
; Sequence 966, Application US/08435628  
; Patent No. 5817796

;; GENERAL INFORMATION:  
;; APPLICANT: Stinchcomb, Dan T.  
;; APPLICANT: Draper, Kenneth  
;; APPLICANT: McSwiggen, James  
;; APPLICANT: Jarvis, Thale  
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
;; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
;; TITLE OF INVENTION: CANCER USING RIBOZYMES  
;; NUMBER OF SEQUENCES: 2627  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071  
;; COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,628  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/373,124  
FILING DATE: January 13, 1995  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 966:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-628-966

Query Match 1.4%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 TTTTATAAACT 724  
|||||  
Db 14 TTTTATAAACT 3

## RESULT 183

US-08-319-492B-28/c  
Sequence 28, Application US/08319492B  
Patent No. 5616488  
GENERAL INFORMATION:  
APPLICANT: Sullivan, Sean M.  
APPLICANT: Draper, Kenneth G.  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES  
TITLE OF INVENTION: OF IL-5  
NUMBER OF SEQUENCES: 751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: IBM storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/319,492B  
FILING DATE: October 7, 1994  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/276  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 28:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-319-492B-28

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 94;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 789 CTTGTCAGAAATTTCT 803  
|||||  
Db 15 CTTGTGGGAATTTCT 1

## RESULT 184

US-08-291-932A-297/c  
Sequence 297, Application US/08291932A  
Patent No. 5658780  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth G.  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: NF-KB  
NUMBER OF SEQUENCES: 830  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/291,932A  
FILING DATE: August 15, 1994  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/157  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 297:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-291-932A-297

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 94;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 180 TGACTGAAGGCTGC 194  
Db 15 TGACTGATAGCCTGC 1

RESULT 185  
US-08-334-847-77/c  
Sequence 77, Application US/08334847  
Patent No. 5693532  
GENERAL INFORMATION:  
APPLICANT: McSwiggen, James  
APPLICANT: Draper, Kenneth  
APPLICANT: Pavco, Pam  
APPLICANT: Woolf, Tod  
TITLE OF INVENTION: METHOD AND REAGENT FOR  
TITLE OF INVENTION: INHIBITING RESPIRATORY  
TITLE OF INVENTION: SYNCYTIAL VIRUS  
NUMBER OF SEQUENCES: 909  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/334,847  
FILING DATE: NO. 5693532ember 4, 1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/032  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 77:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-334-847-77

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 94;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 502 TTGTGGTGTATTCG 516  
Db 15 TTGTGTGAAATTGG 1

RESULT 186  
US-08-292-620A-393  
Sequence 393, Application US/08292620A  
Patent No. 5837542  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620A  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 393:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-292-620A-393

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 73.3%; Pred. No. 94;  
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
QY 39 AGGACCTCGCGTGG 53  
Db 1 AGGACCUCAGCCUGG 15

RESULT 187

US-08-292-620A-656  
 ; Sequence 656, Application US/08292620A  
 ; Patent No. 5837542  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Susan Grimm  
 ; APPLICANT: Dan T. Stinchcomb  
 ; APPLICANT: James McSwiggen  
 ; APPLICANT: Sean Sullivan  
 ; APPLICANT: Kenneth G. Draper  
 ; TITLE OF INVENTION: RIBOZYME TREATMENT OF  
 ; TITLE OF INVENTION: DISEASES OR CONDITIONS  
 ; TITLE OF INVENTION: RELATED TO LEVELS OF  
 ; TITLE OF INVENTION: INTRACELLULAR ADHESION  
 ; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
 ; NUMBER OF SEQUENCES: 2390  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Lyon & Lyon  
 ; STREET: 633 West Fifth Street  
 ; STREET: Suite 4700  
 ; CITY: Los Angeles  
 ; STATE: California  
 ; COUNTRY: U.S.A.  
 ; ZIP: 90071-2066

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

OPERATING SYSTEM: IBM PC DOS 5.0  
 SOFTWARE: Word Perfect 5.1  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/292,620A  
 FILING DATE: August 17, 1994

CLASSIFICATION: 435  
 PRIOR APPLICATION DATA:  
 PRIOR APPLICATION DATA: including application  
 PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895  
 FILING DATE: January 19, 1993  
 APPLICATION NUMBER: 07/989,849  
 FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:  
 NAME: Warburg, Richard J.  
 REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 208/149

TELEPHONE: (213) 489-1600  
 TELEFAX: (213) 955-0440  
 INFORMATION FOR SEQ ID NO: 656:

SEQUENCE CHARACTERISTICS:  
 LENGTH: 15 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

US-08-292-620A-656

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 73.3%; Pred. No. 94;  
 Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 39 AGGACCTCGCGGTGG 53  
 Db 1 AGGACCCACGCCUGG 15

RESULT 188  
 US-08-913-833-34

; Sequence 34, Application US/08913833  
 ; Patent No. 6087093  
 ; GENERAL INFORMATION:

APPLICANT: STUYVER, LIEVEN  
 APPLICANT: LOUWAGIE, JOOST  
 APPLICANT: ROSSAU, RUDI  
 TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED  
 TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE  
 NUMBER OF SEQUENCES: 164  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: ARNOLD, WHITE & DURKEE  
 STREET: P.O. BOX 4433  
 CITY: HOUSTON  
 STATE: TEXAS  
 COUNTRY: USA  
 ZIP: 77210-4433

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Microsoft Word 6.0 / ASCII text output  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/913,833  
 FILING DATE: 15 Sep 1997

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: PCT/EP97/00211  
 FILING DATE: 17 Jan 1997  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: EP 96870005.4  
 FILING DATE: 26 Jan 1996

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: EP 96870081.5  
 FILING DATE: 25 Jun 1996  
 ATTORNEY/AGENT INFORMATION:  
 NAME: KAMMERER, PATRICIA A.

REGISTRATION NUMBER: 29,775  
 REFERENCE/DOCKET NUMBER: INNS:008  
 INFORMATION FOR SEQ ID NO: 34:  
 SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)  
 HYPOTHETICAL: NO  
 ANTI-SENSE: NO

US-08-913-833-34

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 94;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 465 AAAGTACAAAGACAG 479  
 Db 1 AAAGAGAAAGACAG 15

RESULT 189  
 US-09-071-845-393  
 ; Sequence 393, Application US/09071845  
 ; Patent No. 6132967  
 ; GENERAL INFORMATION:

APPLICANT: Susan Grimm  
 APPLICANT: Dan T. Stinchcomb  
 APPLICANT: James McSwiggen  
 APPLICANT: Sean Sullivan  
 APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF  
 TITLE OF INVENTION: DISEASES OR CONDITIONS  
 TITLE OF INVENTION: RELATED TO LEVELS OF  
 TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
 NUMBER OF SEQUENCES: 2390  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Lyon & Lyon  
 STREET: 633 West Fifth Street

US-08-913-833-34

STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 393:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-393

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 73.3%; Pred. No. 94;  
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 39 AGGACCTCGCGCTGG 53  
|||||:|:|:  
Db 1 AGGACCUCAGCCUGG 15

RESULT 190  
US-09-071-845-656  
Sequence 656, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 656:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-656

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 73.3%; Pred. No. 94;  
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 39 AGGACCTCGCGCTGG 53  
|||||:|:|:  
Db 1 AGGACCUCAGCCUGG 15

RESULT 191  
US-09-580-794C-34  
Sequence 34, Application US/09580794C  
Patent No. 6331389  
GENERAL INFORMATION:  
APPLICANT: Stuyver, Lieven  
APPLICANT: Louwagie, Joost  
APPLICANT: Rossau, Rudi  
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE  
TITLE OF INVENTION: TRANSCRIPTASE GENE  
FILE REFERENCE: INNS008--2  
CURRENT APPLICATION NUMBER: US/09/580,794C  
CURRENT FILING DATE: 2000-05-30  
PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093  
PRIOR FILING DATE: 1997-09-15  
PRIOR APPLICATION NUMBER: PCT/EP 97/00211  
PRIOR FILING DATE: 1997-01-17  
PRIOR APPLICATION NUMBER: EP 96870005.4  
PRIOR FILING DATE: 1996-01-26  
PRIOR APPLICATION NUMBER: EP 968700081.5  
PRIOR FILING DATE: 1996-06-25  
NUMBER OF SEQ ID NOS: 164  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 34  
LENGTH: 15  
TYPE: DNA  
ORGANISM: Artificial sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Primer  
US-09-580-794C-34

Query Match 1.4%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 94;



Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 465 AAAGTACAAAGACAG 479  
|||||  
Db 1 AAAGAAGAAAGACAG 15

## RESULT 192

US-09-081-646-586  
; Sequence 586, Application US/09081646  
; Patent No. 6333152

## ; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth  
; APPLICANT: Vogelstein, Bert  
; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646  
; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352  
; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 586  
; LENGTH: 15

; TYPE: DNA  
; ORGANISM: Homo sapiens

US-09-081-646-586

Query Match 1.4%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 94;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 115 CATCATCAATTTCGA 129  
|||||  
Db 1 CATGATCAAGTTTGA 15

## RESULT 193

US-09-943-983C-34

; Sequence 34, Application US/09943983C

; Patent No. 6713251

## ; GENERAL INFORMATION:

; APPLICANT: Stuyver, Lieven

; APPLICANT: Rousseau, Rudi

; APPLICANT: Louwagie, Joost

; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE

; FILE REFERENCE: TRANSCRIPTASE GENE

; CURRENT APPLICATION NUMBER: US/09/943,983C

; CURRENT FILING DATE: 2001-08-31

; PRIOR APPLICATION NUMBER: US 09/580,794

; PRIOR FILING DATE: 2000-05-30

; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093

; PRIOR FILING DATE: 1997-09-15

; PRIOR APPLICATION NUMBER: PCT/EP 97/00211

; PRIOR FILING DATE: 1997-01-17

; PRIOR APPLICATION NUMBER: EP 96870005.4

; PRIOR FILING DATE: 1996-01-26

; PRIOR APPLICATION NUMBER: EP 96870081.5

; PRIOR FILING DATE: 1996-06-25

; NUMBER OF SEQ ID NOS: 164

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 34

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: Synthetic Primer

US-09-943-983C-34

Query Match 1.4%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 94;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 465 AAAGTACAAAGACAG 479  
|||||  
Db 1 AAAGAAGAAAGACAG 15

## RESULT 194

US-09-720-435A-36

; Sequence 36, Application US/09720435A

; Patent No. 6803187

## ; GENERAL INFORMATION:

; APPLICANT: Stuyver, Lieven

; TITLE OF INVENTION: Method

; FILE REFERENCE: 11362.0030, PCUS00 INNS:030

; CURRENT APPLICATION NUMBER: US/09/720,435A

; CURRENT FILING DATE: 2001-06-25

; PRIOR APPLICATION NUMBER: PCT/EP99/04317

; PRIOR FILING DATE: 1999-06-22

; PRIOR APPLICATION NUMBER: 98870143.9

; PRIOR FILING DATE: 1998-06-24

; NUMBER OF SEQ ID NOS: 529

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 36

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Aids-associated retrovirus

US-09-720-435A-36

Query Match

Best Local Similarity 1.4%; Score 11.8; DB 1; Length 15;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 218 GCAGATAATACAGCA 232  
|||||  
Db 1 GCAGATAATACAGTA 15

Search completed: October 6, 2005, 10:41:26

Job time : 3 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 6, 2005, 10:44:11 ; Search time 6 Seconds  
(without alignments)  
3.425 Million cell updates/sec

Title: US-10-633-843-3-COPY  
Perfect score: 874  
Sequence: 1 ctgcagctctctgggtttcc.....tattaaagaatccaattc 874

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 608 seqs, 11755 residues

Total number of hits satisfying chosen parameters: 1216

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 610 summaries

Database : ngsdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	5.7	50	1	ABZ00314 Human leukocyte ge
2	50	5.7	50	1	ABZ01960 Human leukocyte ge
3	48	5.5	48	1	AD52413 Wild-type human SO
4	48	5.5	48	1	ADO43047 Superoxide dismuta
5	46.4	5.3	48	1	AD52414 Human SOD1 mutant
6	46.4	5.3	48	1	ADO43048 Superoxide dismuta
7	40	4.6	40	1	AAQ27817 Primer AO39, Synt
8	35	4.0	35	1	AD52418 Wild-type human SO
9	35	4.0	35	1	ADO43055 Superoxide dismuta
10	28	3.2	28	1	ABK66923 Human gene specifi
11	28	3.2	28	1	ABK66924 Human gene specifi
12	27	3.1	27	1	ABA94683 Antisense S-oligo
13	25	2.9	33	1	ADQ75020 Human superoxide d
14	24	2.7	24	1	AAQ67485 PCR primer for hum
15	24	2.7	24	1	AAV73835 Human SOD1 exon 5
16	24	2.7	24	1	ADO55698 Human cytosolic su
17	23	2.6	23	1	ABA94686 Superoxide dismuta
18	23	2.6	23	1	ABA94685 Superoxide dismuta
19	23	2.6	23	1	ABX12365 Oxidative stress d
20	23	2.6	23	1	ABX12364 Oxidative stress d
21	22.6	2.6	30	1	AAA88139 Mouse (balb/c) for
22	22.6	2.6	30	1	ABK91997 Mouse Cu/Zn-SOD (s
23	22.4	2.6	25	1	AAD13501 Rat superoxide dis
24	22.2	2.5	27	1	ADQ29666 Human Zn-SOD ampli
25	22.2	2.5	27	1	ADQ59161 Human Cu/Zn-supero
26	22.2	2.5	27	1	ADQ06573 Fusion protein rel
27	22.2	2.5	27	1	ADQ74975 Tat-pyridoxal kina
28	22	2.5	22	1	ADG73925 Human superoxide d
29	22	2.5	22	1	ADG73926 Human superoxide d
30	22	2.5	27	1	ADQ59160 Human Cu/Zn-supero
31	22	2.5	27	1	ADQ06572 Fusion protein rel
32	22	2.5	27	1	ADQ74974 Tat-pyridoxal kina
33	22	2.5	29	1	AAV32582 Human SOD-1 cDNA p

C	34	21	2.4	21	1	ABQ73054 Cu/Zn SOD gene rel
C	35	21	2.4	21	1	ABZ79578 Human superoxide d
C	36	21	2.4	21	1	ADD56532 Human gene express
C	37	21	2.4	21	1	ADD56533 Human gene express
C	38	21	2.4	21	1	ADT66493 PCR primer for CuZ
C	39	20.4	2.3	22	1	ABQ73057 Cu/Zn SOD gene rel
C	40	20	2.3	20	1	NAV01383 Superoxide dismuta
C	41	20	2.3	20	1	ACC40898 Human superoxide d
C	42	20	2.3	20	1	ACC40912 Human superoxide d
C	43	20	2.3	20	1	ACC40914 Human superoxide d
C	44	20	2.3	20	1	ACC40930 Human superoxide d
C	45	20	2.3	20	1	ACC40892 Human superoxide d
C	46	20	2.3	20	1	ACC40897 Human superoxide d
C	47	20	2.3	20	1	ACC40932 Human superoxide d
C	48	20	2.3	20	1	ACC40936 Human superoxide d
C	49	20	2.3	20	1	ACC40893 Human superoxide d
C	50	20	2.3	20	1	ACC40904 Human superoxide d
C	51	20	2.3	20	1	ACC40908 Human superoxide d
C	52	20	2.3	20	1	ACC40911 Human superoxide d
C	53	20	2.3	20	1	ACC40913 Human superoxide d
C	54	20	2.3	20	1	ACC40915 Human superoxide d
C	55	20	2.3	20	1	ACC40940 Human superoxide d
C	56	20	2.3	20	1	ACC40882 Human superoxide d
C	57	20	2.3	20	1	ACC40903 Human superoxide d
C	58	20	2.3	20	1	ACC40920 Human superoxide d
C	59	20	2.3	20	1	ACC40943 Human superoxide d
C	60	20	2.3	20	1	ACC40884 Human superoxide d
C	61	20	2.3	20	1	ACC40887 Human superoxide d
C	62	20	2.3	20	1	ACC40896 Human superoxide d
C	63	20	2.3	20	1	ACC40899 Human superoxide d
C	64	20	2.3	20	1	ACC40928 Human superoxide d
C	65	20	2.3	20	1	ACC40944 Human superoxide d
C	66	20	2.3	20	1	ACC40884 Human superoxide d
C	67	20	2.3	20	1	ACC40886 Human superoxide d
C	68	20	2.3	20	1	ACC40889 Human superoxide d
C	69	20	2.3	20	1	ACC40894 Human superoxide d
C	70	20	2.3	20	1	ACC40931 Human superoxide d
C	71	20	2.3	20	1	ACC40937 Human superoxide d
C	72	20	2.3	20	1	ACC40909 Human superoxide d
C	73	20	2.3	20	1	ACC40942 Human superoxide d
C	74	20	2.3	20	1	ACC40919 Human superoxide d
C	75	20	2.3	20	1	ACC40921 Human superoxide d
C	76	20	2.3	20	1	ACC40885 Human superoxide d
C	77	20	2.3	20	1	ABZ79576 Human superoxide d
C	78	20	2.3	20	1	ABZ79577 Human superoxide d
C	79	20	2.3	20	1	ABZ79577 Human superoxide d
C	80	20	2.3	20	1	ACC40900 Human superoxide d
C	81	20	2.3	20	1	ACC40938 Human superoxide d
C	82	20	2.3	20	1	ACC40939 Human superoxide d
C	83	20	2.3	20	1	ACC40905 Human superoxide d
C	84	20	2.3	20	1	ACC40918 Human superoxide d
C	85	20	2.3	20	1	ACC40934 Human superoxide d
C	86	20	2.3	20	1	ACC40941 Human superoxide d
C	87	20	2.3	20	1	ACC40895 Human superoxide d
C	88	20	2.3	20	1	ACC40901 Human superoxide d
C	89	20	2.3	20	1	ACC40916 Human superoxide d
C	90	20	2.3	20	1	ACC40924 Human superoxide d
C	91	20	2.3	20	1	ACC40929 Human superoxide d
C	92	20	2.3	20	1	ACC40925 Human superoxide d
C	93	20	2.3	20	1	ACC40926 Human superoxide d
C	94	20	2.3	20	1	ACC40888 Human superoxide d
C	95	20	2.3	20	1	ACC40891 Human superoxide d
C	96	20	2.3	20	1	ACC40917 Human superoxide d
C	97	20	2.3	20	1	ACC40922 Human superoxide d
C	98	20	2.3	20	1	ACC40923 Human superoxide d
C	99	20	2.3	20	1	ACC40935 Human superoxide d
C	100	20	2.3	20	1	ACC40881 Human superoxide d
C	101	20	2.3	20	1	ACC40890 Human superoxide d
C	102	20	2.3	20	1	ACC40906 Human superoxide d
C	103	20	2.3	20	1	ACC40910 Human superoxide d
C	104	20	2.3	20	1	ACC40933 Human superoxide d
C	105	20	2.3	20	1	ACC40880 Human superoxide d
C	106	20	2.3	20	1	ACC40907 Human superoxide d

c 107	20	2.3	20	1	ACC40927	Human superoxide d	c 180	17.2	2.0	22	1	ACD23495	Human PRO PCR prim
c 108	20	2.3	20	1	ADQ80681	Human cytosolic su	c 181	17.2	2.0	22	1	ADB77533	Human secreted/tra
c 109	20	2.3	20	1	ADR42714	SOD gene analysis	c 182	17.2	2.0	22	1	ADB74669	Human secreted/tra
c 110	20	2.3	20	1	ADR42715	SOD gene analysis	c 183	17.2	2.0	22	1	ADC28315	Human secreted/tra
c 111	20	2.3	21	1	AAO67477	PCR primer for hum	c 184	17.2	2.0	22	1	ADC39515	Human secreted/tra
c 112	20	2.3	21	1	AAV73827	Human SOD1 exon 1	c 185	17.2	2.0	22	1	ADC40029	Human secreted/tra
c 113	20	2.3	21	1	ADO55690	Human cytosolic su	c 186	17.2	2.0	22	1	ADC18857	Human secreted/tra
c 114	20	2.3	25	1	ADO43049	Short interfering	c 187	17.2	2.0	22	1	ADC34153	Human secreted/tra
c 115	19.8	2.3	23	1	ABO75418	CuZn superoxide di	c 188	17.2	2.0	22	1	ADC29208	Human secreted/tra
c 116	19.4	2.2	21	1	ADBS2440	Target DNA sequenc	c 189	17.2	2.0	22	1	ADC28739	Human secreted/tra
c 117	19.4	2.2	21	1	ADBS2403	Target DNA sequenc	c 190	17.2	2.0	22	1	ADC40624	Human secreted/tra
c 118	19.4	2.2	22	1	AAH81808	Probe used to iden	c 191	17.2	2.0	22	1	ADC19281	Human secreted/tra
c 119	19.4	2.2	25	1	ADO43051	Short interfering	c 192	17.2	2.0	22	1	ADC33729	Human secreted/tra
c 120	19.2	2.2	23	1	ADBS2415	siRNA p11 sequence	c 193	17.2	2.0	22	1	ADC12799	Human secreted/tra
c 121	19.2	2.2	23	1	ADBS2417	siRNA p11 sequence	c 194	17.2	2.0	22	1	ADC12251	Human secreted/tra
c 122	19	2.2	19	1	AAH60181	Sequence of probe	c 195	17.2	2.0	22	1	ADD04806	Human secreted/tra
c 123	19	2.2	19	1	ABO73056	Cu/Zn SOD gene rel	c 196	17.2	2.0	22	1	ADD03812	Human secreted/tra
c 124	19	2.2	19	1	ADBS0680	Human cytosolic su	c 197	17.2	2.0	22	1	ADD03388	Human secreted/tra
c 125	19	2.2	23	1	ADBS2425	siRNA p11 sequence	c 198	17.2	2.0	22	1	ADBS34640	Human secreted/tra
c 126	19	2.2	23	1	ADBS2424	siRNA p10 sequence	c 199	17.2	2.0	22	1	ADHS9123	Human secreted/tra
c 127	19	2.2	23	1	ADBS2423	siRNA p9 sequence	c 200	17.2	2.0	22	1	ADI37902	Human secreted/tra
c 128	19	2.2	25	1	ADO43052	Short interfering	c 201	17.2	2.0	22	1	ACA58900	Human PRO PCR prim
c 129	19	2.2	25	1	ADO43053	Short interfering	c 202	17.2	2.0	22	1	ACA58297	PCR primer #2 used
c 130	19	2.2	25	1	ADO43050	Short interfering	c 203	17.2	2.0	22	1	AJ26170	Human secreted/tra
c 131	19	2.2	25	1	ADO43054	Short interfering	c 204	17.2	2.0	22	1	ADE79085	Human secreted/tra
c 132	18.4	2.1	20	1	AAV01384	Superoxide dismuta	c 205	17.2	2.0	22	1	ADE79509	Human secreted/tra
c 133	18.2	2.1	24	1	ADD26381	RT-PCR primer #2 f	c 206	17.2	2.0	22	1	ADE73185	Human secreted/tra
c 134	18	2.1	18	1	ADT66494	PCR primer for CuZ	c 207	17.2	2.0	22	1	ADE73720	Human secreted/tra
c 135	18	2.1	23	1	ADBS2416	siRNA p10 sequence	c 208	17.2	2.0	22	1	ADE99274	Human secreted/tra
c 136	18	2.1	23	1	ADBS2411	Mutant siRNA p10 s	c 209	17.2	2.0	22	1	ADE98393	Human secreted/tra
c 137	17.6	2.0	23	1	ADBS2410	Mutant siRNA p11 s	c 210	17.2	2.0	22	1	ADE98820	Human secreted/tra
c 138	17.6	2.0	23	1	ADBS2412	Mutant siRNA p9 se	c 211	17.2	2.0	22	1	ADG40290	Human secreted/tra
c 139	17.4	2.0	19	1	ADBS2401	Target DNA sequenc	c 212	17.2	2.0	22	1	ADG73684	Human secreted/tra
c 140	17.4	2.0	19	1	ADBS2402	Target DNA sequenc	c 213	17.2	2.0	22	1	ADF73260	Human secreted/tra
c 141	17.4	2.0	20	1	ABZ91893	Human oligonucleot	c 214	17.2	2.0	22	1	ADG92103	Human secreted/tra
c 142	17.4	2.0	20	1	ABZ91893	AA156940-derived o	c 215	17.2	2.0	22	1	ADG92530	Human secreted/tra
c 143	17.4	2.0	21	1	ABZ91893	Human multidrug re	c 216	17.2	2.0	22	1	ADH20319	Human secreted/tra
c 144	17.4	2.0	23	1	ADBS2421	Mutant siRNA p10 s	c 217	17.2	2.0	22	1	ADH07174	Human secreted/tra
c 145	17.4	2.0	23	1	ADBS2420	Mutant siRNA p11 s	c 218	17.2	2.0	22	1	ADH59719	Human secreted/tra
c 146	17.4	2.0	23	1	ADBS2422	Mutant siRNA p9 se	c 219	17.2	2.0	22	1	ADH06747	Human secreted/tra
c 147	17.2	2.0	22	1	AAZ28452	EGF-like/FGF-8 hom	c 220	17.2	2.0	22	1	ADI18489	Human secreted/tra
c 148	17.2	2.0	22	1	AAZ37608	Human PRO217 prime	c 221	17.2	2.0	22	1	ADI65209	Human secreted/tra
c 149	17.2	2.0	22	1	AAZ52278	Primer 28730.r (OL	c 222	17.2	2.0	22	1	ADI37472	Human secreted/tra
c 150	17.2	2.0	22	1	AAZ93682	Primer for amplify	c 223	17.2	2.0	22	1	ADH97276	Human secreted/tra
c 151	17.2	2.0	22	1	AAZ30042	Reverse PCR primer	c 224	17.2	2.0	22	1	ADI65636	Human secreted/tra
c 152	17.2	2.0	22	1	AAZ52217	Reverse primer 287	c 225	17.2	2.0	22	1	ADH60379	Human secreted/tra
c 153	17.2	2.0	22	1	AAZ54087	Primer for amplify	c 226	17.2	2.0	22	1	ADJ99436	Human secreted/tra
c 154	17.2	2.0	22	1	ACD78327	Human PRO protein-	c 227	17.2	2.0	22	1	ADL08629	Human secreted/tra
c 155	17.2	2.0	22	1	AAZ72436	Human PRO oligonuc	c 228	17.2	2.0	22	1	ADM24974	Human secreted/tra
c 156	17.2	2.0	22	1	AAZ00172	PCR primer 4 for H	c 229	17.2	2.0	22	1	ADM29720	Human secreted/tra
c 157	17.2	2.0	22	1	AAZ97412	Human PRO211 PCR p	c 230	17.2	2.0	22	1	ADO06042	Human PRO PCR prim
c 158	17.2	2.0	22	1	AAZ60362	PRO211 reverse PCR	c 231	17.2	2.0	22	1	ADR10894	Human secreted/tra
c 159	17.2	2.0	22	1	ACA60004	Human secreted/tra	c 232	17.2	2.0	22	1	ADR17803	Human secreted/tra
c 160	17.2	2.0	22	1	ACD07404	Secreted ani trans	c 233	17.2	2.0	22	1	ADT03479	Human secreted/tra
c 161	17.2	2.0	22	1	ABX71452	Human secreted/tra	c 234	17.2	2.0	22	1	ADT74442	Human secreted/tra
c 162	17.2	2.0	22	1	ACH06784	Human secreted/tra	c 235	17	1.9	17	1	ABT36210	Tumour suppression
c 163	17.2	2.0	22	1	ABX96021	Human secreted/tra	c 236	17	1.9	17	1	ABT39565	Tumour suppression
c 164	17.2	2.0	22	1	ACA05342	Human secreted pro	c 237	17	1.9	17	1	ADI49574	Human tumour suppr
c 165	17.2	2.0	22	1	ACD20009	Human secreted / t	c 238	17	1.9	17	1	ADI52307	Human tumour suppr
c 166	17.2	2.0	22	1	ACA54812	Secreted and trans	c 239	17	1.9	17	1	ACC53333	Human tumour suppr
c 167	17.2	2.0	22	1	ACD19647	Human secreted / t	c 240	17	1.9	17	1	ACS51634	Human tumour suppr
c 168	17.2	2.0	22	1	ADBS2912	Human secreted/tra	c 241	17	1.9	19	1	ABQ75416	CuZn superoxide di
c 169	17.2	2.0	22	1	ADA18068	Human secreted/tra	c 242	17	1.9	21	1	AAQ67479	Human SOD1 exon 2
c 170	17.2	2.0	22	1	ACD66794	Human secreted/tra	c 243	17	1.9	21	1	AAV73829	Human SOD1 exon 2
c 171	17.2	2.0	22	1	ACD82955	Human PRO PCR prim	c 244	17	1.9	21	1	ADO55692	Human cytosolic su
c 172	17.2	2.0	22	1	ADA16043	Human secreted/tra	c 245	17	1.9	21	1	ADO55743	Human cytosolic su
c 173	17.2	2.0	22	1	ADA42188	Human secreted/tra	c 246	16.8	1.9	20	1	AAT38674	Mouse SOD-1 exon 4
c 174	17.2	2.0	22	1	ACD23133	Human PRO PCR prim	c 247	16.8	1.9	20	1	AAT93934	Primer for exon 23
c 175	17.2	2.0	22	1	ADA16467	Human secreted/tra	c 248	16.8	1.9	21	1	AAQ67482	PCR primer for hum
c 176	17.2	2.0	22	1	ADA12896	Human secreted/tra	c 249	16.8	1.9	21	1	AAV73832	Human SOD1 exon 4
c 177	17.2	2.0	22	1	ADA41764	Human secreted/tra	c 250	16.8	1.9	21	1	ADO55695	Human cytosolic su
c 178	17.2	2.0	22	1	ADA17111	Human secreted/tra	c 251	16.4	1.9	20	1	ADI79800	Human HMG-CoA redu
c 179	17.2	2.0	22	1	ADA42614	Human secreted/tra	c 252	16.4	1.9	20	1	ADI79603	Human HMG-CoA redu

C 253	1.8	17	1	AAFP1027	Human multi drug r
254	1.8	17	1	AD150808	Human tumour suppress
255	1.8	17	1	AD150799	Human tumour suppress
C 256	1.8	18	1	ABK41012	Human obesity-asso
257	1.8	19	1	ABK41012	PAL/alpha-tubulin-
258	1.8	19	1	ADW83390	Coffea arabica PAL
C 259	1.8	20	1	AAFP3235	Antisense oligonuc
C 260	1.8	20	1	AAV85741	LRPS exon primer E
C 261	1.8	20	1	ACC44079	Oligo ISIS 124670
C 262	1.8	20	1	AD159647	Human ESM-1 antise
C 263	1.8	20	1	AD159286	Human ESM-1 antise
C 264	1.8	21	1	AAV72769	Corn kernel oil co
C 265	1.8	21	1	AB598130	Human multitdrug re
266	1.8	21	1	ACF62527	Cancer based on CY
267	1.8	17	1	AD211198	MRP1 based cancer
268	1.8	17	1	AD888287	Human UGT1A1 varia
269	1.8	17	1	AD897270	Human MDR1 varia
270	1.8	17	1	AD892461	Human MDR1 varia
C 271	1.8	17	1	AAFP03382	Hammerhead ribozym
C 272	1.8	17	1	AAFP03383	Hammerhead ribozym
C 273	1.8	20	1	AD181744	Human protein kina
274	1.8	20	1	AD181694	Human protein kina
C 275	1.7	20	1	AAFP08640	Primer for amplify
C 276	1.7	20	1	AAFP3188	Human STAR3 phosph
C 277	1.7	20	1	AAFP57024	Human oestrogen re
278	1.7	20	1	ABQ96805	Human STAR3 antise
279	1.7	20	1	ABQ99746	cuZnSOD primer #2
C 280	1.7	20	1	AB234780	Deoxyuridine monop
281	1.7	20	1	ACF36665	MHC class II trans
282	1.7	20	1	AD899942	Vitamin D nuclear
283	1.7	20	1	ADFP17531	Rhodotorula glutin
284	1.7	20	1	AD290760	Human oligonucleot
285	1.7	20	1	AB290984	Human oligonucleot
286	1.7	20	1	AB266990	H93087-derived oli
287	1.7	20	1	ABD27214	AA180912-derived o
C 288	1.7	20	1	ADL59322	Human ESM-1 antise
C 289	1.7	20	1	ADL59256	Human ESM-1 antise
C 290	1.7	20	1	ADP11305	Set 1 right PCR pr
291	1.7	20	1	ADK21489	Acyl-coenzyme A sy
292	1.7	20	1	ADP70258	Human apoptosis-sp
293	1.7	15	1	AAFP1205	Sequence of probe
294	1.7	15	1	AAQ61567	Human SOD probe
295	1.7	15	1	ADQ43600	Wild type DNA frag
296	1.7	15	1	ADQ43606	Wild type DNA frag
297	1.7	17	1	AAH21294	Human MDR-1 allele
C 298	1.7	17	1	AAH21293	Human MDR-1 allele
C 299	1.7	17	1	AAFP1028	Human multi drug r
300	1.7	17	1	ABT38676	Tumour suppression
C 301	1.7	17	1	ACF62526	Cancer based on CY
C 302	1.7	17	1	ADB21197	MRP1 based cancer
C 303	1.7	17	1	AD888286	Human UGT1A1 varia
C 304	1.7	17	1	AD897269	Human MDR1 varia
C 305	1.7	17	1	AD892460	Human MDR1 varia
C 306	1.7	20	1	AAV13337	Antisense primer E
C 307	1.7	19	1	AAV72612	Glucose-6-phosphat
C 308	1.7	19	1	AAH28298	cdk6 ribozyme bind
C 309	1.7	19	1	AAH58150	Cell-cycle depende
C 310	1.7	19	1	ADH01862	Protein tyrosine p
C 311	1.7	19	1	ADM34090	Mouse RIKEN 492151
312	1.7	19	1	AD890828	Human glucose-6-ph
C 313	1.6	17	1	AAA23007	Integrin subunit b
314	1.6	17	1	AAFP05438	Hammerhead ribozym
C 315	1.6	17	1	AAFP03384	Hammerhead ribozym
C 316	1.6	17	1	AAFP03381	Hammerhead ribozym
C 317	1.6	17	1	ABK02234	Human NOGO DNzyme
318	1.6	17	1	ABK02326	Human NOGO DNzyme
319	1.6	17	1	ABT37806	Tumour suppression
320	1.6	17	1	ABT39717	Tumour suppression
C 321	1.6	17	1	ACF62525	Cancer based on CY
C 322	1.6	17	1	ACF62524	Cancer based on CY
C 323	1.6	17	1	ADB21195	MRP1 based cancer
324	1.6	17	1	ADB21196	MRP1 based cancer
325	1.6	17	1	ADB88285	Human UGT1A1 varia
C 326	1.6	17	1	ADB88284	Human UGT1A1 varia
C 327	1.6	17	1	ADB97267	Human MDR1 varia
C 328	1.6	17	1	ADB97268	Human MDR1 varia
C 329	1.6	17	1	ADB92459	Human MDR1 varia
C 330	1.6	17	1	ADB92458	Tumour suppression
331	1.6	17	1	ADB44992	Human tumour suppress
332	1.6	17	1	AD48262	Antisense inhibiti
C 333	1.6	17	1	ABZ76052	Primer of the inve
C 334	1.6	18	1	ADK00139	Xylulokinase PCR p
C 335	1.6	18	1	AAZ32081	Cyclin A2 ribozyme
C 336	1.6	19	1	AAH83961	Cyclin A2 ribozyme
C 337	1.6	19	1	AAH59123	Human apolipoprote
C 338	1.6	19	1	AD877596	Human apolipoprote
C 339	1.6	19	1	AD879321	Common primer for
C 340	1.6	19	1	AD874990	Human c-myb hamme
341	1.6	17	1	AAH81501	Human c-myb hamme
342	1.6	17	1	AAH81503	Human c-myb hamme
343	1.6	17	1	AAH81500	Human c-myb hamme
344	1.6	17	1	AAH81502	Human NOGO Inozyme
C 345	1.6	17	1	ABK01349	Human NOGO Hamme
C 346	1.6	17	1	ABK00484	Human NOGO Zinzyme
C 347	1.6	17	1	ABK01996	Necrosis factor ka
C 348	1.6	17	1	ACA08316	NFKB sub-unit modu
349	1.6	17	1	ACA09130	Human superoxide d
350	1.6	20	1	ACC40321	Human superoxide d
351	1.6	20	1	ACC40322	Mouse fik-1 VSGF r
C 352	1.6	17	1	AAH73200	Potato citrate syn
353	1.6	17	1	AAV96545	Hammerhead ribozym
354	1.6	17	1	AAV04937	Hammerhead ribozym
355	1.6	17	1	AAV04936	Hammerhead ribozym
356	1.6	17	1	ABK01097	Human NOGO Inozyme
C 357	1.6	17	1	ABK01097	MLH1 mutation corr
C 358	1.6	17	1	ABK02996	Human multi drug r
359	1.6	17	1	ABA80297	Human GMPLP-1 17-m
C 360	1.6	17	1	ABN01029	WNV Zinzyme subatr
361	1.6	17	1	ABN08968	Human MDR27 scanin
362	1.6	17	1	ACN03785	HCV minus strand D
363	1.6	17	1	AD803682	Human PCP1 DNA fr
364	1.6	17	1	ACD62281	Human PTGDR subatr
C 365	1.6	17	1	ADP62659	Human PTGDR subatr
C 366	1.6	17	1	ADL51188	Human PTGDR subatr
C 367	1.6	17	1	ADL51187	HCV DNzyme subatr
C 368	1.6	17	1	ADL51536	HCV DNzyme subatr
369	1.6	17	1	ADL85511	Human GMPLP-1 prob
C 370	1.6	18	1	ACN72058	Primer #2 for swss
C 371	1.6	18	1	AAH16415	Maize retinoblasto
C 372	1.6	18	1	AAV05715	Maize retinoblasto
C 373	1.6	18	1	AAV17082	PCR primer used to
C 374	1.6	18	1	AAH85777	Human OB gene sequ
C 375	1.6	18	1	AAH85777	Cdc 2 kinase hamme
C 376	1.6	18	1	AAA86600	Human Ets-2 phosph
C 377	1.6	18	1	AAA38349	Human OB DNA PCR p
C 378	1.6	18	1	AAA12332	Burkholderia cepac
C 379	1.6	18	1	AAZ51716	Human OB gene sequ
C 380	1.6	18	1	AAH61766	Cdc 2 kinase hamme
C 381	1.6	18	1	AAH61766	Human Ob gene sts
C 382	1.6	18	1	ABX89564	Haematopoietic cel
C 383	1.6	18	1	ABX161438	Human obese (ob) g
384	1.6	18	1	ABX161438	Primer oligo used
C 385	1.6	18	1	ABX96424	Human lymphoid cel
386	1.6	18	1	ADC69987	Chromosomal abnorm
387	1.6	18	1	AD843339	Human APC (adenoma
C 388	1.6	18	1	ADP78324	Human APC DNA frag
C 389	1.6	18	1	ADH53129	Human DNA oligonuc
C 390	1.6	18	1	AD897900	IGF-I oligonucleot
C 391	1.6	18	1	AD808584	IGFBP3 oligonucleo
392	1.5	15	1	AAFP0921	Mutant DNA fragmen
393	1.5	15	1	AAFP46599	DNA fragment from
394	1.5	15	1	ADQ43607	N-acetyltransferas
395	1.5	15	1	ADQ43602	Liver regeneration
C 396	1.5	16	1	AAH15510	Probe/PCR primer f
C 397	1.5	16	1	ABT13505	
398	1.5	16	1	ABZ68236	



545	12.8	1.5	17	1	ACD54822	HBV DNazyme substr
546	12.8	1.5	17	1	ACD58065	HCV DNazyme substr
c 547	12.8	1.5	17	1	ACD51149	HCV hammerhead rib
548	12.8	1.5	17	1	ACD58294	HCV DNazyme substr
c 549	12.8	1.5	17	1	ACD64375	HCV minus strand D
c 550	12.8	1.5	17	1	ACD60388	HCV DNazyme substr
c 551	12.8	1.5	17	1	ACD51150	HBV hammerhead rib
c 552	12.8	1.5	17	1	ACC65880	Murine oligonucleo
c 553	12.8	1.5	17	1	ACD68718	Murine oligonucleo
c 554	12.8	1.5	17	1	AD842880	Tumour suppression
c 555	12.8	1.5	17	1	AD840493	Tumour suppression
c 556	12.8	1.5	17	1	AD840319	Tumour suppression
c 557	12.8	1.5	17	1	AD842533	Tumour suppression
c 558	12.8	1.5	17	1	AD844185	Tumour suppression
c 559	12.8	1.5	17	1	AD825182	Plant growth assoc
c 560	12.8	1.5	17	1	ADP62660	Human PCCP1 DNA fr
c 561	12.8	1.5	17	1	ADP62658	Human PCCP1 DNA fr
c 562	12.8	1.5	17	1	ADP62657	Human PCCP1 DNA fr
c 563	12.8	1.5	17	1	ADP62656	Human PCCP1 DNA fr
c 564	12.8	1.5	17	1	ADP62655	Human tumour suppr
c 565	12.8	1.5	17	1	AD150344	Human tumour suppr
c 566	12.8	1.5	17	1	AD148553	Human tumour suppr
c 567	12.8	1.5	17	1	AD149300	Human tumour suppr
c 568	12.8	1.5	17	1	AD151861	Human tumour suppr
c 569	12.8	1.5	17	1	AD152533	Human tumour suppr
c 570	12.8	1.5	17	1	AD152615	Human tumour suppr
c 571	12.8	1.5	17	1	AD149562	Human tumour suppr
c 572	12.8	1.5	17	1	AD150895	Human tumour suppr
c 573	12.8	1.5	17	1	AB295396	Human fibronectin
c 574	12.8	1.5	17	1	ACC52934	Human tumour suppr
c 575	12.8	1.5	17	1	ACC54188	Human tumour suppr
c 576	12.8	1.5	17	1	AD147045	Human NOGO recept
c 577	12.8	1.5	17	1	AD151186	Human PTGDR substr
c 578	12.8	1.5	17	1	AD151472	Human PTGDR substr
c 579	12.8	1.5	17	1	AD151696	Human PTGDR substr
c 580	12.8	1.5	17	1	AD149040	Human PKR substrat
c 581	12.8	1.5	17	1	AD151189	Human PTGDR substr
c 582	12.8	1.5	17	1	ABD19448	Human fibronectin
c 583	12.8	1.5	17	1	AD1813456	Human glioma endot
c 584	12.8	1.5	17	1	AD182440	Human ER+ breast c
c 585	12.8	1.5	17	1	AD589709	Hepatitis B virus
c 586	12.8	1.5	17	1	AD586112	Hepatitis B virus
c 587	12.8	1.5	17	1	AD589962	Hepatitis B virus
c 588	12.8	1.5	17	1	AD583110	Hepatitis B virus
c 589	12.8	1.5	17	1	AD583311	Hepatitis B virus
c 590	12.8	1.5	17	1	AD184552	HCV DNazyme substr
c 591	12.8	1.5	17	1	AD183405	HCV DNazyme substr
c 592	12.8	1.5	17	1	AD186541	HCV DNazyme substr
c 593	12.8	1.5	17	1	ACN70319	Human GDMPLP-1 prob
c 594	12.8	1.5	17	1	ACN64888	Human GDMPLP-1 prob
c 595	12.8	1.5	17	1	ACN71079	Human GDMPLP-1 prob
c 596	12.8	1.5	17	1	ACN71258	Human GDMPLP-1 prob
c 597	12.8	1.5	17	1	ACN73311	Human GDMPLP-1 prob
c 598	12.8	1.5	17	1	ACN70865	Human GDMPLP-1 prob
c 599	12.8	1.5	17	1	ACN71080	Human GDMPLP-1 prob
c 600	12.8	1.5	17	1	ACN70320	Human GDMPLP-1 prob
c 601	12.8	1.5	17	1	ACN73312	Human GDMPLP-1 prob
c 602	12.8	1.5	17	1	ACN65806	Human GDMPLP-1 prob
c 603	12.8	1.5	17	1	ACN72059	Human GDMPLP-1 prob
c 604	12.8	1.5	17	1	ACN64689	Human GDMPLP-1 prob
c 605	12.8	1.5	17	1	ACN65807	Human GDMPLP-1 prob
c 606	12.8	1.5	17	1	ACN70866	Human GDMPLP-1 prob
c 607	12.8	1.5	17	1	ACN71257	Human GDMPLP-1 prob
c 608	12.6	1.4	13	1	ACN72057	Human GDMPLP-1 prob
c 609	12.6	1.4	13	1	ABH27646	Oligonucleotide SE
c 610	12.6	1.4	15	1	ABH27647	Oligonucleotide SE
					Paraoxonase 2 (PON	

## ALIGNMENTS

RESULT 1  
ABZ00314

ID	ABZ00314	standard; DNA; 50 BP.
XX	ABZ00314;	
AC	ABZ00314;	
XX	09-JAN-2003	(first entry)
DT	09-JAN-2003	(first entry)
DE	Human leukocyte gene expression profiling probe SEQ ID NO 305.	
XX	T7; leukocyte; gene expression profiling; allograft rejection;	
KW	atherosclerosis; congestive heart failure; systemic lupus erythematosus;	
KW	rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;	
ss.		
XX	Homo sapiens.	
OS	WO200257414-A2.	
XX	25-JUL-2002.	
XX	22-OCT-2001; 2001WO-US047856.	
PF	20-OCT-2000; 2000US-0241994P.	
XX	08-JUN-2001; 2001US-0296764P.	
PR	(BIOC-) BIOCARDIA INC.	
XX	Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;	
PI	Ly N, Woodward R, Quertermous T, Johnson F;	
PI	WPI; 2002-636525/68.	
DR	New system for leukocyte expression profiling, diagnosing a disease, or	
XX	monitoring (the rate of) progression of a disease, e.g. atherosclerosis	
XX	or congestive heart failure, comprises diagnostic oligonucleotides.	
XX	Claim 1; Page 336; Opp; English.	
XX	The invention relates to a system for detecting gene expression, which	
CC	comprises one or two isolated DNA molecules that detect expression of a	
CC	gene, where the gene corresponds to any of 8143 oligonucleotides	
CC	(ABZ0010-ABZ08152) each having 50 base pairs (bp). The system is useful	
CC	for leukocyte expression profiling, it is particularly useful for	
CC	diagnosing a disease, monitoring (rate of) progression of a disease,	
CC	predicting therapeutic outcome, determining prognosis for a patient,	
CC	predicting disease complications in an individual or monitoring response	
CC	to treatment in an individual. The diseases include cardiac allograft	
CC	rejection, kidney allograft rejection, liver allograft rejection,	
CC	atherosclerosis, congestive heart failure, systemic lupus erythematosus,	
CC	rheumatoid arthritis, osteoarthritis or cytomegalovirus infection	
XX	Sequence 50 BP; 9 A; 15 C; 9 G; 17 T; 0 U; 0 Other;	
SQ	Query Match 5.7%; Score 50; DB 1; Length 50;	
	Best Local Similarity 100.0%; Pred. No. 0.042;	
	Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	530 ACATTCCCTTGGATGATCTGAGCCCTTAACCTCATCTGTATCTCTGC 579	
Db	1 ACATTCCCTTGGATGATCTGAGCCCTTAACCTCATCTGTATCTCTGC 50	
RESULT 2		
ABZ01960		
ID	ABZ01960	standard; DNA; 50 BP.
XX	ABZ01960;	
AC	ABZ01960;	
XX	09-JAN-2003	(first entry)
DT	09-JAN-2003	(first entry)
DE	Human leukocyte gene expression profiling probe SEQ ID NO 1951.	
XX	T7; leukocyte; gene expression profiling; allograft rejection;	
KW	atherosclerosis; congestive heart failure; systemic lupus erythematosus;	

KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;  
 XX ss.  
 XX Homo sapiens.  
 XX WO200257414-A2.  
 XX 25-JUL-2002.  
 XX 22-OCT-2001; 2001WO-US047856.  
 XX 20-OCT-2000; 2000US-0241994P.  
 XX 08-JUN-2001; 2001US-0296764P.  
 XX (BIOC-) BIOCARDIA INC.  
 XX Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;  
 PI Ly N, Woodward R, Quettermous T, Johnson F;  
 XX WPI; 2002-636525/68.  
 XX New system for leukocyte expression profiling, diagnosing a disease, or  
 PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
 PT or congestive heart failure, comprises diagnostic oligonucleotides.  
 XX  
 PS Claim 1; Page 388; Opp; English.  
 XX The invention relates to a system for detecting gene expression, which  
 CC comprises one or two isolated DNA molecules that detect expression of a  
 CC gene, where the gene corresponds to any of 8143 oligonucleotides  
 CC (AB20010-AB208152) each having 50 base pairs (bp). The system is useful  
 CC for leukocyte expression profiling. It is particularly useful for  
 CC diagnosing a disease, monitoring (rate of) progression of a disease,  
 CC predicting therapeutic outcome, determining prognosis for a patient,  
 CC predicting disease complications in an individual or monitoring response  
 CC to treatment in an individual. The diseases include cardiac allograft  
 CC rejection, kidney allograft rejection, liver allograft rejection,  
 CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
 CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection  
 XX  
 SQ Sequence 50 BP; 9 A; 15 C; 9 G; 17 T; 0 U; 0 Other;  
 Query Match 5.7%; Score 50; DB 1; Length 50;  
 Best Local Similarity 100.0%; Pred. No. 0.042;  
 Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 530 ACATTCCCTTGATCTAGTCTGAGGCCCTTAACCTCATCTGTATCCTGC 579  
 DB 1 ACATTCCCTTGATCTAGTCTGAGGCCCTTAACCTCATCTGTATCCTGC 50  
 RESULT 3  
 ADE52413  
 ID ADE52413 standard; RNA; 48 BP.  
 XX ADE52413;  
 XX 29-JAN-2004 (first entry)  
 XX Wild-type human SOD1 partial RNA sequence.  
 XX Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nontropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW ss.  
 XX Homo sapiens.  
 XX OS

PN US2003180756-A1.  
 XX 25-SEP-2003.  
 XX 21-NOV-2002; 2002US-00301516.  
 XX 21-MAR-2002; 2002US-0366478P.  
 XX (SHIY/) SHI Y.  
 XX (SUIG/) SUI G.  
 XX Shi Y, Sui G;  
 XX WPI; 2003-852231/79.  
 XX New nucleic acids, useful for inhibiting the synthesis of a target  
 PT protein in a eukaryotic cell, or for treating various diseases by  
 PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 PT viral or bacterial infection.  
 XX  
 PS Example 6; Fig 5A; 38pp; English.  
 XX The present invention relates to a method for suppressing gene expression  
 CC in cells, particularly eukaryotic cells. The method involves a new  
 CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 CC sequence, a first target sequence that is essentially complementary to a  
 CC sequence of a target nucleic acid or its complement, a spacer sequence, a  
 CC second target sequence that is essentially complementary to the first  
 CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a partial RNA sequence from the wild-type  
 CC human superoxide dismutase 1 (SOD1) gene.  
 XX  
 SQ Sequence 48 BP; 13 A; 6 C; 18 G; 0 T; 11 U; 0 Other;  
 Query Match 5.5%; Score 48; DB 1; Length 48;  
 Best Local Similarity 77.1%; Pred. No. 0.07;  
 Matches 37; Conservative 11; Mismatches 0; Indels 0; Gaps 0;  
 QY 299 GAGAGGCGATGTTGAGAGCTTGGCAATGCTGCTGCTGCAAGATGGT 346  
 DB 1 GAGAGGCGAUGUGGAGACUUGGGCAUGACUGACUGACUGAAGU 48  
 RESULT 4  
 ADO43047  
 ID ADO43047 standard; mRNA; 48 BP.  
 XX ADO43047;  
 XX 12-AUG-2004 (first entry)  
 XX Superoxide dismutase wild-type target for RNA interference.  
 XX Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
 KW RNA interference; gene silencing; human; ss.  
 XX Homo sapiens.  
 XX Key Location/Qualifiers  
 XX replace(22,c)  
 XX /\*tag= a



XX PN WO2004042027-A2.  
 XX PD 21-MAY-2004.  
 XX PF 04-NOV-2003; 2003WO-US035009.  
 XX PR 04-NOV-2002; 2002US-0423507P.  
 XX PR 18-JUL-2003; 2003US-0488283P.  
 XX PA (UYMA-) UNIV MASSACHUSETTS.  
 XX PI Xu Z, Zamore PD;  
 XX PR WPI; 2004-390611/36.  
 XX PT Inhibiting expression of a target allele in a cell comprising at least  
 XX PT two different alleles of a gene, for treating CNS disorders, comprises  
 XX PT administering to the cell an siRNA specific for the target allele.  
 XX PS Example 1; SEQ ID NO 7; 61pp; English.  
 XX PS The present sequence is a human superoxide dismutase (SOD1) wild-type  
 XX CC target sequence for RNA interference (RNAi). In a mutant allele of SOD1  
 XX CC ADO43048, a single nucleotide change of guanosine to cytosine at position  
 XX CC 256 (relative to the start of translation) causes a Gly to Arg mutation  
 XX CC (G85R). The invention provides methods of specifically inhibiting the  
 XX CC expression of a mutant allele, while preserving the expression of a co-  
 XX CC expressed wild-type allele, using RNA interference (RNAi). The methods  
 XX CC are useful for treating a subject having a disorder correlated with the  
 XX CC presence of a dominant gain of function mutant allele, e.g. amyotrophic  
 XX CC lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and  
 XX CC Parkinson's disease (claimed). Small interfering RNAs (siRNA) are  
 XX CC provided ADO43041-ADO43046 that selectively suppress mutant, but not wild  
 XX CC -type, expression of SOD1, which causes inherited ALS.  
 XX SQ Sequence 48 BP; 13 A; 6 C; 18 G; 0 T; 11 U; 0 Other;  
 XX  
 XX Query Match 5.5%; Score 48; DB 1; Length 48;  
 XX Best Local Similarity 77.1%; Pred. No. 0.07;  
 XX Matches 37; Conservative 11; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 XX QY 299 GAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT 346  
 XX DB 1 GAGAGGCAUGUUGGAGACUUGGGCAUGUGACUGCUGACAAAGAUGGU 48  
 XX  
 XX RESULT 5  
 XX ADE52414  
 XX ID ADE52414 standard; RNA; 48 BP.  
 XX AC ADE52414;  
 XX DT 29-JAN-2004 (first entry)  
 XX DE Human SOD1 mutant (G256C) partial RNA sequence.  
 XX KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 XX KW target DNA sequence; RNA polymerase termination signal;  
 XX KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 XX KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 XX KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 XX KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 XX KW haemostatic; virucide; antibacterial; neuroprotective; neurotropic;  
 XX KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 XX KW G256C mutant; ss.  
 XX OS Synthetic.  
 XX OS Homo sapiens.  
 XX PN US2003180756-A1.  
 XX PD 25-SEP-2003.

XX PF 21-NOV-2002; 2002US-00301516.  
 XX PR 21-MAR-2002; 2002US-0366478P.  
 XX PA (SHIV/) SHI Y.  
 XX PA (SUIG/) SUI G.  
 XX PI Shi Y, Sui G;  
 XX DR WPI; 2003-852231/79.  
 XX PT New nucleic acids, useful for inhibiting the synthesis of a target  
 XX PT protein in a eukaryotic cell, or for treating various diseases by  
 XX PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX PT viral or bacterial infection.  
 XX PS Example 6; Fig 5A; 38pp; English.  
 XX PS The present invention relates to a method for suppressing gene expression  
 XX CC in cells, particularly eukaryotic cells. The method involves a new  
 XX CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 XX CC sequence, a first target sequence that is essentially complementary to a  
 XX CC sequence of a target nucleic acid or its complement, a spacer sequence, a  
 XX CC second target sequence that is essentially complementary to the first  
 XX CC target sequence, and an RNA polymerase termination signal, where an RNA  
 XX CC transcribed from the nucleic acid can inhibit expression of the target  
 XX CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 XX CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 XX CC the polymerase termination signal comprises a number of thymidines  
 XX CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 XX CC are useful for suppressing gene expression in cells, or inhibiting the  
 XX CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 XX CC subject. The nucleic acids can be used for treating various diseases by  
 XX CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 XX CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 XX CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 XX CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 XX CC The present sequence represents a partial RNA sequence from the human  
 XX CC superoxide dismutase 1 (SOD1) G256C mutant gene.  
 XX SQ Sequence 48 BP; 13 A; 7 C; 17 G; 0 T; 11 U; 0 Other;  
 XX  
 XX Query Match 5.3%; Score 46.4; DB 1; Length 48;  
 XX Best Local Similarity 75.0%; Pred. No. 0.11;  
 XX Matches 36; Conservative 11; Mismatches 1; Indels 0; Gaps 0;  
 XX  
 XX QY 299 GAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT 346  
 XX DB 1 GAGAGGCAUGUUGGAGACUUGGGCAUGUGACUGCUGACAAAGAUGGU 48  
 XX  
 XX RESULT 6  
 XX ADO43048  
 XX ID ADO43048 standard; mRNA; 48 BP.  
 XX AC ADO43048;  
 XX DT 12-AUG-2004 (first entry)  
 XX DE Superoxide dismutase mutant allele target for RNA interference.  
 XX KW Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
 XX KW RNA interference; gene silencing; human; ss.  
 XX OS Homo sapiens.  
 XX FH Key  
 XX FT allele  
 XX FT replace(22.g)  
 XX FT /\*tag= a  
 XX PN WO2004042027-A2.  
 XX

```

PD 21-MAY-2004.
XX
PF 04-NOV-2003; 2003WO-US035009.
XX
PR 04-NOV-2002; 2002US-0423507P.
XX
PR 18-JUL-2003; 2003US-0488283P.
XX
PA (UYMA-) UNIV MASSACHUSETTS.
XX
PI Xu Z, Zamore PD;
XX
PI WPI; 2004-390611/36.
XX
PT Inhibiting expression of a target allele in a cell comprising at least
PT two different alleles of a gene, for treating CNS disorders, comprises
PT administering to the cell an siRNA specific for the target allele.
XX
PS Example 1; SEQ ID NO 8; 61pp; English.
XX
CC The present sequence is a human superoxide dismutase (SOD1) mutant allele
CC target sequence for RNA interference (RNAi). In comparison to the wild-
CC type allele ADO43047, a single nucleotide change of guanosine to cytosine
CC at position 256 (relative to the start of translation) causes a Gly to
CC Arg mutation (G85R). The invention provides methods of specifically
CC inhibiting the expression of a mutant allele, while preserving the
CC expression of a co-expressed wild-type allele, using RNA interference
CC (RNAi). The methods are useful for treating a subject having a disorder
CC correlated with the presence of a dominant gain of function mutant
CC allele, e.g. amyotrophic lateral sclerosis (ALS), Huntington's disease,
CC Alzheimer's disease, and Parkinson's disease (claimed). Small interfering
CC RNAs (siRNA) are provided ADO43041-ADO43046 that selectively suppress
CC mutant, but not wild-type, expression of SOD1, which causes inherited
CC ALS.
XX
SQ Sequence 48 BP; 13 A; 7 C; 17 G; 0 T; 11 U; 0 Other;
Query Match 5.3%; Score 46.4; DB 1; Length 48;
Best Local Similarity 75.0%; Pred. No. 0.11;
Matches 36; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
QY 299 GAGAGCGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT 346
Db 1 GAGAGCGCAUGUUGGAGACUUGCGCAUUGUGAGUCGUCGACAAAGAGUGGU 48
RESULT 7
AAQ27817
ID AAQ27817 standard; DNA; 40 BP.
XX
AC AAQ27817;
XX
DT 12-FEB-1993 (first entry)
XX
DE Primer A039.
XX
KW Superoxidase dismutase; SOD; HBS; PCR; polymerase chain reaction; PCR;
KW hypotensive; blood vessel; endothelium; ss.
XX
OS Synthetic.
XX
FN JP04210649-A.
XX
PD 31-JUL-1992.
XX
PF 11-DEC-1990; 90JP-00401323.
XX
PR 11-DEC-1990; 90JP-00401323.
XX
PA (SUNR ) SUNTORY LTD.
PA (INOUE) INOUE M.
XX
DR WPI; 1992-304666/37.
XX
PT New hypotensive agents - comprise superoxidedismutase with attached
PT heparin binding site.
XX
PS Disclosure; Page 4; 9pp; Japanese.
XX
CC The sequences given in AAQ27817-20 are primers which were used to amplify
CC the superoxide dismutase (SOD) gene which is used in the production of
CC a new hypotensive agent. The amplification product of these reactions is
CC ligated to a heparin binding site (HBS). SOD does not naturally contain
CC an HBS. This new construct can exert hypotensive activity in vivo as the
CC active component can be concentrated in the blood vessel endothelial
CC cells
XX
SQ Sequence 40 BP; 14 A; 6 C; 12 G; 8 T; 0 U; 0 Other;
Query Match 4.6%; Score 40; DB 1; Length 40;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 464 GAAAGTACAAAGACAGGAAACGCTGGAAGTCGTTGGCTT 503
Db 1 GAAAGTACAAAGACAGGAAACGCTGGAAGTCGTTGGCTT 40
RESULT 8
ADE52418
ID ADE52418 standard; DNA; 35 BP.
XX
AC ADE52418;
XX
DT 29-JAN-2004 (first entry)
XX
DE Wild-type human SOD1 partial DNA sequence.
XX
KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;
KW target DNA sequence; RNA polymerase termination signal;
KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;
KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;
KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;
KW haemostatic; virucide; antibacterial; neuroprotective; nontropic;
KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;
KW ds.
XX
OS Homo sapiens.
XX
FN US2003180756-A1.
XX
PD 25-SEP-2003.
XX
PF 21-NOV-2002; 2002US-00301516.
XX
PR 21-MAR-2002; 2002US-0366478P.
XX
PA (SHIY/) SHI Y.
PA (SUIG/) SUI G.
XX
PI Shi Y, Sui G;
XX
PI WPI; 2003-852231/79.
XX
PT New nucleic acids, useful for inhibiting the synthesis of a target
PT protein in a eukaryotic cell, or for treating various diseases by
PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,
PT viral or bacterial infection.
XX
PS Example 6; Fig 7A; 38pp; English.
XX
CC The present invention relates to a method for suppressing gene expression
CC in cells, particularly eukaryotic cells. The method involves a new
CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter
CC sequence, a first target sequence that is essentially complementary to a
CC sequence of a target nucleic acid or its complement, a spacer sequence, a

```

CC second target sequence that is essentially complementary to the first  
 CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol. III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a partial DNA sequence from the wild-type  
 CC human superoxide dismutase 1 (SOD1) gene.

XX  
 SQ Sequence 35 BP; 8 A; 6 C; 11 G; 10 T; 0 U; 0 Other;

Query Match 4.0%; Score 35; DB 1; Length 35;  
 Best Local Similarity 100.0%; Pred. No. 2;  
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGGTGGCCGATGTCTAT 363  
 |||||  
 DB 1 ACTGCTGACAAAGATGGTGGCCGATGTCTAT 35

RESULT 9  
 ADD043055  
 ID AD043055 standard; mRNA; 35 BP.  
 XX  
 AC ADO43055;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Superoxide dismutase wild-type target for RNA interference.  
 XX  
 KW Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
 KW RNA interference; gene silencing; human; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO2004042027-A2.  
 XX  
 PD 21-MAY-2004.  
 XX  
 PP 04-NOV-2003; 2003WO-US035009.  
 XX  
 PR 04-NOV-2002; 2002US-0423507P.  
 PR 18-JUL-2003; 2003US-0488283P.  
 XX  
 PA (UYMA-) UNIV MASSACHUSETTS.  
 XX  
 PI Xu Z, Zamore PD;  
 XX  
 DR WPI; 2004-390611/36.  
 XX  
 PT Inhibiting expression of a target allele in a cell comprising at least  
 PT two different alleles of a gene, for treating CNS disorders, comprises  
 PT administering to the cell an siRNA specific for the target allele.  
 XX  
 PS Example 4; SEQ ID NO 15; 61pp; English.  
 XX  
 CC The present sequence is a human superoxide dismutase (SOD1) wild-type  
 CC sequence, which was used to demonstrate the method of the invention. The  
 CC invention provides methods of specifically inhibiting the expression of a  
 CC mutant allele, while preserving the expression of a co-expressed wild-  
 CC type allele, using RNA interference (RNAi). The methods are useful for  
 CC treating a subject having a disorder correlated with the presence of a  
 CC dominant gain of function mutant allele, e.g. amyotrophic lateral  
 CC sclerosis (ALS, caused by SOD mutation), Huntington's disease,  
 CC Alzheimer's disease, and Parkinson's disease (Claimed). To test whether

CC small hairpin RNA (shRNA) can selectively block the expression of a  
 CC mutant but not wild-type SOD1 expression, a plasmid was constructed that  
 CC synthesized an shRNA ADO43056 homologous to a disease-causing mutant  
 CC SOD1, 993A (nucleotide change from G to C at nucleotide position 281,  
 CC placing a G:C mismatch at selective sites between the shRNA and wild-type  
 CC SOD1) under the control of a RNA polymerase III promoter. Results showed  
 CC that when co-transfected with either wild-type or mutant SOD1-GFP  
 CC plasmids, this construct triggered single-nucleotide selective RNAi of  
 CC mutant SOD1 in cultured cells.

XX  
 SQ Sequence 35 BP; 8 A; 6 C; 11 G; 10 T; 0 U; 0 Other;

Query Match 4.0%; Score 35; DB 1; Length 35;  
 Best Local Similarity 100.0%; Pred. No. 2;  
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGGTGGCCGATGTCTAT 363  
 |||||  
 DB 1 ACTGCTGACAAAGATGGTGGCCGATGTCTAT 35

RESULT 10  
 ABK66923  
 ID ABK66923 standard; DNA; 28 BP.  
 XX  
 AC ABK66923;  
 XX  
 DT 02-JUL-2002 (first entry)  
 XX  
 DE Human gene specific PCR primer #1011.  
 XX  
 KW Primer; ss; DNA microarray; differential expression analysis; human.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6352829-B1.  
 XX  
 PD 05-MAR-2002.  
 XX  
 PF 05-JAN-1999; 99US-00225928.  
 XX  
 PR 21-MAY-1997; 97US-00859998.  
 XX  
 PA (CLON-) CLONTECH LAB INC.  
 XX  
 PI Chenchik A, Jokhadze G, Bibilashvili R;  
 XX  
 DR WPI; 2002-314699/35.  
 XX  
 PT Producing sub-population of labeled nucleic acids, useful for analyzing  
 PT differences in RNA profiles between several different physiological  
 PT sources, using set of distinct gene specific primers.  
 XX  
 PS Example 3; SEQ ID NO 1011; 11pp; English.  
 XX  
 CC The invention relates to producing a sub-population of labeled nucleic  
 CC acids (NAs) comprising contacting a NA sample from a physiological  
 CC source, with a pool of 50 distinct gene specific primers under suitable  
 CC conditions to enzymatically generate sub-population of NAs, where each  
 CC gene specific primer has a sequence complementary to a distinct mRNA, and  
 CC each labeled NA is generated using a single gene specific primer. The  
 CC method is useful for producing a sub-population of labeled NAs which is  
 CC useful for analysing the differences in the RNA profiles between several  
 CC different physiological sources, where the method comprises producing  
 CC subpopulation of labeled NAs for the different physiological sources,  
 CC comprising the populations for each physiological source to identify  
 CC differences in the population, where the comparison is preferably  
 CC performed by hybridising the labeled NAs for each of the distinct  
 CC physiological sources to an array of probe NAs stably associated with the  
 CC surface of a substrate to produce a hybridisation pattern for each of the  
 CC sources, and comparing the patterns for each of the sources, where  
 CC differential gene expression assays are utilised in differential  
 CC expression analysis of diseased a normal tissue e.g. neoplastic a normal

CC tissue, or different tissue or sub-tissue types. The present sequence is a  
CC human gene specific PCR primer used in the method of the invention. Note:  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from USPTO  
CC at <http://wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1>  
XX  
SQ Sequence 28 BP; 8 A; 6 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 3.2%; Score 28; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 106 AGTCAGGCGCATCAATTTCGAGCAG 133  
Db 1 AGTCAGGCGCATCAATTTCGAGCAG 28

RESULT 11  
ABK66924/c  
ID ABK66924 standard; DNA; 28 BP.  
XX AC ABK66924;  
XX  
XX  
DT 02-JUL-2002 (first entry)  
DE Human gene specific PCR primer #1012.  
KW Primer; ss; DNA microarray; differential expression analysis; human.  
XX Homo sapiens.  
XX  
XX US6352829-B1.  
XX  
XX 05-MAR-2002.  
XX  
XX 05-JAN-1999; 99US-00225928.  
XX  
XX 21-MAY-1997; 97US-00859998.  
XX  
XX (CLON-) CLONTECH LAB INC.  
XX Chenchik A, Johadze G, Bibilashvili R;  
XX WPI; 2002-314699/35.  
XX  
XX Producing sub-population of labeled nucleic acids, useful for analyzing  
XX differences in RNA profiles between several different physiological  
XX sources, using set of distinct gene specific primers.  
XX  
XX Example 3; SEQ ID NO 1012; 11pp; English.

CC The invention relates to producing a sub-population of labeled nucleic  
CC acids (NAs) comprising contacting a NA sample from a physiological  
CC source, with a pool of 50 distinct gene specific primers under suitable  
CC conditions to enzymatically generate sub-population of NAs, where each  
CC gene specific primer has a sequence complementary to a distinct mRNA, and  
CC each labeled NA is generated using a single gene specific primer. The  
CC method is useful for producing a sub-population of labeled NAs which is  
CC useful for analysing the differences in the RNA profiles between several  
CC different physiological sources, where the method comprises producing  
CC subpopulation of labeled NAs for the different physiological sources,  
CC comprising the populations for each physiological source to identify  
CC differences in the population, where the comparison is preferably  
CC performed by hybridising the labeled NAs for each of the distinct  
CC physiological sources to an array of probe NAs stably associated with the  
CC surface of a substrate to produce a hybridisation pattern for each of the  
CC sources, and comparing the patterns for each of the sources, where  
CC differential gene expression assays are utilised in differential  
CC expression analysis of diseased a normal tissue e.g. neoplastic a normal  
CC tissue, or different tissue or sub-tissue types. The present sequence is a  
CC human gene specific PCR primer used in the method of the invention. Note:  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from USPTO

CC at <http://wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1>  
XX  
SQ Sequence 28 BP; 7 A; 5 C; 9 G; 7 T; 0 U; 0 Other;  
  
Query Match 3.2%; Score 28; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGACCATTCGATC 403  
Db 28 GATCTCACTCTCAGGAGACCATTCGATC 1

RESULT 12  
ABA94683/c  
ID ABA94683 standard; DNA; 27 BP.  
XX AC ABA94683;  
XX  
XX 23-APR-2002 (first entry)  
XX  
XX Antisense S-oligo against superoxide dismutase SOD1.  
XX 2-methoxyestradiol; superoxide anion; superoxide dismutase; SOD;  
KW cytosstatic; cancer; tumour; SOD1; antisense; ss.  
XX Synthetic.  
XX  
XX WO200203979-A2.  
XX  
XX 17-JAN-2002.  
XX  
XX 11-JUL-2001; 2001WO-US022332.  
XX  
XX 12-JUL-2000; 2000US-0217589P.  
XX 05-JUL-2001; 2001US-00899807.  
XX  
XX (TEXA ) UNIV TEXAS SYSTEM.  
XX  
XX Huang P, Plunkett WK, Feng L;  
XX WPI; 2002-164592/21.  
XX  
XX Composition for treating cancer comprises 2-methoxyestradiol and an agent  
XX that increases intracellular superoxide anion.  
XX Disclosure; Page 6; 91pp; English.

CC The invention relates to a composition that comprises 2-methoxyestradiol  
CC and an agent that increases intracellular superoxide anion. 2-  
CC methoxyestradiol inhibits superoxide dismutase (SOD) including cytosolic  
CC SOD1 (CuZn-SOD) and mitochondrial SOD2 (Mn-SOD). It comprises the  
CC cell's ability to eliminate superoxide anion. The composition can be used  
CC for killing cells (preferably cancer cells derived from a solid tumour  
CC especially leukemia cells) in humans; for treating cancer in humans. SOD1  
CC Sequences ABA94683-684 represent antisense S-oligos directed against SOD1  
XX  
SQ Sequence 27 BP; 6 A; 11 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 3.1%; Score 27; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 15;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 61 AGTTATGGCGACGAAGCCCGTGTGCGT 87  
Db 27 AGTTATGGCGACGAAGCCCGTGTGCGT 1

RESULT 13  
ADQ75020/c  
ID ADQ75020 standard; DNA; 33 BP.  
XX  
XX ADQ75020;

XX 09-SEP-2004 (first entry)  
 XX Human superoxide dismutase (SOD) cDNA PCR primer #2.  
 DE Human; Tat; protein translocation domain; Tat-PTEN fusion protein;  
 DE subconjunctival fibroblast;  
 KW transforming growth factor-beta signal transduction; TGF-beta; apoptosis;  
 KW scar formation; PTEN;  
 KW phosphatase and tensin homologue deleted from chromosome 10;  
 KW Tat-SOD fusion protein; superoxide dismutase; ss; PCR; primer.  
 XX Homo sapiens.  
 OS KR2004018598-A.  
 XX 04-MAR-2004.  
 XX 23-AUG-2002; 2002KR-00049979.  
 XX 23-AUG-2002; 2002KR-00049979.  
 XX (COWE-) COWELL INVESTMENT CAPITAL.  
 XX (UYVO-) UNIV YONSEI.  
 XX Lee JH;  
 XX WPI; 2004-465397/44.  
 XX Tat-PTEN fusion protein and process for preparing the same and the use  
 XX thereof.  
 XX Example 1; SEQ ID NO 10; 22pp; Korean.  
 XX The invention relates to a Tat-PTEN fusion protein and a process for  
 XX preparing the same and the use thereof. The Tat-PTEN fusion protein  
 XX penetrates subconjunctival fibroblasts and inhibits transforming growth  
 XX factor (TGF)-beta signal transduction. Therefore, the apoptosis of the  
 XX subconjunctival fibroblast can be induced and the formation of a scar can  
 XX be inhibited. A Tat-PTEN fusion protein contains PTEN (phosphatase and  
 XX tensin homologue deleted from chromosome 10) protein and a protein  
 XX transduction domain (ADQ75011) of HIV-1 Tat protein bound to the amino  
 XX terminal of the PTEN protein, wherein the Tat-PTEN fusion protein has the  
 XX amino acid sequence set forth in ADQ75022. A recombinant polynucleotide  
 XX comprises a DNA sequence encoding the Tat-PTEN fusion protein, wherein  
 XX the recombinant polynucleotide has the nucleotide sequence set forth in  
 XX ADQ75021. A vector expressing the Tat-PTEN fusion protein contains the  
 XX recombinant polynucleotide. A process for preparing the Tat-PTEN fusion  
 XX protein comprises expressing the vector in a microorganism and purifying  
 XX the expressed Tat-PTEN fusion protein, wherein the microorganism is  
 XX Escherichia coli. Also disclosed are a nucleic acid and protein  
 XX comprising a Tat-SOD fusion protein (superoxide dismutase). The present  
 XX sequence is a PCR primer used to isolate the human SOD cDNA used in the  
 XX constructs.  
 XX Sequence 33 BP; 11 A; 8 C; 5 G; 9 T; 0 U; 0 Other;  
 Query Match 2.9%; Score 25; DB 1; Length 33;  
 Best Local Similarity 100.0%; Pred. No. 26;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 506 GGTGTAATTGGGATCGCCCAATAAA 530  
 Db 33 GGTGTAATTGGGATCGCCCAATAAA 9  
 RESULT 14  
 AAQ67485/c  
 ID AAQ67485 standard; DNA; 24 BP.  
 XX AAQ67485;  
 XX 25-MAR-2003 (revised)  
 DT

DT 31-MAY-1995 (first entry)  
 XX PCR primer for human SOD1 exon 5.  
 XX Human superoxide dismutase; hSOD1; neurodegeneration;  
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;  
 KW Hallervorden-Spatz disease; olivopontocerebellar atrophy;  
 KW familial amyotrophic lateral sclerosis; FALS; diagnosis; mutant SOD;  
 KW SSCP analysis; ss.  
 XX Synthetic.  
 OS WO9419493-A1.  
 PN 01-SEP-1994.  
 XX 28-FEB-1994; 94WO-US002089.  
 XX 26-FEB-1993; 93US-00023980.  
 XX (GEHO) GEN HOSPITAL CORP.  
 XX (MASI) MASSACHUSETTS INST TECHNOLOGY.  
 XX Brown R, Horvitz HR, Rosen DR;  
 XX WPI; 1994-294353/36.  
 XX Diagnosis, treatment and prevention of diseases of cell death - e.g.  
 XX amyotrophic lateral sclerosis, which are the result of e.g. decreased SOD  
 XX activity.  
 XX Claim 8; Fig 5; 94pp; English.  
 XX The presence of a mutation in a gene encoding a superoxide dismutase  
 XX (SOD1, SOD2 or SOD3) indicates an increased likelihood of developing a  
 XX cell death disease, specifically a neurodegenerative disease. The DNA can  
 XX be analysed to detect mutant SOD sequences. Analysis is pref. preceded by  
 XX a PCR amplification step. AAQ67476-AAQ67485 are examples of PCR primers  
 XX which are useful for diagnosis of diseases linked to SOD1 mutations.  
 XX (Updated on 25-MAR-2003 to correct PN field.)  
 XX Sequence 24 BP; 9 A; 2 C; 9 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 2.7%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 31;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 556 CCCTTAACATCATCTGTTATCCTGC 579  
 Db 24 CCCTTAACATCATCTGTTATCCTGC 1  
 RESULT 15  
 AAQ73835/c  
 ID AAQ73835 standard; DNA; 24 BP.  
 XX AAQ73835;  
 XX 24-FEB-1999 (first entry)  
 XX Human SOD1 exon 5 PCR primer #2.  
 XX SOD1; SOD2; SOD3; Cu/Zn; superoxide dismutase; mitochondrial; treatment;  
 KW extracellular; neurodegenerative disease; amyotrophic lateral sclerosis;  
 KW familial; ALS; PCR primer; ss.  
 XX Synthetic.  
 OS Homo sapiens.  
 XX US5849290-A.  
 XX 15-DEC-1998.  
 XX

PF 07-JUN-1995; 95US-00486953.  
 XX  
 PR 26-FEB-1993; 93US-00023980.  
 PR 28-FEB-1994; 94US-00204052.  
 XX  
 PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEO ) GEN HOSPITAL CORP.  
 XX  
 PI Rosen DR, Brown R, Horvitz HR;  
 XX WPI; 1999-069657/06.  
 DR  
 XX Treatment of neurodegenerative disease - by administering super-oxide  
 PT dismutase.  
 PT  
 PS Disclosure; Fig 5; 53pp; English.  
 XX  
 CC AAV73826-V73835 are PCR primers used in the amplification of a novel  
 CC human SOD1 gene which encodes a Cu/Zn SOD (superoxide dismutase) protein.  
 CC This protein can be used in a method for treating a neurodegenerative  
 CC disease particularly familial amyotrophic lateral sclerosis (ALS)  
 XX  
 SQ Sequence 24 BP; 9 A; 2 C; 9 G; 4 T; 0 U; 0 Other;  
 Query Match 2.7%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 31;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 556 CCCTTAACCTCATCTGTTATCCTGC 579  
 DB 24 CCCTTAACCTCATCTGTTATCCTGC 1  
 RESULT 16  
 ADO55698/c  
 ID ADO55698 standard; DNA; 24 BP.  
 XX  
 AC ADO55698;  
 XX  
 DT 15-JUL-2004 (first entry)  
 XX  
 DE Human cytosolic superoxide dismutase (Cu/ZnSOD) DNA, SOD1 PCR primer #10.  
 XX  
 KW Human; cytosolic superoxide dismutase; Cu/ZnSOD; SOD; SOD1; PCR; ss;  
 KW neurodegenerative disease; cell death disease; FALS; neoplasm; primer.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6723893-B1.  
 XX  
 PD 20-APR-2004.  
 XX  
 PF 28-FEB-1994; 94US-00204052.  
 XX  
 PR 26-FEB-1993; 93US-00023980.  
 XX  
 PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEO ) GEN HOSPITAL CORP INC.  
 XX  
 PI Brown R, Horvitz HR, Rosen DR;  
 XX WPI; 2004-326924/30.  
 DR  
 XX New transgenic mouse having somatic and germ cells containing a transgene  
 PT encoding and expressing a neurodegenerative disease-causing mutant SOD-1  
 PT polypeptide, useful for research or drug development.  
 XX  
 PS Disclosure; SEQ ID NO 13; 54pp; English.  
 XX  
 CC The invention relates to a transgenic mouse having somatic and germ cells  
 CC containing a transgene encoding and expressing a neurodegenerative  
 CC disease-causing mutant SOD1 polypeptide. The invention also relates to a  
 CC method of diagnosing an increased likelihood of developing cell death

CC disease in a patient, a kit for the diagnosis of cell death disease in a  
 CC patient, a method of treating a patient with a disease involving a mutant  
 CC SOD encoding gene, antibodies reactive with a FALS polypeptide, a method  
 CC of treating a patient with a neoplasm, a bacterial or yeast cell  
 CC containing a purified nucleic acid derived from a FALS gene, a purified  
 CC DNA encoding a purified FALS polypeptide and a purified FALS polypeptide.  
 CC The SOD1 polypeptide is a murine or human SOD1 polypeptide. The  
 CC expression of the mutant polypeptide is under the regulation of the wild-  
 CC type promoter. The transgenic mouse is useful for research or drug  
 CC development. This sequence represents a PCR primer used to amplify SOD1  
 CC DNA encoding the human cytosolic superoxide dismutase (Cu/ZnSOD)  
 CC polypeptide.  
 XX  
 SQ Sequence 24 BP; 9 A; 2 C; 9 G; 4 T; 0 U; 0 Other;  
 Query Match 2.7%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 31;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 556 CCCTTAACCTCATCTGTTATCCTGC 579  
 DB 24 CCCTTAACCTCATCTGTTATCCTGC 1

RESULT 17  
 ABA94686/c  
 ID ABA94686 standard; DNA; 23 BP.  
 XX  
 AC ABA94686;  
 XX  
 DT 23-APR-2002 (first entry)  
 XX  
 DE Superoxide dismutase SOD1 cDNA amplifying reverse primer.  
 XX  
 KW 2-methoxyestradiol; superoxide anion; superoxide dismutase; SOD;  
 KW cytostatic; cancer; tumour; SOD1; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200203979-A2.  
 XX  
 PD 17-JAN-2002.  
 XX  
 PF 11-JUL-2001; 2001WO-US022332.  
 XX  
 PR 12-JUL-2000; 2000US-0217589P.  
 PR 05-JUL-2001; 2001US-00899807.  
 XX  
 PA (TEXA ) UNIV TEXAS SYSTEM.  
 XX  
 PI Huang P, Plunkett WK, Feng L;  
 XX WPI; 2002-164592/21.  
 DR  
 XX Composition for treating cancer comprises 2-methoxyestradiol and an agent  
 PT that increases intracellular superoxide anion.  
 PS  
 XX Example 1; Page 37; 91pp; English.  
 XX  
 CC The invention relates to a composition that comprises 2-methoxyestradiol  
 CC and an agent that increases intracellular superoxide anion. 2-  
 CC methoxyestradiol inhibits superoxide dismutase (SOD) including cytosolic  
 CC SOD1 (CuZn-SOD) and mitochondrial SOD2 (Mn-SOD). It compromises the  
 CC cell's ability to eliminate superoxide anion. The composition can be used  
 CC for killing cells (preferably cancer cells derived from a solid tumour  
 CC especially leukemia cells) in humans; for treating cancer in humans.  
 CC Sequences ABA94685-886 represent PCR primers for amplifying SOD1 cDNA  
 XX  
 SQ Sequence 23 BP; 9 A; 9 C; 3 G; 2 T; 0 U; 0 Other;  
 Query Match 2.6%; Score 23; DB 1; Length 23;  
 Best Local Similarity 100.0%; Pred. No. 40;  
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 486 CTGGAAGTCGTTGGCTTGTGGT 508
DB 23 CTGGAAGTCGTTGGCTTGTGGT 1

RESULT 18
ABA94685
ID ABA94685 standard; DNA; 23 BP.
XX AC ABA94685;
XX DT 23-APR-2002 (first entry)
XX DE Superoxide dismutase SOD1 cDNA amplifying forward primer.
XX KW 2-methoxyestradiol; superoxide anion; superoxide dismutase; SOD;
XX KW cytostatic; cancer; tumour; SOD1; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200203979-A2.
XX PD 17-JAN-2002.
XX PF 11-JUL-2001; 2001WO-US022332.
XX PR 12-JUL-2000; 2000US-0217589P.
XX PR 05-JUL-2001; 2001US-00899807.
XX PA (TEXA ) UNIV TEXAS SYSTEM.
XX PI Huang P, Plunkett WK, Feng L;
XX WPI; 2002-164592/21.
XX DR
XX PT Composition for treating cancer comprises 2-methoxyestradiol and an agent
XX PT that increases intracellular superoxide anion.
XX PS Example 1; Page 37; 91pp; English.
XX CC The invention relates to a composition that comprises 2-methoxyestradiol
XX CC and an agent that increases intracellular superoxide anion. 2-
XX CC methoxyestradiol inhibits superoxide dismutase (SOD) including cytosolic
XX CC SOD1 (CuZn-SOD) and mitochondrial SOD2 (Mn-SOD). It compromises the
XX CC cell's ability to eliminate superoxide anion. The composition can be used
XX CC for killing cells (preferably cancer cells derived from a solid tumour
XX CC especially leukemia cells) in humans; for treating cancer in humans.
XX CC Sequences ABA94685-686 represent PCR primers for amplifying SOD1 cDNA
XX SQ Sequence 23 BP; 5 A; 5 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 ACGAAGCGCGTGTGCGTGTGAA 93
DB 1 ACGAAGCGCGTGTGCGTGTGAA 23

RESULT 19
ABX12365/c
ID ABX12365 standard; DNA; 23 BP.
XX AC ABX12365;
XX DT 10-MAY-2003 (first entry)
XX DE Oxidative stress detection PCR primer #6.
XX KW Oxidative stress detection; PCR; primer; ss; risk factor.

```

```

OS Homo sapiens.
XX WO2003016527-A2.
XX PD 27-FEB-2003.
XX PF 13-AUG-2002; 2002WO-EP009079.
XX PR 14-AUG-2001; 2001BE-00000545.
XX PA (PROB-) PROBIOX SA.
XX PI Pincemail J, Piette J, Marechal D;
XX WPI; 2003-268334/26.
XX PT Determining oxidative stress markers in a group of individuals by
XX PT comparing the amount of each of the oxidative stress markers obtained
XX PT from each of the group of individuals with that of the group of healthy
XX PT individuals.
XX PS Disclosure; Page 34; 67pp; English.
XX CC The invention relates to a method for determining oxidative stress
XX CC markers in a group of individuals. The method comprises determining the
XX CC risk factor for oxidative stress in the group, measuring the amount of at
XX CC least 10 different oxidative stress markers in a sample obtained from
XX CC each of the group of individuals, and comparing the amount of each of the
XX CC oxidative stress markers with the amount of each of the oxidative stress
XX CC markers measured in a group of healthy individuals to determine whether
XX CC the oxidative stress markers are increased or decreased in the group of
XX CC individuals carrying a risk factor for oxidative stress relative to
XX CC healthy individuals. This sequence represents a PCR primer used to detect
XX CC oxidative stress
XX SQ Sequence 23 BP; 6 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.6%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 383 CTCCTCAGGAGACCATTCATCAT 405
DB 23 CTCCTCAGGAGACCATTCATCAT 1

RESULT 20
ABX12364
ID ABX12364 standard; DNA; 23 BP.
XX AC ABX12364;
XX DT 10-MAY-2003 (first entry)
XX DE Oxidative stress detection PCR primer #5.
XX KW Oxidative stress detection; PCR; primer; ss; risk factor.
XX OS Homo sapiens.
XX PN WO2003016527-A2.
XX PD 27-FEB-2003.
XX PF 13-AUG-2002; 2002WO-EP009079.
XX PR 14-AUG-2001; 2001BE-00000545.
XX PA (PROB-) PROBIOX SA.
XX PI Pincemail J, Piette J, Marechal D;
XX WPI; 2003-268334/26.

```





QY 510 TAATCGGATCGCCCAATAACATTCCT 538  
 DB 1 TGATTGGATTGGCGAGTAACATTCCT 29

RESULT 23  
 AAD13501  
 ID AAD13501 standard; DNA; 25 BP.  
 XX  
 AC AAD13501;  
 XX  
 DT 06-NOV-2001 (first entry)  
 XX  
 DE Rat superoxide dismutase (SOD) probe sense strand.  
 XX  
 KW Antioxidative enzyme; catalase; CAT; superoxide dismutase; SOD; therapy;  
 KW reactive oxygen species; ROS; free radical; dietary supplement; stroke;  
 KW AP-1 transcription factor; renal reperfusion damage; cerebral ischaemia;  
 KW myocardial infarction; heart attack; pain; atherosclerosis; neuroleptic;  
 KW trauma; premature aging; neurodegenerative disease; tardive dyskinesia;  
 KW Parkinson's disease; amyotrophic lateral sclerosis; Alzheimer's disease;  
 KW arthritis; inflammatory disease; diabetes; ulcerative colitis; cataract;  
 KW senility; Down's syndrome; macular degeneration; septic shock; epilepsy;  
 KW polytraumatic shock; schizophrenia; antiulcer; clozapine; tranquiliser;  
 KW cardiant; cerebroprotective; vulnerary; neurotropic; Huntington's disease;  
 KW anticonvulsant; neuroprotective; antiarthritic; antiinflammatory; burn;  
 KW cytostatic; leukaemia; ophthalmological; antibacterial;  
 KW immunosuppressive; probe; ss.  
 XX  
 OS Rattus sp.  
 XX  
 XX WO200136454-A1.  
 XX  
 XX 25-MAY-2001.  
 XX  
 XX 17-NOV-2000; 2000WO-US031764.  
 XX  
 XX 18-NOV-1999; 99US-0166381P.  
 XX  
 XX (CERE-) CEREMEDIX INC.  
 XX  
 XX Shashoua VE;  
 XX  
 XX WPI; 2001-496512/54.  
 XX  
 XX Novel peptide compound that up regulates expression of a gene encoding  
 PT antioxidative enzymes, used to treat or prevent conditions caused by  
 PT undesirable elevation of reactive oxygen species and other free radicals.  
 XX  
 XX Example 2; Page 46; 102pp; English.

XX The invention relates to peptide compounds and methods for upregulating  
 CC expression of a gene encoding an antioxidative enzyme, such as catalase  
 CC (CAT) or superoxide dismutase (SOD), to counteract harmful oxidative  
 CC effects of reactive oxygen species (ROS) and other free radicals. The  
 CC peptides are used as components of pharmaceuticals and dietary  
 CC supplements. The peptides are used to treat or to prevent diseases and  
 CC conditions characterised by undesirable elevation of ROS and other free  
 CC radicals, to upregulate AP-1 transcription factor gene expression and to  
 CC treat pain. The diseases or conditions include renal reperfusion damage, to  
 CC cerebral ischaemia (stroke), myocardial infarction (heart attack), head  
 CC trauma, atherosclerosis, brain trauma, oxygen toxicity in premature  
 CC infants, premature aging, spinal cord trauma, neurodegenerative diseases,  
 CC Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis,  
 CC Alzheimer's disease, arthritis and other inflammatory diseases, diabetes,  
 CC ulcerative colitis, human leukaemia and other cancers characterised by  
 CC elevation of ROS or free radicals, age-related elevation of ROS or free  
 CC radicals, senility, Down's syndrome, macular degeneration, cataracts,  
 CC septic shock, polytraumatic shock, schizophrenia, burn injuries,  
 CC epilepsy, radiation and/or drug-induced elevation of ROS and free  
 CC radicals, where the drug is a neuroleptic or a drug such as clozapine  
 CC defined in the specification and tardive dyskinesia. The present sequence

CC 1s rat SOD probe sense strand  
 XX Sequence 25 BP; 5 A; 5 C; 10 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 2.6%; Score 22.4; DB 1; Length 25;  
 Best Local Similarity 95.8%; Pred. No. 48;  
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 312 GAGACTTGGCAATGTGACTGCTG 335  
 DB 1 GAGACCTGGGCAATGTGACTGCTG 24

RESULT 24  
 AAD29666/c  
 ID AAD29666 standard; DNA; 27 BP.  
 XX  
 AC AAD29666;  
 XX  
 DT 17-MAY-2002 (first entry)  
 XX  
 DE Human Zn-SOD amplifying reverse primer.  
 XX  
 KW Oligolysine; transducing domain; oligolysine-cargo molecule complex;  
 KW SOD related disease; angitis; glomerulonephritis; autoimmune disease;  
 KW apoplexy; myocardial infarction; dysrhythmia; angina pectoris; malaria;  
 KW cytoplasm; idiopathic haemochromatosis; radiation treatment; progeria;  
 KW disease-related aging; sickle-cell anaemia; pulmonary emphysema;  
 KW myocardiopathy; autoimmune nephrotic syndrome; Alzheimer's disease;  
 KW betelnut-related oral cancer; hyperbaric oxygen disease; gene therapy;  
 KW Parkinson's disease; cataract; nephrotropic; cytostatic; neurotropic;  
 KW hepatotrophic; neuroprotective; ophthalmological; immunosuppressive;  
 KW protozoaside; cardiant; human; Zn-SOD; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200210219-A1.  
 XX  
 XX 07-FEB-2002.  
 XX  
 XX 21-MAY-2001; 2001WO-KR000835.  
 XX  
 XX 26-JUL-2000; 2000KR-00043022.  
 XX 08-FEB-2001; 2001KR-00006178.  
 XX 03-MAR-2001; 2001KR-00010981.  
 XX 19-MAR-2001; 2001KR-00014147.  
 XX  
 XX (CHOS/) CHO S.  
 XX (CHOI/) CHOI S.  
 XX (PARK/) PARK J.  
 XX (KWON/) KWON H.  
 XX (KANG/) KANG J.  
 XX (KANG/) KANG T.  
 XX (WONM/) WON M.  
 XX (HANK/) HAN K.  
 XX (LEEK/) LEE K.  
 XX  
 XX Choi S, Park J, Kwon H, Kang J, Kang T, Won M, Han K, Lee K;  
 XX WPI; 2002-188723/24.  
 XX  
 XX Novel oligolysine transport domain, useful for introducing oligolysine-  
 PT cargo molecule complex into a cell or cell nucleus, is covalently bound  
 PT to a cargo molecule that is not penetrating into cell or cell nucleus.  
 XX  
 XX Example 10; Page 27; 70pp; English.

XX The invention relates to oligolysine transport domain, an oligolysine  
 CC vector and an oligolysine-cargo molecule complex each of which being  
 CC comprised of a plurality of lysine residues. The oligolysine transducing  
 CC domain-binding fusion protein is efficiently transducible into cytoplasm  
 CC and biologically active. An expression vector comprising a cargo molecule  
 CC cDNA is useful for introducing oligolysine-cargo molecule complex into a

CC cell or cell nucleus. Cargo molecule or expression vector comprising a  
CC cargo molecule cDNA is useful for preventing and treating SOD related  
CC diseases e.g. glomerulonephritis, autoimmune disease, angitis, apoplexy,  
CC myocardial infarction, dysrhythmia, angina pectoris, idiopathic  
CC haemochromatosis, disease occurred from radiation treatment, progeria,  
CC disease-related aging, sickle-cell anaemia, malaria, pulmonary emphysema,  
CC myocardiopathy, autoimmune nephrotic syndrome, Alzheimer's disease,  
CC Beteinut-related oral cancer, Parkinson's disease, hyperbaric oxygen  
CC disease and cataract. The fusion DNA of the invention is used in gene  
CC therapy. The present sequence is a PCR primer used to amplify human Zn-  
CC SOD DNA. This primer is used to prepare vector expressing Lys-SOD fusion  
CC protein  
XX  
SQ Sequence 27 BP; 6 A; 7 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 2.5%; Score 22.2; DB 1; Length 27;  
Best Local Similarity 88.9%; Pred. No. 52;  
Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 509 GTAATTGGGATCGCCCAATAAACATTC 535  
Db 27 GTAATTGGGATCGCCCAATAAGGATCC 1  
RESULT 25  
AD059161/c  
ID AD059161 standard; DNA; 27 BP.  
AC AD059161;  
XX  
XX 15-JUL-2004 (first entry)  
XX Human Cu/Zn-superoxide dismutase (Cu/Zn-SOD) DNA PCR primer #2.  
XX Human; Tat; superoxide dismutase; Tat-superoxide dismutase; PCR; ss;  
KW Cu/Zn-superoxide dismutase; Cu/Zn-SOD; reactive oxygen species; primer.  
XX  
OS Homo sapiens.  
XX KR2002010445-A.  
XX 04-FEB-2002.  
XX 03-MAR-2001; 2001KR-00010980.  
XX 26-JUL-2000; 2000KR-00043039.  
XX 02-FEB-2001; 2001KR-00005094.  
XX (CHOI/) CHOI S Y.  
PA (KANG/) KANG J H.  
PA (KWAN/) KWAN H I.  
PA (PARK/) PARK J S.  
XX  
PI Choi SY, Eum WS, Jang HU, Kang JH, Kang TC, Kwan HI, Lee BR;  
PI Park JS, Ryu JY, Won WH;  
XX  
XX WPI; 2003-436529/41.  
XX Cell-transducing HIV-1 Tat-superoxide dismutase fusion protein, for  
PT countering reactive oxygen species, contains HIV-1 Tat 49-57 residues  
PT linked at amino terminal of Cu, Zn-superoxide dismutase to form covalent  
PT bond.  
XX  
XX Example 1; SEQ ID NO 4; 22pp; Korean.  
XX  
XX The invention relates to a cell-transducing HIV-1 Tat-superoxide  
CC dismutase fusion protein containing HIV-1 Tat residues 49-57 linked at  
CC the amino terminal of Cu/Zn-superoxide dismutase (Cu/Zn-SOD), or its  
CC derivative, to form a covalent bond. The invention also relates to a  
CC recombinant polynucleotide that encodes the Tat-superoxide dismutase  
CC fusion protein, in which the DNA encoding HIV-1 Tat residues 49-57 is  
CC linked at the 5'-terminal of Cu/Zn-superoxide dismutase cDNA or its  
CC derivative and a method of introducing the Tat-superoxide dismutase

CC fusion protein into a cell, by expressing the expression vector in a  
CC microorganism, purifying the expressed Tat-superoxide dismutase fusion  
CC protein and adding the fusion protein to the cell. The sequences and  
CC methods are used for countering reactive oxygen species that cause damage  
CC to macromolecules in the human body. This sequence represents a PCR  
CC primer used to amplify DNA encoding the human Cu/Zn-SOD protein of the  
CC invention.  
XX  
SQ Sequence 27 BP; 6 A; 7 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 2.5%; Score 22.2; DB 1; Length 27;  
Best Local Similarity 88.9%; Pred. No. 52;  
Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 509 GTAATTGGGATCGCCCAATAAACATTC 535  
Db 27 GTAATTGGGATCGCCCAATAAGGATCC 1  
RESULT 26  
AD006573/c  
ID AD006573 standard; DNA; 27 BP.  
XX  
AC AD006573;  
XX  
XX 29-JUL-2004 (first entry)  
XX Fusion protein related human coding sequence PCR primer #2.  
XX fusion protein; transduction domain; superoxide dismutase; aging;  
KW inflammatory disease; PCR; ss; primer.  
XX  
OS Homo sapiens.  
XX WO2004039846-A1.  
XX 13-MAY-2004.  
XX 13-MAR-2003; 2003WO-KR000490.  
XX 31-OCT-2002; 2002KR-00066981.  
XX (UVHA-) UNIV HALLYM.  
XX Choi S, Park J, Han K, Choi J;  
XX WPI; 2004-376167/35.  
XX New transduction domain-target protein-transduction domain fusion protein  
PT having the ability to be transduced into a cell, useful for delivering a  
PT functional protein (i.e. superoxide dismutase) into a cell at enhanced  
PT efficiency.  
XX  
XX Disclosure; Page 38; 47pp; English.  
XX  
XX The present invention relates to a transduction domain-target protein-  
CC transduction domain fusion protein having the ability to be transduced  
CC into a cell, where the transduction domain is covalently bonded to each  
CC of the amino- and carboxyl-terminal ends of the target protein. The  
CC fusion protein is useful for delivering a functional protein or peptide  
CC (i.e. superoxide dismutase) into a cell at enhanced efficiency. The  
CC composition may be used in protein therapy where the superoxide dismutase  
CC playing a main role in removing reactive oxygen species is delivered into  
CC cells to treat diseases. It may be used in cosmetic and health food  
CC industries, in addition to treating various diseases, such as aging or  
CC inflammatory diseases. The present sequence is a PCR primer used in the  
CC exemplification of the invention.  
XX  
SQ Sequence 27 BP; 6 A; 7 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 2.5%; Score 22.2; DB 1; Length 27;  
Best Local Similarity 88.9%; Pred. No. 52;  
Matches 24; Conservative 0; Mismatches 3; Indels 0; Gaps 0;



```

XX AC ADG73926;
XX DT 11-MAR-2004 (first entry)
XX DE Human superoxide dismutase reverse PCR primer.
XX KW Multiple sclerosis; human; diagnosis; superoxide dismutase; PCR; primer;
XX OS ss; enzyme.
XX XX Homo sapiens.
XX PN WO2003102227-A1.
XX PD 11-DEC-2003.
XX PF 02-JUN-2003; 2003WO-AU000684.
XX PR 31-MAY-2002; 2002AU-00002719.
XX PA (UYGR-) UNIV GRIFFITH.
XX PI Griffiths LR, Tajouri L;
XX WPI; 2004-081938/08.
XX DR
XX XX
XX PT Determining whether an individual is predisposed to multiple sclerosis
XX PT (MS), for treating MS, by determining an amount of one or more MS-
XX PT associated nucleic acids or proteins in one or more cells or tissues
XX PT obtained from the individual.
XX PS Example; Page 53; 80pp; English.
XX CC The present sequence is that of a reverse PCR primer from exon 4 of the
XX CC human superoxide dismutase (SOD1) gene. Use with a forward primer
XX CC ADG73925 from exon 3 produces a 99 bp amplicon from cDNA, corresponding
XX CC to a 838 bp sequence of genomic DNA. The primers were used in a SYBR
XX CC Green I real-time quantitative (Q)-PCR analysis of SOD1 in order to
XX CC validate differential expression of the gene in cells and tissues of
XX CC multiple sclerosis (MS) sufferers compared to cells and tissues of non-
XX CC sufferers. Q-PCR indicated 2.0-fold up-regulation of SOD1 in chronic
XX CC active MS tissue and 14.0-fold up-regulation in acute plaque MS tissue.
XX CC The invention provides a method for determining whether an individual is
XX CC predisposed to MS. This comprises determining an amount of one or more MS
XX CC -associated nucleic acids (e.g. SOD1) or proteins in one or more cells or
XX CC tissues obtained from the individual, where if the amount is different to
XX CC a reference amount, the individual is predisposed to MS. The amount of MS
XX CC -associated nucleic acid is determined by nucleic acid array analysis or
XX CC quantitative nucleic acid sequence amplification. The MS-associated
XX CC nucleic acids may carry mutations or other sequence variations that
XX CC affect gene expression and contribute to MS pathophysiology. They may be
XX CC of diagnostic value in predicting a predisposition to MS, confirming
XX CC clinical diagnosis of MS and in the identification of compounds useful
XX CC for treating MS.
XX SQ Sequence 22 BP; 5 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
    Query Match 2.5%; Score 22; DB 1; Length 22;
    Best Local Similarity 100.0%; Pred. No. 52;
    Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 323 AATGTGACTGCTGACAAAGATG 344
Db 22 AATGTGACTGCTGACAAAGATG 1
    |||||
RESULT 30
ADO59160
ID ADO59160 standard; DNA; 27 BP.
XX AC ADO59160;
XX DT 15-JUL-2004 (first entry)

```

```

XX Human Cu/Zn-superoxide dismutase (Cu/Zn-SOD) DNA PCR primer #1.
XX DE
XX KW Human; Tat; superoxide dismutase; Tat-superoxide dismutase; PCR; ss;
XX KW Cu/Zn-superoxide dismutase; Cu/Zn-SOD; reactive oxygen species; primer.
XX OS Homo sapiens.
XX PN KR2002010445-A.
XX PD 04-FEB-2002.
XX PF 03-MAR-2001; 2001KR-00010980.
XX PR 26-JUL-2000; 2000KR-00043039.
XX PR 02-FEB-2001; 2001KR-00005094.
XX PA (CHOI/) CHOI S Y.
XX PA (KANG/) KANG J H.
XX PA (KWAN/) KWAN H I.
XX PA (PARK/) PARK J S.
XX PI Choi SY, Eum WS, Jang HU, Kang JH, Kang TC, Kwan HI, Lee BR;
XX PI Park JS, Ryu JY, Won MH;
XX WPI; 2003-436529/41.
XX CC Cell-transducing HIV-1 Tat-superoxide dismutase fusion protein, for
XX CC counteracting reactive oxygen species, contains HIV-1 Tat 49-57 residues
XX CC linked at amino terminal of Cu, Zn-superoxide dismutase to form covalent
XX CC bond.
XX PS Example 1; SEQ ID NO 3; 22pp; Korean.
XX CC The invention relates to a cell-transducing HIV-1 Tat-superoxide
XX CC dismutase fusion protein containing HIV-1 Tat residues 49-57 linked at
XX CC the amino terminal of Cu/Zn-superoxide dismutase (Cu/Zn-SOD), or its
XX CC derivative, to form a covalent bond. The invention also relates to a
XX CC recombinant polynucleotide that encodes the Tat-superoxide dismutase
XX CC fusion protein, in which the DNA encoding HIV-1 Tat residues 49-57 is
XX CC linked at the 5'-terminal of Cu/Zn-superoxide dismutase cDNA or its
XX CC derivative and a method of introducing the Tat-superoxide dismutase
XX CC fusion protein into a cell, by expressing the expression vector in a
XX CC microorganism, purifying the expressed Tat-superoxide dismutase fusion
XX CC protein and adding the fusion protein to the cell. The sequences and
XX CC methods are used for counteracting reactive oxygen species that cause damage
XX CC to macromolecules in the human body. This sequence represents a PCR
XX CC primer used to amplify DNA encoding the human Cu/Zn-SOD protein of the
XX CC invention.
XX SQ Sequence 27 BP; 4 A; 7 C; 12 G; 4 T; 0 U; 0 Other;
    Query Match 2.5%; Score 22; DB 1; Length 27;
    Best Local Similarity 100.0%; Pred. No. 54;
    Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 67 GGCGACGAAGCGCGTGTGCGTG 88
Db 6 GGCGACGAAGCGCGTGTGCGTG 27
    |||||
RESULT 31
ADO06572
ID ADO06572 standard; DNA; 27 BP.
XX AC ADO06572;
XX DT 29-JUL-2004 (first entry)
XX DE Fusion protein related human coding sequence PCR primer #1.
XX KW fusion protein; transduction domain; superoxide dismutase; aging;
XX KW inflammatory disease; PCR; ss; primer.

```

XX OS Homo sapiens.  
 XX PN WO2004039846-A1.  
 XX XX  
 XX PD 13-MAY-2004.  
 XX XX  
 XX PF 13-MAR-2003; 2003WO-KR000490.  
 XX XX  
 XX PR 31-OCT-2002; 2002KR-00066981.  
 XX XX  
 XX PA (UYHA-) UNIV HALLYM.  
 XX XX  
 XX PI Choi S, Park J, Han K, Choi J;  
 XX XX  
 XX DR WPI; 2004-376167/35.  
 XX XX  
 XX PT New transduction domain-target protein-transduction domain fusion protein  
 XX PT having the ability to be transduced into a cell, useful for delivering a  
 XX PT functional protein (i.e. superoxide dismutase) into a cell at enhanced  
 XX PT efficiency.  
 XX XX  
 XX PS Disclosure; Page 38; 47pp; English.  
 XX XX  
 XX CC The present invention relates to a transduction domain-target protein-  
 XX CC transduction domain fusion protein having the ability to be transduced  
 XX CC into a cell, where the transduction domain is covalently bonded to each  
 XX CC of the amino- and carboxyl-terminal ends of the target protein. The  
 XX CC fusion protein is useful for delivering a functional protein or peptide  
 XX CC (i.e. superoxide dismutase) into a cell at enhanced efficiency. The  
 XX CC composition may be used in protein therapy where the superoxide dismutase  
 XX CC playing a main role in removing reactive oxygen species is delivered into  
 XX CC cells to treat diseases. It may be used in cosmetic and health food  
 XX CC industries, in addition to treating various diseases, such as aging or  
 XX CC inflammatory diseases. The present sequence is a PCR primer used in the  
 XX CC exemplification of the invention.  
 XX XX  
 XX SQ Sequence 27 BP; 4 A; 7 C; 12 G; 4 T; 0 U; 0 Other;  
 Query Match 2.5%; Score 22; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 54;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 67 GCGACGAGGCGGTGCGTG 88  
 Db 6 GCGACGAGGCGGTGCGTG 27  
 RESULT 32  
 ADQ74974  
 ID ADQ74974 standard; DNA; 27 BP.  
 XX AC  
 XX AC ADQ74974;  
 XX XX  
 XX DT 09-SEP-2004 (first entry)  
 XX XX  
 XX DE Tat-pyridoxal kinase fusion protein associated primer seqid 3.  
 XX XX  
 XX KW cell-transduction; Tat-pyridoxal kinase fusion protein; HIV-1; Tat;  
 KW Pyridoxal kinase; PK; growth delay; alopecia; anaemia; seizure;  
 KW convulsion; Epilepsy; Parkinsonism; Huntington's disease; Depression;  
 KW PCR; primer; ss.  
 XX OS  
 XX OS Homo sapiens.  
 XX PN KR2003090457-A.  
 XX XX  
 XX PD 28-NOV-2003.  
 XX XX  
 XX PF 24-MAY-2002; 2002KR-00028940.  
 XX XX  
 XX PR 24-MAY-2002; 2002KR-00028940.  
 XX XX

PA (BAEK/) BAEK N I.  
 PA (CHOS/) CHO S W.  
 PA (CHOI/) CHOI S Y.  
 PA (KANG/) KANG J H.  
 PA (KWON/) KWON O S.  
 PA (LEEK/) LEE K S.  
 PA (PARK/) PARK J S.  
 XX XX  
 XX PI Baek NI, Ban JH, Cho SW, Choi SY, Kang JH, Kim AY, Kim CG;  
 XX PI Kim DW, Kim JA, Kwon OS, Lee KS, Lee YJ, Park JS, Yoon CS;  
 XX XX  
 XX DR WPI; 2004-255654/24.  
 XX XX  
 XX XX Cell-transducing hiv-1 tat-pyridoxal kinase fusion protein and the use  
 XX PT thereof.  
 XX XX  
 XX PS Example 1; SEQ ID NO 3; 19pp; Korean.  
 XX XX  
 XX CC The invention describes a cell-transducing HIV-1 Tat-pyridoxal kinase  
 XX CC fusion protein, wherein HIV-1 Tat 49-57 residues are covalently bound to  
 XX CC the amino terminal of the pyridoxal kinase. The protein is useful for  
 XX CC cell-transducing pyridoxal kinase (PK) for protein therapy. A recombinant  
 XX CC polynucleotide encoding the cell-transducing HIV-1 Tat-pyridoxal kinase  
 XX CC fusion protein has the nucleotide sequence of SEQ ID NO: 6. An expression  
 XX CC vector for expressing the cell-transducing HIV-1 Tat-pyridoxal kinase  
 XX CC fusion protein contains the recombinant polynucleotide of SEQ ID NO: 6.  
 XX CC The cell-transducing HIV-1 Tat-pyridoxal kinase fusion protein is useful  
 XX CC for treatment of growth delay, alopecia, anaemia, seizures, convulsions,  
 XX CC Epilepsy, Parkinsonism, Huntington's disease and Depression. This  
 XX CC sequence represents a primer used in the creation of the HIV-1 Tat-  
 XX CC pyridoxal kinase fusion protein of the invention.  
 XX XX  
 XX SQ Sequence 27 BP; 4 A; 7 C; 12 G; 4 T; 0 U; 0 Other;  
 Query Match 2.5%; Score 22; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 54;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 67 GCGACGAGGCGGTGCGTG 88  
 Db 6 GCGACGAGGCGGTGCGTG 27  
 RESULT 33  
 AAV32582/c  
 ID AAV32582 standard; DNA; 29 BP.  
 XX AC  
 XX AC AAV32582;  
 XX XX  
 XX DT 23-SEP-1998 (first entry)  
 XX XX  
 XX DE Human SOD-1 cDNA primer 2.  
 XX XX  
 XX KW Copper-zinc superoxide dismutase; SOD-1; TTC; SOD:Tet451; primer;  
 KW tetanus toxin fragment C; tetanus holotoxin; nerve cell; stroke; PCR;  
 KW neurological disorder; oxidative stress; brain hypoxia-reperfusion;  
 KW epilepsy; Parkinson's disease; Huntington's disease; amplification; ss.  
 XX OS  
 XX OS Synthetic.  
 XX OS Homo sapiens.  
 XX XX  
 XX PN US5780024-A.  
 XX XX  
 XX PD 14-JUL-1998.  
 XX XX  
 XX PF 21-JUN-1996; 96US-00668381.  
 XX XX  
 XX PR 23-JUN-1995; 95US-0000473P.  
 XX XX  
 XX PA (GEHO) GEN HOSPITAL CORP.  
 XX PA (UYMA-) UNIV MARYLAND BALTIMORE.  
 XX XX  
 XX PI Brown RH, Francis JW, Fishman PS, Hosler BA;

XX WPI; 1998-412999/35.  
XX  
XX New hybrid protein of superoxide dismutase and tetanus toxin fragment C -  
PT having increased uptake by neurons and retention of enzymatic activity in  
PT these cells, for treating neurological diseases associated with oxidative  
PT stress.  
XX  
XX Disclosure; Col 7; 23pp; English.  
PS  
XX  
XX Primers 2 and 1 (AAV32581) were used in a reverse-transcriptase PCR  
CC reaction to isolate the wild-type human SOD-1 cDNA from a lymphoblastoid  
CC cell line. The PCR product was used in the method of the invention which  
CC claims for an enzymatically active human copper-zinc superoxide dismutase  
CC (SOD-1) fused at its carboxyl terminus with the tetanus toxin fragment C  
CC (TTC) moiety. The TTC moiety constitutes amino acid residues 865-1315 of  
CC the tetanus holotoxin. The hybrid protein, referred as SOD:Tet451  
CC (AAW48909), is claimed to have the following properties: (a) it exhibits  
CC Cu/Zn SOD enzymatic activity; (b) the TTC moiety selectively binds to  
CC nerve cells and allows uptake of the hybrid protein into these cells; and  
CC (c) it retains substantial SOD enzymatic activity following cellular  
CC uptake. SOD:Tet451 is claimed to be useful for treating neurological  
CC disorders associated with oxidative stress, e.g. stroke, brain hypoxia-  
CC reperfusion, epilepsy, Parkinson's and Huntington's diseases  
XX  
XX Sequence 29 BP; 9 A; 6 C; 4 G; 10 T; 0 U; 0 Other;  
SQ  
Query Match 2.5%; Score 22; DB 1; Length 29;  
Best Local Similarity 100.0%; Pred. No. 55;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 777 ATGGGTATTAAACTTGTGAGAA 798  
Db 29 ATGGGTATTAAACTTGTGAGAA 8  
RESULT 34  
ABQ73054/c  
ID ABQ73054 standard; DNA; 21 BP.  
AC ABQ73054;  
XX  
XX 24-SEP-2002 (first entry)  
XX  
XX Cu/Zn SOD gene related PCR primer SEQ ID NO:2.  
XX  
XX Amyotrophic lateral sclerosis; ALS; transgenic rat; SOD; Cu/Zn SOD;  
KW superoxide dismutase; PCR primer; ss.  
XX  
XX Rattus sp.  
OS Synthetic.  
XX  
XX JP2002142610-A.  
PN  
XX  
XX 21-MAY-2002.  
PD  
XX  
XX 07-NOV-2000; 2000JP-00339567.  
PF  
XX  
XX 07-NOV-2000; 2000JP-00339567.  
PR  
XX  
XX (TOHO-) TOHOKU TECHNOARCH KK.  
PA  
XX  
XX WPI; 2002-552464/59.  
DR  
XX  
XX An amyotrophic lateral sclerosis model rat for investigation of its  
PT pathology and onset mechanism with introduced exogenic variant Cu/Zn  
PT superoxide dismutase.  
PT  
XX  
XX Example 1; Page 13; 28pp; Japanese.  
PS  
XX  
XX The present invention describes an amyotrophic lateral sclerosis (ALS)  
CC model rat. Also described: (1) a transgenic rat or its progeny having a  
CC DNA with integrated exogenic variant Cu/Zn superoxide dismutase (SOD)

CC gene; and (2) rat embryonic stem cells having human variant Cu/Zn SOD  
CC gene sequence. The transgenic rat can be used in the investigation of the  
CC pathology and the onset mechanism of ALS. The present sequence represents  
CC a PCR primer which is used in an example from the present invention  
XX  
XX Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 2.4%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 66;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 564 TCATCTGTATCCCTGCTAGCT 584  
Db 21 TCATCTGTATCCCTGCTAGCT 1  
RESULT 35  
ABZ79578  
ID ABZ79578 standard; DNA; 21 BP.  
XX  
XX AC ABZ79578;  
XX  
XX 23-MAY-2003 (first entry)  
DT  
XX  
XX Human superoxide dismutase 1 PCR probe sequence.  
DE  
XX  
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
KW PCR; probe; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO2003000707-A2.  
PN  
XX  
XX 03-JAN-2003.  
PD  
XX  
XX 19-JUN-2002; 2002WO-US019664.  
PF  
XX  
XX 21-JUN-2001; 2001US-00888360.  
PR  
XX  
XX (ISIS-) ISIS PHARM INC.  
PA  
XX  
XX Bennett FC, Dobie K;  
PI  
XX  
XX WPI; 2003-184032/18.  
PS  
XX  
XX Novel antisense compounds targeted to nucleic acids encoding human  
PT superoxide dismutase 1, for modulating expression of the dismutase and  
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
XX  
XX Example 13; Page 74; 107pp; English.  
PS  
XX  
XX The invention relates to a compound of 8-50 nucleobases in length,  
CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
CC 1. The compound specifically hybridises with and inhibits the expression  
CC of human superoxide dismutase 1 by hybridising with at least an 8-  
CC nucleobase portion of the nucleic acid molecule encoding the active site  
CC of the enzyme. The activity of compounds of the invention may be  
CC described as neuroprotective, cytostatic and antiinflammatory. The  
CC mechanism of action of compounds of the invention is antisense inhibition  
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
CC Compounds of the invention are useful for inhibiting the expression of  
CC human superoxide dismutase 1 in human cells or tissues, and for treating  
CC a disease or condition associated with this enzyme (antisense therapy),  
CC especially amyotrophic lateral sclerosis, a disease or condition arising  
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
CC used in diagnostics, therapeutics and as a research reagent, e.g.  
CC prophylactically to prevent or delay infection, inflammation or tumour  
CC formation. The current sequence represents the human superoxide dismutase  
CC 1 PCR probe sequence  
XX

SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;  
 Query Match 2.4%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 66;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 ACGAGGCCGTGTGCTGCTG 91  
 |||||  
 Db 1 ACGAGGCCGTGTGCTGCTG 21  
 |||||

RESULT 36  
 ADD56532  
 ID ADD56532 standard; DNA; 21 BP.  
 XX  
 AC ADD56532;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE Human gene expression analysis multiplex Start-PCR primer #52.  
 XX  
 KW Gene expression; multiplex standardised reverse transcriptase-PCR;  
 KW Start-PCR; high density oligonucleotide array; cDNA array;  
 KW small biological sample; fine needle aspirate biopsy;  
 KW laser captured microdissected material; human; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003186246-A1.  
 XX  
 PD 02-OCT-2003.  
 XX  
 PF 28-MAR-2002; 2002US-00109349.  
 XX  
 PR 28-MAR-2002; 2002US-00109349.  
 XX  
 PA (WILL/) WILLEY J C.  
 PA (CRAW/) CRAWFORD E L.  
 XX  
 PI Willey JC, Crawford EL;  
 XX  
 DR WPI; 2003-811730/76.  
 XX  
 PT Direct comparison of numerical gene expression values between samples of  
 PT genes comprises using multiplex standardized reverse transcription-  
 PT polymerase chain reaction.  
 XX  
 PS Example 1; SEQ ID NO 52; 59pp; English.  
 XX  
 CC The present invention relates to a method for the direct comparison of  
 CC numerical gene expression values between samples of genes. The method  
 CC comprises amplifying cDNA in the presence of a competitive template  
 CC mixture and primer pairs for several genes and then amplifying aliquots  
 CC of the PCR products using a primer pair specific for each gene. The  
 CC method of amplification is by multiplex standardised reverse  
 CC transcriptase-polymerase chain reaction (Start-PCR). High density  
 CC oligonucleotide or cDNA arrays are used to measure PCR products following  
 CC quantitative Start-PCR. The method is useful for the assessment of gene  
 CC expression in small biological samples such as fine needle aspirate  
 CC biopsies, and laser captured microdissected materials. The method allows  
 CC for the standardised measurement of hundreds of genes from the same  
 CC sample, which in prior art, could only be assessed for one gene. The  
 CC present sequence represents a multiplex Start-PCR primer which can be  
 CC used in the method of the present invention.  
 XX  
 SQ Sequence 21 BP; 6 A; 1 C; 9 G; 5 T; 0 U; 0 Other;  
 Query Match 2.4%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 66;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 TGAAGGTGTGGGAGCATTAA 173  
 |||||

Db 1 TGAAGGTGTGGGAGCATTAA 21  
 |||||

RESULT 37  
 ADD56533/c  
 ID ADD56533 standard; DNA; 21 BP.  
 XX  
 AC ADD56533;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE Human gene expression analysis multiplex Start-PCR primer #53.  
 XX  
 KW Gene expression; multiplex standardised reverse transcriptase-PCR;  
 KW Start-PCR; high density oligonucleotide array; cDNA array;  
 KW small biological sample; fine needle aspirate biopsy;  
 KW laser captured microdissected material; human; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003186246-A1.  
 XX  
 PD 02-OCT-2003.  
 XX  
 PF 28-MAR-2002; 2002US-00109349.  
 XX  
 PR 28-MAR-2002; 2002US-00109349.  
 XX  
 PA (WILL/) WILLEY J C.  
 PA (CRAW/) CRAWFORD E L.  
 XX  
 PI Willey JC, Crawford EL;  
 XX  
 DR WPI; 2003-811730/76.  
 XX  
 PT Direct comparison of numerical gene expression values between samples of  
 PT genes comprises using multiplex standardized reverse transcription-  
 PT polymerase chain reaction.  
 XX  
 PS Example 1; SEQ ID NO 53; 59pp; English.  
 XX  
 CC The present invention relates to a method for the direct comparison of  
 CC numerical gene expression values between samples of genes. The method  
 CC comprises amplifying cDNA in the presence of a competitive template  
 CC mixture and primer pairs for several genes and then amplifying aliquots  
 CC of the PCR products using a primer pair specific for each gene. The  
 CC method of amplification is by multiplex standardised reverse  
 CC transcriptase-polymerase chain reaction (Start-PCR). High density  
 CC oligonucleotide or cDNA arrays are used to measure PCR products following  
 CC quantitative Start-PCR. The method is useful for the assessment of gene  
 CC expression in small biological samples such as fine needle aspirate  
 CC biopsies, and laser captured microdissected materials. The method allows  
 CC for the standardised measurement of hundreds of genes from the same  
 CC sample, which in prior art, could only be assessed for one gene. The  
 CC present sequence represents a multiplex Start-PCR primer which can be  
 CC used in the method of the present invention.  
 XX  
 SQ Sequence 21 BP; 9 A; 8 C; 2 G; 2 T; 0 U; 0 Other;  
 Query Match 2.4%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 66;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 GTCGTTTGGCTTGTGGTGTA 512  
 |||||  
 Db 21 GTCGTTTGGCTTGTGGTGTA 1  
 |||||

RESULT 38  
 ADT66493  
 ID ADT66493 standard; DNA; 21 BP.  
 XX  
 AC ADT66493;

XX 16-DEC-2004 (first entry)  
 DT PCR primer for CuZn SOD SEQ ID NO:7.  
 DE ss; primer; PCR; CuZn SOD; cancer; antioxidant gene expression analysis;  
 KW irradiation therapy.  
 KW Synthetic.  
 OS KR2004025183-A.  
 PN 24-MAR-2004.  
 XX 18-SEP-2002; 2002KR-00057027.  
 PF 18-SEP-2002; 2002KR-00057027.  
 XX 18-SEP-2002; 2002KR-00057027.  
 PR (PARK/) PARK Y M.  
 PA Choi EM, Han MY, Hwang SY, Jun HJ, Kim YH, Park JH, Park YM;  
 PI WPI; 2004-495260/47.  
 XX Method and DNA chip for monitoring response of cancer patients to  
 PT irradiation therapy using antioxidant gene expression analysis.  
 PT Claim 2; SEQ ID NO 7; 22pp; Korean.  
 PS The invention relates to a novel method and a DNA chip for monitoring a  
 CC response of cancer patients to irradiation therapy using antioxidant gene  
 CC expression analysis, thereby accurately anticipating the response to  
 CC irradiation therapy and minimizing adverse side-effects thereof. A method  
 CC for monitoring a response of cancer patients to irradiation therapy  
 CC comprises: collecting a peripheral blood cell from a human; irradiating  
 CC the peripheral blood cell; extracting RNA according to the time period;  
 CC preparing DNA from the RNA; hybridizing the DNA with antioxidant enzyme  
 CC cDNA; amplifying the hybridized DNA using one or more pairs of primers  
 CC selected from: DNA fragments of ADT66487 and ADT66488; DNA fragments of  
 CC ADT66489 and ADT66490; DNA fragments of ADT66491 and ADT66492; DNA  
 CC fragments of ADT66493 and ADT66494; DNA fragments of ADT66495 and  
 CC ADT66496; and DNA fragments of ADT66497 and ADT66498; and analyzing  
 CC expression pattern of the amplified DNA according to the time period. A  
 CC DNA chip for monitoring a response of cancer patients to irradiation  
 CC therapy amplifies one or more antioxidant genes corresponding to the  
 CC following DNA fragments: DNA fragments of ADT66487 and ADT66488 - Gpx1;  
 CC DNA fragments of ADT66489 and ADT66490 - gamma-GCS; DNA fragments of  
 CC ADT66491 and ADT66492 - catalase; DNA fragments of ADT66493 and ADT66494  
 CC - CuZn SOD; DNA fragments of ADT66495 and ADT66496 - Mn SOD; and DNA  
 CC fragments of ADT66497 and ADT66498 - Prx II. The present sequence  
 CC represents a PCR primer of the invention.  
 XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;  
 SQ Query Match 2.4%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 66;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 65 ATGGCGACGAGCGCGTGTGC 85  
 Db 1 ATGGCGACGAGCGCGTGTGC 21  
 RESULT 39  
 ABQ73057/c  
 ID ABQ73057 standard; DNA; 22 BP.  
 XX AC ABQ73057;  
 XX 24-SEP-2002 (first entry)  
 DT Cu/Zn SOD gene related PCR primer SEQ ID NO:5.  
 DE WPI; 1997-435083/40.  
 XX

KW Amyotrophic lateral sclerosis; ALS; transgenic rat; SOD; Cu/Zn SOD;  
 XX superoxide dismutase; PCR primer; ss.  
 OS Rattus sp.  
 OS Synthetic.  
 XX JP2002142610-A.  
 XX 21-MAY-2002.  
 XX 07-NOV-2000; 2000JP-00339567.  
 PF 07-NOV-2000; 2000JP-00339567.  
 XX 07-NOV-2000; 2000JP-00339567.  
 XX (TOHO-) TOHOKU TECHNOARCH KK.  
 XX WPI; 2002-552464/59.  
 XX An amyotrophic lateral sclerosis model rat for investigation of its  
 PT pathology and onset mechanism with introduced exogenous variant Cu/Zn  
 PT superoxide dismutase.  
 XX Example 2; Page 13; 28pp; Japanese.  
 PS The present invention describes an amyotrophic lateral sclerosis (ALS)  
 CC model rat. Also described: (1) a transgenic rat or its progeny having a  
 CC DNA with integrated exogenous variant Cu/Zn superoxide dismutase (SOD)  
 CC gene; and (2) rat embryonic stem cells having human variant Cu/Zn SOD  
 CC gene sequence. The transgenic rat can be used in the investigation of the  
 CC pathology and the onset mechanism of ALS. The present sequence represents  
 CC a PCR primer which is used in an example from the present invention  
 XX Sequence 22 BP; 7 A; 7 C; 4 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20.4; DB 1; Length 22;  
 Best Local Similarity 95.5%; Pred. No. 78;  
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 193 GCATGGATTCCATGTTTCATGAG 214  
 Db 22 GCATGGATTCCGTTTCATGAG 1  
 RESULT 40  
 AAV01383  
 ID AAV01383 standard; DNA; 20 BP.  
 XX AC AAV01383;  
 XX 23-MAR-1998 (first entry)  
 DT Superoxide dismutase 1 PCR primer for universal mammalian STS's.  
 XX PCR primer; polymerase chain reaction; amplification; UM-STs;  
 KW universal mammalian sequence tagged site; genomic map; clone; ss.  
 XX Synthetic.  
 XX WO9731012-A1.  
 XX 28-AUG-1997.  
 XX 18-FEB-1997; 97WO-0002403.  
 PF 22-FEB-1996; 96US-0012061P.  
 XX (UNMI ) UNIV MICHIGAN.  
 XX (UNMS ) UNIV MICHIGAN STATE.  
 XX Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;  
 XX WPI; 1997-435083/40.  
 XX



PT New oligonucleotide primers amplifying gene regions conserved among  
PT mammals - useful for developing genomic maps, isolating clones and making  
PT cross-species comparisons.

PS Claim 2; Page 13; 26pp; English.

XX The present sequence represents a specifically claimed oligonucleotide  
CC PCR primer. The oligonucleotide can be used for polymerase chain reaction  
CC (PCR) amplification of DNA, specifically regions of specific genes that  
CC are conserved among mammalian species, i.e. pairs of oligonucleotides  
CC from the present specification represent universal mammalian sequence-  
CC tagged site (UM-STS) primers. The primers are used to develop genomic  
CC maps, to isolate clones from libraries, to make cross-species comparisons  
CC and to develop additional genetic markers. UM-STS allow genomic  
CC comparisons to be made between more species

XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 236 TGTACAGTGCAGGTCCTCA 255

Db 1 TGTACAGTGCAGGTCCTCA 20

RESULT 41

ACC40898/c

ID ACC40898 standard; DNA; 20 BP.

XX AC ACC40898;

XX 23-MAY-2003 (first entry)

XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150452.

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-  
FT methylcytosine"

FT modified\_base 1..5

FT /tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003000707-A2.

PN 03-JAN-2003.

XX 19-JUN-2002; 2002WO-US019664.

XX 21-JUN-2001; 2001US-00889360.

XX (ISIS-) ISIS PHARM INC.

XX Bennett FC, Dobie K;

XX WPI; 2003-184032/18.

XX

PT Novel antisense compounds targeted to nucleic acids encoding human  
PT superoxide dismutase 1, for modulating expression of the dismutase and  
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX Claim 3; Page 76; 107pp; English.

XX The invention relates to a compound of 8-50 nucleobases in length,  
CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
CC 1. The compound specifically hybridises with and inhibits the expression  
CC of human superoxide dismutase 1 by hybridising with at least an 8-  
CC nucleobase portion of the nucleic acid molecule encoding the active site  
CC of the enzyme. The activity of compounds of the invention may be  
CC described as neuroprotective, cytostatic and antiinflammatory. The  
CC mechanism of action of compounds of the invention is antisense inhibition  
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
CC Compounds of the invention are useful for inhibiting the expression of  
CC human superoxide dismutase 1 in human cells or tissues, and for treating  
CC a disease or condition associated with this enzyme (antisense therapy),  
CC especially amyotrophic lateral sclerosis, a disease or condition arising  
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
CC used in diagnostics, therapeutics and as a research reagent, e.g.  
CC prophylactically to prevent or delay infection, inflammation or tumour  
CC formation. Sequences given in records ACC40880-ACC40957 represent human  
CC superoxide dismutase 1 antisense inhibitor oligonucleotides

XX Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 212 GAGTTTGGAGATAATACAGC 231

Db 20 GAGTTTGGAGATAATACAGC 1

RESULT 42

ACC40912/c

ID ACC40912 standard; DNA; 20 BP.

XX AC ACC40912;

XX 23-MAY-2003 (first entry)

XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150456.

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-  
FT methylcytosine"

FT modified\_base 1..5

FT /tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003000707-A2.

XX

```

PD 03-JAN-2003.
XX
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00898360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 8 A; 1 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 556 CCCTTAACATCATCTGTTATC 575
XX |||||
XX 20 CCCTTAACATCATCTGTTATC 1
XX
XX
XX RESULT 43
XX ACC40914/c
XX ID ACC40914 standard; DNA; 20 BP.
XX
XX AC ACC40914;
XX
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150468.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages. All cytosines are 5-
XX methylcytosine"

```

```

FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00898360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 7 A; 5 C; 1 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 625 AAAAGTGTAAATTGTGTGACT 644
XX |||||
XX 20 AAAAGTGTAAATTGTGTGACT 1
XX
XX
XX RESULT 44
XX ACC40930/c
XX ID ACC40930 standard; DNA; 20 BP.
XX
XX AC ACC40930;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150484.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX

```

```

KW SS.
XX Homo sapiens.
OS Synthetic.
XX Key
XX Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX 03-JAN-2003.
XX 19-JUN-2002; 2002WO-US019664.
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Example 15; Page 77; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX Sequence 20 BP; 9 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 787 AACTTGTTCAGATTCTTTC 806
Db 20 AACTTGTTCAGATTCTTTC 1

```

RESULT 45  
ACC40892/c

```

ID ACC40892 standard; DNA; 20 BP.
XX AC ACC40892;
XX DT 23-MAY-2003 (first entry)
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150446.
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX 03-JAN-2003.
XX 19-JUN-2002; 2002WO-US019664.
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Claim 3; Page 76; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
XX SQ

```

```
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 142 TAAATGACCAAGTGAAGTGT 161
Db 20 TAAATGACCAAGTGAAGTGT 1

RESULT 46
ACC40897/c
ID ACC40897 standard; DNA; 20 BP.
XX
AC ACC40897;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150451.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003000707-A2.
XX
PD 03-JAN-2003.
XX
PP 19-JUN-2002; 2002WO-US019664.
XX
PR 21-JUN-2001; 2001US-00888360.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Dobie K;
XX
DR WPI; 2003-184032/18.
XX
PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
PS Claim 3; Page 76; 107pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
```

```
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 205 TGTTCATGAGTTGGAGATA 224
Db 20 TGTTCATGAGTTGGAGATA 1

RESULT 47
ACC40932/c
ID ACC40932 standard; DNA; 20 BP.
XX
AC ACC40932;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150486.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003000707-A2.
XX
PD 03-JAN-2003.
XX
PP 19-JUN-2002; 2002WO-US019664.
XX
PR 21-JUN-2001; 2001US-00888360.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Dobie K;
XX
DR WPI; 2003-184032/18.
XX
PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
PS Example 15; Page 77; 107pp; English.
XX
```

CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 9 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TCTTTGTCATTCAGCCTGT 820  
 |||||  
 Db 20 TCTTTGTCATTCAGCCTGT 1

RESULT 48  
 ACC40936/c  
 ID ACC40936 standard; DNA; 20 BP.  
 XX  
 AC ACC40936;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150490.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.

Key Location/Qualifiers  
 modified\_base 1..20  
 /tag= a  
 /mod\_base= OTHER  
 /note= "Phosphorothioate linkages. All cytosines are 5-  
 modified\_base 1..5  
 /tag= b  
 /mod\_base= OTHER  
 /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 modified\_base 16..20  
 /tag= c  
 /mod\_base= OTHER  
 /note= "2'-methoxyethyl (2'-MOE) nucleotides"

WO2003000707-A2.  
 03-JAN-2003.  
 19-JUN-2002; 2002WO-US019664.  
 21-JUN-2001; 2001US-00888360.  
 (ISIS-) ISIS PHARM INC.

XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 DR  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 FT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 PS Claim 3; Page 77; 107pp; English.

XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX

SQ Sequence 20 BP; 6 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 TGTGAATAAAACCCCTGTAT 837  
 |||||  
 Db 20 TGTGAATAAAACCCCTGTAT 1

RESULT 49  
 ACC40893/c  
 ID ACC40893 standard; DNA; 20 BP.  
 XX  
 AC ACC40893;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150447.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.

Key Location/Qualifiers  
 modified\_base 1..20  
 /tag= a  
 /mod\_base= OTHER  
 /note= "Phosphorothioate linkages. All cytosines are 5-  
 modified\_base 1..5  
 /tag= b  
 /mod\_base= OTHER  
 /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 modified\_base 16..20  
 /tag= c  
 /mod\_base= OTHER

```

FT XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003000707-A2.
XX
XX PD 03-JAN-2003.
XX
XX PF 19-JUN-2002; 2002WO-US019664.
XX
XX PR 21-JUN-2001; 2001US-00888360.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett FC, Dobie K;
XX
XX DR WPI; 2003-184032/18.
XX
XX PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX PS Example 15; Page 76; 107pp; English.
XX
XX CC The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX SQ Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 144 ATGGACCACTGAAGTGTGG 163
DB 20 ATGGACCACTGAAGTGTGG 1

RESULT 50
ACC40904/c
ID ACC40904 standard; DNA; 20 BP.
XX
XX AC ACC40904;
XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150458.
XX
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX OS Homo sapiens.
XX Synthetic.
XX
XX FH Key Location/Qualifiers
FT modified_base 1..20

```

```

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT FT methylcytosine"
FT FT modified_base 1..5
FT FT /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT modified_base 16..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX PN WO2003000707-A2.
XX
XX PD 03-JAN-2003.
XX
XX PF 19-JUN-2002; 2002WO-US019664.
XX
XX PR 21-JUN-2001; 2001US-00888360.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett FC, Dobie K;
XX
XX DR WPI; 2003-184032/18.
XX
XX PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX PS Claim 3; Page 77; 107pp; English.
XX
XX CC The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX SQ Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 AGATGGTGTGCCCATGTGT 359
DB 20 AGATGGTGTGCCCATGTGT 1

RESULT 51
ACC40908/c
ID ACC40908 standard; DNA; 20 BP.
XX
XX AC ACC40908;
XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150462.

```

```

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 410 CGCACACTGGTGGTCCATGA 429
XX |||||||||||||||||||
XX DB 20 CGCACACTGGTGGTCCATGA 1

```

```

RESULT 52
ACC40911/c
ID ACC40911 standard; DNA; 20 BP.
XX
XX ACC40911;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150465.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX

```

```

CC superoxide dismutase 1 antisense inhibitor oligonucleotides
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
  Query Match      2.3%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 84;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 535 CCTTGGATGTAAGTCTGAGG 554
Db 20 CCTTGGATGTAAGTCTGAGG 1

RESULT 53
ACC40913/c
ID ACC40913 standard; DNA; 20 BP.
XX
AC ACC40913;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150467.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003000707-A2.
XX
PD 03-JAN-2003.
XX
PF 19-JUN-2002; 2002WO-US019664.
XX
PR 21-JUN-2001; 2001US-00888360.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Dobie K;
XX
DR WPI; 2003-184032/18.
XX
PS Example 15; Page 77; 107pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The

```

---

```

CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 8 A; 4 C; 1 G; 7 T; 0 U; 0 Other;
  Query Match      2.3%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 84;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTGTAAATTGTG 639
Db 20 ATCTTAAAGTGTAAATTGTG 1

RESULT 54
ACC40915/c
ID ACC40915 standard; DNA; 20 BP.
XX
AC ACC40915;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150469.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003000707-A2.
XX
PD 03-JAN-2003.
XX
PF 19-JUN-2002; 2002WO-US019664.
XX
PR 21-JUN-2001; 2001US-00888360.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Dobie K;
XX
DR WPI; 2003-184032/18.
XX
PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and

```



```

PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
PS Claim 3; Page 77; 107pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 658 TTTAAAGTACCTGTACTGAG 677
DB 20 TTTAAAGTACCTGTACTGAG 1

RESULT 55
ACC40940/C
ID ACC40940 standard; DNA; 20 BP.
XX
AC ACC40940;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150494.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.

```

```

XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
PT Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
PS Example 15; Page 77; 107pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 832 CTGTATGGCACTTATTATGA 851
DB 20 CTGTATGGCACTTATTATGA 1

RESULT 56
ACC40882/C
ID ACC40882 standard; DNA; 20 BP.
XX
AC ACC40882;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 146145.
XX
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER

```

```

FT modified_base /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 76; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 4 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 81 TGTGCGTCTGAAGGCGGAC 100
XX |||||
XX 20 TGTGCGTCTGAAGGCGGAC 1
XX
XX RESULT 57
XX ACC40903/c
XX ID ACC40903 standard; DNA; 20 BP.
XX
XX AC ACC40903;
XX
XX 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150457.
XX
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX AC Homo sapiens.

```

```

OS Synthetic.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 76; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 337 CAAAGATGGTGTGCCCGATG 356
XX |||||
XX 20 CAAAGATGGTGTGCCCGATG 1
XX
XX RESULT 58
XX ACC40920/c
XX ID ACC40920 standard; DNA; 20 BP.
XX
XX AC ACC40920;

```

XX 23-MAY-2003 (first entry)  
 XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150474.  
 XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Example 15; Page 77; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40850-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGGAGAGATTGTAT 710  
 DB |||||  
 20 ATCACTTGGAGAGATTGTAT 1  
 RESULT 59  
 ACC40943/c  
 ID ACC40943 standard; DNA; 20 BP.  
 XX AC ACC40943;  
 XX 23-MAY-2003 (first entry)  
 XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150497.  
 XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Example 15; Page 77; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising

CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides

XX  
 SQ Sequence 20 BP; 8 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 843 TTATTATGAGGCTATTAAAA 862

Db 20 TTATTATGAGGCTATTAAAA 1

RESULT 60

ACC40883/c

ID ACC40883 standard; DNA; 20 BP.

XX  
 AC ACC40883;

DT 23-MAY-2003 (first entry)

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150437.

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT WO2003000707-A2.

PN 03-JAN-2003.

PD 19-JUN-2002; 2002WO-US019664.

XX 21-JUN-2001; 2001US-00888360.

XX (ISIS-) ISIS PHARM INC.

XX Bennett FC, Dobie K;

PI WPI; 2003-184032/18.

XX Novel antisense compounds targeted to nucleic acids encoding human

PT superoxide dismutase 1, for modulating expression of the dismutase and

PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX Example 15; Page 76; 107pp; English.

PS The invention relates to a compound of 8-50 nucleobases in length,

CC targeted to a nucleic acid molecule encoding human superoxide dismutase

CC 1. The compound specifically hybridises with and inhibits the expression

CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides

XX SQ Sequence 20 BP; 7 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 14 GGTTCCTGTCAGTCCTCG 33

Db 20 GGTTCCTGTCAGTCCTCG 1

RESULT 61

ACC40887/c

ID ACC40887 standard; DNA; 20 BP.

XX  
 AC ACC40887;

DT 23-MAY-2003 (first entry)

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150441.

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003000707-A2.

PN 03-JAN-2003.

PD 19-JUN-2002; 2002WO-US019664.

XX 21-JUN-2001; 2001US-00888360.

XX (ISIS-) ISIS PHARM INC.

XX Bennett FC, Dobie K;

PI WPI; 2003-184032/18.

XX Novel antisense compounds targeted to nucleic acids encoding human

PT superoxide dismutase 1, for modulating expression of the dismutase and

PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX Example 15; Page 76; 107pp; English.

PS The invention relates to a compound of 8-50 nucleobases in length,

CC targeted to a nucleic acid molecule encoding human superoxide dismutase

CC 1. The compound specifically hybridises with and inhibits the expression

DR WPI; 2003-184032/18.  
 XX  
 PT Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 PS Claim 3; Page 76; 107pp; English.  
 XX  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 38 CAGGACCTCGCGTGGCCTA 57  
 Db |||||||  
 20 CAGGACCTCGCGTGGCCTA 1  
 RESULT 62  
 ACC40896/c  
 ID ACC40896 standard; DNA; 20 BP.  
 XX  
 AC ACC40896;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150450.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT methylcytosine  
 FT modified\_base 1..5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX  
 PN WO2003000707-A2.

XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX  
 PR 21-JUN-2001; 2001US-00888360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX  
 PT Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 PS Claim 3; Page 76; 107pp; English.  
 XX  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 174 AAGGACTGACTGAGGCCTG 193  
 Db |||||||  
 20 AAGGACTGACTGAGGCCTG 1  
 RESULT 63  
 ACC40899/c  
 ID ACC40899 standard; DNA; 20 BP.  
 XX  
 AC ACC40899;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150453.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT  
 FT

```

FT FT      methylcytosine"
FT modified_base 1. .5
FT FT      /*tag= b
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16. .20
FT FT      /*tag= c
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 76; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match      2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY      221 GATAATACAGCAGGCTGTAC 240
XX      |||||
XX      20 GATAATACAGCAGGCTGTAC 1
XX
XX Db
XX
XX RESULT 64
XX ACC40928/c
XX ID ACC40928 standard; DNA; 20 BP.
XX
XX AC ACC40928;
XX
XX XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150482.
XX
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antinflammatory; amyotrophic lateral sclerosis; apoptosis;

```

```

KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key      Location/Qualifiers
XX modified_base 1. .20
XX FT      /*tag= a
XX FT      /mod_base= OTHER
XX FT      /note= "Phosphorothioate linkages. All cytosines are 5-
XX methylcytosine"
XX modified_base 1. .5
XX FT      /*tag= b
XX FT      /mod_base= OTHER
XX FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16. .20
XX FT      /*tag= c
XX FT      /mod_base= OTHER
XX FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
XX
XX Query Match      2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY      769 AATCACAGATGGGTATTAAA 788
XX      |||||
XX      20 AATCACAGATGGGTATTAAA 1
XX
XX Db
XX
XX RESULT 65

```



Compounds of the invention are useful for inhibiting the expression of human superoxide dismutase 1 in human cells or tissues, and for treating a disease or condition associated with this enzyme (antisenase therapy), especially amyotrophic lateral sclerosis, a disease or condition arising from aberrant apoptosis and a hyperproliferative disorder. It may also be used in diagnostics, therapeutics and as a research reagent, e.g. prophylactically to prevent or delay infection, inflammation or tumour formation. Sequences given in records ACC40880-ACCA0957 represent human superoxide dismutase 1 antisense inhibitor oligonucleotides

Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

The invention relates to a compound of 8-50 nucleobases in length, targeted to a nucleic acid molecule encoding human superoxide dismutase 1. The compound specifically hybridises with and inhibits the expression of human superoxide dismutase 1 by hybridising with at least an 8-nucleobase portion of the nucleic acid molecule encoding the active site of the enzyme. The activity of compounds of the invention may be described as neuroprotective, cytostatic and anti-inflammatory. The mechanism of action of compounds of the invention is antisense inhibition of human superoxide dismutase 1 expression by chimeric phosphorothioate oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. Compounds of the invention are useful for inhibiting the expression of human superoxide dismutase 1 in human cells or tissues, and for treating a disease or condition associated with this enzyme (antisenese therapy), especially amyotrophic lateral sclerosis, a disease or condition arising from aberrant apoptosis and a hyperproliferative disorder. It may also be used in diagnostics, therapeutics and as a research reagent, e.g. prophylactically to prevent or delay infection, inflammation or tumour formation. Sequences given in records ACC40860-ACC40957 represent human superoxide dismutase 1 antisense inhibitor oligonucleotides.  
 Sequence 20 BP: 3 A: 5 C: 8 G: 4 T: 0 U: 0 Other:



```

PA (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Claim 3; Page 76; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40890-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 96 GCGACGGCCCGAGTGCAGGGC 115
Db 20 GCGACGGCCCGAGTGCAGGGC 1

RESULT 69
ACC40894/c
ID ACC40894 standard; DNA; 20 BP.
XX ACC40894;
XX
XX 23-MAY-2003 (first entry)
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150448.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c

```

---

```

FT FT /mod_base= OTHER
XX XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Claim 3; Page 76; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40890-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
SQ Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 TGGGGAAGCATTAAGGACT 180
Db 20 TGGGGAAGCATTAAGGACT 1

RESULT 70
ACC40931/c
ID ACC40931 standard; DNA; 20 BP.
XX ACC40931;
XX
XX 23-MAY-2003 (first entry)
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150485.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c

```

```

FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 9 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 795 AGAATTCTTGTGATTCAA 814
XX |||||||
XX 20 AGAATTCTTGTGATTCAA 1
XX
XX RESULT 71
XX ACC40937/c
XX ID ACC40937 standard; DNA; 20 BP.
XX
XX AC ACC40937;
XX
XX DT 23-MAY-2003 (first entry)
XX

```

```

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150491.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 820 TGAATAAAACCCCTGATGG 839
XX |||||||

```

Db 20 TGAATATAAACCTGTATCG 1

RESULT 72  
ACC40909/c  
ID ACC40909 standard; DNA; 20 BP.  
XX  
AC ACC40909;  
XX  
DT 23-MAY-2003 (first entry)  
XX  
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150463.  
XX  
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"  
FT modified\_base 1..5  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 16..20  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
XX  
PN WO2003000707-A2.  
XX  
PD 03-JAN-2003.  
XX  
PF 19-JUN-2002; 2002WO-US019664.  
XX  
PR 21-JUN-2001; 2001US-00888360.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Bennett FC, Dobie K;  
XX  
DR WPI; 2003-184032/18.  
XX  
PT Novel antisense compounds targeted to nucleic acids encoding human  
PT superoxide dismutase 1, for modulating expression of the dismutase and  
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
XX  
PS Claim 3; Page 77; 107pp; English.  
XX  
CC The invention relates to a compound of 8-50 nucleobases in length,  
CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
CC 1. The compound specifically hybridises with and inhibits the expression  
CC of human superoxide dismutase 1 by hybridising with at least an 8-  
CC nucleobase portion of the nucleic acid molecule encoding the active site  
CC of the enzyme. The activity of compounds of the invention may be  
CC described as neuroprotective, cytostatic and antinflammatory. The  
CC mechanism of action of compounds of the invention is antisense inhibition  
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
CC Compounds of the invention are useful for inhibiting the expression of  
CC human superoxide dismutase 1 in human cells or tissues, and for treating  
CC a disease or condition associated with this enzyme (antisense therapy),  
CC especially amyotrophic lateral sclerosis, a disease or condition arising  
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
CC used in diagnostics, therapeutics and as a research reagent, e.g.  
CC prophylactically to prevent or delay infection, inflammation or tumour

CC formation. Sequences given in records ACC40880-ACC40957 represent human  
CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
XX  
SQ Sequence 20 BP; 6 A; 8 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 84;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 504 GTGGTGTAAATGGGATCGCC 523  
|||||  
Db 20 GTGGTGTAAATGGGATCGCC 1

RESULT 73  
ACC40942/c  
ID ACC40942 standard; DNA; 20 BP.  
XX  
AC ACC40942;  
XX  
DT 23-MAY-2003 (first entry)  
XX  
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150496.  
XX  
KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"  
FT modified\_base 1..5  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 16..20  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
XX  
PN WO2003000707-A2.  
XX  
PD 03-JAN-2003.  
XX  
PF 19-JUN-2002; 2002WO-US019664.  
XX  
PR 21-JUN-2001; 2001US-00888360.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Bennett FC, Dobie K;  
XX  
DR WPI; 2003-184032/18.  
XX  
PT Novel antisense compounds targeted to nucleic acids encoding human  
PT superoxide dismutase 1, for modulating expression of the dismutase and  
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
XX  
PS Example 15; Page 77; 107pp; English.  
XX  
CC The invention relates to a compound of 8-50 nucleobases in length,  
CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
CC 1. The compound specifically hybridises with and inhibits the expression  
CC of human superoxide dismutase 1 by hybridising with at least an 8-  
CC nucleobase portion of the nucleic acid molecule encoding the active site  
CC of the enzyme. The activity of compounds of the invention may be  
CC described as neuroprotective, cytostatic and antinflammatory. The  
CC mechanism of action of compounds of the invention is antisense inhibition  
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
CC Compounds of the invention are useful for inhibiting the expression of  
CC human superoxide dismutase 1 in human cells or tissues, and for treating  
CC a disease or condition associated with this enzyme (antisense therapy),  
CC especially amyotrophic lateral sclerosis, a disease or condition arising  
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
CC used in diagnostics, therapeutics and as a research reagent, e.g.  
CC prophylactically to prevent or delay infection, inflammation or tumour

CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 835 TATGGCACTTATATGAGGC 854  
 |||||  
 Db 20 TATGGCACTTATATGAGGC 1  
 RESULT 74  
 ACC40902/c  
 ID ACC40902 standard; DNA; 20 BP.  
 AC ACC40902;  
 XX  
 DT 23-MAY-2003 (first entry)  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150456.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylycytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX  
 XX 21-JUN-2001; 2001US-00888360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Bennett FC, Dobie K;  
 XX  
 XX WPI; 2003-184032/18.  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human

PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 PS Claim 3; Page 76; 107pp; English.  
 XX  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 335 GACAAAGATGCTGTGGCGA 354  
 |||||  
 Db 20 GACAAAGATGCTGTGGCGA 1  
 RESULT 75  
 ACC40919/c  
 ID ACC40919 standard; DNA; 20 BP.  
 AC ACC40919;  
 XX  
 DT 23-MAY-2003 (first entry)  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150473.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylycytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.

```

PF 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TTATGATCATTGGAAGATT 705
DB 20 TTATGATCATTGGAAGATT 1
|||||

RESULT 76
ACC40921/c
ID ACC40921 standard; DNA; 20 BP.
XX
XX ACC40921;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150475.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT

PF 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TTATGATCATTGGAAGATT 705
DB 20 TTATGATCATTGGAAGATT 1
|||||

RESULT 77
ACC40885/c
ID ACC40885 standard; DNA; 20 BP.
XX
XX ACC40885;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150439.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT

PF 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 707 GTATAGTTTTATAAACTCA 726
DB 20 GTATAGTTTTATAAACTCA 1
|||||

RESULT 77
ACC40885/c
ID ACC40885 standard; DNA; 20 BP.
XX
XX ACC40885;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150439.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT

```

```

OS Homo sapiens.
OS Synthetic.
FH Key
FT modified_base 1..20 Location/Qualifiers
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5 methylv cytosine"
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 76; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 23 TGCAGTCTCGGACACGGA 42
XX
XX DB 20 TGCAGTCTCGGACACGGA 1
XX
XX RESULT 78
XX ABZ79576
XX ID ABZ79576 standard; DNA; 20 BP.
XX

```

```

AC ABZ79576;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 forward primer sequence.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX PCR; primer; ss.
XX
XX Homo sapiens.
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 13; Page 74; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. The current sequence represents the human superoxide dismutase
XX 1 forward primer sequence
XX
XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 49 CGTGGCCTAGCGAGTTATGG 68
XX
XX DB 1 CGTGGCCTAGCGAGTTATGG 20
XX
XX RESULT 79
XX ABZ79577/c
XX ID ABZ79577 standard; DNA; 20 BP.
XX
XX AC ABZ79577;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 reverse primer sequence.
XX

```

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW PCR; primer; ss.  
 OS Homo sapiens.  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Example 13; Page 74; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. The current sequence represents the human superoxide dismutase  
 CC 1 forward primer sequence  
 XX Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 108 TGCAGGGCATCATCAATTC 127  
 DB 20 TGCAGGGCATCATCAATTC 1  
 RESULT 80  
 ACC40900/c  
 ID ACC40900 standard; DNA; 20 BP.  
 XX ACC40900;  
 XX 23-MAY-2003 (first entry)  
 DT Human superoxide dismutase 1 antisense inhibitor # ISIS 150454.  
 DE Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX Homo sapiens.  
 OS Synthetic.  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT 1..5  
 FT modified\_base  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT 16..20  
 FT modified\_base  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Claim 3; Page 76; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 304 GCATGTTGGAGACTTGGCA 323  
 DB 20 GCATGTTGGAGACTTGGCA 1  
 RESULT 81  
 ACC40938/c  
 ID ACC40938 standard; DNA; 20 BP.

```
XX ACC40938;
XX 23-MAY-2003 (first entry)
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150492.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
```

```
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 825 AAAAACCCTGTATGGCACTT 844
DB 20 AAAAACCCTGTATGGCACTT 1
RESULT 82
ACC40939/c
ID ACC40939 standard; DNA; 20 BP.
XX AC ACC40939;
XX 23-MAY-2003 (first entry)
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150493.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
```



CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides

XX Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 829 ACCCTGTATGGCACTTATTA 848  
 DB 20 ACCCTGTATGGCACTTATTA 1

RESULT 83

ACC40905/C  
 ID ACC40905 standard; DNA; 20 BP.

XX AC ACC40905;

DT 23-MAY-2003 (first entry)

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150459.

KW Human; superoxide dismutase 1; antisense; neuroprotective; cytosstatic;  
 KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT methylcytosine"

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT WO2003000707-A2.

PN 03-JAN-2003.

XX 19-JUN-2002; 2002WO-US019664.

XX 21-JUN-2001; 2001US-00888360.

XX (ISIS-) ISIS PHARM INC.

XX Bennett FC, Dobie K;

XX WPI; 2003-184032/18.

XX Novel antisense compounds targeted to nucleic acids encoding human

XX superoxide dismutase 1, for modulating expression of the dismutase and

XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX Claim 3; Page 77; 107pp; English.

XX The invention relates to a compound of 8-50 nucleobases in length,

XX

CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytosstatic and antinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy).  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides

XX Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 343 TGGTGTGGCCGATGTCTA 362  
 DB 20 TGGTGTGGCCGATGTCTA 1

RESULT 84

ACC40918/C

ID ACC40918 standard; DNA; 20 BP.

XX AC ACC40918;

DT 23-MAY-2003 (first entry)

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150472.

KW Human; superoxide dismutase 1; antisense; neuroprotective; cytosstatic;  
 KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT methylcytosine"

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003000707-A2.

XX 03-JAN-2003.

XX 19-JUN-2002; 2002WO-US019664.

XX 21-JUN-2001; 2001US-00888360.

XX (ISIS-) ISIS PHARM INC.

PI Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 XX Example 15; Page 77; 107pp; English.  
 XX  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 7 A; 5 C; 1 G; 7 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 671 TAGTGAGAACTGATTATG 690  
 Db 20 TAGTGAGAACTGATTATG 1  
 RESULT 85  
 ACC40934/c  
 ID ACC40934 standard; DNA; 20 BP.  
 XX  
 AC ACC40934;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150488.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylycytosine"  
 FT modified\_base 1..5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX  
 XX 21-JUN-2001; 2001US-00888360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 XX Claim 3; Page 77; 107pp; English.  
 XX  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 3 A; 3 C; 5 G; 9 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 812 CAGCCTGTGATAAAACC 831  
 Db 20 CAGCCTGTGATAAAACC 1  
 RESULT 86  
 ACC40941/c  
 ID ACC40941 standard; DNA; 20 BP.  
 XX  
 AC ACC40941;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150495.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a



```

XX
SQ Sequence 20 BP; 6 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 309 TTGGAGACTTGGCAATGTG 328
Db 20 TTGGAGACTTGGCAATGTG 1

RESULT 89
ACC40916/c
ID ACC40916 standard; DNA; 20 BP.
XX AC ACC40916;
XX XX
XX 23-MAY-2003 (first entry)
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150470.
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylycytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX XX
XX WO2003000707-A2.
XX XX
XX 03-JAN-2003.
XX XX
XX 19-JUN-2002; 2002WO-US019664.
XX XX
XX 21-JUN-2001; 2001US-00888360.
XX XX
XX (ISIS-) ISIS PHARM INC.
XX XX
XX Bennett FC, Dobie K;
XX XX
XX WPI; 2003-184032/18.
XX XX
XX Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX XX
XX Example 15; Page 77; 107pp; English.
XX XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition

```

CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisenase therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 667 CCTGTAGTGAGAACTGATT 686  
 DB 20 CCTGTAGTGAGAACTGATT 1  
 RESULT 90  
 ACC40929/C  
 ID ACC40929 standard; DNA; 20 BP.  
 XX  
 AC ACC40929;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150483.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX  
 PN WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX  
 XX 21-JUN-2001; 2001US-00888360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Bennett FC, Dobie K;  
 XX  
 XX WPI; 2003-184032/18.  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 XX superoxide dismutase 1, for modulating expression of the dismutase and  
 XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX Example 15; Page 77; 107pp; English.  
 XX  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisenase therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 771 TCACAGATGGGTATTAACT 790  
 DB 20 TCACAGATGGGTATTAACT 1  
 RESULT 91  
 ACC40924/C  
 ID ACC40924 standard; DNA; 20 BP.  
 XX  
 AC ACC40924;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150478.  
 XX  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX  
 PN WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.

```

PR 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 9 A; 3 C; 2 G; 6 T; 0 U; 0 Other;
SQ
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 727 GTTAAATGTCGTTTCAAT 746
Db 20 GTTAAATGTCGTTTCAAT 1

RESULT 92
ACC40925/c
ID ACC40925 standard; DNA; 20 BP.
XX
AC ACC40925;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150479.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylycytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT

```

```

FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
PT superoxide dismutase 1, for modulating expression of the dismutase and
PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
CC targeted to a nucleic acid molecule encoding human superoxide dismutase
CC 1. The compound specifically hybridises with and inhibits the expression
CC of human superoxide dismutase 1 by hybridising with at least an 8-
CC nucleobase portion of the nucleic acid molecule encoding the active site
CC of the enzyme. The activity of compounds of the invention may be
CC described as neuroprotective, cytostatic and antiinflammatory. The
CC mechanism of action of compounds of the invention is antisense inhibition
CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
CC Compounds of the invention are useful for inhibiting the expression of
CC human superoxide dismutase 1 in human cells or tissues, and for treating
CC a disease or condition associated with this enzyme (antisense therapy),
CC especially amyotrophic lateral sclerosis, a disease or condition arising
CC from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 TAAATGTCGTTTCAATGA 748
Db 20 TAAATGTCGTTTCAATGA 1

RESULT 93
ACC40926/c
ID ACC40926 standard; DNA; 20 BP.
XX
AC ACC40926;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150480.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.

```

XX PH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT methylethylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Claim 3; Page 77; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX Sequence 20 BP; 9 A; 3 C; 4 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 736 TCTGTTTCAATGACCTGTAT 755  
 Db 20 TCTGTTTCAATGACCTGTAT 1  
 RESULT 94  
 ACC40888/c  
 ID ACC40888 standard; DNA; 20 BP.  
 XX  
 XX ACC40888;  
 XX

DT 23-MAY-2003 (first entry)  
 XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150442.  
 XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylethylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX 03-JAN-2003.  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX 21-JUN-2001; 2001US-00888360.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Bennett FC, Dobie K;  
 XX WPI; 2003-184032/18.  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX Example 15; Page 76; 107pp; English.  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 53 GCCTAGCGAGTTATGGCGAC 72
Db 20 GCCTAGCGAGTTATGGCGAC 1

RESULT 95
ACC40891/c
ID ACC40891 standard; DNA; 20 BP.
XX AC ACC40891;
XX DT 23-MAY-2003 (first entry)
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150445.
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX KW ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
XX WO2003000707-A2.
XX PD 03-JAN-2003.
XX PF 19-JUN-2002; 2002WO-US019664.
XX PR 21-JUN-2001; 2001US-00888360.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Dobie K;
XX DR WPI; 2003-184032/18.
XX CC Novel antisense compounds targeted to nucleic acids encoding human
XX FT superoxide dismutase 1, for modulating expression of the dismutase and
XX FT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX PS Claim 3; Page 76; 107pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases in length,
XX CC targeted to a nucleic acid molecule encoding human superoxide dismutase
XX CC 1. The compound specifically hybridises with and inhibits the expression
XX CC of human superoxide dismutase 1 by hybridising with at least an 8-
XX CC nucleobase portion of the nucleic acid molecule encoding the active site
XX CC of the enzyme. The activity of compounds of the invention may be
XX CC described as neuroprotective, cytostatic and antiinflammatory. The
XX CC mechanism of action of compounds of the invention is antisense inhibition
XX CC of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX CC Compounds of the invention are useful for inhibiting the expression of
XX CC human superoxide dismutase 1 in human cells or tissues, and for treating
XX CC a disease or condition associated with this enzyme (antisense therapy),
XX CC especially amyotrophic lateral sclerosis, a disease or condition arising
XX CC from aberrant apoptosis and a hyperproliferative disorder. It may also be

```

---

```

CC used in diagnostics, therapeutics and as a research reagent, e.g.
CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC4080-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX SQ Sequence 20 BP; 3 A; 7 C; 2 G; 8 T; 0 U; 0 Other;
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 135 AGGAAAGTAATGGACCACTG 154
Db 20 AGGAAAGTAATGGACCACTG 1
RESULT 96
ACC40917/c
ID ACC40917 standard; DNA; 20 BP.
XX AC ACC40917;
XX DT 23-MAY-2003 (first entry)
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150471.
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX KW hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX KW ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
XX WO2003000707-A2.
XX PD 03-JAN-2003.
XX PF 19-JUN-2002; 2002WO-US019664.
XX PR 21-JUN-2001; 2001US-00888360.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Dobie K;
XX DR WPI; 2003-184032/18.
XX CC Novel antisense compounds targeted to nucleic acids encoding human
XX FT superoxide dismutase 1, for modulating expression of the dismutase and
XX FT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX PS Example 15; Page 77; 107pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases in length,
XX CC targeted to a nucleic acid molecule encoding human superoxide dismutase
XX CC 1. The compound specifically hybridises with and inhibits the expression
XX CC of human superoxide dismutase 1 by hybridising with at least an 8-

```



CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 7 A; 5 C; 1 G; 7 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 670 GTAGTGAGAACTGATTTAT 689  
 DB 20 GTAGTGAGAACTGATTTAT 1  
 RESULT 97  
 ACC40922/c  
 ID ACC40922 standard; DNA; 20 BP.  
 AC ACC40922;  
 XX  
 DT 23-MAY-2003 (first entry)  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150476.  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX  
 PN WO2003000707-A2.  
 XX  
 PD 03-JAN-2003.  
 XX  
 PF 19-JUN-2002; 2002WO-US019664.  
 XX  
 PR 21-JUN-2001; 2001US-00888360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA Bennett FC, Dobie K;  
 XX  
 PI  
 XX WPI; 2003-184032/18.  
 DR

XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 PS Example 15; Page 77; 107pp; English.  
 XX  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 9 A; 2 C; 2 G; 7 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 710 TAGTTTTATAAACTCAGTT 729  
 DB 20 TAGTTTTATAAACTCAGTT 1  
 RESULT 98  
 ACC40923/c  
 ID ACC40923 standard; DNA; 20 BP.  
 XX  
 AC ACC40923;  
 XX  
 DT 23-MAY-2003 (first entry)  
 DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150477.  
 KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX  
 PN WO2003000707-A2.  
 XX

```

PD 03-JAN-2003.
XX
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 721 AACTCAGTTAAATCTCTGT 740
XX 20 AACTCAGTTAAATCTCTGT 1
XX
XX RESULT 99
XX ACC40935/c
XX ID ACC40935 standard; DNA; 20 BP.
XX
XX AC ACC40935;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150489.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX methylcytosine"

```

```

FT modified_base 1..5
FT /*tag= b
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT
FT modified_base 16..20
FT /*tag= c
FT /*mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 84;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 814 AGCCTGTGAATAAAACCCCT 833
XX 20 AGCCTGTGAATAAAACCCCT 1
XX
XX RESULT 100
XX ACC40881/c
XX ID ACC40881 standard; DNA; 20 BP.
XX
XX AC ACC40881;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 146144.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX

```

```

KW 88.
XX Homo sapiens.
OS Synthetic.
XX Key
FH Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX 03-JAN-2003.
XX 19-JUN-2002; 2002WO-US019664.
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Example 15; Page 76; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
SQ Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 78 CCGTGTGCGTGTGAAGGC 97
DB 20 CCGTGTGCGTGTGAAGGC 1
RESULT 101
ACC40890/c

```

```

ID ACC40890 standard; DNA; 20 BP.
XX ACC40890;
XX 23-MAY-2003 (first entry)
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150444.
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX Homo sapiens.
OS Synthetic.
XX Key
FH Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003000707-A2.
XX 03-JAN-2003.
XX 19-JUN-2002; 2002WO-US019664.
XX 21-JUN-2001; 2001US-00888360.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Dobie K;
XX WPI; 2003-184032/18.
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX Claim 3; Page 76; 107pp; English.
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.
XX prophylactically to prevent or delay infection, inflammation or tumour
XX formation. Sequences given in records ACC40880-ACC40957 represent human
XX superoxide dismutase 1 antisense inhibitor oligonucleotides
XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
SQ

```

CC	human superoxide dismutase 1 in human cells or tissues, and for treating
CC	a disease or condition associated with this enzyme (antisenese therapy),
CC	especially amyotrophic lateral sclerosis, a disease or condition arising
CC	from aberrant apoptosis and a hyperproliferative disorder. It may also be
CC	used in diagnostics, therapeutics and as a research reagent, e.g.
CC	prophylactically to prevent or delay infection, inflammation or tumour
CC	formation. Sequences given in records ACC40880-ACC40957 represent human
CC	superoxide dismutase 1 antisense inhibitor oligonucleotides
XX	
SQ	Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
	Query Match            2.3%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred.No. 84;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	404 ATTGGCGGCACACTGGTGGT 423
Db	20 ATTGGCGGCACACTGGTGGT 1
RESULT 103	
ACC40910/c	
ID	ACC40910 standard; DNA; 20 BP.
XX	
AC	ACC40910;
XX	
DT	23-MAY-2003 (first entry)
XX	
DE	Human superoxide dismutase 1 antisense inhibitor # ISIS 150464.
XX	
KW	Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
KW	antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
KW	hyperproliferative disorder; therapy; infection; inflammation; tumour;
KW	ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PH	Key Location/Qualifiers
FT	modified_base 1..20
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate linkages. All cytosines are 5-
FT	methylcytosine"
FT	modified_base 1..5
FT	/tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
PN	WO2003000707-A2.
XX	
PD	03-JAN-2003.
XX	
PF	19-JUN-2002; 2002WO-US019664.
XX	
PR	21-JUN-2001; 2001US-00888360.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Bennett FC, Dobie K;
XX	
DR	WPI; 2003-184032/18.
XX	
PT	Novel antisense compounds targeted to nucleic acids encoding human
PT	superoxide dismutase 1, for modulating expression of the dismutase and
PT	treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX	
PS	Claim 3; Page 77; 107pp; English.
XX	

CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 GATCGCCCAATAACATTCC 536

Db 20 GATCGCCCAATAACATTCC 1

RESULT 104

ACC40933/c

ID ACC40933 standard; DNA; 20 BP.

AC ACC40933;

XX

DT 23-MAY-2003 (first entry)

XX

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150487.

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

OS Homo sapiens.

XX Synthetic.

OS

XX Key Location/Qualifiers

FH modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT methylcytosine"

FT 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT 15..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT W02003000707-A2.

XX

XX 03-JAN-2003.

XX

XX 19-JUN-2002; 2002NO-US019664.

XX

XX 21-JUN-2001; 2001US-00888360.

XX

XX (ISIS-) ISIS PHARM INC.

PA

XX

PI Bennett FC, Dobie K;

XX

DR WPI; 2003-184032/18.

XX

PT Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.

XX

PS Example 15; Page 77; 107pp; English.

XX

XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX

SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 805 TGTCATTCAAGCCTGTGAAT 824

Db 20 TGTCATTCAAGCCTGTGAAT 1

RESULT 105

ACC40880/c

ID ACC40880 standard; DNA; 20 BP.

AC ACC40880;

XX

DT 23-MAY-2003 (first entry)

XX

DE Human superoxide dismutase 1 antisense inhibitor # ISIS 146143.

XX

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antiinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.

XX

OS Homo sapiens.

OS

XX Synthetic.

XX

XX Key Location/Qualifiers

FH modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate linkages. All cytosines are 5-

FT methylcytosine"

FT 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT

```

FT XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003000707-A2.
XX
XX PD 03-JAN-2003.
XX
XX PF 19-JUN-2002; 2002WO-US019664.
XX
XX PR 21-JUN-2001; 2001US-00888360.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Bennett FC, Dobie K;
XX
XX DR WPI; 2003-184032/18.
XX
XX PS Novel antisense compounds targeted to nucleic acids encoding human
    superoxide dismutase 1, for modulating expression of the dismutase and
    treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Claim 3; Page 76; 107pp; English.
XX
XX CC The invention relates to a compound of 8-50 nucleobases in length,
    targeted to a nucleic acid molecule encoding human superoxide dismutase
    1. The compound specifically hybridises with and inhibits the expression
    of human superoxide dismutase 1 by hybridising with at least an 8-
    nucleobase portion of the nucleic acid molecule encoding the active site
    of the enzyme. The activity of compounds of the invention may be
    described as neuroprotective, cytostatic and antiinflammatory. The
    mechanism of action of compounds of the invention is antisense inhibition
    of human superoxide dismutase 1 expression by chimeric phosphorothioate
    oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
    Compounds of the invention are useful for inhibiting the expression of
    human superoxide dismutase 1 in human cells or tissues, and for treating
    a disease or condition associated with this enzyme (antisense therapy),
    especially amyotrophic lateral sclerosis, a disease or condition arising
    from aberrant apoptosis and a hyperproliferative disorder. It may also be
    used in diagnostics, therapeutics and as a research reagent, e.g.
    prophylactically to prevent or delay infection, inflammation or tumour
    formation. Sequences given in records ACC40880-ACC40957 represent human
    superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX SQ Sequence 20 BP; 4 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
    Query Match 2.3%; Score 20; DB 1; Length 20;
    Best Local Similarity 100.0%; Pred. No. 84;
    Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 73 GAAGGCCGTCGTCGTCGTA 92
    |||||
DB 20 GAAGGCCGTCGTCGTCGTA 1
    |||||

RESULT 106
ACC40907/c
ID ACC40907 standard; DNA; 20 BP.
XX
XX AC ACC40907;
XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150461.
XX
XX KW Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
    antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
    hyperproliferative disorder; therapy; infection; inflammation; tumour;
    ss.
XX
XX OS Homo sapiens.
XX
XX SY Synthetic.
XX
XX FH Key Location/Qualifiers
XX
XX modified_base 1..20

```

```

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT FT methylcytosine"
FT FT 1..5
FT FT /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT 16..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX PN WO2003000707-A2.
XX
XX PD 03-JAN-2003.
XX
XX PF 19-JUN-2002; 2002WO-US019664.
XX
XX PR 21-JUN-2001; 2001US-00888360.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX XX Bennett FC, Dobie K;
XX
XX DR WPI; 2003-184032/18.
XX
XX PT Novel antisense compounds targeted to nucleic acids encoding human
    superoxide dismutase 1, for modulating expression of the dismutase and
    treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX PS Claim 3; Page 77; 107pp; English.
XX
XX CC The invention relates to a compound of 8-50 nucleobases in length,
    targeted to a nucleic acid molecule encoding human superoxide dismutase
    1. The compound specifically hybridises with and inhibits the expression
    of human superoxide dismutase 1 by hybridising with at least an 8-
    nucleobase portion of the nucleic acid molecule encoding the active site
    of the enzyme. The activity of compounds of the invention may be
    described as neuroprotective, cytostatic and antiinflammatory. The
    mechanism of action of compounds of the invention is antisense inhibition
    of human superoxide dismutase 1 expression by chimeric phosphorothioate
    oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
    Compounds of the invention are useful for inhibiting the expression of
    human superoxide dismutase 1 in human cells or tissues, and for treating
    a disease or condition associated with this enzyme (antisense therapy),
    especially amyotrophic lateral sclerosis, a disease or condition arising
    from aberrant apoptosis and a hyperproliferative disorder. It may also be
    used in diagnostics, therapeutics and as a research reagent, e.g.
    prophylactically to prevent or delay infection, inflammation or tumour
    formation. Sequences given in records ACC40880-ACC40957 represent human
    superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
    Query Match 2.3%; Score 20; DB 1; Length 20;
    Best Local Similarity 100.0%; Pred. No. 84;
    Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 409 CCGCACACTGGTGGTCCATG 428
    |||||
DB 20 CCGCACACTGGTGGTCCATG 1
    |||||

RESULT 107
ACC40927/c
ID ACC40927 standard; DNA; 20 BP.
XX
XX AC ACC40927;
XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human superoxide dismutase 1 antisense inhibitor # ISIS 150481.

```

XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW 86.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 XX  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT \*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..15  
 FT \*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT \*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT  
 XX WO2003000707-A2.  
 PN  
 XX  
 XX 03-JAN-2003.  
 PD  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 PF  
 XX  
 XX 21-JUN-2001; 2001US-00889360.  
 PR  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 XX  
 XX Bennett FC, Dobie K;  
 PI  
 XX  
 XX WPI; 2003-184032/18.  
 DR  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 PT  
 XX  
 PS Claim 3; Page 77; 107pp; English.  
 CC  
 CC The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 SQ Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;  
 Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 761 CAGACTTAATCAGATGG 780  
 |||||  
 DB 20 CAGACTTAATCAGATGG 1

RESULT 108  
 ADQ80681/c  
 ID ADQ80681 standard; DNA; 20 BP.  
 XX  
 AC ADQ80681;  
 XX  
 XX 21-OCT-2004 (first entry)  
 DT  
 XX Human cytosolic superoxide dismutase 1 RT-PCR primer, hSODc-antisense.  
 DE  
 XX Survival; neuron; tyrosine hydroxylase; tyrosine 3-monooxygenase; TH;  
 KW anti-apoptotic; Bcl-XL; neurological disorder; neuroprotective; TH;  
 KW neotropic; antiparkinsonian; transplantation; drug screening;  
 KW gene profiling; CNS disorder; neurodegenerative disease; primer; ss;  
 KW hSOD1; RT-PCR; human.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO2004062554-A2.  
 PN  
 XX 29-JUL-2004.  
 PD  
 XX  
 XX 07-JAN-2004; 2004WO-DK000008.  
 PF  
 XX 08-JAN-2003; 2003US-0438719P.  
 PR  
 XX 11-APR-2003; 2003DK-00000581.  
 PR  
 XX 22-APR-2003; 2003US-0464546P.  
 XX  
 XX (NSGE-) NSGENE AS.  
 PA  
 XX Martinez-Serrano A, Liste I, Villa A;  
 PI  
 XX WPI; 2004-544027/52.  
 DR  
 XX  
 XX Enhancing the survival of neurons or cells expressing tyrosine  
 PT hydroxylase (TH) for treating neurodegenerative disorders, comprises  
 PT contacting neurons or TH expressing cells with Bcl-XL or its functional  
 PT equivalent.  
 PT  
 XX  
 PS Example 2; Page 42; 108pp; English.  
 CC  
 CC The invention relates to a novel method for enhancing the survival of  
 CC neurons and/or of cells expressing tyrosine hydroxylase (EC 1.14.16.2 -  
 CC Tyrosine 3-monooxygenase) (TH + ). The method comprises contacting a  
 CC population of cells with Bcl-XL or its functional equivalent, where the  
 CC population of cells is selected from: neurons or cells capable of  
 CC differentiating into neurons; or TH expressing cells or cells capable of  
 CC differentiating into TH expressing cells. The invention further  
 CC comprises: a composition of cells obtainable by the method above; a  
 CC composition of isolated mammalian cells overexpressing the anti-apoptotic  
 CC Bcl-XL protein; a neural progenitor cell; a differentiated dopaminergic  
 CC neuron; an implantable cell culture device comprising: a semi-permeable  
 CC membrane permitting the diffusion of a biologically active protein  
 CC through it; and a composition of cells selected from above; a lentiviral  
 CC vector particle being produced based on a lentiviral transfer vector;  
 CC enhancing the survival of TH + cells in vivo; a retroviral particle being  
 CC produced based on a retroviral transfer vector; enhancing the survival of  
 CC in vivo differentiated dopaminergic neurons; a packaging cell line  
 CC capable of producing an infective vector particle; a packaging cell line  
 CC capable of producing an infective vector particle; treatment of a  
 CC neurological disorder; a fusion protein comprising the Bcl-XL sequence  
 CC comprising 233 amino acids ADQ80670 or its functional equivalent and a  
 CC membrane translocation signal; an expression vector comprising a  
 CC polynucleotide sequence coding for the fusion protein and a promoter  
 CC sequence capable of directing the expression of the fusion protein in a  
 CC host cell; a host cell comprising the expression vector; and producing  
 CC the fusion protein. The compositions of the invention have  
 CC neuroprotective, neotropic, and antiparkinsonian activities. The cells  
 CC are useful for transplantation, drug screening, gene profiling, or for  
 CC the preparation of a medicament useful for the treatment of a CNS  
 CC disorder. The CNS disorder is a neurodegenerative disease involving

CC lesioned and traumatic neurons, including traumatic lesions of peripheral  
 CC nerves, the medulla, the spinal chord, cerebral ischaemic neuronal  
 CC damage, neuropathy, peripheral neuropathy, Alzheimer's disease,  
 CC Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis,  
 CC or memory impairment connected to dementia. The method is useful for  
 CC enhancing the survival of neurons and/or of cells expressing tyrosine  
 CC hydroxylase for the treatment of neurodegenerative disorders. This  
 CC polynucleotide sequence represents a primer used in the exemplification  
 CC of the invention.

XX  
 SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 538 TTGGATGTAGTCTGAGGCC 557  
 Db 20 TTGGATGTAGTCTGAGGCC 1

RESULT 109

ADR42714

ID ADR42714 standard; DNA; 20 BP.

XX AC

ADR42714;

XX AC

04-NOV-2004 (first entry)

XX DT

XX DE

XX DE

XX KW

ss; primer; antiparkinsonian; nootropic; neuroprotective;

KW alpha peroxisome proliferator-activated receptor agonist;

KW acylated glycerol; neurodegenerative disorder; Parkinson's disease;

KW Alzheimer's disease; plate sclerosis; gene expression;

KW super-oxide dismutase; catalase; glutathione peroxidase; PCR primer;

KW beta-actin; gene analysis; cyclophilin.

XX OS

Homo sapiens.

XX PI

FR2850870-A1.

XX PN

13-AUG-2004.

XX PD

12-FEB-2003; 2003FR-00001691.

XX PF

12-FEB-2003; 2003FR-00001691.

XX PR

(GENF-) GENFIT SA.

XX PA

Darteil R, Caumont BK, Najib J;

XX PI

WPI; 2004-583505/57.

XX DR

Use of acylated glycerols and their nitrogen and sulfur analogs for the

XX PT

prevention and treatment of neurodegenerative disorders, e.g. Parkinson's

XX PT

disease.

XX PS

Example 27; Page 119; 144pp; French.

XX CC

The invention relates to the use of acylated glycerols, and their

XX CC

nitrogen and sulfur analogue (I), their optical and geometric isomers,

XX CC

racemates, salts, hydrates, and mixtures, for the prevention and

XX CC

treatment of neurodegenerative disorders. The compounds (I) are used for

XX CC

the prevention and treatment of neurodegenerative diseases such as

XX CC

Parkinson's, Alzheimer's, and plate sclerosis. In an example of the

XX CC

invention, the compounds are tested for their effects on the gene

XX CC

expression of several genes including super-oxide dismutase (SOD),

XX CC

catalase, glutathione peroxidase and other anti-oxidant genes. This

XX CC

sequence corresponds to a PCR primer to amplify the SOD gene for gene

analysis.

XX SQ

Sequence 20 BP; 7 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 84;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 263 CCTCTATCCAGAAAACACGG 282  
 Db 1 CCTCTATCCAGAAAACACGG 20

RESULT 110

ADR42715/c

ID ADR42715 standard; DNA; 20 BP.

XX AC

ADR42715;

XX AC

04-NOV-2004 (first entry)

XX DT

XX DE

XX DE

XX KW

SOD gene analysis PCR primer #2 from acetylated glycerol activation.

KW ss; primer; antiparkinsonian; nootropic; neuroprotective;

KW alpha peroxisome proliferator-activated receptor agonist;

KW acylated glycerol; neurodegenerative disorder; Parkinson's disease;

KW Alzheimer's disease; plate sclerosis; gene expression;

KW super-oxide dismutase; catalase; glutathione peroxidase; PCR primer;

KW beta-actin; gene analysis; cyclophilin.

XX OS

Homo sapiens.

XX PI

FR2850870-A1.

XX PN

13-AUG-2004.

XX PD

12-FEB-2003; 2003FR-00001691.

XX PF

12-FEB-2003; 2003FR-00001691.

XX PR

(GENF-) GENFIT SA.

XX PA

Darteil R, Caumont BK, Najib J;

XX PI

WPI; 2004-583505/57.

XX DR

Use of acylated glycerols and their nitrogen and sulfur analogs for the

XX PT

prevention and treatment of neurodegenerative disorders, e.g. Parkinson's

XX PT

disease.

XX PS

Example 27; Page 119; 144pp; French.

XX CC

The invention relates to the use of acylated glycerols, and their

XX CC

nitrogen and sulfur analogue (I), their optical and geometric isomers,

XX CC

racemates, salts, hydrates, and mixtures, for the prevention and

XX CC

treatment of neurodegenerative disorders. The compounds (I) are used for

XX CC

the prevention and treatment of neurodegenerative diseases such as

XX CC

Parkinson's, Alzheimer's, and plate sclerosis. In an example of the

XX CC

invention, the compounds are tested for their effects on the gene

XX CC

expression of several genes including super-oxide dismutase (SOD),

XX CC

catalase, glutathione peroxidase and other anti-oxidant genes. This

XX CC

sequence corresponds to a PCR primer to amplify the SOD gene for gene

XX CC

analysis.

XX SQ

Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 84;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 536 CCTTGGATGTAGTCTGAGGC 555  
 Db 20 CCTTGGATGTAGTCTGAGGC 1

RESULT 111



AAQ67477/c  
 XX AAQ67477 standard; DNA; 21 BP.  
 XX AC AAQ67477;  
 XX XX  
 XX 25-MAR-2003 (revised)  
 XX DT 31-MAY-1995 (first entry)  
 XX XX  
 XX DE PCR primer for human SOD1 exon 1.  
 XX XX  
 XX Human superoxide dismutase; hSOD1; neurodegeneration;  
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;  
 KW Hallervorden-Spatz disease; olivopontocerebellar atrophy;  
 KW familial amyotrophic lateral sclerosis; FALS; diagnosis; mutant SOD;  
 KW SSCP analysis; ss.  
 XX XX  
 XX Synthetic.  
 XX OS  
 XX WO9419493-A1.  
 XX PN  
 XX PD 01-SEP-1994.  
 XX XX  
 XX PF 28-FEB-1994; 94WO-US0002089.  
 XX XX  
 XX PR 26-FEB-1993; 93US-00023980.  
 XX XX  
 XX PA (GEHO ) GEN HOSPITAL CORP.  
 XX PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 XX XX  
 XX PI Brown R, Horvitz HR, Rosen DR;  
 XX DR WPI; 1994-294353/36.  
 XX XX  
 XX PT Diagnosis, treatment and prevention of diseases of cell death - e.g.  
 XX PT amyotrophic lateral sclerosis, which are the result of e.g. decreased SOD  
 XX PT activity.  
 XX XX  
 XX PS Claim 8; Fig 5; 94pp; English.  
 XX CC  
 XX The presence of a mutation in a gene encoding a superoxide dismutase  
 CC (SOD1, SOD2 or SOD3) indicates an increased likelihood of developing a  
 CC cell death disease, specifically a neurodegenerative disease. The DNA can  
 CC be analysed to detect mutant SOD sequences. Analysis is pref. preceded by  
 CC a PCR amplification step. AAQ67476-AAQ67485 are examples of PCR primers  
 CC which are useful for diagnosis of diseases linked to SOD1 mutations.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX XX  
 XX SQ Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
 XX  
 Query Match 2.3%; Score 20; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 85;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 118 CATCAATTCGAGCAGG 137  
 Db 21 CATCAATTCGAGCAGG 2  
 RESULT 112  
 AAV73827/c  
 ID AAV73827 standard; DNA; 21 BP.  
 XX AC AAV73827;  
 XX XX  
 XX DT 24-FEB-1999 (first entry)  
 XX XX  
 XX DE Human SOD1 exon 1 PCR primer #2.  
 XX XX  
 XX SOD1; SOD2; SOD3; Cu/Zn; superoxide dismutase; mitochondrial; treatment;  
 KW extracellular; neurodegenerative disease; amyotrophic lateral sclerosis;  
 KW familial; ALS; PCR primer; ss.  
 XX XX  
 XX Synthetic.

OS Homo sapiens.  
 XX US5849290-A.  
 XX PN  
 XX PD 15-DEC-1998.  
 XX XX  
 XX PF 07-JUN-1995; 95US-00486953.  
 XX XX  
 XX PR 26-FEB-1993; 93US-00023980.  
 XX PR 28-FEB-1994; 94US-00204052.  
 XX XX  
 XX PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 XX PA (GEHO ) GEN HOSPITAL CORP.  
 XX XX  
 XX PI Rosen DR, Brown R, Horvitz HR;  
 XX DR WPI; 1999-069657/06.  
 XX XX  
 XX PT Treatment of neurodegenerative disease - by administering super-oxide  
 XX PT dismutase.  
 XX XX  
 XX PS Disclosure; Fig 5; 53pp; English.  
 XX CC  
 XX AAV73826-V73835 are PCR primers used in the amplification of a novel  
 CC human SOD1 gene which encodes a Cu/Zn SOD (superoxide dismutase) protein.  
 CC This protein can be used in a method for treating a neurodegenerative  
 CC disease particularly familial amyotrophic lateral sclerosis (ALS)  
 XX XX  
 XX SQ Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
 XX  
 Query Match 2.3%; Score 20; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 85;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 118 CATCAATTCGAGCAGG 137  
 Db 21 CATCAATTCGAGCAGG 2  
 RESULT 113  
 ADOS5690/c  
 ID ADOS5690 standard; DNA; 21 BP.  
 XX AC ADOS5690;  
 XX XX  
 XX DT 15-JUL-2004 (first entry)  
 XX XX  
 XX DE Human cytosolic superoxide dismutase (Cu/ZnSOD) DNA, SOD1 PCR primer #2.  
 XX KW Human; cytosolic superoxide dismutase; Cu/ZnSOD; SOD; SOD1; PCR; ss;  
 KW neurodegenerative disease; cell death disease; FALS; neoplasm; primer.  
 XX OS Homo sapiens.  
 XX XX  
 XX PN US6723893-B1.  
 XX PD 20-APR-2004.  
 XX XX  
 XX PF 28-FEB-1994; 94US-00204052.  
 XX XX  
 XX PR 26-FEB-1993; 93US-00023980.  
 XX XX  
 XX PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 XX PA (GEHO ) GEN HOSPITAL CORP INC.  
 XX XX  
 XX PI Brown R, Horvitz HR, Rosen DR;  
 XX DR WPI; 2004-326924/30.  
 XX XX  
 XX New transgenic mouse having somatic and germ cells containing a transgene  
 PT encoding and expressing a neurodegenerative disease-causing mutant SOD-1  
 PT polypeptide, useful for research or drug development.  
 XX XX

PS Disclosure; SEQ ID NO 5; 54pp; English.

XX The invention relates to a transgenic mouse having somatic and germ cells containing a transgene encoding and expressing a neurodegenerative disease-causing mutant SOD1 polypeptide. The invention also relates to a method of diagnosing an increased likelihood of developing cell death disease in a patient, a kit for the diagnosis of cell death disease in a patient, a method of treating a patient with a disease involving a mutant SOD encoding gene, antibodies reactive with a FALS polypeptide, a method of treating a patient with a neoplasm, a bacterial or yeast cell containing a purified nucleic acid derived from a FALS gene, a purified DNA encoding a purified FALS polypeptide and a purified FALS polypeptide. The SOD1 polypeptide is a murine or human SOD1 polypeptide. The expression of the mutant polypeptide is under the regulation of the wild-type promoter. The transgenic mouse is useful for research or drug development. This sequence represents a PCR primer used to amplify SOD1 DNA encoding the human cytosolic superoxide dismutase (Cu/ZnSOD) polypeptide.

XX Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 118 CATCAATTCGAGCAGAGG 137  
Db 21 CATCAATTCGAGCAGAGG 2

RESULT 114  
ADO43049  
ID ADO43049 standard; RNA; 25 BP.  
XX ADO43049;  
AC ADO43049;  
XX ADO43049;  
DT 12-AUG-2004 (first entry)  
XX Short interfering RNA (sense) targeted to wild-type SOD allele (P11).  
DE Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
KW short interfering RNA; siRNA; RNA interference; gene silencing;  
KW DNA-RNA hybrid; human; ss.  
XX Homo sapiens.  
OS Homo sapiens.  
FH Key Location/Qualifiers  
FT modified\_base 20..25  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= T"  
FT /note= "In Fig 1A, bases 22-25 are absent"  
XX WO2004042027-A2.  
XX 21-MAY-2004.  
XX 04-NOV-2003; 2003WO-US035009.  
XX 04-NOV-2002; 2002US-0423507P.  
XX 18-JUL-2003; 2003US-0488283P.  
XX (UYMA-) UNIV MASSACHUSETTS.  
XX Xu Z, Zamore PD;  
XX WPI; 2004-390611/36.  
XX Inhibiting expression of a target allele in a cell comprising at least two different alleles of a gene, for treating CNS disorders, comprises administering to the cell an siRNA specific for the target allele.  
PS Claim 14; SEQ ID NO 9; 61pp; English.

XX The present invention provides methods of specifically inhibiting the expression of a mutant allele, while preserving the expression of a co-expressed wild-type allele, using RNA interference (RNAi). The methods are useful for treating a subject having a disorder correlated with the presence of a dominant gain of function mutant allele, e.g. amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and Parkinson's disease (claimed). Small interfering RNAs (siRNA) and small hairpin RNAs (shRNA) are provided that selectively suppress mutant, but not wild-type, expression of copper zinc superoxide dismutase (SOD1), which causes inherited ALS. In an example from the invention, an allele of SOD1 in which guanosine 256 (relative to the start of translation) was mutated to cytosine, generating a Gly to Arg (G85R) mutation, was selected. 2 Sets of 3 siRNAs ADO43041-ADO43046 and ADO43049-ADO43054, each targeting either wild-type ADO43047 or mutant ADO43048 SOD1 mRNA, were designed. The mutated nucleotide was positioned near the predicted site of SOD1 mRNA cleavage, i.e. position 9 (P9), 10 (P10) or 11 (P11) relative to the 5' end of the antisense strand of the siRNA. The present sequence is the sense strand of wild-type siRNA P11; the antisense sequence is also provided ADO43050. Each of the 6 siRNAs cleaved the corresponding target RNA, although with different efficiencies. P11 was less efficient at cleaving the mRNA than wild-type P9 and P10 siRNAs.

XX Sequence 25 BP; 5 A; 3 C; 7 G; 6 T; 4 U; 0 Other;

Query Match 2.3%; Score 20; DB 1; Length 25;  
Best Local Similarity 80.0%; Pred. No. 89;  
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGCAATCTGACT 331  
Db 1 GAGACUUGGGCAUUGAGCT 20

RESULT 115  
ABQ75418  
ID ABQ75418 standard; DNA; 23 BP.  
XX ABQ75418;  
AC ABQ75418;  
XX 06-NOV-2002 (first entry)  
XX CuZn superoxide dismutase (CuZn-SOD) probe SEQ ID NO:15.  
DE AOP-1; cardiant; neurotropic; neuroprotective; antirheumatic; nephrotropic;  
KW hepatotropic; heart disease; neurodegenerative disease; rheumatism;  
KW kidney disease; liver disease; CuZn superoxide dismutase; CuZn-SOD;  
KW probe; ss.  
XX Synthetic.  
OS Synthetic.  
XX WO200264169-A1.  
XX 22-AUG-2002.  
XX 18-FEB-2002; 2002WO-JP001358.  
XX 16-FEB-2001; 2001JP-00041003.  
XX (SUNR ) SUNTORY LTD.  
XX (SUNR ) SUNTORY BIOMEDICAL RES LTD.  
XX Hattori F, Sugimura K, Furuya M;  
XX WPI; 2002-657567/70.  
XX Remedies for treating diseases associated with a decrease in expression of AOP-1 gene or AOP-1, also drug screening with the protein and encoded gene, applicable e.g. in heart diseases, neurodegenerative diseases and rheumatism.  
XX Example 3; Page 32; 96pp; Japanese.



XX Disclosure; Page 16; 38pp; English.

PS The present invention relates to a method for suppressing gene expression

CC in cells, particularly eukaryotic cells. The method involves a new

CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter

CC sequence, a first target sequence that is essentially complementary to a

CC sequence of a target nucleic acid or its complement, a spacer sequence, a

CC second target sequence that is essentially complementary to the first

CC target sequence, and an RNA polymerase termination signal, where an RNA

CC transcribed from the nucleic acid can inhibit expression of the target

CC gene. The RNA transcribed from the nucleic acid may form a hairpin

CC structure. The polymerase is preferably RNA polymerase III (Pol III) and

CC the polymerase termination signal comprises a number of thymidines

CC sufficient for arresting Pol III activity. The nucleic acids and methods

CC are useful for suppressing gene expression in cells, or inhibiting the

CC synthesis of a target protein in a eukaryotic cell or in a cell of a

CC subject. The nucleic acids can be used for treating various diseases by

CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers

CC such as leukaemia, haemophilia, viral or bacterial infections, and

CC neurodegenerative diseases including Alzheimer's disease, Parkinson's

CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).

CC The present sequence represents a target DNA sequence that can be used to

CC inhibit expression of the human superoxide dismutase 1 (SOD1) G281C

CC (Gly93Ala) mutant gene.

XX Sequence 21 BP; 6 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

SQ

Query Match 2.2%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 99;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 335 GACAAAGATGCTGTGCCCGAT 355

DB 1 GACAAAGATGCTGTGCCCGAT 21

RESULT 118

AAAN81808/c

ID AAAN81808 standard; DNA; 22 BP.

XX

AC AAAN81808;

XX

DT 25-MAR-2003 (revised)

DT 20-SEP-1990 (first entry)

XX

DE Probe used to identify mutant RF M13 clone containing human copper-zinc

DE superoxidisedismutase (hSOD) Cys111 gene.

XX

KW Human copper-zinc superoxidisedismutase Cys111 gene; RF M13 clone;

KW M13rp8SODC111S DNA probe; thermostable mutein; enzyme; hybridisation.

XX

OS Synthetic.

XX

PN EP275202-A.

XX

PD 20-JUL-1988.

XX

PF 14-JAN-1988; 88EP-00300294.

XX

PR 15-JAN-1987; 87US-00003578.

XX

PA (CHIR ) CHIRON CORP.

XX

PI Hallelwell RA, Tekampolso P;

XX

DR WPI; 1988-199638/29.

XX

PT Mutein of human copper-zinc superoxidisedismutase - having cysteine

PT residues replaced with an uncharged amino acid, for increased

PT thermostability.

XX

PS Example; Page 5; 15pp; English.

XX RF M13 clone containing hSOD Cys111 gene is designated M13rp8SODC111S.

CC The probe is (32)P-labelled. The patent is for a mutein of hSOD in which

CC at least one of the cysteine residues at positions 6 and 111 is replaced

CC with an uncharged AA. DNA encoding the mutein is also claimed. Substn. of

CC the free cysteines of hSOD with uncharged AAs increases thermostability.

CC Cloning and sequencing of hSOD cDNA and the prodn. of hSOD in bacteria

CC and yeast are described in EP-138111. (Updated on 25-MAR-2003 to correct

CC PF field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated on 25-

CC MAR-2003 to correct PI field.)

XX Sequence 22 BP; 8 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

SQ

Query Match 2.2%; Score 19.4; DB 1; Length 22;

Best Local Similarity 95.2%; Pred. No. 1e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 368 GATTCTGTGATCACTCTCA 388

DB 22 GATTCTGTGATCACTCTCA 2

RESULT 119

ADO43051

ID ADO43051 standard; RNA; 25 BP.

XX

AC ADO43051;

XX

DT 12-AUG-2004 (first entry)

XX

DE Short interfering RNA (sense) targeted to wild-type SOD allele (P10).

XX

KW Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;

KW short interfering RNA; siRNA; RNA interference; gene silencing;

KW DNA-RNA hybrid; human; ss.

XX

OS Homo sapiens.

XX

PH Key Location/Qualifiers

FT modified\_base 20..25

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "OTHER= T"

FT /note= "In Fig 1A, bases 22-25 are absent"

XX

PN WO2004042027-A2.

XX

PD 21-MAY-2004.

XX

PF 04-NOV-2003; 2003WO-US035009.

XX

PR 04-NOV-2002; 2002US-0423507P.

PR 18-JUL-2003; 2003US-0488283P.

XX

PA (UYMA-) UNIV MASSACHUSETTS.

XX

PI Xu Z, Zamore PD;

XX

WPI; 2004-390611/36.

XX

PT Inhibiting expression of a target allele in a cell comprising at least

PT two different alleles of a gene, for treating CNS disorders, comprises

PT administering to the cell an siRNA specific for the target allele.

XX

PS Claim 14; SEQ ID NO 11; 61pp; English.

XX

CC The present invention provides methods of specifically inhibiting the

CC expression of a mutant allele, while preserving the expression of a co-

CC expressed wild-type allele, using RNA interference (RNAi). The methods

CC are useful for treating a subject having a disorder correlated with the

CC presence of a dominant gain of function mutant allele, e.g. amyotrophic

CC lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and

CC Parkinson's disease (claimed). Small interfering RNAs (siRNA) and small

CC hairpin RNAs (shRNA) are provided that selectively suppress mutant, but  
 CC not wild-type, expression of copper zinc superoxide dismutase (SOD1),  
 CC which causes inherited ALS. In an example from the invention, an allele  
 CC of SOD1 in which guanosine 256 (relative to the start of translation) was  
 CC mutated to cytosine, generating a Gly to Arg (G85R) mutation, was  
 CC selected. 2 Sets of 3 siRNAs ADO43041-ADO43046 and ADO43049-ADO43054,  
 CC each targeting either wild-type ADO43047 or mutant ADO43048 SOD1 mRNA,  
 CC were designed. The mutated nucleotide was positioned near the predicted  
 CC site of SOD1 mRNA cleavage, i.e. position 9 (p9), 10 (p10) or 11 (p11)  
 CC relative to the 5' end of the antisense strand of the siRNA. The present  
 CC sequence is the sense strand of wild-type siRNA p10; the antisense  
 CC sequence is also provided ADO43052. Each of the 6 siRNAs cleaved the  
 CC corresponding target RNA, although with different efficiencies. p10 wild-  
 CC type siRNA triggered rapid cleavage of the wild-type target, but also  
 CC produced significant cleavage of the mutant RNA, thus showing poor  
 CC selectivity.  
 XX  
 SQ Sequence 25 BP; 5 A; 2 C; 8 G; 6 T; 4 U; 0 Other;

Query Match 2.2%; Score 19.4; DB 1; Length 25;  
 Best Local Similarity 76.2%; Pred. No. 1e+02;  
 Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGACT 331  
 |||||:|||||:|||||:|||||:  
 Db 1 GGAGACUUGGGCAUAUGUATT 21

RESULT 120  
 ADE52415  
 ID ADE52415 standard; RNA; 23 BP.  
 XX  
 AC ADE52415;

29-JAN-2004 (first entry)

siRNA p9 sequence #1 for wild-type human SOD1 gene.

Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 target DNA sequence; RNA polymerase termination signal;  
 hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 haemostatic; virucide; antibacterial; neuroprotective; nootropic;  
 anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 small interfering RNA; siRNA; ss.

Homo sapiens.

US2003180756-A1.

25-SEP-2003.

21-NOV-2002; 2002US-00301516.

21-MAR-2002; 2002US-0366478P.

(SHIY/) SHI Y.

(SUIG/) SUI G.

Shi Y, Sui G;

WPI; 2003-852231/79.

New nucleic acids, useful for inhibiting the synthesis of a target  
 protein in a eukaryotic cell, or for treating various diseases by  
 inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 viral or bacterial infection.

Example 6; Fig 5A; 38pp; English.

The present invention relates to a method for suppressing gene expression

CC in cells, particularly eukaryotic cells. The method involves a new  
 CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 CC sequence, a first target sequence that is essentially complementary to a  
 CC sequence of a target nucleic acid or its complement, a spacer sequence, a  
 CC second target sequence that is essentially complementary to the first  
 CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a small interfering RNA (siRNA) that can  
 CC be used to target the wild-type human superoxide dismutase 1 (SOD1) gene.  
 XX  
 SQ Sequence 23 BP; 5 A; 3 C; 7 G; 2 T; 4 U; 2 Other;

Query Match 2.2%; Score 19.2; DB 1; Length 23;

Best Local Similarity 75.0%; Pred. No. 1.1e+02;

Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 312 GGAGACTTGGCAATGTGACT 331  
 |||||:|||||:|||||:|||||:  
 Db 1 GGAGACUUGGGCAUAUGUACD 20

RESULT 121  
 ADE52417

ID ADE52417 standard; RNA; 23 BP.

AC ADE52417;

29-JAN-2004 (first entry)

siRNA p11 sequence #1 for wild-type human SOD1 gene.

Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 target DNA sequence; RNA polymerase termination signal;  
 hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 haemostatic; virucide; antibacterial; neuroprotective; nootropic;  
 anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 small interfering RNA; siRNA; ss.

Homo sapiens.

US2003180756-A1.

25-SEP-2003.

21-NOV-2002; 2002US-00301516.

21-MAR-2002; 2002US-0366478P.

(SHIY/) SHI Y.

(SUIG/) SUI G.

Shi Y, Sui G;

WPI; 2003-852231/79.

New nucleic acids, useful for inhibiting the synthesis of a target  
 protein in a eukaryotic cell, or for treating various diseases by  
 inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 viral or bacterial infection.

XX Example 6; Fig 5A; 38pp; English.

PS The present invention relates to a method for suppressing gene expression

CC in cells, particularly eukaryotic cells. The method involves a new

CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter

CC sequence, a first target sequence that is essentially complementary to a

CC sequence of a target nucleic acid or its complement, a spacer sequence, a

CC second target sequence that is essentially complementary to the first

CC target sequence, and an RNA polymerase termination signal, where an RNA

CC transcribed from the nucleic acid can inhibit expression of the target

CC gene. The RNA transcribed from the nucleic acid may form a hairpin

CC structure. The polymerase is preferably RNA polymerase III (Pol III) and

CC the polymerase termination signal comprises a number of thymidines

CC sufficient for arresting Pol III activity. The nucleic acids and methods

CC are useful for suppressing gene expression in cells, or inhibiting the

CC synthesis of a target protein in a eukaryotic cell or in a cell of a

CC subject. The nucleic acids can be used for treating various diseases by

CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers

CC such as leukaemia, haemophilia, viral or bacterial infections, and

CC neurodegenerative diseases including Alzheimer's disease, Parkinson's

CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).

CC The present sequence represents a small interfering RNA (siRNA) that can

CC be used to target the wild-type human superoxide dismutase 1 (SOD1) gene.

XX

SQ Sequence 23 BP; 4 A; 2 C; 8 G; 2 T; 5 U; 2 Other;

Query Match 2.2%; Score 19.2; DB 1; Length 23;

Best Local Similarity 70.0%; Pred. No. 1.1e+02;

Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTGA 329

Db :|||||:|||||:|:

1 UGGAGACUUGGCAUGUGD 20

RESULT 122

AAAG60181/c

ID AAAG60181 standard; DNA; 19 BP.

XX AC AAAG60181;

XX 25-MAR-2003 (revised)

DT 15-AUG-1991 (first entry)

XX

DE Sequence of probe complementary to the base sequence corresponding to the

DE C-terminus of human Cu-Zn superoxide dismutase (SOD).

XX

KW Anti-inflammatory; regulatory gene; enzyme; ss.

XX Homo sapiens.

XX EP180964-A.

XX 14-MAY-1986.

XX 05-NOV-1985; 85EP-00114073.

XX 06-NOV-1984; 84JP-00232395.

XX (UBEI ) UBE IND LTD.

XX Kumahara H, Maruyama M, Anpelji S, Owa T;

XX WPI; 1986-126415/20.

XX Recombinant DNA for transforming microorganism - comprising regulatory

PT gene and human copper-zinc superoxidizedismutase structural gene.

XX Example; Page 16; 40pp; English.

PS

XX The claimed Cu-Zn SOD structural gene may be a cDNA derived from mRNA

CC sepd. from normal human tissues or a synthetic gene for the same AA SQ in

CC which the codons for some AAs are replaced by codons which are frequently

CC used in a host organism. The regulatory gene of the colicin E1 gene in

CC the present invention contains the base sequence from No. 143 to No.359

CC in AAG60182 as an essential segment. (Updated on 25-MAR-2003 to correct

CC PA field.) (Updated on 25-MAR-2003 to correct PI field.)

XX

SQ Sequence 19 BP; 4 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.2%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 511 AATTGGGATCGCCCAATAA 529

Db :|||||:|||||:|:

19 AATTGGGATCGCCCAATAA 1

RESULT 123

ABQ73056/c

ID ABQ73056 standard; DNA; 19 BP.

XX AC ABQ73056;

XX 24-SEP-2002 (first entry)

DT

XX

DE Cu/Zn SOD gene related PCR primer SEQ ID NO:4.

XX

KW Amyotrophic lateral sclerosis; ALS; transgenic rat; SOD; Cu/Zn SOD;

KW superoxide dismutase; PCR primer; ss.

XX

OS Rattus sp.

OS Synthetic.

XX JP2002142610-A.

XX 21-MAY-2002.

XX 07-NOV-2000; 2000JP-00339567.

XX 07-NOV-2000; 2000JP-00339567.

XX (TOHO-) TOHOKU TECHNOARCH KK.

XX WPI; 2002-552464/59.

XX

PT An amyotrophic lateral sclerosis model rat for investigation of its

PT pathology and onset mechanism with introduced exogenic variant Cu/Zn

PT superoxide dismutase.

XX

PS Example 1; Page 13; 28pp; Japanese.

XX

CC The present invention describes an amyotrophic lateral sclerosis (ALS)

CC model rat. Also described: (1) a transgenic rat or its progeny having a

CC DNA with integrated exogenic variant Cu/Zn superoxide dismutase (SOD)

CC gene; and (2) rat embryonic stem cells having human variant Cu/Zn SOD

CC gene sequence. The transgenic rat can be used in the investigation of the

CC pathology and the onset mechanism of ALS. The present sequence represents

CC a PCR primer which is used in an example from the present invention

XX

SQ Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GTCTGAGGCCCTTAATC 565

Db :|||||:|||||:|:

19 GTCTGAGGCCCTTAATC 1

RESULT 124

ADQ80680

ID ADQ80680 standard; DNA; 19 BP.

XX ADQ80680;  
XX 21-OCT-2004 (first entry)  
XX Human cytosolic superoxide dismutase (SOD)1 RT-PCR primer, hSODC-sense.  
XX  
XX Survival; neuron; tyrosine hydroxylase; tyrosine 3-monooxygenase; TH;  
KW anti-apoptotic; Bcl-XL; neurological disorder; neuroprotective; TH;  
KW neurotropic; antiparkinsonian; transplantation; drug screening;  
KW gene profiling; CNS disorder; neurodegenerative disease; primer; ss;  
KW hSOD1; RT-PCR; human.  
XX  
XX Homo sapiens.  
XX WO2004062554-A2.  
XX 29-JUL-2004.  
XX 07-JAN-2004; 2004WO-DK000008.  
XX 08-JAN-2003; 2003US-0438719P.  
XX 11-APR-2003; 2003DK-00000581.  
XX 22-APR-2003; 2003US-0464546P.  
XX (NSGE-) NSGENE AS.  
XX Martinez-Serrano A, Liste I, Villa A;  
XX WPI; 2004-544027/52.  
XX Enhancing the survival of neurons or cells expressing tyrosine  
PT hydroxylase (TH) for treating neurodegenerative disorders, comprises  
PT contacting neurons or TH expressing cells with Bcl-XL or its functional  
PT equivalent.  
XX  
XX Example 2; Page 42; 108pp; English.  
XX  
XX The invention relates to a novel method for enhancing the survival of  
CC neurons and/or of cells expressing tyrosine hydroxylase (EC 1.14.16.2 -  
CC Tyrosine 3-monooxygenase) (TH + ). The method comprises contacting a  
CC population of cells with Bcl-XL or its functional equivalent, where the  
CC population of cells is selected from: neurons or cells capable of  
CC differentiating into neurons; or TH expressing cells or cells capable of  
CC differentiating into TH expressing cells. The invention further  
CC comprises: a composition of cells obtainable by the method above; a  
CC composition of isolated mammalian cells overexpressing the anti-apoptotic  
CC Bcl-XL protein; a neural progenitor cell; a differentiated dopaminergic  
CC neuron; an implantable cell culture device comprising: a semi-permeable  
CC membrane permitting the diffusion of a biologically active protein  
CC through it; and a composition of cells selected from above; a lentiviral  
CC vector particle being produced based on a lentiviral transfer vector;  
CC enhancing the survival of TH + cells in vivo; a retroviral particle being  
CC produced based on a retroviral transfer vector; enhancing the survival of  
CC in vivo differentiated dopaminergic neurons; a packaging cell line  
CC capable of producing an infective vector particle; a packaging cell line  
CC capable of producing an infective vector particle; treatment of a  
CC neurological disorder; a fusion protein comprising the Bcl-XL sequence  
CC comprising 233 amino acids ADQ80670 or its functional equivalent and a  
CC membrane translocation signal; an expression vector comprising a  
CC polynucleotide sequence coding for the fusion protein and a promoter  
CC sequence capable of directing the expression of the fusion protein in a  
CC host cell; a host cell comprising the expression vector; and producing  
CC the fusion protein. The compositions of the invention have  
CC neuroprotective, neurotropic, and antiparkinsonian activities. The cells  
CC are useful for transplantation, drug screening, gene profiling, or for  
CC the preparation of a medicament useful for the treatment of a CNS  
CC disorder. The CNS disorder is a neurodegenerative disease involving  
CC lesioned and traumatic neurons, including traumatic lesions of peripheral  
CC nerves, the medulla, the spinal chord, cerebral ischaemic neuronal  
CC damage, neuropathy, peripheral neuropathy, Alzheimer's disease,  
CC Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis,  
CC or memory impairment connected to dementia. The method is useful for

CC enhancing the survival of neurons and/or of cells expressing tyrosine  
CC hydroxylase for the treatment of neurodegenerative disorders. This  
CC polynucleotide sequence represents a primer used in the exemplification  
CC of the invention.  
XX  
XX Sequence 19 BP; 3 A; 4 C; 7 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 2.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 48 GCGTGGCCTAGCGAGTTAT 66  
DB 1 GCGTGGCCTAGCGAGTTAT 19  
RESULT 125  
ADE52425/c  
ID ADE52425 standard; RNA; 23 BP.  
XX  
XX ADE52425;  
XX 29-JAN-2004 (first entry)  
XX  
XX siRNA pl1 sequence #2 for wild-type human SOD1 gene.  
XX  
XX Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
KW target DNA sequence; RNA polymerase termination signal;  
KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cystostatic;  
KW haemostatic; viricide; antibacterial; neuroprotective; neurotropic;  
KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
KW small interfering RNA; siRNA; ss.  
XX  
XX Homo sapiens.  
XX  
XX US2003180756-A1.  
XX 25-SEP-2003.  
XX 21-NOV-2002; 2002US-00301516.  
XX 21-MAR-2002; 2002US-0366478P.  
XX (SHY/) SHI Y.  
XX (SUIG/) SUI G.  
XX Shi Y, Sui G;  
XX WPI; 2003-852231/79.  
XX  
XX New nucleic acids, useful for inhibiting the synthesis of a target  
PT protein in a eukaryotic cell, or for treating various diseases by  
PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
PT viral or bacterial infection.  
XX  
XX Example 6; Fig 5A; 38pp; English.  
XX  
XX The present invention relates to a method for suppressing gene expression  
CC in cells, particularly eukaryotic cells. The method involves a new  
CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
CC sequence, a first target sequence that is essentially complementary to a  
CC sequence of a target nucleic acid or its complement, a spacer sequence, a  
CC second target sequence that is essentially complementary to the first  
CC target sequence, and an RNA polymerase termination signal, where an RNA  
CC transcribed from the nucleic acid can inhibit expression of the target  
CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
CC the polymerase termination signal comprises a number of thymidines  
CC sufficient for arresting Pol III activity. The nucleic acids and methods  
CC are useful for suppressing gene expression in cells, or inhibiting the

CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a small interfering RNA (siRNA) that can  
 CC be used to target the wild-type human superoxide dismutase 1 (SOD1) gene.

XX  
 SQ Sequence 23 BP; 5 A; 8 C; 2 G; 2 T; 4 U; 2 Other;

Query Match 2.2%; Score 19; DB 1; Length 23;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328  
 |||||  
 Db 19 TGGAGACTTGGCAATGTG 1

RESULT 126  
 ADE52424/c  
 ID ADE52424 standard; RNA; 23 BP.

XX AC ADE52424;

XX DT 29-JAN-2004 (first entry)

XX DE siRNA p10 sequence #2 for wild-type human SOD1 gene.

XX KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW small interfering RNA; siRNA; ss.

XX OS Homo sapiens.

XX US 2003180756-A1.

XX PD 25-SEP-2003.

XX PF 21-NOV-2002; 2002US-00301516.

XX PR 21-MAR-2002; 2002US-0366478P.

XX PA (SHIY/) SHI Y.

XX PA (SUIG/) SUI G.

XX PI Shi Y, Sui G;

XX WPI; 2003-852231/79.

XX PT New nucleic acids, useful for inhibiting the synthesis of a target  
 PT protein in a eukaryotic cell, or for treating various diseases by  
 PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 PT viral or bacterial infection.

XX PS Example 6; Fig 5A; 38pp; English.

XX CC The present invention relates to a method for suppressing gene expression  
 CC in cells, particularly eukaryotic cells. The method involves a new  
 CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 CC sequence, a first target sequence that is essentially complementary to a  
 CC second target sequence that is essentially complementary to the first  
 CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin

CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a small interfering RNA (siRNA) that can  
 CC be used to target the wild-type human superoxide dismutase 1 (SOD1) gene.

XX SQ Sequence 23 BP; 4 A; 8 C; 2 G; 2 T; 5 U; 2 Other;

Query Match 2.2%; Score 19; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 GGAGACTTGGGCAATGTGA 329  
 |||||  
 Db 19 GGAGACTTGGGCAATGTGA 1

RESULT 127

ADE52423/c

ID ADE52423 standard; RNA; 23 BP.

XX AC ADE52423;

XX DT 29-JAN-2004 (first entry)

XX DE siRNA p9 sequence #2 for wild-type human SOD1 gene.

XX KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW small interfering RNA; siRNA; ss.

XX OS Homo sapiens.

XX US 2003180756-A1.

XX PD 25-SEP-2003.

XX PF 21-NOV-2002; 2002US-00301516.

XX PR 21-MAR-2002; 2002US-0366478P.

XX PA (SHIY/) SHI Y.

XX PA (SUIG/) SUI G.

XX PI Shi Y, Sui G;

XX WPI; 2003-852231/79.

XX PT New nucleic acids, useful for inhibiting the synthesis of a target  
 PT protein in a eukaryotic cell, or for treating various diseases by  
 PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 PT viral or bacterial infection.

XX PS Example 6; Fig 5A; 38pp; English.

XX CC The present invention relates to a method for suppressing gene expression  
 CC in cells, particularly eukaryotic cells. The method involves a new  
 CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 CC sequence, a first target sequence that is essentially complementary to a  
 CC second target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin





PT two different alleles of a gene, for treating CNS disorders, comprises  
 PT administering to the cell an siRNA specific for the target allele.  
 XX  
 XX  
 PS Claim 14; SEQ ID NO 13; 61pp; English.  
 XX  
 CC The present invention provides methods of specifically inhibiting the  
 CC expression of a mutant allele, while preserving the expression of a co-  
 CC expressed wild-type allele, using RNA interference (RNAi). The methods  
 CC are useful for treating a subject having a disorder correlated with the  
 CC presence of a dominant gain of function mutant allele, e.g. amyotrophic  
 CC lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and  
 CC Parkinson's disease (claimed). Small interfering RNAs (siRNA) and small  
 CC hairpin RNAs (shRNA) are provided that selectively suppress mutant-, but  
 CC not wild-type, expression of copper zinc superoxide dismutase (SOD1),  
 CC which causes inherited ALS. In an example from the invention, an allele  
 CC of SOD1 in which guanosine 256 (relative to the start of translation) was  
 CC mutated to cytosine, generating a Gly to Arg (G85R) mutation, was  
 CC selected. 2 Sets of 3 siRNAs ADO43041-ADO43046 and ADO43049-ADO43054,  
 CC each targeting either wild-type ADO43047 or mutant ADO43048 SOD1 mRNA,  
 CC were designed. The mutated nucleotide was positioned near the predicted  
 CC site of SOD1 mRNA cleavage, i.e. position 9 (P9), 10 (P10) or 11 (P11)  
 CC relative to the 5' end of the antisense strand of the siRNA. The present  
 CC sequence is the sense strand of wild-type siRNA P9; the antisense  
 CC sequence is also provided ADO43054. Each of the 6 siRNAs cleaved the  
 CC corresponding target RNA, although with different efficiencies. P9 wild-  
 CC type siRNA triggered rapid cleavage of the wild-type target, but also  
 CC produced significant cleavage of the mutant RNA, thus showing poor  
 CC selectivity.  
 XX  
 SQ Sequence 25 BP; 4 A; 2 C; 8 G; 6 T; 5 U; 0 Other;

Query Match 2.2%; Score 19; DB 1; Length 25;  
 Best Local Similarity 73.7%; Pred. No. 1.1e+02;  
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328

DB 1 UGGAGACUUGGCAATGUG 19

RESULT 130  
 ADO43050/c  
 ID ADO43050 standard; RNA; 25 BP.

XX ADO43050;

XX 12-AUG-2004 (first entry)

XX Short interfering RNA (antisense) targeted to wild-type SOD (P11).

XX Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
 KW short interfering RNA; siRNA; RNA interference; gene silencing;  
 KW DNA-RNA hybrid; human; ss.

XX Homo sapiens.

XX Key Location/Qualifiers  
 FT modified\_base 20..25  
 FT /tag= a  
 FT /mod\_base= OTHER

FT /note= "OTHER= T"

FT /note= "In Fig 1A, bases 22-25 are absent"

XX WO2004042027-A2.

XX 21-MAY-2004.

XX 04-NOV-2003; 2003WO-US035009.

XX 04-NOV-2002; 2002US-0423507P.

XX 18-JUL-2003; 2003US-0488283P.

XX (UYMA-) UNIV MASSACHUSETTS.

XX Xu Z, Zamore PD;  
 XX WPI; 2004-390611/36.  
 XX  
 XX

XX Inhibiting expression of a target allele in a cell comprising at least  
 PT two different alleles of a gene, for treating CNS disorders, comprises  
 PT administering to the cell an siRNA specific for the target allele.

PS Claim 14; SEQ ID NO 10; 61pp; English.

XX The present invention provides methods of specifically inhibiting the  
 CC expression of a mutant allele, while preserving the expression of a co-  
 CC expressed wild-type allele, using RNA interference (RNAi). The methods  
 CC are useful for treating a subject having a disorder correlated with the  
 CC presence of a dominant gain of function mutant allele, e.g. amyotrophic  
 CC lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and  
 CC Parkinson's disease (claimed). Small interfering RNAs (siRNA) and small  
 CC hairpin RNAs (shRNA) are provided that selectively suppress mutant-, but  
 CC not wild-type, expression of copper zinc superoxide dismutase (SOD1),  
 CC which causes inherited ALS. In an example from the invention, an allele  
 CC of SOD1 in which guanosine 256 (relative to the start of translation) was  
 CC mutated to cytosine, generating a Gly to Arg (G85R) mutation, was  
 CC selected. 2 Sets of 3 siRNAs ADO43041-ADO43046 and ADO43049-ADO43054,  
 CC each targeting either wild-type ADO43047 or mutant ADO43048 SOD1 mRNA,  
 CC were designed. The mutated nucleotide was positioned near the predicted  
 CC site of SOD1 mRNA cleavage, i.e. position 9 (P9), 10 (P10) or 11 (P11)  
 CC relative to the 5' end of the antisense strand of the siRNA. The present  
 CC sequence is the guide (antisense) strand of wild-type siRNA P11; the  
 CC sense sequence is also provided ADO43049. Each of the 6 siRNAs cleaved  
 CC the corresponding target RNA, although with different efficiencies. P11  
 CC was less efficient at cleaving the mRNA than wild-type P9 and P10 siRNAs.

SQ Sequence 25 BP; 4 A; 7 C; 3 G; 6 T; 5 U; 0 Other;

Query Match 2.2%; Score 19; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGCAATGTGAC 330

DB 19 GAGACTTGGCAATGTGAC 1

RESULT 131

ADO43054/c

ID ADO43054 standard; RNA; 25 BP.

XX ADO43054;

XX 12-AUG-2004 (first entry)

XX Short interfering RNA (antisense) targeted to wild-type SOD allele (P9).

XX Superoxide dismutase; SOD; enzyme; amyotrophic lateral sclerosis;  
 KW short interfering RNA; siRNA; RNA interference; gene silencing;  
 KW DNA-RNA hybrid; human; ss.

XX Homo sapiens.

XX Key Location/Qualifiers  
 FT modified\_base 20..25  
 FT /tag= a  
 FT /mod\_base= OTHER

FT /note= "OTHER= T"

FT /note= "In Fig 1A, bases 22-25 are absent"

XX WO2004042027-A2.

XX 21-MAY-2004.

XX 04-NOV-2003; 2003WO-US035009.

PR 04-NOV-2002; 2002US-0423507P.  
 PR 18-JUL-2003; 2003US-0488283P.  
 XX  
 PA (UYMA-) UNIV MASSACHUSETTS.  
 XX  
 PI Xu Z, Zamore PD;  
 XX  
 DR WPI; 2004-390611/36.  
 XX  
 PT Inhibiting expression of a target allele in a cell comprising at least  
 PT two different alleles of a gene, for treating CNS disorders, comprises  
 PT administering to the cell an siRNA specific for the target allele.  
 XX  
 PS Claim 14; SEQ ID NO 14; 61pp; English.  
 XX  
 CC The present invention provides methods of specifically inhibiting the  
 CC expression of a mutant allele, while preserving the expression of a co-  
 CC expressed wild-type allele, using RNA interference (RNAi). The methods  
 CC are useful for treating a subject having a disorder correlated with the  
 CC presence of a dominant gain of function mutant allele, e.g. amyotrophic  
 CC lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, and  
 CC Parkinson's disease (claimed). Small interfering RNAs (siRNA) and small  
 CC hairpin RNAs (shRNA) are provided that selectively suppress mutant, but  
 CC not wild-type, expression of copper zinc superoxide dismutase (SOD1),  
 CC which causes inherited ALS. In an example from the invention, an allele  
 CC of SOD1 in which guanosine 256 (relative to the start of translation) was  
 CC mutated to cytosine, generating a Gly to Arg (G85R) mutation, was  
 CC selected. 2 Sets of 3 siRNAs ADO43041-ADO43046 and ADO43049-ADO43054,  
 CC each targeting either wild-type ADO43047 or mutant ADO43048 SOD1 mRNA,  
 CC were designed. The mutated nucleotide was positioned near the predicted  
 CC site of SOD1 mRNA cleavage, i.e. position 9 (P9), 10 (P10) or 11 (P11)  
 CC relative to the 5' end of the antisense strand of the siRNA. The present  
 CC sequence is the guide (antisense) strand of wild-type siRNA P9; the sense  
 CC sequence is also provided ADO43053. Each of the 6 siRNAs cleaved the  
 CC corresponding target RNA, although with different efficiencies. P9 wild-  
 CC type siRNA triggered rapid cleavage of the wild-type target, but also  
 CC produced significant cleavage of the mutant RNA, thus showing poor  
 CC selectivity.  
 XX  
 SQ Sequence 25 BP; 5 A; 8 C; 2 G; 6 T; 4 U; 0 Other;  
  
 Query Match 2.2%; Score 19; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 QY 310 TGGAGACTTGGGCAATGTG 328  
 Db |||||  
 19 TGGAGACTTGGGCAATGTG 1  
  
 RESULT 132  
 AAV01384/C  
 ID AAV01384 standard; DNA; 20 BP.  
 XX  
 AC AAV01384;  
 XX  
 DT 23-MAR-1998 (first entry)  
 XX  
 DE Superoxide dismutase 1 PCR primer for universal mammalian STS's.  
 XX  
 KW PCR primer; polymerase chain reaction; amplification; UM-STS;  
 KW universal mammalian sequence tagged site; genomic map; clone; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9731012-A1.  
 XX  
 PD 28-AUG-1997.  
 XX  
 PF 18-FEB-1997; 97WO-US002403.  
 XX  
 XX 22-FEB-1996; 96US-0012061P.  
 XX

PA (UNMI ) UNIV MICHIGAN.  
 PA (UNMS ) UNIV MICHIGAN STATE.  
 XX  
 PI Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;  
 XX  
 DR WPI; 1997-435083/40.  
 XX  
 PT New oligonucleotide primers amplifying gene regions conserved among  
 PT mammals - useful for developing genomic maps, isolating clones and making  
 PT cross-species comparisons.  
 XX  
 PS Claim 2; Page 13; 26pp; English.  
 XX  
 CC The present sequence represents a specifically claimed oligonucleotide  
 CC PCR primer. The oligonucleotide can be used for polymerase chain reaction  
 CC (PCR) amplification of DNA, specifically regions of specific genes that  
 CC are conserved among mammalian species, i.e. pairs of oligonucleotides  
 CC from the present specification represent universal mammalian sequence-  
 CC tagged site (UM-STS) primers. The primers are used to develop genomic  
 CC maps, to isolate clones from libraries, to make cross-species comparisons  
 CC and to develop additional genetic markers. UM-STS allow genomic  
 CC comparisons to be made between more species  
 XX  
 SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;  
  
 Query Match 2.1%; Score 18.4; DB 1; Length 20;  
 Best Local Similarity 95.0%; Pred. No. 1.3e+02;  
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
 QY 302 AGGCATGTTGGGACTTGGG 321  
 Db |||||  
 20 AGGCATGTTGGGACTTGGG 1  
  
 RESULT 133  
 ADD26381/C  
 ID ADD26381 standard; DNA; 24 BP.  
 XX  
 AC ADD26381;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE RT-PCR primer #2 for DNA encoding human interleukin 1-14.08.  
 XX  
 DE Human; interleukin 1-14.08; cancer; infection;  
 KW systemic lupus erythematosus; SLE; rheumatoid arthritis; nephritis;  
 KW pernicious anaemia; reverse transcriptase-PCR; RT-PCR; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN CN1382733-A.  
 XX  
 PD 04-DEC-2002.  
 XX  
 PF 26-APR-2001; 2001CN-00112731.  
 XX  
 PR 26-APR-2001; 2001CN-00112731.  
 XX  
 PA (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.  
 XX  
 PI Mao Y, Xie Y;  
 XX  
 DR WPI; 2003-279524/28.  
 XX  
 PT Polypeptide-human interleukin 1-14.08 and polynucleotide for coding it.  
 XX  
 PS Example 3; Page 19; 31pp; Chinese.  
 XX  
 CC The present invention relates to the isolation of human interleukin 1-  
 CC 14.08, and the the polynucleotide encoding it. Also described is the  
 CC process for preparing the protein by DNA recombination and the  
 CC application of the polypeptide and polynucleotide in treating various  
 CC diseases such as cancer, infection, systemic lupus erythematosus (SLE),

CC rheumatoid arthritis, nephritis, and pernicious anaemia. The present  
CC sequence represents a reverse transcriptase (RT)-PCR primer used in the  
CC examples of the present invention.

SQ Sequence 24 BP; 7 A; 3 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 2.1%; Score 18.2; DB 1; Length 24;  
Best Local Similarity 87.0%; Pred. No. 1.4e+02;  
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 768 AATACACAGATGGTATTAACT 790  
Db 23 AATACACAGATGGCATTAACT 1

RESULT 134  
ADT66494/C  
ID ADT66494 standard; DNA; 18 BP.

XX ADT66494;

XX 16-DEC-2004 (first entry)

XX PCR primer for CuZn SOD SEQ ID NO:8.

XX ss; primer; PCR; CuZn SOD; cancer; antioxidant gene expression analysis;  
KW irradiation therapy.

XX Synthetic.

XX KR2004025183-A.

XX 24-MAR-2004.

XX 18-SEP-2002; 2002KR-00057027.

XX 18-SEP-2002; 2002KR-00057027.

XX (PARK/) PARK Y M.

XX Choi EM, Han MY, Hwang SY, Jun HJ, Kim YH, Park JH, Park YM;

XX WPI; 2004-495260/47.

XX Method and DNA chip for monitoring response of cancer patients to  
PT irradiation therapy using antioxidant gene expression analysis.

XX Claim 2; SEQ ID NO 8; 22pp; Korean.

XX The invention relates to a novel method and a DNA chip for monitoring a  
CC response of cancer patients to irradiation therapy using antioxidant gene  
CC expression analysis, thereby accurately anticipating the response to  
CC irradiation therapy and minimizing adverse side-effects thereof. A method  
CC for monitoring a response of cancer patients to irradiation therapy  
CC comprises: collecting a peripheral blood cell from a human; irradiating  
CC the peripheral blood cell; extracting RNA according to the time period;  
CC preparing DNA from the RNA; hybridizing the DNA with antioxidant enzyme  
CC cDNA; amplifying the hybridized DNA using one or more pairs of primers  
CC selected from: DNA fragments of ADT66487 and ADT66488; DNA fragments of  
CC ADT66489 and ADT66490; DNA fragments of ADT66491 and ADT66492; DNA  
CC fragments of ADT66493 and ADT66494; DNA fragments of ADT66495 and  
CC ADT66496; and DNA fragments of ADT66497 and ADT66498; and analyzing  
CC expression pattern of the amplified DNA according to the time period. A  
CC DNA chip for monitoring a response of cancer patients to irradiation  
CC therapy amplifies one or more antioxidant genes corresponding to the  
CC following DNA fragments: DNA fragments of ADT66487 and ADT66488 - GPx1;  
CC DNA fragments of ADT66489 and ADT66490 - gamma-GCS; DNA fragments of  
CC ADT66491 and ADT66492 - catalase; DNA fragments of ADT66493 and ADT66494  
CC - CuZn SOD; DNA fragments of ADT66495 and ADT66496 - Mn SOD; and DNA  
CC fragments of ADT66497 and ADT66498 - Prx II. The present sequence  
CC represents a PCR primer of the invention.

XX Sequence 18 BP; 4 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 509 GTAATTGGATCGCCAA 526  
Db 18 GTAATTGGATCGCCAA 1

RESULT 135  
ADE52416  
ID ADE52416 standard; RNA; 23 BP.

XX ADE52416;

XX 29-JAN-2004 (first entry)

XX siRNA p10 sequence #1 for wild-type human SOD1 gene.

XX Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
KW target DNA sequence; RNA polymerase termination signal;  
KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
KW small interfering RNA; siRNA; ss.

XX Homo sapiens.

XX US2003180756-A1.

XX 25-SEP-2003.

XX 21-NOV-2002; 2002US-00301516.

XX 21-MAR-2002; 2002US-0366478P.

XX (SHIY/) SHI Y.

XX (SUIG/) SUI G.

XX Shi Y, Sui G;

XX WPI; 2003-852231/79.

XX New nucleic acids, useful for inhibiting the synthesis of a target  
PT protein in a eukaryotic cell, or for treating various diseases by  
PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
PT viral or bacterial infection.

XX Example 6; Fig 5A; 38pp; English.

XX The present invention relates to a method for suppressing gene expression  
CC in cells, particularly eukaryotic cells. The method involves a new  
CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
CC sequence, a first target sequence that is essentially complementary to a  
CC sequence of a target nucleic acid or its complement, a spacer sequence, a  
CC second target sequence that is essentially complementary to the first  
CC target sequence, and an RNA polymerase termination signal, where an RNA  
CC transcribed from the nucleic acid can inhibit expression of the target  
CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
CC the polymerase termination signal comprises a number of thymidines  
CC sufficient for arresting Pol III activity. The nucleic acids and methods  
CC are useful for suppressing gene expression in cells, or inhibiting the  
CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
CC subject. The nucleic acids can be used for treating various diseases by  
CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
CC such as leukaemia, haemophilia, viral or bacterial infections, and  
CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).

CC The present sequence represents a small interfering RNA (siRNA) that can  
 CC be used to target the wild-type human superoxide dismutase 1 (SOD1) gene.  
 XX

SQ Sequence 23 BP; 5 A; 3 C; 7 G; 2 T; 4 U; 2 Other;  
 Query Match 2.1%; Score 18; DB 1; Length 23;  
 Best Local Similarity 68.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGACTG 332  
 |||||:|||||:|:  
 Db 1 GGAGACUUGCGCAUUGADTD 22

RESULT 136  
 ADE52411  
 ID ADE52411 standard; RNA; 23 BP.  
 XX  
 AC ADE52411;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Mutant siRNA p10 sequence #1 for human SOD1 G256C mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytosstatic;  
 KW haemostatic; virucide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 XX US2003180756-A1.  
 XX 25-SEP-2003.  
 XX  
 XX 21-NOV-2002; 2002US-00301516.  
 XX  
 XX 21-MAR-2002; 2002US-0366478P.  
 XX  
 XX (SHIY/) SHI Y.  
 XX (SUIG/) SUI G.  
 XX  
 XX Shi Y, Sui G;  
 XX  
 XX WPI; 2003-852231/79.  
 XX  
 XX New nucleic acids, useful for inhibiting the synthesis of a target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.  
 XX  
 XX Example 6; Fig 5A; 38pp; English.  
 XX  
 XX The present invention relates to a method for suppressing gene expression  
 XX in cells, particularly eukaryotic cells. The method involves a new  
 XX nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 XX sequence, a first target sequence that is essentially complementary to a  
 XX sequence of a target nucleic acid or its complement, a spacer sequence, a  
 XX second target sequence that is essentially complementary to the first  
 XX target sequence, and an RNA polymerase termination signal, where an RNA  
 XX transcribed from the nucleic acid can inhibit expression of the target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.

CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC that can be used to target the human superoxide dismutase 1 (SOD1) G256C  
 CC (Gly85Arg) mutant gene.  
 XX  
 SQ Sequence 23 BP; 5 A; 3 C; 7 G; 2 T; 4 U; 2 Other;  
 Query Match 2.1%; Score 18; DB 1; Length 23;  
 Best Local Similarity 68.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGACTG 332  
 |||||:|||||:|:  
 Db 1 GGAGACUUGCGCAUUGADTD 22

RESULT 137  
 ADE52410  
 ID ADE52410 standard; RNA; 23 BP.  
 XX  
 AC ADE52410;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Mutant siRNA p11 sequence #1 for human SOD1 G256C mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytosstatic;  
 KW haemostatic; virucide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 XX US2003180756-A1.  
 XX 25-SEP-2003.  
 XX  
 XX 21-NOV-2002; 2002US-00301516.  
 XX  
 XX 21-MAR-2002; 2002US-0366478P.  
 XX  
 XX (SHIY/) SHI Y.  
 XX (SUIG/) SUI G.  
 XX  
 XX Shi Y, Sui G;  
 XX  
 XX WPI; 2003-852231/79.  
 XX  
 XX New nucleic acids, useful for inhibiting the synthesis of a target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.  
 XX  
 XX Example 6; Fig 5A; 38pp; English.  
 XX  
 XX The present invention relates to a method for suppressing gene expression  
 XX in cells, particularly eukaryotic cells. The method involves a new  
 XX nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 XX sequence, a first target sequence that is essentially complementary to a  
 XX sequence of a target nucleic acid or its complement, a spacer sequence, a  
 XX second target sequence that is essentially complementary to the first  
 XX target sequence, and an RNA polymerase termination signal, where an RNA  
 XX transcribed from the nucleic acid can inhibit expression of the target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.

CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC (Gly85Arg) mutant gene.  
 XX  
 SQ Sequence 23 BP; 4 A; 3 C; 7 G; 2 T; 5 U; 2 Other;  
 Query Match 2.0%; Score 17.6; DB 1; Length 23;  
 Best Local Similarity 65.0%; Pred. No. 1.6e+02;  
 Matches 13; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
 QY 310 TGGAGACTTGGCAATGTGCA 329  
 Db 1 UGGAGACUUGCGCAUUGUD 20  
 RESULT 138  
 ADE52412  
 ID ADE52412 standard; RNA; 23 BP.  
 AC ADE52412;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Mutant siRNA p9 sequence #1 for human SOD1 G256C mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytosstatic;  
 KW haemostatic; virucide; antibacterial; neuroprotective; nontropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN US2003180756-A1.  
 XX  
 PD 25-SEP-2003.  
 XX  
 PF 21-NOV-2002; 2002US-00301516.  
 XX  
 PR 21-MAR-2002; 2002US-0366478P.  
 XX  
 PA (SHIY/) SHI Y.  
 PA (SUIG/) SUI G.  
 XX  
 PI Shi Y, Sui G;  
 XX  
 DR WPI; 2003-852231/79.  
 XX  
 PT New nucleic acids, useful for inhibiting the synthesis of a target  
 PT protein in a eukaryotic cell, or for treating various diseases by  
 PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 PT viral or bacterial infection.  
 XX  
 PS Example 6; Fig 5A; 38pp; English.  
 PS  
 CC The present invention relates to a method for suppressing gene expression  
 CC in cells, particularly eukaryotic cells. The method involves a new

CC nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 CC sequence, a first target sequence that is essentially complementary to a  
 CC second target sequence that is essentially complementary to the first  
 CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC that can be used to target the human superoxide dismutase 1 (SOD1) G256C  
 CC (Gly85Arg) mutant gene.  
 XX  
 SQ Sequence 23 BP; 5 A; 4 C; 6 G; 2 T; 4 U; 2 Other;  
 Query Match 2.0%; Score 17.6; DB 1; Length 23;  
 Best Local Similarity 70.0%; Pred. No. 1.6e+02;  
 Matches 14; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
 QY 312 GAGACTTGGCAATGTGACT 331  
 Db 1 GAGACUUGCGCAUUGUACD 20  
 RESULT 139  
 ADE52401  
 ID ADE52401 standard; DNA; 19 BP.  
 XX  
 AC ADE52401;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Target DNA sequence #1 for human SOD1 G256C (Gly85Arg) mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytosstatic;  
 KW haemostatic; virucide; antibacterial; neuroprotective; nontropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN US2003180756-A1.  
 XX  
 PD 25-SEP-2003.  
 XX  
 PF 21-NOV-2002; 2002US-00301516.  
 XX  
 PR 21-MAR-2002; 2002US-0366478P.  
 XX  
 PA (SHIY/) SHI Y.  
 PA (SUIG/) SUI G.  
 XX  
 PI Shi Y, Sui G;  
 XX  
 DR WPI; 2003-852231/79.  
 XX  
 PT New nucleic acids, useful for inhibiting the synthesis of a target  
 PT protein in a eukaryotic cell, or for treating various diseases by  
 PT inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,



PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
 PI Miller S, Tang L, Shahabuddin S;  
 DR WPI; 2003-229219/22.  
 XX  
 XX Pharmaceutical composition for treating ailments associated with impaired  
 PT respiration, has oligo(s) antisense to specific gene(s) or its  
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
 PT ubiquinone.  
 XX  
 PS Disclosure; SEQ ID NO 7135; 872pp; English.  
 XX  
 CC The invention relates to a novel pharmaceutical composition, which has a  
 CC first active agent comprising an oligonucleotide antisense to the  
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
 CC junctions of genes encoding a polypeptide associated with lung and/or  
 CC nasal airway dysfunction and a second active agent comprising an  
 CC antiinflammatory steroid and ubiquinone. A composition of the invention  
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,  
 CC immunosuppressive, and cytostatic activity. The composition may have a  
 CC use in antisense gene therapy. The composition is useful for treating or  
 CC preventing a respiratory, lung or malignant disease or condition, also  
 CC for enhancing the prophylactic or therapeutic respiratory effect of an  
 CC antiinflammatory steroid in a subject, for reducing or depleting levels  
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
 CC lung inflammation, lung allergies, or a respiratory disease or condition.  
 CC Note: The sequence data for this patent is not represented in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 20 BP; 10 A; 2 C; 5 G; 3 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.4; DB 1; Length 20;  
 Best Local Similarity 94.7%; Pred. No. 1.6e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 131 CAGAGGAGAAAGTAATGGAC 149  
 DB 1 CAGAGGAGAAAGTAATGGAC 19  
 RESULT 142  
 ABD28123  
 ID ABD28123 standard; DNA; 20 BP.  
 AC ABD28123;  
 XX  
 DT 29-JUL-2004 (first entry)  
 XX  
 DE AA156940-derived oligonucleotide SEQ ID 7135.  
 XX  
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;  
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;  
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;  
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;  
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;  
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;  
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;  
 KW pulmonary transplantation rejection; ss; primer.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200285309-A2.  
 XX  
 PD 31-OCT-2002.  
 XX  
 XX 23-APR-2002; 2002WO-US013143.  
 PF  
 PR 24-APR-2001; 2001US-0286036P.  
 XX

PA (EPIG-) EPIGENESIS PHARM INC.  
 XX  
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
 PI Miller S, Tang L, Shahabuddin S;  
 XX  
 DR WPI; 2003-093058/08.  
 XX  
 XX Pharmaceutical composition for treating asthma, has antisense  
 PT oligonucleotide containing less percentage of adenosine, targeted to  
 PT nucleic acids associated with lung airway or lung dysfunction, and  
 PT bronchodilating agent.  
 XX  
 PS Claim 15; SEQ ID NO 7135; 763pp; English.  
 XX  
 CC This invention describes a novel composition (a) a first active agent,  
 CC comprising oligonucleotides, effective for alleviating  
 CC bronchoconstriction, respiratory tract inflammation, allergies and  
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
 CC surfactant depletion or hyposecretion, when administered to a mammal. The  
 CC oligonucleotides are derived from a gene encoding or regulating  
 CC expression of a target polypeptide associated with lung airway or lung  
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
 CC The invention also describes a kit, that comprises: (a) a delivery  
 CC device, in separate containers, (b) the oligonucleotides, (c)  
 CC instructions for adding a carrier and for use of the kit. The composition  
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,  
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
 CC beta-adrenergic agonist. The composition is useful for preventing or  
 CC treating a respiratory, lung or malignant disease. The administered  
 CC composition comprises oligo and is administered to reduce the production  
 CC or availability, or to increase the degradation of the target mRNA or to  
 CC reduce the amount of target polypeptide present in the lungs. The  
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
 CC inflammation, allergies and/or surfactant hypoproduction are associated  
 CC with a disease or condition such as pulmonary vasoconstriction,  
 CC inflammation, allergies, asthma, impeded respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.  
 CC The reduced adenosine content of the anti-sense oligos corresponding to  
 CC thymidines present in the target RNA serves to prevent the breakdown of  
 CC the oligonucleotides into products that free adenosine into the system  
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to  
 CC prevent any unwanted effects due to it  
 XX  
 SQ Sequence 20 BP; 10 A; 2 C; 5 G; 3 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.4; DB 1; Length 20;  
 Best Local Similarity 94.7%; Pred. No. 1.6e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 131 CAGAGGAGAAAGTAATGGAC 149  
 DB 1 CAGAGGAGAAAGTAATGGAC 19  
 RESULT 143  
 ABS98129/c  
 ID ABS98129 standard; DNA; 21 BP.  
 XX  
 AC ABS98129;  
 XX  
 DT 23-DEC-2002 (first entry)  
 XX  
 DE Human multidrug resistance gene polymorphic sequence #31.  
 XX  
 KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;  
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTP;  
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;  
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;



KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;  
 KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;  
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;  
 KW multidrug resistance associated protein 3; cancer; prostate;  
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
 KW altered drug metabolism; cardiovascular function; colorectal tumour;  
 KW central nervous system; pulmonary; immunological; SNP;  
 KW single nucleotide polymorphism.

OS Homo sapiens.

XX WO200257410-A2.

XX 25-JUL-2002.

XX 28-NOV-2001; 2001WO-US044838.

XX 28-NOV-2000; 2000US-00724389.

XX (DNAS-) DNA SCI LAB INC.

XX Guida M, Hall J;

XX WPI; 2002-698522/75.

XX Isolated nucleic acid molecules having polymorphisms in known human genes  
 e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers  
 for locating, identifying and characterizing the genes responsible for  
 disorder-related traits.

XX Example 22; Page 144; 714pp; English.

XX This invention relates to the sequence of an isolated nucleic acid  
 molecule comprising at least one base variation from that of a known  
 human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),  
 cytochrome P450 2E1 (CYP4502E1), adrenergic receptor beta1 (ADBR1),  
 aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
 (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
 inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating  
 protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl  
 transferase (HNMT), kallikrein 2) KLK2, nicotinamide -N-methyl  
 transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
 sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
 transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
 (MRP1), lactotransferrin (LTF), multidrug resistance associated protein 3  
 (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic  
 receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
 The polymorphisms in the human genes cited in the invention are useful as  
 genetic linkage markers for locating and characterizing the genes that  
 are responsible for specific traits within the genome and eventually  
 identifying the genes responsible for a variety of disorder-related  
 traits as a result of their e.g., overexpression, constitutive  
 expression, mutation or underexpression, which may be used in diagnosing  
 and/or treating the disorders. The nucleic acid molecules comprising the  
 polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,  
 ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
 MDR1 and/or MDR3 are useful for screening individuals for altered drug  
 metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,  
 AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
 susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
 used to screen for altered cardiovascular function. In COX2 for altered  
 susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
 nervous system function, in FLAP and HNMT for altered pulmonary,  
 immunological or haematological function, in KLK2 for altered serine  
 protease activity in the prostate, in LTF for altered immunological or  
 haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
 peripheral nervous system function. The present sequence represents a  
 polymorphic DNA sequence of the invention

XX Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.4; DB 1; Length 21;  
 Best Local Similarity 94.7%; Pred. No. 1.6e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 318 TGGGCAATGTGACTGCTGA 336  
 Db 21 TGTGCAATGTGACTGCTGA 3

RESULT 144

AD52421/c

XX ID AD52421 standard; RNA; 23 BP.

XX AC AD52421;

XX DT 29-JAN-2004 (first entry)

XX DE Mutant siRNA p10 sequence #2 for human SOD1 G256C mutant gene.

XX KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cystostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN US2003180756-A1.

XX PD 25-SEP-2003.

XX PF 21-NOV-2002; 2002US-00301516.

XX PR 21-MAR-2002; 2002US-0366478P.

XX PA (SHY/) SHI Y.

XX PA (SUIG/) SUI G.

XX PI Shi Y, Sui G;

XX WPI; 2003-852231/79.

XX New nucleic acids, useful for inhibiting the synthesis of a target  
 protein in a eukaryotic cell, or for treating various diseases by  
 inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 viral or bacterial infection.

XX Example 6; Fig 5A; 38pp; English.

XX The present invention relates to a method for suppressing gene expression  
 in cells, particularly eukaryotic cells. The method involves a new  
 nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 sequence, a first target sequence that is essentially complementary to a  
 sequence of a target nucleic acid or its complement, a spacer sequence, a  
 second target sequence that is essentially complementary to the first  
 target sequence, and an RNA polymerase termination signal, where an RNA  
 transcribed from the nucleic acid can inhibit expression of the target  
 gene. The RNA transcribed from the nucleic acid may form a hairpin  
 structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 the polymerase termination signal comprises a number of thymidines  
 sufficient for arresting Pol III activity. The nucleic acids and methods  
 are useful for suppressing gene expression in cells, or inhibiting the  
 synthesis of a target protein in a eukaryotic cell or in a cell of a  
 subject. The nucleic acids can be used for treating various diseases by  
 inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 such as leukaemia, haemophilia, viral or bacterial infections, and  
 neurodegenerative diseases including Alzheimer's disease, Parkinson's

CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC that can be used to target the human superoxide dismutase 1 (SOD1) G256C  
 CC (Gly85Arg) mutant gene.  
 XX  
 SQ Sequence 23 BP; 4 A; 7 C; 3 G; 2 T; 5 U; 2 Other;  
 Query Match 2.0%; Score 17.4; DB 1; Length 23;  
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 311 GGAGACTTGGCAATGTGA 329  
 Db 19 GGAGACTTGGCAATGTGA 1  
 RESULT 145  
 ADE52420/c  
 ID ADE52420 standard; RNA; 23 BP.  
 XX  
 AC ADE52420;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Mutant siRNA p11 sequence #2 for human SOD1 G256C mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 XX US2003180756-A1.  
 XX  
 PD 25-SEP-2003.  
 XX  
 XX 21-NOV-2002; 2002US-00301516.  
 XX  
 XX 21-MAR-2002; 2002US-0366478P.  
 XX  
 PA (SHIY/) SHI Y.  
 PA (SUIG/) SUI G.  
 XX  
 PI Shi Y, Sui G;  
 XX  
 DR WPI; 2003-852231/79.  
 XX  
 XX New nucleic acids, useful for inhibiting the synthesis of a target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.  
 XX  
 PS Example 6; Fig 5A; 38pp; English.  
 XX  
 XX The present invention relates to a method for suppressing gene expression  
 XX in cells, particularly eukaryotic cells. The method involves a new  
 XX nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 XX sequence, a first target sequence that is essentially complementary to a  
 XX sequence of a target nucleic acid or its complement, a spacer sequence, a  
 XX second target sequence that is essentially complementary to the first  
 XX target sequence, and an RNA polymerase termination signal, where an RNA  
 XX transcribed from the nucleic acid can inhibit expression of the target  
 XX gene. The RNA transcribed from the nucleic acid may form a hairpin  
 XX structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 XX the polymerase termination signal comprises a number of thymidines  
 XX sufficient for arresting Pol III activity. The nucleic acids and methods

CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC that can be used to target the human superoxide dismutase 1 (SOD1) G256C  
 CC (Gly85Arg) mutant gene.  
 XX  
 SQ Sequence 23 BP; 5 A; 7 C; 3 G; 2 T; 4 U; 2 Other;  
 Query Match 2.0%; Score 17.4; DB 1; Length 23;  
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 310 TGGAGACTTGGCAATGTG 328  
 Db 19 TGGAGACTTGGCAATGTG 1  
 RESULT 146  
 ADE52422/c  
 ID ADE52422 standard; RNA; 23 BP.  
 XX  
 AC ADE52422;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Mutant siRNA p9 sequence #2 for human SOD1 G256C mutant gene.  
 XX  
 KW Suppression of gene expression; eukaryotic cell; RNA polymerase promoter;  
 KW target DNA sequence; RNA polymerase termination signal;  
 KW hairpin structure; RNA polymerase III; RNA Pol III; mutated protein;  
 KW cancer; leukaemia; haemophilia; viral infection; bacterial infection;  
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; amyotrophic lateral sclerosis; ALS; cytostatic;  
 KW haemostatic; viricide; antibacterial; neuroprotective; nootropic;  
 KW anticonvulsant; antiparkinsonian; human; superoxide dismutase 1; SOD1;  
 KW G256C mutant; Gly85Arg mutant; small interfering RNA; siRNA; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 XX US2003180756-A1.  
 XX  
 PD 25-SEP-2003.  
 XX  
 XX 21-NOV-2002; 2002US-00301516.  
 XX  
 XX 21-MAR-2002; 2002US-0366478P.  
 XX  
 PA (SHIY/) SHI Y.  
 PA (SUIG/) SUI G.  
 XX  
 PI Shi Y, Sui G;  
 XX  
 DR WPI; 2003-852231/79.  
 XX  
 XX New nucleic acids, useful for inhibiting the synthesis of a target  
 XX protein in a eukaryotic cell, or for treating various diseases by  
 XX inhibiting the expression of abnormal or mutated proteins, e.g. leukemia,  
 XX viral or bacterial infection.  
 XX  
 PS Example 6; Fig 5A; 38pp; English.  
 XX  
 XX The present invention relates to a method for suppressing gene expression  
 XX in cells, particularly eukaryotic cells. The method involves a new  
 XX nucleic acid comprising in a 5'-3' order: an RNA polymerase promoter  
 XX sequence, a first target sequence that is essentially complementary to a  
 XX sequence of a target nucleic acid or its complement, a spacer sequence, a  
 XX second target sequence that is essentially complementary to the first  
 XX target sequence, and an RNA polymerase termination signal, where an RNA  
 XX transcribed from the nucleic acid can inhibit expression of the target  
 XX gene. The RNA transcribed from the nucleic acid may form a hairpin  
 XX structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 XX the polymerase termination signal comprises a number of thymidines  
 XX sufficient for arresting Pol III activity. The nucleic acids and methods

CC target sequence, and an RNA polymerase termination signal, where an RNA  
 CC transcribed from the nucleic acid can inhibit expression of the target  
 CC gene. The RNA transcribed from the nucleic acid may form a hairpin  
 CC structure. The polymerase is preferably RNA polymerase III (Pol III) and  
 CC the polymerase termination signal comprises a number of thymidines  
 CC sufficient for arresting Pol III activity. The nucleic acids and methods  
 CC are useful for suppressing gene expression in cells, or inhibiting the  
 CC synthesis of a target protein in a eukaryotic cell or in a cell of a  
 CC subject. The nucleic acids can be used for treating various diseases by  
 CC inhibiting the expression of abnormal or mutated proteins, e.g. cancers  
 CC such as leukaemia, haemophilia, viral or bacterial infections, and  
 CC neurodegenerative diseases including Alzheimer's disease, Parkinson's  
 CC disease, Huntington's disease and amyotrophic lateral sclerosis (ALS).  
 CC The present sequence represents a mutant small interfering RNA (siRNA)  
 CC that can be used to target the human superoxide dismutase 1 (SOD1) G256C  
 CC (Gly85Arg) mutant gene.

SQ Sequence 23 BP; 4 A; 6 C; 4 G; 2 T; 5 U; 2 Other;

Query Match 2.0%; Score 17.4; DB 1; Length 23;  
 Best Local Similarity 94.7%; Pred. No. 1.7e+02;  
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGCAATGTGAC 330  
 DB 19 GAGACTTGGCAATGTGAC 1

RESULT 147  
 AAX28452/c  
 ID AAX28452 standard; DNA; 22 BP.  
 XX  
 AC AAX28452;  
 XX  
 DT 22-JUN-1999 (first entry)  
 XX  
 DE EGF-like/FGF-8 homologue coding sequence primer SEQ ID No 70.  
 XX  
 KW Antibody; PRO187; PRO533; PRO214; PRO240; PRO211; PRO230; PRO261; PRO246;  
 KW EBAF-2; inhibitor; tumour growth; cancer; EGF-like homologue; primer;  
 KW FGF-8 homologue; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9914327-A2.  
 XX  
 PD 25-MAR-1999.  
 XX  
 PF 10-SEP-1998; 98WO-US018824.  
 XX  
 PR 17-SEP-1997; 97US-0059114P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 25-NOV-1997; 97US-0066840P.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Botstein D, Goddard A, Gurney A, Hillan K, Lawrence DA, Roy M;  
 PI Wood WI;  
 XX  
 DR WPI; 1999-229532/19.  
 XX  
 PT Antibodies against specific proteins overexpressed in tumors.  
 XX  
 PS Example 1; Page 45; 130pp; English.  
 XX  
 CC This sequence represents a primer used to isolate DNA encoding a protein

CC recognised by the antibodies of the inveniton. The invention relates to  
 CC antibodies (Ab) that bind to any of the polypeptides (I) designated  
 CC PRO187; PRO533; PRO214; PRO240; PRO211; PRO230; PRO261; PRO246 or EBAF-2.  
 CC The Ab, or other agents that inhibit expression and/or activity of (I)  
 CC are used: (i) to inhibit growth of tumours; and (ii) as  
 CC diagnostic/prognostic reagents for detection or quantification of (I) in  
 CC cells or tissues, by standard immunoassays, with overexpression being  
 CC indicative of cancer. For therapeutic use, the Ab may be conjugated to a  
 CC toxin, chemotherapeutic agent or radioisotope. Genes expressing (I), many  
 CC of which are growth factor homologues, are overexpressed in some cases of  
 CC cancer

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCGACTTA 768  
 DB 22 GACCTGTATTTCGCGACTTA 1

RESULT 148  
 AAX37608/c  
 ID AAX37608 standard; DNA; 22 BP.  
 XX  
 AC AAX37608;  
 XX  
 DT 11-SEP-2000 (first entry)  
 XX  
 DE Human PRO17 primer OLI518.  
 XX  
 KW Inflammatory cell infiltration; immune response; T cell proliferation;  
 KW anti-inflammatory; anti-autoimmune; anti-diabetic; spondyloarthritis;  
 KW T cell-mediated disease; spondyloarthritis; sclerosis; renal disease;  
 KW inflammatory myopathy; hemolytic anemia; thrombocytopenia; thyroiditis;  
 KW diabetes mellitus; demyelinating polyneuropathy; Guillain-Barre syndrome;  
 KW multiple sclerosis; polyneuropathy; hepatitis; cirrhosis; enteropathy;  
 KW sclerosing cholangitis; inflammatory bowel disease; Whipple's disease;  
 KW skin disease; dermatitis; psoriasis; asthma; allergic rhinitis; tumor;  
 KW food hypersensitivity; urticaria; eosinophilic pneumonia; transplant;  
 KW idiopathic pulmonary fibrosis; graft rejection; PRO245; PRO217; human;  
 KW primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9914241-A2.  
 XX  
 PD 25-MAR-1999.  
 XX  
 PF 17-SEP-1998; 98WO-US019437.  
 XX  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 04-JUN-1998; 98US-0088026P.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Fong S, Goddard A, Gurney AL, Tumas D, Wood WI;  
 PI WPI; 1999-229499/19.  
 XX  
 DR Composition containing novel polypeptide PRO245, its agonist or  
 PT antagonist.  
 XX  
 PS Example 1; Page 46; 177pp; English.  
 XX  
 CC This invention describes a novel composition containing (apart from a

CC carrier or excipient), a novel PRO245 polypeptide (I), its agonist or  
 CC antagonist, or their fragments, for modulating: (i) infiltration of  
 CC inflammatory cells into tissue; (ii) an immune response; or (iii) T cell  
 CC proliferation. The composition increases or decreases any of the effects  
 CC (i)-(iii). The products of the invention have anti-inflammatory, anti-  
 CC autoimmune and anti-diabetic activity. (I), and its (ant)agonists and  
 CC their fragments, are used to treat immune-related diseases, particularly  
 CC T cell-mediated diseases. The diseases treated include systemic lupus  
 CC erythematosus, rheumatoid arthritis, juvenile chronic arthritis,  
 CC spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic  
 CC inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's  
 CC syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia  
 CC (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune  
 CC thrombocytopenia (idiopathic thrombocytopenic purpura immune-mediated  
 CC thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis,  
 CC juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes  
 CC mellitus, immune-mediated renal disease (glomerulonephritis,  
 CC tubulointerstitial nephritis), multiple sclerosis, idiopathic  
 CC demyelinating polyneuropathy, Guillain-Barre syndrome, chronic  
 CC inflammatory demyelinating polyneuropathy, infectious hepatitis  
 CC (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune  
 CC chronic active hepatitis, primary biliary cirrhosis, granulomatous  
 CC hepatitis, and sclerosing cholangitis, inflammatory bowel disease  
 CC (ulcerative colitis: Crohn's disease), gluten-sensitive enteropathy, and  
 CC Whipple's disease. Autoimmune or immune-mediated skin diseases including  
 CC bullous skin diseases, erythema multiforme, contact dermatitis, psoriasis,  
 CC asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity,  
 CC urticaria, eosinophilic pneumonia, idiopathic pulmonary fibrosis,  
 CC hypersensitivity pneumonitis, and transplantation associated diseases  
 CC (graft rejection, and graft-versus-host-disease). (I), its (ant)agonists  
 CC or fragment can also be used as an adjuvant in treatment of tumors.  
 CC Antibodies against (I) can also be used for diagnosing such diseases.  
 CC This sequence represents a primer used in the isolation of the human  
 CC PRO217 protein described in the invention  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGCCAGACTTA 768  
 Db 22 GACCTGTATTTGCCAGACTTA 1  
 RESULT 149  
 AAX52278/c  
 ID AAX52278 standard; DNA; 22 BP.  
 XX  
 AC AAX52278;  
 XX  
 XX 25-JUN-1999 (first entry)  
 XX  
 DE Primer 28730.r (OLI518) used to isolate cDNA encoding PRO211 and PRO219.  
 XX  
 KW Secreted protein; transmembrane protein; human; enterocolitis;  
 KW Zollinger-Ellison syndrome; gastrointestinal ulceration;  
 KW congenital microvillus atrophy; skin disease; cell growth;  
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
 KW Parkinson's disease; Alzheimer's disease; AIDS; neuropathy; fibromodulin;  
 KW dermal scarring; Usher Syndrome; Atrophia areata; anti-thrombotic;  
 KW wound healing; tissue repair; probe; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX WO9914228-A2.  
 XX  
 XX 25-MAR-1999.  
 XX  
 XX 16-SEP-1998; 98WO-US019330.  
 XX  
 XX 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.

(GETH ) GENENTECH INC.

Wood WI, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;

WPI; 1999-229533/19.

New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration.

Example 2; Page 115; 320pp; English.

Oligonucleotides AAX52276-532 represent PCR primers and probes used to isolate and amplify cDNA encoding secreted and transmembrane human proteins (see AAX52213-74 and AAY13344-403). The cDNA sequences are obtained from cDNA libraries, prepared from fetal lung, fetal kidney, fetal brain, fetal liver and fetal retina. The encoded polypeptides have specific uses based on their homology to known polypeptides, e.g. PRO211 and PRO217 can be used for disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial cancers such as lung squamous cell carcinoma of the

CC vulva and gliomas), potent effects on cell growth and development,  
 CC diseases related to growth or survival of nerve cells including  
 CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.  
 CC PRO265 can be used as for fibromodulin, e.g. for reducing dermal  
 CC scarring. PRO264 can be used as a target for anti-tumor drugs. PRO533 may  
 CC be used in the treatment of Usher Syndrome or Atrophia areata; PRO269 can  
 CC be used as an anti-thrombotic agent; PRO287 polypeptides and portions may  
 CC have therapeutic applications in wound healing and tissue repair; PRO317  
 CC can be used for treating problems of the kidney, uterus, endometrium,  
 CC blood vessels, or related tissue, e.g. in the heart of genital tract  
 XX  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGGCCGACTTA 768  
 DB 22 GACCTGTATTGGCCGACTTA 1  
 RESULT 150  
 AAZ93682/c  
 ID AAZ93682 standard; DNA; 22 BP.  
 XX AC  
 XX AAZ93682;  
 DT 16-AUG-2000 (first entry)  
 XX  
 XX Primer for amplifying PRO211 cDNA.  
 DE Inhibition; cancer; neoplasia; tumour; breast; ovary; renal; colorectal;  
 KW uterus; prostate; lung; bladder; central nervous system; CNS; melanoma;  
 KW leukaemia; PRO211; PRO228; PRO338; PRO172; PRO182; human; probe; primer;  
 KW ss.  
 XX  
 XX Homo sapiens.  
 XX  
 XX WO200021996-A2.  
 XX 20-APR-2000.  
 XX  
 XX 05-OCT-1999; 99WO-US023089.  
 XX  
 XX 13-OCT-1998; 98US-0104080P.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Ashkenazi A, Goddard A, Gurney AL, Klein RD, Napier M, Wood WI;  
 PI Yuan J;  
 XX  
 XX WPI; 2000-317943/27.  
 XX  
 XX Composition for inhibiting neoplastic cell growth and treating cancers of  
 PT ovary, uterus, prostate, lung and bladder, comprises PRO211, PRO228,  
 PT PRO538, PRO172 or PRO182 polypeptide or their agonist.  
 XX  
 XX Example 1a; Page 75; 122pp; English.  
 XX  
 XX Compositions comprising a PRO211, PRO228, PRO538, PRO172 or PRO182  
 CC polypeptide or their agonists, mixed with a carrier is useful for  
 CC inhibiting neoplastic growth and treating tumors such as cancers of  
 CC breast, ovary, renal, colorectal, uterus, prostate, lung, bladder,  
 CC central nervous system, melanoma and leukaemia. Two primers (AAZ93681,  
 CC AAZ93682) were used to amplify the PRO211 cDNA  
 XX  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCGACTTA 768  
 DB 22 GACCTGTATTGGCCGACTTA 1  
 RESULT 151  
 AAZ30042/c  
 ID AAZ30042 standard; DNA; 22 BP.  
 XX AC  
 XX AAZ30042;  
 DT 09-AUG-2000 (first entry)  
 XX  
 XX Reverse PCR primer for PRO211 nucleotide sequence identification.  
 DE Anticancer; PRO187; PRO533; PRO214; PRO240; PRO211; PRO230; PRO261; PRO246;  
 KW PRO317; tumour growth inhibitor; cancer; diagnosis; treatment; human;  
 KW cell growth; proliferation; epidermal growth factor; EGF; ADSEPT;  
 KW antibody dependent enzyme mediated prodrug therapy; PCR primer; ss.  
 XX  
 XX Homo sapiens.  
 XX  
 XX WO200015666-A2.  
 XX 23-MAR-2000.  
 XX  
 XX 08-SEP-1999; 99WO-US020594.  
 XX  
 XX 10-SEP-1998; 98US-0099803P.  
 XX 10-SEP-1998; 98WO-US018824.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Goddard A, Gurney AL, Hillan KJ, Roy MA, Wood WI, Botstein D;  
 PI  
 XX WPI; 2000-271386/23.  
 XX  
 XX New isolated antibodies which bind to specific polypeptides used for  
 PT diagnosis and treatment of neoplastic cell growth and proliferation.  
 PT  
 XX  
 XX Example 5; Page 78; 200pp; English.  
 XX  
 XX This sequence represents a PCR primer used in the identification of the  
 CC human PRO211 nucleotide sequence. PRO211 shares sequence homology with  
 CC the epidermal growth factor protein sequence. The invention relates to  
 CC isolated antibodies which bind to a polypeptide. The "PRO" polypeptides  
 CC are encoded by genes which are over expressed in the genome of tumour  
 CC cells. Vectors and host cells comprising the nucleic acid encoding the  
 CC antibodies are used in the production of the antibodies. The antibodies  
 CC and nucleic acids encoding them are used for diagnosing a tumour in a  
 CC mammal. The antibodies are used for inhibiting the growth of tumour cells  
 CC and identifying compounds that inhibit a biological or immunological  
 CC activity of and/or expression of a PRO187, PRO533, PRO214, PRO240,  
 CC PRO211, PRO230, PRO261, PRO246 or PRO317 polypeptide. The antibody can be  
 CC used in antibody dependent enzyme mediated prodrug therapy (ADEPT) by  
 CC conjugating the antibody to a prodrug-activating enzyme which converts a  
 CC prodrug to an anti-cancer drug. The antibodies can be fluorescently  
 CC labelled and monitored by light microscopy, flow cytometry or fluorimetry  
 CC for diagnosis and prognosis of tumours  
 XX  
 XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGGCCGACTTA 768  
 DB 22 GACCTGTATTGGCCGACTTA 1  
 RESULT 152  
 AAZ52217/c



```

RESULT 154
ID ADC78327/c
XX ADC78327 standard; DNA; 22 BP.
AC
XX ADC78327;
AC
XX 01-JAN-2004 (first entry)
DT
XX Human PRO protein-related reverse PCR primer SEQ ID 7.
DE
XX antinflammatory; antiulcer; cytostatic; antipsoriatic; antiparkinsonian;
KW neurotrophic; neuroprotective; vasotropic; chemotactic; angiogenic;
KW antidiabetic; osteoprotective; antisthmatic; antiarthritic; antirheumatic;
KW antidiabetic; cardiatic; antidiabetic; cerebroprotective;
KW thrombolytic; immunomodulator; enterocolitis; Zollinger-Ellison syndrome;
KW gastrointestinal ulceration; psoriasis; cancer; Parkinson's disease;
KW Alzheimer's; ALS; neuropathy; dermal scarring; wound healing;
KW nerve repair; thrombosis; bone; cartilage formation; angiogenesis;
KW asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disorder;
KW atherosclerosis; cardiac injury; infertility; premature aging; AIDS;
KW diabetes; stroke; gene therapy; transgenic; PRO; human; ss; primer; PCR.
XX
XX Homo sapiens.
OS
XX WO200015796-A2.
XX
XX 23-MAR-2000.
XX
XX 15-SEP-1999; 99WO-US021090.
XX
XX 16-SEP-1998; 98WO-US019330.
XX
XX (GETH ) GENENTECH INC.
XX
XX Chen J, Goddard A, Gurney AL, Hillan K, Pennica D, Wood WI;
PI Yuan J;
XX
XX WPI; 2000-271434/23.
XX
XX Novel nucleic acids encoding secreted and transmembrane polypeptides with
PT homology, e.g. to growth and cancer-associated antigens.
XX
XX Example 2; SEQ ID NO 7; 355pp; English.
XX
XX The invention relates to a novel nucleic acid encoding a PRO polypeptide.
CC The polypeptides and polynucleotides of the invention may be useful as
CC research tools and as therapeutics for treating enterocolitis, Zollinger-
CC Ellison syndrome, gastrointestinal ulceration, psoriasis, cancer,
CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies, dermal
CC scarring and wound healing, nerve repair, thrombosis, bone and/or
CC cartilage formation, angiogenesis, asthma, rheumatoid arthritis, multiple
CC sclerosis, inflammatory disorders, atherosclerosis, cardiac injury,
CC infertility, premature aging, AIDS, diabetes complications and stroke.
CC The molecules may also be utilised during gene therapy procedures and
CC transgenic animal production. The current sequence is that of the PCR
CC primer of the invention which was used to analyse the human PRO DNA of
CC the invention.
XX
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 747 GACCTGTATTGTCGAGACTTA 768
DB 22 GACCTGTATTGTCGAGACTTA 1

```

RESULT 155  
AAF72436/c

ID AAF72436 standard; DNA; 22 BP.  
XX  
AC AAF72436;  
XX  
DT 24-APR-2001 (first entry)  
XX  
DE Human PRO oligonucleotide OLI518.  
XX  
XX Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;  
KW antiparkinsonian neurotropic; neuroprotective; vulnary; cardiac;  
KW antiangiogenic; vasotropic; antisthmatic; antirheumatic; cancer;  
KW antiarthritic; antiinfertility; antidiabetic; antitubercular; diabetes;  
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;  
KW ischaemia; inflammation; PCR primer; probe; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO200104311-A1.  
XX  
PD 18-JAN-2001.  
XX  
PF 22-FEB-2000; 2000WO-US004414.  
XX  
XX 07-JUL-1999; 99US-0143048P.  
XX 26-JUL-1999; 99US-0145698P.  
XX 28-JUL-1999; 99US-0146222P.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US020944.  
XX 15-SEP-1999; 99WO-US021090.  
XX 15-SEP-1999; 99WO-US021547.  
XX 05-OCT-1999; 99WO-US023089.  
XX 29-NOV-1999; 99WO-US028214.  
XX 30-NOV-1999; 99WO-US028313.  
XX 02-DEC-1999; 99WO-US028564.  
XX 16-DEC-1999; 99WO-US028565.  
XX 20-DEC-1999; 99WO-US030911.  
XX 20-DEC-1999; 99WO-US030999.  
XX 05-JAN-2000; 2000WO-US000219.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski FJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2001-081051/09.  
XX  
XX Sixty one nucleic acids encoding PRO polypeptides which are useful in the  
PT treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous  
PT cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's  
PT disease).  
XX  
XX Example 2; Page 152; 393pp; English.  
XX  
XX The present sequence is an oligonucleotide used in the isolation of one  
CC of sixty one nucleic acids encoding novel secreted and transmembrane PRO  
CC polypeptides. The PRO polypeptides are useful for treating skin diseases  
CC (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma),  
CC gastrointestinal disorders (e.g. enterocolitis), neurodegenerative  
CC diseases (e.g. Alzheimer's disease, Parkinson's disease), wound repair,  
CC cardiovascular disorders (e.g. endometrial bleeding angiogenesis,  
CC ischaemia such as coronary ischaemia, atherosclerosis), inflammatory  
CC disorders (e.g. asthma, rheumatoid arthritis, multiple sclerosis),  
CC infertility, AIDS and diabetes and retinal disorders such as retinitis  
CC pigmentosa. The PRO nucleic acids have applications in molecular  
CC biology, including use as hybridization probes, and in chromosome and  
CC gene mapping.  
XX  
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

```

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGGCCAGACTTA 768
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 156
AAS00172/c
ID AAS00172 standard; DNA; 22 BP.
XX AAS00172;
XX 04-JUL-2001 (first entry)
XX PCR primer 4 for Human cDNA clone encoding PRO217 (UNQ191).
XX Human; PRO217; UNQ191; immune response; osteoarthritis;
KW systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis;
KW juvenile chronic arthritis; spondyloarthropathy; Sjogren's syndrome;
KW idiopathic inflammatory myopathy; polymyositis; systemic vasculitis;
KW sarcoidosis; autoimmune haemolytic anaemia; immune pancytopenia;
KW autoimmune thrombocytopenia; idiopathic thrombocytopenic purpura;
KW thyroiditis; Grave's disease; Hashimoto's thyroiditis; diabetes mellitus;
KW glomerulonephritis; demyelinating disease; multiple sclerosis;
KW Guillain-Barre syndrome; hepatobiliary disease;
KW chronic inflammatory demyelinating polyneuropathy; infectious hepatitis;
KW auto immune chronic active hepatitis; primary biliary cirrhosis;
KW granulomatous hepatitis; sclerosing cholangitis; ulcerative colitis;
KW inflammatory bowel disease; Crohn's disease; Whipple's disease;
KW erythema multiforme; psoriasis; asthma; allergic rhinitis; urticaria;
KW food hypersensitivity; eosinophilic pneumonia; graft rejection;
KW idiopathic pulmonary fibrosis; graft-versus-host-disease; immunogon;
KW antibody; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200119991-A1.
XX
PD 22-MAR-2001.
XX
PF 20-MAR-2000; 2000WO-US007377.
XX
PR 15-SEP-1999; 99WO-US021547.
XX
PA (GETH ) GENENTECH INC.
XX
PI Fong S, Goddard A, Gurney AL, Hillan KJ, Tumas D, Wood WI;
XX
PT WPI; 2001-226823/23.
XX
DR Comparison for diagnosing and treating immune related diseases, e.g.
PT rheumatoid arthritis and diabetes mellitus, comprises a PRO polypeptide,
PT agonist, antagonist or fragment.
XX
PS Example 1; Page 85; 138pp; English.
XX
CC The sequence represents a PCR primer used to isolate a cDNA encoding
CC Human PRO217 (UNQ191), a protein involved in the immune response. PRO
CC polypeptides, and (ant)agonists to them, are used in compositions for
CC modulating infiltration of inflammatory cells into a tissue, modulating
CC an immune response and modulating proliferation of T-lymphocytes in
CC response to an antigen. Immune related diseases can be treated with the
CC compositions, such as, systemic lupus erythematosus, rheumatoid
CC arthritis, osteoarthritis, juvenile chronic arthritis,
CC spondyloarthropathies, systemic sclerosis, idiopathic inflammatory
CC myopathies (e.g. polymyositis), Sjogren's syndrome, systemic vasculitis,
CC sarcoidosis, autoimmune haemolytic anaemia (e.g. immune pancytopenia),
CC autoimmune thrombocytopenia (e.g. idiopathic thrombocytopenic purpura),
CC thyroiditis (e.g. Grave's disease, Hashimoto's thyroiditis), diabetes
CC mellitus, immune-mediated renal disease (e.g. glomerulonephritis)

```

---

```

CC demyelinating diseases of the central and peripheral nervous systems e.g.
CC multiple sclerosis or Guillain-Barre syndrome, and chronic inflammatory
CC demyelinating polyneuropathy, hepatobiliary diseases such as infectious
CC hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses),
CC auto immune chronic active hepatitis, primary biliary cirrhosis,
CC granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel
CC disease (ulcerative colitis, Crohn's disease and Whipple's disease),
CC autoimmune or immune-mediated skin diseases (e.g. erythema multiforme
CC and psoriasis), asthma, allergic rhinitis, urticaria, food
CC hypersensitivity, immunologic diseases of the lung such as eosinophilic
CC pneumonias, idiopathic pulmonary fibrosis, transplantation associated
CC diseases including graft-versus-host-disease and graft rejection. PRO
CC polypeptides can be used to diagnose immune related diseases, to identify
CC inhibitors, and to stimulate the proliferation of T lymphocytes. Anti-PRO
CC antibodies can be used to detect PRO and in diagnosis. PRO polypeptides,
CC antibodies and (ant)agonists can be used in rational drug design
XX
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

```

```

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGGCCAGACTTA 768
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 157
AAC97412/c
ID AAC97412 standard; DNA; 22 BP.
XX AAC97412;
XX 28-FEB-2001 (first entry)
XX Human PRO211 PCR primer, SEQ ID NO:60.
XX
KW Human; angiogenesis-associated protein; PRO; endothelial cell growth;
KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
KW Alzheimer's disease; Huntington's disease; stroke; drug screening;
KW gene therapy; transgenic animal; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200053753-A2.
XX
PD 14-SEP-2000.
XX
PF 05-JAN-2000; 2000WO-US000219.
XX
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
XX
PA (GETH ) GENENTECH INC.
XX

```



PI Ashtenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;  
 PI Godowski PJ, Gurney AL, Hillan KJ, Kuo SS, Mark MR, Marsters SA;  
 XX Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;  
 DR WPI; 2001-090793/10.  
 XX  
 XX New isolated nucleic acid for producing a PRO polypeptide, analyzing  
 PT genetic disorders and treating cardiovascular, endothelial or angiogenic  
 PT disorders, such as atherosclerosis, wounds or cancer.  
 XX  
 XX Example 15; Page 133; 293pp; English.  
 XX  
 CC The invention relates to novel human angiogenesis-associated proteins  
 CC designated PRO proteins (AAH53064-B53097), and to nucleic acids encoding  
 CC PRO proteins. The invention also relates to vectors and host cells  
 CC comprising a PRO nucleic acid, the recombinant production of a PRO  
 CC protein, PRO antibodies specific for a PRO protein, fusion proteins  
 CC comprising a PRO protein, agonists or antagonists of a PRO protein, and  
 CC compounds which inhibit the expression of a PRO gene. The invention  
 CC additionally encompasses methods of identifying modulators of PRO  
 CC expression or activity; diagnosing a cardiovascular, endothelial or  
 CC angiogenic disorder, or a susceptibility to such a disorder by detecting  
 CC mutations in a PRO gene, or the expression level of a PRO gene within a  
 CC particular tissue; treating a cardiovascular, endothelial or angiogenic  
 CC disorder via the administration of a PRO protein, PRO nucleic acid, or  
 CC PRO agonist or antagonist; a retroviral gene therapy vector comprising a  
 CC PRO nucleic acid; and methods of inhibiting or stimulating endothelial  
 CC cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the  
 CC administration of a PRO protein, or an agonist or antagonist thereof. PRO  
 CC nucleic acids, PRO proteins, antibodies against PRO proteins, PRO  
 CC agonists and PRO antagonists may be used as therapeutic agents to treat  
 CC cardiovascular, endothelial or angiogenic disorders, such as  
 CC atherosclerosis, osteoporosis, myocardial infarction, hypertension,  
 CC diabetic retinopathy, rheumatoid arthritis, Crohn's disease, Huntington's  
 CC endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Huntington's  
 CC disease, or stroke. PRO nucleic acids are additionally useful in the  
 CC recombinant production of PRO proteins, as hybridisation probes to screen  
 CC libraries to isolate cDNAs with sequence identity to PRO proteins, to map  
 CC genes encoding PRO proteins, to analyse genetic disorders, and in gene  
 CC therapy. PRO nucleic acids can also be used to produce transgenic animals  
 CC useful for the development and screening of potential therapeutic agents.  
 CC The present sequence represents a PCR primer used in the isolation of a  
 CC cDNA encoding a PRO protein of the invention  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGCCAGACTTA 768  
 Db 22 GACCTGTATTTGCCAGACTTA 1  
 ||||| | ||||| |||||  
 RESULT 158  
 ID AAF60362/c  
 XX AAF60362 standard; DNA; 22 BP.  
 AC AAF60362;  
 XX  
 XX 27-APR-2001 (first entry)  
 DE PRO211 reverse PCR primer #1.  
 XX  
 XX Cytostatic; PRO protein; tumour; cancer; PCR primer; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO200105836-A1.  
 PN  
 XX 25-JAN-2001.  
 PD  
 XX

PF 20-DEC-1999; 99WO-US030999.  
 XX  
 XX 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 02-DEC-1999; 99WO-US028564.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Botstein D, Goddard A, Gurney AL, Hillan KJ, Roy MA, Wood WI;  
 PI WPI; 2001-091968/10.  
 XX  
 DR New antibody that binds to a PRO polypeptide, e.g. PRO187 and PRO533,  
 PT useful for diagnosing and treating cancers.  
 XX  
 PS Example 5; Page 95; 196pp; English.  
 XX  
 CC The present invention relates to PRO proteins and coding sequences. The  
 CC present sequence is a PCR primer for one such PRO coding sequence. It was  
 CC found that the PRO genes are amplified in the genome of tumour cells. The  
 CC gene amplification is expected to be associated with the overexpression  
 CC of the gene product and contributes to tumorigenesis. Therefore,  
 CC antagonists of PRO proteins are useful for the treatment of benign or  
 CC malignant tumours, leukaemias, lymphoid malignancies and other disorders  
 CC such as neuronal, glial, astrocytal, hypothalamic, glandular, epithelial,  
 CC inflammatory and immunologic disorders  
 CC  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGCCAGACTTA 768  
 Db 22 GACCTGTATTTGCCAGACTTA 1  
 ||||| | ||||| |||||  
 RESULT 159  
 ID ACA60004/c  
 XX ACA60004 standard; DNA; 22 BP.  
 AC ACA60004;  
 XX  
 XX 12-JUN-2003 (first entry)  
 DT  
 XX Human secreted/transmembrane protein PRO211/217 PCR primer #2.  
 DE  
 XX Human; ss; PCR; secreted protein; transmembrane protein; PRO;  
 KW Gene therapy; chromosome identification; chromosome marker; primer.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2003003530-A1.  
 PN  
 XX 02-JAN-2003.  
 PD  
 XX 11-JUL-2001; 2001US-00904011.  
 XX  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.

```
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063511P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 01-DEC-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US007377.
PR 22-MAY-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US014042.
PR 28-JUL-2000; 2000WO-US015264.
PR 24-AUG-2000; 2000WO-US020710.
PR 18-SEP-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
PA (GETH ) GENENTECH INC.

XX PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-329602/31.
XX
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, in generating probes and in tissue typing.
XX
XX Example 2; Page 87; 484pp; English.
XX
XX The invention relates to an isolated nucleic acid with at least 80%
CC nucleic acid sequence identity to a nucleotide sequence encoding one of
CC 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
CC PRO protein extracellular domain. Also included are a vector comprising
CC the PRO nucleic acid, a host cell comprising the vector, producing a PRO
CC polypeptide (by culturing the host cell for the expression of the PRO
CC polypeptide, and recovering the PRO polypeptide from the cell culture),
CC an isolated PRO polypeptide (having at least 80% sequence identity to: (
CC a) an amino acid sequence selected from the 61 PRO proteins; (b) an amino
CC acid sequence encoded by a nucleic acid molecule deposited with an ATCC
CC number (detailed in the specification); or (c) an extracellular domain of
CC a PRO polypeptide or to a PRO polypeptide lacking its associated signal
CC peptide), a chimeric molecule comprising a PRO polypeptide of fused to a
CC heterologous amino acid sequence, an anti-PRO antibody, detecting a
CC PRO245 or PRO1868 in a sample suspected of containing the polypeptide,
CC linking a bioactive molecule to a cell expressing a PRO245 or PRO1868 and
CC modulating at least one biological activity of a cell expressing a PRO245
CC or PRO1868. Nucleic acids which encode PRO can be used to generate either
CC transgenic animals or knock-out animals which may be used in the
CC development and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. The present sequence is a PCR primer used to isolate a cDNA
CC encoding a PRO protein
XX
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 747 GACCTGTATTTCGACACTTA 768
Db 22 GACCTGTATTTCGACACTTA 1
|||||
RESULT 160
ACD07404/C
ID ACD07404 standard; DNA; 22 BP.
XX ACD07404;
XX
XX 07-AUG-2003 (first entry)
XX
XX Secreted and transmembrane protein associated oligonucleotide #3.
XX
XX Human; secreted and transmembrane protein; PRO; pharmaceutical;
KW diagnostic; biosensor; bioreactor; Parkinson's disease;
KW Alzheimer's disease; inflammation; nephritis; wound healing;
KW nerve repair; collateral blood vessel formation; cancer;
KW colorectal cancer; haemorrhage; rheumatoid arthritis; diabetes;
KW cirrhosis; fibrosis; restenosis; dermal fibrotic condition; keloid;
KW scarring; ischaemia; stroke; hypertension; heart attack; atherosclerosis;
```

infertility; gene therapy; ss.

Homo sapiens.

US2002197671-A1.

26-DEC-2002.

17-JUL-2001; 2001US-00907824.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059119P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

15-OCT-1997; 97US-0062125P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0062814P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063127P.

24-OCT-1997; 97US-0063128P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063549P.

28-OCT-1997; 97US-0063550P.

28-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063732P.

29-OCT-1997; 97US-0063733P.

29-OCT-1997; 97US-0063738P.

29-OCT-1997; 97US-0064215P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

03-NOV-1997; 97US-0064248P.

07-NOV-1997; 97US-0064809P.

12-NOV-1997; 97US-0065186P.

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

05-JAN-2000; 2000WO-US000219.

11-FEB-2000; 2000WO-US003565.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US005004.

02-MAR-2000; 2000WO-US007377.

30-MAR-2000; 2000WO-US008439.

22-MAY-2000; 2000WO-US014042.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

24-AUG-2000; 2000WO-US023328.

18-SEP-2000; 2000US-00665350.

XX

PA (GETH ) GENENTECH INC.

XX

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX

DR WPI; 2003-370793/35.

XX

PT New genes and secreted and transmembrane polypeptides (e.g. PRO245 or

PT PRO335), useful for treating or diagnosing e.g. Alzheimer's disease,

PT cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia

PT or strokes.

XX

Example 2; Page 80; 482pp; English.

XX

The invention describes a new isolated nucleic acid molecule comprising

CC the full length coding sequence of the DNA deposited with the American

CC Type Culture Collection (e.g. ATCC Deposit No. 209258) or a sequence

CC with at least 80% identity to a DNA encoding a PRO polypeptide comprising

CC any of 61 sequences having 164-1119 amino acids fully defined in the

CC specification. The PRO polypeptides or polynucleotides are useful as

CC pharmaceuticals, diagnostics, biosensors or bioreactors. These are

CC particularly useful for detecting or treating e.g. Parkinson's disease,

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

XX AC ABX71452;  
 XX DT 10-MAR-2003 (first entry)  
 XX DE Human secreted/transmembrane proteins PRO211/217 PCR primer #3.  
 XX KW Human; PRO; secreted protein; transmembrane protein; enterocolitis;  
 KW gastrointestinal ulceration; skin disease; ss; PCR; primer;  
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
 KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;  
 KW amyotrophic lateral sclerosis; inflammatory disease;  
 KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;  
 KW atherosclerosis; cardiac injury; infertility; birth defect;  
 KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;  
 KW diabetic complication; wound repair.  
 XX OS Homo sapiens.  
 XX PN US2002132240-A1.  
 XX PD 19-SEP-2002.  
 XX PF 18-JUL-2001; 2001US-00909330.  
 XX PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063733P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065884P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.

PR 24-NOV-1997; 97US-0066772P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 06-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

XX ASkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 DR WPI; 2003-147434/14.

XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing or  
 PT treating inflammatory diseases, organ failure, atherosclerosis, cardiac  
 PT injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's  
 PT disease.

XX Example 2; Page 81; 473pp; English.

XX The invention relates to an isolated PRO polypeptide having at least 80%  
 CC amino acid sequence identity to: (a) any one of 61 fully defined amino  
 CC acid sequences given in the specification (appearing as ABUS4347-  
 CC ABUS4407); (b) an amino acid sequence encoded by the nucleotide sequence  
 CC deposited under American Type Culture Collection (accession numbers  
 CC listed in the specification); (c) any one of the PRO sequences which  
 CC lacks its associated signal peptide; (d) an extracellular domain of the  
 CC PRO polypeptide with its associated signal peptide; or (e) an  
 CC extracellular domain of the PRO polypeptide which lacks its associated  
 CC signal peptide. Also include are the nucleic acids encoding the PRO  
 CC polypeptides, vectors, host cells and anti-PRO antibodies. The PRO  
 CC polypeptides and nucleic acids are useful in diagnosing or treating  
 CC enterocolitis, gastrointestinal ulceration, skin diseases associated with  
 CC abnormal keratinocyte differentiation, e.g. psoriasis or epithelial  
 CC cancers such as squamous cell carcinoma, Alzheimer's disease, Parkinson's  
 CC disease, amyotrophic lateral sclerosis, inflammatory diseases, e.g.  
 CC rheumatoid arthritis, asthma or multiple sclerosis, organ failure  
 CC atherosclerosis, cardiac injury, infertility, birth defects, premature  
 CC aging, AIDS, cancer, diabetic complications, or mutations in general. The  
 CC polypeptides are also useful for wound repair and associated therapies  
 CC concerned with re-growth of tissue. The nucleotide sequences may be used  
 CC as hybridisation probes in chromosome and gene mapping, or in generating  
 CC antisense RNA and DNA. PRO nucleic acids are also useful in preparing PRO  
 CC polypeptides, in assays to identify other proteins or molecules involved

CC in binding reaction, to generate transgenic animals or knockout animals,  
 CC which in turn are useful in the development and screening of  
 CC therapeutically useful reagents, for chromosome identification, and  
 CC tissue typing. The PRO polypeptides and nucleic acid molecules are also  
 CC useful in gene therapy, and as molecular weight markers for protein  
 CC electrophoresis purposes. The anti-PRO antibodies may be used in  
 CC diagnostic assays for PRO, or for the affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The present sequence is a  
 CC PCR primer used to isolate a cDNA encoding a PRO polypeptide  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
 Db 22 GACCTGTATTTGCCAGACTTA 1

RESULT 162  
 ACH06784/c  
 ID ACH06784 standard; DNA; 22 BP.

XX ACH06784;

XX 08-OCT-2003 (first entry)

XX Human secreted/transmembrane polypeptide PRO217 reverse primer #1.

KW Human; PCR; primer; abnormal bleeding; gynaecological disease; tumour;  
 KW hysterectomy; angiogenesis; coronary ischaemic condition; skin disease;  
 KW gastrointestinal mucosa disorder; acute mucosal lesion; neuropathy; ALS;  
 KW chronic mucosal lesion; abnormal keratinocyte differentiation; psoriasis;  
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;  
 KW uncontrolled cell growth; cancer; blood coagulation cascade; thrombosis;  
 KW haemorrhage; endometrial bleeding; angiogenesis; wound healing; asthma;  
 KW tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing;  
 KW ss.

XX Homo sapiens.

XX US2003044839-A1.

XX 06-MAR-2003.

XX 10-JUL-2001; 2001US-00902903.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0062814P.

XX 24-OCT-1997; 97US-0063045P.

XX 24-OCT-1997; 97US-0063120P.

PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-009803P.  
 PR 10-SEP-1998; 98US-009803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0100262P.  
 PR 17-SEP-1998; 98US-0100588P.  
 PR 17-SEP-1998; 98US-0100588P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 05-OCT-1999; 99US-0146222P.  
 PR 29-NOV-1999; 99US-0146222P.  
 PR 30-NOV-1999; 99US-0146222P.  
 PR 01-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 16-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 05-JAN-2000; 2000US-0000219.  
 PR 11-FEB-2000; 2000US-00003565.  
 PR 22-FEB-2000; 2000US-00004414.  
 PR 24-FEB-2000; 2000US-00005004.  
 PR 02-MAR-2000; 2000US-00005841.  
 PR 20-MAR-2000; 2000US-00007377.  
 PR 30-MAR-2000; 2000US-00008439.  
 PR 22-MAY-2000; 2000US-0014042.  
 PR 02-JUN-2000; 2000US-0015264.  
 PR 28-JUL-2000; 2000US-0020710.  
 PR 24-AUG-2000; 2000US-0023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-492258/46.  
XX Novel secreted and transmembrane polypeptides and polynucleotides  
PT encoding them useful for treating abnormal bleeding involved in  
PT gynecological diseases, skin diseases and neurodegenerative diseases.  
XX Example 2; Page 86; 478pp; English.  
XX The invention relates to an isolated PRO polypeptide. PRO317 is useful in  
CC diagnosing or treating abnormal bleeding involved in gynecological  
CC diseases e.g. to avoid or lessen the need for hysterectomy. PRO317 may  
CC also be useful as an agent that affects angiogenesis and PRO317 is useful  
CC in anti-tumour indications or in treating coronary ischaemic conditions.  
CC PRO211 and PRO217 polypeptides are useful for treating disorders  
CC associated with the preservation and maintenance of gastrointestinal  
CC mucosa and the repair of acute and chronic mucosal lesions, skin diseases  
CC associated with abnormal keratinocyte differentiation (e.g. psoriasis).  
CC PRO187 polypeptide is useful for treating Parkinson's disease,  
CC Alzheimer's disease, amyotrophic lateral sclerosis (ALS), neuropathies  
CC and disease related to uncontrolled cell growth, e.g. cancer. PRO219  
CC polypeptide plays a regulatory role in the blood coagulation cascade.  
CC PRO246 polypeptides which serves as tumour specific antigens may be  
CC exploited as therapeutic targets for anti-tumour drugs. PRO269  
CC polypeptide is useful as an antithrombotic agent with reduced risk for  
CC haemorrhage as compared with heparin. PRO317 polypeptide is useful in  
CC treating endometrial bleeding angiogenesis. PRO287 polypeptides and  
CC portion have therapeutic applications in wound healing and tissue repair.  
CC PRO234 polypeptides are useful for treating asthma, rheumatoid arthritis,  
CC psoriasis and multiple sclerosis. The polypeptide and its nucleic acid  
CC are useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC present sequence represents a human secreted/transmembrane PRO  
CC polypeptide PCR primer  
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
SQ Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTAATTTGCCAGACTTA 768  
Db ||||| ||||| ||||| ||||| |||||  
22 GACCTGTAATTTGCCAGACTTA 1  
RESULT 163  
ABX96021/C  
ID ABX96021 standard; DNA; 22 BP.  
AC ABX96021;  
XX  
XX 13-MAY-2003 (first entry)  
DT  
XX Human secreted/transmembrane protein cDNA, #1, probe.  
DE  
XX Human; probe; ss; PRO; secreted; transmembrane; pharmaceutical;  
KW diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;  
KW endometriosis; cancer; tumour; ischaemia; coronary arterial disease;  
KW polycystic kidney disease; renal failure; inflammatory response; asthma;  
KW rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;  
KW cytoskeletal; gynecological; cardiac; nephrotropic; hepatotropic;  
antiinflammatory.  
XX  
XX Homo sapiens.  
OS  
XX US2002160374-A1.  
PN  
XX

PD 31-OCT-2002.  
XX  
XX 12-JUL-2001; 2001US-00905291.  
XX  
PR 17-SEP-1997; 97US-00591113P.  
PR 17-SEP-1997; 97US-00591115P.  
PR 17-SEP-1997; 97US-00591117P.  
PR 17-SEP-1997; 97US-00591119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0063126P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 28-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 10-SEP-1998; 98WO-US018924.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 01-DEC-1998; 98WO-US025108.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 20-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 99WO-US030999.  
PR 11-FEB-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023228.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WT;  
 XX  
 DR WPI; 2003-288105/28.  
 XX  
 XX New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)  
 PT and genes encoding them, useful for detecting or treating e.g.  
 PT hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease  
 PT or inflammations.  
 XX  
 XX Example 2; Page 87; 477pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. The PRO polypeptides or  
 CC polynucleotides are also useful as pharmaceuticals, diagnostics,  
 CC biosensors or bioreactors, for detecting or treating e.g. hyperplasia,  
 CC endometriosis, cancers (e.g. those involving solid tumours), ischaemia,  
 CC coronary arterial disease, polycystic kidney disease, chronic or acute  
 CC renal failure, or inflammatory responses (e.g. asthma, rheumatoid  
 CC arthritis, psoriasis or multiple sclerosis) in mammals. The PRO genes may  
 CC also be used in gene therapy, particularly for replacing a defective  
 CC gene. The sequences presented in ABX96017-ABX96378 are the genes  
 CC encoding, the primers amplifying and the probes detecting the PRO  
 CC polynucleotides of the invention  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGCGCAGACTTA 768  
 Db ||||| ||||| ||||| ||||| |||||  
 22 GACCTGTATTGCGCAGACTTA 1  
 RESULT 164  
 ACA05342/C  
 ID ACA05342 standard; DNA; 22 BP.  
 XX  
 AC ACA05342;  
 XX  
 DT 29-MAY-2003 (first entry)  
 XX  
 DE Human secreted protein PRO211 primer 28730r.  
 XX  
 KW Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;  
 KW psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;  
 KW Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;  
 KW atrophila areata; inflammatory disease; asthma; rheumatoid arthritis;  
 KW ischaemia; ss; primer; PCR.  
 XX  
 OS Homo sapiens.  
 XX

PN US2003023054-A1.  
 XX 30-JAN-2003.  
 XX 16-JUL-2001; 2001US-00906742.  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 18-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063545P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.

PR	13-SEP-1999;	99WO-US020944.	XX
PR	15-SEP-1999;	99WO-US021090.	AC
PR	15-SEP-1999;	99WO-US021547.	XX
PR	05-OCT-1999;	99WO-US023089.	DT
PR	29-NOV-1999;	99WO-US028214.	XX
PR	30-NOV-1999;	99WO-US028313.	XX
PR	01-DEC-1999;	99WO-US028301.	XX
PR	02-DEC-1999;	99WO-US028564.	KW
PR	02-DEC-1999;	99WO-US028565.	KW
PR	16-DEC-1999;	99WO-US030095.	KW
PR	20-DEC-1999;	99WO-US030911.	KW
PR	20-DEC-1999;	99WO-US030999.	KW
PR	05-JAN-2000;	2000WO-US000219.	XX
PR	11-FEB-2000;	2000WO-US003565.	OS
PR	22-FEB-2000;	2000WO-US004414.	XX
PR	24-FEB-2000;	2000WO-US005004.	PN
PR	02-MAR-2000;	2000WO-US005841.	XX
PR	20-MAR-2000;	2000WO-US007377.	XX
PR	30-MAR-2000;	2000WO-US008439.	PD
PR	22-MAY-2000;	2000WO-US014042.	XX
PR	02-JUN-2000;	2000WO-US015264.	XX
PR	28-JUL-2000;	2000WO-US020710.	PF
PR	24-AUG-2000;	2000WO-US023328.	XX
PR	18-SEP-2000;	2000US-00645350.	XX
PA	(GETH ) GENENTECH INC.		
XX			
PI	Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;		
PI	Pilvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;		
PI	Godowski PJ, Gramaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;		
PI	Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;		
PI	Williams PM, Wood WJ;		
XX			
DR	WPI; 2003-331485/31.		
XX			
PT	Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245		
PT	or PRO1868, useful in chromosome and gene mapping, in generating		
PT	antisense RNA and DNA, and in treating cancer and Alzheimer's disease.		
XX			
PS	Example 2; Page 86; 481pp; English.		
XX			
CC	The invention relates to sixty one nucleic acids encoding PRO		
CC	polypeptides (secreted and transmembrane). The polynucleotide is useful		
CC	in molecular biology, including uses as hybridisation probes, in		
CC	chromosome and gene mapping, in generating antisense RNA and DNA, and in		
CC	gene therapy. The polynucleotide may also be used in preparing PRO		
CC	polypeptides by recombinant techniques, and in generating either		
CC	transgenic animals or knock-out animals which, in turn, are useful in the		
CC	development and screening of therapeutically useful reagents. The PRO		
CC	polypeptide or the antibody is used in preparing a medicament for		
CC	treating a condition responsive to the polypeptide or antibody, such as		
CC	mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g.		
CC	psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease		
CC	e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome,		
CC	atrophia areata, angiogenesis, inflammatory disease e.g. asthma and		
CC	rheumatoid arthritis, ischaemia, and in various diagnostic assays. The		
CC	present sequence represents an PCR primer used in isolating a PRO		
CC	polypeptide		
XX			
SQ	Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;		
	Query Match 2.0%; Score 17.2; DB 1; Length 22;		
	Best Local Similarity 86.4%; Pred. NO. 1.7e+02;		
	Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
Qy	747 GACCTGTATTTGCCAGACTTA 768		
Db	22 GACCTGTATTTGCCAGACTTA 1		
	RESULT 165		
	ACD20009/c		
ID	ACD20009 standard; DNA; 22 BP.		

XX	ACD20009;		
XX	25-AUG-2003 (first entry)		
DT			
XX	Human secreted / transmembrane polypeptide PRO211 primer 28730.r.		
DE			
KW	Human; ss; PCR; primer; gene therapy; tumour; tissue typing; obesity;		
KW	diabetes; hypoinsulinaemia; hyperinsulinaemia; vascular permeability;		
KW	cardiac insufficiency disorder; immune response; regeneration; cartilage;		
KW	auditory hair cell; hearing loss; bone disorder; sports injury;		
KW	arthritis.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003036060-A1.		
XX			
PD	20-FEB-2003.		
XX			
PF	12-JUL-2001; 2001US-00904859.		
XX			
PR	17-SEP-1997; 97US-00591113P.		
PR	17-SEP-1997; 97US-00591115P.		
PR	17-SEP-1997; 97US-00591117P.		
PR	17-SEP-1997; 97US-00591119P.		
PR	17-SEP-1997; 97US-00591212P.		
PR	17-SEP-1997; 97US-00591213P.		
PR	17-SEP-1997; 97US-0059184P.		
PR	18-SEP-1997; 97US-0059263P.		
PR	18-SEP-1997; 97US-0059286P.		
PR	15-OCT-1997; 97US-0062125P.		
PR	17-OCT-1997; 97US-0062287P.		
PR	21-OCT-1997; 97US-0063486P.		
PR	24-OCT-1997; 97US-0062814P.		
PR	24-OCT-1997; 97US-0062816P.		
PR	24-OCT-1997; 97US-0063045P.		
PR	24-OCT-1997; 97US-0063120P.		
PR	24-OCT-1997; 97US-0063121P.		
PR	24-OCT-1997; 97US-0063127P.		
PR	24-OCT-1997; 97US-0063128P.		
PR	27-OCT-1997; 97US-0063327P.		
PR	27-OCT-1997; 97US-0063329P.		
PR	28-OCT-1997; 97US-0063541P.		
PR	28-OCT-1997; 97US-0063542P.		
PR	28-OCT-1997; 97US-0063544P.		
PR	28-OCT-1997; 97US-0063549P.		
PR	28-OCT-1997; 97US-0063550P.		
PR	28-OCT-1997; 97US-0063584P.		
PR	29-OCT-1997; 97US-0063435P.		
PR	29-OCT-1997; 97US-0063704P.		
PR	29-OCT-1997; 97US-0063732P.		
PR	29-OCT-1997; 97US-0063734P.		
PR	29-OCT-1997; 97US-0063735P.		
PR	29-OCT-1997; 97US-0063738P.		
PR	31-OCT-1997; 97US-0064215P.		
PR	31-OCT-1997; 97US-0064103P.		
PR	03-NOV-1997; 97US-0064248P.		
PR	07-NOV-1997; 97US-0064809P.		
PR	12-NOV-1997; 97US-0065186P.		
PR	17-NOV-1997; 97US-0065846P.		
PR	18-NOV-1997; 97US-006593P.		
PR	21-NOV-1997; 97US-0066120P.		
PR	21-NOV-1997; 97US-0066364P.		
PR	24-NOV-1997; 97US-0066453P.		
PR	24-NOV-1997; 97US-0066466P.		
PR	24-NOV-1997; 97US-0066511P.		
PR	24-NOV-1997; 97US-0066770P.		
PR	24-NOV-1997; 97US-0066772P.		
PR	25-NOV-1997; 97US-0066840P.		
PR	12-DEC-1997; 97US-0069425P.		
PR	04-JUN-1998; 98US-0088026P.		



PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98US-01009330.  
 PR 17-SEP-1998; 98WO-US0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 98US-0143048P.  
 PR 26-JUL-1999; 98US-0145698P.  
 PR 28-JUL-1999; 98US-0146222P.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000213.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WT;  
 XX  
 DR WPI; 2003-417923/39.  
 XX  
 PT Novel secreted and transmembrane polypeptide for modulating biological  
 PT activity of cell expressing the polypeptide, identifying agonists or  
 PT antagonists of polypeptide, and as molecular weight markers.  
 XX  
 PS Example 2; Page 86; 469pp; English.  
 XX  
 CC The invention relates to an isolated, secreted and transmembrane  
 CC polypeptide, termed PRO polypeptide. The polypeptide is useful for  
 CC identifying agonists or antagonists of the polypeptide, for preparing  
 CC variants of the polypeptide, as molecular weight markers for protein  
 CC electrophoresis purpose and the nucleic acid is useful for recombinantly  
 CC expressing those markers. The polypeptide is also useful as therapeutic  
 CC agent. PRO is useful in assays to identify other proteins or molecules  
 CC involved in binding interaction. The nucleic acid is useful as  
 CC hybridisation probes, in chromosome and gene mapping, in generation of  
 CC antisense RNA and DNA, in the preparation of PRO polypeptide, for  
 CC generating transgenic animals or knockout animals which in turn are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents, to construct hybridisation probes for mapping the gene which  
 CC encodes the PRO and for the genetic analysis of individuals with genetic  
 CC disorders, in gene therapy, for chromosome identification, as chromosome  
 CC marker, and for generating probes for polymerase chain reaction (PCR),  
 CC Northern analysis, Southern analysis and Western analysis. PRO antibody

CC is useful in diagnostic assays for PRO, e.g. detecting its expression in  
 CC specific cells, tissues or serum and for affinity purification of PRO or  
 CC from recombinant cell culture or natural sources. The polypeptide or its  
 CC antibody is useful for the preparation of medicament for treating  
 CC conditions which is responsive to the PRO polypeptide or anti-PRO  
 CC antibody e.g. tumour. The polypeptide and the nucleic acid is useful for  
 CC tissue typing. The polypeptide is useful for treating obesity, diabetes  
 CC or hypo- or hyper-insulinaemia and cardiac insufficiency disorders, for  
 CC inhibiting tumour growth, enhances vascular permeability and immune  
 CC response, for inducing regeneration of auditory hair cells and for  
 CC treating hearing loss in mammals and for treating bone and/or cartilage  
 CC disorders such as sports injuries and arthritis. The present sequence  
 CC represents a human secreted and transmembrane PRO polypeptide PCR primer  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGTCGAGACTTA 768  
 Db 22 GACCTGTATTGTCGAGACTTA 1  
 RESULT 166  
 ACAS4812/c  
 ID ACAS4812 standard; DNA; 22 BP.  
 XX  
 AC ACAS4812;  
 XX  
 DT 05-JUN-2003 (first entry)  
 XX  
 DE Secreted and transmembrane protein associated oligonucleotide #3.  
 KW Human; secreted and transmembrane protein; gene therapy; psoriasis;  
 KW enterocolitis; gastrointestinal ulceration; skin disease;  
 KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;  
 KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;  
 KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;  
 KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;  
 KW infertility; birth defect; premature aging; AIDS; cancer;  
 KW diabetic complication; wound repair; tissue re-growth; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003017463-A1.  
 XX  
 PD 23-JAN-2003.  
 XX  
 PF 11-JUL-2001; 2001US-00903640.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.

```

PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-00633541P.
PR 28-OCT-1997; 97US-00633542P.
PR 28-OCT-1997; 97US-00633543P.
PR 28-OCT-1997; 97US-00633544P.
PR 28-OCT-1997; 97US-00633549P.
PR 28-OCT-1997; 97US-00633550P.
PR 28-OCT-1997; 97US-00633564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0068453P.
PR 24-NOV-1997; 97US-0068466P.
PR 24-NOV-1997; 97US-0068511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0068425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113298P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99WO-US020594.
PR 08-SEP-1999; 99WO-US02222P.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
( GETH ) GENENTECH INC.

PA 27-OCT-1997; 97US-0063329P.
PA 28-OCT-1997; 97US-00633541P.
PA 28-OCT-1997; 97US-00633542P.
PA 28-OCT-1997; 97US-00633543P.
PA 28-OCT-1997; 97US-00633544P.
PA 28-OCT-1997; 97US-00633549P.
PA 28-OCT-1997; 97US-00633550P.
PA 28-OCT-1997; 97US-00633564P.
PA 29-OCT-1997; 97US-0063435P.
PA 29-OCT-1997; 97US-0063704P.
PA 29-OCT-1997; 97US-0063732P.
PA 29-OCT-1997; 97US-0063734P.
PA 29-OCT-1997; 97US-0063735P.
PA 29-OCT-1997; 97US-0063738P.
PA 29-OCT-1997; 97US-0064215P.
PA 31-OCT-1997; 97US-0063870P.
PA 31-OCT-1997; 97US-0064103P.
PA 03-NOV-1997; 97US-0064248P.
PA 07-NOV-1997; 97US-0064809P.
PA 12-NOV-1997; 97US-0065186P.
PA 17-NOV-1997; 97US-0065846P.
PA 18-NOV-1997; 97US-0065693P.
PA 21-NOV-1997; 97US-0066120P.
PA 21-NOV-1997; 97US-0066364P.
PA 24-NOV-1997; 97US-0068453P.
PA 24-NOV-1997; 97US-0068466P.
PA 24-NOV-1997; 97US-0068511P.
PA 24-NOV-1997; 97US-0066770P.
PA 24-NOV-1997; 97US-0066772P.
PA 25-NOV-1997; 97US-0066840P.
PA 12-DEC-1997; 97US-0068425P.
PA 04-JUN-1998; 98US-0088026P.
PA 10-SEP-1998; 98US-0099803P.
PA 10-SEP-1998; 98WO-US018824.
PA 14-SEP-1998; 98US-0100262P.
PA 14-SEP-1998; 98WO-US019177.
PA 16-SEP-1998; 98WO-US019330.
PA 17-SEP-1998; 98US-0100858P.
PA 17-SEP-1998; 98WO-US019437.
PA 13-OCT-1998; 98US-0104080P.
PA 20-NOV-1998; 98US-0109304P.
PA 01-DEC-1998; 98WO-US025108.
PA 22-DEC-1998; 98US-0113298P.
PA 07-JUL-1999; 99US-0143048P.
PA 26-JUL-1999; 99US-0145698P.
PA 28-JUL-1999; 99WO-US020594.
PA 08-SEP-1999; 99WO-US02222P.
PA 13-SEP-1999; 99WO-US020944.
PA 15-SEP-1999; 99WO-US021090.
PA 15-SEP-1999; 99WO-US021547.
PA 05-OCT-1999; 99WO-US023089.
PA 29-NOV-1999; 99WO-US028214.
PA 30-NOV-1999; 99WO-US028313.
PA 01-DEC-1999; 99WO-US028301.
PA 02-DEC-1999; 99WO-US028564.
PA 02-DEC-1999; 99WO-US028565.
PA 16-DEC-1999; 99WO-US030095.
PA 20-DEC-1999; 99WO-US030911.
PA 20-DEC-1999; 99WO-US030999.
PA 05-JAN-2000; 2000WO-US000219.
PA 11-FEB-2000; 2000WO-US003565.
PA 22-FEB-2000; 2000WO-US004414.
PA 24-FEB-2000; 2000WO-US005004.
PA 02-MAR-2000; 2000WO-US005841.
PA 20-MAR-2000; 2000WO-US007377.
PA 30-MAR-2000; 2000WO-US008439.
PA 22-MAY-2000; 2000WO-US014042.
PA 02-JUN-2000; 2000WO-US015264.
PA 28-JUL-2000; 2000WO-US020710.
PA 24-AUG-2000; 2000WO-US023328.
PA 18-SEP-2000; 2000US-00665350.
( GETH ) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-341586/32.
XX
XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing or
XX treating inflammatory diseases, organ failure, atherosclerosis, cardiac
XX injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's
XX disease.
XX
XX Example 2; Page 80; 473pp; English.
XX
XX The invention describes sixty one nucleic acids encoding PRO polypeptides
XX (secreted and transmembrane). The PRO polypeptides and nucleic acids are
XX useful in diagnosing or treating enterocolitis, gastrointestinal
XX ulceration, skin diseases associated with abnormal keratinocyte
XX differentiation, e.g. psoriasis or epithelial cancers such as squamous
XX cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
XX lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
XX asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
XX injury, infertility, birth defects, premature aging, AIDS, cancer,
XX diabetic complications, or mutations in general. The polypeptides are
XX also useful for wound repair and associated therapies concerned with re-
XX growth of tissue. The PRO polypeptides and nucleic acid molecules are
XX also useful in gene therapy, and as molecular weight markers for protein
XX electrophoresis purposes. The anti-PRO antibodies may be used in
XX diagnostic assays for PRO, or for the affinity purification of PRO from
XX recombinant cell culture or natural sources. This sequence represents a
XX novel human PRO polypeptide associated oligonucleotide
XX
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGGCAGACTTA 768
Db 22 GACCTGTATTTTGGCAGACTTA 1

RESULT 167
ACD19647/c
ID ACD19647 standard; DNA; 22 BP.
AC ACD19647;
XX
XX 22-AUG-2003 (first entry)
XX
XX Human secreted / transmembrane polypeptide PRO211 primer 28730.r.
XX
XX Human; ss; PCR; primer; gene therapy; apoptosis; bleeding; tumour; ALS;
XX gynaecological disease; hysterectomy; angiogenesis; skin disease; cancer;
XX coronary ischaemic condition; gastrointestinal mucosa disorder; asthma;
XX mucosal lesion repair; keratinocyte differentiation; psoriasis;
XX Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;
XX neuropathy; blood coagulation cascade disorder; thrombosis; haemorrhage;
XX neurodegenerative disease; endometrial bleeding; wound healing; tissue
XX tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing.
XX
XX Homo sapiens.
XX
XX US2003027143-A1.
XX
XX 06-FEB-2003.
XX
XX 16-JUL-2001; 2001US-00906838.
XX
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.

```



AC ADB29212;  
 XX 20-NOV-2003 (first entry)  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX Human; PCR; primer; ss; PRO; secreted; transmembrane;  
 KW gastrointestinal mucosa; mucosal lesion; skin disease;  
 KW keratinocyte differentiation; psoriasis; Parkinson's disease;  
 KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;  
 KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;  
 KW anthranthemic agent; haemorrhage; endometrial bleeding angiogenesis;  
 KW kidney tissue; apoptosis; therapeutic; tissue typing;  
 KW immunohistochemical staining; gene therapy; neuroprotective;  
 KW cytostatic; virucide; anticoagulant.  
 XX Homo sapiens.  
 OS US2003092002-A1.  
 XX 15-MAY-2003.  
 XX 10-JUL-2001; 2001US-00902615.  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065848P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0098033P.  
 PR 14-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019130.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98WO-US019304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005044.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 02-MAY-2000; 2000WO-US014042.  
 PR 22-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 PA Ashkenazi A, Botstein D, Deanovsers L, Eaton DL, Ferrara N;  
 PI Pivaroff E, Pong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX MPI; 2003-765473/72.  
 DR Novel isolated native PRO polypeptide useful for treating Parkinson's  
 PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal  
 PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher  
 PT syndrome.  
 XX Example 2; Page 80; 469pp; English.  
 PS The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 CC for treating disorders associated with the preservation and maintenance  
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocytes  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's

CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serves as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.

XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 747 GACCTGTATTGCGCAGACTTA 768

Db 22 GACCTGTATTGCGCAGACTTA 1

RESULT 169

ADA18068/c

ID ADA18068 standard; DNA; 22 BP.

XX AC ADA18068;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane;  
 KW gastrointestinal mucosa; mucosal lesion; skin disease;  
 KW keratinocyte differentiation; psoriasis; Parkinson's disease;  
 KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;  
 KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;  
 KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;  
 KW kidney tissue; apoptosis; therapeutic; tissue typing;  
 KW immunohistochemical staining; gene therapy; neuroprotective;  
 KW cytostatic; virucide; anticoagulant.

XX OS Homo sapiens.

XX PN US2003039971-A1.

XX PD 27-FEB-2003.

XX PF 16-JUL-2001; 2001US-00906646.

XX PP 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059268P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 31-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-009803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0101917P.  
 PR 16-SEP-1998; 98US-0101933P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0101943P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0025108P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0020594P.  
 PR 13-SEP-1999; 99US-0020944P.  
 PR 15-SEP-1999; 99US-0021090P.  
 PR 15-SEP-1999; 99US-0021547P.  
 PR 05-OCT-1999; 99US-0023089P.  
 PR 29-NOV-1999; 99US-0028214P.  
 PR 30-NOV-1999; 99US-0028313P.  
 PR 01-DEC-1999; 99US-0028301P.

PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-0065350.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PU, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PW, Wood WT;  
 XX  
 DR WPI; 2003-503392/47.  
 XX  
 XX  
 PT New secreted and transmembrane polypeptides useful for treating skin,  
 PT neurodegenerative diseases, asthma, rheumatoid arthritis, psoriasis and  
 PT multiple sclerosis.  
 XX  
 PS Example 2; SEQ ID NO 7; 471pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 CC for treating disorders associated with the preservation and maintenance  
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serve as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in

CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTCGACGACTTA 768  
 Db 22 GACCTGTATTTCGACGACTTA 1  
 RESULT 170  
 ACD66794/c  
 ID ACD66794 standard; DNA; 22 BP.  
 XX  
 AC ACD66794;  
 XX  
 DT 17-SEP-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein PRO211 PCR primer #2.  
 XX  
 KW Human; ss; PRO; secreted and transmembrane protein; inflammation;  
 KW rheumatoid arthritis; psoriasis; multiple sclerosis; atherosclerosis;  
 KW infertility; birth defect; premature aging; malignancy; cancer; stroke;  
 KW heart attack; hypertension; gastrointestinal ulceration;  
 KW Parkinson's disease; Alzheimer's disease; AIDS; cholesterol uptake;  
 KW wound healing; tissue repair; gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003045693-A1.  
 XX  
 PD 06-MAR-2003.  
 XX  
 PF 11-JUL-2001; 2001US-00903749.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-00637332P.  
PR 29-OCT-1997; 97US-00637334P.  
PR 29-OCT-1997; 97US-00637335P.  
PR 29-OCT-1997; 97US-00637338P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064803P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-008026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100859P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
XX Williams PM, Wood WT;  
DR WPI; 2003-512316/48.  
XX New genes and secreted and transmembrane polypeptides (e.g. PRO245 or

PT PRO1868), useful for treating or diagnosing e.g. cancers,  
PT atherosclerosis, infertility, stroke, AIDS or multiple sclerosis in  
PT mammals.  
XX Example 2; Page 80; 476pp; English.  
XX The invention relates to an isolated nucleic acid molecule comprising a  
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of  
CC 61 PRO (secreted and transmembrane protein) polypeptides appearing as  
CC AB032756-AB032816; or (b) any of 61 nucleotide sequences having 50-4053bp  
CC fully defined in the specification; or the full length coding sequence of  
CC any these 61 nucleotide sequences. Also included are the isolated PRO  
CC polypeptide (lacking its associated signal peptide or an extracellular  
CC domain of the PRO polypeptide, with or lacking its associated signal  
CC peptide), a vector comprising the nucleic acid molecule, a host cell  
CC comprising the vector (used to produce the PRO polypeptide), a chimeric  
CC molecule comprising the PRO polypeptide fused to a heterologous amino  
CC acid sequence, an anti-PRO antibody, detecting PRO245 or PRO1868  
CC polypeptide in a sample suspected of containing any of these PRO  
CC polypeptides, linking a bioactive molecule to a cell expressing a PRO245  
CC or PRO1868 polypeptide and modulating at least one biological activity of  
CC a cell expressing the PRO245 or PRO1868 polypeptide. The PRO polypeptides  
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors  
CC or bioreactors. These are particularly useful for diagnosing or treating  
CC e.g. inflammations, rheumatoid arthritis, psoriasis, multiple sclerosis,  
CC atherosclerosis, infertility, birth defects, premature aging, malignancy  
CC (e.g. cancers), strokes, heart attacks, hypertension, gastrointestinal  
CC ulcerations, Parkinson's diseases, Alzheimer's disease, or AIDS in  
CC mammals. These are also useful for modulating cholesterol uptake in the  
CC body, and in wound healing or tissue repair. The PRO polypeptides are  
CC useful in drug screening. The PRO polypeptides are also useful as  
CC molecular weight markers, or for chromosome identification. The PRO genes  
CC are useful as hybridisation probes, or for screening libraries of human  
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene  
CC therapy, particularly for replacing a defective gene. The present  
CC sequence is an oligonucleotide (PCR primer or probe) used in the  
CC isolation of a PRO cDNA.  
XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTCGACACTTA 768  
Db 22 GACCTGTATTTCGACACTTA 1  
|||||  
RESULT 171  
ACD82955/c  
ID ACD82955 standard; DNA; 22 BP.  
XX AC ACD82955;  
XX 22-SEP-2003 (first entry)  
DE Human PRO PCR primer #2.  
XX Human; PRO; primer; ss; secreted polypeptide; transmembrane polypeptide;  
KW abnormal bleeding; gynaecological disease; hysterectomy; mucosal lesion;  
KW coronary ischaemic condition; gastrointestinal mucosa; skin disease; ALS;  
KW keratinocyte differentiation; psoriasis; Parkinson's disease; asthma;  
KW Alzheimer's disease; rheumatoid arthritis; multiple sclerosis; cancer;  
KW amyotrophic lateral sclerosis; neuropathy; uncontrolled cell growth; PCR.  
XX Homo sapiens.  
OS US200304793-A1.  
XX 06-MAR-2003.  
XX 11-JUL-2001; 2001US-00903786.

```

XX 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062288P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 04-JUN-1998; 97US-0069425P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98US-0113296P.
PR 27-DEC-1998; 98US-0143048P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.

```

```

PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH ) GENENTECH INC.
PA
XX
XX Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-492256/46.
DR
XX
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating abnormal bleeding involved in
PT gynecological diseases, skin diseases and neurodegenerative diseases.
XX
XX Example 2; Page 80; 475pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides can be used in diagnosing or
CC treating abnormal bleeding involved in gynaecological diseases e.g. to
CC avoid or lessen the need for hysterectomy. They can also be used in
CC treating coronary ischaemic conditions, disorders associated with the
CC preservation and maintenance of gastrointestinal mucosa and the repair of
CC acute and chronic mucosal lesions, skin diseases associated with abnormal
CC keratinocyte differentiation (e.g. psoriasis), Parkinson's disease,
CC Alzheimer's disease, asthma, rheumatoid arthritis, multiple sclerosis,
CC amyotrophic lateral sclerosis (ALS), neuropathies and diseases related to
CC uncontrolled cell growth, such as cancer. This sequence represents a PCR
CC primer used to isolate a human PRO polynucleotide of the invention
XX
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 747 GACCTGTATTTCGACACTTA 768
Db 22 GACCTGTAAATGTCGGACTTA 1
|||||||
RESULT 172
ADAL6043/c
ID ADAL6043 standard; DNA; 22 BP.
XX
XX AC ADAL6043;
XX
XX 06-NOV-2003 (first entry)
XX
XX Human secreted/transmembrane protein, #1, PCR primer #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;

```



KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulvovaginal; cytostatic; ophthalmological;  
 KW osteoporosis; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003049621-A1.

XX 13-MAR-2003.

XX 11-JUL-2001; 2001US-00904113.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059113P.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019330.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

PR 22-DEC-1998; 98US-0113286P.

PR 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 05-JAN-2000; 2000WO-US030999.

PR 11-FEB-2000; 2000WO-US030555.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 30-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015284.

PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00665350.

XX (GETH) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;

PI Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2003-521801/49.

XX New genes encoding for secreted and transmembrane PRO polypeptides,

useful for treating e.g. cardiac insufficiency disorders, wounds, cancers, obesity, diabetes, hyperinsulinemia, hypoinsulinemia, or arthritis.

Example 2; SEQ ID NO 7; 476pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinemia.

CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768

Db 22 GACCTGTAATGTGCCGACTTA 1

RESULT 173

ADA42188/c

ID ADA42188 standard; DNA; 22 BP.

XX AC ADA42188;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane;  
 KW gastrointestinal mucosa; mucosal lesion; skin disease;  
 KW keratinocyte differentiation; psoriasis; Parkinson's disease;  
 KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;  
 KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;  
 KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;  
 KW kidney tissue; apoptosis; therapeutic; tissue typing;  
 KW immunohistochemical staining; gene therapy; neuroprotective;  
 KW cytostatic; virucide; anticoagulant.

XX OS Homo sapiens.

XX PN US2003054401-A1.

XX PD 20-MAR-2003.

XX PF 11-JUL-2001; 2001US-00903520.

XX PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065933P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 08-DEC-1999; 99WO-US020594.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-0065350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashtenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini J;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2003-755054/71.  
 XX  
 XX Novel PRO polypeptides useful for treating Parkinson's disease,  
 PT Alzheimer's disease, enterocolitis, Zollinger-Ellison syndrome,  
 PT psoriasis, epidermoid carcinoma of the vulva and gliomas, gynecological  
 PT diseases.  
 XX  
 PS Example 2; SEQ ID NO 7; 479pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 CC for treating disorders associated with the preservation and maintenance  
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serve as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. NO. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTTGGCAGACTTA 768  
 ||||| ||||| ||||| |||||  
 DB 22 GACCTGTATTTTGGCAGACTTA 1

## RESULT 174

ACD23133/c  
 ID ACD23133 standard; DNA; 22 BP.  
 XX  
 AC ACD23133;  
 XX  
 DT 26-AUG-2003 (first entry)  
 XX  
 DE Human PRO PCR primer #192.  
 XX  
 KW Human; PRO; primer; ss; Parkinson's disease; Alzheimer's disease; ALS;  
 KW amyotrophic lateral sclerosis; neuropathy; cancer; viral infection; AIDS;  
 KW Usher's syndrome; haemorrhage; enterocolitis; Zollinger-Ellison syndrome;  
 KW gastrointestinal ulceration; congenital microvillus atrophy; psoriasis;  
 KW skin diseases; endometrial bleeding; angiogenesis; ischaemic condition;  
 KW asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disease;  
 KW atherosclerosis; infertility; birth defect; premature aging; stroke; PCR;  
 KW diabetic complication.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003064367-A1.  
 PD 03-APR-2003.  
 XX  
 PF 13-JUL-2001; 2001US-00904485.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 18-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065893P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018828.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski P, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WF;  
 XX  
 DR WPI; 2003-567176/53.  
 XX  
 XX  
 PT Novel isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for  
 PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic  
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.  
 XX  
 PS Example 2; Page 80; 477pp; English.  
 XX  
 XX The invention relates to human PRO polypeptides and the polynucleotides

CC encoding them. The polypeptides and polynucleotides are used for treating  
 CC diseases related to growth or survival of nerve cells such as Parkinson's  
 CC disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and  
 CC neuropathies, diseases related to uncontrolled cell growth such as  
 CC cancer, viral infections, Usher's syndrome, haemorrhage, enterocolitis,  
 CC Zollinger-Ellison syndrome, gastrointestinal ulceration, congenital  
 CC microvillus atrophy, skin diseases such as psoriasis and epithelial  
 CC cancers, endometrial bleeding, angiogenesis, ischaemic conditions,  
 CC asthma, rheumatoid arthritis, multiple sclerosis, inflammatory diseases,  
 CC atherosclerosis, cardiac injury, infertility, birth defects, premature  
 CC aging, AIDS, stroke and diabetic complications. The polynucleotides are  
 CC also useful in chromosome and gene mapping. This sequence represents a  
 CC PCR primer used in isolation of a human PRO polynucleotide of the  
 CC invention  
 XX

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGATTTTGGCAGACTTA 768

Db 22 GACCTGATTTTGGCAGACTTA 1

RESULT 175

ADA16467/c

ID ADA16467 standard; DNA; 22 BP.

XX

AC ADA16467;

XX

DT 06-NOV-2003 (first entry)

XX

DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX

KW Human; PCR; primer; ss; PRO; secreted; transmembrane;  
 KW gastrointestinal mucosa; mucosal lesion; skin disease;  
 KW keratinocyte differentiation; psoriasis; Parkinson's disease;  
 KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;  
 KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;  
 KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;  
 KW kidney tissue; apoptosis; therapeutic; tissue typing;  
 KW immunohistochemical staining; gene therapy; neuroprotective;  
 KW cytosolic; virucide; anticoagulant.

OS Homo sapiens.

XX

PN US2003039969-A1.

XX

PD 27-FEB-2003.

XX

PF 12-JUL-2001; 2001US-00904786.

XX

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.



RESULT 176	
ADAI2896/C	
ID ADAI2896 standard; DNA; 22 BP.	
XX AC	
XX AD	
XX AC	
XX DT	
XX DT	
XX DE	
XX KW	Human secreted/transmembrane protein, #1, PCR primer #2.
XX KW	Human; PCR; primer; ss; PRO; secreted; transmembrane;
XX KW	gastrointestinal mucosa; mucosal lesion; skin disease;
XX KW	keratinocyte differentiation; psoriasis; Parkinson's disease;
XX KW	Alzheimer's disease; amyotrophic lateral sclerosis; ALS; neuropathy;
XX KW	cell growth; cancer; tumour; viral infection; neurodegenerative disease;
XX KW	antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;
XX KW	kidney tissue; apoptosis; therapeutic; tissue typing;
XX KW	immunohistochemical staining; gene therapy; nootropic; neuroprotective;
XX KW	cytostatic; virucide; anticoagulant.
XX OS	Homo sapiens.
XX FN	US2003049622-A1.
XX PD	13-MAR-2003.
XX PF	14-JUL-2001; 2001US-00904956.
XX XX	17-SEP-1997; 97US-0059113P.
PR	17-SEP-1997; 97US-0059115P.
PR	17-SEP-1997; 97US-0059117P.
PR	17-SEP-1997; 97US-0059119P.
PR	17-SEP-1997; 97US-0059121P.
PR	17-SEP-1997; 97US-0059122P.
PR	17-SEP-1997; 97US-0059184P.
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	15-OCT-1997; 97US-0062125P.
PR	17-OCT-1997; 97US-0062285P.
PR	17-OCT-1997; 97US-0062287P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0062814P.
PR	24-OCT-1997; 97US-0062816P.
PR	24-OCT-1997; 97US-0063045P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	24-OCT-1997; 97US-0063127P.
PR	24-OCT-1997; 97US-0063128P.
PR	27-OCT-1997; 97US-0063327P.
PR	27-OCT-1997; 97US-0063329P.
PR	28-OCT-1997; 97US-0063341P.
PR	28-OCT-1997; 97US-0063342P.
PR	28-OCT-1997; 97US-0063344P.
PR	28-OCT-1997; 97US-0063349P.
PR	28-OCT-1997; 97US-0063350P.
PR	28-OCT-1997; 97US-0063356P.
PR	29-OCT-1997; 97US-0063435P.
PR	29-OCT-1997; 97US-0063704P.
PR	29-OCT-1997; 97US-0063732P.
PR	29-OCT-1997; 97US-0063734P.
PR	29-OCT-1997; 97US-0063735P.
PR	29-OCT-1997; 97US-0063738P.
PR	29-OCT-1997; 97US-0064215P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	03-NOV-1997; 97US-0064248P.
PR	07-NOV-1997; 97US-0064809P.
PR	12-NOV-1997; 97US-0065186P.
PR	17-NOV-1997; 97US-0065846P.
PR	18-NOV-1997; 97US-0065693P.
PR	21-NOV-1997; 97US-0066120P.
PR	21-NOV-1997; 97US-0066364P.
PR	24-NOV-1997; 97US-0066453P.
PR	24-NOV-1997; 97US-0066456P.
PR	24-NOV-1997; 97US-0066511P.
PR	24-NOV-1997; 97US-0066770P.
PR	24-NOV-1997; 97US-0066772P.
PR	25-NOV-1997; 97US-0066840P.
PR	12-DEC-1997; 97US-0069425P.
PR	04-JUN-1998; 98US-0088026P.
PR	10-SEP-1998; 98US-0099803P.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98US-0100262P.
PR	16-SEP-1998; 98WO-US019177.
PR	17-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98US-0100858P.
PR	17-SEP-1998; 98WO-US019437.
PR	13-OCT-1998; 98US-0104080P.
PR	20-NOV-1998; 98US-0109304P.
PR	01-DEC-1998; 98WO-US025108.
PR	22-DEC-1998; 98US-0113296P.
PR	07-JUL-1999; 99US-0143048P.
PR	26-JUL-1999; 99US-0145698P.
PR	28-JUL-1999; 99US-0146222P.
PR	08-SEP-1999; 99WO-US020594.
PR	13-SEP-1999; 99WO-US020944.
PR	15-SEP-1999; 99WO-US021090.
PR	15-SEP-1999; 99WO-US021547.
PR	05-OCT-1999; 99WO-US023089.
PR	29-NOV-1999; 99WO-US028214.
PR	30-NOV-1999; 99WO-US028313.
PR	01-DEC-1999; 99WO-US028301.
PR	02-DEC-1999; 99WO-US028564.
PR	02-DEC-1999; 99WO-US028565.
PR	16-DEC-1999; 99WO-US030095.
PR	20-DEC-1999; 99WO-US030911.
PR	20-DEC-1999; 99WO-US030999.
PR	05-JAN-2000; 2000WO-US000219.
PR	11-FEB-2000; 2000WO-US003565.
PR	22-FEB-2000; 2000WO-US004414.
PR	24-FEB-2000; 2000WO-US005004.
PR	02-MAR-2000; 2000WO-US005841.
PR	20-MAR-2000; 2000WO-US007377.
PR	30-MAR-2000; 2000WO-US008439.
PR	22-MAY-2000; 2000WO-US014042.
PR	02-JUN-2000; 2000WO-US015264.
PR	28-JUL-2000; 2000WO-US020710.
PR	24-AUG-2000; 2000WO-US023328.
PR	

CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serves as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGAGACTTA 768

||||| | | | | | | | | |  
 Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 177

ADA41764/c

ID ADA41764 standard; DNA; 22 BP.

XX ADA41764;

XX ADA41764;

XX 20-NOV-2003 (first entry)

DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane;

KW gastrointestinal mucosa; mucosal lesion; skin disease;

KW keratinocyte differentiation; psoriasis; Parkinson's disease;

KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;

KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;

KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;

KW kidney tissue; apoptosis; therapeutic; tissue typing;

KW immunohistochemical staining; gene therapy; neuroprotective;

KW cytoskeletal; virucide; anticoagulant.

XX Homo sapiens.

OS US2003082540-A1.

XX 01-MAY-2003.

XX

PF 10-JUL-2001; 2001US-00902634.  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065848P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0101917P.  
 PR 16-SEP-1998; 98US-0101933P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100859P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 98US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 05-OCT-1999; 99US-0146222P.

PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 14-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2003-755103/71.  
 XX  
 XX New PRO polypeptides useful for treating Parkinson's disease,  
 PT enterocolitis, Zollinger-Ellison syndrome gastrointestinal ulceration,  
 PT Alzheimer's disease, amyotrophic lateral sclerosis and Usher syndrome.  
 XX  
 PS Example 2; SEQ ID NO 7; 469pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 CC for treating disorders associated with the preservation and maintenance  
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serves as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can also be used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO

CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGACACTTA 768  
 Db 22 GACCTGTAATGTCGGACTTA 1

RESULT 178

ADAL7111/c

ID ADAL7111 standard; DNA; 22 BP.

XX

AC ADAL7111;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX

KW Human; PCR; primer; ss; PRO; secreted; transmembrane;

KW gastrointestinal mucosa; mucosal lesion; skin disease;

KW keratinocyte differentiation; psoriasis; Parkinson's disease;

KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;

KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;

KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;

KW kidney tissue; apoptosis; therapeutic; tissue typing;

KW immunohistochemical staining; gene therapy; nontropic; neuroprotective;

KW cytostatic; virucide; anticoagulant.

XX Homo sapiens.

OS

XX US2003017498-A1.

PN

XX 23-JAN-2003.

PD

XX 17-JUN-2001; 2001US-00908093.

PF

XX 17-SEP-1997; 97US-0059113P.

PR

XX 17-SEP-1997; 97US-0059115P.

PR

XX 17-SEP-1997; 97US-0059117P.

PR

XX 17-SEP-1997; 97US-0059119P.

PR

XX 17-SEP-1997; 97US-0059121P.

PR

XX 17-SEP-1997; 97US-0059122P.

PR

XX 18-SEP-1997; 97US-0059263P.

PR

XX 18-SEP-1997; 97US-0059266P.

PR

XX 15-OCT-1997; 97US-0062125P.

PR

XX 17-OCT-1997; 97US-0062285P.

PR

XX 17-OCT-1997; 97US-0062287P.

PR

XX 21-OCT-1997; 97US-0063486P.

PR

XX 24-OCT-1997; 97US-0062814P.

PR

XX 24-OCT-1997; 97US-0062816P.

PR

XX 24-OCT-1997; 97US-0063120P.

PR

XX 24-OCT-1997; 97US-0063121P.

PR

XX 24-OCT-1997; 97US-0063127P.

PR

XX 27-OCT-1997; 97US-0063128P.

PR

XX 27-OCT-1997; 97US-0063327P.

PR

XX 28-OCT-1997; 97US-0063329P.

PR

XX 28-OCT-1997; 97US-0063541P.

PR

XX 28-OCT-1997; 97US-0063542P.

PR





XX 20-NOV-2003 (first entry)  
XX Human secreted/transmembrane protein, #1, PCR primer #2.  
XX  
XX  
XX Human; PCR; primer; ss; PRO; secreted; transmembrane;  
KW Gastrointestinal mucosa; mucosal lesion; skin disease;  
KW Keratinocyte differentiation; psoriasis; Parkinson's disease;  
KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;  
KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;  
KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;  
KW kidney tissue; apoptosis; therapeutic; tissue typing;  
KW Immunohistochemical staining; Gene therapy; nootropic; neuroprotective;  
KW cytotatic; virucide; anticoagulant.  
XX Homo sapiens.  
XX  
XX US2003054351-A1.  
XX  
XX 20-MAR-2003.  
XX  
XX 13-JUL-2001; 2001US-00904462.  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.  
XX 18-SEP-1997; 97US-0059266P.  
XX 15-OCT-1997; 97US-0062125P.  
XX 17-OCT-1997; 97US-0062285P.  
XX 17-OCT-1997; 97US-0062287P.  
XX 21-OCT-1997; 97US-0063486P.  
XX 24-OCT-1997; 97US-0062814P.  
XX 24-OCT-1997; 97US-0062816P.  
XX 24-OCT-1997; 97US-0063045P.  
XX 24-OCT-1997; 97US-0063120P.  
XX 24-OCT-1997; 97US-0063121P.  
XX 24-OCT-1997; 97US-0063127P.  
XX 24-OCT-1997; 97US-0063128P.  
XX 27-OCT-1997; 97US-0063327P.  
XX 27-OCT-1997; 97US-0063329P.  
XX 28-OCT-1997; 97US-0063541P.  
XX 28-OCT-1997; 97US-0063542P.  
XX 28-OCT-1997; 97US-0063544P.  
XX 28-OCT-1997; 97US-0063549P.  
XX 28-OCT-1997; 97US-0063550P.  
XX 28-OCT-1997; 97US-0063564P.  
XX 29-OCT-1997; 97US-0063435P.  
XX 29-OCT-1997; 97US-0063704P.  
XX 29-OCT-1997; 97US-0063732P.  
XX 29-OCT-1997; 97US-0063734P.  
XX 29-OCT-1997; 97US-0063735P.  
XX 29-OCT-1997; 97US-0063738P.  
XX 29-OCT-1997; 97US-0064215P.  
XX 31-OCT-1997; 97US-0063870P.  
XX 31-OCT-1997; 97US-0064103P.  
XX 03-NOV-1997; 97US-0064248P.  
XX 07-NOV-1997; 97US-0064809P.  
XX 12-NOV-1997; 97US-0065186P.  
XX 17-NOV-1997; 97US-0065846P.  
XX 18-NOV-1997; 97US-0065693P.  
XX 21-NOV-1997; 97US-0066120P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 24-NOV-1997; 97US-0066453P.  
XX 24-NOV-1997; 97US-0066466P.  
XX 24-NOV-1997; 97US-0066511P.  
XX 24-NOV-1997; 97US-0066570P.  
XX 24-NOV-1997; 97US-0066772P.  
XX 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100859P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Pong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart FA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-755052/71.

Novel isolated secreted and transmembrane PRO polypeptide, useful for tissue typing, treating Parkinson's disease, Alzheimer's disease, birth defects, cancer.

Example 2; SEQ ID NO 7; 464pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. PRO polypeptides are also useful for treating disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's diseases, amyotrophic lateral sclerosis (ALS), neuropathies and additionally, disease related to uncontrolled cell growth, e.g. cancer.

CC PRO polypeptides also serves as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768

DB 22 GACCTGTATTTGCCGACTTA 1

RESULT 190

ACD23495/C

ID ACD23495 standard; DNA; 22 BP.

XX

AC ACD23495;

XX 26-AUG-2003 (first entry)

XX Human PRO PCR primer #192.

XX

XX Human; PRO; primer; ss; secreted polypeptide; transmembrane polypeptide;  
 KW leukocyte homing; rheumatoid arthritis; psoriasis; multiple sclerosis;  
 KW mucosal lesion; enterocolitis Zollinger Ellison syndrome; asthma; PCR;  
 KW antiasthmatic; antirheumatic; antiarthritic; neuroprotective.

XX Homo sapiens.

XX US2003064923-A1.

XX 03-APR-2003.

XX 13-JUL-2001; 2001US-00905348.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0086026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019310.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.

```

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH ) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-567190/53.
DR
XX
XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
XX Example 2; Page 80; 471pp; English.
PS
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC polypeptides are useful for detecting PRO polypeptides and for linking a
CC bioactive molecule to a cell expressing the polypeptides, where the
CC bioactive molecule is a toxin, radiolabel or an antibody. The bioactive
CC material causes the death of the cell. The polypeptides or antibodies
CC specific to the polypeptides are useful for modulating at least one
CC biological activity of a cell expressing the polypeptides. The
CC polypeptides are useful for treating disorders associated with leukocyte
CC homing such as asthma, rheumatoid arthritis, psoriasis and multiple
CC sclerosis, repair of acute and chronic mucosal lesions such as
CC enterocolitis and Zollinger Ellison syndrome and for identifying agonists
CC or antagonists of the polypeptides. The polynucleotides are useful as
CC hybridization probes, in chromosome and gene mapping, in generation of
CC antisense RNA and DNA, in the preparation of PRO polypeptides and for
CC generating probes for polymerase chain reaction (PCR), Northern analysis,
CC Southern analysis and Western analysis. This sequence represents a PCR
CC primer used in isolation of a human PRO polynucleotide of the invention
XX
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCAGACTTA 768
Db 22 GACCTGTATTGGCCAGACTTA 1

RESULT 181
ADB77533/c
ID ADB77533 standard; DNA; 22 BP.
XX
AC ADB77533;
XX
XX 04-DEC-2003 (first entry)
XX
XX Human secreted/transmembrane protein, #1, PCR primer #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane;
KW gastrointestinal mucosa; mucosal lesion; skin disease;
KW keratinocyte differentiation; psoriasis; Parkinson's disease;
KW Alzheimer's diseases; amyotrophic lateral sclerosis; ALS; neuropathy;
KW cell growth; cancer; tumour; viral infection; neurodegenerative disease;
KW antithrombotic agent; haemorrhage; endometrial bleeding angiogenesis;

```

```

KW kidney tissue; apoptosis; therapeutic; tissue typing;
KW immunohistochemical staining; gene therapy; neuroprotective;
XX cytostatic; virucide; anticoagulant.
OS Homo sapiens.
XX
XX US2003077654-A1.
XX
XX 24-APR-2003.
XX
XX 10-JUL-2001; 2001US-00902759.
XX
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063104P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 14-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.

```



PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063322P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98WO-US019177.  
 PR 17-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100859P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98WO-US025108.  
 PR 07-JUL-1999; 99US-0113296P.  
 PR 26-JUL-1999; 99US-0143048P.  
 PR 28-JUL-1999; 99US-0145698P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 PR (GETH ) GENENTECH INC.  
 PR Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 PR WPI; 2003-765412/72.  
 PR Novel isolated native PRO polypeptide useful for tissue typing,  
 PT modulating biological activity of cell, as molecular weight markers in  
 PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison  
 PT syndrome.  
 PR Example 2; Page 80; 475pp; English.  
 PR The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 CC for treating disorders associated with the preservation and maintenance  
 CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 CC PRO polypeptides also serves as tumour specific antigens which may be  
 CC exploited as therapeutic targets for anti-tumour drugs, and are also  
 CC employed therapeutically in vivo for lessening the effects of viral  
 CC infection. The PRO polypeptides can be also used in assays to determine  
 CC if it has a role in neurodegenerative diseases or their reversal, as an  
 CC antithrombotic agent with reduced risk for haemorrhage as compared with  
 CC heparin, in treating other PRO-associated disorders, in modulating  
 CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
 CC tissue. PRO polypeptides and their portions affect the expression of  
 CC genes which have a role in apoptosis. The polynucleotides are useful in  
 CC molecular biology including uses as hybridisation probes for cDNA library  
 CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for recombinantly  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a PCR primer which was used to amplify a PRO  
 CC polynucleotide of the invention.  
 PR Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCAGACTTA 768  
 ||||| | ||| |||||  
 Db 22 GACCTGTAATGTCGGGACTTA 1  
  
 RESULT 193  
 ADC28315/c  
 ID ADC28315 standard; DNA; 22 BP.  
 XX  
 AC ADC28315;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 KW Human; PCR; primer; as; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003059772-A1.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 18-JUL-2001; 2001US-00909064.  
 XX  
 PR 17-SEP-1997; 97US-00591113P.  
 PR 17-SEP-1997; 97US-00591113P.  
 PR 17-SEP-1997; 97US-00591117P.  
 PR 17-SEP-1997; 97US-00591119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0098033P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100263P.  
 PR 16-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100859P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 05-OCT-1999; 99US-0146222P.  
 PR 29-NOV-1999; 99US-0146222P.  
 PR 30-NOV-1999; 99US-0146222P.  
 PR 01-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 16-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 05-JAN-2000; 2000US-0000219P.  
 PR 11-FEB-2000; 2000US-0000219P.  
 PR 22-FEB-2000; 2000US-0000219P.  
 PR 24-FEB-2000; 2000US-0000219P.  
 PR 02-MAR-2000; 2000US-0000219P.  
 PR 30-MAR-2000; 2000US-0000219P.  
 PR 22-MAY-2000; 2000US-0000219P.  
 PR 02-JUN-2000; 2000US-0000219P.  
 PR 28-JUL-2000; 2000US-0000219P.  
 PR 24-AUG-2000; 2000US-0000219P.  
 PR 18-SEP-2000; 2000US-0000219P.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Deanovs L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 WPI; 2003-540670/51.  
 XX  
 Novel secreted and transmembrane polypeptides and polynucleotides  
 encoding them useful for treating skin, neurodegenerative diseases, as an  
 antithrombotic agent and for inducing endothelial cell apoptosis.  
 XX  
 Example 2; SEQ ID NO 7; 470pp; English.  
 XX  
 The invention discloses isolated PRO secreted/transmembrane polypeptides  
 and the nucleic acid encoding them. The polypeptides can be used to raise  
 antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGACACTTA 768

Db 22 GACCTGTATTTCGCGACTTA 1

RESULT 184

ID ADC39515/C

XX ADC39515 standard; DNA; 22 BP.

AC ADC39515;

DT 18-DEC-2003 (first entry)

DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

OS Homo sapiens.  
 XX US2003059828-A1.  
 PN 27-MAR-2003.  
 PD 13-JUL-2001; 2001US-00904553.  
 XX 17-SEP-1997; 97US-0059113P.  
 XX 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063322P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065933P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 98US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.



PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004144.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 XX  
 PI Ashtenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A,  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ,  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D,  
 PI Williams PM, Wood WT,  
 XX WPI; 2003-540675/51.  
 XX  
 PT Novel secreted and transmembrane polypeptides and polynucleotides  
 PT encoding them useful for treating skin, neurodegenerative diseases, as an  
 PT antithrombotic agent and for inducing endothelial cell apoptosis.  
 XX  
 PS Example 2; SEQ ID NO 7; 477pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generating of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for

CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCAGACTTA 768  
 ||||| | | | | | | | | | |  
 Db 22 GACCTGTATTGGCAGACTTA 1

RESULT 185  
 ADC40029/c  
 ID ADC40029 standard; DNA; 22 BP.

XX ADC40029;

XX 18-DEC-2003 (first entry)

DE Human secreted/transmembrane protein, #1, PCR primer #2.

KW Human; PCR; primer; as; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; bone disorder; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003059829-A1.

XX 27-MAR-2003.

XX 13-JUL-2001; 2001US-00905381.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0062814P.

XX 24-OCT-1997; 97US-0062816P.

XX 24-OCT-1997; 97US-0063045P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 24-OCT-1997; 97US-0063127P.





CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypolinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCACGACTTA 768  
 ||||| | |||||  
 Db 22 GACCTGTATTGTCACGACTTA 1

RESULT 187

ADC34153/c

ID ADC34153 standard; DNA; 22 BP.

XX ADC34153;

AC ADC34153;

XX 18-DEC-2003 (first entry)

XX Human secreted/transmembrane protein, #1, PCR primer #2.

XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypolinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003036094-A1.

XX 20-FEB-2003.

XX 13-JUL-2001; 2001US-00904820.

PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 27-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 05-JAN-2000; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, KJavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2003-615763/58.  
 XX  
 XX Novel secreted and transmembrane polypeptides and polynucleotides  
 PT encoding them useful for treating cancers, asthma, rheumatoid arthritis,  
 PT neurological diseases, and skin diseases.  
 XX  
 PS Example 2; SEQ ID NO 7; 478pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypotension, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its

CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTCGCCAGACTTA 768  
 Db 22 GACCTGTATTTCGCCAGACTTA 1  
 RESULT 188  
 ADC29208/c  
 ID ADC29208 standard; DNA; 22 BP.  
 XX  
 AC ADC29208;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypotension; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnarary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 KW  
 XX Homo sapiens.  
 XX  
 XX US2003049676-A1.  
 PD 13-MAR-2003.  
 XX  
 PF 10-JUL-2001; 2001US-00902736.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.

```

PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065933P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 13-OCT-1998; 98US-0104080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028544.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005084.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
PA (GETH ) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Ann Roy M, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-585107/55.
XX
PT Novel isolated PRO polypeptides e.g. PRO334 (useful for treating
PT rheumatoid arthritis, psoriasis and multiple sclerosis) and PRO187
PT (useful for treating Alzheimer's disease, cancer).
XX
XX Example 2; SEQ ID NO 7; 451pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC reinitis pigmentum), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention.
XX
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 747 GACCTGTATTTTCCGACCTTA 768
Db 22 GACCTGTAATGTCCGACCTTA 1
RESULT 189
ADC28739/c
ID ADC28739 standard; DNA; 22 BP.
XX
AC ADC28739;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human secreted/transmembrane protein, #1, PCR primer #2.
XX

```

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinemia;  
 KW hypotension; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003049677-A1.

PN 13-MAR-2003.

PD 17-JUL-2001; 2001US-00907794.

PF 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 98US-0143048P.  
 PR 26-JUL-1999; 98US-0145698P.  
 PR 28-JUL-1999; 98US-0146222P.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

PI Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;  
 PI Pilvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski FO, Grimaldi JC, Gurney AL, Hillan KJ, Kijavir LJ;  
 PI Mathier JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PW, Wood WI;

WPI; 2003-615797/58.

Novel secreted and transmembrane polypeptides and polynucleotides encoding them useful for treating skin, neurodegenerative diseases, as an antithrombotic agent and for inducing endothelial cell apoptosis.

Example 2; SEQ ID NO 7; 470pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or PFA uptake, inducing proliferation and/or re differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosum), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCGGACTTA 768

Db 22 GACCTGTATTTGCGGACTTA 1

RESULT 190

ADCA0624/C

ID ADCA0624 standard; DNA; 22 BP.

XX AC ADCA0624;

XX DT 18-DEC-2003 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cadiant; vulnerable; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.

XX FN US2003054400-A1.

XX PD 20-MAR-2003.

XX PF 10-JUL-2001; 2001US-00902692.

XX PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 25-NOV-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0098033P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 08-DEC-1999; 99WO-US020594.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.



PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 02-MAY-2000; 2000WO-US014042.  
 PR 22-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mathew JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WJ;  
 XX  
 WI WPI; 2003-708343/67.  
 XX  
 XX Novel PRO polypeptides useful for treating Parkinson's disease,  
 PT Alzheimer's disease, enterocolitis, Zollinger-Ellison syndrome,  
 PT psoriasis, epidermoid carcinoma of the vulva and gliomas, gynecological  
 PT diseases.  
 XX  
 PS Example 2; SEQ ID NO 7; 473pp; English.  
 XX  
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. NO. 1.7e-02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGTCGACACTTA 768  
 |||||  
 Db 22 GACCTGTATTGTCGACACTTA 1  
 |||||  
 RESULT 191  
 ADC19281/c  
 ID ADC19281 standard; DNA; 22 BP.  
 XX  
 AC ADC19281;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnarary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 KW  
 OS Homo sapiens.  
 XX  
 XX US2003054441-A1.  
 PN  
 PD 20-MAR-2003.  
 XX  
 PF 12-JUL-2001; 2001US-00905056.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.



KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnery; cytostatic; ophthalmological;  
 XX osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

PN US2003073077-A1.

XX 17-APR-2003.

XX 12-JUL-2001; 2001US-00905088.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0062816P.

XX 24-OCT-1997; 97US-0063045P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 24-OCT-1997; 97US-0063127P.

XX 24-OCT-1997; 97US-0063128P.

XX 27-OCT-1997; 97US-0063327P.

XX 28-OCT-1997; 97US-0063329P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063542P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063549P.

XX 28-OCT-1997; 97US-0063550P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063435P.

XX 29-OCT-1997; 97US-0063704P.

XX 29-OCT-1997; 97US-0063732P.

XX 29-OCT-1997; 97US-0063734P.

XX 29-OCT-1997; 97US-0063735P.

XX 29-OCT-1997; 97US-0063738P.

XX 29-OCT-1997; 97US-0064215P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 03-NOV-1997; 97US-0064248P.

XX 07-NOV-1997; 97US-0064809P.

XX 12-NOV-1997; 97US-0065186P.

XX 17-NOV-1997; 97US-0065846P.

XX 18-NOV-1997; 97US-0065893P.

XX 21-NOV-1997; 97US-0066120P.

XX 21-NOV-1997; 97US-0066364P.

XX 24-NOV-1997; 97US-0066453P.

XX 24-NOV-1997; 97US-0066466P.

XX 24-NOV-1997; 97US-0066511P.

XX 24-NOV-1997; 97US-0066770P.

XX 24-NOV-1997; 97US-0066772P.

XX 25-NOV-1997; 97US-0066840P.

XX 12-DEC-1997; 97US-006425P.

XX 04-JUN-1998; 98US-0088026P.

XX 10-SEP-1998; 98US-009803P.

XX 10-SEP-1998; 98US-009803P.

XX 14-SEP-1998; 98US-0100262P.

XX 14-SEP-1998; 98US-0100262P.

XX 16-SEP-1998; 98US-0101917P.

XX 16-SEP-1998; 98US-0101930P.

XX 17-SEP-1998; 98US-0100858P.

XX 17-SEP-1998; 98US-0100858P.

XX 13-OCT-1998; 98US-0101943P.

XX 13-OCT-1998; 98US-0104080P.

XX 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

PR 22-DEC-1998; 98US-0113296P.

PR 07-JUL-1999; 99US-0143048P.

PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-0146222P.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028584.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 05-JAN-2000; 2000WO-US000219.

PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000US-00665350.

XX (GETH ) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2003-695953/66.

XX Novel isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for

PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic

PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.

XX Example 2; SEQ ID NO 7; 476pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides

CC and the nucleic acid encoding them. The polypeptides can be used to raise

CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating

CC at least one biological activity of a cell. PRO polypeptides are useful

CC for detecting other PRO polypeptides in a sample and for linking a

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO

CC polypeptide antibodies are useful for modulating the biological activity

CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or

CC bioreactors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated

CC proliferation of endothelial cells, modulating the proliferation of

CC stimulated T-lymphocytes, enhancing the survival or proliferation of

CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re

CC differentiation of chondrocytes. In particular, these are useful for

CC detecting or treating cardiac insufficiency disorders, wounds, cancerous

CC tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,

CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or

CC arthritis) in mammals. PRO polypeptides and their portions affect the

CC expression of genes which have a role in cell death. The polynucleotides

CC are useful in molecular biology including uses as hybridisation probes

CC for cDNA library to isolate the full-length PRO cDNA or to isolate other

CC cDNAs; in chromosome and gene mapping, in the generation of antisense RNA

CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinant expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGCACAGACTTA 768  
 ||||| | |||||  
 Db 22 GACCTGTAATGTGCCGACTTA 1

RESULT 193

ADCI12799/c

ID ADCI12799 standard; DNA; 22 BP.

XX AC ADCI12799;

XX DT 18-DEC-2003 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

XX KW tissue typing; immunohistochemical staining; gene therapy;

XX KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

XX KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

XX KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;

XX KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;

XX KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

XX KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;

XX KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

XX KW osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.

XX FN US2003073079-A1.

XX PD 17-APR-2003.

XX PF 17-JUL-2001; 2001US-00907575.

XX PR 17-SEP-1997; 97US-00591113P.

PR 17-SEP-1997; 97US-00591115P.

PR 17-SEP-1997; 97US-00591117P.

PR 17-SEP-1997; 97US-00591119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 29-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065846P.

PR 18-NOV-1997; 97US-0065693P.

PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.

PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.

PR 24-NOV-1997; 97US-0066770P.

PR 24-NOV-1997; 97US-0066772P.

PR 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069425P.

PR 04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-0099803P.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98US-0100262P.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.

PR 17-SEP-1998; 98WO-US019437.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

PR 22-DEC-1998; 98US-0113296P.

PR 07-JUL-1999; 99US-0143048P.

PR 28-JUL-1999; 99US-0146222P.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 05-DEC-1999; 99WO-US030999.

PR 05-JAN-2000; 2000WO-US000219.

PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US01042.

PR 02-JUN-2000; 2000WO-US015264.



PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066320P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099681P.  
 PR 10-SEP-1998; 98US-01001882P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0101937P.  
 PR 16-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0101937P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-02020594.  
 PR 13-SEP-1999; 99US-02020944.  
 PR 15-SEP-1999; 99US-02021090.  
 PR 15-SEP-1999; 99US-02021547.  
 PR 05-OCT-1999; 99US-02023089.  
 PR 29-NOV-1999; 99US-02028214.  
 PR 30-NOV-1999; 99US-02028313.  
 PR 01-DEC-1999; 99US-02028301.  
 PR 02-DEC-1999; 99US-02028564.  
 PR 02-DEC-1999; 99US-02028565.  
 PR 16-DEC-1999; 99US-02030099.  
 PR 20-DEC-1999; 99US-02030911.  
 PR 20-DEC-1999; 99US-02030999.  
 PR 05-JAN-2000; 2000US-0000219.  
 PR 11-FEB-2000; 2000US-0003565.  
 PR 22-FEB-2000; 2000US-0004414.  
 PR 24-FEB-2000; 2000US-0005004.  
 PR 02-MAR-2000; 2000US-0005841.  
 PR 20-MAR-2000; 2000US-0007377.  
 PR 30-MAR-2000; 2000US-0008439.  
 PR 22-MAY-2000; 2000US-0014042.  
 PR 02-JUN-2000; 2000US-0015264.  
 PR 28-JUL-2000; 2000US-0020710.  
 PR 24-AUG-2000; 2000US-0023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 PA  
 PI Ashkenazi A, Bolstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WT;  
 XX WPI; 2003-743881/70.  
 DR  
 XX New secreted transmembrane PRO polypeptides and nucleic acids encoding  
 PT the polypeptides, useful in gene therapy, in identifying chromosomes, as  
 PT chromosome markers, in generating probes and in tissue typing.  
 XX  
 PS Example 2; SEQ ID NO 7; 487pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re-  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGTCGACACTTA 768  
 Db 22 GACCTGTATTGTCGACACTTA 1  
 RESULT 195  
 ADD04806/C  
 ID ADD04806 standard; DNA; 22 BP.  
 XX  
 AC ADD04806;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnerable; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003104469-A1.

XX 05-JUN-2003. 17-JUL-2001; 2001US-00907652.

PR 17-SEP-1997; 97US-00591113P.

PR 17-SEP-1997; 97US-00591115P.

PR 17-SEP-1997; 97US-00591117P.

PR 17-SEP-1997; 97US-00591119P.

PR 17-SEP-1997; 97US-00591211P.

PR 17-SEP-1997; 97US-00591222P.

PR 17-SEP-1997; 97US-00591848P.

PR 18-SEP-1997; 97US-00592633P.

PR 18-SEP-1997; 97US-00592666P.

PR 15-OCT-1997; 97US-00621255P.

PR 17-OCT-1997; 97US-00622858P.

PR 17-OCT-1997; 97US-00622877P.

PR 21-OCT-1997; 97US-00634868P.

PR 24-OCT-1997; 97US-00628148P.

PR 24-OCT-1997; 97US-00630455P.

PR 24-OCT-1997; 97US-00631208P.

PR 24-OCT-1997; 97US-00631218P.

PR 24-OCT-1997; 97US-00631278P.

PR 24-OCT-1997; 97US-00631288P.

PR 27-OCT-1997; 97US-00633278P.

PR 27-OCT-1997; 97US-00633298P.

PR 28-OCT-1997; 97US-00635418P.

PR 28-OCT-1997; 97US-00635428P.

PR 28-OCT-1997; 97US-00635448P.

PR 28-OCT-1997; 97US-00635498P.

PR 28-OCT-1997; 97US-00635508P.

PR 28-OCT-1997; 97US-00635648P.

PR 29-OCT-1997; 97US-00634358P.

PR 29-OCT-1997; 97US-00637048P.

PR 29-OCT-1997; 97US-00637328P.

PR 29-OCT-1997; 97US-00637348P.

PR 29-OCT-1997; 97US-00637358P.

PR 29-OCT-1997; 97US-00637388P.

PR 29-OCT-1997; 97US-00642158P.

PR 31-OCT-1997; 97US-00638708P.

PR 31-OCT-1997; 97US-00641038P.

PR 03-NOV-1997; 97US-00642488P.

PR 07-NOV-1997; 97US-00648098P.

PR 12-NOV-1997; 97US-00651868P.

PR 17-NOV-1997; 97US-00658468P.

PR 18-NOV-1997; 97US-00656938P.

PR 21-NOV-1997; 97US-00661208P.

PR 21-NOV-1997; 97US-00663648P.

PR 24-NOV-1997; 97US-00664538P.

PR 24-NOV-1997; 97US-00664668P.

PR 24-NOV-1997; 97US-00665118P.

PR 24-NOV-1997; 97US-00667708P.

PR 24-NOV-1997; 97US-00667728P.

PR 25-NOV-1997; 97US-00668408P.

PR 12-DEC-1997; 97US-00694258P.

PR 04-JUN-1998; 98US-00880268P.

PR 10-SEP-1998; 98US-00998038P.

PR 10-SEP-1998; 98WO-US018824P.

PR 14-SEP-1998; 98US-01002628P.

PR 14-SEP-1998; 98WO-US019177P.

PR 16-SEP-1998; 98WO-US019330P.

PR 17-SEP-1998; 98WO-US019330P.

PR 17-SEP-1998; 98WO-US019337P.

PR 13-OCT-1998; 98US-01040808P.

PR 20-NOV-1998; 98US-01093048P.

PR 01-DEC-1998; 98WO-US025108P.

PR 22-DEC-1998; 98US-01132968P.

PR 07-JUL-1999; 99US-01430408P.

PR 26-JUL-1999; 99US-01456988P.

PR 28-JUL-1999; 99US-01462228P.

PR 08-SEP-1999; 99WO-US020594P.

PR 13-SEP-1999; 99WO-US020944P.

PR 15-SEP-1999; 99WO-US021090P.

PR 15-SEP-1999; 99WO-US021547P.

PR 05-OCT-1999; 99WO-US023089P.

PR 29-NOV-1999; 99WO-US028214P.

PR 30-NOV-1999; 99WO-US028313P.

PR 01-DEC-1999; 99WO-US028301P.

PR 02-DEC-1999; 99WO-US028564P.

PR 02-DEC-1999; 99WO-US028585P.

PR 16-DEC-1999; 99WO-US030095P.

PR 20-DEC-1999; 99WO-US030911P.

PR 05-JAN-2000; 99WO-US030999P.

PR 20-DEC-1999; 2000WO-US000219P.

PR 11-FEB-2000; 2000WO-US003555P.

PR 22-FEB-2000; 2000WO-US004414P.

PR 24-FEB-2000; 2000WO-US005004P.

PR 02-MAR-2000; 2000WO-US005841P.

PR 20-MAR-2000; 2000WO-US007377P.

PR 30-MAR-2000; 2000WO-US008439P.

PR 22-MAY-2000; 2000WO-US014042P.

PR 02-JUN-2000; 2000WO-US015284P.

PR 28-JUL-2000; 2000WO-US020710P.

PR 24-AUG-2000; 2000WO-US023328P.

PR 18-SEP-2000; 2000US-00665350P.

XX (GETH ) GENENTECH INC.

PA Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N; Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A; Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ; Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D; Williams PM, Wood WI; WPI; 2003-801231/75.

DR Novel isolated native PRO polypeptide useful for tissue typing, modulating biological activity of cell, as molecular weight markers in protein electrophoresis, for treating enterocolitis, Zollinger-Ellison syndrome.

PT

PT

XX Example 2; SEQ ID NO 7; 474pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis.

CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768

Db 22 GACCTGTATGTGCCGACTTA 1

RESULT 196

ADD03812/C

ID ADD03812 standard; DNA; 22 BP.

XX

AC ADD03812;

XX

DT 01-JAN-2004 (first entry)

XX

DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

KW tissue typing; immunohistochemical staining; gene therapy;

KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;

KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;

KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

KW osteopathic; antiarthritic; anorectic.

XX

OS Homo sapiens.

XX

PN US2003104381-A1.

XX

PD 05-JUN-2003.

XX

PF 11-JUL-2001; 2001US-00903823.

XX

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062818P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 24-OCT-1997; 97US-0063128P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063435P.

PR 29-OCT-1997; 97US-0063704P.

PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.

PR 31-OCT-1997; 97US-0064215P.

PR 31-OCT-1997; 97US-00643870P.

PR 31-OCT-1997; 97US-0064103P.

PR 31-OCT-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.

PR 12-NOV-1997; 97US-0065186P.

PR 17-NOV-1997; 97US-0065846P.

PR 18-NOV-1997; 97US-0065693P.

PR 21-NOV-1997; 97US-0066120P.

PR 21-NOV-1997; 97US-0066364P.

PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066511P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-NOV-1997; 97US-0066772P.

PR 25-NOV-1997; 97US-0066840P.

PR 12-DEC-1997; 97US-0069445P.

PR 04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-0099803P.

PR 14-SEP-1998; 98US-0100262P.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98US-0100858P.

PR 17-SEP-1998; 98WO-US019437.

PR 18-SEP-1998; 98WO-US018824.

PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.

PR 01-DEC-1998; 98WO-US025108.

PR 22-DEC-1998; 98US-0113296P.

PR 26-JUL-1999; 99US-0145698P.

PR 08-SEP-1999; 99US-0146222P.

PR 13-SEP-1999; 99WO-US020594.

PR 15-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 05-JAN-2000; 2000WO-US000219.

PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 30-MAR-2000; 2000WO-US007377.

PR 22-MAY-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US014042.

PR 28-JUL-2000; 2000WO-US015264.

PR 24-AUG-2000; 2000WO-US020710.

PR 18-SEP-2000; 2000WO-US023328.

PR 18-SEP-2000; 2000WO-US065350.

(GETH ) GENENTECH INC.

PA

XX



PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-801226/75.  
XX DR  
XX  
XX Novel isolated native PRO polypeptide useful for treating Parkinson's  
PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal  
PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher  
PT syndrome.  
XX  
XX  
PS Example 2; SEQ ID NO 7; 487pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.  
XX  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. NO. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 747 GACCTGTATTTCGACACTTA 768  
||||| ||||| ||||| ||||| |||||  
DB 22 GACCTGTATTTCGACACTTA 1  
  
RESULT 197  
ADD03388/c  
ID ADD03388 standard; DNA; 22 BP.

XX ADD03388;  
XX 01-JAN-2004 (first entry)  
XX Human secreted/transmembrane protein, #1, PCR primer #2.  
XX  
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX  
XX Homo sapiens.  
XX  
XX US2003108983-A1.  
XX 12-JUN-2003.  
XX  
XX 10-JUL-2001; 2001US-00902572.  
XX  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.  
XX 15-OCT-1997; 97US-0062125P.  
XX 17-OCT-1997; 97US-0062285P.  
XX 17-OCT-1997; 97US-0062287P.  
XX 21-OCT-1997; 97US-0063486P.  
XX 24-OCT-1997; 97US-0062814P.  
XX 24-OCT-1997; 97US-0062816P.  
XX 24-OCT-1997; 97US-0063045P.  
XX 24-OCT-1997; 97US-0063120P.  
XX 24-OCT-1997; 97US-0063121P.  
XX 24-OCT-1997; 97US-0063127P.  
XX 24-OCT-1997; 97US-0063128P.  
XX 27-OCT-1997; 97US-0063327P.  
XX 27-OCT-1997; 97US-0063329P.  
XX 28-OCT-1997; 97US-0063541P.  
XX 28-OCT-1997; 97US-0063542P.  
XX 28-OCT-1997; 97US-0063544P.  
XX 28-OCT-1997; 97US-0063549P.  
XX 28-OCT-1997; 97US-0063550P.  
XX 28-OCT-1997; 97US-0063564P.  
XX 29-OCT-1997; 97US-0063435P.  
XX 29-OCT-1997; 97US-0063704P.  
XX 29-OCT-1997; 97US-0063732P.  
XX 29-OCT-1997; 97US-0063734P.  
XX 29-OCT-1997; 97US-0063735P.  
XX 29-OCT-1997; 97US-0063738P.  
XX 29-OCT-1997; 97US-0064215P.  
XX 31-OCT-1997; 97US-0063870P.  
XX 31-OCT-1997; 97US-0064103P.  
XX 03-NOV-1997; 97US-0064248P.  
XX 07-NOV-1997; 97US-0064809P.  
XX 12-NOV-1997; 97US-0065186P.  
XX 17-NOV-1997; 97US-0065846P.  
XX 18-NOV-1997; 97US-0065693P.  
XX 21-NOV-1997; 97US-0066120P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 24-NOV-1997; 97US-0066453P.  
XX 24-NOV-1997; 97US-0066466P.  
XX 24-NOV-1997; 97US-0066511P.



PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 17-OCT-1997; 97US-0062288P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063556P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 26-NOV-1997; 97US-0066480P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0100930P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-01019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 05-OCT-1999; 99US-0146222P.  
 PR 29-NOV-1999; 99US-0146222P.  
 PR 30-NOV-1999; 99US-0146222P.

PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 WPI; 2003-777194/73.  
 XX  
 DR New isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for  
 PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic  
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.  
 XX  
 PS Example 2; SEQ ID NO 7; 474pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its

CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.

XX  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGACACTTA 768  
||||||| ||||| |||||  
Db 22 GACCTGTATTTCGCGACTTA 1

RESULT 199

ADH59123/c

ID ADH59123 standard; DNA; 22 BP.

XX AC

ADH59123;

DT 25-MAR-2004 (first entry)

XX Human secreted/transmembrane protein, #1, PCR primer #2.

DE Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

XX tissue typing; immunohistochemical staining; gene therapy;

KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;

KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;

KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;

KW osteopathic; antiarthritic; anorectic.

XX OS

Homo sapiens.

XX US2003039972-A1.

PN 27-FEB-2003.

XX 16-JUL-2001; 2001US-00906700.

PF 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 18-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.

PR 27-OCT-1997; 97US-0063327P.

PR 27-OCT-1997; 97US-0063329P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063542P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063549P.

PR 28-OCT-1997; 97US-0063550P.

PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 04-JUN-1998; 97US-0069425P.  
PR 10-SEP-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0100263P.  
PR 16-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100859P.  
PR 17-SEP-1998; 98US-01019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0109308P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 05-OCT-1999; 99US-0146222P.  
PR 29-NOV-1999; 99US-0146222P.  
PR 30-NOV-1999; 99US-0146222P.  
PR 01-DEC-1999; 99US-0146222P.  
PR 02-DEC-1999; 99US-0146222P.  
PR 16-DEC-1999; 99US-0146222P.  
PR 20-DEC-1999; 99US-0146222P.  
PR 20-DEC-1999; 99US-0146222P.  
PR 05-JAN-2000; 2000US-0000219.  
PR 11-FEB-2000; 2000US-0003565.  
PR 22-FEB-2000; 2000US-0004414.  
PR 24-FEB-2000; 2000US-0005004.  
PR 02-MAR-2000; 2000US-0005841.  
PR 30-MAR-2000; 2000US-0007377.  
PR 30-MAR-2000; 2000US-0008439.  
PR 22-MAY-2000; 2000US-014042.  
PR 02-JUN-2000; 2000US-015264.  
PR 28-JUL-2000; 2000US-020710.  
PR 24-AUG-2000; 2000US-0203328.  
PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
XX Fliviaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX

DR WPI; 2003-503393/47.  
XX New isolated PRO polypeptides e.g. PRO211, PRO217 and PRO230, useful for  
PT treating Parkinson's disease, Alzheimer's disease, amyotrophic lateral  
PT sclerosis, cancer, neuropathies and psoriasis.  
XX Example 2; SEQ ID NO 7; 476pp; English.  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e-02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTGCCAGACTTA 768  
||||| ||||| ||||| ||||| |||||  
Db 22 GACCTGTATTTGCCAGACTTA 1  
RESULT 200  
ADI37902/c  
ID ADI37902 standard; DNA; 22 BP.  
XX  
AC ADI37902;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human secreted/transmembrane protein, #1, PCR primer #2.  
XX

KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypotension; bone disorder; cartilage disorder; sport injury;  
KW osteoarthritis; vulnary; cytostatic; ophthalmological;  
XX osteopathic; antiarthritic; anorectic.  
OS Homo sapiens.  
XX US2003054352-A1.  
XX 20-MAR-2003.  
XX 17-JUL-2001; 2001US-00907925.  
XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059124P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 29-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065863P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.



PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 01-DEC-1999; 98WO-US025108.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 (GETH ) GENENTECH INC.  
 PA Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 XX PI

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;  
 XX Williams PM, Wood WI;  
 DR WPI; 2003-328338/31.  
 XX Isolated nucleic acid useful for e.g., treating pathological disorders  
 PT encodes a secreted or transmembrane protein.  
 XX Example 2; Page 80; 473pp; English.  
 XX The invention relates to human PRO polypeptides (secreted or  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC PRO polypeptides and polynucleotides can be used in treating pathological  
 CC disorders and tumors, in therapeutic treatment of cardiac insufficiency  
 CC disorders and in therapeutic treatment of disorders involving protein  
 CC secretion by the pancreas, including diabetes. They can also be used in  
 CC treating disorders associated with the preservation and maintenance of  
 CC gastrointestinal mucosa and the repair of acute and chronic mucosal  
 CC lesions, and skin diseases associated with abnormal keratinocyte  
 CC differentiation (e.g., psoriasis, epithelial carcinoma of the vulva and gliomas).  
 CC Squamous cell carcinoma, epidermoid carcinoma of the vulva and gliomas).  
 CC The sequences can be used as molecular markers for protein  
 CC electrophoresis purposes and can be utilized in protein-protein binding  
 CC assays, biochemical screening assays, immunoassays and cell-based assays.  
 CC This sequence represents a PCR primer used to isolate a human PRO  
 CC polynucleotide of the invention  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGTCGACACTTA 768  
 DB 22 GACCTGTATTGTCGACACTTA 1  
 RESULT 202  
 ACAS8297/c  
 ID ACAS8297 standard; DNA; 22 BP.  
 XX AC ACAS8297;  
 AC ACAS8297;  
 DT 10-JUN-2003 (first entry)  
 XX  
 DE PCR primer #2 used to isolate cDNA encoding a human PRO polypeptide.  
 XX Human; secreted and transmembrane protein; PRO polypeptide; cancer;  
 KW Alzheimer's disease; ischaemia; cytostatic; neurotropic; vasotropic;  
 KW neuroprotective; PCR; primer; ss.  
 XX Homo sapiens.  
 OS US2002192659-A1.  
 PN 19-DEC-2002.  
 PD 19-DEC-2002.  
 XX  
 PF 10-JUL-2001; 2001US-00902853.  
 XX  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.

```

PR 17-OCT-1997; 97US-0062287P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 24-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 29-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066468P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005084.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX
XX (GETH ) GENENTECH INC.
PI Ashkenazi A, Borstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
```

Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
Williams EM, Wood WI;  
WPI; 2003-361832/34.  
New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or  
PRO1868, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.  
Example 2; Page 80; 474pp; English.  
The present invention relates to the isolation of novel human secreted  
and transmembrane proteins (PRO polypeptides), and the polynucleotide  
sequences encoding them. The polynucleotide sequences are useful in  
molecular biology, as hybridisation probes, in chromosome and gene  
mapping, in generating antisense RNA and DNA, and in gene therapy. The  
polynucleotide sequences may also be used in preparing PRO polypeptides  
by recombinant techniques, and in generating either transgenic animals or  
knock-out animals which, in turn, are useful in the development and  
screening of therapeutically useful reagents. The PRO polypeptides or  
their antibodies are useful in preparing a medicament for treating a  
condition responsive to the polypeptide or antibody, such as cancer.  
Alzheimer's disease or ischaemia, and in various diagnostic assays. The  
present sequence represents a PCR primer used in the examples of the  
present invention  
Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Oy 747 GACCTGTATTTTGGCAGACTTA 768  
Db 22 GACCTGTAATGTGCGGACTTA 1  
RESULT 203  
ADJ26170/c  
ID ADJ26170 standard; DNA; 22 BP.  
XX  
AC ADJ26170;  
XX  
DT 20-MAY-2004 (first entry)  
XX Human secreted/transmembrane protein, #1, PCR primer #2.  
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
tissue typing; immunohistochemical staining; gene therapy;  
neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
endothelial cell; stimulated T-lymphocyte; retinal neuron;  
rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
arthritis; cardiac; vulnery; cytostatic; ophthalmological;  
osteopathic; antiarthritic; anorectic.  
XX Homo sapiens.  
XX US2003054349-A1.  
XX  
XX 20-MAR-2003.  
XX  
XX 11-JUL-2001; 2001US-00903943.  
XX  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.



PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0101917P.  
 PR 16-SEP-1998; 98US-0101917P.  
 PR 17-SEP-1998; 98US-0101937P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 15-SEP-1999; 99US-0146222P.  
 PR 05-OCT-1999; 99US-0146222P.  
 PR 29-NOV-1999; 99US-0146222P.  
 PR 30-NOV-1999; 99US-0146222P.  
 PR 01-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 02-DEC-1999; 99US-0146222P.  
 PR 16-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 20-DEC-1999; 99US-0146222P.  
 PR 05-JAN-2000; 2000US-0000219.

PR 11-FEB-2000; 2000US-0003565.  
 PR 22-FEB-2000; 2000US-0004414.  
 PR 24-FEB-2000; 2000US-0005004.  
 PR 02-MAR-2000; 2000US-0005841.  
 PR 20-MAR-2000; 2000US-0007377.  
 PR 30-MAR-2000; 2000US-0008439.  
 PR 22-MAY-2000; 2000US-0014042.  
 PR 02-JUN-2000; 2000US-0015264.  
 PR 28-JUL-2000; 2000US-0020710.  
 PR 24-AUG-2000; 2000US-0023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 PA  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini JI;  
 PI Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2003-708341/67.  
 XX  
 PT Novel isolated native PRO polypeptide useful for tissue typing,  
 PT modulating biological activity of cell, as molecular weight markers in  
 PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison  
 PT syndrome.  
 XX  
 XX Example 2; SEQ ID NO 7; 483pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCAGACTTA 768  
 ||||| | |||||  
 Db 22 GACCTGTATTGTCAGACTTA 1

RESULT 204  
 ADE79085/c  
 ID ADE79085 standard; DNA; 22 BP.  
 AC ADE79085;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypotension; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cystostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003135025-A1.  
 XX  
 PD 17-JUL-2003.  
 XX  
 PF 12-JUL-2001; 2001US-00904992.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0063738P.  
 29-OCT-1997; 97US-0064215P.  
 31-OCT-1997; 97US-0063870P.  
 31-OCT-1997; 97US-0064103P.  
 03-NOV-1997; 97US-0064248P.  
 07-NOV-1997; 97US-0064809P.  
 12-NOV-1997; 97US-0065186P.  
 17-NOV-1997; 97US-0065846P.  
 18-NOV-1997; 97US-0065693P.  
 21-NOV-1997; 97US-0066120P.  
 21-NOV-1997; 97US-0066364P.  
 24-NOV-1997; 97US-0066453P.  
 24-NOV-1997; 97US-0066466P.  
 24-NOV-1997; 97US-0066511P.  
 24-NOV-1997; 97US-0066770P.  
 24-NOV-1997; 97US-0066772P.  
 25-NOV-1997; 97US-0066840P.  
 12-DEC-1997; 97US-0069425P.  
 10-SEP-1998; 98US-008026P.  
 10-SEP-1998; 98US-0099803P.  
 14-SEP-1998; 98US-0099803P.  
 14-SEP-1998; 98US-0100262P.  
 16-SEP-1998; 98US-0100262P.  
 17-SEP-1998; 98US-0100858P.  
 17-SEP-1998; 98US-0100858P.  
 13-OCT-1998; 98US-0104080P.  
 20-NOV-1998; 98US-0109304P.  
 01-DEC-1998; 98US-0109304P.  
 22-DEC-1998; 98US-0113296P.  
 07-JUL-1999; 99US-0143048P.  
 26-JUL-1999; 99US-0145698P.  
 28-JUL-1999; 99US-0146222P.  
 08-SEP-1999; 99US-0146222P.  
 13-SEP-1999; 99US-0146222P.  
 15-SEP-1999; 99US-0146222P.  
 05-OCT-1999; 99US-0146222P.  
 29-NOV-1999; 99US-0146222P.  
 30-NOV-1999; 99US-0146222P.  
 01-DEC-1999; 99US-0146222P.  
 02-DEC-1999; 99US-0146222P.  
 02-DEC-1999; 99US-0146222P.  
 16-DEC-1999; 99US-0146222P.  
 20-DEC-1999; 99US-0146222P.  
 20-DEC-1999; 99US-0146222P.  
 05-JAN-2000; 2000US-0000219.  
 11-FEB-2000; 2000US-0003565.  
 22-FEB-2000; 2000US-0004414.  
 02-MAR-2000; 2000US-0005841.  
 30-MAR-2000; 2000US-0007377.  
 30-MAR-2000; 2000US-0008439.  
 22-MAY-2000; 2000US-014042.  
 02-JUN-2000; 2000US-015264.  
 28-JUL-2000; 2000US-020710.  
 24-AUG-2000; 2000US-0203328.  
 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.  
 Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 Williams PM, Wood WI;  
 WPI; 2004-031331/03.  
 New nucleic acid encoding a PRO polypeptide, for producing a recombinant  
 PRO polypeptide and for treating e.g. cancer, infertility, kidney  
 disorders, and cardiac disfunctions.



PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashtenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WT;  
 XX  
 DR WPI; 2004-020353/02.  
 XX  
 PT New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor or for tissue typing.  
 XX  
 PS Example 2; SEQ ID NO 7; 480pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA

CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Oy 747 GACCTGTATTTCGACACTTA 768  
 Db 22 GACCTGTATTTCGACACTTA 1  
 ||||| | |||||  
 ||||| | |||||  
 RESULT 206  
 ADE73185/c  
 ID ADE73185 standard; DNA; 22 BP.  
 XX  
 AC ADE73185;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardant; vulnarary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 PN US2003129592-A1.  
 XX  
 PD 10-JUL-2003.  
 XX  
 PF 13-JUL-2001; 2001US-00905449.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059124P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0086026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099824P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100304P.  
 PR 16-SEP-1998; 98US-0109330.  
 PR 17-SEP-1998; 98US-010858P.  
 PR 17-SEP-1998; 98US-0109437P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0202094.  
 PR 15-SEP-1999; 99US-0202094.  
 PR 15-SEP-1999; 99US-0202109.  
 PR 15-SEP-1999; 99US-0202154P.  
 PR 05-OCT-1999; 99US-0203089.  
 PR 29-NOV-1999; 99US-0203089.  
 PR 30-NOV-1999; 99US-0203113.  
 PR 01-DEC-1999; 99US-0203101.  
 PR 02-DEC-1999; 99US-0203564.  
 PR 02-DEC-1999; 99US-0203564.  
 PR 16-DEC-1999; 99US-0203564.  
 PR 16-DEC-1999; 99US-0203564.  
 PR 20-DEC-1999; 99US-030911.  
 PR 20-DEC-1999; 99US-030999.  
 PR 05-JAN-2000; 2000US-0000219.  
 PR 11-FEB-2000; 2000US-0003565.  
 PR 22-FEB-2000; 2000US-0004414.  
 PR 24-FEB-2000; 2000US-0005004.  
 PR 02-MAR-2000; 2000US-0005841.  
 PR 20-MAR-2000; 2000US-0007377.  
 PR 30-MAR-2000; 2000US-0008439.  
 PR 22-MAY-2000; 2000US-0014042.  
 PR 02-JUN-2000; 2000US-0015264.

PR 28-JUL-2000; 2000US-0020710.  
 PR 24-AUG-2000; 2000US-0023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 (GETH ) GENENTECH INC.  
 Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 Mathew JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;  
 Williams PM, Wood WI;  
 WPI; 2004-020333/02.  
 New nucleic acids encoding polypeptides designated PRO have sequence identity to various secreted proteins and transmembrane proteins and are useful in molecular techniques and as therapeutic agents.  
 Example 2; SEQ ID NO 7; 474pp; English.  
 The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.  
 Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 747 GACCTGTATTTGCCAGACTTA 768  
 22 GACCTGTATTTGCCAGACTTA 1

RESULT 207  
 ADE73720/c  
 ID ADE73720 standard; DNA; 22 BP.  
 XX  
 AC ADE73720;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003148370-A1.  
 XX  
 XX 07-AUG-2003.  
 PD  
 XX  
 PF 13-JUL-2001; 2001US-00904838.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 18-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065848P.  
 PR 18-NOV-1997; 97US-0065933P.

PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 22-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;  
 Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 Godowski PJ, Grimaldi JC, Gurney AU, Hillan KJ, Kljavin IJ;  
 Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 Williams PM, Wood WI;

WPI; 2004-020440/02.

Isolated secreted and transmembrane PRO nucleic acids and the proteins they encode, e.g. PRO245, PRO269 and PRO1868, useful for preventing, diagnosing and treating e.g. disorders relating to blood coagulation.

Example 2; SEQ ID NO 7; 1pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO

polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.

Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGACACTTA 768  
Db ||||| ||||| ||||| |||||  
22 GACCTGTATTGTCGACACTTA 1

RESULT 208

AD99274/C

ID AD99274 standard; DNA; 22 BP.

AC AD99274;

DT 12-FEB-2004 (first entry)

DE Human secreted/transmembrane protein, #1, PCR primer #2.

Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
tissue typing; immunohistochemical staining; gene therapy;  
neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
endothelial cell; stimulated T-lymphocyte; retinal neuron;  
rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
arthritis; cardiac; vulnery; cytotoxic; ophthalmological;  
osteopathic; antiarthritic; anorectic.

Homo sapiens.

OS US2003211576-A1.

PN

XX

PD 13-NOV-2003.

XX 18-NOV-2002; 2002US-00298993.

XX 22-FEB-2000; 2000WO-US004414.

PR 18-SEP-2000; 2000US-00665350.

XX (GETH ) GENENTECH INC.

PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

XX Pilyavoff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PU, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2004-021580/02.

DR New PRO polypeptide for preparing a medicament for treating a condition

PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

PT inflammatory diseases, cancer or acquired immunodeficiency syndrome.

XX Example 2; SEQ ID NO 7; 476pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY      747 GACCTGTATTGTCAGACTTA 768
      ||||| ||||| ||||| |||||
Db      22 GACCTGTATTGTCGCGACTTA 1

RESULT 209
ADE98393/c
ID      ADE98393 standard; DNA; 22 BP.
XX
XX
AC      ADE98393;
XX
DT      12-FEB-2004 (first entry)
XX
DE      Human secreted/transmembrane protein, #1, PCR primer #2.
XX
XX      Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW      tissue typing; immunohistochemical staining; gene therapy; proliferation;
KW      neonatal heart; vascular endothelial growth factor; VEGF;
KW      endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW      rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;
KW      cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;
KW      retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW      hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW      arthritis; cadiant; vulnerable; cyostatic; ophthalmological;
KW      osteopathic; antiarthritic; anorectic.
XX
OS      Homo sapiens.
XX
XX      US2003211569-A1.
XX
PD      13-NOV-2003.
XX
XX      12-JUL-2001; 2001US-00904938.
XX
PR      17-SEP-1997; 97US-0059113P.
PR      17-SEP-1997; 97US-0059113P.
PR      17-SEP-1997; 97US-0059117P.
PR      17-SEP-1997; 97US-0059119P.
PR      17-SEP-1997; 97US-0059121P.
PR      17-SEP-1997; 97US-0059122P.
PR      17-SEP-1997; 97US-0059184P.
PR      18-SEP-1997; 97US-0059263P.
PR      18-SEP-1997; 97US-0059266P.
PR      15-OCT-1997; 97US-0062125P.
PR      17-OCT-1997; 97US-0062285P.
PR      17-OCT-1997; 97US-0062287P.
PR      21-OCT-1997; 97US-0063486P.
PR      24-OCT-1997; 97US-0062814P.
PR      24-OCT-1997; 97US-0062816P.
PR      24-OCT-1997; 97US-0063045P.
PR      24-OCT-1997; 97US-0063120P.
PR      24-OCT-1997; 97US-0063121P.
PR      24-OCT-1997; 97US-0063127P.
PR      24-OCT-1997; 97US-0063128P.
PR      27-OCT-1997; 97US-0063327P.
PR      27-OCT-1997; 97US-0063329P.
PR      28-OCT-1997; 97US-0063541P.
PR      28-OCT-1997; 97US-0063542P.
PR      28-OCT-1997; 97US-0063544P.
PR      28-OCT-1997; 97US-0063549P.
PR      28-OCT-1997; 97US-0063550P.
PR      28-OCT-1997; 97US-0063564P.
PR      29-OCT-1997; 97US-0063435P.
PR      29-OCT-1997; 97US-0063704P.
PR      29-OCT-1997; 97US-0063732P.
PR      29-OCT-1997; 97US-0063734P.
PR      29-OCT-1997; 97US-0063735P.
PR      29-OCT-1997; 97US-0063738P.
PR      29-OCT-1997; 97US-0064215P.
PR      31-OCT-1997; 97US-0063870P.
PR      31-OCT-1997; 97US-0064103P.
PR      03-NOV-1997; 97US-0064248P.
PR      07-NOV-1997; 97US-0064809P.

PR      12-NOV-1997; 97US-0065186P.
PR      17-NOV-1997; 97US-0065846P.
PR      18-NOV-1997; 97US-0065693P.
PR      21-NOV-1997; 97US-0066120P.
PR      21-NOV-1997; 97US-0066364P.
PR      24-NOV-1997; 97US-0066453P.
PR      24-NOV-1997; 97US-0066466P.
PR      24-NOV-1997; 97US-0066511P.
PR      24-NOV-1997; 97US-0066770P.
PR      24-NOV-1997; 97US-0066772P.
PR      25-NOV-1997; 97US-0066840P.
PR      12-DEC-1997; 97US-0069425P.
PR      04-JUN-1998; 98US-0088026P.
PR      10-SEP-1998; 98US-0099803P.
PR      10-SEP-1998; 98WO-US018824.
PR      14-SEP-1998; 98US-0100262P.
PR      14-SEP-1998; 98WO-US019177.
PR      16-SEP-1998; 98WO-US019330.
PR      17-SEP-1998; 98US-0100858P.
PR      17-SEP-1998; 98WO-US019437.
PR      13-OCT-1998; 98US-0104080P.
PR      20-NOV-1998; 98US-0109304P.
PR      01-DEC-1998; 98WO-US025108.
PR      22-DEC-1998; 98US-0113296P.
PR      07-JUL-1999; 99US-0143048P.
PR      26-JUL-1999; 99US-0145698P.
PR      28-JUL-1999; 99US-0146222P.
PR      08-SEP-1999; 99WO-US020594.
PR      13-SEP-1999; 99WO-US020944.
PR      15-SEP-1999; 99WO-US021090.
PR      15-SEP-1999; 99WO-US021147.
PR      05-OCT-1999; 99WO-US023089.
PR      29-NOV-1999; 99WO-US028214.
PR      30-NOV-1999; 99WO-US028313.
PR      01-DEC-1999; 99WO-US028301.
PR      02-DEC-1999; 99WO-US028564.
PR      02-DEC-1999; 99WO-US028565.
PR      16-DEC-1999; 99WO-US030095.
PR      20-DEC-1999; 99WO-US030911.
PR      20-DEC-1999; 99WO-US030999.
PR      05-JAN-2000; 2000WO-US000219.
PR      11-FEB-2000; 2000WO-US003565.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US005004.
PR      02-MAR-2000; 2000WO-US005841.
PR      20-MAR-2000; 2000WO-US007377.
PR      30-MAR-2000; 2000WO-US008439.
PR      22-MAY-2000; 2000WO-US014042.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUL-2000; 2000WO-US020710.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00665350.
XX
XX      (GETH ) GENENTECH INC.
XX
XX      Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI      Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI      Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI      Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI      Williams PM, Wood WI;
XX
XX      WPI; 2004-021576/02.
XX
XX      New isolated native PRO polypeptide useful for treating Parkinson's
PT      disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal
PT      ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, or Usher
PT      syndrome.
XX
XX      Example 2; SEQ ID NO 7; 469pp; English.
PS
XX      The invention discloses isolated PRO secreted/transmembrane polypeptides
CC      and the nucleic acid encoding them. The polypeptides can be used to raise
CC      antibodies that specifically bind to the PRO polypeptide, for linking a

```





```

XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
      Query Match      2.0%; Score 17.2; DB 1; Length 22;
      Best Local Similarity 86.4%; Pred. No. 1.7e+02;
      Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTATTTCGCCAGACTTA 1

RESULT 211
ADG40290/c
ID ADG40290 standard; DNA; 22 BP.
XX ADG40290;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #1, PCR primer #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiant; vulnarary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
OS Homo sapiens.
XX
XX US2003225253-A1.
XX
PD 04-DEC-2003.
XX
XX 29-MAY-2003; 2003US-00448923.
XX
PR 24-OCT-1997; 97US-0063128P.
PR 16-SEP-1998; 98WO-US019330.
PR 30-NOV-1999; 99WO-US028313.
PR 22-FEB-2000; 2000WO-US004414.
PR 18-SEP-2000; 2000US-00665350.
PR 12-JUL-2001; 2001US-00905125.
XX
PA (DESN/) DESNOYERS L.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (MATH/) MATHER J P.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
XX Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-022084/02.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Example 2; SEQ ID NO 7; 463pp; English.
PS
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a

```

```

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulation of chondrocytes. In particular, these are useful for
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention.
XX
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
      Query Match      2.0%; Score 17.2; DB 1; Length 22;
      Best Local Similarity 86.4%; Pred. No. 1.7e+02;
      Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTATTTCGCCAGACTTA 1

RESULT 212
ADF73684/c
ID ADF73684 standard; DNA; 22 BP.
XX ADF73684;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein, #1, PCR primer #2.
XX
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiant; vulnarary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
OS Homo sapiens.
XX
XX US2003180312-A1.

```

XX PD 25-SEP-2003.

XX PF 18-NOV-2002; 2002US-00299976.

XX PR 22-FEB-2000; 2000WO-US004414.

XX PR 18-SEP-2000; 2000US-00665350.

XX PA (GETH ) GENENTECH INC.

XX PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;

PI Mather JP, Pan J, Faoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2004-031838/03.

XX New PRO polypeptide useful for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g. inflammatory diseases, cancer or acquired immunodeficiency syndrome.

XX Example 2; SEQ ID NO 7; 473pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypotension, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.

XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
 |||||  
 DB 22 GACCTGTATTTGCCAGACTTA 1

RESULT 213  
 ADF73260/c  
 ID ADF73260 standard; DNA; 22 BP.

XX AC ADF73260;

XX DT 26-FEB-2004 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;

XX KW tissue typing; immunohistochemical staining; gene therapy; proliferation;

XX KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

XX KW endothelial cell; stimulated T-lymphocyte; retinal neuron;

XX KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

XX KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;

XX KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;

XX KW hypotension; bone disorder; cartilage disorder; sport injury;

XX KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;

XX KW osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.

XX PN US2003166051-A1.

XX PD 04-SEP-2003.

XX PF 13-JUL-2001; 2001US-00904920.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059119P.

XX PR 17-SEP-1997; 97US-0059121P.

XX PR 17-SEP-1997; 97US-0059122P.

XX PR 17-SEP-1997; 97US-0059184P.

XX PR 18-SEP-1997; 97US-0059263P.

XX PR 18-SEP-1997; 97US-0059266P.

XX PR 15-OCT-1997; 97US-0062125P.

XX PR 17-OCT-1997; 97US-0062285P.

XX PR 17-OCT-1997; 97US-0062287P.

XX PR 21-OCT-1997; 97US-0063486P.

XX PR 24-OCT-1997; 97US-0062814P.

XX PR 24-OCT-1997; 97US-0062816P.

XX PR 24-OCT-1997; 97US-0063045P.

XX PR 24-OCT-1997; 97US-0063120P.

XX PR 24-OCT-1997; 97US-0063121P.

XX PR 24-OCT-1997; 97US-0063127P.

XX PR 24-OCT-1997; 97US-0063128P.

XX PR 27-OCT-1997; 97US-0063327P.

XX PR 27-OCT-1997; 97US-0063329P.

XX PR 28-OCT-1997; 97US-0063541P.

XX PR 28-OCT-1997; 97US-0063542P.

XX PR 28-OCT-1997; 97US-0063544P.

XX PR 28-OCT-1997; 97US-0063549P.

XX PR 28-OCT-1997; 97US-0063550P.

XX PR 28-OCT-1997; 97US-0063564P.

XX PR 29-OCT-1997; 97US-0063435P.

XX PR 29-OCT-1997; 97US-0063704P.

XX PR 29-OCT-1997; 97US-0063732P.

XX PR 29-OCT-1997; 97US-0063734P.

XX PR 29-OCT-1997; 97US-0063735P.

XX PR 29-OCT-1997; 97US-0063738P.

XX PR 29-OCT-1997; 97US-0064215P.

XX PR 31-OCT-1997; 97US-0063870P.

XX PR 31-OCT-1997; 97US-0064103P.

XX PR 03-NOV-1997; 97US-0064248P.

```

PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065893P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 25-NOV-1997; 97US-0066840P.
PR 12-DEC-1997; 97US-0069425P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 18-SEP-1998; 98US-0101080P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
PA (GETH ) GENENTECH INC.
XX
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI William PM, Wood WI;
XX
XX WPI; 2004-020549/02.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, in chromosome and gene mapping, as chromosome markers,
XX in tissue typing, in identifying chromosomes, and for treating e.g. tumor
XX or arthritis.
PS Example 2; SEQ ID NO 7; 478pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XX and the nucleic acid encoding them. The polypeptides can be used to raise
XX antibodies that specifically bind to the PRO polypeptide, for linking a

```

```

CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. PRO polypeptides are useful
CC for detecting other PRO polypeptides in a sample and for linking a
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
CC polypeptide antibodies are useful for modulating the biological activity
CC of a cell expressing PRO polypeptides. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
CC proliferation of endothelial cells, modulating the proliferation of
CC stimulated T-lymphocytes, enhancing the survival or proliferation of
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
CC -differentiation of chondrocytes. In particular, these are useful for
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
CC tumours, retinal disorders or injuries (e.g. loss of sight due to
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
CC arthritis) in mammals. PRO polypeptides and their portions affect the
CC expression of genes which have a role in cell death. The polynucleotides
CC are useful in molecular biology including uses as hybridisation probes
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
CC and DNA, for preparing PRO polypeptides, for generating transgenic
CC animals or knockout animals which are useful in the development and
CC screening of therapeutically useful reagents, as probes and for the
CC genetic analysis of individuals with genetic disorders as well as for
CC recombinantly expressing the protein and for chromosome identification.
CC The proteins are useful as molecular marker for protein electrophoresis
CC purposes, as therapeutic agents, for screening compounds to identify
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
CC useful for tissue typing. PRO antibodies are useful for
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
CC expression in specific cells, tissues or serum and for affinity
CC purification of PRO from recombinant cell culture or natural sources. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequence presented is a PCR primer which was used to
CC amplify a PRO polynucleotide of the invention.
XX
XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 747 GACCTGTATTTTGGCAGACTTA 768
Db 22 GACCTGTATTTGTCGCGACTTA 1
|||||
RESULT 214
ADG92103/C
ID ADG92103 standard; DNA; 22 BP.
XX
XX AC ADG92103;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human secreted/transmembrane protein, #1, PCR primer #2.
XX
XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
XX tissue typing; immunohistochemical staining; gene therapy;
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;
XX hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
XX arthritis; cardiant; vulnery; cyostatic; ophthalmological;
XX osteopathic; antiarthritic; anorectic.
XX

```

OS Homo sapiens.  
XX US2003027145-A1.  
XX 06-FEB-2003.  
XX 17-JUL-2001; 2001US-00907613.  
XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065593P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.

PR 28-JUL-1999; 99US-01456222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
PI Pilvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2004-118832/12.  
XX New nucleic acid encoding a PRO polypeptide for use as hybridization  
PT probes, in chromosome and gene mapping, in generating antisense RNA and  
PT DNA, and in gene therapy for treating e.g. cancer, Parkinson's disease  
PT and wounds.  
XX Example 2; SEQ ID NO 7; 471pp; English.  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
CC -differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the

CC Genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCAGACTTA 768

Db 22 GACCTGTATTGGCCAGACTTA 1

RESULT 215

ADG92530/c

ID ADG92530 standard; DNA; 22 BP.

XX ADG92530;

AC 11-MAR-2004 (first entry)

DT Human secreted/transmembrane protein, #1, PCR primer #2.

DE Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypotension; hypotension; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulvular; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

XX US2003027146-A1.

XX 06-FEB-2003.

XX 17-JUL-2001; 2001US-00907942.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062288P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0062814P.

XX 24-OCT-1997; 97US-0062816P.

XX 24-OCT-1997; 97US-0063045P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

PR 24-OCT-1997; 97US-0063127P.  
 PR 27-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 25-NOV-1997; 97US-0066772P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98WO-US021090.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 22-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 02-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

```

XX PA (GETH ) GENENTECH INC.
XX PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
XX PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
XX PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;
XX PI Macher JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
XX PI Williams PM, Wood WI;
XX DR WPI; 2004-106404/11.
XX XX Isolated nucleic acid encoding a polypeptide useful for various
XX PT applications e.g. hybridization probes.
XX PS Example 2; SEQ ID NO 7; 474pp; English.
XX CC The invention discloses isolated PRO secreted/transmembrane polypeptides
XX CC and the nucleic acid encoding them. The polypeptides can be used to raise
XX CC antibodies that specifically bind to the PRO polypeptide, for linking a
XX CC bioactive molecule to a cell expressing a PRO protein and for modulating
XX CC at least one biological activity of a cell. PRO polypeptides are useful
XX CC for detecting other PRO polypeptides in a sample and for linking a
XX CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO
XX CC polypeptide antibodies are useful for modulating the biological activity
XX CC of a cell expressing PRO polypeptides. The PRO polypeptides or
XX CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
XX CC bioreactors. These are useful for stimulating hypertrophy of neonatal
XX CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated
XX CC proliferation of endothelial cells, modulating the proliferation of
XX CC stimulated T-lymphocytes, enhancing the survival or proliferation of
XX CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial
XX CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re
XX CC -differentiation of chondrocytes. In particular, these are useful for
XX CC detecting or treating cardiac insufficiency disorders, wounds, cancerous
XX CC tumours, retinal disorders or injuries (e.g. loss of sight due to
XX CC retinitis pigmentosum), obesity, diabetes, hyperinsulinaemia,
XX CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or
XX CC arthritis) in mammals. PRO polypeptides and their portions affect the
XX CC expression of genes which have a role in cell death. The polynucleotides
XX CC are useful in molecular biology including uses as hybridisation probes
XX CC for cDNA library to isolate the full-length PRO cDNA or to isolate other
XX CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA
XX CC and DNA, for preparing PRO polypeptides, for generating transgenic
XX CC animals or knockout animals which are useful in the development and
XX CC screening of therapeutically useful reagents, as probes and for the
XX CC genetic analysis of individuals with genetic disorders as well as for
XX CC recombinantly expressing the protein and for chromosome identification.
XX CC The proteins are useful as molecular marker for protein electrophoresis
XX CC purposes, as therapeutic agents, for screening compounds to identify
XX CC those that mimic the PRO polypeptide (agonists) or prevent the effect of
XX CC the PRO polypeptide (antagonists). The polynucleotides and proteins are
XX CC useful for tissue typing. PRO antibodies are useful for
XX CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO
XX CC antibodies are useful in diagnostic assays for PRO e.g. detecting its
XX CC expression in specific cells, tissues or serum and for affinity
XX CC purification of PRO from recombinant cell culture or natural sources. The
XX CC PRO genes may also be used in gene therapy, particularly for replacing a
XX CC defective gene. The sequence presented is a PCR primer which was used to
XX CC amplify a PRO polynucleotide of the invention.
XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. NO. 1.7e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGATATTTCCGACTTA 768
DB 22 GACCTGATATGTCGCGACTTA 1
|||||
|||||

RESULT 216
ADH20319/C

```

```

ID ADH20319 standard; DNA; 22 BP.
XX AC ADH20319;
XX DT 25-MAR-2004 (first entry)
XX DE Human secreted/transmembrane protein, #1, PCR primer #2.
XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;
KW tissue typing; immunohistochemical staining; gene therapy;
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;
KW retinitis pigmentosum; obesity; diabetes; hyperinsulinaemia;
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;
KW osteopathic; antiarthritic; anorectic.
XX OS Homo sapiens.
XX PN US2004005553-A1.
XX PD 08-JAN-2004.
XX PF 18-JUL-2001; 2001US-00908576.
XX PR 17-SEP-1997; 97US-0059113P.
XX PR 17-SEP-1997; 97US-0059115P.
XX PR 17-SEP-1997; 97US-0059117P.
XX PR 17-SEP-1997; 97US-0059119P.
XX PR 17-SEP-1997; 97US-0059121P.
XX PR 17-SEP-1997; 97US-0059122P.
XX PR 17-SEP-1997; 97US-0059184P.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 15-OCT-1997; 97US-0062125P.
XX PR 17-OCT-1997; 97US-0062285P.
XX PR 17-OCT-1997; 97US-0062287P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0062814P.
XX PR 24-OCT-1997; 97US-0062816P.
XX PR 24-OCT-1997; 97US-0063045P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 24-OCT-1997; 97US-0063127P.
XX PR 24-OCT-1997; 97US-0063128P.
XX PR 27-OCT-1997; 97US-0063327P.
XX PR 27-OCT-1997; 97US-0063329P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063542P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063549P.
XX PR 28-OCT-1997; 97US-0063550P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063435P.
XX PR 29-OCT-1997; 97US-0063704P.
XX PR 29-OCT-1997; 97US-0063732P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 29-OCT-1997; 97US-0063735P.
XX PR 29-OCT-1997; 97US-0063738P.
XX PR 29-OCT-1997; 97US-0064215P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
XX PR 03-NOV-1997; 97US-0064248P.
XX PR 07-NOV-1997; 97US-0064809P.
XX PR 12-NOV-1997; 97US-0065186P.
XX PR 17-NOV-1997; 97US-0065846P.
XX PR 18-NOV-1997; 97US-0065693P.
XX PR 21-NOV-1997; 97US-0066120P.
XX PR 21-NOV-1997; 97US-0066364P.
XX PR 24-NOV-1997; 97US-0066453P.
XX PR 24-NOV-1997; 97US-0066466P.

```

PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0100330P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100943P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0113296P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-02020594.  
 PR 15-SEP-1999; 99US-02020944.  
 PR 15-SEP-1999; 99US-02021090.  
 PR 15-SEP-1999; 99US-02021547.  
 PR 05-OCT-1999; 99US-02023089.  
 PR 29-NOV-1999; 99US-02028214.  
 PR 30-NOV-1999; 99US-02028313.  
 PR 01-DEC-1999; 99US-02028301.  
 PR 02-DEC-1999; 99US-02028564.  
 PR 02-DEC-1999; 99US-02028564.  
 PR 16-DEC-1999; 99US-02028565.  
 PR 20-DEC-1999; 99US-02030095.  
 PR 20-DEC-1999; 99US-02030911.  
 PR 20-DEC-1999; 99US-02030999.  
 PR 05-JAN-2000; 2000US-0200219.  
 PR 11-FEB-2000; 2000US-02003565.  
 PR 22-FEB-2000; 2000US-02004414.  
 PR 24-FEB-2000; 2000US-02005004.  
 PR 02-MAR-2000; 2000US-02005841.  
 PR 20-MAR-2000; 2000US-02007377.  
 PR 30-MAR-2000; 2000US-02008439.  
 PR 22-MAY-2000; 2000US-02014042.  
 PR 02-JUN-2000; 2000US-02015264.  
 PR 28-JUL-2000; 2000US-02020710.  
 PR 24-AUG-2000; 2000US-02023328.  
 PR 18-SEP-2000; 2000US-020665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashtenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PU, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2004-081703/08.  
 XX  
 PT New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor, for chromosome mapping or for tissue  
 PT typing.  
 XX  
 XX Example 2; SEQ ID NO 7; 126pp; English.  
 PS  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTCGACACTTA 768  
 DB 22 GACCTGTATTTCGACACTTA 1  
 RESULT 217  
 ADH07174/C  
 ID ADH07174 standard; DNA; 22 BP.  
 AC ADH07174;  
 XX  
 DT 25-MAR-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 XX Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 XX tissue typing; immunohistochemical staining; gene therapy;  
 XX protein therapy.  
 OS Homo sapiens.  
 XX  
 XX US2004006211-A1.  
 PN  
 XX  
 XX 08-JAN-2004.  
 PD  
 XX 29-MAY-2003; 2003US-00448713.  
 PF  
 XX 24-OCT-1997; 97US-0063128P.  
 PR 16-SEP-1998; 98US-0019330.  
 PR 30-NOV-1999; 99US-02028313.  
 PR 22-FEB-2000; 2000US-02004414.  
 PR 18-SEP-2000; 2000US-020665350.  
 PR 12-JUL-2001; 2001US-00905125.  
 XX







PT the PRO polypeptide or anti-PRO antibody, e.g. inflammatory diseases,  
 PT Cancer or AIDS.  
 XX  
 XX Example 2; SEQ ID NO 7; 462bp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. The PRO sequences can be used in gene and protein therapy.  
 CC The PRO polypeptide, the agonist or antagonist or the anti-PRO antibody  
 CC can be used in the preparation of a medicament for the treatment of a  
 CC condition which is responsive to the PRO polypeptide, the agonist or  
 CC antagonist or the anti-PRO antibody. The nucleic acids encoding PRO  
 CC polypeptides are used as hybridisation probes for gene mapping,  
 CC generating transgenic animals useful in the development and screening of  
 CC useful reagents, in chromosome identification or for tissue typing. The  
 CC PRO polypeptides are also useful in gene therapy, may be employed as  
 CC molecular weight markers for protein electrophoresis or as therapeutic  
 CC agents. Anti-PRO antibodies are useful in diagnostic assays or for the  
 CC affinity purification of PRO for recombinant cell culture or natural  
 CC sources. The sequence presented is a PCR primer which was used to amplify  
 CC a PRO polynucleotide of the invention.  
 XX  
 XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. NO. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 OY 747 GACCTGTATTTCGACACTTA 768  
 Db 22 GACCTGTATTTCGACACTTA 1  
 RESULT 220  
 AD118489/c  
 ID AD118489 standard; DNA; 22 BP.  
 XX  
 AC AD118489;  
 XX  
 DT 15-APR-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; as; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypolipulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003152999-A1.  
 PN  
 XX 14-AUG-2003.  
 PD  
 XX 12-JUL-2001; 2001US-00904766.  
 PF  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 10-SEP-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-01019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-01019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-020594.  
 PR 13-SEP-1999; 99US-020594.  
 PR 15-SEP-1999; 99US-020594.  
 PR 05-OCT-1999; 99US-0203089P.  
 PR 29-NOV-1999; 99US-0203089P.  
 PR 30-NOV-1999; 99US-0203089P.  
 PR 01-DEC-1999; 99US-0203089P.  
 PR 02-DEC-1999; 99US-0203089P.  
 PR 02-DEC-1999; 99US-0203089P.

PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
DR WPI; 2004-020479/02.  
XX  
XX Sixty two isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245  
PT or PRO1868, useful for treating psoriasis and epithelial cancers such as  
PT lung squamous cell carcinoma.  
XX  
PS Example 2; SEQ ID NO 7; 426pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
CC -differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a

CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.  
XX  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTTGGCAGACTTA 768  
Db 22 GACCTGTATTTTGGCAGACTTA 1  
RESULT 221  
ADI65209/c  
ID ADI65209 standard; DNA; 22 BP.  
XX  
AC ADI65209;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Human secreted/transmembrane protein, #1, PCR primer #2.  
XX  
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; hyperinsulinaemia;  
KW retinitis pigmentosa; obesity; diabetes; cartilage disorder; sport injury;  
KW hypoparathyroidism; bone disorder; cytostatic; ophthalmological;  
KW arthritis; cardiant; vulnary; anorectic.  
KW osteopathic; antiarthritic;  
XX  
OS Homo sapiens.  
XX  
XX US2003148419-A1.  
XX  
PD 07-AUG-2003.  
XX  
PF 11-JUL-2001; 2001US-00903603.  
XX  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063341P.  
PR 28-OCT-1997; 97US-0063342P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 28-OCT-1997; 97US-0063435P.  
PR 23-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063732P.  
 29-OCT-1997; 97US-0063733P.  
 29-OCT-1997; 97US-0063735P.  
 29-OCT-1997; 97US-0063738P.  
 29-OCT-1997; 97US-0064215P.  
 31-OCT-1997; 97US-0063870P.  
 31-OCT-1997; 97US-0064103P.  
 03-NOV-1997; 97US-0064248P.  
 07-NOV-1997; 97US-0064809P.  
 12-NOV-1997; 97US-0065186P.  
 17-NOV-1997; 97US-0065846P.  
 18-NOV-1997; 97US-0065693P.  
 21-NOV-1997; 97US-0066120P.  
 21-NOV-1997; 97US-0066364P.  
 24-NOV-1997; 97US-0066453P.  
 24-NOV-1997; 97US-0066466P.  
 24-NOV-1997; 97US-0066511P.  
 24-NOV-1997; 97US-0066770P.  
 24-NOV-1997; 97US-0066772P.  
 25-NOV-1997; 97US-0066840P.  
 12-DEC-1997; 97US-0069425P.  
 04-JUN-1998; 98US-0088026P.  
 10-SEP-1998; 98US-0099803P.  
 10-SEP-1998; 98WO-US018824.  
 14-SEP-1998; 98US-0100262P.  
 14-SEP-1998; 98WO-US019177.  
 16-SEP-1998; 98WO-US019330.  
 17-SEP-1998; 98US-0100858P.  
 17-SEP-1998; 98WO-US019437.  
 13-OCT-1998; 98US-0104080P.  
 20-NOV-1998; 98US-0109304P.  
 01-DEC-1998; 98WO-US025108.  
 22-DEC-1998; 98US-0113296P.  
 07-JUL-1999; 99US-0143048P.  
 26-JUL-1999; 99US-0145698P.  
 28-JUL-1999; 99US-0146222P.  
 08-SEP-1999; 99WO-US020594.  
 13-SEP-1999; 99WO-US020944.  
 15-SEP-1999; 99WO-US021090.  
 15-SEP-1999; 99WO-US021547.  
 15-OCT-1999; 99WO-US023099.  
 29-NOV-1999; 99WO-US028214.  
 30-NOV-1999; 99WO-US028313.  
 01-DEC-1999; 99WO-US028301.  
 02-DEC-1999; 99WO-US028564.  
 02-DEC-1999; 99WO-US028565.  
 16-DEC-1999; 99WO-US030095.  
 20-DEC-1999; 99WO-US030911.  
 20-DEC-1999; 99WO-US030999.  
 05-JAN-2000; 2000WO-US000219.  
 11-FEB-2000; 2000WO-US003565.  
 22-FEB-2000; 2000WO-US004414.  
 24-FEB-2000; 2000WO-US005004.  
 02-MAR-2000; 2000WO-US005841.  
 20-MAR-2000; 2000WO-US007377.  
 30-MAR-2000; 2000WO-US008439.  
 22-MAY-2000; 2000WO-US014042.  
 02-JUN-2000; 2000WO-US015264.  
 28-JUL-2000; 2000WO-US020710.  
 24-AUG-2000; 2000WO-US023328.  
 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2004-020444/02.  
 XX  
 PT New isolated secreted and transmembrane PRO nucleic acids and

polypeptides, useful for preventing, diagnosing and treating disorders associated with their aberrant expression and activity.  
 Example 2; SEQ ID NO 7; 476pp; English.  
 The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.  
 Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGGCAGACTTA 768  
 Db 22 GACCTGTATTGGCAGACTTA 1  
 RESULT 222  
 ADI37472/c  
 ID ADI37472 standard; DNA; 22 BP.  
 XX  
 AC ADI37472;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1. PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;

Thu Oct 6 10:44:32 2005

endothelial cell; stimulated T-lymphocyte; retinal neuron; rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte; cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder; reinitis pigmentosa; obesity; diabete; hyperinsulinaemia; hypoinsulinaemia; bone disorder; cartilage disorder; sport injury; arthritis; arthralgia; vulnery; cytostatic; ophthalmological; osteopathic; antiarthritic; anorectic.

**Homo sapiens.**

US2003096340-A1.

22-MAY-2003.

16-JUL-2001: 2001US-00906760.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059117P;  
17-SEP-1997; 97US-0059117P;

17-SEP-1997; 97US-0059121P;  
17-SEP-1997; 97US-0059121P;

17-SEP-1997; 97US-0059184P.  
17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059266P.

17-OCT-1997; 97US-0062285P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063327P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063550P.

29-OCT-1997; 97US-0063435P.

29-OCT-1997; 97US-0063732P.

29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0064215P.

31-OCT-1997; 97US-0064103P.

07-NOV-1997; 97US-0064809P.

17-NOV-1997; 97US-0065846P.

21-NOV-1997; 97US-0066120P.

24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066772P.

12-DEC-1997; 97US-0069425P.

10-SEP-1998; 98US-0099803P.

14-SEP-1998; 98US-0100262P.

16-SEP-1998; 98WO-US019330.

17-SEP-1998;	98US-011008587.
17-SEP-1998;	98WU-050194337.
13-OCT-1998;	98WU-0104080P.
20-NOV-1998;	98US-0109304P.
01-DEC-1998;	98WU-0502108.
22-DEC-1998;	98US-0113296P.
07-JUL-1999;	98WU-0143048P.
26-JUN-1999;	99US-0145698P.
28-JUL-1999;	99US-0146222P.
08-SEP-1999;	99WU-05020594.
13-SEP-1999;	99WU-05020944.
15-SEP-1999;	99WU-05021090.
05-OCT-1999;	99WU-05021547.
30-NOV-1999;	99WU-05023089.
30-NOV-1999;	99WU-05028214.
30-NOV-1999;	99WU-05028313.
01-DEC-1999;	99WU-05028301.
02-DEC-1999;	99WU-05028564.
02-DEC-1999;	99WU-05028565.
16-DEC-1999;	99WU-05030095.
20-DEC-1999;	99WU-05030911.
20-DEC-1999;	99WU-05030999.
05-JAN-2000;	2000WU-05000219.
11-FEB-2000;	2000WU-05003565.
22-FEB-2000;	2000WU-05004414.
24-FEB-2000;	2000WU-05005004.
02-MAR-2000;	2000WU-05005841.
02-MAR-2000;	2000WU-05007377.
30-MAR-2000;	2000WU-05008439.
22-MAY-2000;	2000WU-05014042.
02-JUN-2000;	2000WU-05015264.
28-JUL-2000;	2000WU-05020710.
24-AUG-2000;	2000WU-05023328.
18-SEP-2000;	2000US-00665350.

(GETH ) GENENTECH INC.

Askenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
Gadowski P, Grimaldi JC, Gurney AL, Hillan KJ, Klatvin IJ;  
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
Williams PM, Wood WI;

WPI; 2004-008942/01.

New PRO nucleic acid, useful for producing a PRO polypeptide, manufacturing a medicament for diagnosing or treating tumor, or for tissue typing.

Example 2: SEQ ID NO 7: 474pp: English:

The invention discloses isolated PRO secreted/transmembrane polypeptides and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. PRO polypeptides are useful for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re-differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the

expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a PCR primer which was used to amplify a PRO polynucleotide of the invention.

Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Beat Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTGCCGAGACTTA 768  
Dy 22 GACCTGTATTTGCCGAGACTTA 1

RESULT 223

ADH97276/c  
ID ADH97276 standard; DNA; 22 BP.

XX ADH97276;

AC 22-APR-2004 (first entry)

DE Human secreted/transmembrane protein, #1, PCR primer #2.

Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
tissue typing; immunohistochemical staining; gene therapy;  
neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
endothelial cell; stimulated T-lymphocyte; retinal neuron;  
rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
osteopathic; antiarthritic; anorectic.

XX Homo sapiens.

OS US2003190610-A1.

PN 09-OCT-2003.

PD 16-JUL-2001; 2001US-00906618.

XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0061255P.  
PR 17-OCT-1997; 97US-0062285P.

PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0098033P.  
PR 10-SEP-1998; 98US-0098034P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0101917P.  
PR 16-SEP-1998; 98US-0101930P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0101943P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0113296P.  
PR 22-DEC-1998; 98US-0143048P.  
PR 07-JUL-1999; 99US-0145698P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0145698P.  
PR 08-SEP-1999; 99US-0145698P.  
PR 13-SEP-1999; 99US-0145698P.  
PR 15-SEP-1999; 99US-0145698P.  
PR 15-SEP-1999; 99US-0145698P.  
PR 05-OCT-1999; 99US-0145698P.  
PR 29-NOV-1999; 99US-0145698P.  
PR 30-NOV-1999; 99US-0145698P.  
PR 01-DEC-1999; 99US-0145698P.  
PR 02-DEC-1999; 99US-0145698P.  
PR 02-DEC-1999; 99US-0145698P.  
PR 16-DEC-1999; 99US-0145698P.  
PR 20-DEC-1999; 99US-0145698P.  
PR 20-DEC-1999; 99US-0145698P.  
PR 05-JAN-2000; 2000US-0000219P.  
PR 11-FEB-2000; 2000US-0003565P.  
PR 22-FEB-2000; 2000US-000414P.  
PR 24-FEB-2000; 2000US-0005004P.  
PR 02-MAR-2000; 2000US-0005841P.

PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski P, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2004-032142/03.  
 XX  
 XX New nucleic acid encoding a PRO polypeptide, useful for producing a  
 PT recombinant PRO polypeptide and for treating tumors by gene therapy.  
 XX  
 PS Example 2; SEQ ID NO 7; 47pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGGCAGACTTA 768  
 ||||| | |||||  
 Db 22 GACCTGTATTTTGGCAGACTTA 1  
 RESULT 224  
 ADI65636/c  
 ID ADI65636 standard; DNA; 22 BP.  
 XX AC ADI65636;  
 XX DT 22-APR-2004 (first entry)  
 XX DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX OS Homo sapiens.  
 XX PN US2003148371-A1.  
 XX PD 07-AUG-2003.  
 XX PF 16-JUL-2001; 2001US-00906777.  
 XX PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 31-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.



PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0101917P.  
 PR 17-SEP-1998; 98US-0101933P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0101943P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0143698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0146222P.  
 PR 13-SEP-1999; 99US-0202094P.  
 PR 15-SEP-1999; 99US-0202094P.  
 PR 15-SEP-1999; 99US-0202109P.  
 PR 15-SEP-1999; 99US-0202154P.  
 PR 05-OCT-1999; 99US-0203089P.  
 PR 29-NOV-1999; 99US-0208214P.  
 PR 30-NOV-1999; 99US-0208214P.  
 PR 01-DEC-1999; 99US-0208313P.  
 PR 02-DEC-1999; 99US-0208313P.  
 PR 02-DEC-1999; 99US-0208564P.  
 PR 16-DEC-1999; 99US-0208564P.  
 PR 16-DEC-1999; 99US-0208564P.  
 PR 20-DEC-1999; 99US-030095P.  
 PR 20-DEC-1999; 99US-030095P.  
 PR 20-DEC-1999; 99US-030095P.  
 PR 05-JAN-2000; 2000US-0000219P.  
 PR 11-FEB-2000; 2000US-0000219P.  
 PR 22-FEB-2000; 2000US-0004414P.  
 PR 24-FEB-2000; 2000US-0005004P.  
 PR 02-MAR-2000; 2000US-0005841P.  
 PR 20-MAR-2000; 2000US-0007377P.  
 PR 30-MAR-2000; 2000US-0008439P.  
 PR 22-MAY-2000; 2000US-0014042P.  
 PR 02-JUN-2000; 2000US-0015264P.  
 PR 28-JUL-2000; 2000US-0020710P.  
 PR 24-AUG-2000; 2000US-0023328P.  
 PR 18-SEP-2000; 2000US-00665350.  
 PR XX (GETH ) GENENTECH INC.  
 PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 PR XX WPI; 2004-020441/02.  
 DR Isolated secreted and transmembrane PRO nucleic acids and the proteins  
 XX they encode, e.g. PRO245, PRO249 and PRO1868, useful for preventing,  
 PT diagnosing and treating e.g. disorders relating to blood coagulation.  
 PT  
 XX Example 2; SEQ ID NO 7; 478bp; English.  
 PS The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating

CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the survival or proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or rFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypotension, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e-02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTTCCGACCTTA 768  
 Db 22 GACCTGTATTTTCCGACCTTA 1  
 RESULT 225  
 ADH60379/c  
 ID ADH60379 standard; DNA; 22 BP.  
 XX  
 AC ADH60379;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; rFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypotension; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX Homo sapiens.  
 OS

XX US2004023331-A1.  
XX 05-FEB-2004.  
XX 28-APR-2003; 2003US-00425447.  
XX  
XX 24-OCT-1997; 97US-0063128P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 30-NOV-1999; 99WO-US028313.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 18-SEP-2000; 2000US-00665350.  
PR 17-JUL-2001; 2001US-00907794.  
XX  
XX (DESN/) DESNOYERS L.  
PA (GODD/) GODDARD A.  
PA (GODO/) GODOWSKI P J.  
PA (GURN/) GURNEY A L.  
PA (MATH/) MATHER J P.  
PA (WILL/) WILLIAMS P M.  
PA (WOOD/) WOOD W I.  
XX  
PI Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2004-142655/14.  
XX  
XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.  
XX  
XX Example 2; SEQ ID NO 7; 428pp; English.  
XX  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC -differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity

CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.  
XX  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTCGACGACTTA 768  
Db 22 GACCTGTATTTCGCGGACTTA 1  
RESULT 226  
ADJ99436/C  
ID ADJ99436 standard; DNA; 22 BP.  
XX  
XX AC ADJ99436;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Human secreted/transmembrane protein, #1, PCR primer #2.  
XX  
KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnarary; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX  
OS Homo sapiens.  
XX  
XX US2003187238-A1.  
XX  
XX 02-OCT-2003.  
XX  
PD 11-JUL-2001; 2001US-00903562.  
XX  
XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 18-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062185P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063433P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 02-DEC-1997; 97US-0069425P.  
 PR 12-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 14-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US018825.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 22-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 PA  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WT;  
 XX WPI; 2004-032054/03.  
 XX  
 XX Isolated nucleic acid for making vector for host cell, comprises  
 PT specified sequence identity to nucleotide sequence that encodes  
 PT polypeptide having amino acid sequence.  
 XX  
 PS Example 2; SEQ ID NO 7; 470pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 and the nucleic acid encoding them. The polypeptides can be used to raise  
 antibodies that specifically bind to the PRO polypeptide, for linking a  
 bioactive molecule to a cell expressing a PRO protein and for modulating  
 at least one biological activity of a cell. PRO polypeptides are useful  
 for detecting other PRO polypeptides in a sample and for linking a  
 bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 polypeptide antibodies are useful for modulating the biological activity  
 of a cell expressing PRO polypeptides. The PRO polypeptides or  
 polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 proliferation of endothelial cells, modulating the proliferation of  
 stimulated T-lymphocytes, enhancing the survival or proliferation of  
 retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 cells, modulating glucose or PFA uptake, inducing proliferation and/or re-  
 differentiation of chondrocytes. In particular, these are useful for  
 detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 tumors, retinal disorders or injuries (e.g. loss of sight due to  
 retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 hypotension, or bone or cartilage disorders (e.g. sports injuries or  
 arthritis) in mammals. PRO polypeptides and their portions affect the  
 expression of genes which have a role in cell death. The polynucleotides  
 are useful in molecular biology including uses as hybridisation probes  
 for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 and DNA, for preparing PRO polypeptides, for generating transgenic  
 animals or knockout animals which are useful in the development and  
 screening of therapeutically useful reagents, as probes and for the  
 genetic analysis of individuals with genetic disorders as well as for  
 recombinantly expressing the protein and for chromosome identification.  
 The proteins are useful as molecular marker for protein electrophoresis  
 purposes, as therapeutic agents, for screening compounds to identify  
 those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 useful for tissue typing. PRO antibodies are useful for  
 immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 expression in specific cells, tissues or serum and for affinity  
 purification of PRO from recombinant cell culture or natural sources. The  
 PRO genes may also be used in gene therapy, particularly for replacing a  
 defective gene. The sequence presented is a PCR primer which was used to  
 amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTCGCCAGACTTA 768  
 Db 22 GACCTGTATTTCGCCAGACTTA 1  
 RESULT 227  
 ADL08629/c  
 ID ADL08629 standard; DNA; 22 BP.  
 XX  
 AC ADL08629;  
 XX  
 DT 06-MAY-2004 (first entry)  
 XX Human secreted/transmembrane protein, #1, PCR primer #2.  
 DE Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW

tissue typing; immunohistochemical staining; gene therapy;  
 neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
 osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003186358-A1.

02-OCT-2003.

12-JUL-2001; 2001US-00904877.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059119P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059123P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

15-OCT-1997; 97US-0062125P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

24-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063128P.

27-OCT-1997; 97US-0063327P.

28-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063549P.

28-OCT-1997; 97US-0063550P.

28-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063435P.

29-OCT-1997; 97US-0063704P.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98US-0100858P.

17-SEP-1998; 98WO-US019437.

13-OCT-1998; 98US-0104080P.

20-NOV-1998; 98US-0109304P.

01-DEC-1998; 98WO-US025108.

22-DEC-1998; 98US-0113296P.

07-JUL-1999; 99US-0143048P.

26-JUL-1999; 99US-0145698P.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

01-DEC-1999; 99WO-US028301.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

05-JAN-2000; 2000WO-US000219.

11-FEB-2000; 2000WO-US003565.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US005004.

02-MAR-2000; 2000WO-US005841.

20-MAR-2000; 2000WO-US007377.

30-MAR-2000; 2000WO-US008439.

22-MAY-2000; 2000WO-US014042.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

24-AUG-2000; 2000WO-US023328.

18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

XX

PA

XX

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2004-041195/04.

XX

XX

PT New isolated nucleic acid molecule for use in molecular biology, as

PT hybridization probe, in chromosome and gene mapping, and in generation of

PT anti-sense ribonucleic acid and deoxyribonucleic acid.

XX

XX

PS Example 2; SEQ ID NO 7; 472pp; English.

XX

XX

CC The invention discloses isolated PRO secreted/transmembrane polypeptides

CC and the nucleic acid encoding them. The polypeptides can be used to raise

CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating

CC at least one biological activity of a cell. PRO polypeptides are useful

CC for detecting other PRO polypeptides in a sample and for linking a

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO

CC polypeptide antibodies are useful for modulating the biological activity

CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or

CC bioeffectors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated

CC proliferation of endothelial cells, modulating the proliferation of

CC stimulated T-lymphocytes, enhancing the survival or proliferation of

CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re

CC differentiation of chondrocytes. In particular, these are useful for

CC detecting or treating cardiac insufficiency disorders, wounds, cancerous

CC tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,

CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or

CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knock-out animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.

XX SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCAGACTTA 768

Db 22 GACCTGTATTGGCCAGACTTA 1

RESULT 228

ADM24974/c

ID ADM24974 standard; DNA; 22 BP.

XX AC ADM24974;

XX DT 20-MAY-2004 (first entry)

XX DE Human secreted/transmembrane protein, #1, PCR primer #2.

XX KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiant; vulnery; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.

XX OS Homo sapiens.

XX PN US2003096233-A1.

XX PD 22-MAY-2003.

XX PF 11-JUL-2001; 2001US-00903925.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059119P.

XX PR 17-SEP-1997; 97US-0059122P.

XX PR 17-SEP-1997; 97US-0059184P.

XX PR 18-SEP-1997; 97US-0059263P.

XX PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 12-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0098803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US001565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2004-096547/10.  
 XX  
 XX Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245  
 PT or PRO1868, useful in chromosome and gene mapping, in generating  
 PT antisense RNA and DNA, and in treating cancer and Alzheimer's disease.  
 XX  
 XX Example 2; SEQ ID NO 7; 483pp; English.  
 XX  
 PS The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiating of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, diabetes, hyperinsulinaemia,  
 CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTGTCGACACTTA 768  
 ||||| | |||||  
 Db 22 GACCTGTATTGTCGACACTTA 1  
 RESULT 229  
 ADM29720/c  
 ID ADM29720 standard; DNA; 22 BP.  
 XX  
 AC ADM29720;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnery; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003190611-A1.  
 XX  
 XX 09-OCT-2003.  
 XX  
 PF 17-JUL-2001; 2001US-00907728.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.

PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 97US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98US-0099824P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 16-SEP-1998; 98US-0100262P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0109304P.  
PR 02-DEC-1998; 98US-0109304P.  
PR 07-JUL-1999; 99US-0113296P.  
PR 26-JUL-1999; 99US-0143048P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 13-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 29-NOV-1999; 99US-0202814P.  
PR 30-NOV-1999; 99US-0202814P.  
PR 01-DEC-1999; 99US-0202814P.  
PR 02-DEC-1999; 99US-0202814P.  
PR 02-DEC-1999; 99US-0202814P.  
PR 16-DEC-1999; 99US-0202814P.  
PR 20-DEC-1999; 99US-0202814P.  
PR 20-DEC-1999; 99US-0202814P.  
PR 05-JAN-2000; 2000US-0000219P.  
PR 11-FEB-2000; 2000US-0003565P.  
PR 22-FEB-2000; 2000US-0004414P.  
PR 24-FEB-2000; 2000US-0005004P.  
PR 02-MAR-2000; 2000US-0005841P.  
PR 20-MAR-2000; 2000US-0007377P.  
PR 30-MAR-2000; 2000US-0008439P.  
PR 02-JUN-2000; 2000US-0014042P.  
PR 02-JUN-2000; 2000US-0015264P.  
PR 28-JUL-2000; 2000US-0020710P.  
PR 24-AUG-2000; 2000US-0023328P.  
PR 18-SEP-2000; 2000US-00665350.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PV, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
DR WPI; 2004-020978/02.  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX  
PS Example 2; SEQ ID NO 7; 472pp; English.  
XX  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a PCR primer which was used to  
CC amplify a PRO polynucleotide of the invention.  
XX  
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTGCCAGACTTA 768  
DB 22 GACCTGTATTTGCCAGACTTA 1  
RESULT 230  
AD006042/c  
ID AD006042 standard; DNA; 22 BP.  
XX  
AC AD006042;  
XX  
DT 01-JUL-2004 (first entry)  
XX  
DE Human PRO PCR primer #2.  
XX  
KW Human; PRO; ss; affinity purification; PCR; primer.  
XX  
OS Homo sapiens.  
XX  
XX US6686451-B1.  
XX  
PD 03-FEB-2004.  
XX  
PF 10-JUL-2001; 2001US-00902775.  
XX  
XX 24-OCT-1997; 97US-0063128P.  
XX

PR 16-SEP-1998; 98WO-US019330.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX (GETH ) GENENTECH INC.  
 XX Desnoyers L, Goddard A, Godowski PJ, Gurney AL, Mather JP;  
 PI Williams PM, Wood WI;  
 XX WPI; 2004-106364/11.  
 DR  
 XX New antibodies binding PRO polypeptides, useful in gene therapy, or in  
 PT diagnostic assays for the PRO polypeptides, or for the affinity  
 PT purification of PRO polypeptides from recombinant cell culture or natural  
 PT sources.  
 XX  
 PS Example 2; SEQ ID NO 7; 445pp; English.  
 XX  
 CC The invention relates to an antibody that binds to a human PRO  
 CC polypeptide. The invention also relates to human PRO polynucleotides  
 CC encoding the PRO polypeptides of the invention. The antibody is a  
 CC monoclonal or humanised antibody, or is an antibody fragment, and is  
 CC preferably labelled. The anti-PRO antibodies may be used in diagnostic  
 CC assays for PRO, or for the affinity purification of PRO from recombinant  
 CC cell culture or natural sources. This sequence represents a PCR primer  
 CC used in isolation of a human PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGCCGACTTA 768  
 Db 22 GACCTGTATTTGCCGACTTA 1  
 RESULT 231  
 ID ADR10894/c  
 ID ADR10894 standard; DNA; 22 BP.  
 AC ADR10894;  
 XX 07-OCT-2004 (first entry)  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 KW Human; PCR; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnarary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 OS  
 PN US2004137561-A1.  
 PN  
 XX 15-JUL-2004.  
 PD  
 XX 08-AUG-2002; 2002US-00215371.  
 PF  
 XX 17-OCT-1997; 97US-0062285P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 18-SEP-2000; 2000US-00665350.

XX (GETH ) GENENTECH INC.  
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Pilvaroff E, Pong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX WPI; 2004-623793/60.  
 DR  
 XX New isolated nucleic acids encoding PRO polypeptides, useful in gene  
 PT therapy for treating asthma, rheumatoid arthritis, psoriasis, or multiple  
 PT sclerosis, or as molecular weight markers for protein electrophoresis.  
 XX  
 PS Example 2; SEQ ID NO 7; 262pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis.  
 CC Those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGCCGACTTA 768  
 Db 22 GACCTGTATTTGCCGACTTA 1  
 RESULT 232



ADRI17803/c  
 ID ADRI17803 standard; DNA; 22 BP.  
 XX  
 AC ADRI17803;  
 XX  
 DT 21-OCT-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnerary; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2004147017-A1.  
 XX  
 XX 29-JUL-2004.  
 XX  
 XX 09-MAR-2004; 2004US-00797366.  
 XX  
 XX 28-JUL-1999; 99US-0146222P.  
 XX  
 XX 22-FEB-2000; 2000WO-US004414.  
 XX  
 XX 28-JUL-2000; 2000WO-US020710.  
 XX  
 XX 24-AUG-2000; 2000WO-US023328.  
 XX  
 XX 18-SEP-2000; 2000US-00665350.  
 XX  
 XX (ASHK/) ASHKENAZI A.  
 XX (BOTS/) BOTSTEIN D.  
 XX (DESN/) DESNOYERS L.  
 XX (EATO/) EATON D L.  
 XX (FERR/) FERRARA N.  
 XX (FILV/) FILVAROFF E.  
 XX (FONG/) FONG S.  
 XX (GAOM/) GAO W.  
 XX (GERB/) GERBER H.  
 XX (GERR/) GERRITSEN M E.  
 XX (GODD/) GODDARD A.  
 XX (GODO/) GODOWSKI P J.  
 XX (GRIM/) GRIMALDI C J.  
 XX (GURN/) GURNEY A L.  
 XX (HILL/) HILLAN K J.  
 XX (KLJA/) KLJAVIN I J.  
 XX (MATH/) MATHYER J P.  
 XX (PANJ/) PAN J.  
 XX (PAON/) PAONI N F.  
 XX (ROYM/) ROY M A.  
 XX (STEW/) STEWART T A.  
 XX (TUNA/) TUNAS D.  
 XX (WILL/) WILLIAMS P M.  
 XX (WOOD/) WOOD W I.  
 XX  
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 XX Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 XX Godowski PJ, Grimaldi C, Gurney AL, Hillan KJ, Kljavin IJ;  
 XX Mathy JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tunas D;  
 XX Williams PM, Wood WI;  
 XX  
 XX WPI; 2004-623857/60.  
 XX  
 XX New isolated nucleic acids encoding PRO polypeptides, useful in gene  
 XX therapy for treating asthma, rheumatoid arthritis, psoriasis, or multiple  
 XX sclerosis, or as molecular weight markers for protein electrophoresis.  
 XX  
 XX Example 2; SEQ ID NO 7; 261pp; English.  
 XX

CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.  
 XX  
 XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 1.7e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTTGGCAGACTTA 768  
 Db 22 GACCTGTATTTTGGCAGACTTA 1  
 RESULT 233  
 ADT03479/c  
 ID ADT03479 standard; DNA; 22 BP.  
 XX  
 AC ADT03479;  
 XX  
 XX 22-APR-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #1, PCR primer #2.  
 XX  
 KW Human; PCR; primer; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;

arthrititis; cardiant; vulnerary; cytostatic; ophthalmological;  
osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003152922-A1.

14-AUG-2003.

13-JUL-2001; 2001US-00904532.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

15-OCT-1997; 97US-0062125P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0063281P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

24-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063328P.

27-OCT-1997; 97US-0063327P.

28-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063549P.

28-OCT-1997; 97US-0063550P.

29-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063435P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063732P.

29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0063738P.

29-OCT-1997; 97US-0064215P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

03-NOV-1997; 97US-0064248P.

07-NOV-1997; 97US-0064809P.

KW

KW

XX

OS

XX

PN

PD

XX

PF

XX

XX

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

22-DEC-1998; 99US-0113296P.

07-JUL-1999; 99US-0143048P.

26-JUL-1999; 99US-0145698P.

28-JUL-1999; 99US-0146222P.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

01-DEC-1999; 99WO-US028301.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

05-JAN-2000; 2000WO-US000219.

11-FEB-2000; 2000WO-US003565.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US005004.

02-MAR-2000; 2000WO-US005841.

20-MAR-2000; 2000WO-US007377.

30-MAR-2000; 2000WO-US008439.

22-MAY-2000; 2000WO-US014042.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

24-AUG-2000; 2000WO-US023328.

18-SEP-2000; 2000US-00665350.

XX (GETH ) GENENTECH INC.

PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX WPI; 2004-020478/02.

DR Sixty two isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245

PT or PRO1869, useful for treating psoriasis and epithelial cancers such as

XX lung squamous cell carcinoma.

XX Example 2; SEQ ID NO 7; 486pp; English.

PS The invention discloses isolated PRO secreted/transmembrane polypeptides

CC and the nucleic acid encoding them. The polypeptides can be used to raise

CC antibodies that specifically bind to the PRO polypeptide, for linking a

CC bioactive molecule to a cell expressing a PRO protein and for modulating

CC at least one biological activity of a cell. PRO polypeptides are useful

CC for detecting other PRO polypeptides in a sample and for linking a

CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO

CC polypeptide antibodies are useful for modulating the biological activity

CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or

CC bioeffectors. These are useful for stimulating hypertrophy of neonatal

CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated

CC proliferation of endothelial cells, modulating the proliferation of

CC stimulated T-lymphocytes, enhancing the survival or proliferation of

CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial

CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re

CC differentiation of chondrocytes. In particular, these are useful for

CC detecting or treating cardiac insufficiency disorders, wounds, cancerous

CC tumours, retinal disorders or injuries (e.g. loss of sight due to

CC retinitis pigmentosa), obesity, diabetes, hyperinsulinemia,

CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or

CC arthritis) in mammals. PRO polypeptides and their portions affect the

CC expression of genes which have a role in cell death. The polynucleotides

CC are useful in molecular biology including uses as hybridisation probes

CC for cDNA library to isolate the full-length PRO cDNA or to isolate other

CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA

CC and DNA, for preparing PRO polypeptides, for generating transgenic

CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a PCR primer which was used to  
 CC amplify a PRO polynucleotide of the invention.

XX Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768

Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 234

AD574442/C

ID AD574442 standard; DNA; 22 BP.

XX AC AD574442;

XX AD574442;

DT 16-DEC-2004 (first entry)

XX Human secreted/transmembrane protein, #1, PCR primer #2.

XX Human; secreted; transmembrane; PCR; primer; ss; enterocolitis;

KW Zollinger-Ellison syndrome; gastrointestinal ulceration;

KW congenital microvillus atrophy; psoriasis; epithelial cancer;

KW Parkinson's disease; Alzheimer's disease; ALS;

KW amyotrophic lateral sclerosis; neuropathy; wound healing; tissue repair;

KW bone formation; endometrial bleeding; angiogenesis; asthma;

KW rheumatoid arthritis; multiple sclerosis; colon cancer; AIDS;

KW atherosclerosis; diabetes; stroke; inflammation; organ failure;

KW cardiac injury; infertility; birth defect; premature aging.

XX Homo sapiens.

OS US2004185531-A1.

XX US2004185531-A1.

XX 23-SEP-2004.

XX 02-FEB-2004; 2004US-00771187.

XX 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 05-JAN-2000; 2000WO-US000219.

PR 22-FEB-2000; 2000WO-US004414.

PR 18-SEP-2000; 2000WO-US006530.

PR 18-JUL-2001; 2001US-00909064.

XX (ASHK/) ASHKENAZI A.

PA (BOTS/) BOTSTEIN D.

PA (DESN/) DESNOYERS L.  
 PA (EATO/) EATON D L.  
 PA (FERR/) FERRARA N.  
 PA (FILV/) FILVAROFF E.  
 PA (FONG/) FONG S.  
 PA (GAOW/) GAO W.  
 PA (GERB/) GERBER H.  
 PA (GERR/) GERRITSEN M E.  
 PA (GODD/) GODDARD A.  
 PA (GODO/) GODOWSKI P J.  
 PA (GRIM/) GRIMALDI C J.  
 PA (GURN/) GURNEY A L.  
 PA (HILL/) HILLAN K J.  
 PA (KLJA/) KLJAVIN I J.  
 PA (MATH/) MATHER J P.  
 PA (PANJ/) PAN J.  
 PA (PAON/) PAONI N F.  
 PA (ROYM/) ROY M A.  
 PA (STEW/) STEWART T A.  
 PA (TUMA/) TUMAS D.  
 PA (WILL/) WILLIAMS P M.  
 PA (WOOD/) WOOD W I.

XX

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;

PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

PI Williams PM, Wood WI;

XX

DR WPI; 2004-735510/72.

XX

PT New nucleic acids encoding secreted and transmembrane PRO polypeptides  
 PT with potential therapeutic applications in treating cancer, stroke,  
 PT diabetes, psoriasis and Alzheimer's disease.

XX

PS Example 2; SEQ ID NO 7; 458pp; English.

XX

CC The invention relates to human secreted/transmembrane PRO polypeptides  
 CC and the PRO polynucleotides encoding them. The PRO polypeptides and  
 CC polynucleotides may have therapeutic applications in enterocolitis,  
 CC Zollinger-Ellison syndrome, gastrointestinal ulceration, congenital  
 CC microvillus atrophy, psoriasis, epithelial cancers, Parkinson's disease,  
 CC Alzheimer's disease, ALS (amyotrophic lateral sclerosis), neuropathies,  
 CC wound healing, tissue repair, inducing bone formation, endometrial  
 CC bleeding, angiogenesis, asthma, rheumatoid arthritis, multiple sclerosis,  
 CC colon cancer, AIDS, atherosclerosis, diabetes, stroke, inflammation,  
 CC organ failure, cardiac injury, infertility, birth defects and premature  
 CC aging. The PRO polypeptides may be also be used in screening assays to  
 CC identify agonists or antagonists of the PRO polypeptides. This sequence  
 CC represents a PCR primer used in isolating a human PRO polynucleotide of  
 CC the invention.

XX

SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 1.7e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768

Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 235

ABT36210/c

ID ABT36210 standard; DNA; 17 BP.

XX AC ABT36210;

XX DT 12-JUN-2003 (first entry)

XX

XX Tumour suppression related human fukutin oligo SEQ ID No 1847.

XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX Homo sapiens.  
 OS  
 XX WO2003025175-A2.  
 XX  
 XX PD 27-MAR-2003.  
 XX  
 XX PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 XX PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 XX PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 XX PI Telerman A, Amson R, Tuijnder M;  
 XX  
 XX DR WPI; 2003-313353/30.  
 XX  
 XX New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 PT  
 XX PS Disclosure; Page 249; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 CC  
 XX SQ Sequence 17 BP; 7 A; 4 C; 2 G; 4 T; 0 U; 0 Other;  
 Query Match 1.9%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 363 TTGAAGATTCGTGATC 379  
 |||||  
 DB 17 TTGAAGATTCGTGATC 1  
 RESULT 236  
 ABT39565  
 ID ABT39565 standard; DNA; 17 BP.  
 XX  
 XX AC ABT39565;  
 XX  
 XX DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID No 5202.  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX Homo sapiens.  
 OS  
 XX WO2003025175-A2.  
 XX  
 XX PD 27-MAR-2003.  
 XX  
 XX PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 XX PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 XX PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 XX PI Telerman A, Amson R, Tuijnder M;  
 XX  
 XX DR WPI; 2003-313353/30.  
 XX  
 XX New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 PT  
 XX PS Disclosure; Page 642; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 CC  
 XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 1.9%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 690 GATCACTTGGAGATTT 706  
 |||||  
 DB 1 GATCACTTGGAGATTT 17  
 RESULT 237  
 ADI49574  
 ID ADI49574 standard; DNA; 17 BP.  
 XX  
 XX AC ADI49574;  
 XX  
 XX DT 15-APR-2004 (first entry)  
 XX  
 DE Human tumour suppression/reversion-related DNA sequence SeqID2077.  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; nootropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

```

XX OS Homo sapiens.
XX PN WO2003025177-A2.
XX XX
XX PD 27-MAR-2003.
XX XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX XX
XX PI Telerman A, Amson R, Tuijnder M;
XX XX
XX DR WPI; 2003-313354/30.
XX XX
XX CC This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 17; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 690 GATCACTTGGAGATT 706
XX |||||
XX Db 1 GATCACTTGGAGATT 17
XX
XX RESULT 238
XX ADI52307
XX ID ADI52307 standard; DNA; 17 BP.
XX XX
XX AC ADI52307;
XX XX
XX DT 15-APR-2004 (first entry)
XX XX
XX DE Human tumour suppression/reversion-related DNA sequence SeqID4810.
XX XX
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; da; human.
XX XX
XX OS Homo sapiens.
XX PN WO2003025177-A2.
XX XX
XX PD 27-MAR-2003.
XX XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX XX
XX PI Telerman A, Amson R, Tuijnder M;
XX XX
XX DR WPI; 2003-313354/30.
XX XX
XX CC This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 17; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 690 GATCACTTGGAGATT 706
XX |||||
XX Db 1 GATCACTTGGAGATT 17
XX
XX RESULT 238
XX ADI52307
XX ID ADI52307 standard; DNA; 17 BP.
XX XX
XX AC ADI52307;
XX XX
XX DT 15-APR-2004 (first entry)
XX XX
XX DE Human tumour suppression/reversion-related DNA sequence SeqID4810.
XX XX
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; da; human.
XX XX
XX OS Homo sapiens.
XX PN WO2003025177-A2.
XX XX
XX PD 27-MAR-2003.
XX XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX XX
XX PI Telerman A, Amson R, Tuijnder M;
XX XX
XX DR WPI; 2003-313354/30.
XX XX
XX CC This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.9%; Score 17; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 517 GATCGCCCAATAACAT 533
XX |||||
XX Db 1 GATCGCCCAATAACAT 17
XX
XX RESULT 239
XX ACC53333
XX ID ACC53333 standard; DNA; 17 BP.
XX XX
XX AC ACC53333;
XX XX
XX DT 27-JUN-2003 (first entry)
XX XX
XX DE Human tumour suppressor sequence #2100.
XX XX
XX KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
XX tumour regression; apoptosis; virus resistance; diagnosis;
XX cellular degeneration.
XX XX
XX OS Homo sapiens.
XX PN FR2626373-A1.
XX XX
XX DT 27-DEC-2002.
XX XX
XX PF 20-JUN-2001; 2001FR-00008139.
XX XX
XX PR 20-JUN-2001; 2001FR-00008139.
XX XX
XX PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX XX
XX PI Tuijnder M, Telerman A, Amson R;
XX XX
XX DR WPI; 2003-250498/25.
XX XX

```

PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
XX disease, development of tumor cells and cell degeneration.

PS Claim 1; Page 525; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 517 GATCGCCCAATAAACAT 533

Db 1 GATCGCCCAATAAACAT 17

RESULT 240

ACC51634

ID ACC51634 standard; DNA; 17 BP.

XX

AC ACC51634;

XX

DT 27-JUN-2003 (first entry)

XX

DE Human tumour suppressor sequence #401.

XX

KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.

OS Homo sapiens.

XX

FN FR2826373-A1.

XX

PD 27-DEC-2002.

XX

PF 20-JUN-2001; 2001FR-00008139.

XX

PR 20-JUN-2001; 2001FR-00008139.

XX

PA (MOLE-) MOLECULAR ENGINES LAB SA.

XX

PI Tuijnder M, Telerman A, Anson R;

XX

DR WPI; 2003-250498/25.

XX

PT New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.

XX

PS Claim 1; Page 133; 798pp; French.

XX

CC This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX

SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.9%; Score 17; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 690 GATCACTTGGAGATT 706

Db 1 GATCACTTGGAGATT 17

RESULT 241

ABQ75416

ID ABQ75416 standard; DNA; 19 BP.

XX

AC ABQ75416;

XX

DT 06-NOV-2002 (first entry)

XX

DE CuZn superoxide dismutase (CuZn-SOD) PCR primer SEQ ID NO:13.

XX

KW AOP-1; cardiant; nootropic; neuroprotective; antirheumatic; nephrotropic;  
KW hepatotropic; heart disease; neurodegenerative disease; rheumatism;  
KW kidney disease; liver disease; CuZn superoxide dismutase; CuZn-SOD;  
KW PCR primer; ss.

XX

OS Synthetic.

XX

FN WO200264169-A1.

XX

PD 22-AUG-2002.

XX

PF 18-FEB-2002; 2002WO-JP001358.

XX

PR 16-FEB-2001; 2001JP-00041003.

XX

PA (SUNR ) SUNTORY LTD.

PA (SUNR ) SUNTORY BIOMEDICAL RES LTD.

XX

PI Hattori F, Sugimura K, Furuya M;

XX

DR WPI; 2002-657567/70.

XX

PT Remedies for treating diseases associated with a decrease in expression  
PT of AOP-1 gene or AOP-1, also drug screening with the protein and encoded  
PT gene, applicable e.g. in heart diseases, neurodegenerative diseases and  
PT rheumatism.

XX

PS Example 3; Page 31; 96pp; Japanese.

XX

CC The present invention describes a method for preventing or treating  
CC diseases associated with a decrease in the expression of AOP-1 gene or  
CC AOP-1 comprises: (a) transferring e.g. a nucleic acid encoding AOP-1 gene  
CC ; or (b) administering a substance enhancing the expression of AOP-1  
CC gene, a substance enhancing production of AOP-1 or a substance enhancing  
CC the function of AOP-1. AOP-1 has cardiant, nootropic, neuroprotective,  
CC antirheumatic, nephrotropic and hepatotropic activities. The method can  
CC be used for treating diseases associated with a decrease in the  
CC expression of AOP-1 gene or AOP-1, including heart diseases,  
CC neurodegenerative diseases, rheumatism, kidney diseases and liver  
CC diseases. The present sequence represents a PCR primer for CuZn  
CC superoxide dismutase (CuZn-SOD), which is used in an example from the  
CC present invention

SQ Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.9%; Score 17; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.8e+02;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 292 GGATGAGAGAGGCATG 308

Db 3 GGATGAGAGAGGCATG 19

RESULT 242

AAQ67479/c

ID AAQ67479 standard; DNA; 21 BP.  
 XX  
 AC AAQ67479;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 31-MAY-1995 (first entry)  
 XX  
 DE PCR primer for human SOD1 exon 2.  
 XX  
 XX Human superoxide dismutase; hSOD1; neurodegeneration;  
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;  
 KW Hallervorden-Spatz disease; olivopontocerebellar atrophy;  
 KW familial amyotrophic lateral sclerosis; FALS; diagnosis; mutant SOD;  
 KW SSCP analysis; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX WO9419493-A1.  
 PN  
 XX  
 XX 01-SEP-1994.  
 PD  
 XX 28-FEB-1994; 94WO-US002089.  
 PF  
 XX 26-FEB-1993; 93US-00023980.  
 PR  
 XX (GEHO ) GEN HOSPITAL CORP.  
 XX (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA  
 XX Brown R, Horvitz HR, Rosen DR;  
 PI  
 XX WPI; 1994-294353/36.  
 DR  
 XX  
 XX Diagnosis, treatment and prevention of diseases of cell death - e.g.  
 PT amyotrophic lateral sclerosis, which are the result of e.g. decreased SOD  
 PT activity.  
 XX  
 XX Claim 8; Fig 5; 94pp; English.  
 PS  
 XX The presence of a mutation in a gene encoding a superoxide dismutase  
 CC (SOD1, SOD2 or SOD3) indicates an increased likelihood of developing a  
 CC cell death disease, specifically a neurodegenerative disease. The DNA can  
 CC be analysed to detect mutant SOD sequences. Analysis is pref. preceded by  
 CC a PCR amplification step. AAQ67476-AAQ67485 are examples of PCR primers  
 CC which are useful for diagnosis of diseases linked to SOD1 mutations.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 XX Sequence 21 BP; 3 A; 9 C; 2 G; 7 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.9%; Score 17; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 218 GGAGATAATACAGCAGG 234  
 Db 21 GGAGATAATACAGCAGG 5  
 RESULT 243  
 AAV73829/c  
 ID AAV73829 standard; DNA; 21 BP.  
 XX  
 XX AAV73829;  
 AC  
 XX 24-FEB-1999 (first entry)  
 DT  
 XX Human SOD1 exon 2 PCR primer #2.  
 DE  
 XX SOD1; SOD2; SOD3; Cu/Zn; superoxide dismutase; mitochondrial; treatment;  
 KW extracellular; neurodegenerative disease; amyotrophic lateral sclerosis;  
 KW familial; ALS; PCR primer; ss.  
 XX  
 XX Synthetic.  
 OS  
 OS Homo sapiens.

XX US5849290-A.  
 PN  
 XX 15-DEC-1998.  
 PD  
 XX 07-JUN-1995; 95US-00486953.  
 PF  
 XX 26-FEB-1993; 93US-00023980.  
 PR 28-FEB-1994; 94US-00204052.  
 XX  
 XX (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEHO ) GEN HOSPITAL CORP.  
 XX Rosen DR, Brown R, Horvitz HR;  
 PI  
 XX WPI; 1999-069657/06.  
 DR  
 XX Treatment of neurodegenerative disease - by administering super-oxide  
 PT dismutase.  
 PT  
 XX Disclosure; Fig 5; 53pp; English.  
 PS  
 XX AAV73826-V73835 are PCR primers used in the amplification of a novel  
 CC human SOD1 gene which encodes a Cu/Zn SOD (superoxide dismutase) protein.  
 CC This protein can be used in a method for treating a neurodegenerative  
 CC disease particularly familial amyotrophic lateral sclerosis (ALS)  
 XX  
 XX Sequence 21 BP; 3 A; 9 C; 2 G; 7 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.9%; Score 17; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 218 GGAGATAATACAGCAGG 234  
 Db 21 GGAGATAATACAGCAGG 5  
 RESULT 244  
 ADO55692/c  
 ID ADO55692 standard; DNA; 21 BP.  
 XX  
 XX ADO55692;  
 AC  
 XX 15-JUL-2004 (first entry)  
 DT  
 XX Human cytosolic superoxide dismutase (Cu/ZnSOD) DNA, SOD1 PCR primer #4.  
 DE  
 XX Human; cytosolic superoxide dismutase; Cu/ZnSOD; SOD; SOD1; PCR; ss;  
 KW neurodegenerative disease; cell death disease; FALS; neoplasm; primer.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US6723893-B1.  
 PN  
 XX 20-APR-2004.  
 PD  
 XX 28-FEB-1994; 94US-00204052.  
 PF  
 XX 26-FEB-1993; 93US-00023980.  
 PR  
 XX (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEHO ) GEN HOSPITAL CORP INC.  
 XX  
 XX Brown R, Horvitz HR, Rosen DR;  
 PI  
 XX WPI; 2004-326924/30.  
 DR  
 XX New transgenic mouse having somatic and germ cells containing a transgene  
 PT encoding and expressing a neurodegenerative disease-causing mutant SOD-1  
 PT polypeptide, useful for research or drug development.  
 XX  
 XX Disclosure; SEQ ID NO 7; 54pp; English.  
 PS

XX The invention relates to a transgenic mouse having somatic and germ cells  
 CC containing a transgene encoding and expressing a neurodegenerative  
 CC disease-causing mutant SOD1 polypeptide. The invention also relates to a  
 CC method of diagnosing an increased likelihood of developing cell death  
 CC disease in a patient, a kit for the diagnosis of cell death disease in a  
 CC patient, a method of treating a patient with a disease involving a mutant  
 CC SOD encoding gene, antibodies reactive with a FALS polypeptide, a method  
 CC of treating a patient with a neoplasm, a bacterial or yeast cell  
 CC containing a purified nucleic acid derived from a FALS gene, a purified  
 CC DNA encoding a purified FALS polypeptide and a purified FALS polypeptide.  
 CC The SOD1 polypeptide is a murine or human SOD1 polypeptide. The  
 CC expression of the mutant polypeptide is under the regulation of the wild-  
 CC type promoter. The transgenic mouse is useful for research or drug  
 CC development. This sequence represents a PCR primer used to amplify SOD1  
 CC DNA encoding the human cytosolic superoxide dismutase (Cu/ZnSOD)  
 CC polypeptide.  
 XX  
 SQ Sequence 21 BP; 3 A; 9 C; 2 G; 7 T; 0 U; 0 Other;  
 Query Match 1.9%; Score 17; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 218 GGAGATAATACAGCAGG 234  
 Db ||||||||||||||||  
 21 GGAGATAATACAGCAGG 5  
 RESULT 245  
 ADOS5743/c  
 ID ADOS5743 standard; DNA; 21 BP.  
 XX  
 AC ADOS5743;  
 XX  
 DT 15-JUL-2004 (first entry)  
 XX  
 DE Human cytosolic superoxide dismutase (Cu/ZnSOD) DNA, SOD1 PCR primer #13.  
 XX  
 KW Human; cytosolic superoxide dismutase; Cu/ZnSOD; SOD; SOD1; PCR; ss;  
 KW neurodegenerative disease; cell death disease; FALS; neoplasm; primer.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6723893-B1.  
 XX  
 PD 20-APR-2004.  
 XX  
 PF 28-FEB-1994; 94US-00204052.  
 XX  
 PR 26-FEB-1993; 93US-00023980.  
 XX  
 PA (MASI) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEO) GEN HOSPITAL CORP INC.  
 XX  
 PI Brown R, Horvitz HR, Rosen DR;  
 XX  
 PS WPI; 2004-326924/30.  
 XX  
 PT New transgenic mouse having somatic and germ cells containing a transgene  
 PT encoding and expressing a neurodegenerative disease-causing mutant SOD-1  
 PT polypeptide, useful for research or drug development.  
 XX  
 PS Example; Col 17-18; 54pp; English.  
 XX  
 CC The invention relates to a transgenic mouse having somatic and germ cells  
 CC containing a transgene encoding and expressing a neurodegenerative  
 CC disease-causing mutant SOD1 polypeptide. The invention also relates to a  
 CC method of diagnosing an increased likelihood of developing cell death  
 CC disease in a patient, a kit for the diagnosis of cell death disease in a  
 CC patient, a method of treating a patient with a disease involving a mutant  
 CC SOD encoding gene, antibodies reactive with a FALS polypeptide, a method  
 CC of treating a patient with a neoplasm, a bacterial or yeast cell

CC containing a purified nucleic acid derived from a FALS gene, a purified  
 CC DNA encoding a purified FALS polypeptide and a purified FALS polypeptide.  
 CC The SOD1 polypeptide is a murine or human SOD1 polypeptide. The  
 CC expression of the mutant polypeptide is under the regulation of the wild-  
 CC type promoter. The transgenic mouse is useful for research or drug  
 CC development. This sequence represents a PCR primer used to amplify SOD1  
 CC DNA encoding the human cytosolic superoxide dismutase (Cu/ZnSOD)  
 CC polypeptide.  
 XX  
 SQ Sequence 21 BP; 3 A; 9 C; 2 G; 7 T; 0 U; 0 Other;  
 Query Match 1.9%; Score 17; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 218 GGAGATAATACAGCAGG 234  
 Db ||||||||||||||||  
 21 GGAGATAATACAGCAGG 5  
 RESULT 246  
 AAT38674/c  
 ID AAT38674 standard; DNA; 20 BP.  
 XX  
 AC AAT38674;  
 XX  
 DT 21-JUL-1997 (first entry)  
 XX  
 DE Mouse SOD-1 exon 4 PCR primer EH129r.  
 XX  
 KW Murine; mouse; amyloid; precursor; protein; APP; SOD-1; humanisation;  
 KW homozygous; heterozygous; human; Abeta; Swedish; familial; Alzheimer's;  
 KW disease; FAD; mutation; tool; model; elucidation; pathology;  
 KW symptomatology; screen; inhibition; transgenic;  
 KW polymerase chain reaction; primer; PCR; amplification; exon 4; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9634097-A1.  
 XX  
 PD 31-OCT-1996.  
 XX  
 PF 26-APR-1996; 96WO-US005824.  
 XX  
 PR 26-APR-1995; 95US-00429207.  
 PR 23-APR-1996; 96US-00636876.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Scott RW, Reaume AG, Trusko SP, Siman R, Hoffman EK;  
 XX  
 PS WPI; 1996-497629/49.  
 XX  
 PT Transgenic mice with humanised amyloid precursor protein gene - having at  
 PT least 1 Swedish FAD mutation, useful as tools or models to elucidate role  
 PT of human A-beta in Alzheimer's disease.  
 XX  
 PS Example 16; Page 68; 123pp; English.  
 XX  
 CC The present sequence is a primer for the PCR amplification of exon 4 of  
 CC the murine SOD-1 gene, which was used to distinguish SOD deficient mice  
 CC that have lost both or 1 copy of the SOD-1 gene. The SOD-1 deficient mice  
 CC were used in the preparation of mice homozygous or heterozygous for a  
 CC targeted amyloid precursor protein (APP) encoding gene, comprising a  
 CC human Abeta peptide encoding sequence in place of the endogenous murine  
 CC sequence, and at least 1 Swedish Familial Alzheimer's Disease (FAD)  
 CC mutation. The mice can be used as tools, or models to elucidate the role  
 CC of human Abeta in AD pathology and symptomatology. They can also be used  
 CC to screen chemical compounds for the ability to inhibit in vivo  
 CC processing of APP, to yield the human Abeta peptide by administering the  
 CC chemical compounds to a mouse and measuring the relative amounts of  
 CC amyloidogenic and nonamyloidogenic processing of APP in a sample from the  
 CC mouse at an appropriate interval after administration of the chemical



```

CC compounds
XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
SQ
  Query Match      1.9%; Score 16.8; DB 1; Length 20;
  Best Local Similarity 90.0%; Pred. No. 1.9e+02;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 389 GGAGACATTCATCTGG 408
Db 20 GGAGACATTCATCTGG 1

RESULT 247
AAAT93934/C
ID AAT93934 standard; DNA; 20 BP.
XX
AC AAT93934;
XX
DT 03-FEB-1998 (first entry)
XX
DE Primer for exon 23 of endothelial nitrogen monoxide synthase gene.
XX
KW Exon 23; PCR primer; single stranded conformational polymorphism; SSCP;
KW analysis; endothelial nitrogen monoxide synthase; eNOS;
KW genetic screening; coronary arterial spasm; angina pectoris; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX WO9718327-A1.
XX
PD 22-MAY-1997.
XX
PF 13-NOV-1996; 96WO-JP003324.
XX
PR 13-NOV-1995; 95JP-00319504.
PR 28-JUN-1996; 96JP-00168761.
XX
PA (SHIO ) SHIONOGI & CO LTD.
XX
PI Yasue H, Yoshimura M;
XX
DR WPI; 1997-289303/26.
XX
PT Genetic screening for diseases associated with coronary arterial spasm -
PT by assessment of the occurrence of specific mutation(s) of the
PT endothelial nitrogen monoxide synthase gene.
XX
PS Example 1; Page 14; 47pp; Japanese.
XX
CC The present sequence is an exon 23 primer for the polymerase chain
CC reaction-single stranded conformational polymorphism (PCR-SSCP) analysis
CC of the endothelial nitrogen monoxide synthase (eNOS) gene. The PCR-SSCP
CC analysis was used in an example of genetic screening method for diseases
CC associated with coronary arterial spasm, which comprises determining if 1
CC or more specific nucleotides in the eNOS gene have been substituted,
CC specifically G894T, C774T, T(-786)C, A(-922)G and T(-1468)A. Screening
CC for diseases associated with coronary spasm, e.g angina pectoris, cannot
CC be easily carried out by existing methods, this method allows rapid and
CC easy detection
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
  Query Match      1.9%; Score 16.8; DB 1; Length 20;
  Best Local Similarity 90.0%; Pred. No. 1.9e+02;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 168 GCATTAAGGACTGCTGAA 187
Db 20 GCATTAAGGACTGCTGAA 1

ngs.res
RESULT 248
AAQ67482
ID AAQ67482 standard; DNA; 21 BP.
XX
AC AAQ67482;
XX
DT 25-MAR-2003 (revised)
DT 31-MAY-1995 (first entry)
XX
DE PCR primer for human SOD1 exon 4.
XX
KW Human superoxide dismutase; hSOD1; neurodegeneration;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW Hallervorden-Spatz disease; olivopontocerebellar atrophy;
KW familial amyotrophic lateral sclerosis; FALS; diagnosis; mutant SOD;
KW SSCP analysis; ss.
XX
OS Synthetic.
XX WO9419493-A1.
XX
PD 01-SEP-1994.
XX
PF 28-FEB-1994; 94WO-US002089.
XX
PR 26-FEB-1993; 93US-00023980.
XX
PA (GEO ) GEN HOSPITAL CORP.
PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI Brown R, Horvitz HR, Rosen DR;
XX
DR WPI; 1994-294353/36.
XX
PT Diagnosis, treatment and prevention of diseases of cell death - e.g.
PT amyotrophic lateral sclerosis, which are the result of e.g. decreased SOD
PT activity.
XX
PS Claim 8; Fig 5; 94pp; English.
XX
CC The presence of a mutation in a gene encoding a superoxide dismutase
CC (SOD1, SOD2 or SOD3) indicates an increased likelihood of developing a
CC cell death disease, specifically a neurodegenerative disease. The DNA can
CC be analysed to detect mutant SOD sequences. Analysis is pref. preceded by
CC a PCR amplification step. AAQ67476- AAQ67485 are examples of PCR primers
CC which are useful for diagnosis of diseases linked to SOD1 mutations.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 21 BP; 6 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
  Query Match      1.9%; Score 16.8; DB 1; Length 21;
  Best Local Similarity 90.0%; Pred. No. 1.9e+02;
  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 AGAGAGGCATCTGGAGACT 317
Db 2 ATATAGGCATCTGGAGACT 21

RESULT 249
AAV73832
ID AAV73832 standard; DNA; 21 BP.
XX
AC AAV73832;
XX
DT 24-FEB-1999 (first entry)
XX
DE Human SOD1 exon 4 PCR primer #1.
XX
KW SOD1; SOD2; SOD3; Cu/Zn; superoxide dismutase; mitochondrial; treatment;
KW extracellular; neurodegenerative disease; amyotrophic lateral sclerosis;
KW familial; ALS; PCR primer; ss.
XX

```

OS Synthetic.  
 XX Homo sapiens.  
 PN US5849290-A.  
 XX  
 PD 15-DEC-1998.  
 XX  
 PF 07-JUN-1995; 95US-00486953.  
 XX  
 PR 26-FEB-1993; 93US-00023980.  
 PR 28-FEB-1994; 94US-00204052.  
 XX  
 PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEOH ) GEN HOSPITAL CORP.  
 XX  
 PI Rosen DR, Brown R, Horvitz HR;  
 XX  
 DR WPI; 1999-069657/06.  
 XX  
 PT Treatment of neurodegenerative disease - by administering super-oxide  
 PT dismutase.  
 XX  
 PS Disclosure; Fig 5; 53pp; English.  
 XX  
 CC AAV73826-V73835 are PCR primers used in the amplification of a novel  
 CC human SOD1 gene which encodes a Cu/Zn SOD (superoxide dismutase) protein.  
 CC This protein can be used in a method for treating a neurodegenerative  
 CC disease particularly familial amyotrophic lateral sclerosis (ALS)  
 XX  
 SQ Sequence 21 BP; 6 A; 3 C; 6 G; 6 T; 0 U; 0 Other;  
 XX  
 Query Match 1.9%; Score 16.8; DB 1; Length 21;  
 Best Local Similarity 90.0%; Pred. No. 1.9e+02;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 298 AGAGAGGCATGTTGGAGACT 317  
 DB | | | | | | | | | | | | | | | | | |  
 2 ATATAGGCATGTTGGAGACT 21  
 XX  
 RESULT 250  
 AD055695  
 ID AD055695 standard; DNA; 21 BP.  
 XX  
 AC AD055695;  
 XX  
 DT 15-JUL-2004 (first entry)  
 XX  
 DE Human cytosolic superoxide dismutase (Cu/ZnSOD) DNA, SOD1 PCR primer #7.  
 XX  
 KW Human; cytosolic superoxide dismutase; Cu/ZnSOD; SOD; SOD1; PCR; ss;  
 KW neurodegenerative disease; cell death disease; FALS; neoplasm; primer.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6723893-B1.  
 XX  
 PD 20-APR-2004.  
 XX  
 PF 28-FEB-1994; 94US-00204052.  
 XX  
 PR 26-FEB-1993; 93US-00023980.  
 XX  
 PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.  
 PA (GEOH ) GEN HOSPITAL CORP INC.  
 XX  
 PI Brown R, Horvitz HR, Rosen DR;  
 XX  
 DR WPI; 2004-326924/30.  
 XX  
 PT New transgenic mouse having somatic and germ cells containing a transgene  
 PT encoding and expressing a neurodegenerative disease-causing mutant SOD-1  
 PT polypeptide, useful for research or drug development.

XX Disclosure; SEQ ID NO 10; 54pp; English.  
 PS  
 XX  
 CC The invention relates to a transgenic mouse having somatic and germ cells  
 CC containing a transgene encoding and expressing a neurodegenerative  
 CC disease-causing mutant SOD1 polypeptide. The invention also relates to a  
 CC method of diagnosing an increased likelihood of developing cell death  
 CC disease in a patient, a kit for the diagnosis of cell death disease in a  
 CC patient, a method of treating a patient with a disease involving a mutant  
 CC SOD encoding gene, antibodies reactive with a FALS polypeptide, a method  
 CC of treating a patient with a neoplasm, a bacterial or yeast cell  
 CC containing a purified nucleic acid derived from a FALS gene, a purified  
 CC DNA encoding a purified FALS polypeptide and a purified FALS polypeptide.  
 CC The SOD1 polypeptide is a murine or human SOD1 polypeptide. The  
 CC expression of the mutant polypeptide is under the regulation of the wild-  
 CC type promoter. The transgenic mouse is useful for research or drug  
 CC development. This sequence represents a PCR primer used to amplify SOD1  
 CC DNA encoding the human cytosolic superoxide dismutase (Cu/ZnSOD)  
 CC polypeptide.  
 XX  
 SQ Sequence 21 BP; 6 A; 3 C; 6 G; 6 T; 0 U; 0 Other;  
 XX  
 Query Match 1.9%; Score 16.8; DB 1; Length 21;  
 Best Local Similarity 90.0%; Pred. No. 1.9e+02;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 298 AGAGAGGCATGTTGGAGACT 317  
 DB | | | | | | | | | | | | | | | | | |  
 2 ATATAGGCATGTTGGAGACT 21  
 XX  
 RESULT 251  
 ADI79800/c  
 ID ADI79800 standard; DNA; 20 BP.  
 XX  
 AC ADI79800;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE Human HMG-CoA reductase antisense oligonucleotide, SEQ ID No 323.  
 XX  
 KW HMG-CoA reductase; 3-hydroxy-3-methylglutaryl-Coenzyme A;  
 KW HMG-CoA reductase; cardiant; antiarteriosclerotic; antilipemic;  
 KW antisense gene therapy; cardiovascular disorder; cholesterol metabolism;  
 KW human; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004006031-A1.  
 XX  
 PD 08-JAN-2004.  
 XX  
 PF 02-JUL-2002; 2002US-00190366.  
 XX  
 PR 02-JUL-2002; 2002US-00190366.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Dean NM, Freier SM, Dobie KW;  
 XX  
 DR WPI; 2004-081743/08.  
 XX  
 PT New compounds, particularly antisense oligonucleotides targeted to a  
 PT nucleic acid encoding HMG-CoA reductase, useful for treating  
 PT atherosclerosis, or a disease involving cholesterol metabolism or  
 PT angiogenesis.  
 XX  
 PS Example 16; SEQ ID NO 323; 110pp; English.  
 XX  
 CC The invention relates to novel compounds of 8-80 nucleobases in length  
 CC targeted to, and which specifically hybridises with, a nucleic acid  
 CC molecule encoding 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA)  
 CC reductase, and inhibits the expression of HMG-CoA reductase. The novel

CC compounds have cardiant, antiarteriosclerotic, and antilipaeamic activities. The compound can be used to treat disorders by antisense gene therapy. The compounds, compositions and methods are useful for treating a disease or condition associated with HMG-CoA reductase, such as a cardiovascular disorder e.g. atherosclerosis, or a disease or condition involving cholesterol metabolism. They are also useful in research and diagnostics for modulating the expression of HMG-CoA reductase. This polynucleotide sequence represents an antisense oligonucleotide of the invention.

XX  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 2e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 TCATTCAAGCCTGTGAAT 824  
DB 18 TCATTCAAGCCTGTCAAT 1

RESULT 252  
ADI79603  
ID ADI79603 standard; DNA; 20 BP.  
XX  
XX ADI79603;  
XX  
XX  
DT 22-APR-2004 (first entry)  
XX  
XX Human HMG-CoA reductase antisense oligonucleotide, SEQ ID NO 126.  
XX  
XX HMG-CoA reductase; 3-hydroxy-3-methylglutaryl-Coenzyme A;  
KW HMG-CoA reductase; cardiant; antiarteriosclerotic; antilipaeamic;  
KW antisense gene therapy; cardiovascular disorder; cholesterol metabolism;  
KW human; ss.  
XX  
XX Homo sapiens.

XX  
XX US2004006031-A1.  
XX  
XX 08-JAN-2004.  
XX  
XX 02-JUL-2002; 2002US-00190366.  
XX  
XX 02-JUL-2002; 2002US-00190366.  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Dean NM, Freier SM, Dobie KW;  
XX  
XX WPI; 2004-081743/08.  
XX  
XX New compounds, particularly antisense oligonucleotides targeted to a nucleic acid encoding HMG-CoA reductase, useful for treating atherosclerosis, or a disease involving cholesterol metabolism or angiogenesis.

XX  
XX Example 15; SEQ ID NO 126; 110pp; English.  
XX  
XX The invention relates to novel compounds of 8-80 nucleobases in length targeted to, and which specifically hybridises with, a nucleic acid molecule encoding 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase, and inhibits the expression of HMG-CoA reductase. The novel compounds have cardiant, antiarteriosclerotic, and antilipaeamic activities. The compound can be used to treat disorders by antisense gene therapy. The compounds, compositions and methods are useful for treating a disease or condition associated with HMG-CoA reductase, such as a cardiovascular disorder e.g. atherosclerosis, or a disease or condition involving cholesterol metabolism. They are also useful in research and diagnostics for modulating the expression of HMG-CoA reductase. This polynucleotide sequence represents an antisense oligonucleotide of the invention.

XX

SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;  
Query Match 1.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 2e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 TCATTCAAGCCTGTGAAT 824  
DB 3 TCATTCAAGCCTGTCAAT 20

RESULT 253  
AAF91027/c  
ID AAF91027 standard; DNA; 17 BP.  
XX  
XX AAF91027;  
XX  
XX 04-MAY-2001 (first entry)  
XX  
XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 114.  
XX  
XX Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;  
KW inflammatory disease; neuronal disease; CNS disease;  
KW cardiovascular disease; PCR primer; ss.  
XX  
XX Homo sapiens.

XX  
XX WO200109183-A2.  
XX  
XX 08-FEB-2001.  
XX  
XX 28-JUL-2000; 2000WO-EP007314.  
XX  
XX 30-JUL-1999; 99EP-00114938.  
XX  
XX 22-FEB-2000; 2000EP-00103361.  
XX  
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX  
XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;  
XX  
XX WPI; 2001-159855/16.  
XX  
XX New polynucleotide encoding a molecular variant Multi Drug Resistance (MDR)-1 polypeptide is useful for diagnosing and treating diseases associated with abnormal MDR-1 expression or function, e.g. cancer.  
XX  
XX Claim 36; Page 100; 154pp; English.

XX  
XX The present invention provides nucleotides encoding molecular variants of the human multi drug resistance-1 (MDR-1) protein. These can be used to identify compounds capable of treating multidrug resistance and sensitivity interfering resulting from polymorphisms in MDR-1, which can lead to difficulties in treating cancer, cardiovascular, neuronal, inflammatory and CNS diseases

XX  
XX Sequence 17 BP; 5 A; 5 C; 3 G; 4 T; 0 U; 0 Other;  
Query Match 1.8%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCATGTGACTGCTGA 336  
DB 16 GCATGTGACTGCTGA 1

RESULT 254  
ADI50808  
ID ADI50808 standard; DNA; 17 BP.  
XX  
XX ADI50808;  
XX  
XX 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID3311.  
 XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosolic; virucide; neuroprotective; neurotropic; virucide; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
 XX OS Homo sapiens.  
 XX PN WO2003025177-A2.  
 XX PD 27-MAR-2003.  
 XX PF 17-SEP-2002; 2002WO-IB004523.  
 XX PR 17-SEP-2001; 2001FR-00011980.  
 XX PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX PI Telerman A, Amson R, Tuijnder M;  
 XX PI WPI; 2003-313354/30.  
 XX DR New isolated nucleic acid, useful for treating viral diseases associated  
 XX PT with tumors and cell degeneration, also related polypeptides, antibodies  
 XX PT and transfected cells.  
 XX PS Disclosure; SEQ ID NO 3311; 30pp; French.  
 XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration.  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX SQ Sequence 17 BP; 8 A; 5 C; 2 G; 2 T; 0 U; 0 Other;  
 Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 517 GATCGCCCAATAACA 532  
 DB 1 GATCGCCCAATAACA 16  
 RESULT 255  
 ADI50799  
 ID ADI50799 standard; DNA; 17 BP.  
 XX AC ADI50799;  
 XX DT 15-APR-2004 (first entry)  
 XX DE Human tumour suppression/reversion-related DNA sequence SeqID3302.  
 XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosolic; virucide; neuroprotective; neurotropic; virucide; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

OS Homo sapiens.  
 XX PN WO2003025177-A2.  
 XX PD 27-MAR-2003.  
 XX PF 17-SEP-2002; 2002WO-IB004523.  
 XX PR 17-SEP-2001; 2001FR-00011980.  
 XX PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX PI Telerman A, Amson R, Tuijnder M;  
 XX PI WPI; 2003-313354/30.  
 XX DR New isolated nucleic acid, useful for treating viral diseases associated  
 XX PT with tumors and cell degeneration, also related polypeptides, antibodies  
 XX PT and transfected cells.  
 XX PS Disclosure; SEQ ID NO 3302; 30pp; French.  
 XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration.  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX SQ Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 1.8%; Score 16; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 690 GATCACTTGGAGATT 705  
 DB 1 GATCACTTGGAGATT 16  
 RESULT 256  
 ABK41012/c  
 ID ABK41012 standard; DNA; 18 BP.  
 XX AC ABK41012;  
 XX DT 21-MAY-2002 (first entry)  
 XX DE Human obesity-associated biallelic marker upstream PCR primer #89.  
 XX KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;  
 KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;  
 KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;  
 KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.  
 XX OS Homo sapiens.  
 XX PN WO200206525-A2.  
 XX PD 24-JAN-2002.  
 XX PF 28-JUN-2001; 2001WO-IB001477.

PR 18-JUL-2000; 2000US-0219704P.  
 XX (GEST ) GENSET.  
 XX Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;  
 XX WPI; 2002-155043/20.  
 XX Set of novel map-related biallelic markers, preferably located on obesity  
 PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,  
 PT useful, for e.g. detecting statistical correlations between marker allele  
 PT and a phenotype.  
 XX Example 2; Page 246; 311pp; English.  
 XX The invention relates to a set of novel map-related biallelic markers,  
 CC preferably located on obesity disorder-associated chromosomal regions on  
 CC chromosomes 3, 10 and 19. The markers are useful for genotyping or  
 CC estimating the frequency of an allele in a population, for detecting an  
 CC association between a genotype or haplotype and a phenotype, e.g. a  
 CC disease involving drug responses, obesity or disorders related to  
 CC obesity, such as hyperuricaemia, digestive pathology, hepatic function  
 CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,  
 CC insulin disorders, atherosclerotic disease and cardiac insufficiency. The  
 CC markers are useful for detecting a statistical correlation between a  
 CC biallelic marker allele and a phenotype. This sequence represents a PCR primer used to  
 CC amplify a human obesity-associated biallelic marker  
 XX Sequence 18 BP; 3 A; 10 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 16; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 TGAAGGTGTGGGGAAG 168  
 DB 16 TGAAGGTGTGGGGAAG 1

RESULT 257  
 AAL50752  
 ID AAL50752 standard; DNA; 19 BP.  
 XX  
 XX AAL50752;  
 AC  
 DT 15-JAN-2004 (first entry)  
 XX  
 XX PAL/alpha-tubulin-related unpredictable PCR (UP-PCR) primer #13.  
 XX  
 XX PAL promoter; transgenic plant; protein expression; UP-PCR; primer;  
 KW alpha-tubulin promoter; ss.  
 XX  
 XX Unidentified.  
 OS  
 XX US6441273-B1.  
 PN  
 XX 27-AUG-2002.  
 PD  
 XX 07-APR-2000; 2000US-00545686.  
 PF  
 XX 08-FEB-2000; 2000US-0184934P.  
 PR  
 XX (CORR ) CORNELL RES FOUND INC.  
 PA  
 XX Aldwinckle HS, Gaitan AL;  
 PI  
 XX WPI; 2002-711537/77.  
 DR  
 XX A novel DNA promoter, preferably a phenylalanine ammonia lyase promoter,  
 PT useful for making a transgenic plant, induces expression of protein  
 PT encoded by a second DNA operably associated with a DNA promoter.  
 XX

PS Example 11; Col 28; 48pp; English.  
 XX  
 XX The invention comprises the PAL promoter sequence isolated from Coffea  
 CC arabica (coffee) which is capable of inducing the expression of a protein  
 CC that it is operably associated with. The promoter sequence of the  
 CC invention is useful in the production of a transgenic plant and in  
 CC directing protein expression in plants. The present DNA sequence  
 CC represents a primer that was used in an unpredictable-PCR (UP-PCR)  
 CC protocol in an example of the invention  
 XX Sequence 19 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 2 Other;

Query Match 1.8%; Score 16; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 195 ATGGATTCCATGTCATG 212  
 DB 1 ATGGATTCCATGTCATG 18

RESULT 258  
 ADM83390  
 ID ADM83390 standard; DNA; 19 BP.  
 XX  
 XX ADM83390;  
 AC  
 DT 03-JUN-2004 (first entry)  
 XX  
 XX Coffea arabica PAL gene gene-walking PCR primer 13.  
 XX  
 XX Promoter; alpha-tubulin promoter; phenylalanine ammonia lyase promoter;  
 KW PAL; protein expression; pathogen resistant cultivar; coffee; PCR;  
 KW primer; ss.  
 XX  
 XX Coffea arabica.  
 OS  
 XX US2003163837-A1.  
 PN  
 XX 28-AUG-2003.  
 PD  
 XX 16-JUL-2002; 2002US-00197280.  
 PF  
 XX 08-FEB-2000; 2000US-0180934P.  
 PR  
 XX 07-APR-2000; 2000US-00545686.  
 PA  
 XX (ALDW/) ALDWINCKLE H S.  
 PA (GAIT/) GAITAN A L.  
 XX  
 XX Aldwinckle HS, Gaitan AL;  
 PI  
 XX WPI; 2003-897980/82.  
 DR  
 XX  
 XX New DNA promoter for inducing expression of a protein encoded by a second  
 PT DNA operably associated with the DNA promoter isolated from coffee,  
 PT useful for directing protein expression in plants.  
 XX

Example 11; SEQ ID NO 27; 50pp; English.  
 XX  
 XX The present invention relates to the isolation of two DNA promoters  
 CC (alpha-tubulin and phenylalanine ammonia lyase) from a coffee plant  
 CC capable of inducing the expression of a second DNA operably linked to the  
 CC promoter. The invention is useful for directing protein expression in  
 CC plants. The invention is also useful for the development of pathogen  
 CC resistant cultivars of coffee, improve other characteristics of coffee  
 CC plants such as hardness, production and cup quality and overcoming the  
 CC deficiencies of the methods for fighting disease in the coffee plant. The  
 CC present sequence is coffee arabica PAL gene gene-walking PCR primer. The  
 CC primer is used in the exemplification of the invention.  
 XX Sequence 19 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 2 Other;

Query Match 1.8%; Score 16; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 195 ATGGATTCCATGTTTCATG 212  
DB 1 ATGGNTTCATGTTCATG 18  
|||||

RESULT 259

AAAT93235/C  
ID AAT93235 standard; DNA; 20 BP.  
XX AC AAT93235;  
XX 25-MAR-2003 (revised)  
DT 25-FEB-1998 (first entry)  
XX  
DE Antisense oligonucleotide AS C2.  
XX  
KW Antisense oligonucleotide; immunoglobulin; autoimmune disease; leukaemia;  
KW Lyn tyrosine kinase; toxin delivery; CD22+ B cell; CD19-binding antibody;  
KW CD22-binding immunotoxin; antibody HD37; immunotherapy; cancer;  
KW xenograft rejection; non-Hodgkin's lymphoma; transplant rejection; ss.  
XX

OS Synthetic.  
OS Mus musculus.  
XX US5686072-A.  
PN 11-NOV-1997.  
XX  
PD  
XX  
PF 22-FEB-1994; 94US-00202042.  
XX  
PR 17-JUN-1992; 92US-00899781.  
XX  
PA (TEXA) UNIV TEXAS.  
XX  
XX Scheuermann RH, Uhr JW, Witetta ES;  
XX WPI; 1997-558086/51.  
XX

PT Enhancing B-cell cytotoxicity of CD22-binding immuno-toxin - by co-  
PT administration of CD19-binding antibody, for immuno-therapy of e.g.  
PT cancers, auto-immune disease etc.  
XX  
PS Example 4; Col 28; 34pp; English.

XX AAT93234-T93239 represent antisense oligonucleotides targeted against the  
CC immunoglobulin associated Lyn tyrosine kinase. These sequences were used  
CC to test the method of the invention. The method of the invention is for  
CC delivering a toxin to a CD22+ B cell. The method comprises contacting the  
CC B cell with a CD22-binding immunotoxin and a CD19-binding antibody that  
CC binds to the epitope bound by the antibody HD37, or a CD19-binding  
CC fragment or conjugate of such an antibody, in a combined amount effective  
CC to kill the CD22+ cell. The method may be used for immunotherapy of  
CC various diseases including cancer and autoimmune diseases, especially  
CC leukaemia or non-Hodgkin's lymphoma, and for treating recipients of  
CC transplants or xenografts to prevent rejection. The CD19-binding antibody  
CC potentiates the B-cell cytotoxicity of the immunotoxin. (Updated on 25-  
CC MAR-2003 to correct PF field.)

XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 2.4e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 ACTGAAGCCCTGATGAT 200  
DB 20 ACTGAAGCCCTGCAAGAT 2  
|||||

RESULT 260

AAV85741/c  
ID AAV85741 standard; DNA; 20 BP.  
XX AC AAV85741;  
XX 10-FEB-1999 (first entry)  
DT  
XX LRP5 exon primer ElxV 1r.

DE  
XX LRP5; LDL-receptor related protein; LRP-3; IDDM; diagnosis; endocytosis;  
KW insulin dependent diabetes mellitus; autoimmune disease;  
KW glomerulonephritis; inflammation; viral infection; osteoporosis;  
KW hypercholesterolemia; Alzheimer's disease; low density lipoprotein;  
KW PCR primer; ss.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX WO9846743-A1.  
PN 22-OCT-1998.  
XX  
PF 15-APR-1998; 98WO-GB001102.  
XX  
PR 15-APR-1997; 97US-0043553P.  
PR 05-JUN-1997; 97US-0048740P.  
XX  
PA (WELL) WELLCOME TRUST LTD.  
PA (MERI) MERCK & CO INC.  
XX

XX Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H;  
PI Hey P, Kawaguchi Y, Merriman TR, Metzker ML, Nakagawa Y;  
PI Phillips MS, Twelle RCJ;  
XX  
XX WPI; 1998-594573/50.  
XX  
XX New isolated LDL-receptor related protein - used to develop products for  
XX treating, e.g. elevated triglyceride levels, diabetes, autoimmune  
XX disorders, inflammation or Alzheimer's disease.  
XX  
XX Claim 12; Page 104; 200pp; English.

XX The present invention describes LRP5 (low density lipoprotein (LDL)  
CC receptor related protein, previously designated LRP-3). AAV85587 to  
CC AAV85822 represent exon primers used for obtaining LRP5 cDNA. Nucleic  
CC acid molecules (NAMS) encoding LRP5 can be used for determining if an  
CC individual is susceptible to insulin dependent diabetes mellitus (IDDM).  
CC The NAMS or proteins can be used for reducing triglyceride levels in the  
CC serum of an individual. Therapies that affect LRP5 may also be useful in  
CC the treatment of autoimmune diseases such as glomerulonephritis, diseases  
CC and disorders involving disruption of endocytosis and/or antigen  
CC presentation, cytokine clearance and/or inflammation, viral infection,  
CC pathogenic bacterial toxin contamination, elevation of free fatty acids  
CC or hypercholesterolemia, type 2 diabetes, osteoporosis, Alzheimer's  
CC disease and cardiovascular disease. Products from the present invention  
CC can also be used for detection, diagnosis and drug screening

XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 2.4e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAAT 460  
DB 20 CTTGGGCAAGGTGGATAT 2  
|||||

RESULT 261  
ACC44079  
ID ACC44079 standard; DNA; 20 BP.  
XX  
XX AC ACC44079;

XX DT 30-MAY-2003 (first entry)

XX DE Oligo ISIS 124670 for CD40 ligand gene expression inhibition.

XX DE ss; cytostatic; antiinflammatory; immunomodulator; antisense;

XX KW gene therapy; human; CD40 ligand; phosphorothioate; 2'MOE wings; cancer;

XX KW autoimmune disorder; inflammatory disorder; apoptosis.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT misc\_difference 1..20

XX FT /tag= a

XX FT /note= "contains phosphorothioate internucleotide bonds

XX FT in the backbone replacing phosphodiester internucleotide

XX FT bonds"

XX FT modified\_base 1..20

XX FT /tag= d

XX FT /note= "all cytidine nucleotides are 5-methylcytidine"

XX FT modified\_base 1..5

XX FT /tag= b

XX FT /mod\_base= 2'-O-methoxyethyl nucleotides

XX FT modified\_base 16..20

XX FT /tag= c

XX FT /mod\_base= 2'-O-methoxyethyl nucleotides

XX PN WO2003008433-A1.

XX XX 30-JAN-2003.

XX XX 15-JUL-2002; 2002WO-US022635.

XX PF 18-JUL-2001; 2001US-00909595.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Bennett CF, Baker BF, Wyatt JR, Davis SE;

XX PI WPI; 2003-239305/23.

XX DR New antisense oligonucleotides targeted to nucleic acids encoding a CD40

XX PT ligand, useful in diagnostic and research applications, or for treating

XX PT diseases associated with expression of CD40 ligand, e.g. cancer or

XX PT autoimmune disorder.

XX PS Claim 3; Page 79; 108pp; English.

XX XX The invention relates to novel antisense oligonucleotide targeted to the

XX CC human CD40 ligand gene. The oligonucleotides contain either

XX CC phosphorothioate internucleotide bonds replacing the usual phosphodiester

XX CC internucleotide bonds or have a peptide amide backbone replacing the

XX CC sugar phosphate backbone. The nucleotides flanking the central 10

XX CC nucleotides have 2'-methoxyethyl nucleotides (2'MOE wings) and the

XX CC cytidine nucleotides are all 5-methylcytidines. The antisense compounds

XX CC are useful for modulating the expression of CD40 ligand and for treating

XX CC diseases or conditions associated with expression of CD40 ligand, e.g.

XX CC cancer, autoimmune disorder, inflammatory disorder, or a disease or

XX CC condition arising from aberrant apoptosis. The antisense compounds are

XX CC also useful for diagnostics, therapeutics, prophylaxis, e.g. to prevent

XX CC or delay infection, inflammation or tumor formation, as research reagents

XX CC and kits, and in distinguishing between functions of various members of a

XX CC biological pathway. Oligonucleotides ACC44014-ACC44091 represent the

XX CC antisense oligonucleotides of the invention to inhibit expression of the

XX CC human CD40 ligand gene

XX SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 2.4e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGAGAC 394

Db 2 GATCTCACTCTCAGGAGAC 20

RESULT 262

ADL59647/c

ID ADL59647 standard; DNA; 20 BP.

XX AC ADL59647;

XX DT 03-JUN-2004 (first entry)

XX DE Human ESM-1 antisense oligonucleotide seqid 1896.

XX KW cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;

XX KW gene therapy; endothelial specific molecule-1; ESM-1;

XX KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;

XX KW angiogenic disorder; immunological disorder; cardiovascular disorder;

XX KW neurological disorder; antisense technology; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT modified\_base 1..20

XX FT /tag= b

XX FT /mod\_base= OTHER

XX FT /note= "OTHER= phosphorothioate backbone. All cytidine

XX FT residues are 5-methylcytidines"

XX FT modified\_base 1..5

XX FT /tag= a

XX FT /mod\_base= OTHER

XX FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"

XX FT modified\_base 16..20

XX FT /tag= c

XX FT /mod\_base= OTHER

XX FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"

XX PN WO2004021978-A2.

XX XX 18-MAR-2004.

XX XX 19-AUG-2003; 2003WO-US025833.

XX XX 19-AUG-2002; 2002US-0404495P.

XX XX (PHAA ) PHARMACIA CORP.

XX XX Weinstein EJ, Griggs DW;

XX XX WPI; 2004-248358/23.

XX DR New antisense compound, having a sequence targeted to a nucleic acid

XX PT encoding endothelial specific molecule-1 (ESM-1), useful for preparing a

XX PT composition for treating e.g., diabetes, cancer or cardiovascular

XX PT disorder..

XX PS Claim 3; SEQ ID NO 1896; 555pp; English.

XX XX The invention describes a new antisense compound, having a sequence

XX CC comprising 8-30 bp targeted to a nucleic acid encoding endothelial

XX CC specific molecule-1 (ESM-1), that specifically hybridises with the

XX CC nucleic acid ESM-1 and inhibits its expression. Also described are: a

XX CC composition; inhibiting the expression of ESM-1 in cells or tissues; and

XX CC treating an animal having a disease or condition associated with ESM-1.

XX CC The compound is useful for preparing a composition for treating diabetes,

XX CC cancer, ischaemia or reperfusion injury, or angiogenic, immunological,

XX CC cardiovascular or neurological disorder. This sequence represents an

XX CC antisense oligonucleotide that can be used to modulate expression of

XX CC endothelial specific molecule-1 (ESM-1).

XX SQ Sequence 20 BP; 12 A; 0 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 1.8%; Score 15.8; DB 1; Length 20;

```

Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 703 ATTTGTATAGTTTATATAA 721
    ||||| ||||| ||||| |||||
DB 20 ATTTATATATTTTATATAA 2

RESULT 263
ADL59286/c
ID ADL59286 standard; DNA; 20 BP.
XX AC ADL59286;
XX DT 03-JUN-2004 (first entry)
XX DE Human ESM-1 antisense oligonucleotide seqid 1535.
XX KW cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW gene therapy; endothelial specific molecule-1; ESM-1;
KW ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW angiogenic disorder; immunological disorder; cardiovascular disorder;
KW neurological disorder; antisense technology; ss.
XX KW Homo sapiens.
OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone. All cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2004021978-A2.
XX 18-MAR-2004.
XX 19-AUG-2003; 2003WO-US025833.
XX 19-AUG-2002; 2002US-0404495P.
XX (PHAA ) PHARMACIA CORP.
XX Weinstein EJ, Griggs DW;
XX WPI; 2004-248358/23.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
XX composition for treating e.g., diabetes, cancer or cardiovascular
XX disorder.
XX
XX Claim 3; SEQ ID NO 1535; 555pp; English.
XX
XX The invention describes a new antisense compound, having a sequence
XX comprising 8-30 bp targeted to a nucleic acid encoding endothelial
XX specific molecule-1 (ESM-1), that specifically hybridises with the
XX nucleic acid ESM-1 and inhibits its expression. Also described are: a
XX composition; inhibiting the expression of ESM-1 in cells or tissues; and
XX treating an animal having a disease or condition associated with ESM-1.
XX The compound is useful for preparing a composition for treating diabetes,
XX cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
XX cardiovascular or neurological disorder. This sequence represents an
XX antisense oligonucleotide that can be used to modulate expression of
XX endothelial specific molecule-1 (ESM-1).

XX SQ Sequence 20 BP; 12 A; 0 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 703 ATTTGTATAGTTTATATAA 721
    ||||| ||||| ||||| |||||
DB 19 ATTTATATATTTTATATAA 1

RESULT 264
AAV72769
ID AAV72769 standard; DNA; 21 BP.
XX AC AAV72769;
XX DT 17-FEB-1999 (first entry)
XX DE Corn kernel oil concentration controlling loci marker s1931 primer 2.
XX KW Corn kernel oil concentration controlling loci marker s1931 primer 2.
XX KW Corn; kernel oil; concentration; trait controlling loci; genetic marker;
XX Zea mays; breeding; PCR primer; ss.
XX
XX Synthetic.
XX OS Zea mays.
XX PN WO9842870-A1.
XX PD 01-OCT-1998.
XX PF 19-MAR-1998; 98WO-US005550.
XX PR 24-MAR-1997; 97US-0041515P.
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX Reiter RS;
XX WPI; 1998-609896/51.
XX
XX Breeding corn with increased oil concentration - comprises use of genetic
XX markers to identify trait loci controlling kernel oil concentration.
XX
XX Example 2; Page 7; 50pp; English.
XX
XX A new method has been developed of breeding for corn with increased
XX kernel oil concentration. The method comprises: (a) selecting a corn
XX plant from a breeding population using at least one of the genetic
XX markers s1375, s1384, s1394, s1416, s1422, s1432, s1457, s1480, s1476,
XX s1478, s1484, s1500, s1513, s1529, s1544, s1545, s1630, s1633, s1647,
XX s1750, s1756, s1757, s1772, s1774, s1780, s1797, s1813, s1816,
XX s1817, s1836, s1853, s1860, s1870, s1921, s1922, s1925, s1931, s1933,
XX s1939, s1946, s1949, s2054, s2055, s2057, s2058, s2097, s2122, s2125,
XX s2150, s2156, and s2175; and (b) crossing the selected plant with a second
XX plant and obtaining progeny with increased kernel oil concentration. Also
XX described are: (1) a method for identifying corn plants or lines for use
XX a parents to create a breeding population, comprising: (a) genotyping
XX corn plants or lines with one or more of the above genetic markers; and
XX (b) identifying plants or lines which are predicted to produce
XX transgressive segregants for kernel oil concentration; and (2) trait loci
XX controlling kernel oil concentration mapped by the above genetic markers,
XX with the exception of s1480. AAV72694 to AAV72797 represent PCR primers
XX which are used to amplify the genetic markers for use in the method of
XX the invention
XX
XX SQ Sequence 21 BP; 7 A; 2 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 1.8%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```



QY 669 TGTACTGAGAACTGATTT 687  
 DB 1 TGGACTGAGAACTGATTT 19

RESULT 265  
 ABS98130/c  
 ID ABS98130 standard; DNA; 21 BP.  
 AC ABS98130;  
 XX  
 XX  
 XX  
 XX 23-DEC-2002 (first entry)  
 XX  
 XX Human multidrug resistance gene polymorphic sequence #32.  
 KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;  
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;  
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;  
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;  
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;  
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;  
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;  
 KW multidrug resistance associated protein 3; cancer; prostate;  
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
 KW altered drug metabolism; cardiovascular function; colorectal tumour;  
 KW central nervous system; pulmonary; immunological; SNP;  
 KW single nucleotide polymorphism.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200257410-A2.  
 XX  
 XX 25-JUL-2002.  
 XX  
 XX 28-NOV-2001; 2001WO-US044838.  
 XX  
 XX 28-NOV-2000; 2000US-00724389.  
 XX  
 XX (DNAS-) DNA SCI LAB INC.  
 XX  
 XX Guida M, Hall J;  
 XX  
 XX WPI; 2002-698522/75.  
 XX  
 XX Isolated nucleic acid molecules having polymorphisms in known human genes  
 PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers  
 PT for locating, identifying and characterizing the genes responsible for  
 PT disorder-related traits.  
 XX  
 XX Example 22; Page 144; 714pp; English.  
 XX  
 XX This invention relates to the sequence of an isolated nucleic acid  
 CC molecule comprising at least one base variation from that of a known  
 CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),  
 CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),  
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
 CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating  
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl  
 CC transferase (HNMT), kallikrein 2 (KLK2), nicotinamide-N-methyl  
 CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4  
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
 CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1  
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
 CC (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic  
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
 CC The polymorphisms in the human genes cited in the invention are useful as

CC genetic linkage markers for locating and characterising the genes that  
 CC are responsible for specific traits within the genome and eventually  
 CC identifying the genes responsible for a variety of disorder-related  
 CC traits as a result of their e.g., overexpression, constitutive  
 CC expression, mutation or underexpression. The nucleic acid molecules comprising the  
 CC and/or treating the disorders. The nucleic acid molecules comprising the  
 CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
 CC ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,  
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug  
 CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
 CC used to screen for altered cardiovascular function, in COX2 for altered  
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
 CC nervous system function, in FLAP and HNMT for altered pulmonary,  
 CC immunological or haematological function, in KLK2 for altered serine  
 CC protease activity in the prostate, in LTF for altered immunological or  
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
 CC peripheral nervous system function. The present sequence represents a  
 CC polymorphic DNA sequence of the invention  
 XX  
 SQ Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 1.8%; Score 15.8; DB 1; Length 21;  
 Best Local Similarity 89.5%; Pred. No. 2.4e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 318 TGGGCAATGTGACTGCTGA 336  
 DB 21 TGTGCAATGTAAGTCTGA 3  
 RESULT 266  
 ACF62527  
 ID ACF62527 standard; DNA; 17 BP.  
 XX  
 AC ACF62527;  
 XX  
 XX 08-OCT-2003 (first entry)  
 XX  
 XX Cancer based on CYP3A5 related oligonucleotide SEQ ID NO:356.  
 DE  
 XX  
 XX Cancer; CYP3A5; irinotecan; pharmaceutical; malignant glioma;  
 KW cytochrome P450; subfamily IIA; nifedipine oxidase; polypeptide 5;  
 KW cytosolic; PCR primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX WO2003013534-A2.  
 XX  
 XX 20-FEB-2003.  
 XX  
 XX 23-JUL-2002; 2002WO-EP008219.  
 XX  
 XX 23-JUL-2001; 2001EP-00117608.  
 XX 24-MAY-2002; 2002EP-00011710.  
 XX  
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 PA  
 XX Heinrich G, Kerb R;  
 PI  
 XX WPI; 2003-268144/26.  
 XX  
 XX New use of irinotecan for preparation of compositions for treating cancer  
 PT in subject having genome with variant allele comprising cytochrome P450,  
 PT subfamily IIA, polypeptide 5 polynucleotide, termed CYP3A5.  
 PT  
 XX Disclosure; Page 42; 86pp; English.  
 PS  
 XX The present invention describes the use of irinotecan (I) or its  
 CC derivative for the preparation of a pharmaceutical composition for  
 CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic  
 CC cancer, or malignant glioma in a subject having a genome with a variant

CC allele which comprises a cytochrome p450, subfamily IIIA (nifedipine  
 CC oxidase), polypeptide 5 (CYP3A5) polynucleotide (II). (I) and (II) have  
 CC cytostatic activity. The therapeutic applications of (I) is improved,  
 CC since it is possible to individually treat a subject with an appropriate  
 CC dosage and/or an appropriate derivative of (I). Therefore, undesirable,  
 CC harmful or toxic effects are efficiently avoided. Unnecessary and  
 CC potentially harmful treatment of those subjects who do not respond to the  
 CC treatment with substances (nonresponders), as well as the development of  
 CC drug resistances due to suboptimal drug dosing can be avoided. ACF62200  
 CC to ACF62751 and ABM34912 to ABM35013 represent sequences used in the  
 CC exemplification of the present invention

XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 1.8%; Score 15.6; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336  
 Db 2 GCAATGTRACTGCTGA 17

## RESULT 267

ADB21198

ID ADB21198 standard; DNA; 17 BP.

XX AC ADB21198;

DT 20-NOV-2003 (first entry)

XX DE MRP1 based cancer related nucleic acid SEQ ID NO:356.

XX KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
 KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
 KW variant allele; multidrug resistance protein 1; MRP1; cytostatic; gene;  
 KW ds.

XX OS Unidentified.

XX PN WO2003013533-A2.

XX PD 20-FEB-2003.

XX PF 23-JUL-2002; 2002WO-EP008200.

XX PR 23-JUL-2001; 2001EP-00117608.

XX PR 24-MAY-2002; 2002EP-00011710.

XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX PI Heinrich G, Kerb R;

XX WPI; 2003-354397/33.

XX Use of irinotecan or its derivative for preparation of a pharmaceutical  
 PT composition for treating cancer in a subject having a genome with a  
 PT variant allele comprising a multidrug resistance protein 1  
 PT polynucleotide.

XX PS Disclosure; Page 51; 100pp; English.

XX The present invention describes a method for the use of irinotecan (I) or  
 CC its derivative for the preparation of a pharmaceutical composition for  
 CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic  
 CC cancer, or malignant glioma in a subject having a genome with a variant  
 CC allele which comprises a multidrug resistance protein 1 (MRP1)  
 CC polynucleotide (II). (I) has cytostatic activity. (I) or its derivative  
 CC can be used for the preparation of a pharmaceutical composition for  
 CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic  
 CC cancer, or malignant glioma in a subject, where the subject is a human  
 CC (preferably African or Asian) or a mouse. The present sequence represents  
 CC a sequence which is used in the exemplification of the present invention.

XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 1.8%; Score 15.6; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336  
 Db 2 GCAATGTRACTGCTGA 17

## RESULT 268

ADB88287

ID ADB88287 standard; DNA; 17 BP.

XX AC ADB88287;

XX DT 04-DEC-2003 (first entry)

XX DE Human UGT1A1 variant allele sequence fragment SEQ ID NO:328.

XX KW ss; irinotecan; cancer; UGT1A1; cytostatic; topoisomerase I inhibitor;  
 KW colorectal cancer; cervical cancer; gastric cancer; lung cancer;  
 KW ovarian cancer; pancreatic cancer; malignant glioma;  
 KW uridine diphosphate glycosyltransferase1 member A1.

XX OS Homo sapiens.

XX PN WO2003013536-A2.

XX PD 20-FEB-2003.

XX PF 23-JUL-2002; 2002WO-EP008217.

XX PR 23-JUL-2001; 2001EP-00117608.

XX PR 24-MAY-2002; 2002EP-00011710.

XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX PI Heinrich G, Kerb R;

XX WPI; 2003-289896/28.

XX Use of irinotecan to treat cancer patient by determining if patient has  
 PT variant alleles of UGT1A1 gene, administering increased/decreased amounts  
 PT of irinotecan based on increased/decreased levels of UGT1A1 gene product.

XX PS Disclosure; Page 55; 107pp; English.

XX The invention relates to the novel use of irinotecan to treat a patient  
 CC suffering from cancer. This involves determining if the patient has one  
 CC or more variant alleles of the UGT1A1 gene, and if the patient has one or  
 CC more of such variant alleles, irinotecan is administered in an increased  
 CC or decreased amount in comparison to the amount that is administered  
 CC without regard to the patient's alleles in the UGT1A1 gene. The invention  
 CC has cytostatic activity. A composition of the invention acts as a  
 CC topoisomerase I inhibitor. The method is useful for treating a patient,  
 CC an animal e.g. mouse or a human, preferably African or Asian, suffering  
 CC from cancer such as colorectal, cervical, gastric cancer, lung, ovarian,  
 CC pancreatic cancer or malignant glioma. The present sequence is used in  
 CC the exemplification of the invention.

XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 1.8%; Score 15.6; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336

Db 2 GCAATGTRACTGCTGA 17

```

RESULT 269
ADB97270
ID ADB97270 standard; DNA; 17 BP.
XX
XX AC ADB97270;
XX
XX DT 04-DEC-2003 (first entry)
XX
XX DE Human MDR1 variant allele sequence fragment SEQ ID NO:356.
XX
XX KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;
XX KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
XX KW multidrug resistance 1; MDR1; cytostatic; human; ds; Cyp3A5; MRP1; MDR1;
XX KW TOP1.
XX
XX OS Homo sapiens.
XX
XX PN WO2003013537-A2.
XX
XX PD 20-FEB-2003.
XX
XX PF 23-JUL-2002; 2002WO-EP008218.
XX
XX PR 23-JUL-2001; 2001EP-00117608.
XX PR 24-MAY-2002; 2002EP-00011710.
XX
XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
XX PI Heinrich G, Kerb R;
XX
XX WPI; 2003-268145/26.
XX
XX New use of irinotecan for preparation of pharmaceutical compositions for
PT treating cancer in subject having genome with variant allele comprising
PT multidrug resistance 1 polynucleotide.
XX
XX PS Disclosure; Page 79; 130pp; English.
XX
XX CC The invention relates to the novel use of irinotecan or its derivative
CC for the preparation of pharmaceutical compositions for treating
CC colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or
CC malignant glioma in a subject having a genome with a variant allele which
CC comprises a multidrug resistance 1 (MDR1) polynucleotide. A composition
CC of the invention has cytostatic activity. The invention is useful for the
CC preparation of pharmaceutical compositions for treating colorectal,
CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant
CC glioma in a subject (preferably human, more preferably African or Asian)
CC or a mouse. The present sequence is used in the exemplification of the
CC invention.
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other;
XX
XX Query Match 1.8%; Score 15.6; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 2.4e+02;
XX Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 321 GCAATGTGACTGCTGA 336
XX Db 2 GCAATGTRACTGCTGA 17
XX
XX RESULT 270
XX AAF03382/c
XX ID AAF03382 standard; DNA; 17 BP.
XX
XX AC AAF03382;
XX
XX DT 16-FEB-2001 (first entry)
XX
XX DE Hammerhead ribozyme substrate #1677.
XX
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200061729-A2.
XX
XX PD 19-OCT-2000.
XX
XX PF 11-APR-2000; 2000WO-US009721.
XX
XX PR 12-APR-1999; 99US-0129390P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX DR

```

---

```

RESULT 269
ADB97270
ID ADB97270 standard; DNA; 17 BP.
XX
XX AC ADB97270;
XX
XX DT 04-DEC-2003 (first entry)
XX
XX DE Human MDR1 variant allele sequence fragment SEQ ID NO:356.
XX
XX KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;
XX KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
XX KW multidrug resistance 1; MDR1; cytostatic; human; ds; Cyp3A5; MRP1; MDR1;
XX KW TOP1.
XX
XX OS Homo sapiens.
XX
XX PN WO2003013537-A2.
XX
XX PD 20-FEB-2003.
XX
XX PF 23-JUL-2002; 2002WO-EP008218.
XX
XX PR 23-JUL-2001; 2001EP-00117608.
XX PR 24-MAY-2002; 2002EP-00011710.
XX
XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
XX PI Heinrich G, Kerb R;
XX
XX WPI; 2003-268145/26.
XX
XX New use of irinotecan for preparation of pharmaceutical compositions for
PT treating cancer in subject having genome with variant allele comprising
PT multidrug resistance 1 polynucleotide.
XX
XX PS Disclosure; Page 79; 130pp; English.
XX
XX CC The invention relates to the novel use of irinotecan or its derivative
CC for the preparation of pharmaceutical compositions for treating
CC colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or
CC malignant glioma in a subject having a genome with a variant allele which
CC comprises a multidrug resistance 1 (MDR1) polynucleotide. A composition
CC of the invention has cytostatic activity. The invention is useful for the
CC preparation of pharmaceutical compositions for treating colorectal,
CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant
CC glioma in a subject (preferably human, more preferably African or Asian)
CC or a mouse. The present sequence is used in the exemplification of the
CC invention.
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other;
XX
XX Query Match 1.8%; Score 15.6; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 2.4e+02;
XX Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 321 GCAATGTGACTGCTGA 336
XX Db 2 GCAATGTRACTGCTGA 17
XX
XX RESULT 270
XX ADB92461
XX ID ADB92461 standard; DNA; 17 BP.
XX
XX AC ADB92461;
XX
XX DT 04-DEC-2003 (first entry)
XX
XX DE Human MDR1 variant allele sequence fragment SEQ ID NO:356.
XX
XX KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;

```

lung cancer; ovarian cancer; pancreatic cancer; malignant glioma; multidrug resistance 1; MDR1; cytostatic; ds; human; UGT1A1; MRP1; TOP1. Homo sapiens. WO2003013535-A2. 20-FEB-2003. 23-JUL-2002; 2002WO-EP008220. 23-JUL-2001; 2001EP-00117608. 24-MAY-2002; 2002EP-00011710. (EPID-) EPIDAUROS BIOTECHNOLOGIE AG. Heinrich G, Kerb R; WPI; 2003-342400/32. New use of irinotecan for preparation of pharmaceutical compositions for treating cancer in subject having genome with variant allele comprising multidrug resistance 1 polynucleotide. Disclosure; Page 50; 104pp; English. The invention relates to a novel use of irinotecan or its derivative for the preparation of a pharmaceutical composition for treating colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or malignant glioma in a subject having a genome with a variant allele which comprises a multidrug resistance 1 (MDR1) polynucleotide. A composition of the invention has cytostatic activity. The present sequence is used in the exemplification of the invention. Sequence 17 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 1 Other; Query Match 1.8%; Score 15.6; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No. 2.4e+02; Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336 Db 2 GCAATGTRACTGCTGA 17 RESULT 271 AAF03382/c ID AAF03382 standard; DNA; 17 BP. XX AC AAF03382; XX DT 16-FEB-2001 (first entry) XX DE Hammerhead ribozyme substrate #1677. XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor; interferon alpha; ss. XX OS Homo sapiens. XX PN WO200061729-A2. XX PD 19-OCT-2000. XX PF 11-APR-2000; 2000WO-US009721. XX PR 12-APR-1999; 99US-0129390P. XX PA (RIBO-) RIBOZYME PHARM INC. XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J; XX WPI; 2000-647423/62. XX DR

XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX Claim 37; Page 94; 164pp; English.  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX Sequence 17 BP; 2 A; 3 C; 1 G; 11 T; 0 U; 0 Other;  
SQ  
Query Match 1.8%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.5e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 459 ATGAAGAAGTACAAAG 475  
Db 17 ATGAAGAAGTACAAAG 1  
RESULT 272  
NAF03383/C  
ID AAF03383 standard; DNA; 17 BP.  
XX AC AAF03383;  
XX 16-FEB-2001 (first entry)  
DT DT  
DE Hammerhead ribozyme substrate #1678.  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
XX Homo sapiens.  
XX WO200061729-A2.  
PN 19-OCT-2000.  
PD 11-APR-2000; 2000WO-US009721.  
PF 12-APR-1999; 99US-0129390P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
XX WPI; 2000-647423/62.  
DR Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX Claim 37; Page 94; 164pp; English.  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX Sequence 17 BP; 2 A; 2 C; 1 G; 12 T; 0 U; 0 Other;  
SQ

Query Match 1.8%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.5e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 458 AATGAAGAAGTACAAA 474  
Db 17 AATGAAGAAGTACAAA 1  
RESULT 273  
AD181744/C  
ID AD181744 standard; DNA; 20 BP.  
XX AC AD181744;  
XX 22-APR-2004 (first entry)  
DT Human protein kinase C- $\iota$  antisense oligonucleotide target region #16.  
DE Human; protein kinase C- $\iota$ ; ss; antisense oligonucleotide; PKC- $\iota$ ;  
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;  
KW 5-methylcytosine; aberrant apoptosis; hyperproliferative disorder;  
KW cancer; inflammatory disorder; cytostatic; antiinflammatory.  
XX Homo sapiens.  
XX OS  
XX US2004014049-A1.  
PN 22-JAN-2004.  
PD 19-JUL-2002; 2002US-00199674.  
XX PF 19-JUL-2002; 2002US-00199674.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA  
XX Cowser LM, Freier SM, Dobie KW;  
PI WPI; 2004-121555/12.  
DR New antisense oligonucleotides for modulating human protein kinase C- $\iota$  (PKC- $\iota$ ) expression, useful for diagnosing, preventing or treating conditions associated with PKC- $\iota$ , e.g. cancer or inflammatory disorders.  
XX Example 15; SEQ ID NO 99; 59pp; English.  
XX The invention relates to an antisense oligonucleotide targeted to a  
CC nucleic acid molecule encoding human protein kinase C- $\iota$  (PKC- $\iota$ ),  
CC which specifically hybridizes with the nucleic acid molecule encoding PKC- $\iota$  and inhibits the expression of PKC- $\iota$ . The antisense oligonucleotide comprises at least one modified internucleoside linkage, i.e. a phosphorothioate linkage, at least one modified sugar moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase comprising a 5-methylcytosine. The antisense oligonucleotides are useful for inhibiting the expression of PKC- $\iota$  in cells or tissues to treat diseases associated with their expression, such as a condition arising from aberrant apoptosis, a hyperproliferative disorder (e.g. cancer) or an inflammatory disorder. This sequence represents an antisense oligonucleotide target region of the invention.  
XX Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 2.6e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 835 TATGGCACTTATTATGA 851  
Db 19 TATGGCACTTATTATGA 3  
RESULT 274

```

AD181684
ID AD181684 standard; DNA; 20 BP.
XX
XX
AC AD181684;
XX
DT 22-APR-2004 (first entry)
XX
DE Human protein kinase C- $\iota$ -iota (PKC- $\iota$ -iota) DNA antisense oligonucleotide #27.
XX
XX Human; protein kinase C- $\iota$ -iota; ss; antisense oligonucleotide; PKC- $\iota$ -iota;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; aberrant apoptosis; hyperproliferative disorder;
XX cancer; inflammatory disorder; cytostatic; antiinflammatory.
XX
XX Homo sapiens.
OS
XX
XX US2004014049-A1.
PN
XX
XX 22-JAN-2004.
PD
XX
XX 19-JUL-2002; 2002US-00199674.
PF
XX
XX 19-JUL-2002; 2002US-00199674.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Cowseert LM, Freier SM, Dobie KW;
PI
XX
XX WPI; 2004-121555/12.
DR
XX
XX New antisense oligonucleotides for modulating human protein kinase C- $\iota$ -iota
PT (PKC- $\iota$ -iota) expression, useful for diagnosing, preventing or treating
PT conditions associated with PKC- $\iota$ -iota, e.g. cancer or inflammatory
PT disorders.
XX
XX
XX Example 15; SEQ ID NO 39; 59pp; English.
PS
XX
XX The invention relates to an antisense oligonucleotide targeted to a
CC nucleic acid molecule encoding human protein kinase C- $\iota$ -iota (PKC- $\iota$ -iota),
CC which specifically hybridizes with the nucleic acid molecule encoding PKC
CC - $\iota$ -iota and inhibits the expression of PKC- $\iota$ -iota. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage,
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense oligonucleotides
CC are useful for inhibiting the expression of PKC- $\iota$ -iota in cells or tissues
CC to treat diseases associated with their expression, such as a condition
CC arising from aberrant apoptosis, a hyperproliferative disorder (e.g.
CC cancer) or an inflammatory disorder. This sequence represents an
CC antisense oligonucleotide of the invention.
XX
XX
XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 835 TATGGCATTATATGA 851
Db 2 TATGGCATTCTATGA 18

RESULT 275
AAX08640/c
ID AAX08640 standard; DNA; 20 BP.
XX
XX
AC AAX08640;
XX
XX 27-SEP-1999 (first entry)
DT
XX
XX Primer for amplifying N-acetylmuramidase of Streptomyces.
DE
XX
XX Streptomyces; cell wall lytic enzyme; precursor; mature protein;

N-acetylmuramidase; food industry; food preparation; enzyme extraction;
PCR primer; ss.
N-acetylmuramidase; food industry; food preparation; enzyme extraction;
PCR primer; ss.
Streptomyces rutgersensis.
Streptomyces rutgersensis.
GB2331750-A.
GB2331750-A.
02-JUN-1999.
02-JUN-1999.
02-APR-1998; 98GB-00006989.
02-APR-1998; 98GB-00006989.
01-DEC-1997; 97JP-00343630.
01-DEC-1997; 97JP-00343630.
(NORQ) NAT FOOD RES INST MIN AGRIC.
(NORQ) NAT FOOD RES INST MIN AGRIC.
(BIOO-) BIO-ORIENTED TECHNOLOGY RES ADVANCEMENT.
(BIOO-) BIO-ORIENTED TECHNOLOGY RES ADVANCEMENT.
Shimonishi T, Kaneko S, Nirasawa S, Hayashi K, Haraguchi K;
Shimonishi T, Kaneko S, Nirasawa S, Hayashi K, Haraguchi K;
WPI; 1999-280487/24.
WPI; 1999-280487/24.
Cell wall lytic enzyme gene is able to degrade walls and is useful in the
Cell wall lytic enzyme gene is able to degrade walls and is useful in the
food industry.
food industry.
Disclosure; Page 17; 21pp; English.
Disclosure; Page 17; 21pp; English.
The gene for a cell wall lytic enzyme (or a precursor of this enzyme) is
The gene for a cell wall lytic enzyme (or a precursor of this enzyme) is
derived from a Streptomyces organism. The enzyme, which is a N-
derived from a Streptomyces organism. The enzyme, which is a N-
acetylmuramidase, is able to degrade bacterial cell walls. The enzyme is
acetylmuramidase, is able to degrade bacterial cell walls. The enzyme is
useful in the food industry and also in applications in which it is
useful in the food industry and also in applications in which it is
necessary to extract enzymes and DNA present in the inside of bacteria.
necessary to extract enzymes and DNA present in the inside of bacteria.
Two primers (AAX08640, AAX08641) synthesised based on peptide fragments
Two primers (AAX08640, AAX08641) synthesised based on peptide fragments
of the Streptomyces N-acetylmuramidase were used to amplify and clone a
of the Streptomyces N-acetylmuramidase were used to amplify and clone a
nucleotide sequence encoding a full length N-acetylmuramidase
nucleotide sequence encoding a full length N-acetylmuramidase
Sequence 20 BP; 4 A; 2 C; 7 G; 2 T; 0 U; 5 Other;
Sequence 20 BP; 4 A; 2 C; 7 G; 2 T; 0 U; 5 Other;

Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 521 GCCCAATAAACATTCCTTG 540
Db 20 GCCCATCSACRTTSCCTTG 1

RESULT 276
AAX93188
ID AAC93188 standard; DNA; 20 BP.
XX
XX
AC AAC93188;
XX
XX 15-FEB-2001 (first entry)
DT
XX
XX Human STAT3 phosphorothioate antisense oligonucleotide SEQ ID NO:39.
DE
XX
XX Human; mouse; STAT3; phosphorothioate; antisense oligonucleotide;
XX modulation; signal transducer and activator of transcription;
XX DNA-binding protein; signal transduction; inhibition; apoptosis;
XX inflammatory disease; cancer; antiinflammatory; antirheumatic;
XX cytostatic; immunostimulatory; rheumatoid arthritis; leukaemia; myeloma;
XX melanoma; lymphoma; diagnosis; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2000061602-A1.
PN
XX
XX 19-OCT-2000.
PD
XX
XX 06-APR-2000; 2000WO-US009054.
PF
XX
XX 08-APR-1999; 99US-00288461.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA

```

```

XX Karras JG;
XX WPI; 2000-619223/59.
XX
XX New antisense compound for inhibiting the expression of signal transducer
XX and activator of transcription 3 (STAT3) in cells or tissues and treating
XX diseases or condition associated with STAT3, such as rheumatoid arthritis
XX and cancer.
XX
XX Example 2; Page 46; 104pp; English.
XX
XX The present invention describes an antisense compound (I), 8 to 30
XX nucleobases in length, that is targeted to a nucleic acid molecule
XX encoding STAT3 (Signal Transducer and Activator of Transcription) and
XX which inhibits the expression of it. (I) has antiinflammatory,
XX antirheumatic, cytostatic and immunostimulatory activities. (I) is used
XX for inhibiting the expression of STAT3 in cells or tissues, treating an
XX animal having a disease or condition associated with STAT3 or a human
XX having a disease or condition characterised by a reduction in apoptosis,
XX and inducing apoptosis in a cell. Diseases or conditions that are treated
XX are rheumatoid arthritis, cancer of the breast, prostate, brain, head
XX and/or neck, leukaemia, myeloma, melanoma or lymphoma. (I) can also be
XX used for diagnostic methods in detecting and determining the role of
XX STAT3 in various cell functions, physiological processes and conditions
XX and for diagnosing the conditions associated with expression of STAT3.
XX (I) can be used alone or with other drugs as an immunostimulator. (I) is
XX used in sandwich and colourimetric assays, involving enzyme conjugation
XX and radiolabeling and is used in diagnostic kits. AAC93150 encodes human
XX STAT3 and AAC93231 encodes mouse STAT3 as given in the exemplification of
XX the present invention. AAC93151 to AAC93230 and AAC93232 to AAC93299
XX represent STAT3 phosphorothioate antisense oligonucleotides, and AAC93300
XX represents a mismatch control oligonucleotide which are used in example
XX from the present invention
XX
XX Sequence 20 BP; 3 A; 5 C; 2 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.7e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 200 TTCATGTTTCATGACTTTGG 219
XX ||||| ||||| |||||
XX Db 1 TTCATGTTTCATCACTTTTG 20
XX
XX RESULT 277
XX AAH57024/c
XX ID AAH57024 standard; DNA; 20 BP.
XX AC AAH57024;
XX
XX DT 10-SEP-2001 (first entry)
XX
XX DE Human oestrogen receptor alpha search PCR primer 49.
XX
XX KW Ligand dependent transcriptional factor; oestrogen receptor; ER;
XX glucocorticoid receptor protein; GR; mineralocorticoid receptor protein;
XX MR; peroxisome proliferator-activated receptor protein; PPAR;
XX progesterone receptor protein; PR; pregnane X receptor protein; PXR;
XX thyroid hormone receptor protein; TR; vitamin D receptor protein; VDR;
XX transactivation; ERalpha; breast cancer; PCR primer; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200142307-A1.
XX
XX PD 14-JUN-2001.
XX
XX PF 01-DEC-2000; 2000WO-JP008553.
XX
XX PR 07-DEC-1999; 99JP-00348022.
XX 27-DEC-1999; 99JP-00370667.

```

```

PR 07-JUL-2000; 2000JP-00207011.
PR 21-JUL-2000; 2000JP-00220508.
PR 02-AUG-2000; 2000JP-00234053.
PR 03-AUG-2000; 2000JP-00235460.
PR 03-AUG-2000; 2000JP-00235461.
PR 03-AUG-2000; 2000JP-00235463.
XX (SUMO ) SUMITOMO CHEM CO LTD.
XX
XX Saito K, Ohe N, Satoh H;
XX WPI; 2001-367866/38.
XX
XX Ligand dependent transcriptional factors, nucleic acids encoding them and
XX cells comprising them and a specified reporter gene, useful for screening
XX agents for the treatment of breast cancer.
XX
XX Example 9; Page 223; 276pp; English.
XX
XX The present invention relates to ligand dependent transcriptional factors
XX including oestrogen receptor (ER) alpha and beta protein, glucocorticoid
XX receptor protein (GR), mineralocorticoid receptor protein (MR),
XX peroxisome proliferator-activated receptor protein (PPAR), progesterone
XX receptor protein (PR), pregnane X receptor protein (PXR), thyroid hormone
XX acids encoding them and cells comprising them and a specified reporter
XX gene for the ligand dependent transcriptional factor. These proteins are
XX useful in the modulation of ligand dependent transcriptional factor
XX activity. The cells, mutant ERalpha and the polynucleotide encoding it
XX may be used in assays for qualitatively analysing an activity for
XX transactivation of a reporter gene by a test ERalpha, for screening an
XX mutant ligand dependent transcriptional factors, for evaluating an
XX activity for transactivation of a reporter gene by a test ERalpha and/or
XX for screening a compound useful for treating a disorder of a mutant
XX ERalpha, especially breast cancer
XX
XX Sequence 20 BP; 4 A; 11 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 2.7e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 295 TGAAGAGAGGCATCTTGGAG 314
XX ||||| ||||| |||||
XX Db 20 TGTAGAGGGGCATGCTGGAG 1
XX
XX RESULT 278
XX AAS96805
XX ID AAS96805 standard; DNA; 20 BP.
XX AC AAS96805;
XX
XX DT 26-FEB-2002 (first entry)
XX
XX DE Human STAT3 antisense phosphorothioate oligodeoxynucleotide #38.
XX
XX KW STAT3; human; signal transducer and activator of transcription; ss; STAT;
XX antisense gene therapy; Fas-mediated apoptosis; inflammatory disease;
XX autoimmune disease; rheumatoid arthritis; cancer; breast; prostate; head;
XX neck; brain; leukaemia; myeloma; melanoma; lymphoma; apoptosis;
XX antinflammatory; immunosuppressive; antirheumatic; antiarthritic;
XX cytostatic.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX PN US2001029250-A1.
XX
XX PD 11-OCT-2001.
XX
XX PF 11-JAN-2001; 2001US-00758881.
XX
XX

```

PR 08-APR-1999; 99US-00288461.  
 PR 06-APR-2000; 2000WO-US009054.  
 PA (KARR/) KARRAS J G.  
 PI Karras JG;  
 XX WPI; 2002-009991/01.  
 DR  
 XX  
 XX Novel antisense compound useful for treating and diagnosing inflammatory diseases and cancers, is targeted to a nucleic acid molecule encoding signal transducer and activator of transcription proteins.  
 PT  
 PT  
 XX Example 2; Page 13; 2lpp; English.  
 PS  
 XX The invention relates to antisense compounds targeted to a nucleic acid molecule encoding a signal transducer and activator of transcription (STAT) protein, specifically STAT3, where the antisense compounds inhibit the expression of STAT3. The antisense sequences are useful for inhibiting the expression of STAT3 in cells or tissues, inducing Fas-mediated apoptosis in cells, and sensitizing cells to apoptosis. They are also useful for treating an animal having a disease or condition associated with STAT3. These disorders include inflammatory or autoimmune disease, particularly rheumatoid arthritis, cancers, such as those of the breast, prostate, brain and head and neck and leukemias, myelomas, melanomas and lymphomas. Also treatable are human diseases or conditions characterized by a reduction in apoptosis or an insensitivity to apoptotic signals. The sequences of the invention can be used in clinical research, for detecting and determining the role of STAT3 in various cell functions and physiological processes and for diagnosing conditions associated with the expression of STAT3. The sequences represent cDNA encoding human STAT3 and human STAT3 oligonucleotides  
 XX  
 SQ Sequence 20 BP; 3 A; 5 C; 2 G; 10 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 200 TTCCATGTTTCATGAGTTTGG 219  
 Db 1 TTCCATGTTTCATCATTG 20  
 RESULT 279  
 ABQ9746  
 ID ABQ99746 standard; DNA; 20 BP.  
 XX  
 AC ABQ99746;  
 XX  
 DT 15-NOV-2002 (first entry)  
 XX  
 DE cuZnSOD primer #2 to determine mRNA levels using quantitative RT-PCR.  
 KW Antidiabetic; Nephrotropic; Anti-inflammatory;  
 KW gamma-glutamyl transpeptidase; gamma-GT; degenerative disease;  
 KW chronic renal disease; focal glomerulosclerosis; cuZnSOD;  
 KW segmental glomerulosclerosis; nephrosis; inflammatory glomerulopathy;  
 KW diabetic nephropathy; autoimmune glomerulopathy; sensorineural deafness;  
 KW aminoglycoside; cisplatin derivative; otosclerosis; PCR; primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200266047-A1.  
 XX  
 PD 29-AUG-2002.  
 XX  
 PF 20-FEB-2002; 2002WO-BF001799.  
 XX  
 PR 20-FEB-2001; 2001EP-00104063.  
 XX  
 PA (GTXP-) GTX PHARM GMBH.  
 PA (WEI/) WEIHER H.

XX Weiher H, Sies H, Wagner G;  
 PI WPI; 2002-674893/72.  
 XX  
 DR  
 XX Use of gamma-glutamyl transpeptidase inhibitors in the preparation of a pharmaceutical composition for the treatment of degenerative diseases such as chronic renal disease.  
 PT  
 PT  
 XX Example 1; Page 9; 28pp; English.  
 PS  
 XX This invention relates to the preparation of a pharmaceutical composition for the treatment of a degenerative disease, in which gamma-glutamyl transpeptidase (gamma-GT) inhibitors are used. These gamma-GT inhibitors are antidiabetic, nephrotropic and anti-inflammatory in their action. The inhibitors are used in the preparation of pharmaceutical composition for the treatment of degenerative disease such as chronic renal disease induced by reactive oxygen species (ROS) including focal glomerulosclerosis, segmental glomerulosclerosis, minimal change nephrosis, inflammatory glomerulopathies, diabetic nephropathy and autoimmune glomerulopathies, and ROS induced inner ear injury including sensorineural deafness induced by age, physiological status metabolic status or drugs (e.g. aminoglycosides or cisplatin derivatives), or inner ear degenerative condition e.g. otosclerosis. The gamma-GT inhibitor successfully and effectively prevents the progress of the chronic tissue damage imposed by elevated ROS level in kidney and inner ear. This sequence represents a primer used to determine mRNA levels using quantitative RT-PCR, this primer is annealed to its counterpart  
 XX  
 SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 66 TGGCGACGAAGCCGTTGTC 85  
 Db 1 TGGCGATGAAGCCGTTGTC 20  
 RESULT 280  
 ABZ24780/c  
 ID ABZ24780 standard; DNA; 20 BP.  
 XX  
 AC ABZ24780;  
 XX  
 DT 07-APR-2003 (first entry)  
 XX  
 DE Deoxyuridine monophosphate-containing oligonucleotide U-ODN 13b.  
 XX  
 KW Immunostimulant; oligodeoxynucleic acid; ODN; vaccine; DNA-RNA hybrid; ss.  
 KW  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "thiophosphate backbone"  
 XX  
 PN WO200295027-A2.  
 XX  
 PD 28-NOV-2002.  
 XX  
 PF 17-MAY-2002; 2002WO-EP005448.  
 XX  
 PR 21-MAY-2001; 2001AT-00000805.  
 XX  
 PA (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.  
 PA (CIST-) CISTEM BIOTECHNOLOGIES GMBH.  
 XX  
 XX Lingnau K, Schellack C, Schmidt W;

XX WPI; 2003-183880/18.  
 XX New oligodeoxynucleic acid molecules useful for the preparation of  
 XX vaccine.  
 PT  
 XX  
 XX Example 1; Page 20; 57pp; English.  
 PS  
 XX The present sequence is U-ODN 13b, a deoxyuridine monophosphate  
 CC containing oligodeoxynucleic acid (U-ODN) molecule. U-ODN 13b was  
 CC compared with U-ODN 13 (see AB224776), having a thiophosphate substituted  
 CC backbone, for the generation of specific immune responses against  
 CC melanoma-derived peptide TRP-2/181-188 (see ABP58360) in an example from  
 CC the invention. A high number of TRP-2/181-188-specific T cells were  
 CC induced in mice by injection of TRP-2/181-188/U-ODN 13 in the presence or  
 CC absence of the polycation poly-L-arginine. When U-ODN 13b, which is not  
 CC substituted with thiophosphates, was used, a high immune response was  
 CC only induced upon co-injection of poly-L-arginine. The invention is based  
 CC on the discovery that U-ODNs have an immunostimulatory effect comparable  
 CC to, or in many cases greater than, CpG ODNs, producing higher numbers of  
 CC specific T cells to a given antigen. Such U-ODNs do not induce the  
 CC systemic production of pro-inflammatory cytokines and, unlike CpG ODNs,  
 CC are not dependent on a specific motif or a palindromic sequence. Use of U  
 CC -ODNs for the preparation of a vaccine is claimed. Combining the U-ODN  
 CC with an antigen strongly increases the potential of the antigen to raise  
 CC the protection/immune response of a vaccinated individual  
 XX  
 SQ Sequence 20 BP; 3 A; 6 C; 3 G; 7 T; 1 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 OY 129 AGCAGAGGAAAGTAATGGA 148  
 DB 20 AGCATCAGGAAAGTATGGA 1  
 RESULT 281  
 ACF39665  
 ID ACF39665 standard; DNA; 20 BP.  
 XX  
 AC ACF39665;  
 XX  
 DT 29-SEP-2003 (first entry)  
 XX  
 DE MHC class II transactivator antisense oligonucleotide SEQ ID NO:68.  
 XX  
 KW Human; major histocompatibility complex class II transactivator;  
 KW MHC class II transactivator; antisense modulation; immunosuppressive;  
 KW antimicrobial; antidiabetic; antirheumatic; antiarthritic; cytostatic;  
 KW neutropic; neuroprotective; immunostimulant; autoimmune disorder;  
 KW MHC Class II transactivator inhibitor; infection; transplant rejection;  
 KW diabetes; rheumatoid arthritis; cancer; Alzheimer's disease;  
 KW multiple sclerosis; severe combined immunodeficiency disease;  
 KW phosphorothioate; antisense oligonucleotide; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "phosphorothioate linkages; all cytidine residues  
 FT are 5-methylcytidines"  
 FT 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-O-methoxyethyls"  
 FT 16..20  
 FT modified\_base  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT

FT  
 XX  
 PN WO2003050247-A2.  
 XX  
 PD 19-JUN-2003.  
 XX  
 PF 04-DEC-2002; 2002WO-US038616.  
 XX  
 PR 05-DEC-2001; 2001US-00006366.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 PI Bennett FC, Dobie KW;  
 XX  
 DR WPI; 2003-577294/54.  
 XX  
 PT New antisense oligonucleotides for modulating MHC class II transactivator  
 PT gene expression, particularly useful for treating autoimmune disorders  
 PT such as transplant rejection, Alzheimer's disease, or multiple sclerosis,  
 PT or infection.  
 XX  
 PS Example 15; Page 84; 129pp; English.  
 XX  
 CC The present invention describes a compound (I) that is 8-50 nucleobases  
 CC in length: (a) targets a nucleic acid molecule encoding major  
 CC histocompatibility complex (MHC) class II transactivator, and  
 CC specifically hybridises with the nucleic acid encoding the MHC class II  
 CC transactivator, and inhibits the expression of MHC class II  
 CC transactivator; or (b) specifically hybridises with at least an 8-  
 CC nucleobase portion of an active site on a nucleic acid molecule encoding  
 CC MHC class II transactivator. (I) has immunosuppressive, antimicrobial,  
 CC antidiabetic, antirheumatic, antiarthritic, cytostatic, neutropic,  
 CC neuroprotective and immunostimulant activities, and can be used as an MHC  
 CC Class II transactivator inhibitor. The MHC class II transactivator  
 CC antisense oligonucleotides can be used for treating an animal having a  
 CC disease or condition associated with MHC class II transactivator, e.g.  
 CC autoimmune disorder or infection. The antisense oligonucleotides can be  
 CC used for inhibiting the expression of MHC class II transactivator in  
 CC cells or tissues. In particular, these diseases include transplant  
 CC rejection, diabetes, rheumatoid arthritis, cancer, Alzheimer's disease,  
 CC multiple sclerosis, or severe combined immunodeficiency disease. The  
 CC antisense compounds are useful for diagnostics, prophylaxis, or as  
 CC research reagents or kits. The present sequence represents a human MHC  
 CC class II transactivator chimeric phosphorothioate antisense  
 CC oligonucleotide, which is used in an example from the present invention  
 XX  
 SQ Sequence 20 BP; 5 A; 3 C; 9 G; 3 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 OY 437 GATGACTTGGCAAGGTGG 456  
 DB 1 GAGGACTTGAGCCCAAGGTGG 20  
 RESULT 282  
 ADB99942  
 ID ADB99942 standard; DNA; 20 BP.  
 XX  
 AC ADB99942;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 81.  
 XX  
 KW Cytostatic; gene therapy; antisense oligonucleotide; human;  
 KW vitamin D nuclear receptor; cancer; developmental disorder;  
 KW phosphorothioate; ss.  
 XX  
 OS Synthetic.  
 XX

/note= "2'-O-methoxyethyls"



```

FH Key      Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX WO2003041657-A2.
XX
XX PD 22-MAY-2003.
XX
XX PF 13-NOV-2002; 2002WO-US036692.
XX
XX PR 14-NOV-2001; 2001US-00000213.
XX
XX PA (ISIS-) ISIS PHARM INC.
XX
XX PI Baker BF, Dobie K, Roach MP;
XX
XX DR WPI; 2003-468578/44.
XX
XX PT New antisense oligonucleotides for modulating vitamin D nuclear receptor
XX gene expression, particularly useful for treating or preventing cancer or
XX developmental disorder, or as diagnostics or research reagents.
XX
XX PS Claim 3; SEQ ID NO 81; 122pp; English.
XX
XX CC The present invention relates to novel antisense oligonucleotides
XX (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
XX receptor coding sequence (ADB99864), and specifically hybridizes with and
XX inhibits the expression of vitamin D nuclear receptor. The antisense
XX oligonucleotides are useful for treating an animal having a disease or
XX condition associated with vitamin D nuclear receptor, e.g. cancer or
XX developmental disorder.
XX
XX SQ Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
    Query Match      1.7%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. NO. 2.7e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 215 TTTGAGATATATACAGCAGG 234
DB 1 TTTGAAATCATTCAGCAGG 20
|||||
|||||

RESULT 283
ADF17531
ID ADF17531 standard; DNA; 20 BP.
XX
XX AC ADF17531;
XX
XX DT 12-FEB-2004 (first entry)
XX
XX DE Rhodotorula glutinis carbonyl reductase PCR primer SEQ ID NO:4.
XX
XX KW 2-chloro-1-(3'-chlorophenyl)ethanone; NADPH; NADH coenzyme;
XX carbonyl reductase; 2-chloro-1-(3'-chlorophenyl)ethanol;
XX 3-hydroxy ester derivative; pharmaceutical; agrochemical; enzyme;
XX PCR primer; ss.
XX
XX OS Synthetic.
XX OS Rhodotorula glutinis.
XX
XX XX WO2003093477-A1.
XX
XX PD 13-NOV-2003.
XX
XX PF 30-APR-2003; 2003WO-JP005500.
XX
XX PR 30-APR-2002; 2002JP-00128648.

```

```

XX (KANF ) KANEKA CORP.
XX
XX PI Kizaki N, Horikawa M, Yasohara Y;
XX
XX DR WPI; 2003-877521/81.
XX
XX PT Rhodotorula glutinis-originated carbonyl reductase, encoded gene and
XX transformant, applicable in synthesis of e.g. (R)-2-chloro-1-(3'-
XX chlorophenyl)ethanol as pharmaceutical and agrochemical intermediate.
XX
XX PS Example 3; SEQ ID NO 4; 49pp; Japanese.
XX
XX CC The present invention describes a polypeptide having physicochemical
XX properties of: (a) acting on 2-chloro-1-(3'-chlorophenyl)ethanone in the
XX presence of NADPH or NADH coenzyme to give (R)-2-chloro-1-(3'-
XX chlorophenyl)ethanol; (b) optimum pH at 5-6; (c) optimum operating
XX temperature at 40-50 degrees Celsius; and (d) molecular weight about
XX 40,000 (gel filtration analysis) and about 30,000 (SDS polyacrylamide
XX electrophoresis). Also described: (1) a polypeptide which is: (a) a
XX polypeptide containing the carbonyl reductase amino acid sequence of 249
XX amino acids (see ADF17528); or (b) a polypeptide based on the sequence of
XX ADF17528 but with some amino acids substituted, inserted, deleted or
XX the ketone into an optically-active alcohol; (2) a polynucleotide
XX encoding the polypeptide; (3) a polynucleotide which is: (a) a
XX polynucleotide containing the carbonyl reductase base sequence of 750
XX base pairs (see ADF17529); or (b) a polynucleotide hybridizable with a
XX polynucleotide containing a base sequence complementary to that of
XX with the already-defined biological activity; (4) an expression vector
XX containing any of the polynucleotides; (5) a transformant obtained by
XX transforming a host cell with the expression vector; and (6) a process
XX for producing an optically active alcohol by reacting a carbonyl compound
XX with a cultured material of the transformant or its processed material.
XX The carbonyl reductase can be used in asymmetric synthesis of e.g.
XX optically active (R)-2-chloro-1-(3'-chlorophenyl)ethanol and 3-hydroxy
XX ester derivatives for use as pharmaceutical and agrochemical
XX intermediates. The present sequence represents a PCR primer for carbonyl
XX reductase isolated from Rhodotorula glutinis var dairenensis, which is
XX used in an example from the present invention.
XX
XX SQ Sequence 20 BP; 5 A; 3 C; 3 G; 4 T; 0 U; 5 Other;
    Query Match      1.7%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 70.0%; Pred. NO. 2.7e+02;
    Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 818 TGTGAATATAAACCTGTAT 837
DB 1 TNGARTATAAACCTGTGCAT 20
|||||
|||||

RESULT 284
ABZ90760
ID ABZ90760 standard; DNA; 20 BP.
XX
XX AC ABZ90760;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.

```

```

XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPiG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 6002; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
    Query Match 1.7%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 2.7e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 524 CAATAAACATTCCTTGGAT 543
Db 1 CAAAAACCATTCCTTGGCT 20
RESULT 285
ABZ90984
ID ABZ90984 standard; DNA; 20 BP.
XX AC ABZ90984;
XX DT 17-OCT-2003 (first entry)
XX DE Human oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX FN WO200285308-A2.

```

```

XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPiG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 6226; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 5 A; 2 C; 8 G; 5 T; 0 U; 0 Other;
    Query Match 1.7%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 2.7e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 436 AGATGACTTGGCGAAAGGTG 455
Db 1 AGATGACTTGGTCATAGGTG 20
RESULT 286
ABD26990
ID ABD26990 standard; DNA; 20 BP.
XX AC ABD26990;
XX DT 29-JUL-2004 (first entry)
XX DE H93087-derived oligonucleotide SEQ ID 6002.
XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX KW pulmonary transplantation rejection; ss; primer.
XX OS Homo sapiens.

```



```

Db      1 AGATGACTGGTGCATAGGTG 20
||||||| | ||| |||||
Best Local Similarity 85.0%; Pred. NO. 2.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      700 AAGATTTCATAGTTTATA 719
      || ||| ||| ||| ||| |||
Db      20 AATATTTATATTTTATA 1

RESULT 289
ADL59322/c
ID      ADL59322 standard; DNA; 20 BP.
XX
AC      ADL59322;
XX
DT      03-JUN-2004 (first entry)
XX
DE      Human ESM-1 antisense oligonucleotide seqid 1571.
XX
KW      cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW      gene therapy; endothelial specific molecule-1; ESM-1;
KW      ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW      angiogenic disorder; immunological disorder; cardiovascular disorder;
KW      neurological disorder; antisense technology; ss.
XX
OS      Homo sapiens.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "OTHER= phosphorothioate backbone. All cytidine
FT      residues are 5-methylcytidines"
FT      modified_base 1..5
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN      WO2004021978-A2.
XX
PD      18-MAR-2004.
XX
PF      19-AUG-2003; 2003WO-US025833.
XX
PR      19-AUG-2002; 2002US-0404495P.
XX
PA      (PHAA ) PHARMACIA CORP.
XX
PI      Weinstein EJ, Griggs DW;
XX
DR      WPI; 2004-248358/23.
XX
PS      Claim 3; SEQ ID NO 1571; 555pp; English.
XX
CC      The invention describes a new antisense compound, having a sequence
CC      comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC      specific molecule-1 (ESM-1), that specifically hybridises with the
CC      nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC      composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC      treating an animal having a disease or condition associated with ESM-1.
CC      The compound is useful for preparing a composition for treating diabetes,
CC      cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC      cardiovascular or neurological disorder. This sequence represents an
CC      antisense oligonucleotide that can be used to modulate expression of
CC      endothelial specific molecule-1 (ESM-1).
XX
SQ      Sequence 20 BP; 12 A; 0 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 1.7%; Score 15.2; DB 1; Length 20;

RESULT 289
ADL59322/c
ID      ADL59322 standard; DNA; 20 BP.
XX
AC      ADL59322;
XX
DT      03-JUN-2004 (first entry)
XX
DE      Human ESM-1 antisense oligonucleotide seqid 1571.
XX
KW      cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW      gene therapy; endothelial specific molecule-1; ESM-1;
KW      ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW      angiogenic disorder; immunological disorder; cardiovascular disorder;
KW      neurological disorder; antisense technology; ss.
XX
OS      Homo sapiens.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "OTHER= phosphorothioate backbone. All cytidine
FT      residues are 5-methylcytidines"
FT      modified_base 1..5
FT      /*tag= a
FT      /mod_base= OTHER
FT      /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN      WO2004021978-A2.
XX
PD      18-MAR-2004.
XX
PF      19-AUG-2003; 2003WO-US025833.
XX
PR      19-AUG-2002; 2002US-0404495P.
XX
PA      (PHAA ) PHARMACIA CORP.
XX
PI      Weinstein EJ, Griggs DW;
XX
DR      WPI; 2004-248358/23.
XX
PS      Claim 3; SEQ ID NO 1571; 555pp; English.
XX
CC      The invention describes a new antisense compound, having a sequence
CC      comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC      specific molecule-1 (ESM-1), that specifically hybridises with the
CC      nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC      composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC      treating an animal having a disease or condition associated with ESM-1.
CC      The compound is useful for preparing a composition for treating diabetes,
CC      cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC      cardiovascular or neurological disorder. This sequence represents an
CC      antisense oligonucleotide that can be used to modulate expression of
CC      endothelial specific molecule-1 (ESM-1).
XX
SQ      Sequence 20 BP; 12 A; 0 C; 0 G; 8 T; 0 U; 0 Other;
Query Match 1.7%; Score 15.2; DB 1; Length 20;

```

XX SQ Sequence 20 BP; 12 A; 0 C; 0 G; 8 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 701 AGATTGTATAGTTTATATAA 720  
 | | | | | | | | | | | | | | | | | | | | | |  
 Db 20 ATATTATATATATTTTATATAA 1  
 | | | | | | | | | | | | | | | | | | | | | |  
 RESULT 290  
 ADP11305/c  
 ID ADP11305 standard; DNA; 20 BP.  
 XX AC ADP11305;  
 XX DT 12-AUG-2004 (first entry)  
 XX DE Set 1 right PCR primer for marker probe #319.  
 XX KW transplant rejection; immune system; rheumatoid arthritis; lupus;  
 XX KW inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.  
 XX OS Homo sapiens.  
 XX PN WO2004042346-A2.  
 XX PD 21-MAY-2004.  
 XX PF 24-APR-2003; 2003WO-US012946.  
 XX PR 24-APR-2002; 2002US-00131831.  
 XX PR 20-DEC-2002; 2002US-00325899.  
 XX PA (EXPR-) EXPRESSION DIAGNOSTICS INC.  
 XX PI Wohlgemuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;  
 PI Rosenberg S;  
 XX WPI; 2004-400724/37.  
 XX Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,  
 PT pancreas, pancreatic islet, lung, bone marrow or stem cell transplant  
 PT rejection, in an individual, comprises detecting the expression level of  
 PT the genes.  
 XX Claim 58; SEQ ID NO 1314; 1762pp; English.  
 XX The present invention relates to diagnosing or monitoring transplant  
 CC rejection, e.g. cardiac or kidney transplant rejection, in an individual  
 CC comprises detecting the expression level of one or more genes. The  
 CC methods, system and kits are useful in diagnosing or monitoring  
 CC transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic  
 CC islet, lung, bone marrow or stem cell transplant rejection,  
 CC xenotransplant rejection or mechanical organ replacement rejection, in an  
 CC individual. The method is also useful in assessing the immune status of  
 CC an individual. The methods are also useful in diagnosing and monitoring  
 CC diseases that involve the immune system, e.g. rheumatoid arthritis,  
 CC lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or  
 CC viral, bacterial or fungal infection. The present sequence represents a  
 CC primer for a 50 mer oligonucleotide marker for diagnosis and monitoring  
 CC of allograft rejection and other disorders.  
 XX Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 477 CAGGAACGCTGAGTCGT 496  
 | | | | | | | | | | | | | | | | | | | | | |  
 Db 20 CAGGAACGCTGAGTCGT 1  
 | | | | | | | | | | | | | | | | | | | | | |  
 RESULT 291  
 ADK21489  
 ID ADK21489 standard; DNA; 20 BP.  
 XX AC ADK21489;  
 XX DT 18-NOV-2004 (first entry)  
 XX DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #1566.  
 XX KW acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;  
 XX KW metabolic syndrome X; cardiovascular disorder; cancer; infection;  
 XX KW inflammation; tumour; antisense; ss.  
 XX OS Synthetic.  
 XX PN WO2004016749-A2.  
 XX PD 26-FEB-2004.  
 XX PF 14-AUG-2003; 2003WO-US025389.  
 XX PR 14-AUG-2002; 2002US-0403591P.  
 XX PA (PHAA ) PHARMACIA CORP.  
 XX PI Ross SA;  
 XX WPI; 2004-203782/19.  
 XX New antisense compounds targeted to nucleic acid molecules encoding acyl-  
 PT coenzyme A synthetase 1 (ACS1), useful for treating diseases or  
 PT conditions associated with aberrant expression of ACS1, e.g. diabetes,  
 PT obesity or cancer.  
 XX Claim 3; SEQ ID NO 1566; 940pp; English.  
 XX The invention relates to an antisense compound targeted to a nucleic acid  
 CC molecule encoding acyl-coenzyme A synthetase 1 (ACS1). The antisense  
 CC compound specifically hybridises with and inhibits the expression of  
 CC ACS1. The antisense oligonucleotides or compounds are useful for  
 CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACS1), and for  
 CC treating diseases or conditions associated with aberrant expression of  
 CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular  
 CC disorder or cancer. The antisense compounds are also useful as research  
 CC reagents and kits, or in diagnostic, therapeutic and prophylactic  
 CC applications, e.g. to prevent or delay infection, inflammation or tumour  
 CC formation. The present sequence represents an acyl-coenzyme A synthetase  
 CC 1, ACS1, antisense oligonucleotide.  
 XX Sequence 20 BP; 5 A; 1 C; 3 G; 11 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 704 TTTCGTATAGTTTATATAAAC 723  
 | | | | | | | | | | | | | | | | | | | | | |  
 Db 1 TTTCGTATAGTTTATATAAAC 20  
 | | | | | | | | | | | | | | | | | | | | | |  
 RESULT 292  
 ADR70258  
 ID ADR70258 standard; DNA; 20 BP.  
 XX AC ADR70258;  
 XX DT 02-DEC-2004 (first entry)  
 XX DE Human apoptosis-specific eIF-5A antisense oligonucleotide.

XX	apoptosis-specific eukaryotic initiation factor 5A1; eiF5A1;
KW	apoptosis factor 5A; apoptosis factor 5A1; small inhibitory RNA; siRNA;
KW	RNA interference; cytokine inhibitor; p53 inhibitor; Bcl-2;
KW	tumour necrosis factor alpha inhibitor; TNF-alpha inhibitor;
KW	interleukin 1; IL-1; interleukin 6; IL-6; pathological condition;
KW	monocyte differentiation inhibitor; antiinflammatory; antirheumatic;
KW	antiarthritic; osteopathic; antiasthmatic; antiallergic;
KW	immunosuppressive; gastrointestinal; cytostatic; cardiac; vasotropic;
KW	antiadrenergic; neuroprotective; ophthalmological; antipsoriatic;
KW	dermatological; antithyroid; antibacterial; gene therapy;
KW	rheumatoid arthritis; osteoarthritis; asthma; allergy;
KW	arterial inflammation; Crohn's disease; inflammatory bowel disease;
KW	ulcerative colitis; coronary heart disease; cystic fibrosis; diabetes;
KW	lupus; multiple sclerosis; Graves disease; periodontitis; glaucoma;
KW	macular degeneration; ocular surface disease; keratoconus; ischaemia;
KW	refusion injury; sepsis; multiple myeloma; organ transplant rejection;
KW	psoriasis; eczema; human; eiF-5A; antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FN	WO2004078940-A2.
XX	
PD	16-SEP-2004.
XX	
XX	05-MAR-2004; 2004WO-US006598.
PF	
XX	
PR	05-MAR-2003; 2003US-0451677P.
PR	10-MAR-2003; 2003US-00383614.
PR	06-JUN-2003; 2003US-0476194P.
PR	22-SEP-2003; 2003US-0504731P.
XX	
XX	(SENE-) SENECSO TECHNOLOGIES INC.
PA	
XX	
FI	Thompson JE, Taylor C;
XX	
XX	WPI; 2004-662416/64.
DR	
XX	
PT	Apoptosis factor 5A1 polynucleotide, and siRNA, useful in treating e.g.,
PT	cancer, asthma and lupus.
XX	
PS	Example 7; Page 58; 188pp; English.
XX	
CC	The present invention describes the apoptosis-specific eukaryotic
CC	initiation factor 5A1 (eiF5A1) polynucleotide, and small inhibitory RNA
CC	(siRNA) molecules complementary to eiF5A1 which can be used for reducing
CC	expression of eiF5A1. Also described: (1) reducing levels of a cytokine
CC	in a cell by administering an agent capable of reducing expression of
CC	eiF5A1; (2) a method for reducing the expression of p53 comprising
CC	administering an agent capable of reducing expression of eiF5A1; (3) a
CC	method for increasing expression of Bcl-2 comprising administering an
CC	agent capable of reducing expression of eiF5A1; (4) a method for reducing
CC	levels of tumour necrosis factor (TNF)-alpha in a patient comprising
CC	administering to patient the antisense polynucleotide or the siRNA; (5) a
CC	method of treating pathological conditions characterised by an increased
CC	interleukin (IL)-1, TNF-alpha, or IL-6 level comprising administering to
CC	a mammal having the pathological condition, an agent to reduce expression
CC	of eiF5A1; (6) a method for inhibiting or eliminating monocyte
CC	differentiation by administering an agent capable of reducing expression
CC	of eiF5A1; (7) a method for preventing retinal ganglion cell death in a
CC	glaucomatous eye by suppressing expression of apoptosis-specific eiF5A1
CC	in retinal ganglion cells; (8) a method of suppressing expression of
CC	eiF5A1 in lamina cribosa cells comprising transfecting lamina cribosa
CC	cells with antisense oligonucleotides targeted against human eiF5A1; and
CC	(9) a method of suppressing expression of eiF5A1 in astrocyte cells,
CC	comprising transfecting astrocyte cells with antisense oligonucleotides
CC	targeted against human eiF5A1. eiF5A1 has antiinflammatory,
CC	antirheumatic, antiarthritic, osteopathic, antiasthmatic, antiallergic,
CC	immunosuppressive, gastrointestinal, cytostatic, cardiac, vasotropic,
CC	antiadrenergic, neuroprotective, ophthalmological, antipsoriatic,
CC	dermatological, antithyroid and antibacterial activities, and can be used
CC	in gene therapy. The methods, polynucleotides and siRNA are useful for

```

CC treating pathological conditions characterised by an increased IL-1, TNF-
CC alpha, or IL-6 level, such as arthritis-rheumatoid and osteoarthritis,
CC asthma, allergies, arterial inflammation, Crohn's disease, inflammatory
CC bowel disease, ulcerative colitis, coronary heart disease, cystic
CC fibrosis, diabetes, lupus, multiple sclerosis, Graves disease,
CC periodontitis, glaucoma and macular degeneration, ocular surface diseases
CC including keratoconus, organ ischaemia-heart, kidney, reperfusion injury,
CC sepsis, multiple myeloma, organ transplant rejection, psoriasis and
CC eczema. The present sequence represents a human eIF-5A antisense
CC oligonucleotide, which is used in the exemplification of the present
CC invention.
XX
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

      Query Match      1.7%; Score 15.2; DB 1; Length 20;
      Best Local Similarity 85.0%; Pred. No. 2.7e+02;
      Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0

QY 40 GGACCTCGCGCTGGCGCTAGC 59
      ||||| ||||| ||||| ||
Db 1 GGACCTTGGCGTGGCCGTC 20

RESULT 293
AAAN71205
ID AAAN71205 standard; cDNA; 15 BP.
AC AAAN71205;
XX
XX
XX 03-MAY-1991 (first entry)
XX
XX DE Sequence of probe for human superoxide dismutase (hsOD).

```

Query Match	1.7%	Score 15;	DB 1;	Length 15;
Best Local Similarity	100.0%;	Pred. No. 2.7e+02;		
Matches	15;	Conservative	0;	Mismatches 0; Indels
QY	65	ATGCGCAGCAAGGCC	79	
Db	1	ATGCGCAGCAAGGCC	15	



```

XX PF 23-OCT-2003; 2003WO-GB004614.
XX XX
XX PR 23-OCT-2002; 2002GB-00024663.
XX XX
XX PA (ISIS-) ISIS INNOVATION LTD.
XX PI Beeson D, Wood M, Abdelgany A;
XX XX
XX DR WPI; 2004-365523/34.
XX XX
XX PT New DNzyme that cleaves mutant polynucleotides, useful in treating a
XX PT dominantly inherited disorder associated with a mutant allele, such as
XX PT achondroplasia, amyotrophic lateral sclerosis, Marfan syndrome and
XX PT hypercholesterolemia.
XX XX
XX PS Disclosure; Page 8; 24pp; English.
XX XX
CC CC The specification describes a DNzyme which selectively cleaves a mutant
CC CC polynucleotide by cleaving at a site remote from the mutation site. The
CC CC DNzyme binds selectively to a mutant allele or its expressed product,
CC CC and comprises a central catalytic motif (Helix II) and two flanking
CC CC regions (helix I and III) where at least one of the flanking regions has
CC CC a polynucleotide sequence complementary to a region that includes the
CC CC mutation in the mutant allele or to that of the expressed product. Both
CC CC flanking regions are complementary to mutated regions of the mutant
CC CC allele or the expressed product. The complement of the mutation is 2 or 3
CC CC nucleotides upstream or downstream of the site of cleavage, preferably in
CC CC helix I. Helix I and III are of different lengths, where helix I is
CC CC shorter than helix III, and their length is 21-7 or 15-8 nucleotides.
CC CC Helix I preferably comprises 9 nucleotides and helix III 13 nucleotides.
CC CC At least one of the flanking regions comprises ribonucleic acid. The
CC CC DNzyme further comprises a stem-loop structure at either or both
CC CC terminus. The DNzyme is useful in therapy, in particular for the
CC CC manufacture of a medicament for the treatment of a disorder associated
CC CC with a mutant allele in a patient, where the DNzyme comprises a central
CC CC catalytic motif and two flanking substrate-binding regions, and where at
CC CC least one flanking region binds at the site of mutation in the mutant
CC CC allele or its expressed product and the catalytic motif cleaves at a site
CC CC remote from the site of mutation. The disorder is a dominantly inherited
CC CC disorder, such as achondroplasia, amyotrophic lateral sclerosis with SOD1
CC CC mutation, Marfan syndrome, hypercholesterolemia, osteogenesis imperfecta
CC CC and SCCMS. ADO43606-ADO43607 represent the wild type and mutant DNA
CC CC fragments, respectively, of the Cu/Zn superoxide dismutase (SOD-1) gene
CC CC where a L26S mutation occurs, and causes amyotrophic lateral sclerosis.
CC CC These sequences are suitable for the design of DNzymes of the invention
CC CC (see ADO43608).
XX XX
SQ Sequence 15 BP; 5 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 437 GATGACTTGGGCAA 451
Db 1 GATGACTTGGGCAA 15

RESULT 297
AAH21294
ID AAH21294 standard; DNA; 17 BP.
XX AC
XX AAH21294;
XX DT 13-SEP-2001 (first entry)
XX DE Human MDR-1 allele ex12/+44 counterstrain.
XX MDR-1; human; multidrug resistance gene; genotyping; SNP; screening;
XX KW single nucleotide polymorphism; ds.
XX XX Homo sapiens.
XX OS

Query Match 1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 319 GGCAATGTGACTGCTG 335
Db 1 GTGCAATGTRACTGCTG 17

RESULT 298
AAH21293/c
ID AAH21293 standard; DNA; 17 BP.
XX AC
XX AAH21293;
XX DT 13-SEP-2001 (first entry)
XX DE Human MDR-1 allele ex12/+44.
XX MDR-1; human; multidrug resistance gene; genotyping; SNP; screening;
XX KW single nucleotide polymorphism; ds.
XX XX Homo sapiens.
XX OS

DEI9963490-A1.
05-JUL-2001.
28-DEC-1999; 99DE-01063490.
28-DEC-1999; 99DE-01063490.
(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
Kostrzewa M, Hoffmeyer S, Brinkmann U;
WPI; 2001-426633/46.
Genotyping multidrug resistance gene-1, useful for assessing doses of
pharmaceuticals, by mass spectrometric analysis of primer extension
products.
Disclosure; Page 11; 22pp; German.
This invention describes a novel method for genotyping the human MDR-1
(multidrug resistance-1) gene by mass spectrometric detection of the
mutational status at some or all of 16 point mutations (single nucleotide
polymorphism; SNPs). Genotyping the MDR-1 gene may indicate altered
expression or function of the encoded protein (which regulates the
transport of compounds, including drugs, across cell membranes), and thus
may indicate that changes in drug dosage are required. The method is
rapid, valid and inexpensive, and provides a high throughput screen with
only a few genotypic characteristics expected. Particularly mass analysis
takes only 4 seconds, so a four-fold multiplex reaction will allow all
positions to be determined in about 16 sec
SQ Sequence 17 BP; 3 A; 3 C; 5 G; 5 T; 0 U; 1 Other;

Query Match 1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 319 GGCAATGTGACTGCTG 335
Db 1 GTGCAATGTRACTGCTG 17

RESULT 298
AAH21293/c
ID AAH21293 standard; DNA; 17 BP.
XX AC
XX AAH21293;
XX DT 13-SEP-2001 (first entry)
XX DE Human MDR-1 allele ex12/+44.
XX MDR-1; human; multidrug resistance gene; genotyping; SNP; screening;
XX KW single nucleotide polymorphism; ds.
XX XX Homo sapiens.
XX OS

DEI9963490-A1.
05-JUL-2001.
28-DEC-1999; 99DE-01063490.
28-DEC-1999; 99DE-01063490.
(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
Kostrzewa M, Hoffmeyer S, Brinkmann U;
WPI; 2001-426633/46.
Genotyping multidrug resistance gene-1, useful for assessing doses of
pharmaceuticals, by mass spectrometric analysis of primer extension
products.
Disclosure; Page 11; 22pp; German.
This invention describes a novel method for genotyping the human MDR-1
(multidrug resistance-1) gene by mass spectrometric detection of the
mutational status at some or all of 16 point mutations (single nucleotide
polymorphism; SNPs). Genotyping the MDR-1 gene may indicate altered
expression or function of the encoded protein (which regulates the
transport of compounds, including drugs, across cell membranes), and thus
may indicate that changes in drug dosage are required. The method is
rapid, valid and inexpensive, and provides a high throughput screen with
only a few genotypic characteristics expected. Particularly mass analysis
takes only 4 seconds, so a four-fold multiplex reaction will allow all
positions to be determined in about 16 sec
SQ Sequence 17 BP; 3 A; 3 C; 5 G; 5 T; 0 U; 1 Other;

```



PT Genotyping multidrug resistance gene-1, useful for assessing doses of  
PT pharmaceuticals, by mass spectrometric analysis of primer extension  
XX products.  
PS  
PS Disclosure; Page 11; 22pp; German.  
XX  
XX This invention describes a novel method for genotyping the human MDR-1  
CC (multidrug resistance-1) gene by mass spectrometric detection of the  
CC mutational status at some or all of 16 point mutations (single nucleotide  
CC polymorphism; SNPs). Genotyping the MDR-1 gene may indicate altered  
CC expression or function of the encoded protein (which regulates the  
CC transport of compounds, including drugs, across cell membranes), and thus  
CC may indicate that changes in drug dosage are required. The method is  
CC rapid, valid and inexpensive, and provides a high throughput screen with  
CC only a few genotypic characteristics expected. Particularly mass analysis  
CC takes only 4 seconds, so a four-fold multiplex reaction will allow all  
CC positions to be determined in about 16 sec  
XX  
XX  
SQ Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;  
Query Match 1.7%; Score 15; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 319 GGGCAATGCTGCTGCTG 335  
DB 17 GTGCAATGCTGCTGCTG 1  
RESULT 299  
AAF91028/c  
ID AAF91028 standard; DNA; 17 BP.  
XX  
XX AAF91028;  
XX  
XX 04-MAY-2001 (first entry)  
XX  
XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 115.  
DE Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;  
KW inflammatory disease; neuronal disease; CNS disease;  
KW cardiovascular disease; PCR primer; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200109183-A2.  
PN  
XX 08-FEB-2001.  
PD  
XX 28-JUL-2000; 2000WO-BP007314.  
PF  
XX 30-JUL-1999; 99BP-00114938.  
PR  
XX 22-FEB-2000; 2000EP-00103361.  
XX  
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
PA  
XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;  
PI WPI; 2001-159855/16.  
XX  
XX New polynucleotide encoding a molecular variant Multi Drug Resistance  
PT (MDR)-1 polypeptide is useful for diagnosing and treating diseases  
PT associated with abnormal MDR-1 expression or function, e.g. cancer.  
XX  
XX Claim 36; Page 101; 154pp; English.  
PS  
XX The present invention provides nucleotides encoding molecular variants of  
CC the human multi drug resistance-1 (MDR-1) protein. These can be used to  
CC identify compounds capable of treating multidrug resistance and  
CC sensitivity interfering resulting from polymorphisms in MDR-1, which can  
CC lead to difficulties in treating cancer, cardiovascular, neuronal,  
CC inflammatory and CNS diseases  
XX

SQ Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;  
Query Match 1.7%; Score 15; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 319 GGGCAATGCTGCTGCTG 335  
DB 17 GTGCAATGCTGCTGCTG 1  
RESULT 300  
ABT38676  
ID ABT38676 standard; DNA; 17 BP.  
XX  
XX ABT38676;  
XX  
XX 12-JUN-2003 (first entry)  
XX  
XX Tumour suppression related human fukutin oligo SEQ ID No 4313.  
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
XX Homo sapiens.  
OS  
XX WO2003025175-A2.  
PN  
XX 27-MAR-2003.  
PD  
XX 17-SEP-2002; 2002WO-IB004208.  
PF  
XX 17-SEP-2001; 2001PR-00011978.  
PR  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA  
XX Telerman A, Amson R, Tuijnder M;  
PI WPI; 2003-313353/30.  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
XX Disclosure; Page 538; 720pp; French.  
PS  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
XX Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

```
Query Match      1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      811 TCAAGCCTGTGAATA 825
Db      | | | | | | | | | | | | | | | |
      3 TCAAGCCTGTGAATA 17

RESULT 301
ACF62526/c
ID ACF62526 standard; DNA; 17 BP.
XX
AC ACF62526;
XX
08-OCT-2003 (first entry)
XX
Cancer based on CYP3A5 related oligonucleotide SEQ ID NO:355.
XX
Cancer; CYP3A5; irinotecan; pharmaceutical; malignant glioma;
KW cytochrome p450; subfamily IIIA; nifedipine oxidase; polypeptide 5;
KW cytostatic; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO2003013534-A2.
XX
20-FEB-2003.
XX
23-JUL-2002; 2002WO-EP008219.
XX
23-JUL-2001; 2001EP-00117608.
PR
24-MAY-2002; 2002EP-00011710.
XX
(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
Heinrich G, Kerb R;
XX
WPI; 2003-268144/26.
XX
New use of irinotecan for preparation of compositions for treating cancer
PT in subject having genome with variant allele comprising cytochrome p450,
PT subfamily IIIA, polypeptide 5 polynucleotide, termed CYP3A5.
XX
Disclosure; Page 42; 86pp; English.
XX
The present invention describes the use of irinotecan (I) or its
CC derivative for the preparation of a pharmaceutical composition for
CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
CC cancer, or malignant glioma in a subject having a genome with a variant
CC allele which comprises a cytochrome p450, subfamily IIIA (nifedipine
CC oxidase), polypeptide 5 (CYP3A5) polynucleotide (II). (I) and (II) have
CC cytostatic activity. The therapeutic applications of (I) is improved,
CC since it is possible to individually treat a subject with an appropriate
CC dosage and/or an appropriate derivative of (I). Therefore, undesirable,
CC harmful or toxic effects are efficiently avoided. Unnecessary and
CC potentially harmful treatment of those subjects who do not respond to the
CC treatment with substances (nonresponders), as well as the development of
CC drug resistances due to suboptimal drug dosing can be avoided. ACF62200
CC to ACF62751 and ABM34912 to ABM35013 represent sequences used in the
CC exemplification of the present invention
XX
Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;

Query Match      1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      319 GGGCAATGTGACTGCTG 335
Db      | | | | | | | | | | | | | | | |
      17 GTGCAATGTRACTGCTG 1

RESULT 302
ACF62526/c
ID ADB21197 standard; DNA; 17 BP.
XX
AC ADB21197;
XX
20-NOV-2003 (first entry)
XX
MRP1 based cancer related nucleic acid SEQ ID NO:355.
XX
irinotecan; colorectal cancer; cervical cancer; gastric cancer;
KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
KW variant allele; multidrug resistance protein 1; MRP1; cytostatic; gene;
KW ds.
XX
OS Unidentified.
XX
PN WO2003013533-A2.
XX
20-FEB-2003.
XX
23-JUL-2002; 2002WO-EP008200.
XX
23-JUL-2001; 2001EP-00117608.
PR
24-MAY-2002; 2002EP-00011710.
XX
(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
Heinrich G, Kerb R;
XX
WPI; 2003-354397/33.
XX
Use of irinotecan or its derivative for preparation of a pharmaceutical
PT composition for treating cancer in a subject having a genome with a
PT variant allele comprising a multidrug resistance protein 1
PT polynucleotide.
XX
Disclosure; Page 51; 100pp; English.
XX
The present invention describes a method for the use of irinotecan (I) or
CC its derivative for the preparation of a pharmaceutical composition for
CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
CC cancer, or malignant glioma in a subject having a genome with a variant
CC allele which comprises a multidrug resistance protein 1 (MRP1)
CC polynucleotide (II). (I) has cytostatic activity. (I) or its derivative
CC can be used for the preparation of a pharmaceutical composition for
CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
CC cancer, or malignant glioma in a subject, where the subject is a human
CC (preferably African or Asian) or a mouse. The present sequence represents
CC a sequence which is used in the exemplification of the present invention.
XX
Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;

Query Match      1.7%; Score 15; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      319 GGGCAATGTGACTGCTG 335
Db      | | | | | | | | | | | | | | | |
      17 GTGCAATGTRACTGCTG 1

RESULT 303
ADB88286/c
ID ADB88286 standard; DNA; 17 BP.
XX
AC ADB88286;
XX
04-DEC-2003 (first entry)
XX
Human UGT1A1 variant allele sequence fragment SEQ ID NO:327.
XX
ss; irinotecan; cancer; UGT1A1; cytostatic; topoisomerase I inhibitor;
```

KW colorectal cancer; cervical cancer; gastric cancer; lung cancer;  
 KW ovarian cancer; pancreatic cancer; malignant glioma;  
 KW uridine diphosphate glycosyltransferase1 member A1.  
 XX Homo sapiens.  
 XX WO2003013536-A2.  
 XX 20-FEB-2003.  
 XX 23-JUL-2002; 2002WO-EP008217.  
 XX 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX Heinrich G, Kerb R;  
 XX WPI; 2003-289896/28.  
 XX Use of irinotecan to treat cancer patient by determining if patient has  
 PT variant alleles of UGT1A1 gene, administering increased/decreased amounts  
 PT of irinotecan based on increased/decreased levels of UGT1A1 gene product.  
 XX  
 PS Disclosure; Page 55; 107pp; English.  
 XX The invention relates to the novel use of irinotecan to treat a patient  
 CC suffering from cancer. This involves determining if the patient has one  
 CC or more variant alleles of the UGT1A1 gene, and if the patient has one or  
 CC more of such variant alleles, irinotecan is administered in an increased  
 CC or decreased amount in comparison to the amount that is administered  
 CC without regard to the patient's alleles in the UGT1A1 gene. The invention  
 CC has cytostatic activity. A composition of the invention acts as a  
 CC topoisomerase I inhibitor. The method is useful for treating a patient.  
 CC an animal e.g. mouse or a human, preferably African or Asian, suffering  
 CC from cancer such as colorectal, cervical, gastric cancer, lung, ovarian,  
 CC pancreatic cancer or malignant glioma. The present sequence is used in  
 CC the exemplification of the invention.  
 XX Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;  
 SQ  
 Query Match 1.7%; Score 15; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 319 GGGCAATGTGACTGCTG 335  
 DB 17 GTGCAATGTRACTGCTG 1  
 RESULT 304  
 ADB97269/c  
 ID ADB97269 standard; DNA; 17 BP.  
 XX ADB97269;  
 XX 04-DEC-2003 (first entry)  
 XX Human MDR1 variant allele sequence fragment SEQ ID NO:355.  
 XX irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
 KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
 KW multidrug resistance 1; MDR1; cytostatic; human; ds; Cyp3A5; MRP1; MDR1;  
 KW TOP1.  
 XX Homo sapiens.  
 OS WO2003013537-A2.  
 XX 20-FEB-2003.  
 XX 23-JUL-2002; 2002WO-EP008218.  
 PF

XX 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX Heinrich G, Kerb R;  
 XX WPI; 2003-268145/26.  
 XX New use of irinotecan for preparation of pharmaceutical compositions for  
 PT treating cancer in subject having genome with variant allele comprising  
 PT multidrug resistance 1 polynucleotide.  
 XX  
 PS Disclosure; Page 79; 130pp; English.  
 XX The invention relates to the novel use of irinotecan or its derivative  
 CC for the preparation of pharmaceutical compositions for treating  
 CC colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or  
 CC malignant glioma in a subject having a genome with a variant allele which  
 CC comprises a multidrug resistance 1 (MDR1) polynucleotide. A composition  
 CC of the invention has cytostatic activity. The invention is useful for the  
 CC preparation of pharmaceutical compositions for treating colorectal,  
 CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant  
 CC glioma in a subject (preferably human, more preferably African or Asian)  
 CC or a mouse. The present sequence is used in the exemplification of the  
 CC invention.  
 XX Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;  
 SQ  
 Query Match 1.7%; Score 15; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 319 GGGCAATGTGACTGCTG 335  
 DB 17 GTGCAATGTRACTGCTG 1  
 RESULT 305  
 ADB92460/c  
 ID ADB92460 standard; DNA; 17 BP.  
 XX ADB92460;  
 XX 04-DEC-2003 (first entry)  
 XX Human MDR1 variant allele sequence fragment SEQ ID NO:355.  
 XX irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
 KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
 KW multidrug resistance 1; MDR1; cytostatic; ds; human; UGT1A1; MRP1; TOP1.  
 XX Homo sapiens.  
 OS WO2003013535-A2.  
 XX 20-FEB-2003.  
 XX 23-JUL-2002; 2002WO-EP008220.  
 XX 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX Heinrich G, Kerb R;  
 XX WPI; 2003-342400/32.  
 XX New use of irinotecan for preparation of pharmaceutical compositions for  
 PT treating cancer in subject having genome with variant allele comprising  
 PT multidrug resistance 1 polynucleotide.

XX Disclosure; Page 50; 104pp; English.

PS The invention relates to a novel use of irinotecan or its derivative for

CC the preparation of a pharmaceutical composition for treating colorectal,

CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant

CC glioma in a subject having a genome with a variant allele which comprises

CC a multidrug resistance 1 (MDR1) polynucleotide. A composition of the

CC invention has cytostatic activity. The present sequence is used in the

CC exemplification of the invention.

XX

SQ Sequence 17 BP; 5 A; 5 C; 3 G; 3 T; 0 U; 1 Other;

Query Match 1.7%; Score 15; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.8e+02;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGCTG 335

DB 17 GTGCAATGTRACTGCTG 1

RESULT 306

AAV13337

ID AAV13337 standard; DNA; 20 BP.

AC AAV13337;

XX

DT 14-MAY-1998 (first entry)

XX

DE Antisense primer Exon 1 for human 5-lipoxygenase gene.

XX

KW Inflammatory disease; polymorphism; 5-lipoxygenase; asthma;

KW ulcerative colitis; bronchitis; sinusitis; psoriasis; rhinitis;

KW arthritis; diagnosis; treatment; PCR primer; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9742347-A2.

XX

PD 13-NOV-1997.

XX

PF 29-APR-1997; 97WO-US0007137.

XX

PR 06-MAY-1996; 96US-0016890P.

PR 25-APR-1997; 97US-00846020.

XX

PA (BGHM ) BRIGHAM & WOMENS HOSPITAL.

XX

PI Drazen JM, In K, Asano K, Beier D, Grobholz J;

XX

DR WPI; 1997-558997/51.

XX

PT Classifying patients with inflammatory disease, specifically asthma -

PT according to polymorphisms in 5-lipoxygenase gene regulatory region, e.g.

PT to identify candidates for lipoxygenase inhibitor treatment.

XX

PS Example 1; Page 19; 56pp; English.

XX

CC The present sequence was used in the development of a novel method for

CC classifying patients suffering from an inflammatory disease. The method

CC comprises identifying in DNA from at least 1 patient a sequence

CC polymorphism, as compared with the normal 5-lipoxygenase (5-LOX) gene

CC (AAT8431), in a 5-LOX regulatory gene sequence. The method can be

CC applied to subjects with asthma, ulcerative colitis, bronchitis,

CC sinusitis, psoriasis, allergic and non-allergic rhinitis, lupus or

CC rheumatoid arthritis. Specifically it can be used to diagnose asthma or

CC susceptibility to disease, identify treatments suitable for individual

CC patients or assess the likely success of treatment

XX

SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.8e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 ACGCTGGAAGTCGTT 497

DB 3 ACGCTGGAAGTCGTT 17

RESULT 307

AAV72612/C

ID AAV72612 standard; DNA; 19 BP.

XX

AC AAV72612;

XX

DT 12-FEB-1999 (first entry)

XX

DE Glucose-6-phosphate gene mutation correction oligonucleotide #2.

XX

KW Recombinogenic; genetic lesion; hepatocyte; mutation; Gaucher disease;

KW clathrin coated pit receptor; Crigler-Najjar syndrome; haemophilia B;

KW alpha 1-antitrypsin deficiency; familial hypercholesterolaemia;

KW type 1 glycogen storage disease; galactosaemia; phenylketonuria;

KW hyperphenylalaninaemia; atherosclerosis; chimeric mutational vector; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9849350-A1.

XX

PD 05-NOV-1998.

XX

PF 30-APR-1998; 98WO-US008834.

XX

PR 30-APR-1997; 97US-0045288P.

PR 05-AUG-1997; 97US-0054837P.

PR 10-NOV-1997; 97US-0064996P.

XX

PA (MINU ) UNIV MINNESOTA.

PA (STEE/) STEER C J.

PA (KREN/) KREN B T.

PA (BAND/) BANDYOPADHYAY P T.

XX

DR WPI; 1999-009447/01.

XX

PT Composition containing oligonucleotide formulated with macromolecular

PT carrier - used to target genes, particularly in hepatocytes, useful for

PT treatment of genetic disease, and effective transduction of non-

PT proliferating cells.

XX

PS Disclosure; Page 17; 62pp; English.

XX

CC The present invention describes a composition (A) comprising: (a) a

CC recombinogenic oligonucleobase (I); (b) an aqueous carrier; and (c) as

CC macromolecular carrier (B): (i) a lipid vesicle with (I) in its aqueous

CC core; (ii) a lipid nanosphere containing a lipophilic salt of (I); or

CC (iii) a polycation (II) of molecular weight 500-1.3 MDA that forms a salt

CC with (I). When a ligand (L) for a clathrin-coated pit receptor (CCPR) is

CC covalently linked to (B), the compositions are used for altering a target

CC gene in mammalian tissue, particularly hepatocytes (in vivo or in vitro),

CC especially for treatment of genetic disease involving changes in, or

CC insertion/deletion of, 1-30 (particularly 1-6) nucleotides. Particular

CC applications are treatment of von Willebrand's disease, haemophilia B,

CC alpha 1-antitrypsin deficiency, familial hypercholesterolaemia, Gaucher

CC disease, type 1 glycogen storage disease, Crigler-Najjar syndrome,

CC galactosaemia, phenylketonuria or hyperphenylalaninaemia, and also

CC atherosclerosis (by truncation of the apoB gene). (A) introduce specific

CC genetic changes into endogenous gene, in vivo, and efficiently transduce

CC non-proliferating cells. When derivatised with (L), they are internalised

CC through CCP into endosomes. A single (A) may target several locations in

CC the same gene or locations in several different genes. (L) increases both

CC amount and specificity of uptake into targeted cells. The present

CC sequence represents a chimeric mutational vector (CMV) oligonucleotide

CC used to correct the glucose-6- phosphate gene mutation which causes type  
 CC 1 glycogen storage disease  
 XX  
 SQ Sequence 19 BP; 1 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 37 CCAGGACCTCGCGTGGC 54  
 |||||  
 Db 19 CCAGGACCTCGCGAGGC 2  
 |||||

RESULT 308  
 AAH52988/c  
 ID AAH52988 standard; DNA; 19 BP.  
 XX  
 AC AAH52988;  
 XX  
 DT 04-DEC-2000 (first entry)  
 XX  
 DE cdk6 ribozyme binding site #48.  
 XX  
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
 XX  
 OS Mammalia.  
 XX  
 PN WO200032765-A2.  
 XX  
 PD 08-JUN-2000.  
 XX  
 PF 06-DEC-1999; 99WO-US028772.  
 XX  
 PR 04-DEC-1998; 98US-0110954P.  
 XX  
 PA (IMMU-) IMMUSOL INC.  
 XX  
 PI Tritz R, Welch PJ, Barber JR, Robbins JM;  
 XX  
 DR WPI; 2000-412314/35.  
 XX  
 PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
 PT PCNA and Cyclin B1.  
 XX  
 PS Disclosure; Page 54; 109pp; English.  
 XX  
 CC The present invention relates to a hairpin or hammerhead ribozyme,  
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AAH52415 to AAH56787. The ribozyme of the invention is useful for  
 CC inhibiting restenosis by introduction of the ribozyme into cells. The  
 CC ribozyme is resistant to endonuclease activity and hence is efficient in  
 CC restenosis treatment  
 XX  
 SQ Sequence 19 BP; 4 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 452 GGTGGAAATGAAGAAAGT 469  
 |||||  
 Db 19 GGTGTGATGAAGAAAGT 2  
 |||||

RESULT 309  
 AAH58150/c  
 ID AAH58150 standard; DNA; 19 BP.  
 XX  
 AC AAH58150;

XX 10-SEP-2001 (first entry)  
 XX  
 DE Cell-cycle dependent kinase cdk6 ribozyme binding site SEQ ID NO:574.  
 XX  
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulvuary;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO200130362-A2.  
 XX  
 PD 03-MAY-2001.  
 XX  
 PF 26-OCT-2000; 2000WO-US029500.  
 XX  
 PR 26-OCT-1999; 99US-0161532P.  
 XX  
 PA (IMMU-) IMMUSOL INC.  
 XX  
 PI Robbins JM, Tritz R;  
 XX  
 DR WPI; 2001-300427/31.  
 XX  
 PT Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
 XX  
 PS Example 1; Page 113; 408pp; English.  
 XX  
 CC The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,  
 CC ophthalmological, vulvuary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 19 BP; 4 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 452 GGTGGAAATGAAGAAAGT 469  
 |||||  
 Db 19 GGTGTGATGAAGAAAGT 2  
 |||||

RESULT 310  
 ADH01862/c  
 ID ADH01862 standard; RNA; 19 BP.

XX ADH01862;  
 AC  
 XX  
 DT 11-MAR-2004 (first entry)  
 XX  
 DE Protein tyrosine phosphatase siRNA sequence, SEQ ID No 474.  
 XX  
 KW small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;  
 KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;  
 KW antiinflammatory; neuroprotective; cytotatic; immunosuppressive;  
 KW antimicrobial; gene therapy; ss; siRNA.  
 XX  
 OS Unidentified.  
 XX  
 PN WO2003099227-A2.  
 XX  
 PD 04-DEC-2003.  
 XX  
 XX 23-MAY-2003; 2003WO-US016651.  
 XX  
 XX 23-MAY-2002; 2002US-0383249P.  
 PR 14-APR-2003; 2003US-0462942P.  
 XX  
 XX (CBPT-) CEPTYR INC.  
 PA  
 XX Lewis SP, Klinghoffer R, Wilson LK;  
 PI  
 XX WPI; 2004-035036/03.  
 DR  
 XX  
 XX New small interfering polynucleotide that modulates protein tyrosine  
 PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating  
 PT disorders associated with altered PTP1B signal transduction, e.g.  
 PT diabetes or cancer.  
 XX  
 XX Example 3; SEQ ID NO 474; 234pp; English.  
 PS  
 XX The invention relates to a novel isolated small interfering RNA (siRNA)  
 CC polynucleotide, comprising at least one nucleotide sequence from any of  
 CC the 20 fully defined sequences given in the specification. The invention  
 CC further relates to: a pharmaceutical composition comprising a new siRNA  
 CC polynucleotide and a physiological carrier; a recombinant nucleic acid  
 CC construct, comprising a polynucleotide that is capable of directing  
 CC transcripction of an siRNA; a host cell transformed or transfected with  
 CC the above recombinant nucleic acid construct; a method for interfering  
 CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or  
 CC its variant; a method for identifying a component of a PTP1B signal  
 CC transduction pathway; a method for modulating an insulin receptor protein  
 CC phosphorylation state in a cell; and a method for altering a Jak2 protein  
 CC associated disorder. The siRNA has the following activities:  
 CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytotatic,  
 CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can  
 CC be used in gene therapy to treat disorders. The composition and methods  
 CC are useful in treating disorders associated with PTP1B-mediated signal  
 CC transduction, such as diabetes, obesity, hyperglycaemia-induced  
 CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune  
 CC diseases or infection. This polynucleotide sequence represents an siRNA  
 CC used for modulating the signal transduction of a protein tyrosine  
 CC phosphatase of the invention.  
 XX  
 XX Sequence 19 BP; 6 A; 5 C; 5 G; 0 T; 3 U; 0 Other;  
 SQ  
 Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 314 GACTTGGGCAATGTGACT 331  
 |||||  
 Db 18 GACTTGGGCAATGTGCT 1  
 RESULT 311  
 ADM34090/c

ID  
 XX ADM34090 standard; DNA; 19 BP.  
 AC  
 XX ADM34090;  
 XX  
 DT 01-JUL-2004 (first entry)  
 XX  
 DE Mouse RIKEN 4921514I20 gene forward PCR primer SEQ:7.  
 XX  
 KW CG7042; CG61401 homologous protein; energy homeostasis regulation;  
 KW metabolism; triglyceride; antilipaeamic; cardiant; hypotensive;  
 KW hepatotropic; anorectic; antidiabetic; osteopathic; gene therapy;  
 KW metabolic disease; metabolic dysfunction; metabolic syndrome; obesity;  
 KW diabetes; eating disorder; cachexia; hypertension;  
 KW coronary heart disease; hypercholesterolaemia; dyslipidaemia;  
 KW osteoarthritis; gallstone; liver fibrosis; mouse; RIKEN 4921514I20 gene;  
 KW PCR; primer; ss.  
 XX  
 XX Mus sp.  
 OS Synthetic.  
 XX  
 XX WO2004028554-A2.  
 XX  
 PD 08-APR-2004.  
 XX  
 XX 29-SEP-2003; 2003WO-EP010799.  
 PF  
 XX 27-SEP-2002; 2002EP-00021916.  
 PR  
 XX (DEVE-) DEVELOPENTWICKLUNGSBIOLOGISCHE FORSCH.  
 PA  
 XX Eulenber K, Broenner G;  
 PI  
 XX WPI; 2004-305115/28.  
 DR  
 XX New pharmaceutical composition comprising a CG7042, astray, string or  
 PT CG61401 homologous protein, useful in the manufacture of an agent for  
 PT diagnosing, treating or preventing metabolic dysfunctions, e.g. obesity  
 PT or diabetes.  
 XX  
 XX Example 4; SEQ ID NO 7; 86pp; English.  
 PS  
 XX The present invention describes a composition comprising a CG7042,  
 CC astray, string or CG61401 homologous protein or its fragment or nucleic  
 CC acid molecule encoding the protein, or the modulator/affecter of the  
 CC nucleic acid molecule or the protein and carriers, diluents or additives.  
 CC Also described: (1) a non-human transgenic animal exhibiting a modified  
 CC expression of a CG7042, astray, string or CG1401 homologous polypeptide;  
 CC (2) a recombinant host cell exhibiting a modified expression of a CG7042,  
 CC astray, string or CG1401 homologous polypeptide; (3) a method of  
 CC identifying a (poly)peptide involved in the regulation of energy  
 CC homeostasis or metabolism of triglycerides in a mammal; (4) a method of  
 CC screening for an agent which modulates/effects the interaction of a  
 CC CG7042, astray, string or CG1401 homologous polypeptide with a binding  
 CC target; (5) a method for screening for an agent, which modulates/effects  
 CC the activity of a CG7042, astray, string or CG1401 homologous polypeptide  
 CC ; and (6) a method of producing a composition comprising the  
 CC (poly)peptide or the agent and a carrier, diluent or additive. The  
 CC compositions has antilipaeamic, cardiant, hypotensive, hepatotropic,  
 CC anorectic, antidiabetic and osteopathic activities, and can be used in  
 CC gene therapy. The pharmaceutical composition can be used in the  
 CC manufacture of an agent for detecting or verifying, treating or  
 CC preventing metabolic diseases or dysfunctions, including metabolic  
 CC syndrome, obesity or diabetes, as well as related disorders such as  
 CC eating disorder, cachexia, hypertension, coronary heart disease,  
 CC hypercholesterolaemia, dyslipidaemia, osteoarthritis, gallstones, or  
 CC liver fibrosis, in cells, cell masses, organs or subjects. The present  
 CC sequence represents a mouse RIKEN 4921514I20 gene forward PCR primer,  
 CC which is used in an example from the present invention.  
 XX  
 XX Sequence 19 BP; 6 A; 6 C; 4 G; 3 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 9 TCTGGGTTCCGTTGCA 26  
 ||||| |||||

Db 19 TCTGGGAGTTCGTTGCA 2

RESULT 312  
 ADR80828  
 ID ADR80828 standard; DNA; 19 BP.  
 XX  
 AC ADR80828;  
 XX  
 DT 16-DEC-2004 (first entry)  
 XX  
 DE Human glucose-6-phosphatase oligonucleotide seqid 5327.  
 XX  
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosolic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004080406-A2.  
 XX  
 PD 23-SEP-2004.  
 XX  
 PF 08-MAR-2004; 2004WO-US007070.  
 XX  
 PR 07-MAR-2003; 2003US-0452682P.  
 PR 12-MAR-2003; 2003US-0454265P.  
 PR 13-MAR-2003; 2003US-0454962P.  
 PR 13-MAR-2003; 2003US-0455050P.  
 PR 14-APR-2003; 2003US-0462894P.  
 PR 17-APR-2003; 2003US-0463772P.  
 PR 25-APR-2003; 2003US-0465665P.  
 PR 25-APR-2003; 2003US-0465802P.  
 PR 09-MAY-2003; 2003US-0469612P.  
 PR 08-AUG-2003; 2003US-0493986P.  
 PR 11-AUG-2003; 2003US-0494597P.  
 PR 26-SEP-2003; 2003US-0506341P.  
 PR 09-OCT-2003; 2003US-0510246P.  
 PR 10-OCT-2003; 2003US-0510318P.  
 PR 07-NOV-2003; 2003US-0518453P.  
 XX  
 PA (ALNY-) ALNYLAM PHARM.  
 XX  
 PI Manoharan M, Bumcrot D;  
 XX  
 XX WPI; 2004-677362/66.  
 DR  
 XX  
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery  
 PT disease, diabetes, cancer or neurological disease, comprises sense  
 PT sequence and antisense sequence which has specific modifications.  
 XX  
 XX Example 5; SEQ ID NO 5327; 378pp; English.  
 PS  
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
 CC sense sequence and an antisense sequence, where the sense sequences have  
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
 CC sequences have one or more asymmetrical phosphorothioate modifications  
 CC and the antisense sequence targets a human gene sequence. Also described  
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100  
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
 CC stabilising (I); involves selecting a sequence with activity and  
 CC introducing one or more asymmetrical modification in the sequence, where  
 CC the modification decreases nuclease sensitivity while not decreasing its

CC activity; a kit comprising (I) and instruction for its use; and a device  
 CC that can be dispense or administer a composition comprising (I). (I) is  
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)  
 CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.  
 CC The subject is suffering from a disorder characterised by elevated or  
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted  
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
 CC hypercholesterolaemia, hypercholesterolaemia, statin-resistant  
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 CC inhibit hepatic glucose production or for treating glucose-metabolism-  
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that  
 CC can be used to control glucose-6-phosphatase gene expression.  
 XX  
 SQ Sequence 19 BP; 7 A; 3 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 1.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 763 GACTTAATCAGATGG 780  
 ||||| ||||| |||||  
 Db 1 GAATTAATCAGGATGG 18

RESULT 313  
 AAA23007/C  
 ID AAA23007 standard; RNA; 17 BP.  
 XX  
 AC AAA23007;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6233.  
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberculous scleritis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9950403-A2.  
 XX  
 PD 07-OCT-1999.  
 XX  
 PF 24-MAR-1999; 99WO-US006507.  
 XX  
 PR 27-MAR-1998; 98US-0079678P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 XX  
 XX WPI; 1999-591315/50.  
 DR  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 XX  
 XX Claim 54; Page 256; 305pp; English.  
 PS  
 CC The present invention describes enzymatic cleavage of RNA molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
CC corresponding target sequences; AAA17695 to AAA18385 and AAA19087 to  
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
CC AAA21596 to AAA21688 represent their corresponding target sequences;  
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
CC AAA23422 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT.  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 1 G; 0 T; 6 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 676 AGAACTGATTATGA 691  
DB 16 AGAACTGATTGTGA 1  
|||||

RESULT 314  
AAF05438  
ID AAF05438 standard; DNA; 17 BP.  
XX  
XX AAF05438;  
AC  
DT 16-FEB-2001 (first entry)  
XX  
DE Hammerhead ribozyme substrate #2657.  
XX  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
KW  
XX Homo sapiens.  
OS  
PN WO200061729-A2.  
XX  
XX 19-OCT-2000.  
PD  
XX 11-APR-2000; 2000WO-US009721.  
PF  
XX 12-APR-1999; 99US-0129390P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
PI WPI; 2000-647423/62.  
DR  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX  
PS Claim 18; Page 116; 164pp; English.  
XX

The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription

CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX

SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;  
Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 AGGAAAGTAATGGACC 150  
DB 1 AGGAACTAATGGACC 16  
|||||

RESULT 315  
AAF03384/C  
ID AAF03384 standard; DNA; 17 BP.  
XX  
XX AAF03384;  
AC  
XX 16-FEB-2001 (first entry)  
DT  
XX  
DE Hammerhead ribozyme substrate #1679.  
XX  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
KW  
XX Homo sapiens.  
OS  
PN WO200061729-A2.  
XX  
XX 19-OCT-2000.  
PD  
XX 11-APR-2000; 2000WO-US009721.  
PF  
XX 12-APR-1999; 99US-0129390P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
PI WPI; 2000-647423/62.  
DR  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX  
XX Claim 37; Page 94; 164pp; English.  
XX

The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX

SQ Sequence 17 BP; 2 A; 2 C; 2 G; 11 T; 0 U; 0 Other;  
Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 AATGAAGAAAGTACAA 473  
DB 16 AATGAAGAAAGTACAA 1  
|||||

RESULT 316



```

AAAF03381/c
ID  AAFA03381 standard; DNA; 17 BP.
AC  AAFA03381;
XX
DT  16-FEB-2001 (first entry)
XX
DE  Hammerhead ribozyme substrate #1676.
XX
KW  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW  interferon alpha; ss.
XX
OS  Homo sapiens.
XX
PN  WO200061729-A2.
XX
PD  19-OCT-2000.
XX
PF  11-APR-2000; 2000WO-US009721.
XX
PR  12-APR-1999; 99US-0129390P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
WPI; 2000-647423/62.
XX
DR  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT  interferon alpha and erythropoietin.
XX
XX
Claim 37; Page 94; 164pp; English.
XX
CC  The present invention relates to enzymatic and antisense nucleic acid
CC  molecules that act as inhibitors of the expression of repressor genes
CC  encoding the R2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC  factor gene, Irf-2 and/or the C/EBP Displacement Protein (CDP).
CC  Inhibition of the repressors removes prevents inhibition (and
CC  consequently increases expression of) genes involved in the production of
CC  erythropoietin, granulocyte colony stimulating factor protein and
CC  interferon alpha
XX
SQ  Sequence 17 BP; 1 A; 4 C; 1 G; 11 T; 0 U; 0 Other;

Query Match          1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  461 GAAGAAAGTACAAGA 476
    ||||| |||||
DB  17 GAAGAAATACAAGA 2

RESULT 317
ABK02234/c
ID  ABK02234 standard; RNA; 17 BP.
XX
AC  ABK02234;
XX
DT  12-MAR-2002 (first entry)
XX
DE  Human NOGO DNazyme #146.
XX
XX
Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
KW  cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW  muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW  DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW  B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW  human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW  MCL; immunocytooma; IMC; immune thrombocytopenia; stroke; dementia;
KW  inflammatory arthropathy; central nervous system injury;
KW  cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;

```

```

KW  chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW  Parkinson's disease; ataxia; Huntington's disease;
KW  Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS  Homo sapiens.
XX
PN  WO200159103-A2.
XX
PD  16-AUG-2001.
XX
PF  09-FEB-2001; 2001WO-US004273.
XX
PR  11-FEB-2000; 2000US-0181797P.
XX
PR  28-FEB-2000; 2000US-0185516P.
XX
PR  06-MAR-2000; 2000US-0187128P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
PA  (BLAT/) BLATT L.
PA  (MCSW/) MCSWIGGEN J.
PA  (CHOW/) CHOWRIRA B M.
XX
PI  Blatt L, Mcswiggen J, Chowrira BM;
XX
WPI; 2001-607195/69.
XX
DR  Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT  constructs, which down regulate expression of a CD20 gene or neurite
PT  growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT  central nervous system injury.
XX
XX
Claim 88; Page 115; 200pp; English.
XX
CC  The invention relates to a nucleic acid molecule which down regulates
CC  expression of a CD20 gene and a nucleic acid molecule which down
CC  regulates expression of a neurite growth inhibitor gene (NOGO). The
CC  nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC  DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC  possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC  an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC  with a VGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC  of CD20 in the presence of a divalent cation that is preferably Mg2+.
CC  Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC  the cell and treat a patient having a condition associated with the level
CC  of CD20. The treatment may further comprise the use of one or more
CC  therapies. In particular, the CD20 targeting nucleic acid may be used to
CC  treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC  Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC  leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC  lymphoma (MCL), immunocytooma (IMC), small B-cell lymphocytic lymphoma,
CC  immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC  targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC  presence of a divalent cation that is preferably Mg2+. Furthermore, the
CC  nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC  cell and treat a patient having a condition associated with the level of
CC  NOGO. The treatment may further comprise the use of one or more
CC  therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC  treat central nervous system (CNS) injury and cerebrovascular accident
CC  (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC  chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC  Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC  disease, muscular dystrophy, and/or other neurodegenerative disease
CC  states which respond to the modulation of NOGO expression. The present
CC  sequence is a DNazyme molecule of the invention
XX
SQ  Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match          1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  857 TTAAAGATCCAAAT 872
    ||||| ||||| |||||

```

Db 17 TTAAAGATTCCAAAT 2

RESULT 318

ABK02326

ID ABK02326 standard; RNA; 17 BP.

XX

AC ABK02326;

XX

DT 12-MAR-2002 (first entry)

XX

DE Human NOGO DNzyme #238.

XX

KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic; cerebroprotective; neurotropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNzyme; inozyme; G-cleaver; amberyze; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia; inflammatory arthropathy; central nervous system injury;

KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease;

KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200159103-A2.

XX

PD 16-AUG-2001.

XX

PF 09-FEB-2001; 2001WO-US004273.

XX

PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX

PI Blatt L, Mcswiggen J, Chowrira BM;

XX

XX WPI; 2001-607195/69.

XX

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.

XX

PS Claim 88; Page 116; 200pp; English.

XX

CC The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr an amberyze (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-

CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present CC sequence is a DNzyme molecule of the invention

XX

XX Sequence 17 BP; 10 A; 2 C; 1 G; 0 T; 4 U; 0 Other;

SQ

Query Match 1.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 68.8%; Pred. No. 3.2e+02;

Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 822 AATAAAACCCCTGTAT 837

||:|||||:|:|:

Db 1 AAUAAAAAACCCUGUAU 16

RESULT 319

ABT37806

ID ABT37806 standard; DNA; 17 BP.

XX

AC ABT37806;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID NO 3443.

XX

KW Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; gene chip; antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease; schizophrenia; protein chip; gene therapy; tumour suppression; human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

XX

XX 27-MAR-2003.

XX

XX 17-SEP-2002; 2002WO-IB004208.

XX

XX 17-SEP-2001; 2001FR-00011978.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

DR

XX

XX New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.

PT

XX Disclosure; Page 436; 720pp; French.

PS

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one component of a gene chip, in vitro as (anti)sense reagents, and for production of recombinant polypeptides. Any of the nucleic acids, polypeptides, vectors containing the nucleic acids, cells containing the

vector or antibodies directed against the polypeptides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrénia. Analysis of the expression of the 17 mer nucleic acids in patient samples is useful for diagnosis and/or prognosis of these diseases. The polypeptides can also be used to generate antibodies, and both the polypeptide and antibodies are useful as components of protein chips. The polypeptide and antibodies are useful as components of protein chips. The nucleic acid sequences of the invention can be used in gene therapy. This polynucleotide sequence represents a tumour suppression related human fukutin oligonucleotide of the invention

Sequence 17 BP; 6 A; 1 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTCTAAT 635  
|||||  
DB 2 ATCTTAAAGTCTTAT 17

RESULT 320  
ABT39717  
ID ABT39717 standard; DNA; 17 BP.  
XX  
AC ABT39717;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 5354.  
XX  
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrénia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004208.  
XX  
PR 17-SEP-2001; 2001PR-00011978.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313353/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.  
XX  
PS Disclosure; Page 659; 720pp; French.  
XX  
CC The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one component of a gene chip, in vitro as (anti)sense reagents, and for production of recombinant polypeptides. Any of the nucleic acids, polypeptides, vectors containing the nucleic acids, cells containing the vector or antibodies directed against the polypeptides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral

diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrénia. Analysis of the expression of the 17 mer nucleic acids in patient samples is useful for diagnosis and/or prognosis of these diseases. The polypeptides can also be used to generate antibodies, and both the polypeptide and antibodies are useful as components of protein chips. The nucleic acid sequences of the invention can be used in gene therapy. This polynucleotide sequence represents a tumour suppression related human fukutin oligonucleotide of the invention

Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGGA 391  
|||||  
DB 1 GATCTCACTCTCAGGA 16

RESULT 321  
ACF62525  
ID ACF62525 standard; DNA; 17 BP.  
XX  
AC ACF62525;  
XX  
DT 08-OCT-2003 (first entry)  
XX  
DE Cancer based on CYP3A5 related oligonucleotide SEQ ID NO:354.  
XX  
KW Cancer; CYP3A5; irinotecan; pharmaceutical; malignant glioma;  
KW cytochrome p450; subfamily IIIA; nifedipine oxidase; polypeptide 5;  
KW cytosstatic; PCR primer; ss.  
XX  
OS Synthetic.  
XX  
PN WO2003013534-A2.  
XX  
PD 20-FEB-2003.  
XX  
PF 23-JUL-2002; 2002WO-EP008219.  
XX  
PR 23-JUL-2001; 2001EP-00117608.  
XX  
PR 24-MAY-2002; 2002EP-00011710.  
XX  
PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
XX  
PI Heinrich G, Kerb R;  
XX  
DR WPI; 2003-268144/26.  
XX  
PT New use of irinotecan for preparation of compositions for treating cancer in subject having genome with variant allele comprising cytochrome p450, subfamily IIIA, polypeptide 5 polynucleotide, termed CYP3A5.  
XX  
PS Disclosure; Page 42; 86pp; English.  
XX  
CC The present invention describes the use of irinotecan (I) or its derivative for the preparation of a pharmaceutical composition for treating colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or malignant glioma in a subject having a genome with a variant allele which comprises a cytochrome p450, subfamily IIIA (nifedipine oxidase), polypeptide 5 (CYP3A5) polynucleotide (II). (I) and (II) have cytostatic activity. The therapeutic applications of (I) is improved, since it is possible to individually treat a subject with an appropriate dosage and/or an appropriate derivative of (I). Therefore, undesirable, harmful or toxic effects are efficiently avoided. Unnecessary and potentially harmful treatment of those subjects who do not respond to the treatment with substances (nonresponders), as well as the development of drug resistances due to suboptimal drug dosing can be avoided. ACP62200 to ACP62751 and ABM34912 to ABM35013 represent sequences used in the exemplification of the present invention

```

XX SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 321 GCAATGTGACTGCTGA 336
Db 2 GCAATGTGACTGCTGA 17

RESULT 322
ACF62524/c
ID ACF62524 standard; DNA; 17 BP.
XX AC ACF62524;
XX DT 08-OCT-2003 (first entry)
XX DE Cancer based on CYP3A5 related oligonucleotide SEQ ID NO:353.
XX KW Cancer; CYP3A5; irinotecan; pharmaceutical; malignant glioma;
XX KW cytochrome p450; subfamily IIIA; nifedipine oxidase; polypeptide 5;
XX KW cytosstatic; PCR primer; ss.
XX OS Synthetic.
XX PN WO2003013534-A2.
XX PD 20-FEB-2003.
XX PF 23-JUL-2002; 2002WO-EP008219.
XX PR 23-JUL-2001; 2001EP-00117608.
XX PR 24-MAY-2002; 2002EP-00011710.
XX XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX PI Heinrich G, Kerb R;
XX WPI; 2003-268144/26.
XX DR
XX PT New use of irinotecan for preparation of compositions for treating cancer
XX PT in subject having genome with variant allele comprising cytochrome p450,
XX PT subfamily IIIA, polypeptide 5 polynucleotide, termed CYP3A5.
XX PS Disclosure; Page 42; 86pp; English.
XX CC The present invention describes the use of irinotecan (I) or its
XX CC derivative for the preparation of a pharmaceutical composition for
XX CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
XX CC cancer, or malignant glioma in a subject having a genome with a variant
XX CC allele which comprises a cytochrome p450, subfamily IIIA (nifedipine
XX CC oxidase), polypeptide 5 (CYP3A5) polynucleotide (II). (I) and (II) have
XX CC cytostatic activity. The therapeutic applications of (I) is improved,
XX CC since it is possible to individually treat a subject with an appropriate
XX CC dosage and/or an appropriate derivative of (I). Therefore, undesirable,
XX CC harmful or toxic effects are efficiently avoided. Unnecessary and
XX CC potentially harmful treatment of those subjects who do not respond to the
XX CC treatment with substances (nonresponders), as well as the development of
XX CC drug resistances due to suboptimal drug dosing can be avoided. ACF62200
XX CC to ACF62751 and ABM34912 to ABM35013 represent sequences used in the
XX CC exemplification of the present invention
XX SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 321 GCAATGTGACTGCTGA 336
Db 2 GCAATGTGACTGCTGA 17

RESULT 323
ACB21195/c
ID ADB21195 standard; DNA; 17 BP.
XX AC ADB21195;
XX DT 20-NOV-2003 (first entry)
XX DE MRP1 based cancer related nucleic acid SEQ ID NO:353.
XX KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;
XX KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
XX KW variant allele; multidrug resistance protein 1; MRP1; cytosstatic; gene;
XX OS ds.
XX OS Unidentified.
XX PN WO2003013533-A2.
XX PD 20-FEB-2003.
XX PF 23-JUL-2002; 2002WO-EP008200.
XX PR 23-JUL-2001; 2001EP-00117608.
XX PR 24-MAY-2002; 2002EP-00011710.
XX XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX PI Heinrich G, Kerb R;
XX WPI; 2003-354397/33.
XX DR
XX PT Use of irinotecan or its derivative for preparation of a pharmaceutical
XX PT composition for treating cancer in a subject having a genome with a
XX PT variant allele comprising a multidrug resistance protein 1
XX PT polynucleotide.
XX PS Disclosure; Page 51; 100pp; English.
XX CC The present invention describes a method for the use of irinotecan (I) or
XX CC its derivative for the preparation of a pharmaceutical composition for
XX CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
XX CC cancer, or malignant glioma in a subject having a genome with a variant
XX CC allele which comprises a multidrug resistance protein 1 (MRP1)
XX CC polynucleotide (II). (I) has cytostatic activity. (I) or its derivative
XX CC can be used for the preparation of a pharmaceutical composition for
XX CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic
XX CC cancer, or malignant glioma in a subject, where the subject is a human
XX CC (preferably African or Asian) or a mouse. The present sequence represents
XX CC a sequence which is used in the exemplification of the present invention.
XX SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 321 GCAATGTGACTGCTGA 336
Db 16 GCAATGTGACTGCTGA 1

RESULT 324
ADB21196
ID ADB21196 standard; DNA; 17 BP.
XX AC ADB21196;
XX DT 20-NOV-2003 (first entry)
XX DT
XX DT
XX DT

```

DE MRP1 based cancer related nucleic acid SEQ ID NO:354.  
 XX  
 KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
 KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
 KW variant allele; multidrug resistance protein 1; MRP1; cytosolic; gene;  
 KW ds.  
 XX  
 OS Unidentified.  
 XX  
 PN WO2003013533-A2.  
 XX  
 PD 20-FEB-2003.  
 XX  
 PF 23-JUL-2002; 2002WO-EP008200.  
 XX  
 PR 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX  
 PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX  
 PI Heinrich G, Kerb R;  
 XX  
 DR WPI; 2003-354397/33.  
 XX  
 PT Use of irinotecan or its derivative for preparation of a pharmaceutical  
 PT composition for treating cancer in a subject having a genome with a  
 PT variant allele comprising a multidrug resistance protein 1  
 PT polynucleotide.  
 XX  
 PS Disclosure; Page 51; 100pp; English.  
 XX  
 CC The present invention describes a method for the use of irinotecan (I) or  
 CC its derivative for the preparation of a pharmaceutical composition for  
 CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic  
 CC cancer, or malignant glioma in a subject having a genome with a variant  
 CC allele which comprises a multidrug resistance protein 1 (MRP1)  
 CC polynucleotide (II). (I) has cytostatic activity. (I) or its derivative  
 CC can be used for the preparation of a pharmaceutical composition for  
 CC treating colorectal, cervical, gastric, lung, ovarian or pancreatic  
 CC cancer, or malignant glioma in a subject, where the subject is a human  
 CC (preferably African or Asian) or a mouse. The present sequence represents  
 CC a sequence which is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 321 GCAATGTGACTGCTGA 336  
 Db 2 GCAATGTGACTGCTGA 17  
 |||||  
 RESULT 325  
 ADB88285  
 ID ADB88285 standard; DNA; 17 BP.  
 XX  
 AC ADB88285;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Human UGT1A1 variant allele sequence fragment SEQ ID NO:326.  
 XX  
 KW ss; irinotecan; cancer; UGT1A1; cytosolic; topoisomerase I inhibitor;  
 KW colorectal cancer; cervical cancer; gastric cancer; lung cancer;  
 KW ovarian cancer; pancreatic cancer; malignant glioma;  
 KW uridine diphosphate glycosyltransferase member A1.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003013536-A2.  
 XX  
 PD 20-FEB-2003.  
 XX  
 PF 23-JUL-2002; 2002WO-EP008217.  
 XX  
 PR 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX  
 PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX  
 PI Heinrich G, Kerb R;  
 XX  
 FN WO2003013536-A2.  
 XX

PD 20-FEB-2003.  
 XX  
 PF 23-JUL-2002; 2002WO-EP008217.  
 XX  
 PR 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX  
 PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX  
 PI Heinrich G, Kerb R;  
 XX  
 DR WPI; 2003-289896/28.  
 XX  
 PT Use of irinotecan to treat cancer patient by determining if patient has  
 PT variant alleles of UGT1A1 gene, administering increased/decreased amounts  
 PT of irinotecan based on increased/decreased levels of UGT1A1 gene product.  
 XX  
 PS Disclosure; Page 55; 107pp; English.  
 XX  
 CC The invention relates to the novel use of irinotecan to treat a patient  
 CC suffering from cancer. This involves determining if the patient has one  
 CC or more variant alleles of the UGT1A1 gene, and if the patient has one or  
 CC more of such variant alleles, irinotecan is administered in an increased  
 CC or decreased amount in comparison to the amount that is administered  
 CC without regard to the patient's alleles in the UGT1A1 gene. The invention  
 CC has cytostatic activity. A composition of the invention acts as a  
 CC topoisomerase I inhibitor. The method is useful for treating a patient,  
 CC an animal e.g. mouse or a human, preferably African or Asian, suffering  
 CC from cancer such as colorectal, cervical, gastric cancer, lung, ovarian,  
 CC pancreatic cancer or malignant glioma. The present sequence is used in  
 CC the exemplification of the invention.  
 XX  
 SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 321 GCAATGTGACTGCTGA 336  
 Db 2 GCAATGTGACTGCTGA 17  
 |||||  
 RESULT 326  
 ADB88284/c  
 ID ADB88284 standard; DNA; 17 BP.  
 XX  
 AC ADB88284;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Human UGT1A1 variant allele sequence fragment SEQ ID NO:325.  
 XX  
 KW ss; irinotecan; cancer; UGT1A1; cytosolic; topoisomerase I inhibitor;  
 KW colorectal cancer; cervical cancer; gastric cancer; lung cancer;  
 KW ovarian cancer; pancreatic cancer; malignant glioma;  
 KW uridine diphosphate glycosyltransferase member A1.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003013536-A2.  
 XX  
 PD 20-FEB-2003.  
 XX  
 PF 23-JUL-2002; 2002WO-EP008217.  
 XX  
 PR 23-JUL-2001; 2001EP-00117608.  
 PR 24-MAY-2002; 2002EP-00011710.  
 XX  
 PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 XX  
 PI Heinrich G, Kerb R;  
 XX

DR WPI; 2003-289896/28.  
XX  
XX Use of irinotecan to treat cancer patient by determining if patient has  
PT variant alleles of UGT1A1 gene, administering increased/decreased amounts  
PT of irinotecan based on increased/decreased levels of UGT1A1 gene product.  
XX  
XX Disclosure; Page 55; 107pp; English.  
PS  
PS The invention relates to the novel use of irinotecan to treat a patient  
CC suffering from cancer. This involves determining if the patient has one  
CC or more variant alleles of the UGT1A1 gene, and if the patient has one or  
CC more of such variant alleles, irinotecan is administered in an increased  
CC or decreased amount in comparison to the amount that is administered  
CC without regard to the patient's alleles in the UGT1A1 gene. The invention  
CC has cytostatic activity. A composition of the invention acts as a  
CC topoisomerase I inhibitor. The method is useful for treating a patient,  
CC an animal e.g. mouse or a human, preferably African or Asian, suffering  
CC from cancer such as colorectal, cervical, gastric cancer, lung, ovarian,  
CC pancreatic cancer or malignant glioma. The present sequence is used in  
CC the exemplification of the invention.  
XX  
XX Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 321 GCAATGTGACTGCTGA 336  
Db 16 GCAATGTAACTGCTGA 1  
RESULT 327  
ADB97267/c  
ID ADB97267 standard; DNA; 17 BP.  
XX  
XX ADB97267;  
AC  
XX  
XX 04-DEC-2003 (first entry)  
DT  
XX  
XX Human MDR1 variant allele sequence fragment SEQ ID NO:353.  
DE  
XX  
XX irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
KW multidrug resistance 1; MDR1; cytostatic; human; ds; Cyp3A5; MRP1; MDR1;  
KW TOP1.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2003013537-A2.  
PN  
XX  
XX 20-FEB-2003.  
PD  
XX  
XX 23-JUL-2002; 2002WO-EP008218.  
PF  
XX  
XX 23-JUL-2001; 2001EP-00117608.  
PR  
XX  
XX 24-MAY-2002; 2002EP-00011710.  
PR  
XX  
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
PA  
XX  
XX Heinrich G, Kerb R;  
PI  
XX  
XX WPI; 2003-268145/26.  
DR  
XX  
XX 20-FEB-2003.  
PD  
XX  
XX 23-JUL-2002; 2002WO-EP008218.  
PF  
XX  
XX 23-JUL-2001; 2001EP-00117608.  
PR  
XX  
XX 24-MAY-2002; 2002EP-00011710.  
PR  
XX  
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
PA  
XX  
XX Heinrich G, Kerb R;  
PI  
XX  
XX WPI; 2003-268145/26.  
DR  
XX  
XX New use of irinotecan for preparation of pharmaceutical compositions for  
PT treating cancer in subject having genome with variant allele comprising  
PT multidrug resistance 1 polynucleotide.  
XX  
XX Claim 1; Page 79; 130pp; English.  
PS  
XX  
XX The invention relates to the novel use of irinotecan or its derivative  
CC for the preparation of pharmaceutical compositions for treating  
CC colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or

CC malignant glioma in a subject having a genome with a variant allele which  
CC comprises a multidrug resistance 1 (MDR1) polynucleotide. A composition  
CC of the invention has cytostatic activity. The invention is useful for the  
CC preparation of pharmaceutical compositions for treating colorectal,  
CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant  
CC glioma in a subject (preferably human, more preferably African or Asian)  
CC or a mouse. The present sequence is used in the exemplification of the  
CC invention.  
XX  
XX Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 321 GCAATGTGACTGCTGA 336  
Db 16 GCAATGTAACTGCTGA 1  
RESULT 328  
ADB97268  
ID ADB97268 standard; DNA; 17 BP.  
XX  
XX ADB97268;  
AC  
XX  
XX 04-DEC-2003 (first entry)  
DT  
XX  
XX Human MDR1 variant allele sequence fragment SEQ ID NO:354.  
DE  
XX  
XX irinotecan; colorectal cancer; cervical cancer; gastric cancer;  
KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;  
KW multidrug resistance 1; MDR1; cytostatic; human; ds; Cyp3A5; MRP1; MDR1;  
KW TOP1.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2003013537-A2.  
PN  
XX  
XX 20-FEB-2003.  
PD  
XX  
XX 23-JUL-2002; 2002WO-EP008218.  
PF  
XX  
XX 23-JUL-2001; 2001EP-00117608.  
PR  
XX  
XX 24-MAY-2002; 2002EP-00011710.  
PR  
XX  
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
PA  
XX  
XX Heinrich G, Kerb R;  
PI  
XX  
XX WPI; 2003-268145/26.  
DR  
XX  
XX New use of irinotecan for preparation of pharmaceutical compositions for  
PT treating cancer in subject having genome with variant allele comprising  
PT multidrug resistance 1 polynucleotide.  
XX  
XX Claim 1; Page 79; 130pp; English.  
PS  
XX  
XX The invention relates to the novel use of irinotecan or its derivative  
CC for the preparation of pharmaceutical compositions for treating  
CC colorectal, cervical, gastric, lung, ovarian or pancreatic cancer, or

Query Match 1.6%; Score 14.4; DB 1; Length 17;

```
Best Local Similarity 93.8%; Pred. No. 3.2e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 15; Conservative 0;

QY 321 GCAATGTGACTGCTGA 336
DB 2 GCAATGTAACTGCTGA 17

RESULT 329
ADB92459
ID ADB92459 standard; DNA; 17 BP.
XX
AC ADB92459;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human MDR1 variant allele sequence fragment SEQ ID NO:354.
XX
KW irinotecan; colorectal cancer; cervical cancer; gastric cancer;
KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
KW multidrug resistance 1; MDR1; cytostatic; ds; human; UGT1A1; MRP1; TOP1.
XX
OS Homo sapiens.
XX
PN WO2003013535-A2.
XX
PD 20-FEB-2003.
XX
PF 23-JUL-2002; 2002WO-EP008220.
XX
PR 23-JUL-2001; 2001EP-00117608.
XX
PR 24-MAY-2002; 2002EP-00011710.
XX
PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI Heinrich G, Kerb R;
XX
DR WPI; 2003-342400/32.
XX
PT New use of irinotecan for preparation of pharmaceutical compositions for
PT treating cancer in subject having genome with variant allele comprising
PT multidrug resistance 1 polynucleotide.
XX
PS Claim 8; Page 50; 104pp; English.
XX
CC The invention relates to a novel use of irinotecan or its derivative for
CC the preparation of a pharmaceutical composition for treating colorectal,
CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant
CC glioma in a subject having a genome with a variant allele which comprises
CC a multidrug resistance 1 (MDR1) polynucleotide. A composition of the
CC invention has cytostatic activity. The present sequence is used in the
CC exemplification of the invention.
XX
SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
DB 2 GCAATGTAACTGCTGA 17

RESULT 330
ADB92458/C
ID ADB92458 standard; DNA; 17 BP.
XX
AC ADB92458;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human MDR1 variant allele sequence fragment SEQ ID NO:353.

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
DB 2 GCAATGTAACTGCTGA 17

RESULT 331
ADB44992
ID ADB44992 standard; DNA; 17 BP.
XX
AC ADB44992;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #5315.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
```

```
XX irinotecan; colorectal cancer; cervical cancer; gastric cancer;
KW lung cancer; ovarian cancer; pancreatic cancer; malignant glioma;
KW multidrug resistance 1; MDR1; cytostatic; ds; human; UGT1A1; MRP1; TOP1.
XX
OS Homo sapiens.
XX
PN WO2003013535-A2.
XX
PD 20-FEB-2003.
XX
PF 23-JUL-2002; 2002WO-EP008220.
XX
PR 23-JUL-2001; 2001EP-00117608.
XX
PR 24-MAY-2002; 2002EP-00011710.
XX
PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI Heinrich G, Kerb R;
XX
DR WPI; 2003-342400/32.
XX
PT New use of irinotecan for preparation of pharmaceutical compositions for
PT treating cancer in subject having genome with variant allele comprising
PT multidrug resistance 1 polynucleotide.
XX
PS Claim 8; Page 50; 104pp; English.
XX
CC The invention relates to a novel use of irinotecan or its derivative for
CC the preparation of a pharmaceutical composition for treating colorectal,
CC cervical, gastric, lung, ovarian or pancreatic cancer, or malignant
CC glioma in a subject having a genome with a variant allele which comprises
CC a multidrug resistance 1 (MDR1) polynucleotide. A composition of the
CC invention has cytostatic activity. The present sequence is used in the
CC exemplification of the invention.
XX
SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336
DB 16 GCAATGTAACTGCTGA 1

RESULT 331
ADB44992
ID ADB44992 standard; DNA; 17 BP.
XX
AC ADB44992;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #5315.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
```

```

XX Telerman A, Amson R, Tuijnder M;
PI WPI; 2003-441574/41.
DR
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX Disclosure; Page 653; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
XX Sequence 17 BP; 6 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTGCTAAT 635
DB 2 ATCTTAAAGTGCTAAT 17
|||||
2 ATCTTAAAGTGCTAAT 17

RESULT 332
ADI48262
ID ADI48262 standard; DNA; 17 BP.
XX
AC ADI48262;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID765.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytosatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
FN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PP 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
PI WPI; 2003-313354/30.
DR

XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 765; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nontropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 7 A; 4 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 261 ATCCTCTATCCAGAAA 276
DB 2 ATCCTATATCCAGAAA 17
|||||
2 ATCCTATATCCAGAAA 17

RESULT 333
ABZ76052/C
ID ABZ76052 standard; DNA; 17 BP.
XX
AC ABZ76052;
XX
DT 29-MAY-2003 (first entry)
XX
DE Antigen inhibiting mammalian cruciform formation.
XX
KW Cruciform; DNA replication; antigen; antibacterial; virucide; fungicide;
KW protozoazide; antihelminthic; anti-HIV; cytostatic; gene therapy; ds.
XX
OS Synthetic.
XX
FN WO2003012097-A2.
XX
PD 13-FEB-2003.
XX
PP 30-JUL-2002; 2002WO-IB003667.
XX
PR 30-JUL-2001; 2001US-0308636P.
XX
PA (PRIC/) PRICE G B.
PA (ZANN/) ZANNIS-HADJOPOULOS M.
XX
PI Price GB, Zannis-Hadjopoulos M;
XX
DR WPI; 2003-248179/24.
XX
XX Inhibiting DNA replication or cell proliferation, useful for treating
XX tumors, comprises contacting a DNA molecule with a nucleic acid antigene
XX that specifically hybridizes to a portion of the DNA molecule having dyad
XX symmetry.
XX
XX Claim 11; Page 16; 54pp; English.
XX
XX The invention relates to inhibiting DNA replication and involves
XX

```



CC contacting a DNA molecule with a nucleic acid antigen comprising at  
 CC least 12 nucleobases selected from natural nucleobases, modified  
 CC nucleobases, and their mixture. The antigen specifically hybridizes to a  
 CC portion of the DNA molecule having dyad symmetry. The method is useful in  
 CC inhibiting DNA replication and, thus, inhibiting the growth of bacteria,  
 CC virus (e.g. HIV), fungi, protozoa, helminths and insects. The method is  
 CC also useful in inhibiting cell proliferation of tumour cells. The present  
 CC sequence represents an antigen inhibiting the cruciform formation of  
 CC mammalian replication origin

XX  
 SQ Sequence 17 BP; 2 A; 7 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 453 GTGGAAATGAAGAAAG 468  
 Db 16 GTGGAGATGAAGAAAG 1

## RESULT 334

ADK00139/c  
 ID ADK00139 standard; DNA; 18 BP.

XX  
 AC ADK00139;

XX  
 DT 20-MAY-2004 (first entry)

XX  
 DE Primer of the invention #8.

XX  
 KW murine genomic region; cancer; Antiinflammatory; Cytostatic;

KW diagnostic reagent; inflammatory disease; acute myeloid leukemia; ss;  
 KW primer.

XX  
 OS Synthetic.

XX  
 PN WO2004016317-A1.

XX  
 PD 26-FEB-2004.

XX  
 PF 14-AUG-2003; 2003WO-NL000583.

XX  
 PR 14-AUG-2002; 2002EP-00078358.

XX  
 PR 19-SEP-2002; 2002US-00252132.

XX  
 PA (UYRO-) UNIV ROTTERDAM ERASMUS CENT MEDICAL.

XX  
 PI Touw IP, Delwel HR, Lowenberg B, Valk PJM;

XX  
 DR WPI; 2004-203739/19.

XX  
 PT Use of a murine genomic region involved in the development of cancer for  
 PT identifying compounds useful for treating or diagnosing cancer or  
 PT inflammatory diseases.

PS Example 1; SEQ ID NO 8; 106pp; English.

XX  
 CC The present invention relates to the use of at least one murine genomic  
 CC region involved in the development of cancer selected from a set of  
 CC genomic regions listed in the specification for preparing a polypeptide  
 CC encoded by the region or for the preparation of an inhibitor able to  
 CC inhibit the transcription product or activity of a polypeptide encoded by  
 CC the region, or affected by transformations in the region. The murine  
 CC genomic region involved in the development of cancer or its human  
 CC homologue or transcription product is useful for preparing its encoded  
 CC polypeptide or inhibitor for preparing a diagnostic reagent for  
 CC diagnosing cancer or for preparing a composition for treating  
 CC inflammatory diseases or cancer, e.g., acute myeloid leukemia. The  
 CC present sequence represents a primer of the invention.

XX  
 SQ Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 TCACCTCTCAGGAGACC 395  
 Db 16 TCACCTCTGAGGAGACC 1

## RESULT 335

AAZ32081/c  
 ID AAZ32081 standard; DNA; 19 BP.

XX  
 AC AAZ32081;

XX  
 DT 11-JAN-2000 (first entry)

XX  
 DE Xylulokinase PCR primer 10.

XX  
 KW Xylulokinase; YAC; yeast artificial chromosome; hypoglycaemia; diabetes;  
 KW NIDDM; non insulin dependent diabetes; PCR primer; ss.

XX  
 OS Synthetic.

XX  
 OS Saccharomyces cerevisiae.

XX  
 PN JP11266870-A.

XX  
 PD 05-OCT-1999.

XX  
 PF 25-MAR-1998; 98JP-00078127.

XX  
 PR 25-MAR-1998; 98JP-00078127.

XX  
 PA (NAKA/) NAKAMURA Y.

XX  
 PA (TAKE ) TAKEDA CHEM IND LTD.

XX  
 DR WPI; 1999-613777/53.

XX  
 PT A new protein and its DNA - used in the treatment or prevention of  
 PT hypoglycemia and diabetes.

XX  
 PS Example 2; Page 32; 36pp; Japanese.

XX  
 CC The present sequence represents a PCR primer for the xylulokinase protein  
 CC from the present invention. The protein, the partial peptide, their salts  
 CC and the polynucleotide encoding the protein are useful for the treatment  
 CC and prevention of diseases such as hypoglycaemia and diabetes. The  
 CC protein was isolated from a YAC (yeast artificial chromosome) clone  
 CC Y936C1 which was introduced into a cosmid vector pWE15 to prepare a  
 CC cosmid library

SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 444 TGGGCAAAAGGTGGAAA 459  
 Db 19 TGGGCAACGGTGGAAA 4

## RESULT 336

AAA83961/c  
 ID AAA83961 standard; DNA; 19 BP.

XX  
 AC AAA83961;

XX  
 DT 04-DEC-2000 (first entry)

XX  
 DE Cyclin A2 ribozyme binding site #139.

XX  
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

```

XX OS Mammalia.
XX PN WO200032765-A2.
XX PD 08-JUN-2000.
XX PF 06-DEC-1999; 99WO-US028772.
XX PR 04-DEC-1998; 98US-0110954P.
XX PA (IMMU-) IMMUSOL INC.
XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX DR New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PT PCNA and Cyclin B1.
XX PS Disclosure; Page 69; 109pp; English.
XX CC The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells. The
XX CC ribozyme is resistant to endonuclease activity and hence is efficient in
XX CC restenosis treatment
XX SQ Sequence 19 BP; 6 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 673 GTGAGAAACTGATTTA 688
Db 16 GTAGAAACTGATTTA 1

RESULT 337
AAH59123/c
ID AAH59123 standard; DNA; 19 BP.
XX AC AAH59123;
XX DT 10-SEP-2001 (first entry)
XX DE Cyclin A2 ribozyme binding site SEQ ID NO:1547.
XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX KW recognition site; target; ribozyme binding site; eye disease; vulnary;
XX KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XX KW antipsoiatric; dermatological; antiseborrheic; antidiabetic; virucide;
XX KW atopic dermatitis; actinic keratosis; keratolytic; gene therapy; viral wart;
XX KW basal cell carcinoma; squamous cell carcinoma;
XX KW sickle cell retinopathy; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200130362-A2.
XX PD 03-MAY-2001.
XX PF 26-OCT-2000; 2000WO-US029500.
XX XX

```

```

PR 26-OCT-1999; 99US-0161532P.
XX (IMMU-) IMMUSOL INC.
XX PI Robbins JM, Tritz R;
XX WPI; 2001-300427/31.
XX DR Treating proliferative skin or eye diseases and scarring, using ribozymes
XX PT that cleave RNA encoding cytokines involved in inflammation, matrix
XX PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX PS Example 1; Page 184; 408pp; English.
XX CC The present invention describes a method for treating a proliferative
XX CC skin or eye disease and scarring. The method involves administering a
XX CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX CC dependent kinase, growth factor or a reductase, or administering a
XX CC nucleic acid molecule (II) comprising a promoter operably linked to a
XX CC nucleic acid segment encoding (I). (I) can have antipsoiatric,
XX CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,
XX CC ophthalmological, vulnary, keratolytic and virucide activities, and
XX CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX CC in gene therapy. (I) and (II) are useful for treating proliferative skin
XX CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
XX CC also be used for treating proliferative eye diseases such as diabetic
XX CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX CC prematurity and retinal detachment, and for treating and preventing
XX CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
XX CC scar. AAH57577 to AAH62099 represent sequences used in the
XX CC exemplification of the present invention
XX SQ Sequence 19 BP; 6 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 673 GTGAGAAACTGATTTA 688
Db 16 GTAGAAACTGATTTA 1

RESULT 338
ADR77596/c
ID ADR77596 standard; DNA; 19 BP.
XX AC ADR77596;
XX DT 16-DEC-2004 (first entry)
XX DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2081.
XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
XX KW RNA interference; iRNA; antisense technology; lipid metabolism;
XX KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX KW coronary artery disease; CAD; coronary heart disease; CHD;
XX KW atherosclerosis; hepatic glucose production;
XX KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX KW colon cancer; lung cancer; neurological disease; Huntington disease;
XX KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX OS Homo sapiens.
XX PN WO2004080406-A2.
XX PD 23-SEP-2004.
XX PF 08-MAR-2004; 2004WO-US007070.
XX XX

```

```

PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 2081; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apob-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apob-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
XX can be used to control ApoB gene expression.
XX
XX Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 3.2e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 782 TATTAAACTTGTGCAGA 797
XX ||| ||||| |||||
XX Db 17 TATTAAACTTGTGCAGA 2
XX
XX RESULT 339
XX ID ADR79231/c
XX ID ADR79231 standard; DNA; 19 BP.
XX
XX AC ADR79231;

```

```

XX
DT 16-DEC-2004 (first entry)
XX
XX Human apolipoprotein B (ApoB) oligonucleotide seqid 3716.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; aa.
XX
XX Homo sapiens.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454265P.
XX 13-MAR-2003; 2003US-0454962P.
XX 13-MAR-2003; 2003US-0455050P.
XX 14-APR-2003; 2003US-0462894P.
XX 17-APR-2003; 2003US-0463772P.
XX 25-APR-2003; 2003US-0465665P.
XX 25-APR-2003; 2003US-0465802P.
XX 09-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 3716; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apob-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apob-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
XX can be used to control ApoB gene expression.
XX
XX Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 14.4; DB 1; Length 19;
XX Best Local Similarity 93.8%; Pred. No. 3.2e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 782 TATTAAACTTGTGCAGA 797
XX ||| ||||| |||||
XX Db 17 TATTAAACTTGTGCAGA 2
XX
XX RESULT 339
XX ID ADR79231/c
XX ID ADR79231 standard; DNA; 19 BP.
XX
XX AC ADR79231;

```

CC related disorder e.g. diabetes or type-2 diabetes. (1) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
 CC can be used to control ApoB gene expression.

XX  
 SQ Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 782 TATTAAACTTGTGCAGA 797  
 Db 17 TATAAAACTTGTGCAGA 2

RESULT 340  
 ADR74990/C  
 ID ADR74990 standard; DNA; 19 BP.

XX AC ADR74990;

XX 16-DEC-2004 (first entry)

XX Common primer for human stenosis associated marker hCV2769191.

XX Human; ss; PCR; primer; coronary stenosis; angina; ischaemic chest pain;  
 KW myocardial infarction; sudden cardiac death; SNP;  
 KW single nucleotide polymorphism.

XX Homo sapiens.

XX WO2004081186-A2.

XX 23-SEP-2004.

XX 10-MAR-2004; 2004WO-US007140.

XX 10-MAR-2003; 2003US-0453050P.

XX 30-APR-2003; 2003US-0466437P.

XX (APPL-) APPLERA CORP.

XX Cargill M, Devlin JJ, Luke MM;

XX WPI; 2004-668949/65.

XX Identifying an individual who has altered risk for developing stenosis  
 PT comprises detecting single nucleotide polymorphism (SNP), in the  
 PT individual's nucleic acids.

XX Claim 19; SEQ ID NO 68302; 146pp; English.

XX The invention relates to identifying an individual who has altered risk  
 CC for developing coronary stenosis comprising detecting a single nucleotide  
 CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not  
 CC given in the specification), in the individual's nucleic acids, where the  
 CC presence of the SNP is correlated with an altered risk for stenosis in  
 CC the individual. Also included are an isolated nucleic acid molecule  
 CC comprising at least 8 contiguous nucleotides where one of the  
 CC nucleotides is an SNP as cited above, or their complement), an isolated  
 CC polypeptide comprising an amino acid sequence selected from any of the  
 CC 696 amino acid sequences (not defined in the specification), an antibody  
 CC that specifically binds to the polypeptide (or its antigen-binding  
 CC fragment), an amplified polynucleotide containing the SNP as cited (where  
 CC the amplified polynucleotide is between about 16 and about 1,000  
 CC nucleotides in length), an isolated polynucleotide which specifically  
 CC hybridises to a nucleic acid molecule containing the SNP, a kit for  
 CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid  
 CC molecule, detecting a variant polypeptide and identifying an agent useful  
 CC in therapeutically or prophylactically treating stenosis. The detection

CC step of the method is carried out by a process selected from allele-  
 CC specific probe hybridisation, allele-specific primer extension, allele-  
 CC specific amplification, sequencing, 5' nuclease digestion, alular  
 CC beacon assay, oligonucleotide ligation assay, size analysis, and single-  
 CC stranded conformation polymorphism. The method is useful for identifying  
 CC an individual who has altered risk for developing coronary stenosis,  
 CC which can lead to angina (ischaemic chest pain), myocardial infarction  
 CC and ultimately sudden cardiac death. The present sequence is a common  
 CC primer (used with an allele specific primer) for amplifying a SNP-  
 CC containing region of a human marker gene associated with stenosis. NOTE:  
 CC SEQ ID 1-67771 are not shown in the specification but are provided on a  
 CC CD-R named CL001510CDR which was not supplied with the specification.

XX  
 SQ Sequence 19 BP; 7 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 3.2e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 194 CATGATTCATGTC 209  
 Db 17 CATGATTCCTGTC 2

RESULT 341

AAT81501

ID AAT81501 standard; RNA; 17 BP.

XX AC AAT81501;

XX 14-DEC-1997 (first entry)

XX Human c-myb hammerhead ribozyme target sequence (nt. position 2701).

XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;  
 KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;  
 KW coronary angioplasty; ss.

XX Homo sapiens.

XX WO9531541-A2.

XX 23-NOV-1995.

XX 18-MAY-1995; 95WO-US006368.

XX 18-MAY-1994; 94US-00245466.

XX 13-JAN-1995; 95US-00373124.

XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;

XX WPI; 1996-010927/01.

XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,  
 PT for treating restenosis or cancer.

XX Claim 1; Page 76; 128pp; English.

XX The present sequence represents the preferred target sequence for an  
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves  
 CC the human c-myb sequence at the base position indicated in the descriptor  
 CC line. The c-myb sequence was screened for optimal ribozyme target sites  
 CC using a computer folding algorithm, and regions of the mRNA which did not  
 CC form secondary folding structures and contained potential ribozyme  
 CC cleavage sites were identified. Ribozymes were synthesised and their  
 CC activities optimised by either varying the length of the binding arms or  
 CC by modification to prevent degradation by nucleases. The ribozymes cleave  
 CC the c-myb sequence and can be used to prevent smooth muscle cell  
 CC hyperproliferation in restenosis, especially after coronary angioplasty,  
 CC and in cancers

XX

```
SQ Sequence 17 BP; 10 A; 0 C; 1 G; 0 T; 6 U; 0 Other;
Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 709 ATAGTTTATATAAA 722
   3 AUAGUUUUAUAAAA 16
   |:|:::|:|:|
   |:|:::|:|:|

RESULT 342
AAT81503
ID AAT81503 standard; RNA; 17 BP.
AC AAT81503;
XX
XX
XX 14-DEC-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 2703).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
XX coronary angioplasty; ss.
XX Homo sapiens.
XX
XX WO9531541-A2.
XX
XX 23-NOV-1995.
XX
XX 18-MAY-1995; 95WO-US006368.
XX
XX 18-MAY-1994; 94US-00245466.
XX 13-JAN-1995; 95US-00373124.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
XX for treating restenosis or cancer.
XX
XX Claim 1; Page 76; 128pp; English.
XX
XX The present sequence represents the preferred target sequence for an
XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX the human c-myb sequence at the base position indicated in the descriptor
XX line. The c-myb sequence was screened for optimal ribozyme target sites
XX using a computer folding algorithm, and regions of the mRNA which did not
XX form secondary folding structures and contained potential ribozyme
XX cleavage sites were identified. Ribozymes were synthesised and their
XX activities optimised by either varying the length of the binding arms or
XX by modification to prevent degradation by nucleases. The ribozymes cleave
XX the c-myb sequence and can be used to prevent smooth muscle cell
XX hyperproliferation in restenosis, especially after coronary angioplasty,
XX and in cancers
XX
XX SQ Sequence 17 BP; 9 A; 0 C; 1 G; 0 T; 7 U; 0 Other;
Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 709 ATAGTTTATATAAA 722
   1 AUAGUUUUAUAAAA 14
   |:|:::|:|:|
   |:|:::|:|:|

RESULT 343
AAT81500
ID AAT81500 standard; RNA; 17 BP.
AC AAT81500;
XX
XX
XX 14-DEC-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 2702).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
XX coronary angioplasty; ss.
XX Homo sapiens.
XX
XX WO9531541-A2.
XX
XX 23-NOV-1995.
XX
XX 18-MAY-1995; 95WO-US006368.
XX
XX 18-MAY-1994; 94US-00245466.
XX 13-JAN-1995; 95US-00373124.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
XX for treating restenosis or cancer.
XX
XX Claim 1; Page 76; 128pp; English.
XX
XX The present sequence represents the preferred target sequence for an
XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX the human c-myb sequence at the base position indicated in the descriptor
XX line. The c-myb sequence was screened for optimal ribozyme target sites
XX using a computer folding algorithm, and regions of the mRNA which did not
XX form secondary folding structures and contained potential ribozyme
XX cleavage sites were identified. Ribozymes were synthesised and their
XX activities optimised by either varying the length of the binding arms or
XX by modification to prevent degradation by nucleases. The ribozymes cleave
XX the c-myb sequence and can be used to prevent smooth muscle cell
XX hyperproliferation in restenosis, especially after coronary angioplasty,
XX and in cancers
XX
XX SQ Sequence 17 BP; 9 A; 0 C; 1 G; 0 T; 6 U; 0 Other;
Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 709 ATAGTTTATATAAA 722
   4 AUAGUUUUAUAAAA 17
   |:|:::|:|:|
   |:|:::|:|:|

RESULT 344
AAT81502
ID AAT81502 standard; RNA; 17 BP.
AC AAT81502;
XX
XX
XX 14-DEC-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 2702).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
XX coronary angioplasty; ss.
XX Homo sapiens.
XX
```

```

XX PN WO9531541-A2.
XX PD 23-NOV-1995.
XX PF 18-MAY-1995; 95WO-US006368.
XX PR 18-MAY-1994; 94US-00245466.
XX PR 13-JAN-1995; 95US-00373124.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX DR WPI; 1996-010927/01.
XX DR New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
XX PT for treating restenosis or cancer.
XX PS Claim 1; Page 76; 128pp; English.
XX CC The present sequence represents the preferred target sequence for an
XX CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX CC the human c-myb sequence at the base position indicated in the descriptor
XX CC line. The c-myb sequence was screened for optimal ribozyme target sites
XX CC using a computer folding algorithm, and regions of the mRNA which did not
XX CC form secondary folding structures and contained potential ribozyme
XX CC cleavage sites were identified. Ribozymes were synthesised and their
XX CC activities optimised by either varying the length of the binding arms or
XX CC by modification to prevent degradation by nucleases. The ribozymes cleave
XX CC the c-myb sequence and can be used to prevent smooth muscle cell
XX CC hyperproliferation in restenosis, especially after coronary angioplasty,
XX CC and in cancers
XX SQ Sequence 17 BP; 10 A; 0 C; 1 G; 0 T; 6 U; 0 Other;
Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 709 ATAGTTTATAAAA 722
Db 2 AUAUUUUUAAAAA 15
RESULT 345
ID ABK01349/c
XX ABK01349 standard; RNA; 17 BP.
XX AC ABK01349;
XX DT 12-MAR-2002 (first entry)
XX DE Human NOGO Inozyme #619.
XX KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
XX KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
XX KW inflammatory arthropathy; central nervous system injury;
XX KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX KW Parkinson's disease; ataxia; Huntington's disease;
XX KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN W0200159103-A2.

```

```

PD 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004273.
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX Claim 88; Page 87; 200pp; English.
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an INOCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more
XX therapies. In particular, the CD20 targeting nucleic acid may be used to
XX treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
XX targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX cell and treat a patient having a condition associated with the level of
XX NOGO. The treatment may further comprise the use of one or more
XX therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX treat central nervous system (CNS) injury and cerebrovascular accident
XX (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The present
XX sequence is an inozyme of the invention
XX SQ Sequence 17 BP; 7 A; 3 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 1.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 674 TGAGAACTGATTT 687
Db 17 TGAGAACTGATTT 4
RESULT 346
ID ABK00484/c
XX ABK00484 standard; RNA; 17 BP.
XX AC ABK00484;
XX

```

DT 12-MAR-2002 (first entry)  
 XX Human NOGO Hammerhead Ribozyme #484.  
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX WO200159103-A2.  
 XX 16-AUG-2001.  
 XX 09-FEB-2001; 2001WO-US004273.  
 XX 11-FEB-2000; 2000US-0181797P.  
 XX 28-FEB-2000; 2000US-0185516P.  
 XX 06-MAR-2000; 2000US-0187128P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX Blatt L, Mcswiggen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 XX central nervous system injury.  
 PS Claim 88; Page 73; 200pp; English.  
 XX The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a hammerhead ribozyme of the invention  
 XX  
 SQ Sequence 17 BP; 6 A; 3 C; 2 G; 0 T; 6 U; 0 Other;  
 Query Match 1.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.5e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 674 TGAGAACTGATTT 687  
 DB 14 TGAGAACTGATTT 1  
 RESULT 347  
 ABK01996/c  
 ID ABK01996 standard; RNA; 17 BP.  
 XX  
 AC ABK01996;  
 XX 12-MAR-2002 (first entry)  
 XX Human NOGO Zinzyme #318.  
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX WO200159103-A2.  
 XX 16-AUG-2001.  
 XX 09-FEB-2001; 2001WO-US004273.  
 XX 11-FEB-2000; 2000US-0181797P.  
 XX 28-FEB-2000; 2000US-0185516P.  
 XX 06-MAR-2000; 2000US-0187128P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX Blatt L, Mcswiggen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 XX central nervous system injury.  
 PS Claim 88; Page 73; 200pp; English.  
 XX The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a zynzyme molecule of the invention  
 CC  
 CC Sequence 17 BP; 6 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.5e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 TCAGAAACTGATTT 687  
 DB 16 TCAGAAACTGATTT 3

RESULT 348  
 ACA08316  
 ID ACA08316 standard; DNA; 17 BP.

XX ACA08316;

DT 03-JUN-2003 (first entry)

XX Necrosis factor kappa B (NFkB) sub-unit modulating DNazyme #85.

KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zynzyme;  
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; lung cancer;  
 KW prostate cancer; colorectal cancer; brain cancer; oesophageal cancer;  
 KW stomach cancer; bladder cancer; pancreatic cancer; cervical cancer;  
 KW head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma;  
 KW multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy;  
 KW paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide;  
 KW doxorubicin; fluorouracil carboplatin; edatrexate; gencitabine;  
 KW radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

OS Synthetic.

XX US2002177568-A1.

PN 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245456.

PR 15-AUG-1994; 94US-00251932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHOMB D T.

PA (MCSW/) MCSWIGGEN J.

XX (DRAP/) DRAPER K G.

PI Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 48; 72pp; English.

CC The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zynzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gencitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity,  
 CC autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury/  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents an enzymatic nucleic acid used to  
 CC modulate the function of a necrosis factor kappa B sub-unit  
 CC  
 CC Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 3.5e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 830 CCCTGTATGGCACT 843

DB 3 CCCUGAUGGCACU 16

RESULT 349

ACA09130

ID ACA09130 standard; RNA; 17 BP.

XX ACA09130;

XX 03-JUN-2003 (first entry)

DT NFkB sub-unit modulating amberzyme substrate #293.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zynzyme;  
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;



KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 OS Homo sapiens.  
 XX US2002177568-A1.  
 XX  
 PD 28-NOV-2002.  
 XX  
 XX 23-MAY-2001; 2001US-00864785.  
 XX  
 XX 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINCHCOMB D T.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (DRAP/) DRAPER K G.  
 XX  
 XX Stinchcomb DT, Mcswiggen J, Draper KG;  
 XX WPI; 2003-340953/32.  
 XX  
 XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX  
 XX Claim 3; Page 57; 72pp; English.  
 XX  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;  
 Query Match 1.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 3.5e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 830 CCTGTATGGCACT 843  
 Db 1 CCCUGAUGGCACU 14  
 RESULT 350  
 ACC40921  
 ID ACC40921 standard; DNA; 20 BP.  
 XX  
 AC ACC40921;  
 XX  
 DT 23-MAY-2003 (first entry)

XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150475.  
 DE  
 XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;  
 KW antinflammatory; amyotrophic lateral sclerosis; apoptosis;  
 KW hyperproliferative disorder; therapy; infection; inflammation; tumour;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages. All cytosines are 5-  
 FT methylcytosine"  
 FT modified\_base 1..5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 FT modified\_base 16..20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
 XX WO2003000707-A2.  
 XX  
 XX 03-JAN-2003.  
 XX  
 XX 19-JUN-2002; 2002WO-US019664.  
 XX  
 XX 21-JUN-2001; 2001US-00898360.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Bennett FC, Dobie K;  
 PI WPI; 2003-184032/18.  
 XX  
 XX Novel antisense compounds targeted to nucleic acids encoding human  
 PT superoxide dismutase 1, for modulating expression of the dismutase and  
 PT treating diseases or conditions, e.g. amyotrophic lateral sclerosis.  
 XX  
 XX Example 15; Page 77; 107pp; English.  
 XX  
 XX The invention relates to a compound of 8-50 nucleobases in length,  
 CC targeted to a nucleic acid molecule encoding human superoxide dismutase  
 CC 1. The compound specifically hybridises with and inhibits the expression  
 CC of human superoxide dismutase 1 by hybridising with at least an 8-  
 CC nucleobase portion of the nucleic acid molecule encoding the active site  
 CC of the enzyme. The activity of compounds of the invention may be  
 CC described as neuroprotective, cytostatic and antiinflammatory. The  
 CC mechanism of action of compounds of the invention is antisense inhibition  
 CC of human superoxide dismutase 1 expression by chimeric phosphorothioate  
 CC oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.  
 CC Compounds of the invention are useful for inhibiting the expression of  
 CC human superoxide dismutase 1 in human cells or tissues, and for treating  
 CC a disease or condition associated with this enzyme (antisense therapy),  
 CC especially amyotrophic lateral sclerosis, a disease or condition arising  
 CC from aberrant apoptosis and a hyperproliferative disorder. It may also be  
 CC used in diagnostics, therapeutics and as a research reagent, e.g.  
 CC prophylactically to prevent or delay infection, inflammation or tumour  
 CC formation. Sequences given in records ACC40880-ACC40957 represent human  
 CC superoxide dismutase 1 antisense inhibitor oligonucleotides  
 XX  
 XX Sequence 20 BP; 8 A; 2 C; 2 G; 8 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.6%; Score 14; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 711 AGTTTATAAACT 724

```

Db      3 AGTTTATAAACT 16
|||||
RESULT 351
ACC40922
ID ACC40922 standard; DNA; 20 BP.
XX
XX ACC40922;
XX
XX 23-MAY-2003 (first entry)
XX
XX Human superoxide dismutase 1 antisense inhibitor # ISIS 150476.
XX
XX Human; superoxide dismutase 1; antisense; neuroprotective; cytostatic;
XX antiinflammatory; amyotrophic lateral sclerosis; apoptosis;
XX hyperproliferative disorder; therapy; infection; inflammation; tumour;
XX ss.
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages. All cytosines are 5-
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003000707-A2.
XX
XX 03-JAN-2003.
XX
XX 19-JUN-2002; 2002WO-US019664.
XX
XX 21-JUN-2001; 2001US-00888360.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Dobie K;
XX
XX WPI; 2003-184032/18.
XX
XX Novel antisense compounds targeted to nucleic acids encoding human
XX superoxide dismutase 1, for modulating expression of the dismutase and
XX treating diseases or conditions, e.g. amyotrophic lateral sclerosis.
XX
XX Example 15; Page 77; 107pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases in length,
XX targeted to a nucleic acid molecule encoding human superoxide dismutase
XX 1. The compound specifically hybridises with and inhibits the expression
XX of human superoxide dismutase 1 by hybridising with at least an 8-
XX nucleobase portion of the nucleic acid molecule encoding the active site
XX of the enzyme. The activity of compounds of the invention may be
XX described as neuroprotective, cytostatic and antiinflammatory. The
XX mechanism of action of compounds of the invention is antisense inhibition
XX of human superoxide dismutase 1 expression by chimeric phosphorothioate
XX oligonucleotides having 2'-methoxyethyl (2'-MOE) wings and a deoxy gap.
XX Compounds of the invention are useful for inhibiting the expression of
XX human superoxide dismutase 1 in human cells or tissues, and for treating
XX a disease or condition associated with this enzyme (antisense therapy),
XX especially amyotrophic lateral sclerosis, a disease or condition arising
XX from aberrant apoptosis and a hyperproliferative disorder. It may also be
XX used in diagnostics, therapeutics and as a research reagent, e.g.

```

---

```

CC prophylactically to prevent or delay infection, inflammation or tumour
CC formation. Sequences given in records ACC40880-ACC40957 represent human
CC superoxide dismutase 1 antisense inhibitor oligonucleotides
XX
XX Sequence 20 BP; 9 A; 2 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 14; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 3.6e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 711 AGTTTATAAACT 724
XX |||||||
XX 6 AGTTTATAAACT 19
XX
XX RESULT 352
XX AAX73200/c
XX ID AAX73200 standard; RNA; 17 BP.
XX
XX AC AAX73200;
XX
XX DT 28-JUL-1999 (first entry)
XX
XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #633.
XX
XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX KW foetal liver kinase 1; ss.
XX
XX OS Mus sp.
XX PN WO9715662-A2.
XX
XX PD 01-MAY-1997.
XX
XX PP 25-OCT-1996; 96WO-US017480.
XX
XX PR 26-OCT-1995; 95US-0005974P.
XX
XX PR 11-JAN-1996; 96US-00584040.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI (CHIR) CHIRON CORP.
XX
XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 143; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX
XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 3.7e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 543 TGTAAGTCGAGGCCCT 559

```

Db 17 TGCAGTCTGAGGTCCT 1

RESULT 353  
AAV96545  
ID AAV96545 standard; RNA; 17 BP.  
XX  
AC AAF04937;  
XX  
AC AAV96545;  
XX  
XX 01-MAR-1999 (first entry)  
DT  
DT  
DE DE Potato citrate synthase target sequence position 858.  
DE  
KW Solanidine; glucosyltransferase; potato; citrate synthase; target;  
KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;  
KW flower formation; cleavage; solanaceous plant; ss.  
XX  
XX Solanum tuberosum.  
OS  
OS  
PN WO9832843-A2.  
PN  
XX  
PD 30-JUL-1998.  
PD  
XX  
XX 14-JAN-1998; 98WO-US000738.  
XX  
XX 28-JAN-1997; 97US-0036545P.  
PR  
PR 28-JAN-1997; 97US-0036599P.  
PR  
PR 24-NOV-1997; 97US-00979416.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
PA  
PI Zwick MG, Mcswiggen JA;  
PI  
DR WPI; 1998-427939/36.  
DR  
XX  
XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid  
PT biosynthesis or regulating flowering.  
PT  
XX  
XX Claim 53; Page 55; 79pp; English.  
XX  
XX The present invention describes enzymatic nucleic acid molecules with RNA  
CC -cleaving activity (e.g. ribozymes) which are capable of modulating the  
CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or  
CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to  
CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and  
CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to  
CC AAV96734 represent potato solanidine glucosyltransferase target  
CC sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent  
CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.  
CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate  
CC synthase target sequences. Ribozymes of the present invention can be used  
CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,  
CC particularly potato but also tomato, pepper, aubergine and ditura or to  
CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,  
CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf  
CC grass. Also the ribozymes can be used for RNA manipulation in the same  
CC way that restriction endonucleases are for DNA, as well as to examine  
CC genetic drift and mutations in plants and to detect specific RNA. The  
CC ribozymes can be targeted to specific genes or to consensus sequences  
CC within a family of related genes, and being catalytic need to be present  
CC at only very low concentrations  
XX  
XX Sequence 17 BP; 4 A; 3 C; 4 G; 0 T; 6 U; 0 Other;  
SQ Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 3.7e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 839 GCACCTTATTATGAGGCT 855  
Db 1 GAACUCUCUUAUGAGGCU 17

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.9%; Pred. No. 3.7e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 839 GCACCTTATTATGAGGCT 855  
Db 1 GAACUCUCUUAUGAGGCU 17

RESULT 354  
AAF04937  
ID AAF04937 standard; DNA; 17 BP.  
XX  
AC AAF04937;  
XX  
AC AAF04937;  
XX  
XX 16-FEB-2001 (first entry)  
DT  
DT  
DE Hammerhead ribozyme substrate #2453.  
DE  
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
XX  
XX Homo sapiens.  
OS  
OS  
PN WO200061729-A2.  
PN  
XX  
XX 19-OCT-2000.  
PD  
PD  
XX  
XX 11-APR-2000; 2000WO-US009721.  
PF  
PF  
XX  
XX 12-APR-1999; 99US-0129390P.  
PR  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
PA  
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;  
PI  
DR WPI; 2000-647423/62.  
DR  
XX  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
PT  
XX  
XX Claim 4; Page 111; 164pp; English.  
XX  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX  
XX Sequence 17 BP; 4 A; 2 C; 4 G; 7 T; 0 U; 0 Other;  
SQ Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 778 TGGGTATTAACTTGTC 794  
Db 1 TGGGTTTTAAACATGTC 17

RESULT 355  
AAF04936  
ID AAF04936 standard; DNA; 17 BP.  
XX  
AC AAF04936;  
XX  
AC AAF04936;  
XX  
XX 16-FEB-2001 (first entry)  
DT  
DT  
DE Hammerhead ribozyme substrate #2452.  
DE  
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
XX  
XX Homo sapiens.  
OS  
OS  
PN WO200061729-A2.  
PN  
XX  
XX

```

PD 19-OCT-2000.
XX
XX
PF 11-APR-2000; 2000WO-US009721.
XX
XX 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor protein,
XX interferon alpha and erythropoietin.
XX
XX Claim 4; Page 111; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
XX molecules that act as inhibitors of the expression of repressor genes
XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
XX Inhibition of the repressors removes prevents inhibition (and
XX consequently increases expression of) genes involved in the production of
XX erythropoietin, granulocyte colony stimulating factor protein and
XX interferon alpha
XX
XX Sequence 17 BP; 5 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 777 ATGGGTATTAACTTGT 793
XX Db 1 ATGGGTTTAAACATG 17
XX
XX RESULT 356
XX AAF04935
XX ID AAF04935 standard; DNA; 17 BP.
XX
XX AC AAF04935;
XX
XX DT 16-FEB-2001 (first entry)
XX
XX DE Hammerhead ribozyme substrate #2451.
XX
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200061729-A2.
XX
XX PD 19-OCT-2000.
XX
XX PF 11-APR-2000; 2000WO-US009721.
XX
XX PR 12-APR-1999; 99US-0129390P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WPI; 2000-647423/62.
XX
XX DR WPI; 2000-647423/62.
XX
XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor protein,
XX interferon alpha and erythropoietin.
XX
XX PS Claim 4; Page 111; 164pp; English.
XX
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX molecules that act as inhibitors of the expression of repressor genes
XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
XX Inhibition of the repressors removes prevents inhibition (and
XX consequently increases expression of) genes involved in the production of
XX erythropoietin, granulocyte colony stimulating factor protein and
XX interferon alpha
XX
XX Sequence 17 BP; 5 A; 1 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 777 ATGGGTATTAACTTGT 793
XX Db 1 ATGGGTTTAAACATG 17
XX
XX RESULT 357
XX ABK01097/c
XX ID ABK01097 standard; RNA; 17 BP.
XX
XX AC ABK01097;
XX
XX DT 12-MAR-2002 (first entry)
XX
XX DE Human NOGO Inozyme #367.
XX
XX KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX OS Homo sapiens.
XX
XX PN WO200159103-A2.
XX
XX PD 16-AUG-2001.
XX
XX PF 09-FEB-2001; 2001WO-US004273.
XX
XX PR 11-FEB-2000; 2000US-0181797P.
XX
XX PR 28-FEB-2000; 2000US-0185516P.
XX
XX PR 06-MAR-2000; 2000US-0187128P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PA (BLAT/) BLATT L.
XX
XX PA (MCSW/) MCSWIGGEN J.
XX
XX PA (CHOW/) CHOWRIRA B M.
XX
XX PI Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX DR WPI; 2001-607195/69.
XX
XX PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX PS Claim 88; Page 83; 200pp; English.
XX
XX CC The invention relates to a nucleic acid molecule which down regulates

```

expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOMO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapeutics. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOMO-targeting nucleic acid is used to cleave RNA of the NOMO. Furthermore, the presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the nucleic acid may be contacted with a cell to reduce NOMO activity of the cell and treat a patient having a condition associated with the level of NOMO. The treatment may further comprise the use of one or more therapeutics. In particular, the NOMO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOMO expression. The present sequence is an inozyme of the invention

XX SQ Sequence 17 BP; 7 A; 3 C; 1 G; 0 T; 6 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 730 AAAATGCTGTTTCAAT 746  
DB 17 AAAATGTTTGTGCAAT 1

RESULT 358  
ABA80297/C  
ID ABA80297 standard; DNA; 17 BP.

XX AC ABA80297;  
XX DT 24-JAN-2002 (first entry)  
XX DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3143.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CTRP; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;  
KW antilipemic; ss.

XX OS Homo sapiens.  
XX PN WO200173002-A2.  
XX PD 04-OCT-2001.  
XX PF 27-MAR-2001; 2001WO-US009761.  
XX PP 27-MAR-2000; 2000US-0192176P.  
XX PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.  
PR 30-OCT-2000; 2000US-0244989P.  
XX PA (UYDE ) UNIV DELAWARE.  
XX PI Kmtc EB, Gamper HB, Rice MC;  
XX WPI; 2001-639230/73.  
XX DR

XX Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical modification.

XX Claim 7; Page 217; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BRCA1, BRCA2, CTRP, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

XX SQ Sequence 17 BP; 7 A; 2 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 676 AGAAACTGATTATGAT 692  
DB 17 AGATACTCATTTATGAT 1

RESULT 359  
ABA80296  
ID ABA80296 standard; DNA; 17 BP.

XX AC ABA80296;  
XX DT 24-JAN-2002 (first entry)  
XX DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3142.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CTRP; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;  
KW antilipemic; ss.

XX OS Homo sapiens.  
XX PN WO200173002-A2.  
XX PD 04-OCT-2001.  
XX PF 27-MAR-2001; 2001WO-US009761.  
XX PP 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX (UYDE ) UNIV DELAWARE.  
 XX  
 XX Kmiec EB, Gamper HB, Rice MC;  
 XX  
 XX WPI; 2001-639230/73.  
 DR  
 XX  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX  
 XX  
 PS Claim 7; Page 217; 294pp; English.  
 XX  
 XX The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CPTA, cyclin-dependent kinase inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX  
 XX Sequence 17 BP; 6 A; 2 C; 2 G; 7 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 676 AGAACTGATTTATGAT 692  
 DB 1 AGTACTGATTTATGAT 17  
 RESULT 360  
 AAF91029/c  
 ID AAF91029 standard; DNA; 17 BP.  
 XX  
 XX AAF91029;  
 AC  
 XX 04-MAY-2001 (first entry)  
 DT  
 XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 116.  
 DE  
 XX Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;  
 KW inflammatory disease; neuronal disease; CNS disease;  
 KW cardiovascular disease; PCR primer; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX WO200109183-A2.  
 FN  
 XX 08-FEB-2001.  
 PD  
 XX 28-JUL-2000; 2000WO-EP007314.  
 PF  
 XX 30-JUL-1999; 99EP-00114938.  
 PR 22-FEB-2000; 2000EP-00103361.  
 XX  
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.  
 PA  
 XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;  
 PI  
 XX

DR WPI; 2001-159855/16.  
 XX  
 XX New polynucleotide encoding a molecular variant Multi Drug Resistance  
 PT (MDR)-1 polypeptide is useful for diagnosing and treating diseases  
 PT associated with abnormal MDR-1 expression or function, e.g. cancer.  
 XX  
 XX Claim 1; Page 101; 154pp; English.  
 PS  
 XX  
 XX The present invention provides nucleotides encoding molecular variants of  
 CC the human multi drug resistance-1 (MDR-1) protein. These can be used to  
 CC identify compounds capable of treating multidrug resistance and  
 CC sensitivity interfering resulting from polymorphisms in MDR-1, which can  
 CC lead to difficulties in treating cancer, cardiovascular, neuronal,  
 CC inflammatory and CNS diseases  
 XX  
 XX Sequence 17 BP; 5 A; 5 C; 3 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 319 GGGCAATGTGACTGCTG 335  
 DB 17 GTGCAATGTAATGCTG 1  
 RESULT 361  
 ABN08968  
 ID ABN08968 standard; DNA; 17 BP.  
 XX  
 XX ABN08968;  
 AC  
 XX 29-MAY-2002 (first entry)  
 DT  
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8960.  
 DE  
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX WO200192524-A2.  
 FN  
 XX 06-DEC-2001.  
 PD  
 XX 25-MAY-2001; 2001WO-US016981.  
 PF  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 XX (ABOM-) ABOMICA INC.  
 PA  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PI WPI; 2002-179446/23.  
 XX  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 PT

XX Disclosure; SEQ ID NO 8960; 214pp; English.

PS The present invention describes a human genome-derived myosin-like

CC protein 1 (hGMDLP-1). The protein and polynucleotide sequences of hGMDLP-1

CC 1 can be used in gene therapy and vaccine production. The hGMDLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGMDLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGMDLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGMDLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGMDLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGMDLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGMDLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGMDLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGMDLP-1, in particular heart

CC and skeletal muscle disorders. hGMDLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGMDLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence

XX

SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 3.7e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGGCGCTGCATGGA 199

DB 1 CTGAAGGCGCGCATGGA 17

RESULT 362

ACN03785

ID ACN03785 standard; RNA; 17 BP.

XX

AC ACN03785;

XX

DT 22-APR-2004 (first entry)

XX

DE WNV Zinzyme substrate SEQ ID NO 3788.

XX

KW WNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

KW Amberzyme; Zinzyme; ss.

XX

OS West Nile Virus.

XX

PN WO200268637-A2.

XX

PD 06-SEP-2002.

XX

PF 19-OCT-2001; 2001WO-US048350.

XX

PR 20-OCT-2000; 2000US-0242411P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGEN J A.

XX

PI Blatt L, Mcswiggen JA;

XX

DR WPI; 2002-706994/76.

XX

XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX

PS Claim 23; SEQ ID NO 3788; 495pp; English.

XX

CC The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37880

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

SQ Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.7e+02;

Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 163 GCGAAGCATTAAAGGAC 179

DB 1 GCGAAGCAGUGAAGGAC 17

RESULT 363

ADB03682

ID ADB03682 standard; DNA; 17 BP.

XX

AC ADB03682;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human MDZ7 scanning oligonucleotide SEQ ID 4668.

XX

KW Cytostatic; immunostimulant; gene therapy; vaccine; human;

KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;

KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

KW developmental disorder; ss.

XX

OS Homo sapiens.

XX

PN EPI281758-A2.

XX

PD 05-FEB-2003.

XX

PF 30-JUL-2002; 2002EP-00016874.

XX

PR 02-AUG-2001; 2001US-00922181.

XX

PA (AEOM-) AEOMICA INC.

XX

PI Shannon M, Gu Y, Nguyen C;

XX

DR WPI; 2003-423107/40.

XX

XX New zinc finger-containing proteins and nucleic acids, useful in

PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MDZ3,

PT MDZ4, MDZ7 or MDZ12, e.g. cancer.

XX

PS Example 8; SEQ ID NO 4668; 103pp; English.

XX

CC The present invention relates to novel human zinc finger-containing

CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is

CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,

CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome

CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,

CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;  
 SQ Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 CTGAGGCCCTTAATC 565  
 Db 1 CTGAGGCCCTCAGCTC 17

## RESULT 364

ACD62281  
 ID ACD62281 standard; RNA; 17 BP.

XX ACD62281;

DT 23-SEP-2003 (first entry)

DE HCV minus strand DNazyme substrate sequence #480.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.

XX Hepatitis C virus.

OS WO200281494-A1.

FN 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

PF 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGGEN J.

PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.

PA (LEEP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

XX WPI; 2003-229207/22.

DR Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus

PT infection.

XX Claim 1; Page 283; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention

SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 3.7e+02;

Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 271 CAGAAACACCGTGGC 287

Db 1 CAGAAACACCGUGGAC 17

## RESULT 365

ADF62659/C

ID ADF62659 standard; DNA; 17 BP.

XX ADF62659;

DT 12-FEB-2004 (first entry)

XX Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 563.

DE chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;  
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;  
 KW human; ss; probe.

XX Homo sapiens.

OS WO2003050284-A1.

FN 19-JUN-2003.

PD 22-NOV-2002; 2002WO-US037506.

PF 10-DEC-2001; 2001US-0339764P.

PR (AMSH ) AMERSHAM BIOSCIENCES SV CORP.

XX Guo J;

PI WPI; 2003-532916/50.

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a  
 CC composition for treating or preventing a disorder associated with  
 CC decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 563; 164pp; English.

XX The invention relates to a novel isolated nucleic acid that encodes a  
 CC protein with a chromatin organisation modifier (CHROMO) domain. The  
 CC polynucleotide of the invention demonstrates cytostatic activity and may  
 CC be useful for preparing a composition for treating or preventing a



CC disorder associated with decreased or increased expression or activity of  
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as  
 CC during gene therapy and vaccine production procedures. The current  
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-  
 CC directed probe of the invention. Note: The current sequence is not shown  
 CC within the specification per se but was retrieved from the Wipoweb  
 CC database.

XX  
 SQ Sequence 17 BP; 8 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 635 TTGTGTGACTTTTTCAG 651  
 ||| |||||  
 Db 17 TTCTGAGACTTTTTCAG 1

RESULT 366  
 ADL51189/c  
 ID ADL51188 standard; RNA; 17 BP.

XX AC ADL51188;

XX DT 20-MAY-2004 (first entry)

XX DE Human PTGDR substrate sequence #307.

XX KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 161; SEQ ID NO 4721; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.

XX SQ Sequence 17 BP; 1 A; 10 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 87 TGCTGAAGGCGACGGC 103  
 ||| |||||  
 Db 17 TCGGAGGCGGAGGGC 1

RESULT 367  
 ADL51187/c  
 ID ADL51187 standard; RNA; 17 BP.

XX AC ADL51187;

XX DT 20-MAY-2004 (first entry)

XX DE Human PTGDR substrate sequence #306.

XX KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 161; SEQ ID NO 4720; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.

XX SQ Sequence 17 BP; 0 A; 9 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GAAGGGCGAGCCGAC 107  
 ||||| ||||| |||||  
 Db 17 GAAGGGCGAGCCGAC 1

# RESULT 368

ADL51536/c  
 ID ADL51536 standard; RNA; 17 BP.

XX AC ADL51536;

DT 20-MAY-2004 (first entry)

XX DE Human PTGDR substrate sequence #655.

XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 KW substrate; ds.

XX OS Unidentified.

XX FN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;

XX DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite

XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 161; SEQ ID NO 5069; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.

XX SQ Sequence 17 BP; 0 A; 9 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 89 CTGAAGGGCGAGCCGCC 105  
 ||||| ||||| |||||  
 Db 17 CGGAAGGGCGAGCCGCC 1

# RESULT 369

ADI85511  
 ID ADI85511 standard; RNA; 17 BP.

XX AC ADI85511;

DT 03-JUN-2004 (first entry)

XX DE HCV DNazyme substrate sequence #2757.

XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 KW HCV infection; type I interferon; DNazyme.

XX OS Hepatitis C virus.

XX PN US2003125270-A1.

XX PD 03-JUL-2003.

XX PF 18-DEC-2000; 2000US-00740332.

XX PR 18-DEC-2000; 2000US-00740332.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (ROBE/) ROBERTS E.

XX PA (PAVC/) PAVCO P A.

XX PA (MACE/) MACEJACK D.

XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX DR WPI; 2004-031273/03.

XX PT Enzymatic nucleic acid molecules which specifically cleave RNA derived

XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,

XX PT especially in combination with type I interferon therapy.

XX PS Claim 1; SEQ ID NO 2757; 198pp; English.

XX CC The invention relates to an enzymatic nucleic acid molecule which  
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
 CC the binding arms of the enzymatic nucleic acid molecule comprises  
 CC sequences complementary to any of the defined substrate sequences given  
 CC in the specification. The nucleic acid molecule may be administered for  
 CC the treatment of HCV infections, especially in combination with type I  
 CC interferons. The present sequence represents a HCV DNazyme substrate  
 CC sequence.

XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 271 CAGAAACACGGTGGGC 287  
 Db 1 CAGAAACACGGTGGGC 17

RESULT 370  
 ACN72058  
 ID ACN72058 standard; DNA; 17 BP.  
 AC ACN72058;  
 XX  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO:8960.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2004137589-A1.  
 PN  
 XX 15-JUL-2004.  
 PD  
 XX 26-NOV-2003; 2003US-00723361.  
 PF  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PR 25-MAY-2001; 2001US-00866108.  
 XX  
 PA (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 PI WPI; 2004-533378/51.  
 XX  
 DR Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 XX Disclosure; SEQ ID NO 8960; Opp; English.  
 PS  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 98% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103  
 XX  
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 183 CTGAAGGCGCTGCATGGA 199  
 Db 1 CTGAAGGCGCATGGA 17

RESULT 371  
 AAT16415/C  
 ID AAT16415 standard; DNA; 18 BP.  
 XX  
 AC AAT16415;  
 XX  
 DT 13-SEP-1996 (first entry)  
 XX  
 DE Primer #2 for sWSS2588 human obesity gene.  
 XX  
 KW Obesity; mouse; OBP; leptin; hormone; body weight regulation; diabetes;  
 KW food intake; energy expenditure; high blood pressure; cholesterol; human;  
 KW gene therapy; antibody; cancer; Kobe beef; Foie gras; immunoassay; PCR;  
 KW primer; amplify; polymerase chain reaction; ss.  
 XX  
 OS Synthetic.  
 XX GB2292382-A.  
 PN  
 XX 21-FEB-1996.  
 PD  
 XX 17-AUG-1995; 95GB-00016947.  
 PF  
 XX 17-AUG-1994; 94US-00292345.  
 PR 30-NOV-1994; 94US-00347563.  
 PR 10-MAY-1995; 95US-00438431.  
 PR 07-JUN-1995; 95US-00483211.  
 XX  
 XX (UYRQ ) UNIV ROCKEFELLER.  
 XX  
 XX Friedman JM, Zhang Y, Proenca R, Maffei M, Halaas JL, Gajiwala K;  
 PI Burley SK;  
 XX WPI; 1996-099009/11.  
 DR  
 XX Obesity polypeptide(s) able to modulate body wt. - useful for e.g.  
 PT reducing wt. in treatment of diabetes, high blood pressure and high  
 PT cholesterol and for cosmetic reasons.  
 XX  
 XX Example 10; Page 142; 304pp; English.  
 PS  
 XX AAT16392-TJ16429 represent amplification primers for the human obesity  
 CC polypeptide (OBP) gene sequence (see AAT16373). These sequences were used  
 CC to amplify the OBP gene sequence from the YAC contig containing the human  
 CC OBP gene, in a series of sequence tagged-site (STS)-specific PCR assays.  
 CC There were 19 STSs found within the YAC contig human OBP gene sequence.  
 CC This sequence was used in conjunction with AAT16414 to amplify the STS  
 CC sWSS2588. OBP has effects on both food intake and energy expenditure. OBP  
 CC and its analogues are useful for modifying body weight (optionally  
 CC combined with known medicaments), for treating diabetes, high blood  
 CC pressure or high cholesterol. The OBP coding sequence (and sequences  
 CC complementary to it) can be used in gene therapy for modifying body  
 CC weight. The protein can be used for reducing weight for health or  
 CC cosmetic reasons in obese humans, or to produce leaner food animals.  
 CC Antagonists of OBP (including antibodies) are useful for increasing body  
 CC weight, e.g. for treating weight loss associated with cancer, or for  
 CC cosmetic reasons in humans, or for production of Kobe beef or Foie gras  
 CC in domestic animals. OBP antibodies (Ab) can also be used in diagnostic  
 CC immunoassays for the presence of OBP. The formation of Ab-OBP complexes  
 CC enables in vitro evaluation of levels of OBP in a sample, especially to

```

CC detect diseases associated with elevated or decreased levels, and to
CC monitor treatment of these diseases
XX
SQ Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;

Query Match          1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAG 468
Db 18 GGTGGAATGTAGAATG 2

RESULT 372
AAV05715/c
ID AAV05715 standard; DNA; 18 BP.
XX
AC AAV05715;
XX
DT 25-MAR-2003 (revised)
DT 09-JUN-1998 (first entry)
XX
XX Maize retinoblastoma gene probe.
DE
XX Maize; retinoblastoma; Rb; EST; expressed sequence tag; p130; probe;
KW hybridisation; plant; cell cycle; geminivirus; replication; ss.
XX
XX Synthetic.
OS Zea mays.
XX WO9747647-A1.
XX
XX 18-DEC-1997.
XX
XX 13-JUN-1996; 96WO-ES000130.
XX
XX 13-JUN-1996; 96WO-ES000130.
XX (CNSJ ) CONSEJO SUPERIOR INVESTIGACIONES CIENTIF.
XX Gutierrez-Armenta C, Xie Q, Pelayo Sanzburgos A, Suarez Lopez P;
XX WPI; 1998-052241/05.
XX
XX Controlling growth of plant cells or plant viruses - by increasing or
XX decreasing levels of retinoblastoma protein, either to inhibit viral
XX growth or to increase intracellular levels of nucleic acids,
XX respectively.
XX
XX Example 1; Page 7; 39pp; Spanish.
XX
XX This sequence is a probe used to screen a cDNA library for the gene
XX encoding the maize retinoblastoma (Rb) protein (AAV05714). The probe
XX corresponds to an expressed sequence tag (EST) sequence which has
XX homology to the maize p130 sequence, especially to bases 1411-1438. The
XX discovery of an Rb protein in plants which is involved in cell cycle
XX progression (specifically transition from G1 to S phase), allows the use
XX of Rb proteins to control plant cell growth. Also, Rb protein interacts
XX with the IXCXE amino acid motif of geminiviruses and thereby prevents
XX viral replication. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 18 BP; 8 A; 4 C; 2 G; 3 T; 0 U; 1 Other;

Query Match          1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 348 TGGCCGATGTGTCATT 364
Db 17 TGATCGATGTGTCATT 1

RESULT 374
AAV85777/c
ID AAV85777 standard; DNA; 18 BP.
XX
AC AAV85777;
XX
DT 08-SEP-1999 (first entry)
XX
XX PCR primer used to amplify Fc gamma receptor R11B gene.
XX
XX Genotype; Fc receptor; disease prognosis; multiple sclerosis;

```

```

RESULT 373
AAV17082/c
ID AAV17082 standard; DNA; 18 BP.
XX
AC AAV17082;
XX
DT 03-JUN-1998 (first entry)
XX
XX Maize retinoblastoma DNA screening oligonucleotide 1.
DE
XX Retinoblastoma protein; Rb; maize; plant virus; cell proliferation;
KW Geminivirus; screening; ss.
XX
XX Synthetic.
OS Zea mays.
XX WO9747745-A1.
XX
XX 18-DEC-1997.
XX
XX 12-JUN-1997; 97WO-EP003070.
XX
XX 13-JUN-1996; 96WO-ES000130.
XX (CNSJ ) CONSEJO SUPERIOR INVESTIGACIONES CIENTIF.
XX Gutierrez-Armenta C, Xie Q, Pelayo Sanzburgos A, Suarez Lopez P;
XX WPI; 1998-052311/05.
XX
XX Novel nucleic acid encoding maize retinoblastoma protein - useful for
XX controlling growth of plant cells and viruses contained within them.
XX
XX Example 1; Page 6; 39pp; English.
XX
XX This oligonucleotide was designed to be complementary to a known sequence
XX of homologue maize of p130 and was used to screen a portion of maize cDNA
XX library. This was used for isolating a DNA that encodes a maize
XX retinoblastoma (Rb) protein. This plant Rb protein has A and B pocket
XX subdomains and a 30-75 percent sequence homology to the human Rb protein.
XX The plant Rb protein is encoded by a recombinant nucleic acid as DNA or
XX cRNA which has one or more characteristics different from animal Rb
XX proteins. One or more sites of this plant Rb protein are altered or
XX deleted, making it more resistant to phosphorylation, and thus to its
XX functionality such as binding to E2F or a similar function. The protein
XX and anti-sense sequences to the encoding nucleic acid can be used to
XX control the proliferation of plant cells and/or plant virus, especially a
XX Geminivirus, within the cell by increasing or decreasing the level or
XX activity of plant Rb protein, especially where the virus binds an Rb
XX protein to release a transcription factor
XX
SQ Sequence 18 BP; 8 A; 4 C; 2 G; 3 T; 0 U; 1 Other;

Query Match          1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 348 TGGCCGATGTGTCATT 364
Db 17 TGATCGATGTGTCATT 1

RESULT 374
AAV85777/c
ID AAV85777 standard; DNA; 18 BP.
XX
AC AAV85777;
XX
DT 08-SEP-1999 (first entry)
XX
XX PCR primer used to amplify Fc gamma receptor R11B gene.
XX
XX Genotype; Fc receptor; disease prognosis; multiple sclerosis;

```

KW myasthenia gravis; diabetes mellitus; cerebrovascular disease;  
KW cardiovascular disease; atherosclerosis; Addison's disease;  
KW allele-specific binder; Fc gamma receptor RIIA; Fc gamma receptor RIIIB;  
KW PCR primer; ss.  
XX  
OS Synthetic.  
XX  
FN WO9932659-A1.  
XX  
XX PD 01-JUL-1999.  
XX  
XX PD 22-DEC-1998; 98WO-GB003872.  
XX  
XX PD 22-DEC-1997; 97GB-00027055.  
PR 02-FEB-1998; 98GB-00002207.  
XX  
XX (UYBE-) STIFTELSEN UNIVERSITETSFORSKNING BERGEN.  
PA (COCK/) COCKBAIN J.  
XX  
XX PI Nyland HI, Myhr K, Vedeler CA;  
XX  
XX WPI; 1999-418943/35.  
XX  
XX Disease prognosis based on Fc receptor genotyping.  
XX  
XX Disclosure; Page 9; 31pp; English.  
XX  
XX The specification describes a method for determining the genotype of a  
CC human or non-human mammal subject for at least one Fc receptor for  
CC disease prognosis. The method involves determining the genotype of a  
CC human or non-human mammal subject for at least one Fc receptor, and  
CC identifying whether the determined genotype corresponds to a benign or  
CC non-benign prognosis for a disease selected from multiple sclerosis,  
CC myasthenia gravis, diabetes mellitus, cerebrovascular and cardiovascular  
CC diseases, atherosclerosis and Addison's disease. An Fc receptor allele-  
CC specific binder is useful for manufacture of a composition for use in a  
CC method of prognosis, prophylaxis or therapy of a disease chosen from  
CC multiple sclerosis, myasthenia gravis, diabetes mellitus, cerebrovascular  
CC and cardiovascular diseases, atherosclerosis and Addison's disease. In  
CC particular, the Fc receptors are Fc gamma receptors RIIA and/or RIIIB.  
CC The present sequence represents a PCR primer used in the method of the  
CC invention  
XX  
XX Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 229 AGCAGGCTGTACCACTG 245  
Db 17 AGCAGGCTGTACCACTG 1  
RESULT 375  
AAC62610/c  
ID AAC62610 standard; DNA; 18 BP.  
XX  
XX AAC62610;  
XX  
DT 01-FEB-2001 (first entry)  
XX  
XX Human OB gene sequence tagged-site-specific PCR primer #24.  
DE Human; mouse; OB gene; obesity; adiposity; body weight; PCR primer; ss.  
KW Homo sapiens.  
XX  
XX US6124448-A.  
FN  
XX PD 26-SEP-2000.  
XX  
XX 07-JUN-1995; 95US-00488208.  
PF

XX 17-AUG-1994; 94US-00292345.  
PR 30-NOV-1994; 94US-00347563.  
XX 10-MAY-1995; 95US-00438431.  
XX (UYRQ) UNIV ROCKEFELLER.  
XX  
XX Maffei M, Proenca R, Zhang Y, Friedman JM;  
XX WPI; 2000-601556/57.  
XX  
XX Nucleic acid primers and probes useful for detecting mutations in  
PT mammalian OB gene associated with regulation of body weight and  
PT adiposity.  
XX  
XX Example 10; Col 80; 153pp; English.  
XX  
XX The present sequence is a PCR primer which was used in an invention  
CC relating to the control of body weight of animals including humans.  
CC Nucleic acids of at least 10 nucleotides which are hybridisable to a non-  
CC coding region of an OB nucleic acid have been created. The OB gene plays  
CC a critical role in the regulation of body weight and adiposity. The  
CC nucleic acids may be used as probes or as primers for PCR. They are  
CC useful for evaluating the presence of mutations in the human OB gene or  
CC for evaluating the level of expression of OB mRNA. Defects associated  
CC with OB gene expression result in obese phenotypes  
XX  
XX Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 1.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 452 GGTGGAATGAGAAAG 468  
Db 18 GGTGGAATGAGAAAG 2  
RESULT 376  
AAA86600/c  
ID AAA86600 standard; DNA; 18 BP.  
XX  
XX AAA86600;  
XX  
XX 04-DEC-2000 (first entry)  
XX  
XX Cdc 2 kinase hammerhead ribozyme recognition site #31.  
DE  
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
XX  
XX Mammalia.  
XX  
XX WO200032765-A2.  
XX  
XX 08-JUN-2000.  
XX  
XX 06-DEC-1999; 99WO-US028772.  
XX  
XX 04-DEC-1998; 98US-0110954P.  
XX  
XX (IMMU-) IMMUSOL INC.  
XX  
XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
XX WPI; 2000-412314/35.  
XX  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX Example 1; Page 18; 109pp; English.  
XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC

CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AAA02415 to AAA86787. The ribozyme of the invention is useful for  
 CC inhibiting retinoblastoma by introduction of the ribozyme into cells. The  
 CC ribozyme is resistant to endonuclease activity and hence is efficient in  
 CC retinoblastoma treatment  
 XX  
 SQ Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 22 TTGAGTCTCTGGAAAC 38  
 ||||| |||||  
 Db 18 TTGAGTCTAGGAAC 2  
 ||||| |||||  
 RESULT 377  
 AAA38349  
 ID AAA38349 standard; DNA; 18 BP.  
 XX  
 AC AAA38349;  
 XX  
 DT 21-AUG-2000 (first entry)  
 XX  
 DE Human Ets-2 phosphorothioate antisense oligonucleotide, SEQ ID NO:8.  
 XX  
 KW Ets-2; human; transcription factor; chromosome 21q22.3; cancer; invasion;  
 KW metastasis; skeletal abnormality; Down's syndrome; expression inhibition;  
 KW phosphorothioate; antisense; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6054316-A.  
 XX  
 PD 25-APR-2000.  
 XX  
 PF 25-JUN-1999; 99US-00344579.  
 XX  
 PR 25-JUN-1999; 99US-00344579.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Baker BF, Cowsett LM;  
 XX  
 WPI; 2000-338495/29.  
 XX  
 DR Antisense compound, 8-30 nucleobases in length, inhibiting the expression  
 PT Ets-2 is useful for treating cancer and detecting Ets-2 expression.  
 XX  
 PS Example 15; Col 39; 31pp; English.  
 XX  
 CC Sequences AAA38349-A38388 represent antisense oligonucleotides targetted  
 CC to the human Ets-2 gene, which inhibit its expression. The antisense  
 CC oligonucleotides were designed to target different regions of the human  
 CC Ets-2 RNA, and were analysed for their effect on Ets-2 mRNA levels by  
 CC quantitative real-time PCR. The Ets-domain transcription factors are a  
 CC family of proteins which are involved in controlling key cellular events  
 CC such as proliferation, differentiation and development. The Ets domain is  
 CC a DNA-binding domain shared by all members of this family. Through this  
 CC motif, Ets family members bind to the promoter regions of various genes  
 CC at a GCA consensus sequence, thereby acting as either repressors or  
 CC activators of the gene. All but one Ets family protein bind to DNA as a  
 CC monomer. Ets-2 has been implicated in the regulation of cellular  
 CC proliferation and differentiation. The Ets-2 gene is located at  
 CC chromosome 21q22.3, which is within a region known to undergo  
 CC translocations associated with malignancies. Ets-2 has been found to be  
 CC upregulated in several cancers, including lymphoblastic leukaemia. It may  
 CC also play a role in the cancer phenotype, as it activates the urokinase  
 CC plasminogen activator (uPA) promoter and the promoters of  
 CC metalloproteinases in response to epidermal growth factor (EGF)

CC stimulation. High levels of uPA and metalloproteinases are associated  
 CC with tumour invasion and metastasis in breast cancers. As the Ets-2 gene  
 CC is located on chromosome 21, which is triplicated in Down's syndrome, it  
 CC is also thought to be responsible for the skeletal abnormalities present  
 CC in this condition. The antisense oligonucleotides of the invention are  
 CC useful for the treatment or prophylaxis of conditions associated with Ets  
 CC -2 expression, especially cancer  
 XX  
 SQ Sequence 18 BP; 3 A; 3 C; 11 G; 1 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 98 GACGCCCGAGTGCAGGG 114  
 ||||| |||||  
 Db 2 GACGCCCGAGTGCAGGG 18  
 ||||| |||||  
 RESULT 378  
 AAA12332/c  
 ID AAA12332 standard; DNA; 18 BP.  
 XX  
 AC AAA12332;  
 XX  
 DT 18-AUG-2000 (first entry)  
 XX  
 DE Human OB DNA PCR primer SWS2588 #2.  
 XX  
 KW OB gene; body weight; obesity; anorectic; adipose tissue; brain; human;  
 KW PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6048837-A.  
 XX  
 PD 11-APR-2000.  
 XX  
 PF 07-JUN-1995; 95US-00485942.  
 XX  
 PR 17-AUG-1994; 94US-00292345.  
 PR 30-NOV-1994; 94US-00347563.  
 PR 10-MAY-1995; 95US-00438431.  
 XX  
 PA (UVRQ ) UNIV ROCKEFELLER.  
 XX  
 PI Proenca R, Zhang Y, Friedman JW;  
 XX  
 WPI; 2000-302788/26.  
 XX  
 PT Modifying body weight of an animal comprises administering mammalian  
 PT obesity polypeptide obtained from humans and murine.  
 XX  
 PS Example 10; Col 143-144; 153pp; English.  
 XX  
 CC This invention describes a novel method for modifying body weight of an  
 CC animal which comprises administering mammalian obesity (OB) polypeptide.  
 CC The products of the invention have anorectic activity. The OB polypeptide  
 CC at a dose of 5 mg/g/day in 300 micro litres of PBS was injected  
 CC intraperitoneally into mice. Control mice were injected with PBS  
 CC dialysate of the recombinant protein. The body weight of the mice was  
 CC noted. The results shows that recombinant the OB polypeptide is capable  
 CC of reducing a body weight and is found to be effective when it is  
 CC administered daily. The OB polypeptide acts as a part of the signalling  
 CC pathway by which adipose tissue communicates with the brain and other  
 CC organs. (I) is useful for modulating body weight of an animal especially  
 CC humans. This sequence represents a PCR primer used in the amplification  
 CC of a human OB protein described in the method of the invention  
 XX  
 SQ Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 452 GGTGGAATGAAGAAAG 468
DB 18 GGTGGAATGTAGAATG 2

RESULT 379
AAZ51716
ID AAZ51716 standard; DNA; 18 BP.
XX
AC AAZ51716;
XX
XX
DT 04-JUL-2000 (first entry)
XX
DE Burkholderia cepacia recA universal forward primer BCRU1*.
XX
KW recA gene; speciation; Burkholderia cepacia complex; vaccine; flagellin;
KW cystic fibrosis; chronic granulomatous disease; biocontrol strain;
KW agricultural application; identification; bacteria; PCR primer;
KW universal primer; ss.
XX
OS Burkholderia cepacia.
XX
XX WO200014274-A1.
XX
XX 16-MAR-2000.
XX
XX 03-SEP-1999; 99WO-CA000813.
XX
PR 03-SEP-1998; 98US-0099115P.
PR 03-SEP-1998; 98US-0099116P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Mahenthiralingam B;
XX
XX WPI; 2000-257013/22.
XX
XX Methods and reagents for the speciation of Burkholderia cepacia complex
XX bacteria implicated in infections of cystic fibrosis patients.
XX
XX Claim 7; Page 22; 47pp; English.
XX
CC The patent discloses method for identification and speciation of bacteria
CC of the Burkholderia cepacia complex based on the detection of sequence
CC variation within the recA gene. Speciation of the bacteria can be used as
CC a basis for administration of vaccine specific to the flagellin of
CC bacteria as it is known that flagellin is conserved across members of
CC Genomovar III, subgroup RG-B. The method helps in detecting the species
CC of B. cepacia complex that cause problematic infections in patients with
CC cystic fibrosis, chronic granulomatous disease and vulnerable
CC hospitalised patients. Speciation can also be a basis for the selection
CC and/or isolation of industrially useful bacterial species that can be
CC used as biocontrol strains in agricultural applications. The present
CC sequence is a universal forward primer BCRU1* used for PCR amplification
CC of the recA gene of B. cepacia complex. Based on the sequence information of
CC the recA gene, identification and speciation of bacteria of the
CC Burkholderia cepacia complex is carried out
XX
SQ Sequence 18 BP; 2 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 87 TCGTGAAGCGCACGC 103
DB 1 TCGGTATGGCGCACGC 17

RESULT 380
AAC62690/c
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 452 GGTGGAATGAAGAAAG 468
DB 18 GGTGGAATGTAGAATG 2

RESULT 381
AAH61766/c
ID AAH61766 standard; DNA; 18 BP.
XX
AC AAH61766;
XX
XX 10-SEP-2001 (first entry)
XX
DE Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4190.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
```

```
ID AAC62690 standard; DNA; 18 BP.
XX
AC AAC62690;
XX
DT 01-FEB-2001 (first entry)
XX
DE Human OB gene sequence tagged-site-specific PCR primer #24.
XX
KW Human; mouse; anabolic; cytostatic; immunostimulant;
KW OB polypeptide inhibitor; body weight; obesity; OB gene; cancer; AIDS;
KW anorexia nervosa; hypertension; heart disease; Type II diabetes;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
XX US6124439-A.
XX
XX 26-SEP-2000.
XX
XX 07-JUN-1995; 95US-00488214.
XX
XX 17-AUG-1994; 94US-00292345.
XX 30-NOV-1994; 94US-00347563.
XX 10-MAY-1995; 95US-00438431.
XX
XX (UYRQ) UNIV ROCKEFELLER.
XX
XX Proenca R, Zhang Y, Friedman JM;
XX WPI; 2000-611018/58.
XX
XX Novel antibody to mammalian obesity polypeptide useful for diagnosis and
XX treatment of weight loss associated with disorders such as cancer, AIDS
XX and anorexia nervosa.
XX
XX Example 10; Col 80; 150pp; English.
XX
CC The present sequence is a PCR primer which was used in an invention
CC relating to the control of body weight of animals including humans.
CC Antibodies against the mammalian obesity (OB) polypeptide have been
CC identified. The antibodies are useful for modulating the activity of OB
CC to control body weight and fat content and/or to treat certain
CC pathological conditions in which there is abnormal depression or
CC elevation of body weight. The antibodies are used to treat weight loss
CC associated with cancer, AIDS and anorexia nervosa. They are useful for
CC the diagnosis of nutritional disorders such as obesity and diseases
CC associated with obesity, such as hypertension, heart disease and Type II
CC diabetes. The kits are used to determine the presence or amount of OB in
CC the blood or plasma of an individual
XX
SQ Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 452 GGTGGAATGAAGAAAG 468
DB 18 GGTGGAATGTAGAATG 2

RESULT 381
AAH61766/c
ID AAH61766 standard; DNA; 18 BP.
XX
AC AAH61766;
XX
XX 10-SEP-2001 (first entry)
XX
DE Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4190.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
```

KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX  
 PN WO200130362-A2.  
 XX  
 PD 03-MAY-2001.  
 XX  
 XX 26-OCT-2000; 2000WO-US029500.  
 XX  
 PF 26-OCT-1999; 99US-0161532P.  
 XX  
 PR (IMMU-) IMMUSOL INC.  
 XX  
 PA Robbins JM, Tritz R;  
 XX  
 PI WPI; 2001-300427/31.  
 XX  
 DR Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
 XX  
 PS Disclosure; Page 378; 48pp; English.  
 XX  
 CC The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,  
 CC ophthalmological, vulnary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAHS577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 22 TTGCAGTCTCGGAACC 38  
 Db 18 TTGCAGTACTAGGAACC 2  
 ||||| |||||  
 RESULT 382  
 ABX89564/c  
 ID ABX89564 standard; DNA; 18 BP.  
 XX  
 AC ABX89564;  
 XX  
 DT 08-MAY-2003 (first entry)  
 XX  
 DE Human sequence tagged specific PCR primer.  
 XX

KW ss; human; obese polypeptide; body weight; PCR; ob polypeptide; leptin;  
 KW adipocyte; appetite reduction; cosmetic; primer; fat deposit reduction;  
 KW improved body appearance; heart disease; obesity; agricutlure;  
 KW nutritional disorder; cancer associated weight loss; type II diabetes;  
 KW obesity associated disease; AIDS associated weight loss; hypertension;  
 KW gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002107211-A1.  
 XX  
 PD 08-AUG-2002.  
 XX  
 PF 13-DEC-2000; 2000US-00736084.  
 XX  
 PR 07-JUN-1995; 95US-00485943.  
 XX  
 XX (UVRQ ) UNIV ROCKEFELLER.  
 XX  
 PI Friedman JM, Halaas JL, Gajiwala K, Burley SK, Zhang Y;  
 PI Proenca R, Maffei M;  
 XX  
 XX WPI; 2002-722695/78.  
 DR  
 XX  
 PT New obese polypeptide useful for inducing reduction of body weight in an  
 PT animal, for preparing a composition for treating obesity, disease  
 PT associated with obesity such as hypertension, heart disease or type II  
 PT diabetes.  
 XX  
 PS Disclosure; Page 76; 144pp; English.  
 XX  
 CC The invention relates to an obese (ob) polypeptide, also known as leptin,  
 CC expressed predominantly by adipocytes and capable of inducing reduction  
 CC of body weight in an animal. The polypeptide is useful for monitoring  
 CC therapeutic treatment of a disease associated with elevated or decreased  
 CC levels of ob polypeptide in a mammalian subject; for use in  
 CC radioimmunoassays for measuring fat and/or plasma levels of ob protein or  
 CC for detecting the presence and level of receptor for ob on tissues, such  
 CC as hypothalamus; for screening expression libraries to isolate active  
 CC receptors; for use in cosmetics by improving body appearance by reducing  
 CC fat deposits or appetite or both and is used independently or in  
 CC conjugation with other cosmetic strategies e.g. surgery for its cosmetic  
 CC effect; for identifying agonists or antagonists that affect its activity  
 CC and has potential agricultural uses e.g. increasing the body weight of  
 CC animals. Nucleic acid encoding the polypeptide is useful for identifying  
 CC mutation in ob nucleotide, in gene therapy for obesity and in the  
 CC measurement of its encoded RNA and protein in nutritional disorders. A  
 CC host cell transfected with a vector expressing the polypeptide is useful  
 CC in the preparation of modulators of the polypeptide and its nucleic acid.  
 CC An immunogenic fragment of the polypeptide is useful for preparing an  
 CC antibody. The antibody is useful for measuring the presence of the  
 CC polypeptide in a sample; for evaluating the level of ob polypeptide in a  
 CC biological sample to detect or diagnose the presence of a disease  
 CC associated with elevated or decreased levels of ob polypeptide in a  
 CC mammalian subject; for imaging ob polypeptide in situ. A composition  
 CC comprising the polypeptide is useful for reducing body weight of an  
 CC animal, in particular humans. A composition comprising an antagonist of  
 CC the polypeptide is useful for increasing body weight of an animal.  
 CC Compositions containing the polypeptide and the antagonist are useful for  
 CC treating obesity, weight loss associated with cancer or AIDS, disease  
 CC associated with obesity such as hypertension, heart disease or type II  
 CC diabetes. The present sequence represents a human sequence tagged  
 CC specific PCR primer  
 XX  
 SQ Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 452 GGTGGAAATGAAGAAAG 468  
 Db 18 GGTGGAAATGTAGATG 2  
 ||||| |||||  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;



```

RESULT 383
ABL61438/c
ID ABL61438 standard; DNA; 18 BP.
XX
XX ABL61438;
AC
XX
XX
DT 16-OCT-2002 (first entry)
XX
DE Human Ob gene STS sWS2588 PCR primer #2.
XX
KW Ob; human; obese; adiposity; body weight; anorectic; anabolic; PCR;
KW primer; chromosome 7; STS; sequence tagged site; 7q31.3;
KW microsatellite marker; ss.
XX
OS Homo sapiens.
XX
XX US6350730-B1.
PN
XX
XX 26-FEB-2002.
PD
XX
XX 07-JUN-1995; 95US-00488223.
PF
XX
XX 17-AUG-1994; 94US-00292345.
PR
XX 30-NOV-1994; 94US-00347563.
PR
XX 10-MAY-1995; 95US-00438431.
XX
XX (UYRQ ) UNIV ROCKEFELLER.
PA
XX Friedman JM, Zhang Y, Proenca R;
PI
XX WPI; 2002-412914/44.
DR
XX
XX Modifying the body weight of an animal comprises administering an obese
PT gene (OB) polypeptide analog.
PT
XX
XX Example 10; Col 79-80; 152pp; English.
PS
XX
XX This invention describes a novel method of modifying the body weight of
CC an animal comprising administering an obese gene (OB) polypeptide
CC analogue, capable of modulating body weight and adiposity. The invention
CC has anorectic and anabolic activity. ABL61415-ABL61468 represent PCR
CC primers used in the detection of sequence tagged sites (STS's) and
CC microsatellite markers used in the mapping of the human Ob gene onto
CC chromosome 7. These genetic markers represent an important tool for
CC studying the possible role of the Ob gene in inherited forms of human
CC obesity
XX
XX
XX Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAGAAAG 468
DB 18 GGTGGAATGAGAAAG 2
|||||
|

RESULT 384
ABZ10441
ID ABZ10441 standard; DNA; 18 BP.
XX
XX ABZ10441;
AC
XX
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #581.
XX
KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.

```

```

XX Homo sapiens.
OS Synthetic.
XX
XX WO200277272-A2.
PN
XX
XX 03-OCT-2002.
PD
XX
XX 26-MAR-2002; 2002WO-EP003401.
PF
XX
XX 26-MAR-2001; 2001US-0278333P.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwöpe I, Ziebarth H;
XX
XX WPI; 2003-018942/01.
DR
XX
XX Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
XX Claim 15; Page 43; 117pp; English.
PS
XX
XX The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
XX
XX Sequence 18 BP; 3 A; 1 C; 7 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 487 TGGAAAGTCGTTGGCTT 503
DB 2 TGGAAAGCGTTGGATT 18
|||||
|

RESULT 385
ABX96424/c
ID ABX96424 standard; DNA; 18 BP.
XX
XX ABX96424;
AC
XX
XX 13-MAY-2003 (first entry)
DT
XX
XX Human obese (ob) gene associated PCR primer #24.
DE
XX
XX OB polypeptide; obese polypeptide; leptin; body weight; obesity;
KW weight gain; protein therapy; weight loss; cancer; AIDS; human;

```

KW acquired immunodeficiency syndrome; anorexia nervosa; PCR; primer; ss.  
 XX Unidentified.  
 OS US6471956-B1.  
 PN XX  
 XX 29-OCT-2002.  
 PD XX  
 XX 07-JUN-1995; 95US-00489225.  
 XX PF  
 XX 17-AUG-1994; 94US-00292345.  
 PR PR  
 XX 20-NOV-1994; 94US-00347563.  
 PR PR  
 XX 10-MAY-1995; 95US-00438431.  
 XX XX  
 PA (UYRQ ) UNIV ROCKEFELLER.  
 XX XX  
 XX Friedman JM, Zhang Y, Proenca R;  
 PI PI  
 XX WPI; 2003-298093/29.  
 XX XX  
 XX New human or mouse OB polypeptide, also referred to as leptin  
 PT polypeptide, which is capable of modulating body weight, useful for  
 PT treating obesity.  
 PT PT  
 XX Example 10; Col 79-80; 153pp; English.  
 PS PS  
 XX The invention describes an OB (obese) polypeptide (also referred as  
 CC leptin) (I), capable of modulating body weight, comprising amino acids 22  
 CC - 167 of a human or mouse OB polypeptide sequence of 167 amino acids  
 CC (S1), given in the specification, or amino acids 22 - 166 a human or  
 CC mouse OB polypeptide sequence of 166 amino acids (S2), given in the  
 CC specification. The OB polypeptide is useful for reducing body weight in  
 CC conditions of obesity, and as a target for neutralising antibodies which  
 CC results in weight gain (protein therapy), for treating weight loss  
 CC associated with cancer, acquired immunodeficiency syndrome (AIDS) or  
 CC anorexia nervosa. This sequence represents a primer associated with the  
 CC isolation of the human obese (ob) or leptin gene  
 XX XX  
 SQ Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02; Mismatches 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0;  
 QY 452 GGTGGAATGTAGAAG 468  
 DB 18 GGTGGAATGTAGAATG 2  
 RESULT 386  
 ADC69987  
 ID ADC69987 standard; DNA; 18 BP.  
 XX AC  
 AC ADC69987;  
 XX XX  
 DT 18-DEC-2003 (first entry)  
 XX XX  
 DE Primer oligo used for analysing CpG islands in genomic DNA (SeqID 476).  
 KW PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;  
 KW adenocarcinoma; squamous cell carcinoma; cytosstatic; probe; PNA-oligomer;  
 KW cytosine methylation state.  
 XX XX  
 OS Unidentified.  
 OS OS  
 PN WO2003052135-A2.  
 XX XX  
 PD 26-JUN-2003.  
 XX XX  
 PF 10-DEC-2002; 2002WO-EP014026.  
 XX XX  
 PR 14-DEC-2001; 2001DE-01061625.  
 XX XX

PA (EPIG-) EPIGENOMICS AG.  
 XX Burger M, Field JK, Genc B, Liloglou T, Lipscher E, Maier S;  
 PI Nimmrich I;  
 XX WPI; 2003-533029/50.  
 XX XX  
 PT Detecting and differentiating cytosine methylation state of genomic DNA,  
 PT useful for diagnosing, treating prognosticating and/or monitoring lung  
 PT cell proliferative disorders e.g. adenocarcinoma and squamous cell  
 PT carcinoma.  
 XX PS  
 PS Claim 15; SEQ ID NO 476; 58pp; English.  
 XX XX  
 CC This invention relates to a novel method for detecting and  
 CC differentiating between lung cell proliferative disorders associated with  
 CC at least one gene and/or their regulatory regions. Specifically, it  
 CC refers to a method comprising contacting a target nucleic acid in a  
 CC biological sample with at least one reagent, wherein the reagent is able  
 CC to distinguish between methylated and non-methylated CpG dinucleotides  
 CC present in the target DNA. As such, it is possible to further  
 CC differentiate and diagnose medical conditions including adenocarcinoma  
 CC and squamous cell carcinoma, and their respective adjacent lung tissue.  
 CC The present invention describes cytosstatic oligomers and PNA-oligomers  
 CC that are useful as probes for determining the cytosine methylation state  
 CC or single nucleotide polymorphisms (SNPs) of the target sequence. This  
 CC oligonucleotide sequence is a primer oligomer used for the analysis of  
 CC CpG positions within genomic DNA, used in an exemplification of the  
 CC invention.  
 XX SQ  
 SQ Sequence 18 BP; 3 A; 1 C; 7 G; 7 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02; Mismatches 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0;  
 QY 487 TGGAAAGTCGTTGGCTT 503  
 DB 2 TGGAAAGCGTTTGATT 18  
 RESULT 387  
 ADE84339  
 ID ADE84339 standard; DNA; 18 BP.  
 XX AC  
 AC ADE84339;  
 XX XX  
 DT 29-JAN-2004 (first entry)  
 XX XX  
 DE Human lymphoid cell proliferative disorder gene CpG analysis oligo #45.  
 XX KW  
 KW lymphoid cell proliferative disorder; methylation;  
 KW methylated CpG dinucleotide; single nucleotide polymorphism; SNP;  
 KW diffuse large B-cell lymphoma; mantle cell lymphoma;  
 KW chronic lymphocytic leukemia; small lymphocytic lymphoma;  
 KW follicular lymphoma; diagnosis; prognosis; primer; ss.  
 XX XX  
 OS Homo sapiens.  
 OS OS  
 PN WO2003044226-A2.  
 XX XX  
 PD 30-MAY-2003.  
 XX XX  
 PF 25-NOV-2002; 2002WO-EP013265.  
 XX XX  
 PR 23-NOV-2001; 2001DE-01057491.  
 PR 28-DEC-2001; 2001DE-01064501.  
 XX XX  
 PA (EPIG-) EPIGENOMICS AG.  
 XX Burger M, Caldwell C, Genc B, Becker E, Maier S, Nimmrich I;  
 PI WPI; 2003-457621/43.  
 XX XX



DR WPI; 2003-756772/71.  
 XX  
 PT Determining a sequence of a locus of interest comprises replicating a  
 PT region of DNA comprising a locus of interest from a template  
 PT polynucleotide by using a first and a second primer.  
 XX  
 PS Example 5; Page 137; 190pp; English.  
 XX  
 CC The invention relates to a novel method for determining the sequence of a  
 CC locus of interest which comprises replicating a region of DNA comprising  
 CC a locus of interest from a template polynucleotide by using a first and a  
 CC second primer where the second primer contains a sequence that generates  
 CC a recognition site for a restriction enzyme such that that digestion with the  
 CC restriction enzyme generates a 5' overhang containing the locus of  
 CC interest. The method may be useful for determining the sequences of  
 CC multiple loci of interest concurrently and for determining the sequence  
 CC of a mutant allele in the presence of a normal allele. The current  
 CC sequence is that of the human APC (adenomatous polyposis coli) DNA  
 CC fragment of the invention which is located on chromosome 5q21-22 and in  
 CC which mutations are associated with colorectal cancer.  
 XX  
 SQ Sequence 18 BP; 7 A; 3 C; 1 G; 7 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 781 GTATTAAACTTGTCTGCA 797  
 DB 17 GTATTAAATTTGTCTGA 1  
 RESULT 390  
 ADR97900/C  
 ID ADR97900 standard; DNA; 18 BP.  
 XX  
 AC ADR97900;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human APC DNA fragment containing deletion at codon 811.  
 XX  
 KW ds; chromosomal abnormality; detection; foetus; translocation;  
 KW transversion; monosomy; trisomy; aneuploidy; deletion; addition;  
 KW amplification; prenatal diagnosis; SNP; single nucleotide polymorphism;  
 KW human; chromosome 5q21-22; adenomatous polyposis coli; mutation.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO2004079011-A1.  
 XX  
 PD 16-SEP-2004.  
 XX  
 PF 29-AUG-2003; 2003WO-US027308.  
 XX  
 PR 28-FEB-2003; 2003WO-US006198.  
 XX  
 PA (RAVG-) RAVGEN INC.  
 XX  
 PI Dhallan R;  
 XX  
 DR WPI; 2004-677127/66.  
 XX  
 PT Detecting a chromosomal abnormality, e.g. translocations, transversions,  
 PT monosomies, trisomies, aneuploidies, deletions, or arrangements, comprises  
 PT determining the sequence of alleles of a locus of interest in the sample  
 PT from template DNA.  
 XX  
 PS Example 7; Page 150; 429pp; English.  
 XX  
 CC This invention describes a novel method for detecting a chromosomal  
 CC abnormality in a sample which comprises determining the sequence of

CC alleles of a locus of interest in a sample from template DNA where  
 CC determining the sequence of the alleles comprises amplifying the locus of  
 CC interest, hybridising the amplified loci to GeneChip array, washing  
 CC GeneChip array, staining the GeneChip array with detectable reagents, and  
 CC scanning GeneChip array. The amplification method is self-sustained  
 CC sequence reaction, ligase chain reaction, rapid amplification of cDNA  
 CC ends, PCR and ligase chain reaction, Q-beta phage amplification, strand  
 CC displacement amplification, or splice overlap extension PCR, preferably  
 CC PCR. The determination of the sequence of the alleles comprises  
 CC amplifying the locus of interest, fragmenting the amplicon, hybridising  
 CC fragmented amplicons to CodeLink Arrays, extension reaction to  
 CC incorporate a nucleotide and detecting incorporated nucleotides. The  
 CC amplicon fragmentation is by exonuclease digestion. Detecting a  
 CC chromosomal abnormality in a sample comprises determining the sequence of  
 CC alleles of a locus of interest from template DNA, where determining the  
 CC sequence of the alleles comprises using BeadArray Technology. The  
 CC determination of the sequence of the alleles may also be done by  
 CC amplifying the locus of interest, dephosphorylation of the unused  
 CC reagents, in vitro transcription reaction of the products, RNase A  
 CC cleavage of the products, mixing the products with CleanResin,  
 CC transferring products to SpectroCHIP, and analysing the SpectroCHIP. The  
 CC dephosphorylation reaction is with shrimp alkaline phosphatase.  
 CC Alternatively, the determination of the sequence of the alleles comprises  
 CC amplifying the locus of interest, dephosphorylation of the unused  
 CC reagents, hybridising a primer to the locus of interest, incorporating a  
 CC nucleotide, mixing the products with CleanResin, transferring products to  
 CC SpectroCHIP, and analysing the SpectroCHIP. The hybridisation of primer  
 CC is adjacent to the locus of interest. The determination of the sequence  
 CC of the alleles may also comprise amplifying the locus of interest,  
 CC treating the products with exonuclease, single stranded DNA is annealed  
 CC to an oligonucleotide, incorporating a nucleotide using the annealed  
 CC template and primer, and detecting the incorporated nucleotide. The  
 CC method is useful for detecting a chromosomal abnormality in a sample.  
 CC Specifically, the method is useful for detecting chromosomal  
 CC abnormalities in a fetus including translocations, transversions,  
 CC monosomies, trisomies, and other aneuploidies, deletions, additions,  
 CC amplifications, and arrangements. The method of the invention can also be  
 CC used for prenatal diagnosis. This sequence represents a fragment of the  
 CC human adenomatous polyposis coli (APC) gene which contains a nucleotide  
 CC deletion.  
 XX  
 SQ Sequence 18 BP; 7 A; 3 C; 1 G; 7 T; 0 U; 0 Other;  
 Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 3.7e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 781 GTATTAAACTTGTCTGCA 797  
 DB 17 GTATTAAATTTGTCTGA 1  
 RESULT 391  
 ADS08584/C  
 ID ADS08584 standard; DNA; 18 BP.  
 XX  
 AC ADS08584;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human DNA oligonucleotide #73.  
 XX  
 KW Human; nucleic acid detection; cell lysis; chromosomal abnormality;  
 KW cancer; carcinoma; bladder; breast; bronchus; colon; kidney; liver; lung;  
 KW oesophagus; gall bladder; ovary; pancreas; stomach; cervix; thyroid;  
 KW prostate; skin; small cell lung cancer; squamous cell carcinoma;  
 KW leukaemia; lymphoma; myelodysplastic syndrome; fibrosarcoma;  
 KW rhabdomyosarcoma; astrocytoma; neuroblastoma; glioma; schwannoma;  
 KW melanoma; seminoma; teratocarcinoma; osteosarcoma; ds.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.

```

PN WO2004078994-A2.
XX 16-SEP-2004.
XX
XX 01-MAR-2004; 2004WO-US006337.
XX
XX 28-FEB-2003; 2003WO-US006198.
XX
XX (RAVG-) RAVGEN INC.
XX
XX Dhallan R;
XX
XX WPI; 2004-662434/64.
XX
PT Detecting presence or absence of nucleic acid, containing mutation,
PT involves isolating nucleic acid from sample containing cell lysis
PT inhibitor, and detecting presence or absence of nucleic acid.
XX
XX Example 7; Page 159; 440pp; English.
XX
CC The invention relates to a method for detecting a nucleic acid, involving
CC isolating a nucleic acid from a sample, where an agent that impedes cell
CC lysis was added to the sample, and detecting the presence or absence of
CC the nucleic acid. The invention also relates to a method for detecting
CC chromosomal abnormalities in a DNA sample and determining the sequence of
CC foetal DNA from a sample of a pregnant female. The nucleic acid contains
CC at least one mutation chosen from a single point mutation, multiple point
CC mutations, an insertion, a frameshift, a truncation, a deletion, a
CC duplication and a transversion. The method is useful for detecting
CC nucleic acid in a sample obtained from a source chosen from bacteria,
CC viruses, fungi, mycobacteria, protozoa, molds, yeasts, plants, humans,
CC non-humans, multi-cellular parasites, animals and archaeobacteria. The
CC method is useful for detecting, diagnosing or monitoring a disease such
CC as cancer chosen from carcinoma of the bladder, breast, bronchus, colon,
CC kidney, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach,
CC cervix, thyroid, prostate and skin, small cell lung cancer, squamous cell
CC carcinoma, haematopoietic tumours of lymphoid lineage, leukaemia, acute
CC lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-
CC cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell
CC lymphoma, Burkett's lymphoma, haematopoietic tumours of myeloid lineage,
CC acute and chronic myelogenous leukaemias, myelodysplastic syndrome and
CC promyelocytic leukaemia, tumours of mesenchymal origin, fibrosarcoma and
CC rhabdomyosarcoma, tumours of the central and peripheral nervous system,
CC astrocycoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma,
CC teratocarcinoma and osteosarcoma. The method is also useful for
CC monitoring response to treatment chosen from surgery, radiation,
CC of a drug. The drug is chosen from chemotherapeutic agents, anti-
CC bacterial agents, anti-viral agents, anti-fungal agents, targeted-cancer
CC drugs, cytotoxic agents, cytostatic agents and anti-proliferative agents.
CC This sequence represents a DNA oligonucleotide used in the scope of the
CC invention.
XX
XX Sequence 18 BP; 7 A; 3 C; 1 G; 7 T; 0 U; 0 Other;
XX
Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. NO. 3.7e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 781 GTATTAAACTTGTCTACA 797
DB 17 GTATTAAACTTGTCTCA 1

RESULT 392
AAF50921
ID AAF50921 standard; DNA; 15 BP.
XX
XX AAF50921;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #1881.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 73; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. NO. 4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 531 CATTCCTTGATGT 545
DB 1 CATTCCTTGACGT 15

RESULT 393
AAF46599
ID AAF46599 standard; DNA; 15 BP.
XX
XX AAF46599;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP3 oligonucleotide #19.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;

```

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;  
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
KW hyperneovascular condition; hyperplasia; kidney disease;  
KW neovascular condition of the retina; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200078341-A1.  
XX  
PD 28-DEC-2000.  
XX  
XX 21-JUN-2000; 2000WO-AU000693.  
PF  
XX 21-JUN-1999; 99US-0140345P.  
PR  
XX (MURD-) MURDOCH CHILDRENS RES INST.  
PA  
XX  
PI Wright CJ, Werther GA, Edmondson SR;  
XX  
XX WPI; 2001-041421/05.  
DR  
XX  
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
PT inhibits or reduces growth factor mediated cell proliferation and/or  
PT inflammation.  
XX  
XX Example 7; Page 44; 201pp; English.  
PS  
XX The present invention relates to a method for ameliorating the effects of  
CC skin disorders. The method comprises contacting the skin with an  
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
CC inhibiting or reducing growth factor mediated cell proliferation,  
CC inflammation and/or other disorders. The present sequence is an  
CC oligonucleotide which can be used to design the antisense  
CC oligonucleotide of the present invention (see AAF45151 and AAF45153-  
CC F45161). The method is useful for ameliorating the effects of psoriasis,  
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,  
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
CC hyperneovascular condition such as a neovascular condition of the retina,  
CC brain or skin, growth factor-mediated malignancies, other sclerotic  
CC disease, kidney disease, hyperproliferation of the inside of blood  
CC vessels or any other hyperplasia  
XX  
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 190 CCTGCATGGATTCCA 204  
Db 1 CCTGCCTGGATTCCA 15  
  
RESULT 394  
ADO43607  
ID ADO43607 standard; DNA; 15 BP.  
XX  
XX ADO43607;  
AC  
XX 29-JUL-2004 (first entry)  
DT  
XX Mutant DNA fragment of SOD-1 where L26S mutation occurs.  
DE  
XX  
XX DNazyme; dominantly inherited disorder; achondroplasia;  
KW amytrophic lateral sclerosis; Marfan syndrome; hypercholesterolemia;  
XX osteogenesis imperfecta; SCMS; ss; superoxide disutase; SOD-1.  
XX  
XX Homo sapiens.  
OS  
XX WO2004038019-A2.  
PN

XX 06-MAY-2004.  
PD  
XX 23-OCT-2003; 2003WO-GB004614.  
PF  
XX 23-OCT-2002; 2002GB-00024663.  
PR  
XX (ISIS-) ISIS INNOVATION LTD.  
PA  
XX Beeson D, Wood M, Abdelgany A;  
PI  
XX WPI; 2004-365523/34.  
DR  
XX  
XX New DNazyme that cleaves mutant polynucleotides, useful in treating a  
PT dominantly inherited disorder associated with a mutant allele, such as  
PT achondroplasia, amytrophic lateral sclerosis, Marfan syndrome and  
PT hypercholesterolemia.  
XX  
XX Disclosure; Page 8; 24pp; English.  
PS  
XX The specification describes a DNazyme which selectively cleaves a mutant  
CC polynucleotide by cleaving at a site remote from the mutation site. The  
CC DNazyme binds selectively to a mutant allele or its expressed product,  
CC and comprises a central catalytic motif (Helix II) and two flanking  
CC regions (Helix I and III) where at least one of the flanking regions has  
CC a polynucleotide sequence complementary to a region that includes the  
CC mutation in the mutant allele or to that of the expressed product. Both  
CC flanking regions are complementary to mutated regions of the mutant  
CC allele or the expressed product. The complement of the mutation is 2 or 3  
CC nucleotides upstream or downstream of the site of cleavage, preferably in  
CC helix I. Helix I and III are of different lengths, where helix I is  
CC shorter than helix III, and their length is 21-7 or 15-8 nucleotides.  
CC Helix I preferably comprises 9 nucleotides and helix III 13 nucleotides.  
CC At least one of the flanking regions comprises ribonucleic acid. The  
CC DNazyme further comprises a stem-loop structure at either or both  
CC terminus. The DNazyme is useful in therapy, in particular for the  
CC manufacture of a medicament for the treatment of a disorder associated  
CC with a mutant allele in a patient, where the DNazyme comprises a central  
CC catalytic motif and two flanking substrate-binding regions, and where at  
CC least one flanking region binds at the site of mutation in the mutant  
CC allele or its expressed product and the catalytic motif cleaves at a site  
CC remote from the site of mutation. The disorder is a dominantly inherited  
CC disorder, such as achondroplasia, amytrophic lateral sclerosis with SOD1  
CC mutation, Marfan syndrome, hypercholesterolemia, osteogenesis imperfecta  
CC and SCMS. ADO43606-ADO43607 represent the wild type and mutant DNA  
CC fragments, respectively, of the Cu/Zn superoxide disutase (SOD-1) gene  
CC where a L26S mutation occurs, and causes amytrophic lateral sclerosis.  
CC These sequences are suitable for the design of DNazymes of the invention  
CC (see ADO43608).  
XX  
SQ Sequence 15 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 437 GATGACTTGGGC AAA 451  
Db 1 GATGACTCGGGC AAA 15  
  
RESULT 395  
ADO43602  
ID ADO43602 standard; DNA; 15 BP.  
XX  
XX ADO43602;  
AC  
XX 29-JUL-2004 (first entry)  
DT  
XX DNA fragment from DNazyme for SOD-1 G12R mutation.  
DE  
XX  
XX DNazyme; dominantly inherited disorder; achondroplasia;  
KW amytrophic lateral sclerosis; Marfan syndrome; hypercholesterolemia;  
KW

XX osteogenesis imperfecta; SCCMS; ss; superoxide disutase; SOD-1.

XX Homo sapiens.

XX WO2004038019-A2.

XX 06-MAY-2004.

XX 23-OCT-2003; 2003WO-GB004614.

XX 23-OCT-2002; 2002GB-00024663.

XX (ISIS-) ISIS INNOVATION LTD.

XX Beeson D, Wood M, Abdelgany A;

XX WPI; 2004-365523/34.

XX New DNzyme that cleaves mutant polynucleotides, useful in treating a  
 PT dominantly inherited disorder associated with a mutant allele, such as  
 PT achondroplasia, amyotrophic lateral sclerosis, Marfan syndrome and  
 PT hypercholesterolemia.

XX Disclosure; Page 7; 24pp; English.

XX The specification describes a DNzyme which selectively cleaves a mutant  
 CC polynucleotide by cleaving at a site remote from the mutation site. The  
 CC DNzyme binds selectively to a mutant allele or its expressed product,  
 CC and comprises a central catalytic motif (Helix II) and two flanking  
 CC regions (helix I and III) where at least one of the flanking regions has  
 CC a polynucleotide sequence complementary to a region that includes the  
 CC mutation in the mutant allele or to that of the expressed product. Both  
 CC flanking regions are complementary to mutated regions of the mutant  
 CC allele or the expressed product. The complement of the mutation is 2 or 3  
 CC nucleotides upstream or downstream of the site of cleavage, preferably in  
 CC helix I. Helix I and III are of different lengths, where helix I is  
 CC shorter than helix III, and their length is 21-7 or 15-8 nucleotides.  
 CC Helix I preferably comprises 9 nucleotides and helix III 13 nucleotides.  
 CC At least one of the flanking regions comprises ribonucleic acid. The  
 CC DNzyme further comprises a stem-loop structure at either or both  
 CC termini. The DNzyme is useful in therapy, in particular for the  
 CC manufacture of a medicament for the treatment of a disorder associated  
 CC with a mutant allele in a patient, where the DNzyme comprises a central  
 CC catalytic motif and two flanking substrate-binding regions, and where at  
 CC least one flanking region binds at the site of mutation in the mutant  
 CC allele or its expressed product and the catalytic motif cleaves at a site  
 CC remote from the site of mutation. The disorder is a dominantly inherited  
 CC disorder, such as achondroplasia, amyotrophic lateral sclerosis with SOD1  
 CC mutation, Marfan syndrome, hypercholesterolemia, osteogenesis imperfecta  
 CC and SCCMS. The present sequence represents a fragment from a DNzyme for  
 CC the Cu/Zn superoxide disutase (SOD-1) gene where a G12R mutation occurs  
 CC and causes amyotrophic lateral sclerosis.

XX Sequence 15 BP; 2 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 95 GCGACGCGCCAGTG 109  
 |||||  
 DB 1 GCGACGCGCCAGTG 15

RESULT 396  
 AAS1510/c  
 ID AAS15510 standard; DNA; 16 BP.

XX AAS15510;

XX 16-JAN-2002 (first entry)

XX N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #7.

XX N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;  
 KW single nucleotide polymorphism; ss.

XX Synthetic.

XX Key Location/Qualifiers  
 FH variation replace(7,C)  
 FT /\*tag= a

FT /\*standard\_name= "Single nucleotide polymorphism"

FT variation replace(8,G)

FT /\*tag= b

FT /\*standard\_name= "Single nucleotide polymorphism"

XX WO200166804-A2.

XX 13-SEP-2001.

XX 09-MAR-2001; 2001WO-US007775.

XX 09-MAR-2000; 2000US-00521983.

XX 10-JUL-2000; 2000US-00613517.

XX (PROT-) PROTOGENE LAB INC.

XX Cronin MT, Frueh F, Brennan TM;

XX WPI; 2001-616243/71.

XX Determining sequence variation in, or monitoring expression of genes in  
 PT target nucleic acid for high-throughput genotyping of (un)known  
 PT polymorphisms/mutations, comprises hybridization pattern differences  
 PT between target and probe sequences.

XX Example 5; Page 35; 60pp; English.

XX The invention relates to a method of simultaneously determining the  
 CC presence of 2 or more sequence variations in target nucleic acids, or  
 CC simultaneously monitoring expression of 2 or more genes. The method  
 CC comprises determining differences in hybridisation between the target  
 CC nucleic acid and immobilised probes, where differences in hybridisation  
 CC between indicates sequence variations or transcription levels. The method  
 CC is used for simultaneously determining the presence or absence of two or  
 CC more sequence variations in target nucleic acids or simultaneously  
 CC monitoring expression of two or more genes in target nucleic acids. The  
 CC methods are applicable to high-throughput genotyping of known and unknown  
 CC polymorphisms and mutations. The method maximises the information yield  
 CC of hybridisation-based array applications by increasing the number of  
 CC informative array-immobilised polynucleotide probes. The present sequence  
 CC represents N-acetyltransferase 2 (NAT2) G191A single nucleotide  
 CC polymorphism (SNP) hybridisation probe #7

XX Sequence 16 BP; 1 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 272 AGAAACACCGTGGG 286  
 |||||  
 DB 15 AGAAACACCGTGGG 1

RESULT 397  
 ABT13505/c  
 ID ABT13505 standard; DNA; 16 BP.

XX ABT13505;

XX 07-FEB-2003 (first entry)

XX Liver regeneration-related gene panel PCR primer #33.

XX

KW PCR; primer; ss; liver regeneration; gene panel; expression profile;  
 KW drug screening; drug development; hepatitis; liver transplantation.  
 XX Unidentified.  
 XX W0200277222-A1.  
 PN 03-OCT-2002.  
 PD  
 XX 13-MAR-2002; 2002WO-JP002372.  
 XX  
 XX 13-MAR-2001; 2001JP-00070940.  
 PR  
 XX (AJIN ) AJINOMOTO CO INC.  
 PA  
 XX Yokoya F, Okutsu T, Mori M, Takahara Y, Fukuda H, Aburatani H;  
 PI Sonaka I;  
 PI WPI; 2003-018922/01.  
 DR  
 XX Gene panel participating in liver regeneration, applicable in providing  
 PT expression data, diagnosis and development of drugs for promoting liver  
 PT regeneration e.g. after transplantation or removal of liver during  
 PT cancer.  
 XX  
 XX Claim 19; Page 55; 101pp; Japanese.  
 PS  
 XX The invention comprises a gene panel constructed from the expression  
 CC profile of known genes which show a change in expression level between  
 CC normal liver cells and liver cells under regeneration. The gene panel is  
 CC useful for providing expression data and screening/development of drugs  
 CC for liver regeneration (e.g. when treating hepatitis, after  
 CC transplantation or removal of the liver during cancer or hepatitis  
 CC therapy). The present DNA sequence represents a PCR primer used in the  
 CC invention  
 XX  
 XX Sequence 16 BP; 3 A; 5 C; 4 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 310 TGGAGACTTGGCAA 324  
 Db ||||| ||||| ||||| ||||| |||||  
 15 TGGACACTTGGCAA 1  
 RESULT 398  
 ABZ68236  
 ID ABZ68236 standard; DNA; 16 BP.  
 XX  
 AC ABZ68236;  
 XX  
 XX 07-APR-2003 (first entry)  
 DT  
 XX Probe/PCR primer for conserved region of the spoA gene of bacteria.  
 DE  
 XX spoA gene; spore-forming bacteria; Bacillus; Clostridium;  
 KW sporulation gene; paper product; paper making; probe; PCR; primer; ss.  
 KW  
 XX Synthetic.  
 OS  
 XX W0200292853-A1.  
 PN  
 XX 21-NOV-2002.  
 PD  
 XX 15-MAY-2001; 2001WO-US015793.  
 XX  
 XX 15-MAY-2001; 2001WO-US015793.  
 PR  
 XX (HERC ) HERCULES INC.  
 PA  
 XX Breen AW, Singleton FL;  
 PI

XX WPI; 2003-175079/17.  
 DR  
 XX Testing a sample for the presence of spore forming bacteria, by combining  
 XX two primers with sample, hybridizing the primer to the target spore  
 PT forming bacterial spoA gene, and detecting the hybridized product.  
 PT  
 XX Claim 5; Page 16; 40pp; English.  
 PS  
 XX PCR primers and probes ABZ68235-42 are based on highly conserved regions  
 CC of the spoA gene of the spore-forming bacteria Bacillus and Clostridium.  
 CC They are used for detecting the presence of spore-forming bacteria in a  
 CC sample. The probes are useful for testing a sample comprising air, soil,  
 CC water, blood, faecal matter, starch, protein or an epichlorohydrin  
 CC reaction product for the presence of spore forming bacteria. They are  
 CC useful for the systemic identification of sporulation genes in spore-  
 CC forming bacteria. They are useful for detecting spore forming bacteria  
 CC such as Bacillus megaterium, B. licheniformis or B. pertussis in paper  
 CC products and paper making processes, protein-containing samples, and  
 CC medical diagnostic applications  
 XX  
 XX Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 429 AAAAAGCAGTGACT 443  
 Db ||||| ||||| ||||| ||||| |||||  
 2 AAAAAGCAGTTGACT 16  
 RESULT 399  
 ADJ92751  
 ID ADJ92751 standard; DNA; 16 BP.  
 XX  
 AC ADJ92751;  
 XX  
 XX 06-MAY-2004 (first entry)  
 DT  
 XX Bacillus cereus spoA gene amplifying forward PCR primer #1.  
 DE  
 XX Sporulation gene; spore forming bacteria; SFB; paper pulp; spoA gene;  
 KW PCR; primer; ss.  
 KW  
 XX Bacillus cereus.  
 OS  
 XX US2004014122-A1.  
 PN  
 XX 22-JAN-2004.  
 PD  
 XX 27-JUN-2003; 2003US-00608062.  
 XX  
 XX 27-MAY-1998; 98US-00085359.  
 PR  
 XX 20-JUL-1999; 99US-00356677.  
 PR  
 XX 27-JAN-2000; 2000US-00492135.  
 XX  
 XX (BREE/) BREEN A W.  
 PA (SING/) SINGLETON F L.  
 PA  
 XX Breen AW, Singleton FL;  
 PI  
 XX WPI; 2004-098822/10.  
 DR  
 XX Novel primer pair useful for identifying sporulation genes in spore  
 XX forming bacteria and detecting the presence of spore forming bacteria in  
 PT samples e.g. paper pulp.  
 PT  
 XX Claim 1; SEQ ID NO 2; 19pp; English.  
 PS  
 XX The invention relates to methods for the systematic identification of  
 CC sporulation genes in spore forming bacteria (SFB). The method is useful  
 CC for identifying sporulation genes in spore forming bacteria. It is also  
 CC



CC useful for detecting the presence of SFB in sample e.g., paper pulp. The  
 CC present sequence is a PCR primer used for amplifying spore forming  
 CC bacteria spo0A gene. This sequence is used to illustrate the method of  
 CC the invention.

XX SQ Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 429 AAAAGCAGATGACT 443  
 |||||  
 Db 2 AAAAGCAGTTGACT 16

RESULT 400

AAX74883/C  
 ID AAX74883 standard; RNA; 17 BP.

XX AC AAX74883;

XX DT 28-JUL-1999 (first entry)

XX DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #411.

XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
 KW foetal liver kinase 1; ss.

XX OS Mus sp.

XX PN WO9715662-A2.

XX PD 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US017480.

XX PR 26-OCT-1995; 95US-0005974P.

XX PR 11-JAN-1996; 96US-00584040.

XX (RIBO-) RIBOZYME PHARM INC.

PA (CHIR) CHIRON CORP.

XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

XX WPI; 1997-259017/23.

XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
 PT rheumatoid arthritis, etc., in a human patient.

XX PS Claim 4; Page 167; 218pp; English.

XX CC The present invention describes nucleic acid molecules which modulate the  
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
 CC receptors of vascular endothelial growth factor (VEGF). A patient  
 CC (preferably human) having a condition associated with the level of the  
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
 CC treated by administering the nucleic acid molecule or the expression  
 CC vector to the patient. AAX75275 to AAX75752 represent specific examples  
 CC of nucleic acid molecules from the present invention

XX SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;

Query Match

Best Local Similarity 1.5%; Score 13.4; DB 1; Length 17;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCCTC 266  
 |||||  
 Db 16 CTCACCTGTAATCCCTC 2

RESULT 401

AAX71529

ID AAX71529 standard; RNA; 17 BP.

XX AC AAX71529;

XX DT 28-JUL-1999 (first entry)

XX DE Human KDR VEGF receptor hammerhead ribozyme substrate #541.

XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;  
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;  
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;  
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;  
 KW foetal liver kinase 1; ss.

XX OS Homo sapiens.

XX PN WO9715662-A2.

XX PD 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US017480.

XX PR 26-OCT-1995; 95US-0005974P.

XX PR 11-JAN-1996; 96US-00584040.

XX (RIBO-) RIBOZYME PHARM INC.

PA (CHIR) CHIRON CORP.

XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

XX WPI; 1997-259017/23.

XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA  
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,  
 PT rheumatoid arthritis, etc., in a human patient.

XX PS Claim 4; Page 113; 218pp; English.

XX CC The present invention describes nucleic acid molecules which modulate the  
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
 CC receptors of vascular endothelial growth factor (VEGF). A patient  
 CC (preferably human) having a condition associated with the level of the  
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
 CC treated by administering the nucleic acid molecule or the expression  
 CC vector to the patient. AAX75275 to AAX75752 represent specific examples  
 CC of nucleic acid molecules from the present invention

XX SQ Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;

Query Match

Best Local Similarity 1.5%; Score 13.4; DB 1; Length 17;  
 Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTTG 656  
 |||||  
 Db 2 ACGUUUCAGAGUUG 16

RESULT 402

AAX71528

ID AAX71528 standard; RNA; 17 BP.

XX AC AAX71528;

```

DT XX 28-JUL-1999 (first entry)
DE XX Human KDR VEGF receptor hammerhead ribozyme substrate #540.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; f1t-1; f1k-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
XX WO9715662-A2.
PN XX
XX 01-MAY-1997.
PD XX
XX 25-OCT-1996; 96WO-US017480.
PF XX
XX 26-OCT-1995; 95US-0005974P.
PR XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
PR XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 113; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX
XX Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.5%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 53.3%; Pred. No. 4e+02;
XX Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
XX
QY 642 ACTTTTTCAGAGTTG 656
DB 3 ACGUUUCAGAGUUG 17
|| :||:||||:|
|| :||:||||:|

RESULT 403
AAX74882/c
ID AAX74882 standard; RNA; 17 BP.
XX
XX AAX74882;
AC
XX
XX 28-JUL-1999 (first entry)
DT XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #410.
DE XX
XX Vascular endothelial growth factor receptor; VEGF receptor; f1t-1; f1k-1;
XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Mus sp.

```

```

XX WO9715662-A2.
PN XX
XX 01-MAY-1997.
PD XX
XX 25-OCT-1996; 96WO-US017480.
PF XX
XX 26-OCT-1995; 95US-0005974P.
PR XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 167; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX
XX Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.5%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 252 CTCACITTTAATCCTC 266
DB 17 CTCACITTTAATCCTC 3
||| ||| ||| ||| ||| |||
||| ||| ||| ||| ||| |||

RESULT 404
AAX96546
ID AAX96546 standard; RNA; 17 BP.
XX
XX AAX96546;
AC
XX
XX 01-MAR-1999 (first entry)
DT XX
XX Potato citrate synthase target sequence position 859.
DE XX
XX Solanidine; glucosyltransferase; potato; citrate synthase; target;
XX hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
XX flower formation; cleavage; solanaceous plant; ss.
XX
XX Solanum tuberosum.
XX
XX WO9832843-A2.
PN XX
XX 30-JUL-1998.
PD XX
XX 14-JAN-1998; 98WO-US000738.
PF XX
XX 28-JAN-1997; 97US-0036545P.
PR XX
XX 24-JAN-1997; 97US-0036599P.
XX 24-NOV-1997; 97US-00979416.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX

```

PI Zwick MG, Mcswiggen JA;  
 XX WPI; 1998-427939/36.  
 XX  
 XX New enzymatic nucleic acid(a) - useful for, e.g. reducing alkaloid  
 PT biosynthesis or regulating flowering.  
 PT  
 XX Claim 53; Page 55; 79pp; English.  
 XX  
 CC The present invention describes enzymatic nucleic acid molecules with RNA  
 CC -cleaving activity (e.g. ribozymes) which are capable of modulating the  
 CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or  
 CC (ii) involved in flower formation. AAV95882 to AAV96334, and AAV96335 to  
 CC AAV96334 represent potato solanidine glucosyltransferase hammerhead and  
 CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to  
 CC AAV96734 represent potato solanidine glucosyltransferase target  
 CC sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent  
 CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.  
 CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate  
 CC synthase target sequences. Ribozymes of the present invention can be used  
 CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,  
 CC particularly potato but also tomato, pepper, aubergine and ditura or to  
 CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,  
 CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf  
 CC grass. Also the ribozymes can be used for RNA manipulation in the same  
 CC way that restriction endonucleases are for DNA, as well as to examine  
 CC genetic drift and mutations in plants and to detect specific RNA. The  
 CC ribozymes can be targeted to specific genes or to consensus sequences  
 CC within a family of related genes, and being catalytic need to be present  
 CC at only very low concentrations  
 XX  
 SQ Sequence 17 BP; 4 A; 4 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 53.3%; Pred. No. 4e+02;  
 Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
 QY 841 ACTTATTATGAGGCT 855  
 Db 2 ACUUCUUAUGAGGCU 16  
 RESULT 405  
 AAF03385/c  
 ID AAF03385 standard; DNA; 17 BP.  
 XX  
 AC AAF03385;  
 XX  
 DT 16-FEB-2001 (first entry)  
 DE Hammerhead ribozyme substrate #1680.  
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KW interferon alpha; ss.  
 OS Homo sapiens.  
 XX  
 XX WO2000061729-A2.  
 PN  
 XX  
 PD 19-OCT-2000.  
 PF  
 PF 11-APR-2000; 2000WO-US009721.  
 XX  
 XX 12-APR-1999; 99US-0129390P.  
 PR  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
 PI  
 PI WPI; 2000-647423/52.  
 DR  
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT

PT interferon alpha and erythropoietin.  
 XX  
 PS Claim 37; Page 94; 164pp; English.  
 XX  
 CC The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC interferon alpha  
 XX  
 SQ Sequence 17 BP; 2 A; 2 C; 2 G; 11 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 458 AATGAAGAAAGTACA 472  
 Db 15 AATGAAGAAAGTACA 1  
 RESULT 406  
 ABK00398/c  
 ID ABK00398 standard; RNA; 17 BP.  
 XX  
 AC ABK00398;  
 XX  
 DT 12-MAR-2002 (first entry)  
 DE Human NOGO Hammerhead Ribozyme #398.  
 XX  
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX WO200159103-A2.  
 PN  
 XX  
 PD 16-AUG-2001.  
 XX  
 XX 09-FEB-2001; 2001WO-US004273.  
 PF  
 PF 11-FEB-2000; 2000US-0181797P.  
 PR  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX  
 XX Blatt L, Mcswiggen J, Chowrira BM;  
 PI  
 PI WPI; 2001-607195/69.  
 DR  
 XX  
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.

XX PS Claim 88; Page 72; 200pp; English.

XX CC The invention relates to a nucleic acid molecule which down regulates

XX CC expression of a CD20 gene and a nucleic acid molecule which down

XX CC regulates expression of a neurite growth inhibitor gene (NOGO). The

XX CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a

XX CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving a RNA molecule

XX CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) or

XX CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA

XX CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA

XX CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.

XX CC Furthermore, it may be contacted with a cell to reduce CD20 activity of

XX CC the cell and treat a patient having a condition associated with the level

XX CC of CD20. The treatment may further comprise the use of one or more

XX CC therapies. In particular, the CD20 targeting nucleic acid may be used to

XX CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-

XX CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

XX CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell

XX CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,

XX CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-

XX CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the

XX CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the

XX CC nucleic acid may be contacted with a cell to reduce NOGO activity of the

XX CC cell and treat a patient having a condition associated with the level of

XX CC NOGO. The treatment may further comprise the use of one or more

XX CC therapies. In particular, the NOGO-targeting nucleic acid may be used to

XX CC treat central nervous system (CNS) injury and cerebrovascular accident

XX CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),

XX CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

XX CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob

XX CC disease, muscular dystrophy, and/or other neurodegenerative disease

XX CC states which respond to the modulation of NOGO expression. The present

XX CC sequence is a hammerhead ribozyme of the invention

XX SQ Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 4e+02; Mismatches 0; Gaps 0;

Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 857 TTAAGAGATCCAAA 871

Db 15 TTAAGAGATCCAAA 1

RESULT 407

ABA80441/c

ID ABA80441 standard; DNA; 17 BP.

AC ABA80441;

XX 24-JAN-2002 (first entry)

XX MSH2 mutation correcting oligonucleotide SEQ ID NO: 3287.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;

XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;

XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;

XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;

XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;

XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;

XX Alzheimer's disease; cytoskeletal; antiskilling; antianaemic; haemostatic;

XX antileptic; ss.

XX Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

PF 27-MAR-2001; 2001WO-US009761.

XX 27-MAR-2000; 2000US-0192176P.

PR 27-MAR-2000; 2000US-0192179P.

PR 01-JUN-2000; 2000US-0208538P.

XX 30-OCT-2000; 2000US-0244989P.

PA (UYDE ) UNIV DELAWARE.

XX Kmtec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for

XX treating cystic fibrosis, comprises at least one mismatch and chemical

XX modification.

XX Claim 7; Page 224; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can

XX be used for the targeted alteration of genomic sequences, where the

XX oligonucleotide has at least one mismatch compared with the genomic

XX sequence to be altered. In particular, these sequences are directed at

XX the following genes: adenosine deaminase, p53, beta-globin,

XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus

XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,

XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,

XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

XX various syndromes. The present sequence is one of the gene correcting

XX oligonucleotides of the invention

XX SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 4e+02; Mismatches 0; Gaps 0;

Matches 14; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 855 TATTAAAGATCCCA 869

Db 17 TATTAAAGATCCCA 3

RESULT 408

ABA80440

ID ABA80440 standard; DNA; 17 BP.

XX ABA80440;

XX 24-JAN-2002 (first entry)

XX MSH2 mutation correcting oligonucleotide SEQ ID NO: 3286.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;

XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;

XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;

XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;

XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;

XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;

XX Alzheimer's disease; cytoskeletal; antiskilling; antianaemic; haemostatic;

XX antileptic; ss.

XX Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US009761.  
 XX 27-MAR-2000; 2000US-0192176P.  
 PR 27-MAR-2000; 2000US-0192179P.  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX (UYDE ) UNIV DELAWARE.  
 XX Kmiec EB, Gamper HB, Rice MC;  
 XX WPI; 2001-639230/73.  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX Claim 7; Page 224; 294pp; English.  
 XX The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin, inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalasassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 855 TATTAAAGATCCA 869  
 Db 1 TATTAAAGATCCA 15  
 RESULT 409  
 ABT38905/c  
 ID ABT38905 standard; DNA; 17 BP.  
 XX AC ABT38905;  
 XX 12-JUN-2003 (first entry)  
 DE Tumour suppression related human fukutin oligo SEQ ID No 4542.  
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX Homo sapiens.  
 OS WO2003025175-A2.  
 PN 27-MAR-2003.  
 PD 17-SEP-2002; 2002WO-IB004208.  
 XX 17-SEP-2001; 2001FR-00011978.  
 XX 17-SEP-2001; 2001FR-00011978.  
 XX (MOLE-) MOLECULAR ENGINES LAB.

PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-313353/30.  
 XX New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumours and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX Disclosure; Page 565; 720pp; French.  
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX Sequence 17 BP; 6 A; 6 C; 1 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 628 AGTGTAAATTGGTGTA 642  
 Db 17 AGTGTAAATGGTGTA 3  
 RESULT 410  
 ABT38165  
 ID ABT38165 standard; DNA; 17 BP.  
 XX AC ABT38165;  
 XX 12-JUN-2003 (first entry)  
 DE Tumour suppression related human fukutin oligo SEQ ID No 3802.  
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX Homo sapiens.  
 OS WO2003025175-A2.  
 PN 27-MAR-2003.  
 PD 17-SEP-2002; 2002WO-IB004208.  
 XX 17-SEP-2001; 2001FR-00011978.  
 XX 17-SEP-2001; 2001FR-00011978.  
 XX (MOLE-) MOLECULAR ENGINES LAB.

```

PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 478; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
XX Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 690 GATCATTGGGAAGAT 704
DB 1 GATCATTGGGAAT 15
RESULT 411
ABT35779
ID ABT35779 standard; DNA; 17 BP.
XX
XX ABT35779;
AC
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 1416.
XX
XX Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
XX Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 690 GATCATTGGGAAGAT 704
DB 1 GATCATTGGGAAT 15
RESULT 412
ABT34906
ID ABT34906 standard; DNA; 17 BP.
XX
XX ABT34906;
AC
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 543.
XX
XX Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
XX Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 801 TCCTTGTGCATTCAAG 815
DB 3 TCCTTGTGCATTCAAG 17
RESULT 412
ABT34906
ID ABT34906 standard; DNA; 17 BP.
XX
XX ABT34906;
AC
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 543.
XX
XX Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX Homo sapiens.
XX
XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313353/30.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
XX Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 801 TCCTTGTGCATTCAAG 815
DB 3 TCCTTGTGCATTCAAG 17

```



XX PD 17-OCT-2002.  
 XX KW RNA stability; RNA expression; RNA synthesis; antisense;  
 XX KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;  
 XX PF amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 XX KW HBV reverse transcriptase; Enhancer I region; HCV infection; cirrhosis;  
 XX KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX OS Hepatitis C virus.  
 XX XX  
 PN WO200281494-A1.  
 XX PD 17-OCT-2002.  
 XX PF 26-MAR-2002; 2002WO-US009187.  
 XX PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX WPI; 2003-229207/22.  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX Claim 1; Page 266; 387pp; English.  
 XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,  
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNzyme or minus strand DNzyme sequences disclosed in the present  
 XX invention  
 SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 271 CAGAAACACCGTGG 285  
 DB 16 CAGAAGACACCGTGG 2  
 RESULT 415  
 ACDS8596  
 ID ACDS8596 standard; RNA; 17 BP.  
 XX AC ACDS8596;  
 XX 24-SEP-2003 (first entry)  
 DT HCV DNzyme substrate sequence #902.  
 DE Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW

KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; HCV infection; cirrhosis;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 OS Hepatitis C virus.  
 XX  
 PN WO200281494-A1.  
 XX PD 17-OCT-2002.  
 XX PF 26-MAR-2002; 2002WO-US009187.  
 XX PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX WPI; 2003-229207/22.  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX Claim 1; Page 266; 387pp; English.  
 XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,  
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNzyme or minus strand DNzyme sequences disclosed in the present  
 XX invention  
 SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 271 CAGAAACACCGTGG 285  
 DB 16 CAGAAGACACCGTGG 2  
 RESULT 415  
 ACDS8596  
 ID ACDS8596 standard; RNA; 17 BP.  
 XX AC ACDS8596;  
 XX 24-SEP-2003 (first entry)  
 DT HCV DNzyme substrate sequence #902.  
 DE Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 86.7%; Pred. No. 4e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 36 ACCAGGACCTCGCG 50  
 DB 3 ACCAGGACCTCGCG 17





Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 GATCTCACTCTCAGG 390  
 Db 1 GATCTCACTCTCAGG 15

RESULT 418  
 ADIS0752  
 ID ADIS0752 standard; DNA; 17 BP.  
 AC ADIS0752;  
 XX  
 DT 15-APR-2004 (first entry)  
 XX  
 DE Human tumour suppression/reversion-related DNA sequence SeqID3255.  
 XX  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025177-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004523.  
 XX  
 PR 17-SEP-2001; 2001FR-00011980.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-313354/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumours and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; SEQ ID NO 3255; 30pp; French.  
 XX  
 XX This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX  
 SQ Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 801 TCTTTGTCATTCAAG 815  
 Db 3 TCTTTGTCATTAAAG 17

RESULT 419

ADLS0925/c  
 ID ADLS0925 standard; RNA; 17 BP.  
 XX  
 AC ADLS0925;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PTGDR substrate sequence #44.  
 XX  
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; glioma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 KW substrate; ds.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200281628-A2.  
 XX  
 PD 17-OCT-2002.  
 XX  
 PF 03-APR-2002; 2002WO-US010512.  
 XX  
 PR 05-APR-2001; 2001US-00827395.  
 PR 29-MAY-2001; 2001US-0294412P.  
 PR 28-AUG-2001; 2001US-0315315P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
 XX  
 DR WPI; 2003-058513/05.  
 XX  
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite  
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
 XX  
 PS Claim 161; SEQ ID NO 4458; 317pp; English.  
 XX  
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.  
 XX  
 SQ Sequence 17 BP; 0 A; 9 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 91 GAAGGGCGACGGCC 105  
 Db 16 GAAGGGCGAGGGCC 2

RESULT 420

```

ADI84553/c
ID ADI84553 standard; RNA; 17 BP.
XX
AC ADI84553;
XX
XX 03-JUN-2004 (first entry)
XX
DE HCV DNzyme substrate sequence #1799.
XX
XX ss; enzymatic cleavage; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNzyme.
XX KW Hepatitis C virus.
XX OS
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PT especially in combination with type I interferon therapy.
XX
XX PS Claim 1; SEQ ID NO 1799; 198pp; English.
XX
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNzyme substrate
XX CC sequence.
XX
XX SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.5%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 271 CAGAAACACGGTGG 285
XX DB ||||| ||||| |||||
XX 16 CAGAAGACACGGTGG 2
XX
XX RESULT 421
XX ADI85510
XX ID ADI85510 standard; RNA; 17 BP.
XX AC
XX ADI85510;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE HCV DNzyme substrate sequence #2756.
XX
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNzyme.
XX OS Hepatitis C virus.
XX
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PT especially in combination with type I interferon therapy.
XX
XX PS Claim 1; SEQ ID NO 1799; 198pp; English.
XX
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNzyme substrate
XX CC sequence.
XX
XX SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.5%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 4e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 271 CAGAAACACGGTGG 285
XX DB ||||| ||||| |||||
XX 16 CAGAAGACACGGTGG 2
XX
XX RESULT 421
XX ADI85510
XX ID ADI85510 standard; RNA; 17 BP.
XX AC
XX ADI85510;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE HCV DNzyme substrate sequence #2756.
XX
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNzyme.
XX OS Hepatitis C virus.
XX
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PT especially in combination with type I interferon therapy.
XX
XX PS Claim 1; SEQ ID NO 2756; 198pp; English.
XX
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNzyme substrate
XX CC sequence.
XX
XX SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.5%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 86.7%; Pred. No. 4e+02; 1; Indels 0; Gaps 0;
XX Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 271 CAGAAACACGGTGG 285
XX DB ||||| ||||| |||||
XX 3 CAGAAGACACGGUGG 17
XX
XX RESULT 422
XX AAC88558
XX ID AAC88558 standard; RNA; 13 BP.
XX AC
XX AAC88558;
XX
XX DT 02-MAR-2001 (first entry)
XX
XX DE Anti-SOD-1 295 coding sequence fragment.
XX
XX KW Ribozyme; retinal degradation; retinal disease; learning; memory;
XX KW amyotrophic lateral sclerosis; tumour suppression; ss.
XX OS Mus sp.
XX
XX PN WO2000066780-A2.
XX
XX PD 09-NOV-2000.
XX
XX PF 28-APR-2000; 2000WO-US011509.
XX
XX PR 30-APR-1999; 99US-0131942P.
XX
XX PA (UYFL) UNIV FLORIDA.
XX
XX PI Lewin AS, Muzyczka N, Hauswirth WM, Teschendorf C, Burger C;
XX DR WPI; 2000-687548/67.
XX

```

PT Novel methods for identifying genes with selected functions comprising  
PT contacting genes with a library of ribozymes, useful for identifying  
PT genes involved in, e.g. retinal disease, learning or memory and tumor  
PT suppression.

XX Claim 16; Fig 36; 11lpp; English.

CC The present invention relates to a method for identifying a gene with a  
CC selected function comprising contacting genes with a library of ribozymes  
CC and identifying at least 1 ribozyme that alters the selected function of  
CC the gene. The present sequence is a target sequence used in the present  
CC invention. The methods (and ribozymes) are useful for identifying novel  
CC genes involved in retinal degradation, retinal disease, learning or  
CC memory, amyotrophic lateral sclerosis or tumour suppression, and for  
CC producing non-human animal models of diseases

XX Sequence 13 BP; 3 A; 1 C; 3 G; 0 T; 6 U; 0 Other;

SQ Query Match 1.5%; Score 13; DB 1; Length 13;  
Best Local Similarity 53.8%; Pred. No. 4.3e+02;  
Matches 7; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 354 ATGTCTCTATTGA 366  
|:|:|:|:|:|:|

Db 1 AUGUGUCUAUUGA 13

RESULT 423  
AAC88562  
ID AAC88562 standard; RNA; 13 BP.  
XX AC AAC88562;  
XX DT 02-MAR-2001 (first entry)  
XX DE Anti-SOD-1 429 coding sequence fragment.  
XX KW Ribozyme; retinal degradation; retinal disease; learning; memory;  
XX KW amyotrophic lateral sclerosis; tumour suppression; ss.  
XX OS Mus sp.  
XX FN WO2000066780-A2.  
XX PD 09-NOV-2000.  
XX PF 28-APR-2000; 2000WO-US011509.  
XX PR 30-APR-1999; 99US-0131942P.  
XX PA (UYFL ) UNIV FLORIDA.  
XX PI Lewin AS, Muzyczka N, Hauswirth WW, Teschendorf C, Burger C;  
XX WPI; 2000-687548/67.  
XX Novel methods for identifying genes with selected functions comprising  
PT contacting genes with a library of ribozymes, useful for identifying  
PT genes involved in, e.g. retinal disease, learning or memory and tumor  
PT suppression.

XX Claim 16; Fig 36; 11lpp; English.

CC The present invention relates to a method for identifying a gene with a  
CC selected function comprising contacting genes with a library of ribozymes  
CC and identifying at least 1 ribozyme that alters the selected function of  
CC the gene. The present sequence is a target sequence used in the present  
CC invention. The methods (and ribozymes) are useful for identifying novel  
CC genes involved in retinal degradation, retinal disease, learning or  
CC memory, amyotrophic lateral sclerosis or tumour suppression, and for  
CC producing non-human animal models of diseases

XX Sequence 13 BP; 2 A; 1 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 13;  
Best Local Similarity 69.2%; Pred. No. 4.3e+02;  
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 488 GGAAGTCGTTGG 500  
|:|:|:|:|:|:|

Db 1 GGAAGUCGUUUGG 13

RESULT 424  
AAC88560  
ID AAC88560 standard; RNA; 13 BP.  
XX AC AAC88560;  
XX DT 02-MAR-2001 (first entry)  
XX DE Anti-SOD-1 359 coding sequence fragment.  
XX KW Ribozyme; retinal degradation; retinal disease; learning; memory;  
XX KW amyotrophic lateral sclerosis; tumour suppression; ss.  
XX OS Mus sp.  
XX FN WO2000066780-A2.  
XX PD 09-NOV-2000.  
XX PF 28-APR-2000; 2000WO-US011509.  
XX PR 30-APR-1999; 99US-0131942P.  
XX PA (UYFL ) UNIV FLORIDA.  
XX PI Lewin AS, Muzyczka N, Hauswirth WW, Teschendorf C, Burger C;  
XX WPI; 2000-687548/67.  
XX Novel methods for identifying genes with selected functions comprising  
PT contacting genes with a library of ribozymes, useful for identifying  
PT genes involved in, e.g. retinal disease, learning or memory and tumor  
PT suppression.

XX Claim 16; Fig 36; 11lpp; English.

CC The present invention relates to a method for identifying a gene with a  
CC selected function comprising contacting genes with a library of ribozymes  
CC and identifying at least 1 ribozyme that alters the selected function of  
CC the gene. The present sequence is a target sequence used in the present  
CC invention. The methods (and ribozymes) are useful for identifying novel  
CC genes involved in retinal degradation, retinal disease, learning or  
CC memory, amyotrophic lateral sclerosis or tumour suppression, and for  
CC producing non-human animal models of diseases

XX Sequence 13 BP; 3 A; 2 C; 5 G; 0 T; 3 U; 0 Other;

SQ Query Match 1.5%; Score 13; DB 1; Length 13;  
Best Local Similarity 76.9%; Pred. No. 4.3e+02;  
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGTGTCATGAA 430  
|:|:|:|:|:|

Db 1 GGUGGUCCAUGAA 13

RESULT 425  
AAC88556  
ID AAC88556 standard; RNA; 13 BP.  
XX AC AAC88556;  
XX DT 02-MAR-2001 (first entry)



CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 706 TGTATAGTTTAT 718  
 DB 13 TGTATAGTTTAT 1

RESULT 428  
 ABH01040  
 ID ABH01040 standard; DNA; 13 BP.  
 XX  
 AC ABH01040;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 201017 for detecting SNP TSC0049445.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.

06-APR-2001; 2001WO-IB000713.  
 07-APR-2000; 2000DE-01019173.  
 (EPIG-) EPIGENOMICS AG.  
 Olek A, Piepenbrock C, Berlin K;  
 WPI; 2001-657177/75.  
 Set of oligonucleotides, useful for diagnosis and cell typing, is  
 designed to detect single-nucleotide polymorphisms and cytosine  
 methylation status.  
 Claim 1; SEQ ID NO 201017; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic  
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 and cytosine methylation status in chemically pretreated genomic DNA. The  
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 range of diseases including immune system, gastrointestinal, respiratory,  
 central nervous system, cardiovascular and metabolic disorders. The  
 oligomers are also used for detecting cell type differentiation. ABC00010  
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 represent the oligomers described in the invention. NOTE: The sequence  
 data for this patent did not form part of the printed specification, but  
 was obtained in electronic format from WIPO at  
 ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 215 TTTCGAGATAATA 227  
 DB 1 TTTCGAGATAATA 13

RESULT 429  
 ABH01041/C  
 ID ABH01041 standard; DNA; 13 BP.  
 XX  
 AC ABH01041;  
 XX  
 DT 22-FEB-2002 (first entry)  
 XX  
 DE Oligonucleotide SEQ ID NO 201018 for detecting SNP TSC0049445.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
 central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.

06-APR-2001; 2001WO-IB000713.  
 07-APR-2000; 2000DE-01019173.  
 (EPIG-) EPIGENOMICS AG.  
 Olek A, Piepenbrock C, Berlin K;  
 WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is  
 designed to detect single-nucleotide polymorphisms and cytosine  
 methylation status.  
 Claim 1; SEQ ID NO 201018; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic  
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 and cytosine methylation status in chemically pretreated genomic DNA. The  
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 range of diseases including immune system, gastrointestinal, respiratory,  
 central nervous system, cardiovascular and metabolic disorders. The  
 oligomers are also used for detecting cell type differentiation. ABC00010  
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 represent the oligomers described in the invention. NOTE: The sequence  
 data for this patent did not form part of the printed specification, but  
 was obtained in electronic format from WIPO at  
 ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 215 TTTCGAGATAATA 227  
 DB 13 TTTCGAGATAATA 1

RESULT 430  
 ABF54652/C  
 ID ABF54652 standard; DNA; 13 BP.

XX ABF54652;  
AC  
XX  
DT 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 154649 for detecting SNP TSC0039096.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX  
XX WO200177384-A2.  
XX  
XX 18-OCT-2001.  
XX  
PD  
XX  
PP 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPTG-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 154649; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 13; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 527 TAAACATTCCTT 539  
Db 13 TAAACATTCCTT 1  
  
RESULT 431  
ABF56542  
ID ABF56542 standard; DNA; 13 BP.  
XX  
AC ABF56542;  
XX  
XX 21-FEB-2002 (first entry)  
XX  
DE Oligonucleotide SEQ ID NO 156539 for detecting SNP TSC0039466.  
XX  
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;  
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;  
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
XX  
OS Homo sapiens.  
XX

PN WO200177384-A2.  
XX  
PD 18-OCT-2001.  
XX  
PP 06-APR-2001; 2001WO-IB000713.  
XX  
PR 07-APR-2000; 2000DE-01019173.  
XX  
XX (EPIG-) EPIGENOMICS AG.  
XX  
XX Olek A, Piepenbrock C, Berlin K;  
XX  
XX WPI; 2001-657177/75.  
XX  
XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
PS Claim 1; SEQ ID NO 156539; 29pp + Sequence Listing; German.  
XX  
XX This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 13; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 706 TGTATAGTTTAT 718  
Db 1 TGTATAGTTTAT 13  
  
RESULT 432  
AAX54605  
ID AAX54605 standard; DNA; 15 BP.  
XX  
AC AAX54605;  
XX  
XX 05-JUL-1999 (first entry)  
XX  
DE Eosinophil peroxidase antisense oligonucleotide fragment.  
XX  
XX Antisense oligonucleotide; multiple target; antisense treatment;  
KW impaired respiration; inflammation; lung disease;  
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
KW acute asthma; allergy; asthma; impeded respiration;  
KW respiratory distress syndrome; pain; cystic fibrosis;  
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
KW prostate cancer; ss.  
XX  
OS Synthetic.  
XX  
XX WO9913886-A1.  
XX  
XX 25-MAR-1999.  
XX  
XX 17-SEP-1998; 98WO-US019419.  
XX

PR 17-SEP-1997; 97US-0059160P.  
 PR 09-JUN-1998; 98US-00093972.  
 XX (UYEC-) UNIV EAST CAROLINA.  
 PA  
 XX  
 PI Nyce JW;  
 XX  
 DR WPI; 1999-229400/19.  
 XX  
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary  
 PT vasoconstriction.  
 XX  
 PS Disclosure; Page 46; 120pp; English.  
 XX  
 CC The specification describes antisense oligonucleotides (AA52869-X55271)  
 CC directed against at least 2 mRNAs selected from target genes, coding and  
 CC non-coding regions of RNAs corresponding to target genes, gene initiation  
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-  
 CC end and the juxta-section between coding and non-coding regions and all  
 CC segments of RNAs encoding proteins associated with one or more diseases,  
 CC conditions or mixtures. The antisense oligonucleotides may be derived  
 CC from sequences AA5272-74. These multiple target oligonucleotides  
 CC (specifically AA5180-271) can be used for the antisense treatment of  
 CC diseases and conditions. Typical diseases and conditions are those  
 CC associated with impaired respiration and inflammation, including lung  
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,  
 CC acute asthma, allergies, asthma, impaired respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,  
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary  
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.  
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,  
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as  
 CC well as all types of cancers which may metastasize or have metastasized  
 CC to the lungs, including breast and prostate cancer  
 XX  
 SQ Sequence 15 BP; 0 A; 2 C; 7 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 13; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 12 GGGGTTTCCGTTG 24  
 Db |||||  
 3 GGGGTTTCCGTTG 15  
 RESULT 433  
 AAA34052  
 ID AAA34052 standard; DNA; 15 BP.  
 XX  
 AC AAA34052;  
 XX  
 DT 28-JUL-2000 (first entry)  
 XX  
 DE Human adenosine receptor related polynucleotide SEQ ID NO:1741.  
 XX  
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;  
 KW phosphorothioate; impaired respiration; inflammation; allergy;  
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;  
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;  
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;  
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;  
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;  
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200009525-A2.  
 XX  
 PD 24-FEB-2000.  
 XX  
 PF 03-AUG-1999; 99WO-US017712.  
 XX

PR 03-AUG-1998; 98US-0095212P.  
 XX (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI Nyce JW;  
 XX  
 DR WPI; 2000-205971/18.  
 XX  
 PT New antisense oligonucleotides useful for treating e.g. pulmonary  
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,  
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or  
 PT cancers.  
 XX  
 PS Disclosure; Page 481; 1343pp; English.  
 XX  
 CC The present invention describes a new composition comprising an antisense  
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets  
 CC nucleic acids involved in bronchoconstriction, allergies, and/or  
 CC inflammation. The ON can have antiinflammatory, antiallergic,  
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are  
 CC useful for the treatment of diseases associated with inflammation,  
 CC impaired airways, including lung disease and diseases whose secondary  
 CC effects afflict the lungs of a subject. They can be used for treating  
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
 CC impaired respiration, respiratory distress syndrome, pain, cystic  
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,  
 CC carcinomas, and cancers which may metastasize to the lungs, including  
 CC breast and prostate cancer. The reduction of the adenosine content of the  
 CC ONs reduces side effects. The A-containing ONs break down with the  
 CC release of deoxyadenosine which activates adenosine receptors causing  
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the  
 CC nucleotide sequences given in the sequence listing from the present  
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.  
 CC Sequences given in the disclosure of the present invention do not match  
 CC up with their corresponding SEQ ID NO: sequences given in the sequence  
 CC listing  
 XX  
 SQ Sequence 15 BP; 0 A; 2 C; 7 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 13; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 12 GGGGTTTCCGTTG 24  
 Db |||||  
 3 GGGGTTTCCGTTG 15  
 RESULT 434  
 AAF20174  
 ID AAF20174 standard; DNA; 15 BP.  
 XX  
 AC AAF20174;  
 XX  
 DT 14-MAR-2001 (first entry)  
 XX  
 DE Human eosinophil peroxidase polynucleotide fragment #1741.  
 XX  
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
 KW human; airway disorder; bronchoconstriction; lung inflammation;  
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;  
 KW respiratory obstruction; pulmonary obstruction; impaired respiration;  
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
 KW cancer; ss.  
 XX



OS Homo sapiens.  
 XX WO200062736-A2.  
 XX 26-OCT-2000.  
 XX 24-MAR-2000; 2000WO-US008020.  
 XX 06-APR-1999; 99US-0127958P.  
 XX (UYBC-) UNIV EAST CAROLINA.  
 XX (NYCE/) NYCE J W.  
 XX Nyce JW;  
 XX WPI; 2000-679539/66.  
 XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
 PT adenosine receptors during metabolism, useful e.g. for treating cancers  
 PT and respiratory obstructions.  
 XX Claim 14; Page 145; 1592pp; English.  
 XX The present invention describes low adenosine (A) content antisense  
 CC oligonucleotides and compositions (I) comprising them. In the antisense  
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.  
 CC The antisense oligonucleotides and (I) can be used to down-regulate the  
 CC expression and/or activity of target polypeptides associated with  
 CC lung/respiratory disorders and malignancies, such as stimulating and  
 CC activating peptide factors and transmitters, transcription factors,  
 CC immunoglobulins and antibodies, antibody receptors, cytokines and  
 CC chemokines, endogenously produced specific and non-specific enzymes,  
 CC binding proteins, adhesion molecules and their receptors, cytokine and  
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
 CC nervous system (CNS) and peripheral nervous and non-nervous system  
 CC receptors, CNS and peripheral nervous and non-nervous system peptide  
 CC transmitters, defensins, growth factors, vasoactive peptides and  
 CC receptors, binding proteins and malignancy associated proteins. The  
 CC antisense oligonucleotides may be used in this way to treat disorders  
 CC including respiratory obstruction (especially pulmonary obstruction  
 CC and/or bronchoconstriction) and/or lung inflammation, allergies) and/or  
 CC surfactant hypoproduction which are associated with a disease or  
 CC condition selected from pulmonary vasoconstriction, inflammation,  
 CC allergies, asthma, impeded respiration, respiratory distress syndrome  
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 CC fragments and antisense oligonucleotides used in the exemplification of  
 CC the present invention  
 XX Sequence 15 BP; 0 A; 2 C; 7 G; 6 T; 0 U; 0 Other;  
 SQ Query Match 1.5%; Score 13; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 12 GGGGTTTCGGTGG 24  
 |||||  
 DB 3 GGGGTTTCGGTGG 15  
 RESULT 435  
 AAF70268  
 ID AAF70268 standard; DNA; 15 BP.  
 XX  
 AC AAF70268;  
 XX  
 DT 20-APR-2001 (first entry)  
 XX Human DRD2 allele specific oligonucleotide probe SEQ ID NO:11.

XX Human; dopamine receptor D2; DRD2; polymorphism; allele specific;  
 KW drug target isogene; detection; single nucleotide polymorphism; SNP;  
 KW genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;  
 KW probe; PCR primer; ss.  
 XX Homo sapiens.  
 XX WO200105832-A1.  
 XX 25-JAN-2001.  
 XX 19-JUL-2000; 2000WO-US019644.  
 XX 19-JUL-1999; 99US-0144493P.  
 XX (GENA-) GENAISANCE PHARM INC.  
 XX Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;  
 XX WPI; 2001-091967/10.  
 XX Polynucleotides comprising single nucleotide polymorphisms in the human  
 PT dopamine receptor D2, useful for detecting mutations associated with,  
 PT e.g. schizophrenia, Parkinson's and myoclonus dystonia.  
 XX Claim 15; Page 21; 135pp; English.  
 CC The present invention describes polynucleotides comprising single  
 CC nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).  
 CC The polynucleotides may be used in assays to detect and characterise  
 CC polymorphisms in DRD2 that affect its expression and activity and are  
 CC involved in disorders such as schizophrenia, Parkinson's and myoclonus  
 CC dystonia (MD). This information would be useful for studying the  
 CC biological function of DRD2 as well as in identifying drugs targeting  
 CC this protein for the treatment of disorders related to its abnormal  
 CC expression or function. Polymorphisms in the DRD2 gene affect the  
 CC expression of active and functional polypeptides. Therefore it is  
 CC advantageous to detect polymorphisms in the DRD2 gene and how those  
 CC polymorphisms are combined in different copies of the gene. AAF70261 to  
 CC AAF70308 represent human DRD2 allele specific oligonucleotide probes, and  
 CC AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide  
 CC primers which are used in the detection of DRD2 polymorphisms. AAF70405  
 CC to AAF70452 represent oligonucleotide primers for the detection of human  
 CC DRD2 polymorphisms which are given in the exemplification of the present  
 CC invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2  
 CC gene which are used in examples from the present invention  
 XX Sequence 15 BP; 4 A; 3 C; 2 G; 6 T; 0 U; 0 Other;  
 SQ Query Match 1.5%; Score 13; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 737 CTGTTTCAATGAC 749  
 |||||  
 DB 1 CTGTTTCAATGAC 13  
 RESULT 436  
 ABZ95868  
 ID ABZ95868 standard; DNA; 15 BP.  
 XX  
 AC ABZ95868;  
 XX  
 DT 17-OCT-2003 (first entry)  
 XX Human eosinophil peroxidase antisense fragment no.1728.  
 DE  
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;  
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;



```

ID ADH17043 standard; DNA; 15 BP.
XX
AC ADH17043;
XX
DT 11-MAR-2004 (first entry)
XX
DE Tagman probe used to analyse human EphB4 sequence.
XX
XX tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
KW TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW migration inhibitory factor; MIG; probe; ss; human; EphB4.
XX
OS Homo sapiens.
XX
PN WO2003097854-A2.
XX
PD 27-NOV-2003.
XX
PF 19-MAY-2003; 2003WO-US015711.
XX
PR 17-MAY-2002; 2002US-0380872P.
PR 24-FEB-2003; 2003US-0448874P.
PR 24-FEB-2003; 2003US-0448922P.
XX
PA (SUGEN) SUGEN INC.
XX
PI Morimoto A, DePrimo S, O'farrell A, Smolich BD, Manning WC;
PI Walter SA, Schilling JW, Cherrington J;
XX
DR WPI; 2004-042604/04.
XX
XX Determining whether a test compound inhibits tyrosine kinase activity in
PT a mammal by exposing the mammal to the test compound and measuring in the
PT mammal the level of at least one of the measured proteins or mRNA
PT transcripts.
XX
XX Example K; SEQ ID NO 42; 408pp; English.
PS
XX The invention relates to a novel method for determining whether a test
XX compound inhibits tyrosine kinase activity in a mammal comprising
XX measuring in the mammal the level of at least one of the proteins and/or
XX mRNA transcripts or genes for such proteins comprising type 1 plasminogen
XX activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
XX metalloproteinase 1), vinculin, vascular endothelial growth factor
XX (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
XX migration inhibitory factor (MIG), exposing the mammal to the test
XX compound and then measuring in the mammal the level of at least one of
XX the proteins and/or mRNA transcripts previously measured. The method of
XX the invention may be useful for determining whether a test compound
XX inhibits tyrosine kinase activity in a mammal. The current sequence is
XX that of the Tagman probe which was used in the exemplification of the
XX invention.
XX
SQ Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.5%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 ACTTGGGCAAGG 453
DB 13 ACTTGGGCAAGG 1

RESULT 439
ADM56222/c
ID ADM56222 standard; DNA; 16 BP.
XX
AC ADM56222;
XX
DT 03-JUN-2004 (first entry)
XX
XX Aspergillus oryzae TAKA amylase PCR primer AMY5.
XX
KW Host cell; biopesticide; amylase; enzyme; PCR; primer; ss.
XX
OS Aspergillus oryzae.
XX
PN WO2004020611-A1.
XX
PD 11-MAR-2004.
XX
PF 29-AUG-2003; 2003WO-BE000143.
XX
PR 30-AUG-2002; 2002US-0407843P.
XX
PA (PURA-) PURATOS NV.
XX
PI Jonniaux J, Valepyn E, Corbisier A, Dauvrin T;
XX
DR WPI; 2004-239191/22.
XX
XX New Myrothecium host cell comprising at least one recombinant DNA
PT construct, useful as cell factory for industrial enzyme and/or protein
PT production for producing therapeutic drugs, and as source of
PT biopesticide.
XX
XX Example 3; SEQ ID NO 31; 83pp; English.
XX
XX The present sequence is that of PCR primer AMY5. In an example from the
XX invention, this primer and primer GPD2 ADM56221 for the glyceraldehyde-3-
XX phosphate dehydrogenase (GPD) promoter were used to detect the presence
XX of amylase expression vector p2G-S in Myrothecium sp. transformants,
XX verifying integration of the vector in the Myrothecium genome without
XX amplification of the endogenous amylase gene or GPD promoter. The vector
XX was used to transform Myrothecium gramineum (syn. Xepiculopsis graminea)
XX strain MUGL39210 and Aspergillus niger MUC28817 protoplasts. On average,
XX the Myrothecium transformants produced 2.75 times more alpha-amylase than
XX the Aspergillus transformants. The invention relates to the use of
XX Myrothecium spp. as host cells. Myrothecium sp. host cells were found to
XX be easy to transform, easy to culture, to have a high growth rate coupled
XX to high biomass production, and to be suitable for large-scale or
XX industrial production of proteins of interest, such as enzymes (e.g.
XX amylase or xylanase) or therapeutic drugs. Applications include protein
XX and/or enzyme production for food and/or therapeutic applications, and
XX the use of transformed Myrothecium as a biopesticide (claimed).
XX
SQ Sequence 16 BP; 3 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 1.5%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 109 GCAGGGCATCATC 121
DB 14 GCAGGGCATCATC 2

RESULT 440
AAK69153
ID AAK69153 standard; RNA; 17 BP.
XX
AC AAK69153;
XX
DT 28-JUL-1999 (first entry)
XX
XX Human flt1 VEGF receptor hammerhead ribozyme substrate #448.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Homo sapiens.

```

```

XX PN WO9715662-A2.
XX PD
XX PF 01-MAY-1997.
XX PR
XX PF 25-OCT-1996; 96WO-US017480.
XX PR
XX PF 26-OCT-1995; 95US-0005974P.
XX PR
XX PF 11-JAN-1996; 96US-00584040.
XX PR
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (CHIR) CHIRON CORP.
XX PI
XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX DR
XX XX
XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX PT rheumatoid arthritis, etc., in a human patient.
XX PS
XX PS Claim 4; Page 60; 218pp; English.
XX CC
XX CC The present invention describes nucleic acid molecules which modulate the
XX CC synthesis, expression and/or stability of a mRNA encoding 1 or more
XX CC receptors of vascular endothelial growth factor (VEGF). A patient
XX CC (preferably human) having a condition associated with the level of the
XX CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX CC treated by administering the nucleic acid molecule or the expression
XX CC vector to the patient. AAX67275 to AAX75752 represent specific examples
XX CC of nucleic acid molecules from the present invention
XX CC
XX CC Sequence 17 BP; 7 A; 2 C; 5 G; 0 T; 3 U; 0 Other;
XX SQ
XX
XX Query Match 1.5%; Score 13; DB 1; Length 17;
XX Best Local Similarity 76.9%; Pred. No. 4.4e+02;
XX Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 691 ATCACTTGGAGCA 703
XX Bb 3 AUCACUUGAGCA 15
XX
XX RESULT 441
XX ABK00483/C
XX ID ABK00483 standard; RNA; 17 BP.
XX AC ABK00483;
XX XX
XX DT 12-MAR-2002 (first entry)
XX DE
XX DE Human NOGO Hammerhead Ribozyme #483.
XX KW
XX KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
XX KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
XX KW inflammatory arthropathy; central nervous system injury;
XX KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX KW Parkinson's disease; ataxia; Huntington's disease;
XX KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN WO200159103-A2.

```

---

```

PD XX 16-AUG-2001.
XX PF 09-FEB-2001; 2001WO-US004273.
XX PR
XX PR 11-FEB-2000; 2000US-0181797P.
XX PR 28-FEB-2000; 2000US-0185516P.
XX PR 06-MAR-2000; 2000US-0187128P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (CHOW/) CHOWRIRA B M.
XX PI
XX PI Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX DR
XX XX
XX PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX PT constructs, which down regulate expression of a CD20 gene or neurite
XX PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX PT central nervous system injury.
XX PS
XX PS Claim 88; Page 73; 200pp; English.
XX CC
XX CC The invention relates to a nucleic acid molecule which down regulates
XX CC expression of a CD20 gene and a nucleic acid molecule which down
XX CC regulates expression of a neurite growth inhibitor gene (NOGO). The
XX CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
XX CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
XX CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX CC of CD20 in the presence of a divalent cation that is preferably Mg2++.
XX CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX CC the cell and treat a patient having a condition associated with the level
XX CC of CD20. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the CD20 targeting nucleic acid may be used to
XX CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
XX CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX CC presence of a divalent cation that is preferably Mg2++. Furthermore, the
XX CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX CC cell and treat a patient having a condition associated with the level of
XX CC NOGO. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX CC treat central nervous system (CNS) injury and cerebrovascular accident
XX CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX CC disease, muscular dystrophy, and/or other neurodegenerative disease
XX CC states which respond to the modulation of NOGO expression. The present
XX CC sequence is a hammerhead ribozyme of the invention
XX SQ
XX Sequence 17 BP; 6 A; 3 C; 3 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.5%; Score 13; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 675 GAGAACTGATTT 687
XX Bb 17 GAGAACTGATTT 5
XX
XX RESULT 442
XX ID ABK00485/C
XX ID ABK00485 standard; RNA; 17 BP.
XX XX
XX AC ABK00485;
XX XX

```

DT 12-MAR-2002 (first entry)  
 XX Human NOGO Hammerhead Ribozyme #485.  
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX WO200159103-A2.  
 XX 16-AUG-2001.  
 XX 09-FEB-2001; 2001WO-US004273.  
 XX 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX Blatt L, Mcswiggen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX Claim 88; Page 73; 200pp; English.  
 XX The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberyne (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapeutics. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapeutics. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a hammerhead ribozyme of the invention  
 XX SQ Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 674 TGAGAACTGATT 686  
 |||||  
 Db 13 TGAGAACTGATT 1  
 |||||  
 RESULT 443  
 ACA07852  
 ID ACA07852 standard; RNA; 17 BP.  
 XX ACA07852;  
 AC ACA07852;  
 DT 03-JUN-2003 (first entry)  
 XX NFKB sub-unit modulating zinzyme substrate #251.  
 DE Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX Homo sapiens.  
 OS US2002177568-A1.  
 XX 28-NOV-2002.  
 XX 23-MAY-2001; 2001US-00864785.  
 XX 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX (STIN/) STINCHOMB D T.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (DRAP/) DRAPER K G.  
 XX Stinchcomb DT, Mcswiggen J, Draper KG;  
 WPI; 2003-340953/32.  
 XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX Claim 3; Page 41; 72pp; English.  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.

CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC chemotherapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 CC  
 CC Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 17;

Best Local Similarity 76.9%; Pred. No. 4.4e+02; Mismatches 0; Indels 0; Gaps 0;

QY 830 CCTGTATGGCAC 842

Db 5 CCCUGAUGGCAC 17  
 |||:|:|:|:|

RESULT 444

ACA07853  
 ID ACA07853 standard; RNA; 17 BP.

AC ACA07853;

DT 03-JUN-2003 (first entry)

DE NFkB sub-unit modulating zinzyme substrate #252.

KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherap; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

OS Homo sapiens.

XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

XX 18-MAY-1994; 94US-00245466.

XX 15-AUG-1994; 94US-00291932.

XX 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHOMB D T.

PA (MCSW/) MCSWIGGEN J.

PA (DRAP/) DRAPER K G.

PI Stinchcomb DT, Mcswiggen J, Draper KG;

DR WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.

PS Claim 3; Page 41; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC chemotherapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 CC  
 CC Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.5%; Score 13; DB 1; Length 17;

Best Local Similarity 69.2%; Pred. No. 4.4e+02;

Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 831 CCTGTATGGCACT 843

Db 1 CCUGAUGGCACU 13  
 |||:|:|:|:|

RESULT 445

ACC67156/C  
 ID ACC67156 standard; DNA; 17 BP.

XX ACC67156;

XX 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 4403.  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Anson R, Tuijnder M;

```

DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 545; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC6806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 681 CTGATTATGATC 693
DB 13 CTGATTATGATC 1
RESULT 446
ADL51944/c
ID ADL51944 standard; RNA; 17 BP.
XX
AC ADL51944;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PTGDR substrate sequence #1063.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX

```

---

```

PS Claim 161; SEQ ID NO 5477; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/perfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 196 TGGATTCCATGTT 208
DB 16 TGGATTCCATGTT 4
RESULT 447
ADL51759/c
ID ADL51759 standard; RNA; 17 BP.
XX
AC ADL51759;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PTGDR substrate sequence #878.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX

```

PS Claim 161; SEQ ID NO 5292; 317pp; English.  
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.  
 XX  
 SQ Sequence 17 BP; 6 A; 4 C; 3 G; 0 T; 4 U; 0 Other;  
 Query Match 1.5%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 4.4e+02; Mismatches 0; Gaps 0;  
 Matches 13; Conservative 0; Indels 0;  
 QY 196 TGGATTCATGTT 208  
 DB 13 TGGATTCATGTT 1  
 RESULT 448  
 ADL51945/C  
 ID ADL51945 standard; RNA; 17 BP.  
 XX  
 AC ADL51945;  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PTGDR substrate sequence #1064.  
 XX  
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 KW substrate; ds.  
 XX  
 OS Unidentified.  
 XX  
 XX WO200281628-A2.  
 XX  
 PD 17-OCT-2002.  
 XX  
 PF 03-APR-2002; 2002WO-US010512.  
 XX  
 PR 05-APR-2001; 2001US-00827395.  
 PR 29-MAY-2001; 2001US-0294412P.  
 PR 28-AUG-2001; 2001US-0315315P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;  
 PI WPI; 2003-058513/05.  
 DR  
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
 XX

PS Claim 161; SEQ ID NO 5478; 317pp; English.  
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.  
 XX  
 SQ Sequence 17 BP; 6 A; 4 C; 3 G; 0 T; 4 U; 0 Other;  
 Query Match 1.5%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 4.4e+02; Mismatches 0; Gaps 0;  
 Matches 13; Conservative 0; Indels 0;  
 QY 196 TGGATTCATGTT 208  
 DB 15 TGGATTCATGTT 3  
 RESULT 449  
 AAC68370  
 ID AAC68370 standard; DNA; 16 BP.  
 XX  
 AC AAC68370;  
 DT 20-FEB-2001 (first entry)  
 XX  
 DE Human IRRR oligonucleotide #26.  
 XX  
 KW Insulin receptor-related receptor; IRRR; chromosome 1q21-q24; obesity;  
 KW dyslipidemia; diabetes; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO2000065090-A2.  
 XX  
 PD 02-NOV-2000.  
 XX  
 PF 19-APR-2000; 2000WO-US010644.  
 XX  
 PR 22-APR-1999; 99US-00296906.  
 PR 22-JUN-1999; 99US-00337976.  
 XX  
 XX (ZYMO ) ZYMOGENETICS INC.  
 XX  
 XX Lok S, Whitmore TE;  
 XX WPI; 2000-687365/67.  
 XX  
 XX Detecting a chromosome 1q21-q24 abnormality for diagnosing metabolic  
 PT disease, such as human obesity and diabetic disorders, comprises  
 PT examining insulin receptor-related receptor gene and its gene products.  
 XX  
 PS Claim 10; Page 43; 111pp; English.  
 XX  
 CC The present invention relates to insulin receptor-related receptor  
 CC (IRRR). Mutations in this gene indicate a chromosome 1q21-q24  
 CC abnormality. IRRR polypeptides and DNA may be useful in the diagnosis of  
 CC disorders associated with abnormal expression of the IRRR protein, for  
 CC example obesity, dyslipidemia and diabetes  
 XX  
 SQ Sequence 16 BP; 3 A; 5 C; 4 G; 4 T; 0 U; 0 Other;





```

Query Match      1.5%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 94 GGGCGACGCCCGCAGTG 109
Db 1 GGGCGACGCCCGCAGTG 16

RESULT 452
AAQ47893
ID AAQ47893 standard; DNA; 17 BP.
XX
AC AAQ47893;
XX
DT 25-MAR-2003 (revised)
DT 28-MAR-1994 (first entry)
XX
SSP for flavonoid-3',5'-hydroxylase gene.
DE
XX Flavonoid-3',5'-hydroxylase; transformation; plants; petunia; rose;
KW tobacco; pigment alteration; blue; SSP; single specific primer; PCR;
KW polymerase chain reaction; amplification; expression; ss.
XX
OS Synthetic.
XX
XX WO9318155-A1.
XX
PD 16-SEP-1993.
XX
PF 20-NOV-1992; 92WO-JP001520.
XX
PR 02-MAR-1992; 92JP-00044963.
XX
PA (KYOW) KYOWA HAKKO KOGYO CO LTD.
XX
XX Kikuchi Y, Kiyokawa S, Shimada Y, Ohbayashi M, Shimada R;
PI Okinaka Y;
XX
DR WPI; 1993-303469/38.
XX
Gene coding for flavonoid-3',5'-hydroxylase of petunia petals - used to
PT transform plants e.g. petunia, rose or tobacco to give bluer flower
PT colour and altered pigment pattern.
XX
PS Claim 11; Page 64; 82pp; Japanese.
XX
Insertion of the sequences (AAQ47840-42) into plants such as rose,
CC petunia, tobacco and carnation, using a suitable vector such as
CC agrobacterium, gave transformed plants which express the gene, resulting
CC in petals with a bluer colour than normal, and/or pigmentation patterns
CC which do not occur naturally. The sequences were amplified using primers
CC (AAQ47843-70). Related single specific primers using a gene sequence
CC coding for the haem-binding region of cytochrome P450 are shown in
CC (AAQ47871-Q47903). (Updated on 25-MAR-2003 to correct FN field.)
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 2 T; 0 U; 1 Other;

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 CCAGGACCTCGCGGTGG 53
Db 1 CCNGGACATCGCGGTGG 17

RESULT 453
AAQ72611/c
ID AAQ72611 standard; RNA; 17 BP.
XX
AC AAQ72611;
XX

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 790 TTGTGCAGATTTCCTTT 805
Db 16 TTGTGCAGTAIGTCCTTT 1

RESULT 454
AAQ75166
ID AAX75166 standard; RNA; 17 BP.
XX
AC AAX75166;
XX
DT 28-JUL-1999 (first entry)
DE
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #694.
XX
Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
XX WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
(RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
PI WPI; 1997-259017/23.
XX
Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
Claim 4; Page 123; 218pp; English.
XX
The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 9 A; 3 C; 2 G; 0 T; 3 U; 0 Other;

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 790 TTGTGCAGATTTCCTTT 805
Db 16 TTGTGCAGTAIGTCCTTT 1

RESULT 454
AAQ75166
ID AAX75166 standard; RNA; 17 BP.
XX
AC AAX75166;
XX
DT 28-JUL-1999 (first entry)
DE
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #694.
XX
Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.

```



XX CC The present invention describes nucleic acid molecules which modulate the  
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more  
 CC receptors of vascular endothelial growth factor (VEGF). A patient  
 CC (preferably human) having a condition associated with the level of the  
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing  
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour  
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be  
 CC treated by administering the nucleic acid molecule or the expression  
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples  
 CC of nucleic acid molecules from the present invention  
 XX SQ Sequence 17 BP; 6 A; 4 C; 2 G; 0 T; 5 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 357 TGTCTATTGAAGATTC 372  
 Db 17 TGTAGATTGAAGATTC 2  
 RESULT 457  
 AAT76334  
 ID AAT76334 standard; DNA; 17 BP.  
 AC AAT76334;  
 XX DT 15-SEP-1997 (first entry)  
 XX DE Human fibronectin antisense oligonucleotide HUMFNA/HSFIBIASI.  
 XX KW Asthma; airway epithelium; adenosine free; cystic fibrosis;  
 XX KW chronic obstructive pulmonary disease; bronchitis; ss.  
 XX OS Synthetic.  
 XX PN WO9640162-A1.  
 XX PD 19-DEC-1996.  
 XX PF 06-JUN-1996; 96WO-US009306.  
 XX PR 07-JUN-1995; 95US-00474497.  
 XX PA (UYEC-) UNIV EAST CAROLINA.  
 XX PI Nyce JW, Metzger WJ;  
 XX WPI; 1997-051871/05.  
 XX Treatment of airway diseases such as asthma - by topically applying  
 XX adenosine-free antisense oligo:nucleotide to airway epithelium of  
 XX subject.  
 XX Claim 5; Page 36; 71pp; English.  
 XX A method for treating airway disease in a subject has been produced,  
 XX which involves the topical administration of an essentially adenosine  
 XX free antisense oligonucleotide (ON) to the airway epithelium of the  
 XX subject. The present sequence is an antisense oligonucleotide  
 XX HUMFNA/HSFIBIASI specific for the human fibronectin. The method can be  
 XX used to treat airway diseases such as cystic fibrosis, asthma, chronic  
 XX obstructive pulmonary disease, bronchitis and other airway diseases  
 XX characterised by an inflammatory response. By eliminating adenosine from  
 XX the antisense ON, its liberation upon administration is prevented,  
 XX thereby preventing adenosine- induced bronchoconstriction in patients  
 XX with hyper-reactive airways  
 XX SQ Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 14 GGTTCCTTCGTCATC 29  
 Db 2 GGTTCCTTCGTCATC 17  
 RESULT 458  
 AAV97938/c  
 ID AAV97938 standard; RNA; 17 BP.  
 XX AC AAV97938;  
 XX DT 17-MAR-1999 (first entry)  
 XX DE Human EGF-R target sequence nucleotide position 5137.  
 XX KW Human; epidermal growth factor receptor; EGF-R; target sequence;  
 XX KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;  
 XX KW cancer; genetic drift; detection; mutation; ss.  
 XX OS Homo sapiens.  
 XX PN WO9833893-A2.  
 XX PD 06-AUG-1998.  
 XX PF 14-JAN-1998; 98WO-US000730.  
 XX PR 31-JAN-1997; 97US-0036476P.  
 XX PR 04-DEC-1997; 97US-00985162.  
 XX PA (RIBO-) RIBOZYME PHARM INC.  
 XX PA (UYAS-) UNIV ASTON.  
 XX PI Akhtar S, Fell P, Mcswiggen JA;  
 XX WPI; 1998-437449/37.  
 XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal  
 XX growth factor receptor, useful for inhibiting cell proliferation and for  
 XX treating cancers.  
 XX Claim 5; Page 83; 109pp; English.  
 XX The present invention describes enzymatic nucleic acid molecules (NAME)  
 XX which specifically cleave RNA derived from an epidermal growth factor  
 XX receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090  
 XX represent specifically claimed target sequence from human EGF-R. AAV98044  
 XX to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and  
 XX hairpin ribozymes respectively for human EGF-R. The NAMS are useful for  
 XX cleaving EGF-R RNA in the treatment of a condition associated with EGF-R  
 XX expression levels e.g. to inhibit cell proliferation in the prevention or  
 XX treatment of cancers. The NAMS can also be used as diagnostic tools to  
 XX examine genetic drift and mutations within diseased cells or to detect  
 XX the presence of EGF-R RNA in a cell  
 XX SQ Sequence 17 BP; 6 A; 1 C; 3 G; 0 T; 7 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 114 GCATCATCAATTTCGA 129  
 Db 17 GCATTATCAATTTCGA 2  
 RESULT 459  
 AAV96466/c  
 ID AAV96466 standard; RNA; 17 BP.  
 XX

```

AC AAV96466;
XX
DT 01-MAR-1999 (first entry)
XX
DE Potato citrate synthase target sequence position 462.
XX
KW Solanidine, glucosyltransferase; potato; citrate synthase; target;
KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW flower formation; cleavage; solanaceous plant; ss.
XX
OS Solanum tuberosum.
XX
PN WO9832843-A2.
XX
PD 30-JUL-1998.
XX
PF 14-JAN-1998; 98WO-US000738.
XX
PR 28-JAN-1997; 97US-0036545P.
PR 28-JAN-1997; 97US-0036599P.
PR 24-NOV-1997; 97US-00979416.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Zwick MG, Mcswiggen JA;
XX
XX WPI; 1998-427939/36.
XX
XX New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
XX biosynthesis or regulating flowering.
XX
XX Claim 53; Page 53; 79pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with RNA
XX -cleaving activity (e.g. ribozymes) which are capable of modulating the
XX expression of plant genes: (i) involved in biosynthesis of alkaloids; or
XX (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
XX AAV96334 represent potato solanidine glucosyltransferase hammerhead and
XX hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
XX AAV96734 represent potato solanidine glucosyltransferase target
XX sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
XX potato citrate synthase hammerhead and hairpin ribozymes, respectively.
XX AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
XX synthase target sequences. Ribozymes of the present invention can be used
XX to inhibit the synthesis of toxic alkaloids in solanaceous plants,
XX particularly potato but also tomato, pepper, aubergine and ditura or to
XX inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
XX arugula, kale, collards, chard, beet, turnip, sweet potato and turf.
XX grass. Also the ribozymes can be used for RNA manipulation in the same
XX way that restriction endonucleases are for DNA, as well as to examine
XX genetic drift and mutations in plants and to detect specific RNA. The
XX ribozymes can be targeted to specific genes or to consensus sequences
XX within a family of related genes, and being catalytic need to be present
XX at only very low concentrations
XX
SQ Sequence 17 BP; 3 A; 3 C; 4 G; 0 T; 7 U; 0 Other;
    Query Match 1.5%; Score 12.8; DB 1; Length 17;
    Best Local Similarity 87.5%; Pred. No. 4.6e+02;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 CTATTAAAGAAATCCA 869
DB 16 CTGTTAAAGAAAGCCA 1

RESULT 460
AAV49098/c
ID AAV49098 standard; DNA; 17 BP.
XX
AC AAV49098;
XX
DT 15-OCT-1998 (first entry)

```

```

XX rb gene antisense oligonucleotide rb-N-46.
DE
XX rb gene; antisense oligonucleotide; modulate; gene expression; ss.
KW
XX Synthetic.
OS Homo sapiens.
XX
PN EP856579-A1.
XX
PD 05-AUG-1998.
XX
PF 31-JAN-1997; 97EP-00101531.
XX
PR 31-JAN-1997; 97EP-00101531.
XX
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
XX Schlingensiepen K, Bryech W;
XX
XX WPI; 1998-400910/35.
XX
XX Preparation of antisense oligonucleotide(s) which lack long runs of
XX consecutive guanosine or inosine - and have specific ratio of residues
XX able to form two or three hydrogen bonds, have greater activity and
XX reduced toxicity, used therapeutically or to modulate growth of cells in
XX culture.
XX
XX Example 7; Fig 9a; 286pp; English.
XX
XX AAV49008-236 represent antisense oligonucleotides directed against the rb
XX gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
XX downregulation of negative growth control by rb, while oligonucleotides
XX AAV49052-236 had little effect. The oligonucleotides exemplify the
XX invention. The specification describes oligonucleotides that contain 8-30
XX nucleotides, which contain at most 8 nucleotides that can each form three
XX hydrogen bonds to cytosine; do not contain four consecutive nucleotides
XX able to form three H-bonds each to four consecutive cytosines; do not
XX contain two sequences of three consecutive nucleotides each able to form
XX three H-bonds to three consecutive cytosines, and the ratio between
XX residues able to form two H-bonds each (2R) or three such bonds (3R) is
XX given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
XX expression of genes, particularly the genes for p53, ErbB-2, junB, junD,
XX TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
XX (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
XX and/or keratinocytes). The oligonucleotides can also be used to analyse
XX function of proteins (by altering their expression or activity) and
XX therapeutically, e.g. in cases of cancer or (targeting TGF) for
XX stimulating the immune system
XX
XX Sequence 17 BP; 7 A; 1 C; 1 G; 8 T; 0 U; 0 Other;
SQ
    Query Match 1.5%; Score 12.8; DB 1; Length 17;
    Best Local Similarity 87.5%; Pred. No. 4.6e+02;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 730 AAAATGCTCTGTTTCAA 745
DB 16 AAAATGTTTATTTCAA 1

RESULT 461
AAA20557
ID AAA20557 standard; RNA; 17 BP.
XX
XX AAA20557;
XX
XX 19-JUN-2000 (first entry)
DE
XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:3783.
XX
XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiotensin;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;

```

KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberosus scleriosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX WO9950403-A2.  
 FN  
 XX 07-OCT-1999.  
 PD  
 XX  
 XX 24-MAR-1999; 99WO-US006507.  
 PF  
 XX 27-MAR-1998; 98US-0079678P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 PI  
 XX WPI; 1999-591315/50.  
 DR  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 PT  
 XX Claim 55; Page 153; 305pp; English.  
 PS  
 XX The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23262, AAA23343 to  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberosus scleriosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 SQ Sequence 17 BP; 5 A; 1 C; 7 G; 0 T; 4 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 68.8%; Pred. No. 4.6e+02;  
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
 QY 437 GATGACTGGGCAAG 452  
 DB 2 GAUGACUUGGAAGG 17  
 ||:|||||  
 ||:|||||  
 RESULT 462  
 AAA21390/c  
 ID AAA21390 standard; RNA; 17 BP.  
 XX  
 XX  
 AC AAA21390;  
 XX  
 DT 19-JUN-2000 (first entry)

XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4616.  
 DE  
 XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberosus scleriosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX WO9950403-A2.  
 FN  
 XX 07-OCT-1999.  
 PD  
 XX  
 XX 24-MAR-1999; 99WO-US006507.  
 PF  
 XX 27-MAR-1998; 98US-0079678P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 PI  
 XX WPI; 1999-591315/50.  
 DR  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 PT  
 XX Claim 55; Page 205; 305pp; English.  
 PS  
 XX The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23262, AAA23343 to  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberosus scleriosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 SQ Sequence 17 BP; 6 A; 2 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 603 AACATTAAACACTGT 618  
 DB 17 AGACTTTAAACACTGT 2  
 ||:|||||  
 ||:|||||  
 RESULT 463  
 AAA21391/c

ID AAA21391 standard; RNA; 17 BP.  
 AC AAA21391;  
 XX  
 DT 19-JUN-2000 (first entry)  
 DE  
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4617.  
 XX  
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX WO9950403-A2.  
 PN  
 XX  
 XX 07-OCT-1999.  
 XX  
 XX 24-MAR-1999; 99WO-US006507.  
 PF  
 XX 27-MAR-1998; 98US-0079678P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 PI WPI; 1999-591315/50.  
 DR  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 XX  
 XX Claim 55; Page 205; 305pp; English.  
 PS  
 CC The present invention describes enzymatic cleave RNA molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to  
 CC AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,  
 CC and AA17168 to AA17560 and AA17623 to AA17684 represent their  
 CC corresponding target sequences; AA17685 to AA18385 and AA19087 to  
 CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086  
 CC and AA19155 to AA19222 represent their corresponding target sequences;  
 CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and  
 CC AA21596 to AA21688 represent their corresponding target sequences;  
 CC AA21689 to AA22475 and AA23263 to AA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AA22476 to AA23262, AA23343 to  
 CC AA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 SQ Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 603 AAACATTAACACTGT 618  
 | || ||||| |||||

Db 16 AGACTTTAAACACTGT 1  
 RESULT 464  
 AAX54136  
 ID AAX54136 standard; DNA; 17 BP.  
 XX  
 AC AAX54136;  
 XX  
 DT 05-JUL-1999 (first entry)  
 DE  
 DE Human fibronectin antisense oligonucleotide fragment.  
 XX  
 KW Antisense oligonucleotide; multiple target; antisense treatment;  
 KW impaired respiration; inflammation; lung disease;  
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
 KW acute asthma; allergy; asthma; impeded respiration;  
 KW respiratory distress syndrome; pain; cystic fibrosis;  
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
 KW prostate cancer; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX WO9913886-A1.  
 PN  
 XX 25-MAR-1999.  
 PD  
 XX 17-SEP-1998; 98WO-US019419.  
 PF  
 XX 17-SEP-1997; 97US-0059160P.  
 PR  
 XX 09-JUN-1998; 98US-00093972.  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 XX Nyce JW;  
 PI  
 XX WPI; 1999-229400/19.  
 DR  
 XX New antisense oligonucleotides used in treatment of, e.g. pulmonary  
 PT vasoconstriction.  
 XX  
 XX Disclosure; Page 55; 120pp; English.  
 PS  
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)  
 CC directed against at least 2 mRNAs selected from target genes, coding and  
 CC non-coding regions of RNAs corresponding to target genes, gene initiation  
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-  
 CC end and the juxta-section between coding and non-coding regions and all  
 CC segments of RNAs encoding proteins associated with one or more diseases,  
 CC conditions or mixtures. The antisense oligonucleotides may be derived  
 CC from sequences AAX55272-74. These multiple target oligonucleotides  
 CC (specifically AAX55180-271) can be used for the antisense treatment of  
 CC diseases and conditions. Typical diseases and conditions are those  
 CC associated with impaired respiration and inflammation, including lung  
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,  
 CC acute asthma, allergies, asthma, impeded respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,  
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary  
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.  
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,  
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as  
 CC well as all types of cancers which may metastasize or have metastasized  
 CC to the lungs, including breast and prostate cancer  
 XX  
 SQ Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 14 GGTTCCTGTCAGTC 29  
 Db 2 GGTTCCTGTCAGTC 17

RESULT 465  
 AAA33580  
 ID AAA33580 standard; DNA; 17 BP.  
 AC AAA33580;  
 XX  
 DT 28-JUL-2000 (first entry)  
 XX  
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1269.  
 XX  
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;  
 KW phosphorothioate; impaired respiration; inflammation; allergy;  
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;  
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;  
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;  
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;  
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;  
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200009525-A2.  
 XX  
 PD 24-FEB-2000.  
 XX  
 PF 03-AUG-1999; 99WO-US017712.  
 XX  
 PR 03-AUG-1998; 98US-0095212P.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI Nyce JW;  
 XX  
 DR WPI; 2000-205971/18.  
 XX  
 PT New antisense oligonucleotides useful for treating e.g. pulmonary  
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,  
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or  
 PT cancers.  
 XX  
 PS Claim 18; Page 423; 1343pp; English.  
 XX  
 CC The present invention describes a new composition comprising an antisense  
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets  
 CC nucleic acids involved in bronchoconstriction, allergies, and/or  
 CC inflammation. The ON can have antiinflammatory, antiallergic,  
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are  
 CC useful for the treatment of diseases associated with inflammation,  
 CC impaired airways, including lung disease and diseases whose secondary  
 CC effects afflict the lungs of a subject. They can be used for treating  
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,  
 CC carcinomas, and cancers which may metastasize to the lungs, including  
 CC breast and prostate cancer. The reduction of the adenosine content of the  
 CC ONs reduces side effects. The A-containing ONs break down with the  
 CC release of deoxyadenosine which activates adenosine receptors causing  
 CC bronchoconstriction and inflammation. AAA33213 to AAA35312 represent the  
 CC nucleotide sequences given in the sequence listing from the present  
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.  
 CC Sequences given in the disclosure of the present invention do not match  
 CC up with their corresponding SEQ ID NO: sequences given in the sequence  
 CC listing

QY 14 GGTTCCTGTCAGTC 29  
 Db 2 GGTTCCTGTCAGTC 17

RESULT 466  
 AAZ97540  
 ID AAZ97540 standard; DNA; 17 BP.  
 XX  
 AC AAZ97540;  
 XX  
 DT 15-SEP-2003 (revised)  
 DT 26-APR-2000 (first entry)  
 XX  
 DE HIV-1 protease gene probe SEQ ID NO:30.  
 XX  
 KW Human immunodeficiency virus; HIV; protease; probe; detection;  
 KW drug selected mutation; hybridisation; genotyping; infection;  
 KW drug resistance; ss.  
 XX  
 OS Human immunodeficiency virus 1.  
 XX  
 PN WO9967428-A2.  
 XX  
 PD 29-DEC-1999.  
 XX  
 PF 22-JUN-1999; 99WO-EP004317.  
 XX  
 PR 24-JUN-1998; 98EP-00870143.  
 XX  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L;  
 XX  
 DR WPI; 2000-147219/13.  
 XX  
 PT Detection of drug-selected mutations in the HIV protease gene used to  
 PT treat HIV infections.  
 XX  
 PS Claim 3; Page 32; 76pp; English.  
 XX  
 CC The present invention describes the detection of drug-selected mutations  
 CC in the HIV protease gene. The method of detection allows the simultaneous  
 CC characterisation of a range of codons involved in drug resistance using  
 CC sets of probes optimised to function together in a reverse-hybridisation  
 CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use  
 CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV  
 CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and  
 CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,  
 CC and AAZ97516 represents an HIV protease probe used in an example from the  
 CC present invention. The method, probes and primers can be used for the  
 CC detection of drug-selected mutations in the HIV protease gene. The method  
 CC allows the simultaneous characterisation of a range of codons involved in  
 CC drug resistance. The method may also be used for HIV protease genotyping  
 CC assays. The probes are able to discriminate between wild type and mutated  
 CC protease sequences. The method allows rapid and reliable detection of  
 CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS  
 CC field)  
 XX  
 SQ Sequence 17 BP; 8 A; 2 C; 4 G; 3 T; 0 U; 0 Other;  
 XX

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAG 233  
 Db 2 GGTTCCTGTCAGTC 17

RESULT 466  
 AAZ97540  
 ID AAZ97540 standard; DNA; 17 BP.  
 XX  
 AC AAZ97540;  
 XX  
 DT 15-SEP-2003 (revised)  
 DT 26-APR-2000 (first entry)  
 XX  
 DE HIV-1 protease gene probe SEQ ID NO:30.  
 XX  
 KW Human immunodeficiency virus; HIV; protease; probe; detection;  
 KW drug selected mutation; hybridisation; genotyping; infection;  
 KW drug resistance; ss.  
 XX  
 OS Human immunodeficiency virus 1.  
 XX  
 PN WO9967428-A2.  
 XX  
 PD 29-DEC-1999.  
 XX  
 PF 22-JUN-1999; 99WO-EP004317.  
 XX  
 PR 24-JUN-1998; 98EP-00870143.  
 XX  
 PA (INNO-) INNOGENETICS NV.  
 XX  
 PI Stuyver L;  
 XX  
 DR WPI; 2000-147219/13.  
 XX  
 PT Detection of drug-selected mutations in the HIV protease gene used to  
 PT treat HIV infections.  
 XX  
 PS Claim 3; Page 32; 76pp; English.  
 XX  
 CC The present invention describes the detection of drug-selected mutations  
 CC in the HIV protease gene. The method of detection allows the simultaneous  
 CC characterisation of a range of codons involved in drug resistance using  
 CC sets of probes optimised to function together in a reverse-hybridisation  
 CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use  
 CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV  
 CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and  
 CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,  
 CC and AAZ97516 represents an HIV protease probe used in an example from the  
 CC present invention. The method, probes and primers can be used for the  
 CC detection of drug-selected mutations in the HIV protease gene. The method  
 CC allows the simultaneous characterisation of a range of codons involved in  
 CC drug resistance. The method may also be used for HIV protease genotyping  
 CC assays. The probes are able to discriminate between wild type and mutated  
 CC protease sequences. The method allows rapid and reliable detection of  
 CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS  
 CC field)  
 XX  
 SQ Sequence 17 BP; 8 A; 2 C; 4 G; 3 T; 0 U; 0 Other;  
 XX

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 218 GGAGATAATACAGCAG 233  
 Db 2 GGTTCCTGTCAGTC 17



```

Db      2 GCAGATAATACAGTAG 17

RESULT 467
AAZ97701
ID AAZ97701 standard; DNA; 17 BP.
AC AAZ97701;
XX
XX 15-SEP-2003 (revised)
DT 26-APR-2000 (first entry)
XX
XX HIV-1 protease gene probe SEQ ID NO:191.
DE
XX Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.
XX
XX Human immunodeficiency virus 1.
OS
XX WO9967428-A2.
PN
XX 29-DEC-1999.
PD
XX
XX 22-JUN-1999; 99WO-EP004317.
PF
XX
XX 24-JUN-1999; 98EP-00870143.
PR
XX (INNO-) INNOGENETICS NV.
PA
XX
XX Stuyver L;
PI
XX
XX WPI; 2000-147219/13.
DR
XX
XX Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.
PT
XX
XX Claim 3; Page 37; 76pp; English.
PS
XX
XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC drug resistance. The method may also be used for HIV protease genotyping
CC assays. The probes are able to discriminate between wild type and mutated
CC protease sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 712 GTTTTATAAACTCAG 727
Db 1 GTTTTATCAAGTCTAG 16

RESULT 468
AAA36411/C
ID AAA36411 standard; DNA; 17 BP.
XX
XX AAA36411;
AC

```

```

XX 26-JUL-2000 (first entry)
DT
XX Human genomic SNP allele specific oligonucleotide SEQ ID NO:477.
DE
XX Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW genomic classification; identification; DNA fingerprinting;
KW tumour characterisation; hybridisation; ss.
XX
XX Homo sapiens.
OS
XX WO200018960-A2.
PN
XX
XX 06-APR-2000.
PD
XX
XX 24-SEP-1999; 99WO-US022283.
PF
XX
XX 25-SEP-1998; 98US-0101757P.
PR
XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
PA
XX Landers JE, Jordan B, Housman DE, Charest A;
PI
XX WPI; 2000-293181/25.
DR
XX
XX Detection of single nucleotide polymorphisms in genomes by preparation
PT and analysis of reduced complexity genomes, useful for genotyping,
PT fingerprinting and determining allele frequency of SNPs.
PT
XX
XX Disclosure; Page 67; 111pp; English.
PS
XX
XX A method has been developed for detecting the presence or absence of a
CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC method comprises preparing a reduced complexity genome (RCG) from the
CC genomic sample and analysing the RCG for the presence or absence of a SNP
CC allele. The method can be used to characterise a tumour, to generate a
CC genomic pattern for an individual genome or to generate a genomic
CC classification code for a genome. The method can be used to assess
CC whether a subject is at risk for developing a disease or to identify a
CC set of SNP alleles associated with a disease. The method can also be used
CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC used in the exemplification of the present invention. AAA35948 to
CC AAA36632 represent nucleotide sequences containing SNPs
XX
SQ Sequence 17 BP; 1 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 428 GAAAAGCAGATGACT 443
Db 17 GAGAAAGCAGAGGACT 2

RESULT 469
AAF19702
ID AAF19702 standard; DNA; 17 BP.
XX
XX
XX AAF19702;
AC
XX
XX 14-MAR-2001 (first entry)
DT
XX Human fibronectin polynucleotide fragment #1269.
DE
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW

```

KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
 XX cancer; ss.  
 XX Homo sapiens.  
 XX WO200062736-A2.  
 XX 26-OCT-2000.  
 XX 24-MAR-2000; 2000WO-US008020.  
 XX 06-APR-1999; 99US-0127958P.  
 XX (UYEC-) UNIV EAST CAROLINA.  
 XX (NYCE/) NYCE J W.  
 XX Nyce JW;  
 XX WPI; 2000-679539/66.  
 XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
 XX adenosine receptors during metabolism, useful e.g. for treating cancers  
 XX and respiratory obstructions.  
 XX Claim 14; Page 220; 1592pp; English.  
 XX The present invention describes low adenosine (A) content antisense  
 XX oligonucleotides and compositions (I) comprising them. In the antisense  
 XX oligonucleotides the A is replaced by a 'Universal' or alternative base.  
 XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
 XX immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.  
 XX The antisense oligonucleotides and (I) can be used to down-regulate the  
 XX expression and/or activity of target polypeptides associated with  
 XX lung/respiratory disorders and malignancies, such as stimulating and  
 XX activating peptide factors and transmitters, such as stimulating and  
 XX immunoglobulins and antibodies, antibody receptors, cytokines and  
 XX chemokines, endogenously produced specific and non-specific enzymes,  
 XX binding proteins, adhesion molecules and their receptors, cytokine and  
 XX chemokine receptors, adenosine receptors, bradykinin receptors, central  
 XX nervous system (CNS) and peripheral nervous and non-nervous system  
 XX receptors, CNS and peripheral nervous and non-nervous system peptide  
 XX transmitters, defensins, growth factors, vasoactive peptides and  
 XX receptors, binding proteins and malignancy associated proteins. The  
 XX antisense oligonucleotides may be used in this way to treat disorders  
 XX including respiratory obstruction (especially pulmonary obstruction  
 XX and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
 XX surfactant hypoproduction which are associated with a disease or  
 XX condition selected from pulmonary vasoconstriction, inflammation,  
 XX allergies, asthma, impeded respiration, respiratory distress syndrome  
 XX (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 XX hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 XX pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 XX and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 XX fragments and antisense oligonucleotides used in the exemplification of  
 XX the present invention  
 XX Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 14 GGTTCCGTTGCAGTC 29  
 DB 2 GGTTCCCTTGGGTC 17  
 RESULT 470  
 AAF04934  
 ID AAF04934 standard; DNA; 17 BP.  
 XX  
 AC AAF04934;

XX 16-FEB-2001 (first entry)  
 DT  
 XX Hammerhead ribozyme substrate #2450.  
 DE  
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KW interferon alpha; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO200061729-A2.  
 XX 19-OCT-2000.  
 XX 11-APR-2000; 2000WO-US009721.  
 XX 12-APR-1999; 99US-0129390P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX Blatt L, Zwick M, Pavco P, Mcawiggen J;  
 XX WPI; 2000-647423/62.  
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 XX useful for producing e.g. granulocyte colony stimulating factor protein,  
 XX interferon alpha and erythropoietin.  
 XX Claim 4; Page 111; 164pp; English.  
 XX The present invention relates to enzymatic and antisense nucleic acid  
 XX molecules that act as inhibitors of the expression of repressor genes  
 XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
 XX factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
 XX Inhibition of the repressors removes prevents inhibition (and  
 XX consequently increases expression of) genes involved in the production of  
 XX erythropoietin, granulocyte colony stimulating factor protein and  
 XX interferon alpha  
 XX Sequence 17 BP; 5 A; 1 C; 5 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 776 GATGGGTATTAACTT 791  
 DB 2 GATGGGTATTAAACAT 17  
 RESULT 471  
 AAF04293/c  
 ID AAF04293 standard; DNA; 17 BP.  
 XX  
 AC AAF04293;  
 XX  
 XX 16-FEB-2001 (first entry)  
 DT  
 XX Hammerhead ribozyme substrate #1809.  
 DE  
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KW interferon alpha; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO200061729-A2.  
 XX 19-OCT-2000.  
 XX 11-APR-2000; 2000WO-US009721.  
 XX 12-APR-1999; 99US-0129390P.  
 XX



```

AC AAF05354;
XX
XX DT 16-FEB-2001 (first entry)
XX DE
XX DE Hammerhead ribozyme substrate #2573.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US009721.
XX PR 12-APR-1999; 99US-0129390P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX PS WPI; 2000-647423/62.
XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX PT useful for producing e.g. granulocyte colony stimulating factor protein,
XX PT interferon alpha and erythropoietin.
XX PS Claim 18; Page 115; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
XX CC Inhibition of the repressors removes prevents inhibition (and
XX CC consequently increases expression of) genes involved in the production of
XX CC erythropoietin, granulocyte colony stimulating factor protein and
XX CC interferon alpha
XX SQ Sequence 17 BP; 1 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 41 GACCTCGCGTGGCT 56
DB 1 GACCGCGTGGTGGCT 16
XX
RESULT 475
AAF06353/c
ID AAF06353 standard; DNA; 17 BP.
XX AC AAF06353;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #3150.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US009721.
XX PR 12-APR-1999; 99US-0129390P.

```

```

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX PS WPI; 2000-647423/62.
XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX PT useful for producing e.g. granulocyte colony stimulating factor protein,
XX PT interferon alpha and erythropoietin.
XX PS Claim 42; Page 128; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
XX CC Inhibition of the repressors removes prevents inhibition (and
XX CC consequently increases expression of) genes involved in the production of
XX CC erythropoietin, granulocyte colony stimulating factor protein and
XX CC interferon alpha
XX SQ Sequence 17 BP; 6 A; 1 C; 1 G; 0 T; 9 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 619 AATCTTAAAGTGTAA 634
DB 16 AATCTTAAAGTGTAA 1
XX
RESULT 476
ABK01327/c
ID ABK01327 standard; RNA; 17 BP.
XX AC ABK01327;
XX DT 12-MAR-2002 (first entry)
XX DE Human NOGO Inozyme #597.
XX KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
XX KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX KW MCL; immunocytooma; IMC; immune thrombocytopaenia; stroke; dementia;
XX KW inflammatory arthropathy; central nervous system injury;
XX KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX KW Parkinson's disease; ataxia; Huntington's disease;
XX KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200159103-A2.
XX PD 16-AUG-2001.
XX PF 09-FEB-2001; 2001WO-US004273.
XX PR 11-FEB-2000; 2000US-0181797P.
XX PR 28-FEB-2000; 2000US-0185516P.
XX PR 06-MAR-2000; 2000US-0187128P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (CHOW/) CHOWRIRA B M.

```



Db 17 AATGTTTGTGCAATG 2

RESULT 478  
ABA78805/c  
ID ABA78805 standard; DNA; 17 BP.  
XX ABA78805;  
AC  
XX  
DT 24-JAN-2002 (first entry)  
XX  
DE APC mutation correcting oligonucleotide SEQ ID NO: 1651.  
XX  
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;  
KW antilipemic; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO200173002-A2.  
XX  
PD 04-OCT-2001.  
XX  
XX 27-MAR-2001; 2001WO-US009761.  
XX  
PF 27-MAR-2000; 2000US-0192176P.  
XX  
PR 27-MAR-2000; 2000US-0192176P.  
PR  
PR 01-JUN-2000; 2000US-0208538P.  
PR  
PR 30-OCT-2000; 2000US-0244989P.  
XX  
XX (UYDE ) UNIV DELAWARE.  
XX  
XX Kmiec EB, Gamper HB, Rice MC;  
XX  
PI WPI; 2001-639230/73.  
XX  
DR  
XX  
XX Oligonucleotide for targeted alterations of genetic sequences and for  
XX treating cystic fibrosis, comprises at least one mismatch and chemical  
XX modification.  
XX  
PS Claim 7; Page 142; 294pp; English.  
XX  
XX The present invention provides single-stranded oligonucleotides which can  
XX be used for the targeted alteration of genomic sequences, where the  
XX oligonucleotide has at least one mismatch compared with the genomic  
XX sequence to be altered. In particular, these sequences are directed at  
XX the following genes: adenosine deaminase, p53, beta-globin,  
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,  
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
XX various syndromes. The present sequence is one of the gene correcting  
XX oligonucleotides of the invention

Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 728 TTAAATGCTGTTC 743  
Db 16 TGAATGACTGTTC 1

RESULT 479  
ABA80972/c  
ID ABA80972 standard; DNA; 17 BP.  
XX ABA80972;  
AC  
XX  
DT 24-JAN-2002 (first entry)  
XX  
DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3818.  
XX  
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;  
KW antilipemic; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO200173002-A2.  
XX  
PD 04-OCT-2001.  
XX  
XX 27-MAR-2001; 2001WO-US009761.  
XX  
PF 27-MAR-2000; 2000US-0192176P.  
XX  
PR 27-MAR-2000; 2000US-0192176P.  
PR  
PR 01-JUN-2000; 2000US-0208538P.  
PR  
PR 30-OCT-2000; 2000US-0244989P.  
XX  
XX (UYDE ) UNIV DELAWARE.  
XX  
XX Kmiec EB, Gamper HB, Rice MC;  
XX  
PI WPI; 2001-639230/73.  
XX  
DR  
XX  
XX Oligonucleotide for targeted alterations of genetic sequences and for  
XX treating cystic fibrosis, comprises at least one mismatch and chemical  
XX modification.  
XX  
PS Claim 7; Page 251; 294pp; English.  
XX  
XX The present invention provides single-stranded oligonucleotides which can  
XX be used for the targeted alteration of genomic sequences, where the  
XX oligonucleotide has at least one mismatch compared with the genomic  
XX sequence to be altered. In particular, these sequences are directed at  
XX the following genes: adenosine deaminase, p53, beta-globin,  
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,  
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
XX various syndromes. The present sequence is one of the gene correcting  
XX oligonucleotides of the invention

Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 303 GCATGTTGAGACTT 318  
 Db 17 GCCATGTTGAGACTT 2  
 RESULT 480  
 ABA78806  
 ID ABA78806 standard; DNA; 17 BP.  
 XX  
 AC ABA78806;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE APC mutation correcting oligonucleotide SEQ ID NO: 1652.  
 XX  
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytosstatic; antiskilling; antianaemic; haemostatic;  
 KW antilipemic; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200173002-A2.  
 XX  
 PD 04-OCT-2001.  
 XX  
 PF 27-MAR-2001; 2001WO-US009761.  
 XX  
 PR 27-MAR-2000; 2000US-0192176P.  
 PR 27-MAR-2000; 2000US-0192179P.  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX  
 PA (UYDE ) UNIV DELAWARE.  
 XX  
 PI Kmtec EB, Gamper HB, Rice MC;  
 XX  
 WPI; 2001-639230/73.  
 XX  
 DR Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX  
 PS Claim 7; Page 142; 294pp; English.  
 XX  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX  
 SQ Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 728 TTAATAATGCTGTTTC 743  
 Db 2 TGAAATGACTGTTTC 17  
 RESULT 481  
 ABA80973  
 ID ABA80973 standard; DNA; 17 BP.  
 XX  
 AC ABA80973;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3819.  
 XX  
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytosstatic; antiskilling; antianaemic; haemostatic;  
 KW antilipemic; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200173002-A2.  
 XX  
 PD 04-OCT-2001.  
 XX  
 PF 27-MAR-2001; 2001WO-US009761.  
 XX  
 PR 27-MAR-2000; 2000US-0192176P.  
 PR 27-MAR-2000; 2000US-0192179P.  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX  
 PA (UYDE ) UNIV DELAWARE.  
 XX  
 PI Kmtec EB, Gamper HB, Rice MC;  
 XX  
 WPI; 2001-639230/73.  
 XX  
 DR Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX  
 PS Claim 7; Page 251; 294pp; English.  
 XX  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX  
 SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 GGCATGTTGGAGACTT 318  
| | | | | | | | | |  
Db 1 GCCATGTTGCAGACTT 16

## RESULT 482

ABA77178/c

ID ABA77178 standard; DNA; 17 BP.

XX ABA77178;

XX ABA77178;

XX 24-JAN-2002 (first entry)

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 24.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;  
KW antileptic; ss.

XX Homo sapiens.

XX OS

XX PN WO200173002-A2.

XX PD 04-OCT-2001.

XX XX

XX 27-MAR-2001; 2001WO-US009761.

XX PF

XX XX

XX 27-MAR-2000; 2000US-0192176P.

XX PR

XX 27-MAR-2000; 2000US-0192179P.

XX PR

XX 01-JUN-2000; 2000US-0208538P.

XX PR

XX 30-OCT-2000; 2000US-0244989P.

XX PR

XX (UYDE ) UNIV DELAWARE.

XX PA

XX Kmiec EB, Gamper HB, Rice MC;

XX PI WPI; 2001-639230/73.

XX DR

XX Oligonucleotide for targeted alterations of genetic sequences and for

XX PT treating cystic fibrosis, comprises at least one mismatch and chemical

XX PT modification.

XX PS

XX Claim 7; Page 42; 294pp; English.

XX XX

XX The present invention provides single-stranded oligonucleotides which can

XX CC be used for the targeted alteration of genomic sequences, where the

XX CC oligonucleotide has at least one mismatch compared with the genomic

XX CC sequence to be altered. In particular, these sequences are directed at

XX CC the following genes: adenosine deaminase, p53, beta-globin,

XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

XX CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus

XX CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

XX CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

XX CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

XX CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

XX CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

XX CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,

XX CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

XX CC various syndromes. The present invention is one of the gene correcting

XX CC oligonucleotides of the invention

XX XX

XX Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 852 GGCTATTAAAGAATC 867

| | | | | | | | | |

Db 17 GGCTATCAAGAGATC 2

XX

XX RESULT 483

XX ABA77177

XX ID ABA77177 standard; DNA; 17 BP.

XX XX

XX AC ABA77177;

XX XX

XX 24-JAN-2002 (first entry)

XX XX

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 23.

XX DE

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

XX KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;

XX KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;

XX KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;

XX KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;

XX KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;

XX KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

XX KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;

XX KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;

XX KW antileptic; ss.

XX XX

XX Homo sapiens.

XX OS

XX PN WO200173002-A2.

XX PD 04-OCT-2001.

XX XX

XX 27-MAR-2001; 2001WO-US009761.

XX PF

XX XX

XX 27-MAR-2000; 2000US-0192176P.

XX PR

XX 27-MAR-2000; 2000US-0192179P.

XX PR

XX 01-JUN-2000; 2000US-0208538P.

XX PR

XX 30-OCT-2000; 2000US-0244989P.

XX PR

XX (UYDE ) UNIV DELAWARE.

XX PA

XX Kmiec EB, Gamper HB, Rice MC;

XX PI WPI; 2001-639230/73.

XX DR

XX Oligonucleotide for targeted alterations of genetic sequences and for

XX PT treating cystic fibrosis, comprises at least one mismatch and chemical

XX PT modification.

XX PS

XX Claim 7; Page 42; 294pp; English.

XX XX

XX The present invention provides single-stranded oligonucleotides which can

XX CC be used for the targeted alteration of genomic sequences, where the

XX CC oligonucleotide has at least one mismatch compared with the genomic

XX CC sequence to be altered. In particular, these sequences are directed at

XX CC the following genes: adenosine deaminase, p53, beta-globin,

XX CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

XX CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus

XX CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

XX CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

XX CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

XX CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

XX CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

XX CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,

XX CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

XX CC various syndromes. The present invention is one of the gene correcting

XX CC oligonucleotides of the invention

XX XX

XX Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;



```

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 852 GGCTATTAAAGAAATC 867
DB 1 GGCTATCAAAGGATC 16

RESULT 484
ABL54647/c
ID ABL54647 standard; DNA; 17 BP.
XX
AC ABL54647;
XX
DT 31-MAY-2002 (first entry)
XX
DE Human p53AIP1 associated PCR primer SEQ ID NO 20.
XX
KW Human; p53; p53AIP1; p53-dependent apoptosis-associated; apoptosis;
KW cytostatic; cancer; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200212496-A1.
XX
PD 14-FEB-2002.
XX
PF 02-AUG-2001; 2001WO-JP006666.
XX
PR 03-AUG-2000; 2000JP-00240399.
XX
PA (UUTY ) UNIV TOKYO.
XX (ONCO-) ONCOTHERAPY SCI INC.
PI Nakamura Y, Arakawa H;
XX
DR WPI; 2002-217192/27.
XX
PT p53-dependent apoptosis-associated protein and its encoding gene p53AIP1,
PT used for screening apoptosis mediated remedies for cancer and as
PT controllers of apoptosis induction.
XX
PS Example 7; Page 40; 121pp; Japanese.
XX
CC The invention relates to human p53-dependent apoptosis-associated
CC protein, p53AIP1 comprising fully defined 806, 777, 2659 nucleotide
CC sequences (ABL54631-ABL54633 respectively) given in the specification and
CC the three respectively encoded human p53-dependent apoptosis-associated
CC proteins having fully defined 124, 86 and 108 amino acid sequences
CC (AB08837-AB08839 respectively) given in the specification. The protein
CC and encoded gene have cytostatic activity, are useful in screening for
CC regulators of apoptosis for subsequent use as cancer treatments. The
CC present sequence is that of the Human p53AIP1 associated PCR primer,
CC useful to the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 431 AAAGCAGATGACTTGG 446
DB 16 AAAGCAGAGACTTGG 1

RESULT 485
ABL51265/c
ID ABL51265 standard; DNA; 17 BP.
XX
AC ABL51265;

```

```

XX 27-JUN-2002 (first entry)
DT
DE Haemorrhagic Escherichia coli VFN1 PCR primer SEQ ID NO:65.
XX
KW Thermotolerant ribonuclease H; RNase H; RNase HII; RNase HIII; enzyme;
KW genetic engineering; PCR primer; ss.
XX
OS Escherichia coli.
XX
PN WO200222831-A1.
XX
PD 21-MAR-2002.
XX
PF 13-SEP-2001; 2001WO-JP007930.
XX
PR 14-SEP-2000; 2000JP-00280785.
PR 07-MAR-2001; 2001JP-00064074.
XX
PA (TAKI ) TAKARA SHUZO CO LTD.
XX
PI Uemori T, Sato Y, Koyama N, Hirano R, Takakura H, Kobori H;
PI Hashimoto Y, Asada K, Kato I;
XX
DR WPI; 2002-362349/39.
XX
PT Polypeptides with thermotolerant ribonuclease H activity and genes
PT encoding them for genetic engineering application.
XX
PS Example 11; Page 105; 113pp; Japanese.
XX
CC The present invention describes proteins having thermotolerant
CC ribonuclease H (RNase H) activity. The RNase H proteins and
CC polynucleotide sequences encoding them can be used for the preparation of
CC highly active thermotolerant RNase H on an industrial scale for genetic
CC engineering applications. The present sequence represents a PCR primer
CC which is used in an example from the present invention
XX
SQ Sequence 17 BP; 1 A; 3 C; 4 G; 9 T; 0 U; 0 Other;

Query Match      1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836
DB 16 GAAGAAAACCCAGTA 1

RESULT 486
ABN01599
ID ABN01599 standard; DNA; 17 BP.
XX
AC ABN01599;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1591.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.

```

PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 XX 05-FEB-2001; 2001US-0266860P.  
 XX (AEOM-) AEOMICA INC.  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 PT Disclosure; SEQ ID NO 1591; 214pp; English.  
 PS The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;  
 SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 ID Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 AC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX 290 AAGGATGAGAGAGGC 305  
 DB 1 AAGGATGAGAGAGGC 16  
 RESULT 487  
 ABN07776/c  
 ID ABN07776 standard; DNA; 17 BP.  
 XX AC ABN07776;  
 XX 29-MAY-2002 (first entry)  
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7768.  
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.  
 OS WO200192524-A2.  
 XX 06-DEC-2001.  
 XX 25-MAY-2001; 2001WO-US016981.  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 XX 05-FEB-2001; 2001US-0266860P.  
 XX (AEOM-) AEOMICA INC.  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 PT Disclosure; SEQ ID NO 7768; 214pp; English.  
 PS The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;  
 SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 ID Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 AC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX 409 CCGCACACTGGTGGTC 424  
 DB 16 CCGCACACTGGTGGTC 1  
 RESULT 488  
 ABN10222/c

ID ABN10222 standard; DNA; 17 BP.  
XX AC ABN10222;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10214.  
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX PT or as specific biomolecule capture probes for surface-enhanced laser  
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 10214; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX CC nucleic acids can be used as probes to detect, characterise and quantify  
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX CC protein variants having desired phenotypic improvements, and for  
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX CC -1 proteins, as standards in assays used to determine the concentration  
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX CC capture probes for surface-enhanced laser desorption/ionisation, as  
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX CC production, and in vaccines or for replacement therapy. The  
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart  
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX CC The present sequence represents an oligomer used in the screening of the  
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX CC The sequence data for this patent did not form part of the printed  
XX CC specification, but was obtained in electronic format directly from WIPO  
XX CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 6 GGGTCTGGGGTTTCGG 21  
DB 16 GTGTCTGGGGCTTCGG 1  
RESULT 489  
ABN01598  
ID ABN01598 standard; DNA; 17 BP.  
XX AC ABN01598;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1590.  
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) AEOMICA INC.  
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX PT or as specific biomolecule capture probes for surface-enhanced laser  
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX PS Disclosure; SEQ ID NO 1590; 214pp; English.  
XX CC The present invention describes a human genome-derived myosin-like  
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX CC nucleic acids can be used as probes to detect, characterise and quantify  
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX CC protein variants having desired phenotypic improvements, and for  
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX CC -1 proteins, as standards in assays used to determine the concentration  
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX CC capture probes for surface-enhanced laser desorption/ionisation, as  
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 290 AAGGATGAAGAGGC 305  
Db 2 AAGGATGAGAAAGGC 17  
  
RESULT 490  
ABN08969  
ID ABN08969 standard; DNA; 17 BP.  
XX  
AC ABN08969;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8961.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
FN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8961; 214pp; English.  
XX  
FS The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 184 TGAAGGCGCATGGA 199  
Db 1 TGAAGGCGCATGGA 16  
  
RESULT 491  
ABN02717  
ID ABN02717 standard; DNA; 17 BP.  
XX  
AC ABN02717;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2709.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
FN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 2709; 214pp; English.

XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterize and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence

XX Sequence 17 BP; 3 A; 1 C; 6 G; 7 T; 0 U; 0 Other;

XX Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTGGAG 221  
 DB 1 GTTCATGAGTTGGAG 16

RESULT 492

ABN07230

ID ABN07230 standard; DNA; 17 BP.

XX AC ABN07230;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7222.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (ABOM-) ABOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 7222; 214pp; English.

XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterize and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence

XX Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

XX Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAGATGGTGGCC 352  
 DB 1 CAAGATGGTGGCC 16

RESULT 493

ABN07990/C

ID ABN07990 standard; DNA; 17 BP.

XX AC ABN07990;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7992.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

```

PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
KW 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
KW 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 7982; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 8 A; 5 C; 4 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. NO. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 569 TGTATCTCTGCTAGCT 584
DB ||||| ||||| |||||
16 TGTITTCCTGCTGGCT 1
XX
RESULT 494
ABN07989/C
ID ABN07989 standard; DNA; 17 BP.
XX
XX AC ABN07989;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7981.
XX
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 7981; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMLP-1, in particular heart
XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. NO. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 569 TGTATCTCTGCTAGCT 584
DB ||||| ||||| |||||
17 TGTITTCCTGCTGGCT 2
XX
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

RESULT 495  
ABN08168  
ID ABN08168 standard; DNA; 17 BP.  
XX  
XX  
AC ABN08168;  
XX  
XX  
DT 29-MAY-2002 (first entry)  
XX  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8160.  
XX  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO200192524-A2.  
XX  
XX  
PD 06-DEC-2001.  
XX  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX  
DR WPI; 2002-179446/23.  
XX  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 8160; 214pp; English.  
XX  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 291 AGGATGAAGAGAGCA 306  
Db 1 AGTATGAAGAGAGCA 16  
RESULT 496  
ABN10221/c  
ID ABN10221 standard; DNA; 17 BP.  
XX  
XX  
AC ABN10221;  
XX  
XX  
DT 29-MAY-2002 (first entry)  
XX  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10213.  
XX  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO200192524-A2.  
XX  
XX  
PD 06-DEC-2001.  
XX  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX  
DR WPI; 2002-179446/23.  
XX  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 10213; 214pp; English.  
XX  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 6 CGCTCTGGGTTCCG 21  
 Db 17 GTGTCTGGGTTCCG 2  
 RESULT 497  
 ID AEN07775/c  
 XX AEN07775 standard; DNA; 17 BP.  
 AC AEN07775;  
 XX  
 DT 29-MAY-2002 (first entry)  
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7767.  
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX Homo sapiens.  
 OS  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 FA (ABOM-) ABOMICA INC.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PI  
 XX WPT; 2002-179446/23.  
 DR  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 XX or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.  
 PT  
 XX Disclosure; SEQ ID NO 7767; 214pp; English.  
 PS

XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 409 CCGCACACTGGTGTC 424  
 Db 17 CCGCACACTGGTGTC 2  
 RESULT 498  
 ID AEN08167  
 XX AEN08167 standard; DNA; 17 BP.  
 AC AEN08167;  
 XX  
 DT 29-MAY-2002 (first entry)  
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8159.  
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX Homo sapiens.  
 OS  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX



```

PA (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 8159; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 291 AGGATGACAGAGGCA 306
XX |||||||||
XX DB 2 AGTATGAGAGGAAGCA 17
XX
XX RESULT 499
XX ABN08967
XX ID ABN08967 standard; DNA; 17 BP.
XX AC ABN08967;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8959.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX
XX PD 06-DEC-2001.
XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.

```

---

```

PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 8959; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 183 CTGAAGGCGCTGCATGG 198
XX |||||||||
XX DB 2 CTGAAGGCGCGACATGG 17
XX
XX RESULT 500
XX ABN02716
XX ID ABN02716 standard; DNA; 17 BP.
XX AC ABN02716;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2708.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX

```

PN WO200192524-A2.  
 XX 06-DEC-2001.  
 XX 25-MAY-2001; 2001WO-US016981.  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX (AEOM-) AEOMICA INC.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PI WPI; 2002-179446/23.  
 XX  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 XX  
 XX Disclosure; SEQ ID NO 2708; 214pp; English.  
 PS  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 XX Sequence 17 BP; 4 A; 1 C; 6 G; 6 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 206 GTTCATGAGTTTGAG 221  
 Db |||||  
 2 GTTCATGAGTTTGAG 17  
 RESULT 501  
 ABN07229  
 ID ABN07229 standard; DNA; 17 BP.  
 XX  
 AC ABN07229;

XX 29-MAY-2002 (first entry)  
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7221.  
 XX  
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200192524-A2.  
 XX 06-DEC-2001.  
 XX  
 XX 25-MAY-2001; 2001WO-US016981.  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX (AEOM-) AEOMICA INC.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PI WPI; 2002-179446/23.  
 XX  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 XX  
 XX Disclosure; SEQ ID NO 7221; 214pp; English.  
 PS  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 XX Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAAGATGCTGGCC 352  
 DB 2 CAAAGGTGATGGCC 17

RESULT 502  
 AAL46310/C

ID AAL46310 standard; DNA; 17 BP.  
 AC AAL46310;  
 XX  
 XX 19-JUL-2002 (first entry)  
 DT  
 DE Human M33 protein coding sequence intron 4 fragment #2.  
 KW Neurodegenerative disease; M30; M31; M32; M33; stroke;  
 KW fragile X syndrome; Huntington's disease; Parkinson's disease;  
 KW Alzheimer's disease; multiple sclerosis; ovarian cancer;  
 KW neurodegeneration; immune disorder; autoimmune disease; allergy;  
 KW infection; leukaemia; inflammation; neuroprotective; cerebroprotective;  
 KW immunosuppressive; cytostatic; nootropic; antiparkinsonian; antiallergic;  
 KW viricide; antiinflammatory; gene; ds.  
 OS Homo sapiens.  
 XX  
 XX WO200221138-A2.  
 PN  
 XX 14-MAR-2002.  
 PD  
 XX 07-SEP-2001; 2001WO-EP010366.  
 PF  
 XX 07-SEP-2000; 2000US-00657479.  
 PR  
 XX (AXAR-) AXARON BIOSCIENCE AG.  
 PA  
 XX Schneider A, Hiemisch H, Rosner M, Klugmann M, Naim J;  
 PI Eisenhardt G, Kuner R, Lanahan A, Worley P, Spielvogel D, Scheek S;  
 XX WPI; 2002-292287/33.  
 DR  
 XX Diagnosis of neurodegenerative disease comprises detecting level of M30-  
 PT family proteins.  
 PT  
 XX Example 11; Page 48; 130pp; German.  
 PS  
 CC The present invention relates to a method of diagnosing neurodegenerative  
 CC diseases, comprising determining the concentration of a protein in a body  
 CC sample, where the protein may be M30 or a variant thereof, M31, M32 or  
 CC M33. The method is used to diagnose neurodegenerative diseases,  
 CC particularly stroke but also e.g. fragile X syndrome, Huntington's,  
 CC Parkinson's and Alzheimer's diseases, multiple sclerosis etc. Also  
 CC overexpression of M31 can be used for diagnosis of carcinoma and sarcoma,  
 CC especially ovarian cancer. The proteins can be used to identify specific  
 CC ligands, potentially useful for treating neurodegeneration, immune-system  
 CC disorders (e.g. autoimmune diseases, allergy, viral infection, leukaemia,  
 CC inflammation etc.), carcinoma and sarcoma. Inhibitors of the interaction  
 CC between the proteins and the protein kinase IRAK-1 can be used to treat  
 CC neurodegeneration. The present sequence is a fragment of the M33 gene  
 XX  
 SQ Sequence 17 BP; 1 A; 5 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 TCGAGATATACGCA 232  
 DB 16 TGGAGAGACACAGCA 1

RESULT 503  
 ABV82802/C

ID ABV82802 standard; DNA; 17 BP.  
 AC ABV82802;  
 XX  
 XX 03-JAN-2003 (first entry)  
 DT  
 DE Human HTPL scanning oligonucleotide SEQ ID 4048.  
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
 KW human testis expressed Patched like protein; testis; adrenal; liver;  
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX EP1229046-A2.  
 PN  
 XX 07-AUG-2002.  
 PD  
 XX 28-JAN-2002; 2002EP-00001167.  
 PF  
 XX 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 09-OCT-2001; 2001US-0327898P.  
 XX  
 XX (AEOM-) AEOMICA INC.  
 PA  
 XX Zhan J;  
 PI WPI; 2002-676582/73.  
 DR  
 XX Novel isolated human testis expressed Patched like protein (HTPL), useful  
 PT for identifying agonist and antagonist and specific binding partners, and  
 PT for treating subjects having defects in HTPL.  
 PT  
 XX Example 2; Page 594; 718pp; English.  
 PS  
 CC The present invention relates to human testis expressed Patched like  
 CC protein (HTPL, see ABV8759 to ABV8762 and ABV8519 to ABV8520). HTPL  
 CC has two isoforms, with a few single base pair differences between the  
 CC two. One of the single base pair changes introduces a premature stop  
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
 CC shares an overall structure organisation with the Patched protein. The  
 CC shared structural features strongly imply that HTPL plays a role similar  
 CC to that of Patched, and is a potential tumour suppressor. HTPL is  
 CC important in regulating male germ cell development, and the HTPL gene was  
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
 CC therapy and manufacture of a medicament for treatment or prevention of  
 CC such disorder associated with decreased expression or activity of human  
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
 CC clinically useful diagnostic markers and potential therapeutic agents for  
 CC male infertility and cancer. The present oligonucleotide was used in an  
 CC example from the invention  
 XX  
 SQ Sequence 17 BP; 2 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 821 GAATAAAACCCCTGTA 836  
 DB 17 GAAAGAAAACCCCTGTA 2

```
RESULT 504
ABV79526/c
ID ABV79526 standard; DNA; 17 BP.
XX AC ABV79526;
XX DT 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 772.
XX DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX PN EP1229046-A2.
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI Zhan J;
XX PI WPI; 2002-676582/73.
XX DR Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 165; 719pp; English.
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 439 TGACTTGGGCAAGGT 454
Db 17 TGACTTGGCAAGGT 2
```

```
RESULT 505
ABV82803/c
ID ABV82803 standard; DNA; 17 BP.
XX AC ABV82803;
XX DT 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 4049.
XX DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX PN EP1229046-A2.
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI Zhan J;
XX PI WPI; 2002-676582/73.
XX DR Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 594; 718pp; English.
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 2 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 821 GAATATAAACCTGTGA 836
```

Db 16 GAAAGAAAACCTGTA 1  
 RESULT 506  
 ABV79551  
 ID ABV79551 standard; DNA; 17 BP.  
 XX  
 AC ABV79551;  
 XX  
 DT 03-JAN-2003 (first entry)  
 XX  
 DE Human HTPL scanning oligonucleotide SEQ ID 797.  
 XX  
 DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
 KW human testis expressed Patched like protein; testis; adrenal; liver;  
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1229046-A2.  
 XX  
 PD 07-AUG-2002.  
 XX  
 PF 28-JAN-2002; 2002EP-00001167.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 09-OCT-2001; 2001US-0327898P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Zhan J;  
 XX  
 WPI; 2002-676582/73.  
 XX  
 PT Novel isolated human testis expressed Patched like protein (HTPL), useful  
 PT for identifying agonist and antagonist and specific binding partners, and  
 PT for treating subjects having defects in HTPL.  
 XX  
 PS Example 2; Page 168; 718pp; English.  
 XX  
 CC The present invention relates to human testis expressed Patched like  
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL  
 CC has two isoforms, with a few single base pair differences between the  
 CC two. One of the single base pair changes introduces a premature stop  
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
 CC shares an overall structure organisation with the Patched protein. The  
 CC shared structural features strongly imply that HTPL plays a role similar  
 CC to that of Patched, and is a potential tumour suppressor. HTPL is  
 CC important in regulating male germ cell development, and the HTPL gene was  
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
 CC therapy and manufacture of a medicament for treatment or prevention of  
 CC such disorder associated with decreased expression or activity of human  
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
 CC clinically useful diagnostic markers and potential therapeutic agents for  
 CC male infertility and cancer. The present oligonucleotide was used in an  
 CC example from the invention  
 XX  
 SQ Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred No. 4.6e-02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 98 GACGGCCAGTGCAGG 113  
 Db 1 GACGGCGGTGCAGG 16  
 RESULT 507  
 ABV79527/c  
 ID ABV79527 standard; DNA; 17 BP.  
 XX  
 AC ABV79527;  
 XX  
 DT 03-JAN-2003 (first entry)  
 XX  
 DE Human HTPL scanning oligonucleotide SEQ ID 773.  
 XX  
 DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
 KW human testis expressed Patched like protein; testis; adrenal; liver;  
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1229046-A2.  
 XX  
 PD 07-AUG-2002.  
 XX  
 PF 28-JAN-2002; 2002EP-00001167.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 09-OCT-2001; 2001US-0327898P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Zhan J;  
 XX  
 WPI; 2002-676582/73.  
 XX  
 PT Novel isolated human testis expressed Patched like protein (HTPL), useful  
 PT for identifying agonist and antagonist and specific binding partners, and  
 PT for treating subjects having defects in HTPL.  
 XX  
 PS Example 2; Page 165; 718pp; English.  
 XX  
 CC The present invention relates to human testis expressed Patched like  
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL  
 CC has two isoforms, with a few single base pair differences between the  
 CC two. One of the single base pair changes introduces a premature stop  
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
 CC shares an overall structure organisation with the Patched protein. The  
 CC shared structural features strongly imply that HTPL plays a role similar  
 CC to that of Patched, and is a potential tumour suppressor. HTPL is  
 CC important in regulating male germ cell development, and the HTPL gene was  
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
 CC therapy and manufacture of a medicament for treatment or prevention of  
 CC such disorder associated with decreased expression or activity of human  
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
 CC clinically useful diagnostic markers and potential therapeutic agents for  
 CC male infertility and cancer. The present oligonucleotide was used in an  
 CC example from the invention  
 XX  
 SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 439 TGACTTGGCAAGGT 454  
Db 16 TGACTTCTGCAAGGT 1

RESULT 508  
ABV79550  
ID ABV79550 standard; DNA; 17 BP.  
AC ABV79550;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 796.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhan J;  
XX  
DR WPI; 2002-676582/73.  
XX  
PT Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 168; 719pp; English.  
XX  
CC The present invention relates to human testis expressed Patched like  
CC protein (HTPL), see ABV78759 to ABV78762 and ABV98519 to ABV98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 98 GACGGCCAGTGCAGG 113  
Db 2 GACGGCCAGTGCAGG 17

RESULT 509  
ABV91351/c  
ID ABV91351 standard; DNA; 17 BP.  
XX  
AC ABV91351;  
XX  
DT 23-DEC-2002 (first entry)  
XX  
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 2064.  
XX  
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
KW gene therapy; transgenic; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1239051-A2.  
XX  
PD 11-SEP-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001165.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 10-OCT-2001; 2001US-0328205P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Shannon M;  
XX  
DR WPI; 2002-684061/74.  
XX  
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL  
PT -1, useful for treating disorders associated with decreased expression or  
PT activity of human POSHL1.  
XX  
PS Example 2; SEQ ID NO 2064; 60pp + Sequence Listing; English.  
XX  
CC The invention relates to an isolated SH3 domain (POSH)-like signalling  
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino  
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),  
CC (S1) having 95% deviations, especially conservative substitutions or a  
CC fragment of the sequences comprising at least 8 contiguous amino acids.  
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an  
CC adaptor protein that interacts with Rho family small GTPases as well as  
CC downstream components of the signal transduction pathway. (I) is useful  
CC for identifying a specific binding partner. (I) and nucleic acids (II)  
CC encoding (I) are useful for diagnosing, monitoring disease and treating  
CC caused by altered expression of human POSHL1 including diagnosing and  
CC useful in gene therapy. (II) is useful in the development of vaccines and (II) is  
CC useful for measuring and for surveying gene expression and creating  
CC transgenic non-human animals capable of producing the proteins. The  
CC present sequence is that of a scanning oligonucleotide useful in examples  
CC of the invention. Note: The present sequence did not form part of the  
CC printed specification, but is based on sequence information supplied to

CC Derwent by the European Patent Office  
 XX Sequence 17 BP; 9 A; 2 C; 4 G; 2 T; 0 U; 0 Other; 0;  
 SQ Sequence 17 BP; 9 A; 2 C; 4 G; 2 T; 0 U; 0 Other; 0;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 798 ATTCTTTGTCAATCA 813  
 Db 16 ATTCTTTGTCTTCCA 1  
 RESULT 510  
 ABLV91350/c  
 ID ABLV91350 standard; DNA; 17 BP.  
 XX ABLV91350;  
 XX 23-DEC-2002 (first entry)  
 XX Human POSHL1 scanning oligonucleotide SEQ ID NO 2063.  
 XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
 KW gene therapy; transgenic; ss.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX EP1239051-A2.  
 XX 11-SEP-2002.  
 XX 28-JAN-2002; 2002EP-00001165.  
 XX 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 10-OCT-2001; 2001US-0328205P.  
 XX (AEOM-) AEOMICA INC.  
 XX Shannon M;  
 XX WPI; 2002-684061/74.  
 XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL  
 PT -1, useful for treating disorders associated with decreased expression or  
 PT activity of human POSHL1.  
 XX Example 2; SEQ ID NO 2063; 60pp + Sequence Listing; English.  
 PS  
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling  
 CC protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino  
 CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),  
 CC (SI) having 95% deviations, especially conservative substitutions or a  
 CC fragment of the sequences comprising at least 8 contiguous amino acids.  
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an  
 CC adaptor protein that interacts with Rho family small GTPases as well as  
 CC downstream components of the signal transduction pathway. (I) is useful  
 CC for identifying a specific binding partner. (I) and nucleic acids (II)  
 CC encoding (I) are useful for diagnosing, monitoring disease and treating  
 CC caused by altered expression of human POSHL1 including diagnosing and  
 CC treating cancer, they are useful in the development of vaccines and (II) is  
 CC useful in gene therapy. (II) is useful for constructing microarrays which  
 CC are useful for measuring and for surveying gene expression and creating  
 CC transgenic non-human animals capable of producing the proteins. The

CC present sequence is that of a scanning oligonucleotide useful in examples  
 CC of the invention. Note: The present sequence did not form part of the  
 CC printed specification, but is based on sequence information supplied to  
 CC Derwent by the European Patent Office  
 XX Sequence 17 BP; 10 A; 1 C; 4 G; 2 T; 0 U; 0 Other; 0;  
 SQ Sequence 17 BP; 10 A; 1 C; 4 G; 2 T; 0 U; 0 Other; 0;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 798 ATTCTTTGTCAATCA 813  
 Db 17 ATTCTTTGTCTTCCA 2  
 RESULT 511  
 ABL31225/c  
 ID ABL31225 standard; DNA; 17 BP.  
 XX ABL31225;  
 XX 21-MAR-2002 (first entry)  
 XX Human HLA genotyping oligonucleotide SEQ ID NO 714.  
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;  
 KW immunogenetic; transplantation; genetic disease; ss.  
 KW Homo sapiens.  
 OS Homo sapiens.  
 XX WO200192572-A1.  
 XX 06-DEC-2001.  
 XX 01-JUN-2001; 2001WO-JP004662.  
 PR 01-JUN-2000; 2000JP-00164798.  
 XX (NISN) NISSHINBO IND INC.  
 PA (SYST-) SYSTEM RES INC.  
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;  
 XX WPI; 2002-122074/16.  
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of  
 PT individuals e.g. by determining immunogenetic differences when  
 PT transplanting between them.  
 XX Claim 10; Page 228; 345pp; Japanese.  
 XX The invention relates to a typing kit for judging human leukocyte antigen  
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base  
 CC oligonucleotides (ABU30512-ABU31809) originating in the sequences of  
 CC genes e.g. belonging to HLA class I antigens on human genome and  
 CC containing gene polymorphisms as alloantigens have been immobilised as  
 CC primers for amplification of cleaved nucleic acids relating to gene  
 CC polymorphisms. The method is useful for judging HLA genotypes of  
 CC individuals by determining immunogenetic differences before transplanting  
 CC between them, providing genetic information to decide compatibility of  
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,  
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility  
 CC diagnosis of genetic diseases and identifying individuals  
 XX Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other; 0;  
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other; 0;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 104 CCAGTGCAGGCATCA 119  
 Db 104 CCAGTGCAGGCATCA 119

```
Db      17 CCAGTACTGGGCATCA 2
RESULT 512
ABKS6978/c
ID      ABKS6978 standard; RNA; 17 BP.
XX
AC      ABKS6978;
XX
DT      02-JUL-2002 (first entry)
XX
DE      Human CLCA1 gene enzymatic nucleic acid #1349.
XX
KW      Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW      antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW      chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW      oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW      acetylcysteine.
XX
OS      Homo sapiens.
XX
PN      WO200211674-A2.
XX
PD      14-FEB-2002.
XX
PF      09-AUG-2001; 2001WO-US024970.
XX
PR      09-AUG-2000; 2000US-0224383P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
PA      (SYNT) SYNTEX USA LLC.
PA      (THOM) THOMPSON J.
XX
PI      Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE,
PI      Grupe A;
XX
DR      WPI; 2002-217145/27.
XX
PT      Enzymatic polynucleotide that down regulates expression of chloride
PT      channel calcium activated gene, useful for treating Chronic obstructive
PT      pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS      Claim 4; Page 88; 152pp; English.
XX
CC      The invention relates to enzymatic nucleic acid molecules that down
CC      regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC      by cleaving RNA derived from the genes. The nucleic acid sequences are
CC      useful as pharmaceutical agents for treating conditions such as chronic
CC      obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC      fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC      that are related to or will respond to the levels of CLCA1 in a cell or
CC      tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC      hence, are useful for treatment of a patient having a condition
CC      associated with the level of CLCA1, where the invention further comprises
CC      the use of one or more therapies under conditions suitable for the
CC      treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC      antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC      nucleic acids of the invention are also used as diagnostic tools to
CC      examine genetic drift and mutations within diseased cells or to detect
CC      the presence of CLCA1 RNA in a cell. This sequence represents an
CC      enzymatic nucleic acid molecule of the invention
XX
SQ      Sequence 17 BP; 5 A; 5 C; 4 G; 0 T; 3 U; 0 Other;
      Query Match      1.5%; Score 12.8; DB 1; Length 17;
      Best Local Similarity 87.5%; Pred. No. 4.6e+02;
      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      641 GACTTTTTCAGATTG 656
      ||||| |||||
Db      17 GACTTCCTCAGATTG 2

RESULT 514
ACN05534/c
ID      ACN05534 standard; RNA; 17 BP.
XX
AC      ACN05534;
XX
DT      22-APR-2004 (first entry)
XX
DE      WNV minus strand Inozyme substrate SEQ ID NO 11600.
XX
KW      WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW      virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW      encephalitis; myocarditis; meningitis; infection; hepatitis;
KW      liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW      Amberzyme; Zinzyme; ss.
XX
OS      West Nile Virus.
XX
PN      WO200268637-A2.
XX
PD      06-SEP-2002.
XX
PF      19-OCT-2001; 2001WO-US048350.
XX
PR      20-OCT-2000; 2000US-0242411P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
PA      (BLAT) BLATT L.
PA      (MCSW) MCSWIGGEN J A.
XX
PI      Blatt L, Mcswiggen JA;
XX
DR      WPI; 2002-706994/76.
XX
PT      New nucleic acid molecule that modulates replication of West Nile Virus
PT      (WNV), useful for treating a condition related to WNV infection e.g.
PT      pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS      Claim 23; SEQ ID NO 11600; 495pp; English.
XX
CC      The invention relates to nucleic acid molecules that modulate replication
CC      of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC      treating a condition related to WNV infection e.g. pancreatitis,
CC      encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC      liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC      molecule is selected from the group of ribozymes consisting of
CC      Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC      nucleic acid molecules further comprise at least five ribose residues, at
CC      least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC      least three of the 5' terminal nucleotides and a 3' end modification of a
CC      3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC      are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC      in the specification. The present sequence is that of a nucleic acid
CC      molecule of the invention
XX
SQ      Sequence 17 BP; 1 A; 8 C; 2 G; 0 T; 6 U; 0 Other;
      Query Match      1.5%; Score 12.8; DB 1; Length 17;
      Best Local Similarity 87.5%; Pred. No. 4.6e+02;
      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      164 GGAAGCATTAAAGGAC 179
      ||||| |||||
Db      17 GGAAGCAGTGAAGGAC 2

RESULT 514
ACN05534/c
ID      ACN05534 standard; RNA; 17 BP.
XX
AC      ACN05534;
XX
DT      22-APR-2004 (first entry)
```



XX WVNV Amberzyme substrate SEQ ID NO 5537.  
 DE  
 XX  
 XX WVNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN  
 XX  
 XX 06-SEP-2002.  
 PD  
 XX  
 XX 19-OCT-2001; 2001WO-US048350.  
 PF  
 XX  
 XX 20-OCT-2000; 2000US-0242411P.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 XX Blatt L, Mcswiggen JA;  
 PI  
 XX  
 XX WPI; 2002-706994/76.  
 DR  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 PT (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX  
 XX Claim 23; SEQ ID NO 5537; 495pp; English.  
 PS  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication  
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 XX Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 530 ACATTCCCTGGATGT 545  
 DB |||||  
 16 ACCTTCCCTGGAGT 1  
 RESULT 515  
 ACN11447/C  
 ID ACN11447 standard; RNA; 17 BP.  
 XX  
 AC ACN11447;  
 XX  
 XX 22-APR-2004 (first entry)  
 DT  
 XX  
 XX WVNV minus strand Inozyme substrate SEQ ID NO 11450.  
 DE  
 XX  
 XX WVNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN  
 XX  
 XX 06-SEP-2002.  
 PD  
 XX  
 XX 19-OCT-2001; 2001WO-US048350.  
 PF  
 XX  
 XX 20-OCT-2000; 2000US-0242411P.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 XX Blatt L, Mcswiggen JA;  
 PI  
 XX  
 XX WPI; 2002-706994/76.  
 DR  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 PT (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX  
 XX Claim 23; SEQ ID NO 11450; 495pp; English.  
 PS  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication  
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 XX Sequence 17 BP; 1 A; 9 C; 3 G; 0 T; 4 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 68 GCGACGAGGCGGTGT 83  
 DB |||||  
 17 GGGACGAGGCGGTGT 2  
 RESULT 516  
 ACN02441/C  
 ID ACN02441 standard; RNA; 17 BP.  
 XX  
 AC ACN02441;  
 XX  
 XX 22-APR-2004 (first entry)  
 DT  
 XX  
 XX WVNV Inozyme substrate SEQ ID NO 2444.  
 DE  
 XX  
 XX WVNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW viricide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN  
 XX  
 XX 06-SEP-2002.  
 PD

XX 19-OCT-2001; 2001WO-US048350.  
 XX PF  
 XX PA (BLAT/) BLATT L.  
 XX PA (MCSW/) MCSWIGGEN J A.  
 XX PI Blatt L, Mcswiggen JA;  
 XX WIPI; 2002-706994/76.  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX Claim 23; SEQ ID NO 2444; 495pp; English.  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;  
 SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 584 TGTGAAATGTATCTCT 599  
 DB 17 TGTGAAATGTAACT 2  
 RESULT 517  
 ACN11448/c  
 ID ACN11448 standard; RNA; 17 BP.  
 AC ACN11448;  
 XX 22-APR-2004 (first entry)  
 DT WNV minus strand Inozyme substrate SEQ ID NO 11451.  
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX West Nile Virus.  
 OS WO200268637-A2.  
 XX 06-SEP-2002.  
 PD (RIBO-) RIBOZYME PHARM INC.  
 XX 19-OCT-2001; 2001WO-US048350.  
 PF 20-OCT-2000; 2000US-0242411P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (BLAT/) BLATT L.  
 XX (MCSW/) MCSWIGGEN J A.  
 XX PI Blatt L, Mcswiggen JA;  
 XX WIPI; 2002-706994/76.  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX Claim 23; SEQ ID NO 2444; 495pp; English.  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;  
 SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 584 TGTGAAATGTATCTCT 599  
 DB 17 TGTGAAATGTAACT 2  
 RESULT 517  
 ACN11448/c  
 ID ACN11448 standard; RNA; 17 BP.  
 AC ACN11448;  
 XX 22-APR-2004 (first entry)  
 DT WNV minus strand Inozyme substrate SEQ ID NO 11451.  
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX West Nile Virus.  
 OS WO200268637-A2.  
 XX 06-SEP-2002.  
 PD (RIBO-) RIBOZYME PHARM INC.  
 XX 19-OCT-2001; 2001WO-US048350.  
 PF 20-OCT-2000; 2000US-0242411P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.  
 XX Blatt L, Mcswiggen JA;  
 XX WIPI; 2002-706994/76.  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX Claim 23; SEQ ID NO 11451; 495pp; English.  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;  
 SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 68 GCGACGAAGCGCGTGT 83  
 DB 16 GCGACGAAGCGCGGT 1  
 RESULT 518  
 ACN12157  
 ID ACN12157 standard; RNA; 17 BP.  
 AC ACN12157;  
 XX 22-APR-2004 (first entry)  
 DT WNV minus strand Inozyme substrate SEQ ID NO 12160.  
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX West Nile Virus.  
 OS WO200268637-A2.  
 XX 06-SEP-2002.  
 PD (RIBO-) RIBOZYME PHARM INC.  
 XX (BLAT/) BLATT L.  
 XX (MCSW/) MCSWIGGEN J A.  
 XX Blatt L, Mcswiggen JA;  
 XX WIPI; 2002-706994/76.  
 XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX  
 XX  
 XX Claim 23; SEQ ID NO 12160; 495pp; English.  
 CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 XX Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 56.2%; Pred. No. 4.6e+02;  
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Caps 0;  
 QY 530 ACATTCCCTTGATGT 545  
 ||::||::||::||:  
 Db 2 ACCUCCUUGGAAGU 17  
 RESULT 519  
 ACN10975/c  
 ID ACN10975 standard; RNA; 17 BP.  
 XX  
 AC ACN10975;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE WNV minus strand Inozyme substrate SEQ ID NO 10978.  
 XX  
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 XX  
 PD 06-SEP-2002.  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 PR 20-OCT-2000; 2000US-0242411P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX  
 XX Claim 23; SEQ ID NO 10978; 495pp; English.  
 CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 XX Sequence 17 BP; 2 A; 3 C; 3 G; 0 T; 9 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Caps 0;  
 QY 428 GAAAAGCAGATGACT 443  
 |||||::|||::|||:  
 Db 17 GAAAACACAGATCACT 2  
 RESULT 520  
 ACN08680/c  
 ID ACN08680 standard; RNA; 17 BP.  
 XX  
 AC ACN08680;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8683.  
 XX  
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 XX  
 PD 06-SEP-2002.  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 PR 20-OCT-2000; 2000US-0242411P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX  
 XX Claim 23; SEQ ID NO 8683; 495pp; English.  
 CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention

XX SQ Sequence 17 BP; 5 A; 5 C; 2 G; 0 T; 5 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 695 CTTGGAAGATTGTAT 710  
 Db 16 CTTGGAAGATATGGAT 1  
 ||||| ||||| |||||

RESULT 521  
 ACN12972/C  
 ID ACN12972 standard; RNA; 17 BP.

AC ACN12972;

DT 22-APR-2004 (first entry)

XX WNV minus strand Zinzyne substrate SEQ ID NO 12975.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

OS WO200268637-A2.

PN 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus  
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 (WNV), useful for treating a condition related to WNV infection e.g.  
 pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 12975; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication  
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 treating a condition related to WNV infection e.g. pancreatitis,  
 encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 molecule is selected from the group of ribozymes consisting of  
 Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The  
 nucleic acid molecules further comprise at least five ribose residues, at  
 least three of the 5' terminal nucleotides and a 3' end modification of a  
 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 in the specification. The present sequence is that of a nucleic acid  
 molecule of the invention

XX Sequence 17 BP; 2 A; 3 C; 3 G; 0 T; 9 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 428 GAAAAAGCAGATGACT 443  
 Db 16 GAAAAACAGATCACT 1  
 ||||| ||||| |||||

RESULT 522

ACN01916  
 ID ACN01916 standard; RNA; 17 BP.

XX AC ACN01916;

XX 22-APR-2004 (first entry)

XX WNV Inozyme substrate SEQ ID NO 1906.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyne; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus  
 (WNV), useful for treating a condition related to WNV infection e.g.  
 pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 1906; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication  
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 treating a condition related to WNV infection e.g. pancreatitis,  
 encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 molecule is selected from the group of ribozymes consisting of  
 Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The  
 nucleic acid molecules further comprise at least five ribose residues, at  
 least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 least three of the 5' terminal nucleotides and a 3' end modification of a  
 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 in the specification. The present sequence is that of a nucleic acid  
 molecule of the invention

XX Sequence 17 BP; 6 A; 1 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 81.2%; Pred. No. 4.6e+02;  
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 163 GGGAGCATTAAAGGA 178  
 ||||| : |||||

```

Db      2 GGGAGCAGUGAAGGA 17

RESULT 523
ACN13888
ID ACN13888 standard; RNA; 17 BP.
XX
XX ACN13888;
AC
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand DNazyme substrate SEQ ID NO 13891.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX (BLAT/) BLATT L.
PA
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 13891; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 4.6e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 584 TGTAGAAATGTATCCT 599
Db      2 UGUGAAGUAGUACCU 17

RESULT 524
ACN02360
ID ACN02360 standard; RNA; 17 BP.
XX
XX

```

```

AC ACN02360;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 2363.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX (BLAT/) BLATT L.
PA
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 2363; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 9 A; 3 C; 3 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 4.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 428 GAAAGGACGATGACT 443
Db      1 GAAAAACAGACUACU 16

RESULT 525
ACN06009
ID ACN06009 standard; RNA; 17 BP.
XX
XX
XX ACN06009;
AC
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Amberzyme substrate SEQ ID NO 6012.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

```

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyne; ss.  
 XX West Nile Virus.  
 OS  
 XX  
 PN WO200268637-A2.  
 XX  
 PD 06-SEP-2002.  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 PR 20-OCT-2000; 2000US-0242411P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 PT (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX  
 PS Claim 23; SEQ ID NO 6012; 495pp; English.  
 XX  
 CC The invention relates to nucleic acid molecules that modulate replication  
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 81.2%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;  
 Matches 13; Conservative 1;  
 OY 68 GCGACGAGGCGGTGT 83  
 DB 1 GGGACGAGGCGGGU 16  
 |||||  
 RESULT 526  
 ACN11598/c  
 ID ACN11598 standard; RNA; 17 BP.  
 XX  
 AC ACN11598;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE WNV minus strand Inozyme substrate SEQ ID NO 11601.  
 XX  
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyne; ss.  
 XX  
 OS West Nile Virus.  
 XX

PN WO200268637-A2.  
 XX  
 PD 06-SEP-2002.  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 PR 20-OCT-2000; 2000US-0242411P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 PT (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX  
 PS Claim 23; SEQ ID NO 11601; 495pp; English.  
 XX  
 CC The invention relates to nucleic acid molecules that modulate replication  
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyne. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 SQ Sequence 17 BP; 2 A; 8 C; 1 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;  
 Matches 14; Conservative 0;  
 OY 163 GGGAGCGATTAAAGGA 178  
 DB 16 GGGAGCGAGTGAAGGA 1  
 |||||  
 RESULT 527  
 ACN12158  
 ID ACN12158 standard; RNA; 17 BP.  
 XX  
 AC ACN12158;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 DE WNV minus strand Inozyme substrate SEQ ID NO 12161.  
 XX  
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyne; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 PN WO200268637-A2.  
 XX  
 PD 06-SEP-2002.  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 PR 20-OCT-2000; 2000US-0242411P.  
 XX

XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PT (MCSW/) MCSWIGGEN J A.  
 XX Blatt L, Mcswiggen JA;  
 PI  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 PT  
 XX Claim 23; SEQ ID NO 12161; 495pp; English.  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 XX Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 56.2%; Pred. No. 4.6e+02;  
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
 QY 530 ACATTCCCTTGGATGT 545  
 ||::|||::|||:  
 Db 1 ACCUCCUUGGAGU 16  
 RESULT 528  
 ACN05025  
 ID ACN05025 standard; RNA; 17 BP.  
 XX  
 AC ACN05025;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 XX WNV DNazyme substrate SEQ ID NO 5028.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 PN WO200268637-A2.  
 XX  
 XX 06-SEP-2002.  
 PD  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 XX 20-OCT-2000; 2000US-0242411P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX

DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 PT  
 XX Claim 23; SEQ ID NO 5028; 495pp; English.  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 XX Sequence 17 BP; 5 A; 1 C; 6 G; 0 T; 5 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 56.2%; Pred. No. 4.6e+02;  
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
 QY 695 CTTGGAAGATTGTAT 710  
 |::|||::|||:  
 Db 1 COUGGAGAUAUGGAU 16  
 RESULT 529  
 ACN06205  
 ID ACN06205 standard; RNA; 17 BP.  
 XX  
 AC ACN06205;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 XX WNV Amberzyme substrate SEQ ID NO 6208.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 PN WO200268637-A2.  
 XX  
 XX 06-SEP-2002.  
 PD  
 XX  
 PF 19-OCT-2001; 2001WO-US048350.  
 XX  
 XX 20-OCT-2000; 2000US-0242411P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 PI Blatt L, Mcswiggen JA;  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 PT  
 XX Claim 23; SEQ ID NO 6208; 495pp; English.  
 PS

xx The invention relates to nucleic acid molecules that modulate replication  
cc of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
cc treating a condition related to WNV infection e.g. pancreatitis,  
cc encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
cc liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
cc molecule is selected from the group of ribozymes consisting of  
cc Hammerhead, inozyme, G-cleaver, DNasezyme and Zinzyme. The  
cc nucleic acid molecules further comprise at least five ribose residues, at  
cc least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
cc least three of the 5' terminal nucleotides and a 3' end modification of a  
cc 3'-3' inverted basic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
cc are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
cc in the specification. The present sequence is that of a nucleic acid  
cc molecule of the invention

Sequence 17 BP; 5 A; 2 C; 5 G; 0 T; 5 U; 0 Other;

Query Match	1.5%	Score 12.8	DB 1	Length 17
Best Local Similarity	56.2%	Pred. No. 4.6e+02		
Matches	9	Conservative	5	Mismatches 2
				Indels 0
				Gaps 0

Qy 695 CTTGGAAGATTGTAT 710  
|:|:|:|:|:|:|:  
Db 2 CUUGGAAGAUUGGAU 17

RESULT 530  
ABT35891/c  
ID ABT35891 standard: DNA: 17 BP.

ABT35891;  
12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEO ID No 1528.

Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.

xx  
os  
Homo sapiens.

AA  
PN  
WO2003025175-A2.

27-MAR-2003.

17-SEP-2002: 2002WO-IB004208.

PR 17-SEP-2001; 2001FR-00011978.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijinder M:

DR WPI; 2003-313353/30.

New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.

PS Disclosure; Page 211; 720pp; French.

The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one component of a gene chip, in vitro as (anti)sense reagents and for





SQ Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14: Conservative 0; Mismatches 2; Indels

Qy 185 GAAGGCCTGCATGGAT 200  
|||  
Db 17 GAAGGCCTGGGTGGAT 2

RESULT 535  
ABT39947  
ID ABT39947 standard; DNA; 17 BP.

AC ABT39947;

DT 13-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEO ID No 5584.

Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
schizophrenia; protein chip; gene therapy; tumour suppression;  
human fukutin; ds.

OS Homo sapiens.

AA  
PN  
WO2003025175-A2.

PD 27-MAR-2003.

17-SEP-2002; 2002WO-IB004208.

PR 17-SEP-2001; 2001FR-00011978.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-313353/30.

New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.

PS Disclosure: Page 686: 720pp; French:

The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one component of a gene chip, in vitro as (anti-)sense reagents, and for production of recombinant polypeptides. Any of the nucleic acids, polypeptides, vectors containing the nucleic acids, cells containing the vector or antibodies directed against the polypeptides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia. Analysis of the expression of the 17 mer nucleic acids in patient samples is useful for diagnosis and/or prognosis of these diseases. The polypeptides can also be used to generate antibodies, and both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 376 GATCTCCTCTCAGGA 391  
 Db 1 GATCTGCTCTCAGGA 16  
 RESULT 536  
 ACA08213/C  
 ID ACA08213 standard; RNA; 17 BP.  
 XX  
 AC ACA08213;  
 XX  
 DT 03-JUN-2003 (first entry)  
 XX  
 DE NFkB sub-unit modulating DNazyme substrate #20.  
 XX  
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KW G-cleaver; amberyzyme; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002177568-A1.  
 XX  
 PD 28-NOV-2002.  
 XX  
 PF 23-MAY-2001; 2001US-00864785.  
 XX  
 PR 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINCHOMB D T.  
 PA (MCSW/) MCSWIGEN J.  
 PA (DRAP/) DRAPER K G.  
 XX  
 PI Stinchcomb DT, Mcswiggen J, Draper KG;  
 XX  
 XX WPI; 2003-340953/32.  
 XX  
 PT Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX  
 PS Claim 3; Page 43; 72pp; English.  
 XX  
 CC The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in

CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 179 CTGACTGAGCGCTGC 194  
 Db 17 CTGACTGATAGCCTGC 2  
 RESULT 537  
 ADB000031  
 ID ADB000031 standard; DNA; 17 BP.  
 XX  
 AC ADB000031;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human MDZ3 scanning oligonucleotide SEQ ID 1017.  
 XX  
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MDZ3; MD24; MD27; MDZ12; chromosome 7q22.1;  
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KW developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PF 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 XX WPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MDZ3,  
 PT MD24, MD27 or MDZ12, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 1017; 103pp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences: MDZ3, MD24, MD27, MDZ12. MDZ3 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
 CC 15q26.1. The MDZ3, MD24, MD27, and MDZ12 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder

CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
XX  
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 156 AGGTGTGGGGAAGCAT 171  
Db 1 AGGTTTGGGGAAGCCT 16  
|||||  
  
RESULT 538  
ADB00030  
ID ADB00030 standard; DNA; 17 BP.  
XX  
XX ADB00030;  
AC  
XX  
XX 20-NOV-2003 (first entry)  
DT  
XX Human MDZ3 scanning oligonucleotide SEQ ID 1016.  
DE  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX EP1281758-A2.  
FN  
XX  
XX 05-FEB-2003.  
PD  
XX  
XX 30-JUL-2002; 2002EP-00016874.  
PF  
XX  
XX 02-AUG-2001; 2001US-00922181.  
PR  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX  
XX Shannon M, Gu Y, Nguyen C;  
PI  
XX  
XX WPI; 2003-423107/40.  
DR  
XX  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
XX Example 8; SEQ ID NO 1016; 103pp; English.  
PS  
XX  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences; MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as

CC vaccines. The present sequence was used to illustrate the invention.  
XX  
XX Sequence 17 BP; 3 A; 2 C; 8 G; 4 T; 0 U; 0 Other;  
SQ  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 156 AGGTGTGGGGAAGCAT 171  
Db 2 AGGTTTGGGGAAGCCT 17  
|||||  
  
RESULT 539  
ADB03681  
ID ADB03681 standard; DNA; 17 BP.  
XX  
XX ADB03681;  
AC  
XX  
XX 20-NOV-2003 (first entry)  
DT  
XX Human MDZ7 scanning oligonucleotide SEQ ID 4667.  
DE  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX EP1281758-A2.  
FN  
XX  
XX 05-FEB-2003.  
PD  
XX  
XX 30-JUL-2002; 2002EP-00016874.  
PF  
XX  
XX 02-AUG-2001; 2001US-00922181.  
PR  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX  
XX Shannon M, Gu Y, Nguyen C;  
PI  
XX  
XX WPI; 2003-423107/40.  
DR  
XX  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
XX Example 8; SEQ ID NO 4667; 103pp; English.  
PS  
XX  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences; MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is  
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,  
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome  
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MDZ3,  
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
XX Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;  
SQ  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 CTGAGGCCCTTAACCT 564  
 DB 2 CTGAGGCCCTCAGCT 17

RESULT 540  
 ADB03683  
 ID ADB03683 standard; DNA; 17 BP.  
 AC ADB03683;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human MDZ7 scanning oligonucleotide SEQ ID 4669.  
 XX  
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KW developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PF 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 WIPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MD23,  
 PT MD24, MD27 or MD212, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 4669; 103pp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.  
 XX  
 SQ Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 TGAGGCCCTTAACCTC 565  
 DB 1 TGAGGCCCTCAGCTC 16

RESULT 541  
 ABZ60096/c  
 ID ABZ60096 standard; RNA; 17 BP.

XX ABZ60096;  
 AC  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human K-Ras DNzyme substrate #208.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
 KW anti-rheumatic; cancer; AIDS; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PF 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI McSwiggen J;  
 XX  
 WIPI; 2003-140484/13.  
 XX  
 PT Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX  
 PS Claim 58; Page 89; 185pp; English.  
 XX  
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,  
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human  
 CC ribozymes of the invention  
 XX  
 SQ Sequence 17 BP; 7 A; 1 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 613 CACTGTATCTTAAAA 628  
 DB 17 CACTGTATCTTAAAA 2

RESULT 542  
 ABZ60986/c  
 ID ABZ60986 standard; RNA; 17 BP.  
 XX  
 AC ABZ60986;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human K-Ras DNzyme substrate #1098.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
 KW anti-rheumatic; cancer; AIDS; ss.  
 XX



```

PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 150; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyms sequences
CC disclosed in the present invention
XX
XX Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 4.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 389 GGAGACCATTCGATCA 404
Db 2 CGGAACAUCGCAUCA 17
||||| ||: |||: ||
2 CGGAACAUCGCAUCA 17
RESULT 545
ACD54822
ID ACD54822 standard; RNA; 17 BP.
XX
AC ACD54822;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV DNazyme substrate sequence #126.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberyms; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate, ss.
XX
OS Hepatitis B virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX

```

---

```

PF 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 189; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyms sequences
CC disclosed in the present invention
XX
XX Sequence 17 BP; 5 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 4.6e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 376 GATCTCACTTCAGCA 391
Db 2 GAUCUCAAUCUGGGA 17
||||| :||: |||
2 GAUCUCAAUCUGGGA 17
RESULT 546
ACD58065
ID ACD58065 standard; RNA; 17 BP.
XX
AC ACD58065;
XX
DT 23-SEP-2003 (first entry)
XX
DE HCV DNazyme substrate sequence #651.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme;
KW amberyms; G-cleaver ribozyme; decoy molecule; aptamer;

```

KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX Hepatitis C virus.  
 OS  
 XX WO200281494-A1.  
 PN  
 XX 17-OCT-2002.  
 PD  
 XX  
 XX 26-MAR-2002; 2002WO-US009187.  
 PF  
 XX 26-MAR-2001; 2001US-00817879.  
 PR  
 XX 08-JUN-2001; 2001US-00877478.  
 PR  
 XX 08-JUN-2001; 2001US-0296876P.  
 PR  
 XX 24-OCT-2001; 2001US-0335059P.  
 PR  
 XX 05-DEC-2001; 2001US-0337055P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX (BLAT/) BLATT L.  
 PA  
 XX (MACE/) MACEJAK D.  
 PA  
 XX (MCSW/) MCSWIGGEN J.  
 PA  
 XX (MORR/) MORRISSEY D.  
 PA  
 XX (PAVC/) PAVCO P.  
 PA  
 XX (LEEP/) LEE P.  
 PA  
 XX (DRAP/) DRAPER K.  
 PA  
 XX (ROBE/) ROBERTS E.  
 XX  
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX WPI; 2003-229207/22.  
 DR  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PT  
 XX Claim 1; Page 245; 387pp; English.  
 PS  
 XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention  
 XX  
 XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 68.8%; Pred. No. 4.6e+02;  
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
 QY 106 AGTCAGGGGCATCATC 121  
 ||:|||||:|  
 Db 1 AGUGCAUGGCAUCCUC 16  
 RESULT 547  
 ACDS51149/C  
 ID ACDS51149 standard; RNA; 17 BP.

XX ACDS51149;  
 AC  
 XX 23-SEP-2003 (first entry)  
 DT  
 XX HBV hammerhead ribozyme substrate sequence #411.  
 DE  
 XX  
 XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis B virus.  
 OS  
 XX WO200281494-A1.  
 PN  
 XX 17-OCT-2002.  
 PD  
 XX  
 XX 26-MAR-2002; 2002WO-US009187.  
 PF  
 XX 26-MAR-2001; 2001US-00817879.  
 PR  
 XX 08-JUN-2001; 2001US-00877478.  
 PR  
 XX 08-JUN-2001; 2001US-0296876P.  
 PR  
 XX 24-OCT-2001; 2001US-0335059P.  
 PR  
 XX 05-DEC-2001; 2001US-0337055P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX (BLAT/) BLATT L.  
 PA  
 XX (MACE/) MACEJAK D.  
 PA  
 XX (MCSW/) MCSWIGGEN J.  
 PA  
 XX (MORR/) MORRISSEY D.  
 PA  
 XX (PAVC/) PAVCO P.  
 PA  
 XX (LEEP/) LEE P.  
 PA  
 XX (DRAP/) DRAPER K.  
 PA  
 XX (ROBE/) ROBERTS E.  
 XX  
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX WPI; 2003-229207/22.  
 DR  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PT  
 XX Example 1; Page 144; 387pp; English.  
 PS  
 XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HBV  
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyne sequences  
 CC disclosed in the present invention  
 XX  
 XX Sequence 17 BP; 2 A; 5 C; 1 G; 0 T; 9 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;



Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;  
 Matches 14; Conservative 0;  
 QY 126 TCGAGCAGAGGAAAG 141  
 DB 17 TCGAATAGAGGAAAG 2  
 RESULT 548  
 ACD58294  
 ID ACD58294 standard; RNA; 17 BP.  
 XX  
 AC ACD58294;  
 XX  
 DT 24-SEP-2003 (first entry)  
 XX  
 DE HCV DNazyme substrate sequence #768.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN WO200281494-A1.  
 XX  
 PD 17-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX  
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX  
 PS Claim 1; Page 247; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds

CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention  
 XX  
 SQ Sequence 17 BP; 2 A; 3 C; 8 G; 0 T; 4 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 68.8%; Pred. No. 4.6e+02;  
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
 QY 81 TGTGCGTCTGAAGG 96  
 DB 2 UGUGCGGCGCAAGG 17  
 RESULT 549  
 ACD64375/c  
 ID ACD64375 standard; RNA; 17 BP.  
 XX  
 AC ACD64375;  
 XX  
 DT 30-SEP-2003 (first entry)  
 XX  
 DE HCV minus strand DNazyme substrate sequence #1510.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN WO200281494-A1.  
 XX  
 PD 17-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX  
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 XX  
 PS Claim 1; Page 302; 387pp; English.  
 XX

CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention

XX Sequence 17 BP; 3 A; 9 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 81 TGTGCTGCTGAAGGG 96  
 ||||| |||||  
 DB 17 TGTGCGGCTCAAGGG 2

RESULT 550  
 ACD60388/c

ID ACD60388 standard; RNA; 17 BP.

AC ACD60388;

DT 24-SEP-2003 (first entry)

DE HCV DNazyme substrate sequence #1798.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberyms; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.

XX Hepatitis C virus.

OS

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX WPI; 2003-229207/22.

XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.

XX Claim 1; Page 266; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention

SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 AGAAACACGCTGGGC 287

||||| |||||  
 DB 17 AGAAGACACGCTGGAC 2

RESULT 551  
 ACD51150/c

ID ACD51150 standard; RNA; 17 BP.

XX ACD51150;

AC ACD51150;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

HBV hammerhead ribozyme substrate sequence #412.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberyms; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.

OS Hepatitis B virus.

XX WO200281494-A1.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX



PS Disclosure; Page 728; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-ACC6806), which are associated with tumour suppression, tumour reversion, apoptosis and virus resistance. The oligonucleotides are useful as (1) as probes and primers for detecting, identifying, quantifying and/or amplifying nucleic acid, e.g. as one component of a gene chip; in vitro as (anti)sense reagents; and (2) for production of recombinant polypeptides. The oligonucleotides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia.

XX Sequence 17 BP; 2 A; 3 C; 3 G; 9 T; 0 U; 0 Other;

SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 424 CCATGAAGAAAGCAGAT 439  
||| ||||| |||||  
Db 17 CCAAGAAAAGTAGAT 2

RESULT 554  
ADB42880/c  
ID ADB42880 standard; DNA; 17 BP.  
XX AC ADB42880;  
XX DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
XX DE Tumour suppression/reversion associated nucleotide #3203.  
XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX OS Homo sapiens.  
XX PN WO2003040369-A2.  
XX PD 15-MAY-2003.  
XX PF 17-SEP-2002; 2002WO-IB004219.  
XX PR 17-SEP-2001; 2001FR-00011981.  
XX PA (MOLE-) MOLECULAR ENGINES LAB.  
XX PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX Disclosure; Page 406; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and

CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.

XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

SQ Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 185 GAAGCCTGCGATGGAT 200  
||||| |||||  
Db 17 GAAGCCTGGGTGGAT 2

RESULT 555  
ADB40493  
ID ADB40493 standard; DNA; 17 BP.  
XX AC ADB40493;  
XX DT 18-DEC-2003 (revised)  
DT 04-DEC-2003 (first entry)  
XX DE Tumour suppression/reversion associated nucleotide #816.  
XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX OS Homo sapiens.  
XX PN WO2003040369-A2.  
XX PD 15-MAY-2003.  
XX PF 17-SEP-2002; 2002WO-IB004219.  
XX PR 17-SEP-2001; 2001FR-00011981.  
XX PA (MOLE-) MOLECULAR ENGINES LAB.  
XX PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX Disclosure; Page 127; 771pp; French.

XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours

CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
 CC Analysis of the expression of the nucleotides can be used for diagnosis  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
 CC also be used to screen for their specific interactive molecules,  
 CC potentially useful for treating diseases associated with abnormal  
 CC expression of the nucleotides.  
 XX  
 SQ Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 595 ATCTGATTAACATTA 610  
 Db 2 ATCTGCTAAATTA 17  
 RESULT 556  
 ADB40319/C  
 ID ADB40319 standard; DNA; 17 BP.  
 XX  
 AC ADB40319;  
 XX  
 DT 18-DEC-2003 (revised)  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Tumour suppression/reversion associated nucleotide #642.  
 XX  
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
 KW diagnosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003040369-A2.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004219.  
 XX  
 PR 17-SEP-2001; 2001PR-00011981.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-441574/41.  
 XX  
 PT New nucleic acid encoding human prostate membrane-specific antigen,  
 PT useful e.g. for treatment of tumors and viral infection, also related  
 PT polypeptide and antibodies.  
 XX  
 PS Disclosure; Page 107; 771pp; French.  
 XX  
 CC The invention relates to the isolation of 6327 nucleotide sequences,  
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
 CC sequence having at least 80% identity, after optimal alignment, with the  
 CC nucleotides, a sequence that hybridizes under stringent conditions with  
 CC the nucleotides, or the complement, or corresponding RNA, of the  
 CC the nucleotides, or the complement, or corresponding RNA, of the  
 CC nucleotides. The nucleotides are used as probes or primers for detecting,  
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
 CC sense and antisense sequences, of nucleotides involved in tumour  
 CC suppression or reversion, apoptosis and or viral resistance, to produce  
 CC recombinant polypeptides, and to prepare transgenic animals, as  
 CC experimental models. The nucleotides (also vectors containing them and  
 CC cells containing the vectors), the encoded polypeptides and antibodies  
 CC (Ab) against the polypeptide are useful for prevention and/or treatment  
 CC of viral infections or diseases characterized by development of tumours  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
 CC also be used to screen for their specific interactive molecules.  
 CC Analysis of the expression of the nucleotides can be used for diagnosis  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can

CC also be used to screen for their specific interactive molecules,  
 CC potentially useful for treating diseases associated with abnormal  
 CC expression of the nucleotides.  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 2 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 670 GTAGTGAGAACTGAT 685  
 Db 17 GTGTGAAAAAATGAT 2  
 RESULT 557  
 ADB42533  
 ID ADB42533 standard; DNA; 17 BP.  
 XX  
 AC ADB42533;  
 XX  
 DT 18-DEC-2003 (revised)  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Tumour suppression/reversion associated nucleotide #2856.  
 XX  
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
 KW diagnosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003040369-A2.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004219.  
 XX  
 PR 17-SEP-2001; 2001PR-00011981.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-441574/41.  
 XX  
 PT New nucleic acid encoding human prostate membrane-specific antigen,  
 PT useful e.g. for treatment of tumors and viral infection, also related  
 PT polypeptide and antibodies.  
 XX  
 PS Disclosure; Page 365; 771pp; French.  
 XX  
 CC The invention relates to the isolation of 6327 nucleotide sequences,  
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
 CC sequence having at least 80% identity, after optimal alignment, with the  
 CC nucleotides, a sequence that hybridizes under stringent conditions with  
 CC the nucleotides, or the complement, or corresponding RNA, of the  
 CC nucleotides. The nucleotides are used as probes or primers for detecting,  
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
 CC sense and antisense sequences, of nucleotides involved in tumour  
 CC suppression or reversion, apoptosis and or viral resistance, to produce  
 CC recombinant polypeptides, and to prepare transgenic animals, as  
 CC experimental models. The nucleotides (also vectors containing them and  
 CC cells containing the vectors), the encoded polypeptides and antibodies  
 CC (Ab) against the polypeptide are useful for prevention and/or treatment  
 CC of viral infections or diseases characterized by development of tumours  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
 CC also be used to screen for their specific interactive molecules.  
 CC Analysis of the expression of the nucleotides can be used for diagnosis  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can

XX SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 GATCACTTGAAGATT 705  
DB 1 GATCACTTAGAATAATT 16

RESULT 558  
ADB44185/c  
ID ADB44185 standard; DNA; 17 BP.  
XX AC ADB44185;  
XX DT 18-DEC-2003 (first entry)  
XX DE Tumour suppression/reversion associated nucleotide #4508.  
XX KW cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizoprenia;  
KW diagnosis.  
XX OS Homo sapiens.  
XX PN WO2003040369-A2.  
XX PD 15-MAY-2003.  
XX PF 17-SEP-2002; 2002WO-IB004219.  
XX PR 17-SEP-2001; 2001PR-00011981.  
XX PA (MOLE-) MOLECULAR ENGINES LAB.  
XX PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
XX PT New nucleic acid encoding human prostate membrane-specific antigen,  
XX useful e.g. for treatment of tumors and viral infection, also related  
XX polypeptide and antibodies.  
XX PS Disclosure; Page 559; 77lpp; French.  
XX CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizoprenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.

XX SQ Sequence 17 BP; 5 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 689 TGATCACTTGAAGAT 704  
DB 17 TGACCACTTTGAAGAT 2

RESULT 559  
ADE25182/c  
ID ADE25182 standard; DNA; 17 BP.  
XX AC ADE25182;  
XX DT 29-JAN-2004 (first entry)  
XX DE Plant growth associated polynucleotide seq id 157.  
XX KW plant growth; plant growth trait modulation; Brassicaceae; Arabidopsis;  
KW Brassica; Zea; Oryza; Triticum; Hordeum; Lolium; Sorghum; Glycine;  
KW Medicago; Helianthus; Lactuca; Beta; Vitis; Solanum; Lycopersicon;  
KW Capsicum; Gossypium; Hevea; Linum; Prunus; Citrus; Populus; Pinus;  
KW Quercus; ss.  
XX OS Magnoliophyta.  
XX PN US2003188343-A1.  
XX PD 02-OCT-2003.  
XX PF 07-JAN-2003; 2003US-00338777.  
XX PR 09-JAN-2002; 2002US-0347288P.  
XX PA (LYNX-) LYNX THERAPEUTICS INC.  
XX PI Bowen BA, Haudenschild CD, Buckler ES;  
XX WPI; 2003-803305/75.  
XX PT New isolated or recombinant polypeptide for use in modulating a plant  
XX growth trait in a flowering plant e.g. in Arabidopsis, Brassica, Zea, or  
XX Oryza.  
XX PS Example 2; SEQ ID NO 157; 8lpp; English.  
XX CC The invention describes an isolated or recombinant polypeptide (I)  
CC comprising a sequence: (a) comprising 1 of 30 sequences (S1), as given in  
CC the specification, or a conservative variant; (b) encoded by 1 of 30  
CC sequences (S2), as given in the specification, or a conservative variant;  
CC (c) encoded by a sequence that hybridizes under stringent conditions to  
CC S2; and (d) encoded by a sequence 70% identical to S2. The expression or  
CC activity of (I) is modulated to modulate a plant growth trait in a  
CC flowering plant, of the family Brassicaceae, preferably in a plant that  
CC is Arabidopsis, Brassica, Zea, Oryza, Triticum, Hordeum, Lolium, Sorghum,  
CC Glycine, Medicago, Helianthus, Lactuca, Beta, Vitis, Solanum,  
CC Lycopersicon, Capsicum, Gossypium, Hevea, Linum, Prunus, Citrus, Populus,  
CC Pinus, or Quercus. A new method is used to detect genes for a plant  
CC growth trait. This sequence represents a polynucleotide isolated from the  
CC plant growth associated genes of the invention that can be used as a  
CC primer, probe or genetic marker.

XX SQ Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 295 TGAAGAGAGGCATGTT 310  
DB 17 TGAACAGAGGCATGAT 2

```

RESULT 560
ADF62660/c
ID ADF62660 standard; DNA; 17 BP.
XX
XX
AC ADF62660;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 564.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PN New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 564; 164pp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 8 A; 3 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 635 TTGTGTGACTTTTCA 650
DB 16 TTCTGAGACTTTTCA 1

RESULT 561
ADF62658/c
ID ADF62658 standard; DNA; 17 BP.
XX
XX
AC ADF62658;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 562.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX

```

```

OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PN New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
XX Example 2; SEQ ID NO 562; 164pp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC directed probe of the invention. Note: The current sequence is not shown
CC within the specification per se but was retrieved from the Wipoweb
CC database.
XX
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 636 TGTGTGACTTTTTCAG 651
DB 17 TCTGAGACTTTTTCAG 2

RESULT 562
ADF62657/c
ID ADF62657 standard; DNA; 17 BP.
XX
XX
AC ADF62657;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 561.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
XX Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX

```

DR WPI; 2003-532916/50.  
XX  
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a  
PT composition for treating or preventing a disorder associated with  
PT decreased or increased expression or activity of PCCP1 e.g., tumor.  
XX  
PS Example 2; SEQ ID NO 561; 164pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid that encodes a  
CC protein with a chromatin organisation modifier (CHROMO) domain. The  
CC polynucleotide of the invention demonstrates cytostatic activity and may  
CC be useful for preparing a composition for treating or preventing a  
CC disorder associated with decreased or increased expression or activity of  
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as  
CC during gene therapy and vaccine production procedures. The current  
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-  
CC directed probe of the invention. Note: The current sequence is not shown  
CC within the specification per se but was retrieved from the Wipoweb  
CC database.  
XX  
SQ Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 638 TGTGACTTTTTCAGAG 653  
Db 16 TGAGACTTTTTCAGGG 1  
RESULT 563  
ADDF62656/c  
ID ADFF62656 standard; DNA; 17 BP.  
XX  
AC ADFF62656;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 560.  
XX  
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;  
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;  
KW human; ss; probe.  
XX  
OS Homo sapiens.  
XX  
PN WO2003050284-A1.  
XX  
PD 19-JUN-2003.  
XX  
PF 22-NOV-2002; 2002WO-US037506.  
XX  
PR 10-DEC-2001; 2001US-0339764P.  
XX  
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX  
PT Guo J;  
PI  
XX  
DR WPI; 2003-532916/50.  
XX  
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a  
PT composition for treating or preventing a disorder associated with  
PT decreased or increased expression or activity of PCCP1 e.g., tumor.  
XX  
PS Example 2; SEQ ID NO 560; 164pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid that encodes a  
CC protein with a chromatin organisation modifier (CHROMO) domain. The  
CC polynucleotide of the invention demonstrates cytostatic activity and may  
CC be useful for preparing a composition for treating or preventing a  
CC disorder associated with decreased or increased expression or activity of  
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as  
CC during gene therapy and vaccine production procedures. The current  
CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-  
CC directed probe of the invention. Note: The current sequence is not shown  
CC within the specification per se but was retrieved from the Wipoweb  
CC database.  
XX  
SQ Sequence 17 BP; 6 A; 6 C; 2 G; 3 T; 0 U; 0 Other;  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 638 TGTGACTTTTTCAGAG 653  
Db 17 TGAGACTTTTTCAGGG 2  
RESULT 564  
ADIS0344  
ID ADIS0344 standard; DNA; 17 BP.  
XX  
AC ADIS0344;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human tumour suppression/reversion-related DNA sequence SeqID2847.  
XX  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW cytostatic; virucide; neuroprotective; nontoxic; neuroleptic; probe;  
KW primer; PCR; gene chip; antisense; viral disease; tumour;  
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PT Telerman A, Amson R, Tuijnder M;  
PI  
XX  
DR WPI; 2003-313354/30.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; SEQ ID NO 2847; 30pp; French.  
XX  
CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC nontoxic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, identifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpt\_sequences  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;



Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 170 ATTAAGGACTGACTG 185  
 || |||||  
 Db 2 ATCCAAGGACTGACTG 17

## RESULT 565

ADI48553

ID ADI48553 standard; DNA; 17 BP.

XX AC ADI48553;

XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID1056.

XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.

XX XX WO2003025177-A2.

XX XX 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004523.

XX PR 17-SEP-2001; 2001PR-00011980.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313354/30.

XX CC New isolated nucleic acid, useful for treating viral diseases associated  
 CC with tumors and cell degeneration, also related polypeptides, antibodies  
 CC and transfected cells.  
 XX PS Disclosure; SEQ ID NO 1056; 30pp; French.

XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, indentifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences

XX SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 GATCACTTGGAGATT 705  
 |||||  
 Db 1 GATCACTTAGAAATT 16

## RESULT 566

ADI49300/C

ID ADI49300 standard; DNA; 17 BP.

XX AC ADI49300;

XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID1803.

XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX OS Homo sapiens.

XX XX WO2003025177-A2.

XX XX 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004523.

XX PR 17-SEP-2001; 2001PR-00011980.

XX XX (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313354/30.

XX CC New isolated nucleic acid, useful for treating viral diseases associated  
 CC with tumors and cell degeneration, also related polypeptides, antibodies  
 CC and transfected cells.  
 XX PS Disclosure; SEQ ID NO 1803; 30pp; French.

XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, indentifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences

XX SQ Sequence 17 BP; 7 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 AAACGTGATTATGATC 693  
 |||||  
 Db 16 AAACGTGATTCTTGATC 1

## RESULT 567

ADI51861/C

ID ADI51861 standard; DNA; 17 BP.

XX AC ADI51861;

XX DT 15-APR-2004 (first entry)

XX DE Human tumour suppression/reversion-related DNA sequence SeqID4364.  
 XX XX  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; nontropic; neuroleptic; probe;  
 KW primer; PCR; Gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
 XX OS  
 XX Homo sapiens.  
 XX XX  
 PN WO2003025177-A2.  
 XX XX  
 PD 27-MAR-2003.  
 XX XX  
 PF 17-SEP-2002; 2002WO-IB004523.  
 XX XX  
 PR 17-SEP-2001; 2001FR-00011980.  
 XX XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-313354/30.  
 XX XX  
 DR New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumors and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.  
 XX PS Disclosure; SEQ ID NO 4364; 30pp; French.  
 XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
 XX  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 670 GTAGTGAGAACTGAT 685  
 DB 17 GTTGTAGAACTGAT 2  
 XX  
 RESULT 568  
 ADI52533  
 ID ADI52533 standard; DNA; 17 BP.  
 XX AC ADI52533;  
 XX XX  
 DT 15-APR-2004 (first entry)  
 XX Human tumour suppression/reversion-related DNA sequence SeqID5036.  
 DE XX  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; nontropic; neuroleptic; probe;  
 KW primer; PCR; Gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
 XX OS  
 XX Homo sapiens.  
 XX XX  
 PN WO2003025177-A2.  
 XX XX  
 PD 27-MAR-2003.  
 XX XX  
 PF 17-SEP-2002; 2002WO-IB004523.  
 XX XX  
 PR 17-SEP-2001; 2001FR-00011980.  
 XX XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-313354/30.  
 XX XX  
 DR New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumors and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.  
 XX PS Disclosure; SEQ ID NO 4364; 30pp; French.  
 XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

OS Homo sapiens.  
 XX WO2003025177-A2.  
 XX 27-MAR-2003.  
 XX 17-SEP-2002; 2002WO-IB004523.  
 XX 17-SEP-2001; 2001FR-00011980.  
 XX (MOLE-) MOLECULAR ENGINES LAB.  
 XX Telerman A, Amson R, Tuijnder M;  
 XX WPI; 2003-313354/30.  
 XX New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumors and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.  
 XX PS Disclosure; SEQ ID NO 5036; 30pp; French.  
 XX CC This invention relates to novel isolated nucleic acid sequences involved  
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
 CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, identifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences  
 XX SQ Sequence 17 BP; 4 A; 2 C; 3 G; 8 T; 0 U; 0 Other;  
 XX  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTCGCA 762  
 DB 1 GATCTGTATTTCGCA 16  
 XX  
 RESULT 569  
 ADI52615  
 ID ADI52615 standard; DNA; 17 BP.  
 XX AC ADI52615;  
 XX XX  
 DT 15-APR-2004 (first entry)  
 XX Human tumour suppression/reversion-related DNA sequence SeqID5118.  
 DE XX  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW cytosstatic; virucide; neuroprotective; nontropic; neuroleptic; probe;  
 KW primer; PCR; Gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.  
 XX OS  
 XX Homo sapiens.  
 XX XX  
 PN WO2003025177-A2.  
 XX XX  
 PD 27-MAR-2003.  
 XX XX  
 PF 17-SEP-2002; 2002WO-IB004523.  
 XX XX

```

PR 17-SEP-2001; 2001FR-00011980.
XX (MOLE-) MOLECULAR ENGINES LAB.
PA Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; SEQ ID NO 5118; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX SQ Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 747 GACCTGTATTGCGCA 762
DB |||||
1 GATCTGTATTGCGCA 16

RESULT 570
AD149562
ID AD149562 standard; DNA; 17 BP.
XX
XX AC AD149562;
XX
XX DT 15-APR-2004 (first entry)
XX
XX DE Human tumour suppression/reversion-related DNA sequence SeqID2065.
XX
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX OS Homo sapiens.
XX
XX PN WO2003025177-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX
XX DR WPI; 2003-313354/30.
XX
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX PS Disclosure; SEQ ID NO 3398; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX SQ Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 747 GACCTGTATTGCGCA 762
DB |||||
1 GATCTGTATTGCGCA 16

RESULT 571
AD150895
ID AD150895 standard; DNA; 17 BP.
XX
XX AC AD150895;
XX
XX DT 15-APR-2004 (first entry)
XX
XX DE Human tumour suppression/reversion-related DNA sequence SeqID3398.
XX
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX OS Homo sapiens.
XX
XX PN WO2003025177-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX
XX DR WPI; 2003-313354/30.
XX
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX PS Disclosure; SEQ ID NO 3398; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX SQ Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 690 GATCATTGGAAGATT 705
DB |||||
1 GATCCTTAGAAGATT 16

```

CC and/or resistance to viruses. The invention may be useful for the  
 CC development of compounds with a cytostatic, virucide, neuroprotective,  
 CC nootropic or neuroleptic activity. The DNA sequences may be useful as  
 CC probes and primers for detecting, indentifying, quantifying and/or  
 CC amplifying nucleic acid, for example as one component of a gene chip, in  
 CC vitro as antisense reagents and for production of recombinant  
 CC polypeptides. The invention may therefore be useful for preparation of  
 CC pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration.  
 CC are specifically cancer but also Alzheimer's disease and schizophrenia. The  
 CC present sequence is that of a nucleic acid sequence of the invention.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/publishedpct\_sequences

SQ Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 595 ATCCTGATAAACATTA 610  
 ||||| ||||| |||||  
 Db 2 ATCCTGCTAAATATTA 17

RESULT 572

ABZ95396

ID ABZ95396 standard; DNA; 17 BP.

XX AC ABZ95396;

XX AC ABZ95396;

DT 17-OCT-2003 (first entry)

XX Human fibronectin antisense fragment no.1260.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

OS WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubi-quinone.

XX Disclosure; SEQ ID NO 10638; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention  
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,  
 CC immunosuppressive, and cytostatic activity. The composition may have a  
 CC use in antisense gene therapy. The composition is useful for treating or  
 CC preventing a respiratory, lung or malignant disease or condition, also  
 CC for enhancing the prophylactic or therapeutic respiratory effect of an  
 CC antiinflammatory steroid in a subject, for reducing or depleting levels  
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
 CC lung inflammation, lung allergies, or a respiratory disease or condition.  
 CC Note: The sequence data for this patent is not represented in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 14 GGTTTCGTTCCAGTC 29  
 ||||| ||||| |||||  
 Db 2 GGTTTCCTTTCCGTC 17

RESULT 573

ACC52934/C

ID ACC52934 standard; DNA; 17 BP.

XX AC ACC52934;

XX AC ACC52934;

DT 27-JUN-2003 (first entry)

XX Human tumour suppressor sequence #1701.

XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;

KW tumour regression; apoptosis; virus resistance; diagnosis;

KW cellular degeneration.

XX Homo sapiens.

XX FR2826373-A1.

XX 27-DEC-2002.

XX 20-JUN-2001; 2001FR-00008139.

XX 20-JUN-2001; 2001FR-00008139.

XX (MOLE-) MOLECULAR ENGINES LAB SA.

XX Tuijnder M, Telerman A, Amson R;

XX WPI; 2003-250498/25.

XX New nucleic acid sequences associated with tumour suppression, regression,

PT apoptosis or virus resistance are useful to diagnose and treat viral

PT disease, development of tumor cells and cell degeneration.

XX Claim 1; Page 433; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated

CC with tumour suppression or regression, apoptosis or virus resistance. The

CC invention relates to these sequences or sequences having at least 80%

CC identity to them, and polypeptides encoded by the sequences or

CC polypeptides having 80% identity to the polypeptide sequences. The

CC invention is used to diagnose or treat viral disease or disease

CC characterized by development of tumour cells or cellular degeneration

XX Sequence 17 BP; 5 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

SQ Sequence 17 BP; 5 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;  
Matches 14; Conservative 0;

QY 678 AAATGATTATGATC 693  
DB 16 AAAATGATTAGATC 1

RESULT 574  
ID ACC54188 standard; DNA; 17 BP.  
XX  
AC ACC54188;  
XX  
DT 27-JUN-2003 (first entry)  
XX  
XX Human tumour suppressor sequence #2955.  
XX  
XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;  
KW tumour regression; apoptosis; virus resistance; diagnosis;  
KW cellular degeneration.  
XX  
XX Homo sapiens.  
XX  
XX FR2826373-Al.  
XX  
XX 27-DEC-2002.  
XX  
XX 20-JUN-2001; 2001PR-00008139.  
XX  
XX 20-JUN-2001; 2001PR-00008139.  
XX  
XX (MOLE-) MOLECULAR ENGINES LAB SA.  
XX  
XX Tuijnder M, Telerman A, Amson R;  
XX  
XX WPI; 2003-250498/25.  
XX  
XX New nucleic acid sequences associated with tumor suppression, regression,  
PT apoptosis or virus resistance are useful to diagnose and treat viral  
PT disease, development of tumor cells and cell degeneration.  
XX  
XX Claim 1; Page 722; 798pp; French.  
XX  
XX This sequence represents an isolated nucleic acid sequence associated  
CC with tumour suppression or regression, apoptosis or virus resistance. The  
CC invention relates to these sequences or sequences having at least 80%  
CC identity to them, and polypeptides encoded by the sequences or  
CC polypeptides having 80% identity to the polypeptide sequences. The  
CC invention is used to diagnose or treat viral disease or disease  
CC characterized by development of tumour cells or cellular degeneration  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 747 GACCTGTTTGGCCA 762  
DB 1 GATCTGCTTTTGGCCA 16

RESULT 575  
ID ADL47045 standard; RNA; 17 BP.  
XX  
AC ADL47045;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
XX Human NOGO receptor zinzyme substrate sequence #32.  
XX

antisense oligonucleotide; neurite growth inhibitor; NOGO;  
prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
protein kinase PKR; cerebrovascular accident;  
central nervous system injury; CNS injury; spinal cord injury; cancer;  
melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
restenosis; asthma; Crohn's disease; diabetes; obesity;  
autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
allergy; asthma; allergic rhinitis; atopic dermatitis;  
NOGO receptor zinzyme; substrate; ds.  
XX  
XX Unidentified.  
XX  
XX WO200281628-A2.  
XX  
XX 17-OCT-2002.  
XX  
XX 03-APR-2002; 2002WO-US010512.  
XX  
XX 05-APR-2001; 2001US-00827395.  
XX  
XX 29-MAY-2001; 2001US-0294412P.  
XX  
XX 28-AUG-2001; 2001US-0315315P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fossnaugh K;  
XX  
XX WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
XX Claim 9; SEQ ID NO 578; 317pp; English.  
XX  
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human NOGO  
CC receptor zinzyme substrate sequence.  
XX  
SQ Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 4.6e+02;  
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 230 GCAGGCTGTACAGTG 245  
DB 2 GCAGGCTUGGCCUG 17

RESULT 576  
ADL51186/c  
ID ADL51186 standard; RNA; 17 BP.  
XX  
XX ADL51186;  
AC  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Human PTGDR substrate sequence #305.  
XX

antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 protein kinase PKR; cerebrovascular accident;  
 central nervous system injury; CNS injury; spinal cord injury; cancer;  
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 restenosis; asthma; Crohn's disease; diabetes; obesity;  
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 substrate; ds.  
 Unidentified.  
 WO200281628-A2.  
 17-OCT-2002.  
 03-APR-2002; 2002WO-US010512.  
 05-APR-2001; 2001US-00827395.  
 29-MAY-2001; 2001US-0294412P.  
 28-AUG-2001; 2001US-0315315P.  
 (RIBO-) RIBOZYME PHARM INC.  
 Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
 WPI; 2003-058513/05.  
 Novel enzymatic nucleic acid that down-regulates expression of neurite  
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 protein kinase PKR genes, for treating cancer and inflammatory disease.  
 Claim 161; SEQ ID NO 4719; 317pp; English.  
 The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 that down regulate the expression or inhibit the function of a receptor  
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 invention are useful for treating: cerebrovascular accident, central  
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 disease, lupus, multiple sclerosis, transplant/graft rejection,  
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 nucleic acids of the invention are also useful for down-regulating the  
 expression of a target gene and as a diagnostic tool to examine genetic  
 drifts and mutations within diseased cells or to detect the presence of a  
 target RNA in a cell. The present RNA sequence represents a human PKR  
 substrate sequence.  
 Sequence 17 BP; 0 A; 9 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 92 AAGGCGGACGCCCG 107  
 Db 17 AAGGCGGAGGCCCG 2  
 RESULT 577  
 ADL51472/c  
 ID ADL51472 standard; RNA; 17 BP.  
 XX  
 AC ADL51472;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PTGDR substrate sequence #591.  
 XX

antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 protein kinase PKR; cerebrovascular accident;  
 central nervous system injury; CNS injury; spinal cord injury; cancer;  
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 restenosis; asthma; Crohn's disease; diabetes; obesity;  
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 substrate; ds.  
 Unidentified.  
 WO200281628-A2.  
 17-OCT-2002.  
 03-APR-2002; 2002WO-US010512.  
 05-APR-2001; 2001US-00827395.  
 29-MAY-2001; 2001US-0294412P.  
 28-AUG-2001; 2001US-0315315P.  
 (RIBO-) RIBOZYME PHARM INC.  
 Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
 WPI; 2003-058513/05.  
 Novel enzymatic nucleic acid that down-regulates expression of neurite  
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 protein kinase PKR genes, for treating cancer and inflammatory disease.  
 Claim 161; SEQ ID NO 5005; 317pp; English.  
 The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 that down regulate the expression or inhibit the function of a receptor  
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 invention are useful for treating: cerebrovascular accident, central  
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 disease, lupus, multiple sclerosis, transplant/graft rejection,  
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 nucleic acids of the invention are also useful for down-regulating the  
 expression of a target gene and as a diagnostic tool to examine genetic  
 drifts and mutations within diseased cells or to detect the presence of a  
 target RNA in a cell. The present RNA sequence represents a human PKR  
 substrate sequence.  
 Sequence 17 BP; 6 A; 6 C; 2 G; 0 T; 3 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 197 GGATTCATGTCATG 212  
 Db 17 GGATTCATGTTAGT 2  
 RESULT 578  
 ADL51696  
 ID ADL51696 standard; RNA; 17 BP.  
 XX  
 AC ADL51696;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PTGDR substrate sequence #815.  
 XX

antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 protein kinase PKR; cerebrovascular accident;  
 central nervous system injury; CNS injury; spinal cord injury; cancer;  
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 restenosis; asthma; Crohn's disease; diabetes; obesity;  
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
 substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
 WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite  
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 161; SEQ ID NO 5229; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 that down regulate the expression or inhibit the function of a receptor  
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 invention are useful for treating: cerebrovascular accident, central  
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 disease, lupus, multiple sclerosis, transplant/graft rejection,  
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 nucleic acids of the invention are also useful for down-regulating the  
 expression of a target gene and as a diagnostic tool to examine genetic  
 drifts and mutations within diseased cells or to detect the presence of a  
 target RNA in a cell. The present RNA sequence represents a human PKR  
 substrate sequence.

Sequence 17 BP; 8 A; 3 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 81.2%; Pred. No. 4.6e+02;  
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 427 TGAAGAGCAGATGAC 442  
 :|||||  
 DB 2 UGAGAGCAGAGAGAC 17

RESULT 579  
 ADL49040/c  
 ID ADL49040 standard; RNA; 17 BP.  
 XX  
 AC ADL49040;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PKR substrate sequence #154.  
 XX

antisense oligonucleotide; neurite growth inhibitor; NOGO;  
 prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 protein kinase PKR; cerebrovascular accident;  
 central nervous system injury; CNS injury; spinal cord injury; cancer;  
 melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 restenosis; asthma; Crohn's disease; diabetes; obesity;  
 autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
 substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
 WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite  
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
 protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 2573; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 that down regulate the expression or inhibit the function of a receptor  
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 invention are useful for treating: cerebrovascular accident, central  
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 disease, lupus, multiple sclerosis, transplant/graft rejection,  
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 nucleic acids of the invention are also useful for down-regulating the  
 expression of a target gene and as a diagnostic tool to examine genetic  
 drifts and mutations within diseased cells or to detect the presence of a  
 target RNA in a cell. The present RNA sequence represents a human PKR  
 substrate sequence.

Sequence 17 BP; 4 A; 3 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 170 ATTAAGGACTGACTG 185  
 :|||||  
 DB 16 AATAAGGACTTAACGT 1

RESULT 580  
 ADL51189/c  
 ID ADL51189 standard; RNA; 17 BP.  
 XX  
 AC ADL51189;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Human PTGDR substrate sequence #308.  
 XX

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;  
KW substrate; ds.  
XX  
XX  
OS Unidentified.  
XX  
XX WO200281628-A2.  
XX  
XX PD 17-OCT-2002.  
XX  
XX PF 03-APR-2002; 2002WO-US010512.  
XX  
XX PR 05-APR-2001; 2001US-00827395.  
XX  
XX PR 29-MAY-2001; 2001US-0294412P.  
XX  
XX PR 28-AUG-2001; 2001US-0315315P.  
XX  
XX PA (RISO-) RIBOZYME PHARM INC.  
XX  
XX PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;  
XX WPI; 2003-058513/05.  
XX  
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite  
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX PS Claim 161; SEQ ID NO 4722; 317pp; English.  
XX  
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
XX CC that down regulate the expression or inhibit the function of a receptor  
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
XX CC invention are useful for treating: cerebrovascular accident, central  
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
XX CC nucleic acids of the invention are also useful for down-regulating the  
XX CC expression of a target gene and as a diagnostic tool to examine genetic  
XX CC drifts and mutations within diseased cells or to detect the presence of a  
XX CC target RNA in a cell. The present RNA sequence represents a human PKR  
XX CC substrate sequence.  
XX  
XX SQ Sequence 17 BP; 1 A; 10 C; 3 G; 0 T; 3 U; 0 Other;  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 87 TGCTGAAGGGCGACGG 102  
DB 16 TGCAGAGGGCGAGGG 1  
  
RESULT 581  
ABD19448  
ID ABD19448 standard; DNA; 17 BP.  
XX  
XX AC ABD19448;  
XX  
XX DT 29-JUL-2004 (first entry)  
XX  
XX DE Human fibronectin DNA fragment 1260.  
XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;  
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;  
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;  
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;  
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;  
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;  
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;  
XX pulmonary transplantation rejection; ds.  
OS Homo sapiens.  
XX  
XX WO200285309-A2.  
XX  
XX PD 31-OCT-2002.  
XX  
XX PF 23-APR-2002; 2002WO-US013143.  
XX  
XX PR 24-APR-2001; 2001US-0286036P.  
XX  
XX PA (EPIG-) EPIGENESIS PHARM INC.  
XX  
XX PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;  
XX PI Miller S, Tang L, Shahabuddin S;  
XX DR WPI; 2003-093058/08.  
XX  
XX PT Pharmaceutical composition for treating asthma, has antisense  
XX PT oligonucleotide containing less percentage of adenosine, targeted to  
XX PT nucleic acids associated with lung airway or lung dysfunction, and  
XX PT bronchodilating agent.  
XX PS Claim 15; SEQ ID NO 10638; 763pp; English.  
XX  
XX CC This invention describes a novel composition (a) a first active agent,  
XX CC comprising oligonucleotides, effective for alleviating  
XX CC bronchoconstriction, respiratory tract inflammation, allergies and  
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The  
XX CC oligonucleotides are derived from a gene encoding or regulating or  
XX CC expression of a target polypeptide associated with lung airway or lung  
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
XX CC The invention also describes a kit, that comprises: (a) a delivery  
XX CC device, in separate containers, (b) the oligonucleotides, (c)  
XX CC instructions for adding a carrier and for use of the kit. The composition  
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a  
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
XX CC beta-adrenergic agonist. The composition is useful for preventing or  
XX CC treating a respiratory, lung or malignant disease. The administered  
XX CC composition comprises oligo and is administered to reduce the production  
XX CC or availability, or to increase the degradation of the target mRNA or to  
XX CC reduce the amount of target polypeptide present in the lungs. The  
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
XX CC inflammation, allergies and/or surfactant hypoproduction are associated  
XX CC with a disease or condition such as pulmonary vasoconstriction,  
XX CC inflammation, allergies, asthma, impeded respiration, respiratory  
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,  
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
XX CC The reduced adenosine content of the anti-sense oligos corresponding to  
XX CC thymidines present in the target RNA serves to prevent the breakdown of  
XX CC the oligonucleotides into products that free adenosine into the system  
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to  
XX CC prevent any unwanted effects due to it  
XX  
XX SQ Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;  
  
Query Match 1.5%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 14 GGTTCCTTCGTCAGTC 29  
DB 2 GGTTCCTTCGTCAGTC 17



```
RESULT 582
ADK13456
ID ADK13456 standard; DNA; 17 BP.
XX
XX
AC ADK13456;
XX
XX
DT 20-MAY-2004 (first entry)
XX
XX Human glioma endothelial marker (GEM) long tag oligonucleotide.
XX
XX glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
KW anticancer; anti glioma; immune response; cytostatic;
KW multi-drug sensitive glioma; human; long tag; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004016758-A2.
XX
XX 26-FEB-2004.
XX
XX 15-AUG-2003; 2003WO-US025614.
XX
XX 15-AUG-2002; 2002US-0403390P.
PR 01-APR-2003; 2003US-0458978P.
XX
XX (GENZ ) GENZYME CORP.
PA (UVJO ) UNIV JOHNS HOPKINS.
XX
XX Madden SI, Wang CJ, Cook BP, Lattera J, Walter K;
XX
XX WPI; 2004-247973/23.
XX
XX Diagnosing glioma by detecting expression product of any one of 255
XX genes, glioma endothelial markers, in brain tissue sample suspected of
XX being neoplastic, and comparing the expression with expression in normal
XX brain tissue sample.
XX
XX Example 10; Page 71; 114pp; English.
XX
XX The present invention describes a method (M1) for aiding in the diagnosis
XX of glioma. (M1) involves detecting an expression product of at least one
XX gene (I) in a first brain tissue sample (T) suspected of being
XX neoplastic, where (I) is chosen from any one of 255 genes (glioma
XX endothelial markers (GEMs)) as given in specification, and comparing the
XX expression of (I) in (T) with expression of (I) in a second normal brain
XX tissue sample (R), where increased expression of (I) in (T) relative to
XX (R), identifies (T) as likely to be neoplastic. Also described: (1)
XX treating (M2) glioma involves contacting cells of the glioma with an
XX antibody that specifically binds to a extracellular epitope; (2)
XX identifying (M3) a test compound as potential anticancer or anti glioma
XX drug involves contacting a test compound with the cell which expresses
XX (I), monitoring an expression product of the at least one gene and
XX identifying test compound as a potential anticancer drug if it decreases
XX the expression of at least one gene; (3) identifying (M4) a test compound
XX as potential anticancer or anti glioma drug involves contacting a test
XX compound with the cell which expresses mRNA of at least one gene
XX identified by a tag as described above, monitoring mRNA of the gene, and
XX identifying the test compound as a potential anticancer drug if it
XX decreases the expression of at least one gene; and (4) inducing (M5) an
XX immune response to glioma involves administering to a mammal, a protein
XX or (I). (I) have cytostatic activities, and can be used to trigger immune
XX destruction of glioma cells, and as immune response inducers. (M1) is
XX useful for aiding in diagnosing glioma. (M2) is useful for treating multi
XX -drug sensitive glioma in a human. (M5) is useful for inducing an immune
XX response to a glioma in a mammal having glioma or in a mammal who has had
XX a glioma surgically removed. The present sequence represents a human GEM
XX long tag oligonucleotide, which is used in the exemplification of the
XX present invention.
XX
XX Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 668 CTGTAGTGAGAACTG 683
||| |||||
Db 2 CTGCACTGAGAACTG 17

RESULT 583
ADL82440
ID ADL82440 standard; DNA; 17 BP.
XX
XX AC ADL82440;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human ER+ breast cancer differentially expressed sequence #410.
XX
XX gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
XX Homo sapiens.
OS
XX
XX US2003166026-A1.
XX
XX 04-SEP-2003.
XX
XX 08-JAN-2003; 2003US-00339782.
XX
XX 09-JAN-2002; 2002US-0348053P.
PR
XX (LYNX-) LYNX THERAPEUTICS INC.
XX
XX Goodman LJ, Bowen BA;
XX
XX WPI; 2004-069003/07.
XX
XX Vector containing nucleic acid associated with breast cancer, useful for
XX treating, diagnosing and characterizing breast cancer, also related
XX polypeptides and antibodies.
XX
XX Claim 1; SEQ ID NO 411; 61pp; English.
XX
XX The invention relates to a composition which contains at least one vector
XX (B) containing a nucleic acid (I) associated with breast cancer. The
XX vector (B), also polypeptides (II) encoded by (I), are used for treatment
XX of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
XX -specific antibodies (Ab) are used to predict characteristics (e.g.
XX invasiveness or stage) of breast cancer, and (I), or its fragments, are
XX used to modulate characteristics of such cells; to identify breast cancer
XX genes and to detect breast cancer (by detecting polymorphic nucleic acid
XX or its products). The present sequence represents a human ER+ breast
XX cancer differentially expressed sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 595 ATCTGTATAACATTA 610
||| |||||
Db 2 ATCTGTATAACATTA 17

RESULT 584
ADMS9709
ID ADMS9709 standard; RNA; 17 BP.
XX
XX AC ADMS9709;
XX
XX 03-JUN-2004 (first entry)
XX
```

```

XX Hepatitis B virus (HBV) RNA target sequence #1843.
DE
XX
XX Hepatitis B virus; HBV, ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX US2004054156-A1.
PN
XX
XX 18-MAR-2004.
PD
XX
XX
XX 15-JAN-2003; 2003US-00342902.
PF
XX
XX 14-MAY-1992; 92US-00882712.
PR
XX 07-FEB-1994; 94US-00193627.
PR
XX 08-NOV-1999; 99US-00436430.
PR
XX 20-MAR-2000; 2000US-00531025.
PR
XX 09-AUG-2000; 2000US-00636385.
PR
XX 24-OCT-2000; 2000US-00696347.
PR
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA
XX (BLAT/) BLATT L.
PA
XX (MCSW/) MCSWIGGEN J A.
PA
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI
XX WPI; 2004-247781/23.
DR
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1843; 122pp; English.
PS
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. NO. 4.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 389 GGAGACCATTCATCA 404
DB 2 GGAGAACUCCAUCA 17
RESULT 585
ADM58612
ID ADM58612 standard; RNA; 17 BP.
XX
XX ADM58612;
AC
XX 03-JUN-2004 (first entry)
DT
XX

```

```

DE Hepatitis B virus (HBV) RNA target sequence #746.
XX
XX Hepatitis B virus; HBV, ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS Hepatitis B virus.
XX
XX US2004054156-A1.
PN
XX
XX 18-MAR-2004.
PD
XX
XX
XX 15-JAN-2003; 2003US-00342902.
PF
XX
XX 14-MAY-1992; 92US-00882712.
PR
XX 07-FEB-1994; 94US-00193627.
PR
XX 08-NOV-1999; 99US-00436430.
PR
XX 20-MAR-2000; 2000US-00531025.
PR
XX 09-AUG-2000; 2000US-00636385.
PR
XX 24-OCT-2000; 2000US-00696347.
PR
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA
XX (BLAT/) BLATT L.
PA
XX (MCSW/) MCSWIGGEN J A.
PA
XX (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI
XX WPI; 2004-247781/23.
DR
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 746; 122pp; English.
PS
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. NO. 4.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 389 GGAGACCATTCATCA 404
DB 2 GGAGAACUCCAUCA 17
RESULT 586
ADM59962
ID ADM59962 standard; RNA; 17 BP.
XX
XX ADM59962;
AC
XX 03-JUN-2004 (first entry)
DT
XX

```



KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;  
 KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;  
 KW virucide; hepatotropic; antiinflammatory; cytostatic.  
 OS Hepatitis B virus.  
 XX US2004054156-A1.  
 PN 18-MAR-2004.  
 PD  
 XX 15-JAN-2003; 2003US-00342902.  
 PF 14-MAY-1992; 92US-00882712.  
 XX 07-FEB-1994; 94US-00193627.  
 PR 08-NOV-1999; 99US-00436430.  
 PR 20-MAR-2000; 2000US-00531025.  
 PR 09-AUG-2000; 2000US-00636385.  
 PR 24-OCT-2000; 2000US-00696347.  
 PR 08-JUN-2001; 2001US-00877478.  
 XX (DRAP/) DRAPER K.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 PA (MORR/) MORRISSEY D.  
 XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;  
 PI WPI; 2004-247781/23.  
 DR Novel enzymatic nucleic acid molecule such as DNazymes and inozymes  
 XX specifically cleaving RNA derived from hepatitis B virus and comprising  
 PT one or more binding arms, useful for treating hepatitis and cirrhosis.  
 XX Disclosure; SEQ ID NO 445; 122pp; English.  
 XX The invention relates to an enzymatic nucleic acid molecule that  
 CC specifically cleaves RNA derived from hepatitis B virus (HBV) and  
 CC comprising one or more binding arms, without requiring the presence of a  
 CC 2'-OH group within the molecule for activity. The nucleic acids are  
 CC useful for treating hepatitis B virus infection, hepatitis,  
 CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in  
 CC combination with other therapies such as lamivudine and interferons. The  
 CC nucleic acids are useful as diagnostic tools to examine genetic drift and  
 CC mutations within diseased cells, for detecting the presence of HBV RNA in  
 CC a cell, for the study of RNA and for down-regulating gene expression of  
 CC target genes in bacterial, fungal, viral, plant or mammalian cells. This  
 CC sequence represents an HBV RNA target sequence, used in the scope of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
 XX SQ Sequence 17 BP; 2 A; 5 C; 2 G; 0 T; 8 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. NO. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 126 TCGAGCAGAGGAAG 141  
 Db 16 TCGATAGAGGAAG 1  
 RESULT 589  
 ADI84552/C  
 ID ADI84552 standard; RNA; 17 BP.  
 XX AC ADI84552;  
 XX 03-JUN-2004 (first entry)  
 DT HCV DNazyme substrate sequence #1798.  
 DE ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 XX HCV infection; type I interferon; DNazyme.

XX Hepatitis C virus.  
 OS US2003125270-A1.  
 PN 03-JUL-2003.  
 PD 18-DEC-2000; 2000US-00740332.  
 PF 18-DEC-2000; 2000US-00740332.  
 PR (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (ROBE/) ROBERTS E.  
 PA (PAVC/) PAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
 PI WPI; 2004-031273/03.  
 DR Enzymatic nucleic acid molecules which specifically cleave RNA derived  
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
 PT especially in combination with type I interferon therapy.  
 XX Claim 1; SEQ ID NO 1798; 198pp; English.  
 XX The invention relates to an enzymatic nucleic acid molecule which  
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
 CC the binding arms of the enzymatic nucleic acid molecule comprises given  
 CC sequences complementary to any of the defined substrate sequences in  
 CC the specification. The nucleic acid molecule may be administered for  
 CC the treatment of HCV infections, especially in combination with type I  
 CC interferons. The present sequence represents a HCV DNazyme substrate  
 CC sequence.  
 XX SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. NO. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 272 AGAAACACGGTGGC 287  
 Db 17 AGAAGACACGGTGGAC 2  
 RESULT 590  
 ADI83405  
 ID ADI83405 standard; RNA; 17 BP.  
 XX AC ADI83405;  
 XX 03-JUN-2004 (first entry)  
 DT HCV DNazyme substrate sequence #551.  
 DE ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 XX HCV infection; type I interferon; DNazyme.  
 XX Hepatitis C virus.  
 OS US2003125270-A1.  
 PN 03-JUL-2003.  
 PD 18-DEC-2000; 2000US-00740332.  
 PF 18-DEC-2000; 2000US-00740332.  
 PR (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (ROBE/) ROBERTS E.

PA (PAVC/) PAVCO P A.  
 XX (MACE/) MACEJACK D.  
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
 XX WPI; 2004-031273/03.  
 XX  
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived  
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
 PT especially in combination with type I interferon therapy.  
 XX  
 XX Claim 1; SEQ ID NO 651; 198pp; English.  
 XX  
 XX The invention relates to an enzymatic nucleic acid molecule which  
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
 CC the binding arms of the enzymatic nucleic acid molecule comprises  
 CC sequences complementary to any of the defined substrate sequences given  
 CC in the specification. The nucleic acid molecule may be administered for  
 CC the treatment of HCV infections, especially in combination with type I  
 CC interferons. The present sequence represents a HCV DNzyme substrate  
 CC sequence.  
 XX  
 XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
 SQ

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 68.8%; Pred. NO. 4.6e+02;  
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 106 AGTCAGGGCATCATC 121  
 ||:|||||:||||:|  
 Db 1 AGUGCAUGGCAUCCUC 16

RESULT 591  
 ADI86541/C  
 ID ADI86541 standard; RNA; 17 BP.  
 XX  
 XX AC ADI86541;  
 XX  
 XX 03-JUN-2004 (first entry)  
 XX  
 XX HCV DNzyme substrate sequence #3787.  
 XX  
 XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 KW HCV infection; type I interferon; DNzyme.  
 XX  
 XX Hepatitis C virus.  
 XX  
 XX US2003125270-A1.  
 PN  
 XX 03-JUL-2003.  
 PD  
 XX  
 XX 18-DEC-2000; 2000US-00740332.  
 PF  
 XX  
 XX 18-DEC-2000; 2000US-00740332.  
 PR  
 XX  
 XX (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (ROBE/) ROBERTS E.  
 PA (PAVC/) PAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX  
 XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
 PI WPI; 2004-031273/03.  
 XX  
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived  
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
 PT especially in combination with type I interferon therapy.  
 XX  
 XX Claim 1; SEQ ID NO 3787; 198pp; English.  
 XX  
 XX The invention relates to an enzymatic nucleic acid molecule which

CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
 CC the binding arms of the enzymatic nucleic acid molecule comprises  
 CC sequences complementary to any of the defined substrate sequences given  
 CC in the specification. The nucleic acid molecule may be administered for  
 CC the treatment of HCV infections, especially in combination with type I  
 CC interferons. The present sequence represents a HCV DNzyme substrate  
 CC sequence.  
 XX  
 XX Sequence 17 BP; 3 A; 9 C; 3 G; 0 T; 2 U; 0 Other;  
 SQ

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 81 TGTGCGTGTCTGAAGGG 96  
 |||||:|||||  
 Db 17 TGTGCGGCTCAAGGG 2

RESULT 592  
 ACN70319  
 ID ACN70319 standard; DNA; 17 BP.  
 XX  
 XX AC ACN70319;  
 XX  
 XX 02-DEC-2004 (first entry)  
 DT  
 XX Human GDMPLP-1 probe SEQ ID NO:7221.  
 DE  
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2004137589-A1.  
 PN  
 XX 15-JUL-2004.  
 PD  
 XX  
 XX 26-NOV-2003; 2003US-00723361.  
 PF  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR  
 XX 21-SEP-2000; 2000US-0234687P.  
 PR  
 XX 27-SEP-2000; 2000US-0236359P.  
 PR  
 XX 04-OCT-2000; 2000GB-00024263.  
 PR  
 XX 30-JAN-2001; 2001WO-US000661.  
 PR  
 XX 30-JAN-2001; 2001WO-US000662.  
 PR  
 XX 30-JAN-2001; 2001WO-US000663.  
 PR  
 XX 30-JAN-2001; 2001WO-US000664.  
 PR  
 XX 30-JAN-2001; 2001WO-US000665.  
 PR  
 XX 30-JAN-2001; 2001WO-US000666.  
 PR  
 XX 30-JAN-2001; 2001WO-US000667.  
 PR  
 XX 30-JAN-2001; 2001WO-US000668.  
 PR  
 XX 30-JAN-2001; 2001WO-US000669.  
 PR  
 XX 05-FEB-2001; 2001WO-0266860P.  
 PR  
 XX 25-MAY-2001; 2001US-00866108.  
 PR  
 XX (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 PI WPI; 2004-533378/51.  
 XX  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.  
 XX Disclosure; SEQ ID NO 7221; Opp; English.  
 XX  
 CC The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63103  
 XX  
 SQ Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 337 CAAAGTGTGTGGCC 352  
 |||||  
 Db 2 CAAAGTGTGTGGCC 17  
 RESULT 593  
 ACN64688  
 ID ACN64688 standard; DNA; 17 BP.  
 XX ACN64688;  
 XX  
 DT 02-DEC-2004 (first entry)  
 DE Human GDMPLP-1 probe SEQ ID NO:1590.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PR 25-MAY-2001; 2001US-00866108.  
 XX  
 PA (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENNY/) PENN S G.  
 PA (HANK/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.

XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 XX  
 PT Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 PS Disclosure; SEQ ID NO 1590; Opp; English.  
 XX  
 CC The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63102  
 XX  
 SQ Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 290 AAGGATGAAGAGGCG 305  
 |||||  
 Db 2 AAGGATGAAGAGGCG 17  
 RESULT 594  
 ACN71079/c  
 ID ACN71079 standard; DNA; 17 BP.  
 XX ACN71079;  
 XX  
 DT 02-DEC-2004 (first entry)  
 DE Human GDMPLP-1 probe SEQ ID NO:7981.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PR 25-MAY-2001; 2001US-00866108.

```

XX PA (GUY/) GU Y.
XX PA (JIY/) JI Y.
XX PA (PENN/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX DR WPI; 2004-533378/51.
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX PS Disclosure; SEQ ID NO 7981; Opp; English.
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
XX CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX CC defined in the specification, a fragment of at least 8 amino acids of
XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX CC pharmaceutical composition of the invention is useful for treating or
XX CC preventing a disorder associated with decreased expression or activity of
XX CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX CC The present sequence represents a 17-mer nucleotide, used in the
XX CC invention for scanning the sequence represented in ACN63103
XX SQ Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. NO. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 569 TCTATCTCTGCTAGCT 584
DB 17 TGTTCCTCTGCTGGCT 2
RESULT 595
ACN71258
ID ACN71258 standard; DNA; 17 BP.
AC ACN71258;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMLP-1 probe SEQ ID NO:8160.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
30-JAN-2001; 2001WO-US000665.
30-JAN-2001; 2001WO-US000666.
30-JAN-2001; 2001WO-US000667.
30-JAN-2001; 2001WO-US000668.
30-JAN-2001; 2001WO-US000669.
30-JAN-2001; 2001WO-US000670.
05-FEB-2001; 2001WO-US026860P.
25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX PA (JIY/) JI Y.
XX PA (PENN/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX DR WPI; 2004-533378/51.
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX PS Disclosure; SEQ ID NO 8160; Opp; English.
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
XX CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX CC defined in the specification, a fragment of at least 8 amino acids of
XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX CC pharmaceutical composition of the invention is useful for treating or
XX CC preventing a disorder associated with decreased expression or activity of
XX CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX CC The present sequence represents a 17-mer nucleotide, used in the
XX CC invention for scanning the sequence represented in ACN63103
XX SQ Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
XX Query Match 1.5%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. NO. 4.6e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 291 AGGATGAAGAGAGCA 306
DB 1 AGTATGAAGAGAGCA 16
RESULT 596
ACN73311/c
ID ACN73311 standard; DNA; 17 BP.
XX AC ACN73311;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMLP-1 probe SEQ ID NO:10213.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.

```

```

PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 10213; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 6 CGGCTGGGGTTTCGG 21
DB 17 GTGCTGGGGCTTCGG 2
RESULT 597
ACN70865/c
ID ACN70865 standard; DNA; 17 BP.
XX
AC ACN70865;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:7767.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 7767; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention is useful for treating or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 409 CCGCACACTGGTGGTC 424
DB 17 CCGCACACTGGTGGTC 2
RESULT 598
ACN71080/c
ID ACN71080 standard; DNA; 17 BP.
XX
AC ACN71080;
XX

```



DT 02-DEC-2004 (first entry)  
 XX Human GDMPLP-1 probe SEQ ID NO: 7982.  
 DE  
 XX Human; ss: probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2004137589-A1.  
 XX  
 XX 15-JUL-2004.  
 XX  
 XX 26-NOV-2003; 2003US-00723361.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 25-MAY-2001; 2001US-0086860P.  
 XX  
 XX (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 DR  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 XX Disclosure; SEQ ID NO 7982; Opp; English.  
 PS  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63103  
 XX  
 XX Sequence 17 BP; 8 A; 5 C; 4 G; 0 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 569 TGTATCCCTAGCT 584  
 DB 16 TGTATCCCTAGCT 1

RESULT 599  
 ACN70320  
 ID ACN70320 standard; DNA; 17 BP.  
 XX  
 AC ACN70320;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO: 7222.  
 XX  
 KW Human; ss: probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2004137589-A1.  
 XX  
 XX 15-JUL-2004.  
 XX  
 XX 26-NOV-2003; 2003US-00723361.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0286860P.  
 PR 25-MAY-2001; 2001US-008686108.  
 XX  
 XX (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 DR  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 XX Disclosure; SEQ ID NO 7222; Opp; English.  
 PS  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63103  
 XX  
 XX Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 CAAAGATGCTGGCC 352  
 ||||| |||||  
 DB 1 CAAAGTGATGGCC 16

RESULT 600  
 ACN73312/c  
 ID ACN73312 standard; DNA; 17 BP.  
 AC ACN73312;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO:10214.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024283.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 25-MAY-2001; 2001US-0266860P.  
 XX  
 XX (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 WPI; 2004-533378/51.  
 XX  
 Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 Disclosure; SEQ ID NO 10214; Opp; English.  
 PS  
 The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63103  
 XX  
 SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.6e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 CGCTCTGGGTTTCGG 21  
 ||||| |||||  
 DB 16 GTGCTGGGGCTTCGG 1

RESULT 601  
 ACN65806  
 ID ACN65806 standard; DNA; 17 BP.  
 XX  
 AC ACN65806;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO:2708.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024283.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 25-MAY-2001; 2001US-0266860P.  
 XX  
 XX (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 WPI; 2004-533378/51.  
 XX  
 Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.

XX PS Disclosure; SEQ ID NO 2708; Opp; English.

XX CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63102

XX SQ Sequence 17 BP; 4 A; 1 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GTTCATGAGTTTGAG 221

Db 2 GTTCATGAGTTTGAG 17

|||||||

RESULT 602

ACN72059

ID ACN72059 standard; DNA; 17 BP.

XX AC ACN72059;

XX DT 02-DEC-2004 (first entry)

XX DE Human GDMLP-1 probe SEQ ID NO:8961.

XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX OS Homo sapiens.

XX PN US2004137589-A1.

XX PD 15-JUL-2004.

XX PF 26-NOV-2003; 2003US-00723361.

XX PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX PA (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX PT Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX PS Disclosure; SEQ ID NO 8961; Opp; English.

XX CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.5%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 4.6e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 184 TGAAGGCCCTGCATGGA 199

Db 1 TGAAGGCCGACATGGA 16

|||||||

RESULT 603

ACN64689

ID ACN64689 standard; DNA; 17 BP.

XX AC ACN64689;

XX DT 02-DEC-2004 (first entry)

XX DE Human GDMLP-1 probe SEQ ID NO:1591.

XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;

KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

KW skeletal muscle function.

XX OS Homo sapiens.

XX PN US2004137589-A1.

XX PD 15-JUL-2004.

XX PF 26-NOV-2003; 2003US-00723361.

XX PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX

```

PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
PS Disclosure; SEQ ID NO 1591; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 290 AAGGATGAAGAGAGGC 305
DB 1 AAGGATGAGAAAGGC 16
RESULT 604
ACN65807
ID ACN65807 standard; DNA; 17 BP.
XX
XX ACN65807;
AC
XX
XX 02-DEC-2004 (first entry)
DT
XX
XX Human GDMLP-1 probe SEQ ID NO:2709.
DE
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
OS
XX
XX US2004137589-A1.
PN
XX
XX 15-JUL-2004.
PD
XX
XX 26-NOV-2003; 2003US-00723361.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
XX
XX 21-SEP-2000; 2000US-0234687P.
PR
XX
XX 27-SEP-2000; 2000US-0236356P.
PR
XX
XX 04-OCT-2000; 2000GB-00024263.
PR
XX
XX 30-JAN-2001; 2001WO-US000661.
PR
XX
XX 30-JAN-2001; 2001WO-US000662.
PR
XX
XX 30-JAN-2001; 2001WO-US000663.
PR
XX
XX 30-JAN-2001; 2001WO-US000664.
PR
XX
XX 30-JAN-2001; 2001WO-US000665.

```

```

PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
PS Disclosure; SEQ ID NO 2709; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 3 A; 1 C; 6 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 206 GTTCATGAGTTTGAG 221
DB 1 GTTCATGAGTTTGAG 16
RESULT 605
ACN70866/c
ID ACN70866 standard; DNA; 17 BP.
XX
XX ACN70866;
AC
XX
XX 02-DEC-2004 (first entry)
DT
XX
XX Human GDMLP-1 probe SEQ ID NO:7768.
DE
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
OS
XX
XX US2004137589-A1.
PN
XX
XX 15-JUL-2004.
PD
XX
XX 26-NOV-2003; 2003US-00723361.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR

```





KW central nervous system; gastrointestinal; respiratory; immune; metabolic.  
 OS Homo sapiens.  
 XX  
 PN WO200177384-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 XX  
 PF 06-APR-2001; 2001WO-1B000713.  
 XX  
 PR 07-APR-2000; 2000DE-01019173.  
 XX  
 XX (EPIG-) EPIGENOMICS AG.  
 PA  
 PI Olek A, Piepenbrock C, Berlin K;  
 XX  
 XX WPI; 2001-657177/75.  
 XX  
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is  
 PT designed to detect single-nucleotide polymorphisms and cytosine  
 PT methylation status.  
 XX  
 PS Claim 1; SEQ ID NO 227624; 29pp + Sequence Listing; German.  
 XX  
 CC This invention describes novel oligonucleotide primers or peptide nucleic  
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
 CC and cytosine methylation status in chemically pretreated genomic DNA. The  
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
 CC range of diseases including immune system, gastrointestinal, respiratory,  
 CC central nervous system, cardiovascular and metabolic disorders. The  
 CC oligomers are also used for detecting cell type differentiation. ABC00010  
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073  
 CC represent the oligomers described in the invention. NOTE: The sequence  
 CC data for this patent did not form part of the printed specification, but  
 CC was obtained in electronic format from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;  
 Query Match 1.4%; Score 12.6; DB 1; Length 13;  
 Best Local Similarity 92.3%; Pred. NO. 4.7e+02;  
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 OY 600 GATAACATTAAA 612  
 DB :|||||  
 1 RATAAACATTAAA 13  
 RESULT 610  
 ABK28501  
 ID ABK28501 standard; DNA; 15 BP.  
 XX  
 AC ABK28501;  
 XX  
 XX 09-APR-2002 (first entry)  
 XX  
 DE Paraoxonase 2 (PON2), allele specific oligonucleotide primer #8.  
 XX  
 KW Paraoxonase 2; PON2; coronary heart disease; ASO;  
 KW allele specific oligonucleotide; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200188202-A1.  
 XX  
 PD 22-NOV-2001.  
 XX  
 PF 18-MAY-2001; 2001WO-US016352.  
 XX  
 PR 18-MAY-2000; 2000US-0205145P.  
 XX  
 PA (GENA-) GENAISSANCE PHARM INC.  
 XX

PI Anastasio AE, Chew A, Choi JY, Denton RR, Lee HH, Nandabalan K;  
 XX WPI; 2002-121985/16.  
 XX  
 PT An isolated polynucleotide comprising a paraoxonase 2 (PON2) isogene  
 PT encodes a pharmaceutically important protein for the identification of  
 PT polymorphisms at the PON2 locus.  
 XX  
 PS Claim 17; Page 13; 125pp; English.  
 XX  
 CC The invention describes an isolated polynucleotide sequence comprising a  
 CC paraoxonase 2 (PON2) isogene. Primers and probes allow identification of  
 CC this sequence and its polymorphisms and are useful for identifying which  
 CC isoform of paraoxonase 2 a person carries. Identification of a PON2  
 CC isoform allows tailored pharmaceutical treatment to be designed and  
 CC administered. PON2 is a particularly important gene for the treatment of  
 CC coronary heart disease. This sequence represents an allele specific  
 CC oligonucleotide (ASO) primer used for detecting PON2 gene polymorphisms,  
 CC described in the method of the invention  
 XX  
 SQ Sequence 15 BP; 8 A; 2 C; 1 G; 3 T; 0 U; 1 Other;  
 Query Match 1.4%; Score 12.6; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. NO. 4.7e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 OY 717 ATAAACTCAGTTAA 731  
 DB :|||||  
 1 ATAAACACAGTTAA 15  
 Search completed: October 6, 2005, 10:44:21  
 Job time : 10 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 6, 2005, 10:42:42 ; Search time 6 Seconds  
(without alignments)  
3.913 Million cell updates/sec

Title: US-10-633-843-3-COPY  
Perfect score: 874  
Sequence: 1 ctgcagcgtctgggtttcc.....tattaaagaatccaaattc 874

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 633 seqs, 13433 residues

Total number of hits satisfying chosen parameters: 1266

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 637 summaries

Database : pubdb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	5.7	50	1	US-10-131-827-305
2	50	5.7	50	1	US-10-131-827-1951
3	48	5.5	48	1	US-10-301-516-27
4	48	5.5	48	1	US-10-700-816-7
5	46.4	5.3	48	1	US-10-301-516-28
6	46.4	5.3	48	1	US-10-700-816-8
7	42	4.8	42	1	US-10-859-321-11
8	42	4.8	42	1	US-10-859-321-73
9	42	4.8	42	1	US-10-912-440-11
10	42	4.8	42	1	US-10-912-440-73
11	41	4.7	41	1	US-10-859-321-12
12	41	4.7	41	1	US-10-859-321-74
13	41	4.7	41	1	US-10-912-440-12
14	41	4.7	41	1	US-10-912-440-74
15	35	4.0	35	1	US-10-301-516-32
16	35	4.0	35	1	US-10-700-816-15
17	35	4.0	35	1	US-10-894-721-2
18	33.4	3.8	35	1	US-10-894-721-3
19	27	3.1	27	1	US-09-899-807-1
20	25	2.9	25	1	US-10-956-157-19040
21	25	2.9	25	1	US-10-956-157-19041
22	25	2.9	25	1	US-10-956-157-19042
23	25	2.9	25	1	US-10-956-157-19043
24	25	2.9	25	1	US-10-956-157-19044
25	25	2.9	25	1	US-10-956-157-19045
26	25	2.9	25	1	US-10-956-157-19046
27	25	2.9	25	1	US-10-956-157-19047
28	25	2.9	25	1	US-10-956-157-19048
29	25	2.9	25	1	US-10-956-157-19049
30	25	2.9	25	1	US-10-956-157-19050
31	25	2.9	25	1	US-10-956-157-19051
32	25	2.9	25	1	US-10-956-157-19052
33	25	2.9	25	1	US-10-956-157-19053

Sequence 19054, A	US-10-956-157-19054	25	2.9	25	34
Sequence 19055, A	US-10-956-157-19055	25	2.9	25	35
Sequence 19056, A	US-10-956-157-19056	25	2.9	25	36
Sequence 19057, A	US-10-956-157-19057	25	2.9	25	37
Sequence 19058, A	US-10-956-157-19058	25	2.9	25	38
Sequence 19059, A	US-10-956-157-19059	25	2.9	25	39
Sequence 19060, A	US-10-956-157-19060	25	2.9	25	40
Sequence 19061, A	US-10-956-157-19061	25	2.9	25	41
Sequence 19062, A	US-10-956-157-19062	25	2.9	25	42
Sequence 19063, A	US-10-956-157-19063	25	2.9	25	43
Sequence 134047, A	US-10-956-157-134047	25	2.9	25	44
Sequence 134183, A	US-10-956-157-134183	25	2.9	25	45
Sequence 134860, A	US-10-956-157-134860	25	2.9	25	46
Sequence 136056, A	US-10-956-157-136056	25	2.9	25	47
Sequence 13603, A	US-10-956-157-13603	25	2.9	25	48
Sequence 149298, A	US-10-956-157-149298	25	2.9	25	49
Sequence 149376, A	US-10-956-157-149376	25	2.9	25	50
Sequence 150718, A	US-10-956-157-150718	25	2.9	25	51
Sequence 156203, A	US-10-956-157-156203	25	2.9	25	52
Sequence 160696, A	US-10-956-157-160696	25	2.9	25	53
Sequence 171822, A	US-10-956-157-171822	25	2.9	25	54
Sequence 173368, A	US-10-956-157-173368	25	2.9	25	55
Sequence 182879, A	US-10-956-157-182879	25	2.9	25	56
Sequence 184849, A	US-10-956-157-184849	25	2.9	25	57
Sequence 188144, A	US-10-956-157-188144	25	2.9	25	58
Sequence 189649, A	US-10-956-157-189649	25	2.9	25	59
Sequence 196119, A	US-10-956-157-196119	25	2.9	25	60
Sequence 196500, A	US-10-956-157-196500	25	2.9	25	61
Sequence 196788, A	US-10-956-157-196788	25	2.9	25	62
Sequence 206018, A	US-10-956-157-206018	25	2.9	25	63
Sequence 213479, A	US-10-956-157-213479	25	2.9	25	64
Sequence 214062, A	US-10-956-157-214062	25	2.9	25	65
Sequence 214634, A	US-10-956-157-214634	25	2.9	25	66
Sequence 220621, A	US-10-956-157-220621	25	2.9	25	67
Sequence 221193, A	US-10-956-157-221193	25	2.9	25	68
Sequence 224177, A	US-10-956-157-224177	25	2.9	25	69
Sequence 228500, A	US-10-956-157-228500	25	2.9	25	70
Sequence 233553, A	US-10-956-157-233553	25	2.9	25	71
Sequence 239197, A	US-10-956-157-239197	25	2.9	25	72
Sequence 241982, A	US-10-956-157-241982	25	2.9	25	73
Sequence 242800, A	US-10-956-157-242800	25	2.9	25	74
Sequence 247393, A	US-10-956-157-247393	25	2.9	25	75
Sequence 257204, A	US-10-956-157-257204	25	2.9	25	76
Sequence 259305, A	US-10-956-157-259305	25	2.9	25	77
Sequence 261942, A	US-10-956-157-261942	25	2.9	25	78
Sequence 266239, A	US-10-956-157-266239	25	2.9	25	79
Sequence 287005, A	US-10-956-157-287005	25	2.9	25	80
Sequence 246110, A	US-11-070-868-4	25	2.8	24.4	81
Sequence 277195, A	US-10-956-157-246110	25	2.7	23.4	82
Sequence 3, Appli	US-10-956-157-277195	25	2.7	23.4	83
Sequence 4, Appli	US-09-899-807-3	23	2.6	23	84
Sequence 5, Appli	US-09-899-807-4	23	2.6	23	85
Sequence 6, Appli	US-10-487-091-5	23	2.6	23	86
Sequence 7, Appli	US-10-487-091-6	23	2.6	23	87
Sequence 61538, A	US-09-918-421-7	30	2.6	22.6	88
Sequence 12, Appli	US-10-719-900-61538	25	2.6	22.4	89
Sequence 119457, A	US-10-333-578-13	27	2.5	22.2	90
Sequence 52, Appli	US-10-719-900-61537	25	2.5	21.8	91
Sequence 53, Appli	US-10-109-349A-52	21	2.4	21	92
Sequence 6, Appli	US-10-109-349A-53	21	2.4	21	93
Sequence 826010, A	US-10-633-843-6	21	2.4	21	94
Sequence 456063, A	US-10-672-866-6	21	2.4	21	95
Sequence 456198, A	US-10-719-900-826010	25	2.4	21	96
Sequence 488725, A	US-10-719-900-61537	25	2.4	21	97
Sequence 889726, A	US-10-719-900-456063	25	2.4	21	98
Sequence 893797, A	US-10-719-900-284833	25	2.4	21	99
Sequence 967669, A	US-10-719-900-458198	25	2.4	21	100
	US-10-719-900-458199	25	2.4	21	101
	US-10-719-900-458199	25	2.4	21	102
	US-10-719-900-889725	25	2.4	21	103
	US-10-719-900-889726	25	2.4	21	104
	US-10-719-900-893797	25	2.4	21	105
	US-10-719-900-967669	25	2.4	21	106





C 399 17.2 2.0 22 1 US-09-905-056-7 Sequence 7, Appli  
C 400 17.2 2.0 22 1 US-09-909-064-7 Sequence 7, Appli  
C 401 17.2 2.0 22 1 US-09-904-553-7 Sequence 7, Appli  
C 402 17.2 2.0 22 1 US-09-905-381-7 Sequence 7, Appli  
C 403 17.2 2.0 22 1 US-09-904-485-7 Sequence 7, Appli  
C 404 17.2 2.0 22 1 US-09-903-348-7 Sequence 7, Appli  
C 405 17.2 2.0 22 1 US-09-903-088-7 Sequence 7, Appli  
C 406 17.2 2.0 22 1 US-09-907-575-7 Sequence 7, Appli  
C 407 17.2 2.0 22 1 US-09-905-075-7 Sequence 7, Appli  
C 408 17.2 2.0 22 1 US-09-902-759-7 Sequence 7, Appli  
C 409 17.2 2.0 22 1 US-09-902-634-7 Sequence 7, Appli  
C 410 17.2 2.0 22 1 US-09-902-713-7 Sequence 7, Appli  
C 411 17.2 2.0 22 1 US-09-907-979-7 Sequence 7, Appli  
C 412 17.2 2.0 22 1 US-09-902-615-7 Sequence 7, Appli  
C 413 17.2 2.0 22 1 US-09-903-925-7 Sequence 7, Appli  
C 414 17.2 2.0 22 1 US-09-906-760A-7 Sequence 7, Appli  
C 415 17.2 2.0 22 1 US-09-903-823-7 Sequence 7, Appli  
C 416 17.2 2.0 22 1 US-09-907-652-7 Sequence 7, Appli  
C 417 17.2 2.0 22 1 US-09-902-572A-7 Sequence 7, Appli  
C 418 17.2 2.0 22 1 US-09-902-979-7 Sequence 7, Appli  
C 419 17.2 2.0 22 1 US-09-905-125-7 Sequence 7, Appli  
C 420 17.2 2.0 22 1 US-09-906-815A-7 Sequence 7, Appli  
C 421 17.2 2.0 22 1 US-09-905-449-7 Sequence 7, Appli  
C 422 17.2 2.0 22 1 US-09-903-806-7 Sequence 7, Appli  
C 423 17.2 2.0 22 1 US-09-904-992-7 Sequence 7, Appli  
C 424 17.2 2.0 22 1 US-09-904-838-7 Sequence 7, Appli  
C 425 17.2 2.0 22 1 US-09-906-777-7 Sequence 7, Appli  
C 426 17.2 2.0 22 1 US-09-903-603A-7 Sequence 7, Appli  
C 427 17.2 2.0 22 1 US-09-904-532-7 Sequence 7, Appli  
C 428 17.2 2.0 22 1 US-09-904-766-7 Sequence 7, Appli  
C 429 17.2 2.0 22 1 US-09-904-920A-7 Sequence 7, Appli  
C 430 17.2 2.0 22 1 US-09-904-877A-7 Sequence 7, Appli  
C 431 17.2 2.0 22 1 US-09-903-562-7 Sequence 7, Appli  
C 432 17.2 2.0 22 1 US-09-906-618-7 Sequence 7, Appli  
C 433 17.2 2.0 22 1 US-09-907-728-7 Sequence 7, Appli  
C 434 17.2 2.0 22 1 US-09-904-805-7 Sequence 7, Appli  
C 435 17.2 2.0 22 1 US-09-904-938A-7 Sequence 7, Appli  
C 436 17.2 2.0 22 1 US-09-906-722A-7 Sequence 7, Appli  
C 437 17.2 2.0 22 1 US-09-908-576-7 Sequence 7, Appli  
C 438 17.2 2.0 22 1 US-10-299-976-7 Sequence 7, Appli  
C 439 17.2 2.0 22 1 US-10-299-937-7 Sequence 7, Appli  
C 440 17.2 2.0 22 1 US-10-298-993-7 Sequence 7, Appli  
C 441 17.2 2.0 22 1 US-10-448-923-7 Sequence 7, Appli  
C 442 17.2 2.0 22 1 US-10-449-656-7 Sequence 7, Appli  
C 443 17.2 2.0 22 1 US-10-448-713-7 Sequence 7, Appli  
C 444 17.2 2.0 22 1 US-10-425-447-7 Sequence 7, Appli  
C 445 17.2 2.0 22 1 US-10-215-371-7 Sequence 7, Appli  
C 446 17.2 2.0 22 1 US-10-771-187-7 Sequence 7, Appli  
C 447 17.2 2.0 22 1 US-10-963-487-7 Sequence 7, Appli  
C 448 17.2 2.0 22 1 US-10-978-255-7 Sequence 7, Appli  
C 449 17.2 2.0 22 1 US-10-797-366-7 Sequence 7, Appli  
C 450 16.8 1.9 20 1 US-10-672-866-194 Sequence 194, App  
C 451 16.8 1.9 20 1 US-10-672-866-195 Sequence 195, App  
C 452 16.8 1.9 20 1 US-10-672-866-199 Sequence 199, App  
C 453 16.8 1.9 20 1 US-10-672-866-205 Sequence 205, App  
C 454 16.8 1.9 20 1 US-10-672-866-207 Sequence 207, App  
C 455 16.8 1.9 20 1 US-10-672-866-208 Sequence 208, App  
C 456 16.8 1.9 20 1 US-10-672-866-209 Sequence 209, App  
C 457 16.8 1.9 20 1 US-10-672-866-215 Sequence 215, App  
C 458 16.8 1.9 20 1 US-10-672-866-287 Sequence 287, App  
C 459 16.8 1.9 20 1 US-10-672-866-291 Sequence 291, App  
C 460 16.8 1.9 20 1 US-10-672-866-296 Sequence 296, App  
C 461 16.8 1.9 20 1 US-10-672-866-297 Sequence 297, App  
C 462 16.4 1.9 20 1 US-10-190-366-126 Sequence 126, App  
C 463 16.4 1.9 20 1 US-10-190-366-323 Sequence 323, App  
C 464 16.2 1.9 21 1 US-10-786-720-19320 Sequence 19320, A  
C 465 16.2 1.9 21 1 US-10-751-736-20731 Sequence 20731, A  
C 466 16.2 1.9 21 1 US-10-751-736-42828 Sequence 42828, A  
C 467 16 1.8 16 1 US-10-672-866-159 Sequence 159, App  
C 468 16 1.8 16 1 US-10-333-429-260 Sequence 260, App  
C 469 16 1.8 19 1 US-10-197-280A-27 Sequence 27, Appl  
C 470 15.8 1.8 20 1 US-09-909-595-79 Sequence 79, Appl  
C 471 15.8 1.8 20 1 US-10-331-907-236 Sequence 236, App

472 15.8 1.8 20 1 US-10-484-007-79 Sequence 79, Appl  
C 473 15.8 1.8 20 1 US-10-672-866-173 Sequence 173, App  
C 474 15.8 1.8 20 1 US-10-672-866-193 Sequence 193, App  
C 475 15.8 1.8 20 1 US-10-672-866-206 Sequence 206, App  
C 476 15.8 1.8 20 1 US-10-672-866-285 Sequence 285, App  
C 477 15.8 1.8 20 1 US-10-672-866-290 Sequence 290, App  
C 478 15.8 1.8 20 1 US-10-672-866-292 Sequence 292, App  
C 479 15.8 1.8 20 1 US-10-672-866-294 Sequence 294, App  
C 480 15.8 1.8 21 1 US-10-786-720-7376 Sequence 7376, Ap  
C 481 15.8 1.8 21 1 US-10-786-720-9626 Sequence 9626, Ap  
C 482 15.8 1.8 21 1 US-10-847-918-10677 Sequence 10677, A  
C 483 15.8 1.8 21 1 US-10-963-238-5 Sequence 5, Appli  
C 484 15.8 1.8 21 1 US-10-963-394-5 Sequence 5, Appli  
C 485 15.6 1.7 17 1 US-10-484-577-356 Sequence 356, App  
C 486 15.4 1.8 20 1 US-10-199-674-39 Sequence 39, Appl  
C 487 15.4 1.8 20 1 US-10-199-674-99 Sequence 99, Appl  
C 488 15.4 1.8 20 1 US-10-672-866-166 Sequence 166, App  
C 489 15.4 1.8 20 1 US-10-672-866-253 Sequence 253, App  
C 490 15.2 1.7 20 1 US-09-758-481-39 Sequence 39, Appl  
C 491 15.2 1.7 20 1 US-10-000-213-81 Sequence 81, Appl  
C 492 15.2 1.7 20 1 US-10-006-366-68 Sequence 68, Appl  
C 493 15.2 1.7 20 1 US-10-148-835-77 Sequence 77, Appl  
C 494 15.2 1.7 20 1 US-10-383-614-26 Sequence 26, Appl  
C 495 15.2 1.7 20 1 US-10-383-614-35 Sequence 35, Appl  
C 496 15.2 1.7 20 1 US-10-644-325-13 Sequence 13, Appl  
C 497 15.2 1.7 20 1 US-10-672-866-181 Sequence 181, App  
C 498 15.2 1.7 20 1 US-10-672-866-192 Sequence 192, App  
C 499 15.2 1.7 20 1 US-10-672-866-196 Sequence 196, App  
C 500 15.2 1.7 20 1 US-10-672-866-197 Sequence 197, App  
C 501 15.2 1.7 20 1 US-10-672-866-198 Sequence 198, App  
C 502 15.2 1.7 20 1 US-10-672-866-203 Sequence 203, App  
C 503 15.2 1.7 20 1 US-10-672-866-204 Sequence 204, App  
C 504 15.2 1.7 20 1 US-10-672-866-264 Sequence 264, App  
C 505 15.2 1.7 20 1 US-10-672-866-266 Sequence 266, App  
C 506 15.2 1.7 20 1 US-10-672-866-284 Sequence 284, App  
C 507 15.2 1.7 20 1 US-10-672-866-295 Sequence 295, App  
C 508 15.2 1.7 20 1 US-10-773-678-39 Sequence 39, Appl  
C 509 15.2 1.7 20 1 US-10-831-901A-2219 Sequence 2219, Ap  
C 510 15.2 1.7 20 1 US-10-831-901A-3639 Sequence 3639, Ap  
C 511 15.2 1.7 20 1 US-10-831-901A-3640 Sequence 3640, Ap  
C 512 15.2 1.7 20 1 US-10-831-901A-14406 Sequence 14406, A  
C 513 15.2 1.7 20 1 US-10-831-901A-14407 Sequence 14407, A  
C 514 15.2 1.7 20 1 US-10-831-901A-14412 Sequence 14412, A  
C 515 15.2 1.7 20 1 US-10-862-440-37 Sequence 37, Appl  
C 516 15.2 1.7 20 1 US-10-862-440-38 Sequence 38, Appl  
C 517 15.2 1.7 20 1 US-10-862-440-64 Sequence 64, Appl  
C 518 15.2 1.7 20 1 US-10-862-440-67 Sequence 67, Appl  
C 519 15 1.7 15 1 US-10-672-866-139 Sequence 139, App  
C 520 15 1.7 15 1 US-10-672-866-140 Sequence 140, App  
C 521 15 1.7 15 1 US-10-672-866-148 Sequence 148, App  
C 522 15 1.7 17 1 US-10-484-577-355 Sequence 355, App  
C 523 15 1.7 20 1 US-10-672-866-210 Sequence 210, App  
C 524 14.8 1.7 19 1 US-10-444-925-474 Sequence 474, App  
C 525 14.8 1.7 19 1 US-10-883-218-310 Sequence 310, App  
C 526 14.8 1.7 19 1 US-10-883-218-712 Sequence 712, App  
C 527 14.4 1.6 17 1 US-09-863-086-102 Sequence 102, App  
C 528 14.4 1.6 17 1 US-09-863-086-104 Sequence 104, App  
C 529 14.4 1.6 17 1 US-09-780-533A-2234 Sequence 2234, Ap  
C 530 14.4 1.6 17 1 US-09-780-533A-2326 Sequence 2326, Ap  
C 531 14.4 1.6 17 1 US-10-672-238-102 Sequence 102, App  
C 532 14.4 1.6 17 1 US-10-672-238-104 Sequence 104, App  
C 533 14.4 1.6 17 1 US-10-484-577-353 Sequence 353, App  
C 534 14.4 1.6 17 1 US-10-484-577-354 Sequence 354, App  
C 535 14 1.6 17 1 US-09-864-785-2135 Sequence 2135, Ap  
C 536 14 1.6 17 1 US-09-864-785-2949 Sequence 2949, Ap  
C 537 14 1.6 17 1 US-09-780-533A-484 Sequence 484, App  
C 538 14 1.6 17 1 US-09-780-533A-1349 Sequence 1349, Ap  
C 539 14 1.6 17 1 US-09-780-533A-1996 Sequence 1996, Ap  
C 540 14 1.6 20 1 US-10-633-843-54 Sequence 54, Appl  
C 541 14 1.6 20 1 US-10-633-843-55 Sequence 55, Appl  
C 542 14 1.6 20 1 US-10-672-866-54 Sequence 54, Appl  
C 543 14 1.6 20 1 US-10-672-866-55 Sequence 55, Appl  
C 544 13.8 1.6 17 1 US-09-866-108-8960 Sequence 8960, Ap

545	13.8	1.6	17	1	US-09-818-875-3142	Sequence 3142, Ap
c 546	13.8	1.6	17	1	US-09-818-875-3143	Sequence 3143, Ap
c 547	13.8	1.6	17	1	US-09-780-533A-1097	Sequence 1097, Ap
548	13.8	1.6	17	1	US-09-740-332-2757	Sequence 2757, Ap
549	13.8	1.6	17	1	US-09-817-879-2757	Sequence 2757, Ap
c 550	13.8	1.6	17	1	US-10-230-006-533	Sequence 533, App
c 551	13.8	1.6	17	1	US-10-230-006-534	Sequence 534, App
c 552	13.8	1.6	17	1	US-10-230-006-1258	Sequence 1258, App
c 553	13.8	1.6	17	1	US-10-209-787-3142	Sequence 3142, Ap
c 554	13.8	1.6	17	1	US-10-209-787-3143	Sequence 3143, Ap
c 555	13.8	1.6	17	1	US-10-261-185-3142	Sequence 3142, Ap
c 556	13.8	1.6	17	1	US-10-261-185-3143	Sequence 3143, Ap
c 557	13.8	1.6	17	1	US-10-138-674-2787	Sequence 2787, Ap
c 558	13.8	1.6	17	1	US-10-138-674-5100	Sequence 5100, Ap
559	13.8	1.6	17	1	US-10-138-674-6796	Sequence 6796, Ap
c 560	13.8	1.6	17	1	US-10-138-674-7893	Sequence 7893, Ap
c 561	13.8	1.6	17	1	US-10-287-949A-2787	Sequence 2787, Ap
c 562	13.8	1.6	17	1	US-10-287-949A-5100	Sequence 5100, Ap
c 563	13.8	1.6	17	1	US-10-287-949A-6796	Sequence 6796, Ap
c 564	13.8	1.6	17	1	US-10-287-949A-7893	Sequence 7893, Ap
565	13.8	1.6	17	1	US-10-669-841-5350	Sequence 5350, Ap
566	13.8	1.6	17	1	US-10-723-361-8960	Sequence 8960, Ap
567	13.8	1.6	17	1	US-10-681-074-3142	Sequence 3142, Ap
c 568	13.8	1.6	17	1	US-10-681-074-3143	Sequence 3143, Ap
c 569	13.8	1.6	17	1	US-10-712-633-1027	Sequence 1027, Ap
c 570	13.8	1.6	17	1	US-10-498-462-563	Sequence 563, App
c 571	13.8	1.6	18	1	US-09-736-084-62	Sequence 62, Appl
572	13.8	1.6	18	1	US-09-969-373-2985	Sequence 2985, Ap
c 573	13.8	1.6	18	1	US-09-969-373-3559	Sequence 3559, Ap
c 574	13.8	1.6	18	1	US-10-376-770-121	Sequence 121, App
c 575	13.8	1.6	18	1	US-10-661-168-111	Sequence 121, App
c 576	13.8	1.6	18	1	US-10-730-488-62	Sequence 62, Appl
c 577	13.8	1.6	18	1	US-10-473-126-581	Sequence 581, App
c 578	13.8	1.6	18	1	US-10-883-848-7	Sequence 7, Appl
579	13.4	1.5	15	1	US-10-641-960-157	Sequence 157, App
c 580	13.4	1.5	16	1	US-10-608-062-2	Sequence 2, Appl
c 581	13.4	1.5	16	1	US-10-138-674-5942	Sequence 5942, Ap
c 582	13.4	1.5	16	1	US-10-287-949A-5942	Sequence 5942, Ap
583	13.4	1.5	17	1	US-09-818-875-3286	Sequence 3286, Ap
c 584	13.4	1.5	17	1	US-09-818-875-3287	Sequence 3287, Ap
c 585	13.4	1.5	17	1	US-09-818-875-3288	Sequence 3288, Ap
586	13.4	1.5	17	1	US-09-780-533A-398	Sequence 398, App
c 587	13.4	1.5	17	1	US-09-740-332-902	Sequence 902, App
c 588	13.4	1.5	17	1	US-09-740-332-1799	Sequence 1799, Ap
589	13.4	1.5	17	1	US-09-740-332-2756	Sequence 2756, Ap
c 590	13.4	1.5	17	1	US-09-740-332-3653	Sequence 3653, Ap
c 591	13.4	1.5	17	1	US-09-817-879-902	Sequence 902, App
c 592	13.4	1.5	17	1	US-09-817-879-1799	Sequence 1799, Ap
c 593	13.4	1.5	17	1	US-09-817-879-2756	Sequence 2756, Ap
c 594	13.4	1.5	17	1	US-09-817-879-3653	Sequence 3653, Ap
595	13.4	1.5	17	1	US-10-230-006-44	Sequence 44, Appl
c 596	13.4	1.5	17	1	US-10-209-787-3286	Sequence 3286, Ap
c 597	13.4	1.5	17	1	US-10-209-787-3287	Sequence 3287, Ap
c 598	13.4	1.5	17	1	US-10-261-185-3286	Sequence 3286, Ap
c 599	13.4	1.5	17	1	US-10-261-185-3287	Sequence 3287, Ap
600	13.4	1.5	17	1	US-10-138-674-2045	Sequence 2045, Ap
c 601	13.4	1.5	17	1	US-10-138-674-2046	Sequence 2046, Ap
c 602	13.4	1.5	17	1	US-10-138-674-3424	Sequence 3424, Ap
603	13.4	1.5	17	1	US-10-138-674-3425	Sequence 3425, Ap
c 604	13.4	1.5	17	1	US-10-287-949A-2045	Sequence 2045, Ap
c 605	13.4	1.5	17	1	US-10-287-949A-2046	Sequence 2046, Ap
c 606	13.4	1.5	17	1	US-10-287-949A-3424	Sequence 3424, Ap
c 607	13.4	1.5	17	1	US-10-287-949A-3425	Sequence 3425, Ap
c 608	13.4	1.5	17	1	US-10-669-841-3495	Sequence 3495, Ap
c 609	13.4	1.5	17	1	US-10-669-841-4392	Sequence 4392, Ap
c 610	13.4	1.5	17	1	US-10-669-841-6246	Sequence 6246, Ap
c 611	13.4	1.5	17	1	US-10-669-841-6246	Sequence 6246, Ap
c 612	13.4	1.5	17	1	US-10-681-074-3286	Sequence 3286, Ap
c 613	13	1.5	13	1	US-10-681-074-3287	Sequence 3287, Ap
614	13	1.5	13	1	US-10-257-017B-154649	Sequence 154649,
615	13	1.5	13	1	US-10-257-017B-154650	Sequence 154650,
c 616	13	1.5	13	1	US-10-257-017B-156539	Sequence 156539,
c 617	13	1.5	13	1	US-10-257-017B-156540	Sequence 156540,
					US-10-257-017B-201017	Sequence 201017,

ALIGNMENTS

RESULT 1

US-10-131-827-305

Sequence 305, Application US/10131827

Publication No. US20040009479A1

GENERAL INFORMATION:

APPLICANT: Wohlgemuth, Jay

APPLICANT: Fry, Kirk

APPLICANT: Woodward, Robert

APPLICANT: Ly, Ngoc

TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES

FILE REFERENCE: 506612000120

CURRENT APPLICATION NUMBER: US/10/131,827

CURRENT FILING DATE: 2002-09-06

PRIOR APPLICATION NUMBER: US 10/006,290

PRIOR FILING DATE: 2001-10-22

PRIOR APPLICATION NUMBER: US 60/296,764

PRIOR FILING DATE: 2001-06-08

NUMBER OF SEQ ID NOS: 9090

SOFTWARE: Patent in version 3.1

SEQ ID NO 305

LENGTH: 50

TYPE: DNA

ORGANISM: Homo sapiens

US-10-131-827-305

Query Match

Best Local Similarity

Matches

Score 50;

DB 1;

Length 50;

100.0%;

Pred. No. 1.5;

Conservative

0;

Mismatches

0;

Indels

0;

Gaps

0;

OY

530

ACATTCCTTGGATGCTAGTCTGAGGCCCTTAACCTATCTCTTATCTCTGC

579

DB

1

ACATTCCTTGGATGCTAGTCTGAGGCCCTTAACCTATCTCTTATCTCTGC

50

RESULT 2

US-10-131-827-1951

Sequence 1951, Application US/10131827

Publication No. US20040009479A1

GENERAL INFORMATION:

APPLICANT: Wohlgemuth, Jay

APPLICANT: Fry, Kirk

APPLICANT: Woodward, Robert

APPLICANT: Ly, Ngoc

TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES

FILE REFERENCE: 506612000120

CURRENT APPLICATION NUMBER: US/10/131,827

```
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1951
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-1951

Query Match          5.7%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 530 ACATTCCCTGGATGAGTCTGGAGCCCTTAACCTCATCTGTATCTCTGC 579
Db 1 ACATTCCCTGGATGAGTCTGGAGCCCTTAACCTCATCTGTATCTCTGC 50

RESULT 3
US-10-301-516-27
; Sequence 27, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; PRIOR FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 27
; LENGTH: 48
; TYPE: RNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
US-10-301-516-27

Query Match          5.5%; Score 48; DB 1; Length 48;
Best Local Similarity 77.1%; Pred. No. 2.1;
Matches 37; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 299 GAGAGGCATGTTGGAGACTTGGGCAATGTGACTGTGACAAAGATGGT 346
Db 1 GAGAGGCAUGUGGAGACUUGGCGCAAAUGUGACUGCUGACAAAGAUGGU 48

RESULT 4
US-10-700-816-7
; Sequence 7, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuoshang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; PRIOR FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7

Query Match          5.3%; Score 46.4; DB 1; Length 48;
Best Local Similarity 75.0%; Pred. No. 2.9;
Matches 36; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
```

```
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-7

Query Match          5.5%; Score 48; DB 1; Length 48;
Best Local Similarity 77.1%; Pred. No. 2.1;
Matches 37; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 299 GAGAGGCATGTTGGAGACTTGGGCAATGTGACTGTGACAAAGATGGT 346
Db 1 GAGAGGCAUGUGGAGACUUGGCGCAAAUGUGACUGCUGACAAAGAUGGU 48

RESULT 5
US-10-301-516-28
; Sequence 28, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; PRIOR FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 28
; LENGTH: 48
; TYPE: RNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
US-10-301-516-28

Query Match          5.3%; Score 46.4; DB 1; Length 48;
Best Local Similarity 75.0%; Pred. No. 2.9;
Matches 36; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

QY 299 GAGAGGCATGTTGGAGACTTGGGCAATGTGACTGTGACAAAGATGGT 346
Db 1 GAGAGGCAUGUGGAGACUUGGCGCAAAUGUGACUGCUGACAAAGAUGGU 48

RESULT 6
US-10-700-816-8
; Sequence 8, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuoshang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; PRIOR FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-8

Query Match          5.3%; Score 46.4; DB 1; Length 48;
Best Local Similarity 75.0%; Pred. No. 2.9;
Matches 36; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
```

; Sequence 73, Application US/10912440  
 ; Publication No. US20050186586A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZAMORE, PHILLIP D.  
 ; APPLICANT: HUTVAGNER, Gyorgy  
 ; APPLICANT: SCHWARZ, Dianne  
 ; APPLICANT: SIWARD, Martin  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND  
 ; FILE OF INVENTION: SPECIFICITY OF RNAI  
 ; FILE REFERENCE: UMY-066CP  
 ; CURRENT APPLICATION NUMBER: US/10/912,440  
 ; CURRENT FILING DATE: 2004-08-04  
 ; PRIOR APPLICATION NUMBER: 10/859,321  
 ; PRIOR FILING DATE: 2004-06-02  
 ; PRIOR APPLICATION NUMBER: 60/575,268  
 ; PRIOR FILING DATE: 2004-05-28  
 ; PRIOR APPLICATION NUMBER: 60/507,928  
 ; PRIOR FILING DATE: 2003-09-30  
 ; PRIOR APPLICATION NUMBER: 60/475,331  
 ; PRIOR FILING DATE: 2003-06-02  
 ; NUMBER OF SEQ ID NOS: 164  
 ; SOFTWARE: PatentIn Ver. 3.3





```
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 74
; LENGTH: 41
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-74

Query Match          4.7%; Score 41; DB 1; Length 41;
Best Local Similarity 100.0%; Pred. No. 6.7;
Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 GAGGCATGTTGAGACTGGGCAATGTGACTGCTGACAAAG 341
      |||||||||||||||||||||||||||||||||||||||
DB 41 GAGGCATGTTGAGACTGGGCAATGTGACTGCTGACAAAG 1

RESULT 15
US-10-301-516-32
; Sequence 32, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: wild-type sod1
US-10-301-516-32

Query Match          4.0%; Score 35; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 363
      |||||||||||||||||||||||||||||||||||
DB 1 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 35

RESULT 16
US-10-700-816-15
; Sequence 15, Application US/10700816
```

```
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: XU, Zuoshang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-15

Query Match          4.0%; Score 35; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 363
      |||||||||||||||||||||||||||||||||||
DB 1 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 35

RESULT 17
US-10-894-721-2
; Sequence 2, Application US/10894721
; Publication No. US20050130184A1
; GENERAL INFORMATION:
; APPLICANT: XU, Zuoshang
; APPLICANT: XIA, Xugang
; TITLE OF INVENTION: ENHANCED PROMOTERS FOR SYNTHESIS OF
; FILE OF INVENTION: SMALL HAIRPIN RNA
; FILE REFERENCE: UMY-071
; CURRENT APPLICATION NUMBER: US/10/894,721
; CURRENT FILING DATE: 2004-07-19
; PRIOR APPLICATION NUMBER: 60/488,312
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic siRNA target sequence
US-10-894-721-2

Query Match          4.0%; Score 35; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 363
      |||||||||||||||||||||||||||||||||||
DB 1 ACTGCTGACAAAGATGGTGTGCCCGCATGTGTCTAT 35

RESULT 18
US-10-894-721-3
; Sequence 3, Application US/10894721
; Publication No. US20050130184A1
; GENERAL INFORMATION:
; APPLICANT: XU, Zuoshang
; APPLICANT: XIA, Xugang
; TITLE OF INVENTION: ENHANCED PROMOTERS FOR SYNTHESIS OF
; FILE OF INVENTION: SMALL HAIRPIN RNA
; FILE REFERENCE: UMY-071
; CURRENT APPLICATION NUMBER: US/10/894,721
; CURRENT FILING DATE: 2004-07-19
```

```
/ ; PRIOR APPLICATION NUMBER: 60/488,312
/ ; PRIOR FILING DATE: 2003-07-18
/ ; NUMBER OF SEQ ID NOS: 4
/ ; SOFTWARE: FastSeq for Windows Version 4.0
/ ; SEQ ID NO 3
/ ; LENGTH: 35
/ ; TYPE: DNA
/ ; ORGANISM: Artificial Sequence
/ ; FEATURE:
/ ; OTHER INFORMATION: synthetic siRNA target sequence
US-10-894-721-3

Query Match      3.8%; Score 33.4; DB 1; Length 35;
Best Local Similarity 97.1%; Pred. No. 25;
Matches 34; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 329 ACTGCTGACAAAGATGCTGTGCGCGATGTCTAT 363
      |||||
Db 1 ACTGCTGACAAAGATGCTGTGCGCGATGTCTAT 35

RESULT 19
US-09-899-807-1/c
; Sequence 1, Application US/09899807
; Patent No. US20020106348A1
; GENERAL INFORMATION:
; APPLICANT: HUANG, PENG
; APPLICANT: PLUNKETT, WILLIAM
; APPLICANT: FENG, LI
; TITLE OF INVENTION: CANCER THERAPEUTICS INVOLVING THE ADMINISTRATION OF
; TITLE OF INVENTION: 2-METHOXYESTRADIOL AND AN AGENT THAT INCREASES
; FILE REFERENCE: UTSC:618US
; CURRENT APPLICATION NUMBER: US/09/899,807
; CURRENT FILING DATE: 2001-07-05
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 1
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-09-899-807-1

Query Match      3.1%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 AGTTATGGCGACGAAGCGCGTGTGCGT 87
      |||||
Db 27 AGTTATGGCGACGAAGCGCGTGTGCGT 1

RESULT 20
US-10-956-157-19040
; Sequence 19040, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 19040
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19040
```

```
US-10-956-157-19040
Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 CGATGTGCTCTATTGAAGATTCTGTG 376
      |||||
Db 1 CGATGTGCTCTATTGAAGATTCTGTG 25

RESULT 21
US-10-956-157-19041
; Sequence 19041, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 19041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19041

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 351 CCGATGTGCTCTATTGAAGATTCTGT 375
      |||||
Db 1 CCGATGTGCTCTATTGAAGATTCTGT 25

RESULT 22
US-10-956-157-19042
; Sequence 19042, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 19042
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19042

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 353 GATGTGCTCTATTGAAGATTCTGTGA 377
      |||||
Db 1 GATGTGCTCTATTGAAGATTCTGTGA 25

RESULT 23
US-10-956-157-19043
; Sequence 19043, Application US/10956157
; Publication No. US20050118625A1
```

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19043  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-19043

Query Match 2.9%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 350 GCCGATGTCATTGAAGATTCTG 374

Db 1 GCCGATGTCATTGAAGATTCTG 25

## RESULT 24

US-10-956-157-19044  
; Sequence 19044, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19044  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-19044

Query Match 2.9%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 354 ATGTGTCATTGAAGATTCTGTGAT 378

Db 1 ATGTGTCATTGAAGATTCTGTGAT 25

## RESULT 25

US-10-956-157-19045  
; Sequence 19045, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19045  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-19045

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 355 TGTGTCATTGAAGATTCTGTGATC 379

Db 1 TGTGTCATTGAAGATTCTGTGATC 25

## RESULT 26

US-10-956-157-19046  
; Sequence 19046, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19046  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-19046

Query Match 2.9%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 557 CCTTAACATCATCTGTTATCCTGCTA 581

Db 1 CCTTAACATCATCTGTTATCCTGCTA 25

## RESULT 27

US-10-956-157-19047  
; Sequence 19047, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19047  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-19047

Query Match 2.9%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 GTCCTCACTTTAATCCTCTATCCAG 273

Db 1 GTCCTCACTTTAATCCTCTATCCAG 25

## RESULT 28

US-10-956-157-19048  
; Sequence 19048, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19048
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19048

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 558 CTTAACTCATCTGTTATCTCTGCTAG 582
      |||||||||||||||||||||||||||
Db 1 CTTAACTCATCTGTTATCTCTGCTAG 25

RESULT 29
US-10-956-157-19049
; Sequence 19049, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19049
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19049

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 250 TCCTCACTTTAATCTCTATCCAGA 274
      |||||||||||||||||||||||||||
Db 1 TCCTCACTTTAATCTCTATCCAGA 25

RESULT 30
US-10-956-157-19050
; Sequence 19050, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19050
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19050
```

```
Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 248 GGTCTCTCACTTTAATCTCTATCCA 272
      |||||||||||||||||||||||||||
Db 1 GGTCTCTCACTTTAATCTCTATCCA 25

RESULT 31
US-10-956-157-19051
; Sequence 19051, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19051
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19051

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 251 CCTCACTTTAATCTCTATCCAGAA 275
      |||||||||||||||||||||||||||
Db 1 CCTCACTTTAATCTCTATCCAGAA 25

RESULT 32
US-10-956-157-19052
; Sequence 19052, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19052
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19052

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 461 GAAGAAAGTACAAAGACAGGAAACG 485
      |||||||||||||||||||||||||||
Db 1 GAAGAAAGTACAAAGACAGGAAACG 25

RESULT 33
US-10-956-157-19053
; Sequence 19053, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19053
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19053

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 448 CAAAGTGGAAATGAAGAAAGTACA 472
      |||||||||||||||||||||||||
Db 1 CAAAGTGGAAATGAAGAAAGTACA 25

RESULT 34
US-10-956-157-19054
; Sequence 19054, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19054
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19054

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 460 TGAAGAAAGTACAAAGACAGGAAC 484
      |||||||||||||||||||||||||
Db 1 TGAAGAAAGTACAAAGACAGGAAC 25

RESULT 35
US-10-956-157-19055
; Sequence 19055, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19055
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19055

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 460 TGAAGAAAGTACAAAGACAGGAAC 484
      |||||||||||||||||||||||||
Db 1 TGAAGAAAGTACAAAGACAGGAAC 25

RESULT 36
US-10-956-157-19056
; Sequence 19056, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19056
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19056

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 AGGTGGAATGAAGAAAGTACAAAG 475
      |||||||||||||||||||||||||
Db 1 AGGTGGAATGAAGAAAGTACAAAG 25

RESULT 37
US-10-956-157-19057
; Sequence 19057, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19057
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19057

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 446 GCCTGGAATGAAGAAAGTACAAAGA 470
      |||||||||||||||||||||||||
Db 1 GCCTGGAATGAAGAAAGTACAAAGA 25

RESULT 38
US-10-956-157-19058
; Sequence 19058, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAGTACAAAGA 476
      |||||||||||||||||||||||||
Db 1 GGTGGAATGAAGAAAGTACAAAGA 25

RESULT 36
US-10-956-157-19056
; Sequence 19056, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19056
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19056

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 AGGTGGAATGAAGAAAGTACAAAG 475
      |||||||||||||||||||||||||
Db 1 AGGTGGAATGAAGAAAGTACAAAG 25

RESULT 37
US-10-956-157-19057
; Sequence 19057, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19057
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19057

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 446 GCCTGGAATGAAGAAAGTACAAAGA 470
      |||||||||||||||||||||||||
Db 1 GCCTGGAATGAAGAAAGTACAAAGA 25

RESULT 38
US-10-956-157-19058
; Sequence 19058, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19058
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19058

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 165 GAAGCATTAAAGGACTGACTGAAGG 189
      |||||
Db 1 GAAGCATTAAAGGACTGACTGAAGG 25

RESULT 39
US-10-956-157-19059
; Sequence 19059, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19059
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19059

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 164 GGAAGCATTAAAGGACTGACTGAAG 188
      |||||
Db 1 GGAAGCATTAAAGGACTGACTGAAG 25

RESULT 40
US-10-956-157-19060
; Sequence 19060, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19060
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19060

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 164 GGAAGCATTAAAGGACTGACTGAAG 188
      |||||
Db 1 GGAAGCATTAAAGGACTGACTGAAG 25

RESULT 41
US-10-956-157-19061
; Sequence 19061, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19061
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19061

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 447 GCAAAGGTGGAATGAAGAAAGTAC 471
      |||||
Db 1 GCAAAGGTGGAATGAAGAAAGTAC 25

RESULT 42
US-10-956-157-19062
; Sequence 19062, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19062
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-19062

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 450 AAGGTGGAATGAAGAAAGTACAAA 474
      |||||
Db 1 AAGGTGGAATGAAGAAAGTACAAA 25

RESULT 43
US-10-956-157-19063
; Sequence 19063, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
 ; FILE REFERENCE: 031896-043000 (AM 101081)  
 ; CURRENT APPLICATION NUMBER: US/10/956,157  
 ; CURRENT FILING DATE: 2004-10-04  
 ; NUMBER OF SEQ ID NOS: 319805  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 19063  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Probe Sequence  
 US-10-956-157-19063

Query Match 2.9%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 AAGGTGGAAATGAAGAAAGTACAA 473  
 |||||  
 DB 1 AAGGTGGAAATGAAGAAAGTACAA 25

RESULT 44  
 US-10-956-157-134047  
 ; Sequence 134047, Application US/10956157  
 ; Publication No. US20050118625A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts, William  
 ; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
 ; FILE REFERENCE: 031896-043000 (AM 101081)  
 ; CURRENT APPLICATION NUMBER: US/10/956,157  
 ; CURRENT FILING DATE: 2004-10-04  
 ; NUMBER OF SEQ ID NOS: 319805  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 134047  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Probe Sequence  
 US-10-956-157-134047

Query Match 2.9%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 140 AGTAATGGACCAAGTGAAGTGTGGG 164  
 |||||  
 DB 1 AGTAATGGACCAAGTGAAGTGTGGG 25

RESULT 45  
 US-10-956-157-134183  
 ; Sequence 134183, Application US/10956157  
 ; Publication No. US20050118625A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts, William  
 ; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
 ; FILE REFERENCE: 031896-043000 (AM 101081)  
 ; CURRENT APPLICATION NUMBER: US/10/956,157  
 ; CURRENT FILING DATE: 2004-10-04  
 ; NUMBER OF SEQ ID NOS: 319805  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 134183  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Probe Sequence  
 US-10-956-157-134183

Query Match 2.9%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 AGGCTGCATGCATTCATGTTTCAT 211  
 |||||  
 DB 1 AGGCTGCATGCATTCATGTTTCAT 25

RESULT 46  
 US-10-956-157-134860  
 ; Sequence 134860, Application US/10956157  
 ; Publication No. US20050118625A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts, William  
 ; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
 ; FILE REFERENCE: 031896-043000 (AM 101081)  
 ; CURRENT APPLICATION NUMBER: US/10/956,157  
 ; CURRENT FILING DATE: 2004-10-04  
 ; NUMBER OF SEQ ID NOS: 319805  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 134860  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Probe Sequence  
 US-10-956-157-134860

Query Match 2.9%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 398 AGGAGACCATTCATCATTGGCCGC 412  
 |||||  
 DB 1 AGGAGACCATTCATCATTGGCCGC 25

RESULT 47  
 US-10-956-157-136056  
 ; Sequence 136056, Application US/10956157  
 ; Publication No. US20050118625A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts, William  
 ; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
 ; FILE REFERENCE: 031896-043000 (AM 101081)  
 ; CURRENT APPLICATION NUMBER: US/10/956,157  
 ; CURRENT FILING DATE: 2004-10-04  
 ; NUMBER OF SEQ ID NOS: 319805  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 136056  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Probe Sequence  
 US-10-956-157-136056

Query Match 2.9%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 81;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 AGGCGATCATCAATTCGAGCAGAA 135  
 |||||  
 DB 1 AGGCGATCATCAATTCGAGCAGAA 25

RESULT 48  
 US-10-956-157-139603  
 ; Sequence 139603, Application US/10956157  
 ; Publication No. US20050118625A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wyeth  
 ; APPLICANT: Mounts, William  
 ; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 139603  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-139603

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 AGATGGTGTGCCGATGTGTCTATT 364  
|||||  
Db 1 AGATGGTGTGCCGATGTGTCTATT 25

RESULT 49  
US-10-956-157-149298  
; Sequence 149298, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 149298  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-149298

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 182 ACTGAAGCCTCATGGATTCATG 206  
|||||  
Db 1 ACTGAAGCCTCATGGATTCATG 25

RESULT 50  
US-10-956-157-149376  
; Sequence 149376, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 149376  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-149376

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 178 ACTGACTGAAGCCTCATGGATTC 202  
|||||  
Db 1 ACTGACTGAAGCCTCATGGATTC 25

RESULT 51  
US-10-956-157-150718  
; Sequence 150718, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 150718  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-150718

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 ACTTTAATCCTCTATCCAGAAACA 279  
|||||  
Db 1 ACTTTAATCCTCTATCCAGAAACA 25

RESULT 52  
US-10-956-157-156203  
; Sequence 156203, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 156203  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-156203

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 472 AAAGACAGGAAACGCTGGAAGTCGT 496  
|||||  
Db 1 AAAGACAGGAAACGCTGGAAGTCGT 25

RESULT 53  
US-10-956-157-160696  
; Sequence 160696, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)



; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 160696  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-160696

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 AACGCTGGAAGTCGTTGGCTTGTG 506  
|||||  
Db 1 AACGCTGGAAGTCGTTGGCTTGTG 25

## RESULT 54

US-10-956-157-171822  
; Sequence 171822, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 171822  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-171822

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 381 CACTCTCAGGAGACCATTCATCAT 405  
|||||  
Db 1 CACTCTCAGGAGACCATTCATCAT 25

## RESULT 55

US-10-956-157-173368  
; Sequence 173368, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 173368  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-173368

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 278 CACGGTGGCCAAAGGATGAAGAGA 302

Db 1 CACGGTGGCCAAAGGATGAAGAGA 25  
|||||

## RESULT 56

US-10-956-157-182879  
; Sequence 182879, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 182879  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-182879

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 266 CTATCCAGAAAACACGGTGGGCCAA 290  
|||||  
Db 1 CTATCCAGAAAACACGGTGGGCCAA 25

## RESULT 57

US-10-956-157-184849  
; Sequence 184849, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 184849  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-184849

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTCTATCCAGAAA 276  
|||||  
Db 1 CTCACCTTTAATCCTCTATCCAGAAA 25

## RESULT 58

US-10-956-157-188144  
; Sequence 188144, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth

; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157

```

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188144
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188144

```

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 89 CTGAAGGGCGACGGCCAGTGCAGG 113  
|||  
Db 1 CTGAAGGGCGACGGCCAGTGCAGG 25

RESULT 59  
US-10-956-157-189649  
; Sequence 189649, Application US/10956157  
; Publication No. US20050118625A1

```
Query Match          2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. NO. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 372 CTGTGATCTCACTCTCAGGAGACCA 396  
|||||  
Db 1 CTGTGATCTCACTCTCAGGAGACCA 25

RESULT 60  
US-10-956-157-196119  
; Sequence 196119, Application US/10956157  
; Publication No. US20050118625A1

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 CCGCACACTGGTGGTCCATGAAAAA 433

Db 1 CCGCACACTGGTGGTCCATGAAAA 25

RESULT 61  
US-10-956-157-196500  
; Sequence 196500, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 351 CCGATGTGCTCTATTGAAGATTCTGT 375  
 Db 1 CCGATGTGCTCTATTGAAGATTCTGT 25

RESULT 62  
US-10-956-157-196788  
; Sequence 196788, Application US/10956157  
; Publication No. US20050118625A1

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

**Qy**

78 CCGTGTGCTGCTGAAGGGCAGCG 102  
|||||  
**Dβ**

1 CCGTGTGCTGCTGAAGGGCAGCG 25

RESULT 63  
US-10-956-157-206018  
; Sequence 206018, Application US/10956157  
; Publication No. US20050118625A1

```

: APPLICANT: Wyeth
:
: APPLICANT: Mounts, William
:
: TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR
:
: TITLE OF INVENTION: HUMAN OSTEOARTHRITIS
:
: FILE REFERENCE: 031896-043000 (AM 101081)
:
: CURRENT APPLICATION NUMBER: US/10/956,157
:
: CURRENT FILING DATE: 2004-10-04
:

```

```

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04

```

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 206018  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-206018

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 521 GCCCAATAAACATTCCTCTGGATGT 545  
|||||  
Db 1 GCCCAATAAACATTCCTCTGGATGT 25

## RESULT 64

US-10-956-157-213479  
; Sequence 213479, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 213479

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-213479

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 130 GCAGAAGGAAGTAATGGACCAAGTG 154  
|||||  
Db 1 GCAGAAGGAAGTAATGGACCAAGTG 25

## RESULT 65

US-10-956-157-214062  
; Sequence 214062, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 214062

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-214062

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 193 GCATGGATTCCATGTTTCATGAGTTT 217  
|||||  
Db 1 GCATGGATTCCATGTTTCATGAGTTT 25

## RESULT 66

US-10-956-157-214634  
; Sequence 214634, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 214634

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-214634

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 109 GCAGGGCATCATCAATTCGAGCAG 133  
|||||  
Db 1 GCAGGGCATCATCAATTCGAGCAG 25

## RESULT 67

US-10-956-157-220621  
; Sequence 220621, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 220621

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-220621

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 154 GAAGGTGTGGGGAAGCATTAAGGA 178  
|||||  
Db 1 GAAGGTGTGGGGAAGCATTAAGGA 25

## RESULT 68

US-10-956-157-221193  
; Sequence 221193, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221193
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-221193

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 365 GAAGATTCTGTGATCTCACTCTCAG 389
      |||||
Db 1 GAAGATTCTGTGATCTCACTCTCAG 25

RESULT 69
US-10-956-157-224177
; Sequence 224177, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 224177
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-224177

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 273 GAAACACGGTGGGCGCAAGATGA 297
      |||||
Db 1 GAAACACGGTGGGCGCAAGATGA 25

RESULT 70
US-10-956-157-228500
; Sequence 228500, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228500
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228500

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 328 GACTGCTGACAAAGATGTTGTGGCC 352
      |||||
Db 1 GACTGCTGACAAAGATGTTGTGGCC 25

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233553
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233553

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 299 GAGAGGCATGTTGGAGACTTGGGCA 323
      |||||
Db 1 GAGAGGCATGTTGGAGACTTGGGCA 25

RESULT 71
US-10-956-157-233553
; Sequence 233553, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233553
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233553

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 299 GAGAGGCATGTTGGAGACTTGGGCA 323
      |||||
Db 1 GAGAGGCATGTTGGAGACTTGGGCA 25

RESULT 72
US-10-956-157-239197
; Sequence 239197, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 239197
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-239197

Query Match      2.9%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 GATCTCACTCTCAGGAGACCATTCG 400
      |||||
Db 1 GATCTCACTCTCAGGAGACCATTCG 25

RESULT 73
US-10-956-157-241982
; Sequence 241982, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
```

; SEQ ID NO 241982

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-241982

Query Match 2.9%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 81;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 368 GATTCTGTGATCTCACTCTCAGGAG 392

|||||

Db 1 GATTCTGTGATCTCACTCTCAGGAG 25

RESULT 74

US-10-956-157-242800

; Sequence 242800; Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 242800

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-242800

Query Match

Best Local Similarity 2.9%; Score 25; DB 1; Length 25;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 308 GTTGAGACTTGGCAATGTGACTG 332

|||||

Db 1 GTTGAGACTTGGCAATGTGACTG 25

RESULT 75

US-10-956-157-247393

; Sequence 247393; Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 247393

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-247393

Query Match

Best Local Similarity 2.9%; Score 25; DB 1; Length 25;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 593 GTATCCTGATAAACATTAAACACTG 617

|||||

Db 1 GTATCCTGATAAACATTAAACACTG 25

RESULT 76

US-10-956-157-257204

; Sequence 257204; Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 257204

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-257204

Query Match

Best Local Similarity 2.9%; Score 25; DB 1; Length 25;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GTGGTCCATGAAAAAGCAGATGACT 443

|||||

Db 1 GTGGTCCATGAAAAAGCAGATGACT 25

RESULT 77

US-10-956-157-259305

; Sequence 259305; Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 259305

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-259305

Query Match

Best Local Similarity 2.9%; Score 25; DB 1; Length 25;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGCTGCAAAAGAT 343

|||||

Db 1 GGGCAATGTGACTGCTGCAAAAGAT 25

RESULT 78

US-10-956-157-261942

; Sequence 261942; Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 261942

; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-261942

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 162 GGGGAGCATTAAAGACTGACTGA 186  
|||||  
Db 1 GGGGAGCATTAAAGACTGACTGA 25

## RESULT 79

US-10-956-157-266239  
; Sequence 266239, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 266239  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-266239

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 516 GGATCGCCCAATAAACATTCCTTG 540  
|||||  
Db 1 GGATCGCCCAATAAACATTCCTTG 25

## RESULT 80

US-10-956-157-287005  
; Sequence 287005, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 287005  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-287005

Query Match 2.9%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 81;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 83 TCGGTGCTGAAGGGCGAGCCGAC 107  
|||||  
Db 1 TCGGTGCTGAAGGGCGAGCCGAC 25

## RESULT 81

US-11-070-868-4/c  
; Sequence 4, Application US/11070868  
; Publication No. US20050202488A1  
; GENERAL INFORMATION:

; APPLICANT: Brown, Robert H  
; APPLICANT: Broom, Wendy  
; TITLE OF INVENTION: ASSAY FOR THERAPIES THAT INHIBIT EXPRESSION OF THE CYTOSOLIC  
; FILE REFERENCE: M0765.70078US01  
; CURRENT APPLICATION NUMBER: US/11/070,868  
; CURRENT FILING DATE: 2005-03-02  
; PRIOR APPLICATION NUMBER: US 60/549,326  
; PRIOR FILING DATE: 2004-03-02  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 4  
; LENGTH: 32  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic oligonucleotide  
US-11-070-868-4

Query Match 2.8%; Score 24.4; DB 1; Length 32;  
Best Local Similarity 96.2%; Pred. No. 1.2e+02;  
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 48 CGGTGGCCTAGCGAGTTATGGGACG 73  
|||||  
Db 32 CGGTGGCCTAGCGAGTTATGGGACG 7

## RESULT 82

US-10-956-157-246110  
; Sequence 246110, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 246110  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-246110

Query Match 2.7%; Score 23.4; DB 1; Length 25;  
Best Local Similarity 96.0%; Pred. No. 1.1e+02;  
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 214 GTTTGGAGATAATACAGCAGGCTGT 238  
|||||  
Db 1 GTTTGGAGATAATACAGCAGGCTGT 25

## RESULT 83

US-10-956-157-277195  
; Sequence 277195, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 277195  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-277195

Query Match 2.7%; Score 23.4; DB 1; Length 25;  
Best Local Similarity 96.0%; Pred. No. 1.1e+02;  
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 217 TGGAGATAATACAGCGGCTGTACC 241  
DB 1 TGGAGATAATACAGCGGCTGTACC 25

## RESULT 84

US-09-899-807-3  
; Sequence 3, Application US/09899807  
; Patent No. US20020106348A1  
; GENERAL INFORMATION:  
; APPLICANT: HUANG, PENG  
; APPLICANT: PLUNKETT, WILLIAM  
; APPLICANT: FENG, LI  
; TITLE OF INVENTION: CANCER THERAPEUTICS INVOLVING THE ADMINISTRATION OF  
; TITLE OF INVENTION: 2-METHOXYESTRADIOL AND AN AGENT THAT INCREASES  
; TITLE OF INVENTION: INTRACELLULAR SUPEROXIDE ANION  
; FILE REFERENCE: UTSC:618US  
; CURRENT APPLICATION NUMBER: US/09/899,807  
; CURRENT FILING DATE: 2001-07-05  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 3  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-09-899-807-3

Query Match 2.6%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 ACGAAGCCGCTGCGTGTCTGAA 93  
DB 1 ACGAAGCCGCTGCGTGTCTGAA 23

## RESULT 85

US-09-899-807-4/c  
; Sequence 4, Application US/09899807  
; Patent No. US20020106348A1  
; GENERAL INFORMATION:  
; APPLICANT: HUANG, PENG  
; APPLICANT: PLUNKETT, WILLIAM  
; APPLICANT: FENG, LI  
; TITLE OF INVENTION: CANCER THERAPEUTICS INVOLVING THE ADMINISTRATION OF  
; TITLE OF INVENTION: 2-METHOXYESTRADIOL AND AN AGENT THAT INCREASES  
; TITLE OF INVENTION: INTRACELLULAR SUPEROXIDE ANION  
; FILE REFERENCE: UTSC:618US  
; CURRENT APPLICATION NUMBER: US/09/899,807  
; CURRENT FILING DATE: 2001-07-05  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Primer  
US-09-899-807-4

Query Match 2.6%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CTGGAAGTCGTTGGCTTGTGGT 508  
DB 23 CTGGAAGTCGTTGGCTTGTGGT 1

## RESULT 86

US-10-487-091-5  
; Sequence 5, Application US/10487091  
; Publication No. US20050112572A1  
; GENERAL INFORMATION:  
; APPLICANT: Pincemail et al.  
; TITLE OF INVENTION: PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR THE  
; TITLE OF INVENTION: IMPLEMENTATION OF THIS PROCESS  
; FILE REFERENCE: P2097-US  
; CURRENT APPLICATION NUMBER: US/10/487,091  
; CURRENT FILING DATE: 2004-02-13  
; PRIOR APPLICATION NUMBER: BE 2001/0545  
; PRIOR FILING DATE: 2001-08-14  
; PRIOR APPLICATION NUMBER: PCT/EP02/009079  
; PRIOR FILING DATE: 2002-08-13  
; NUMBER OF SEQ ID NOS: 76  
; SOFTWARE: PatentIn Ver. 3.1  
; SEQ ID NO 5  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-487-091-5

Query Match 2.6%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGACAAAGAT 343  
DB 1 GCAATGTGACTGCTGACAAAGAT 23

## RESULT 87

US-10-487-091-6/c  
; Sequence 6, Application US/10487091  
; Publication No. US20050112572A1  
; GENERAL INFORMATION:  
; APPLICANT: Pincemail et al.  
; TITLE OF INVENTION: PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR THE  
; TITLE OF INVENTION: IMPLEMENTATION OF THIS PROCESS  
; FILE REFERENCE: P2097-US  
; CURRENT APPLICATION NUMBER: US/10/487,091  
; CURRENT FILING DATE: 2004-02-13  
; PRIOR APPLICATION NUMBER: BE 2001/0545  
; PRIOR FILING DATE: 2001-08-14  
; PRIOR APPLICATION NUMBER: PCT/EP02/009079  
; PRIOR FILING DATE: 2002-08-13  
; NUMBER OF SEQ ID NOS: 76  
; SOFTWARE: PatentIn Ver. 3.1  
; SEQ ID NO 6  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-487-091-6

Query Match 2.6%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 383 CTCACGAGACCATTCATCAT 405

```

Db      23 CTCACGAGCATTGGCATCAT 1

RESULT 88
US-09-918-421-7
; Sequence 7, Application US/09918421
; Patent No. US2002002553A1
; GENERAL INFORMATION:
; APPLICANT: METHOD OF DETERMINING ANALYTICAL NUCLEOTIDE SEQUENCE USED IN NUCLEIC ACID
; APPLICANT: DETECTION
; TITLE OF INVENTION: OLYMPUS OPTICAL CO., LTD
; FILE REFERENCE: 99S1124P
; CURRENT APPLICATION NUMBER: US/09/918,421
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-918-421-7

Query Match          2.6%; Score 22.6; DB 1; Length 30;
Best Local Similarity 86.2%; Pred. No. 1.6e+02;
Matches 25; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY    510 TAAATGGGATCGCCCAATAAACATTCCCCT 538
       ||||||| | | | | | | | | | | | | | |
DB     1 TGATTTGGGATTGCAGTAATAACATTCCCCT 29

RESULT 89
US-10-719-900-61538
; Sequence 61538, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 61538
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-61538

Query Match          2.6%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY    232 AGGCTGTACCAGTGCAGGTCCTCA 255
       ||||| | | | | | | | | | | | | | |
DB     2 AGGCTGTACCAGTGCAGGACTCA 25

RESULT 90
US-10-333-578-13/c
; Sequence 13, Application US/10333578
; Publication No. US20040058856A1
; GENERAL INFORMATION:
; APPLICANT: CHOI, Soo-Young
; APPLICANT: HAN, Kyu-Hyung
; APPLICANT: PARK, Jinseu
; APPLICANT: KWON, Hyekook-Yil
; APPLICANT: KANG, Jung-Hoon
; APPLICANT: KANG, Tae-Chun
US-10-333-578-13/c

Query Match          2.5%; Score 22; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```



QY 67 GCGCAGCAAGGCGGTGCGTG 88  
|||  
Db 6 GCGCAGCAAGGCGGTGCGTG 27

## RESULT 92

US-10-719-956-119457  
; Sequence 119457, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002-11-20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 119457  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-119457

Query Match 2.5%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 1.5e+02;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 367 AGATTCTGTGATCTCACTCTCAGGA 391  
|||  
Db 1 AGATCGTGTGATCTCACTCTCAGGA 25

## RESULT 93

US-10-109-349A-52  
; Sequence 52, Application US/10109349A  
; Publication No. US20030186246A1  
; GENERAL INFORMATION:  
; APPLICANT: Medical College of Ohio  
; APPLICANT: Willey, James C.  
; APPLICANT: Crawford, Brin L.  
; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN RE  
; FILE REFERENCE: 01154/2001-203  
; CURRENT APPLICATION NUMBER: US/10/109,349A  
; CURRENT FILING DATE: 2002-06-12  
; NUMBER OF SEQ ID NOS: 282  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 52  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-109-349A-52

Query Match 2.4%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 TGAAGGTGTGGGAAGCAATTA 173  
|||  
Db 1 TGAAGGTGTGGGAAGCAATTA 21

## RESULT 94

US-10-109-349A-53/c  
; Sequence 53, Application US/10109349A  
; Publication No. US20030186246A1  
; GENERAL INFORMATION:  
; APPLICANT: Medical College of Ohio  
; APPLICANT: Willey, James C.  
; APPLICANT: Crawford, Brin L.

; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN RE  
; FILE REFERENCE: 01154/2001-203  
; CURRENT APPLICATION NUMBER: US/10/109,349A  
; CURRENT FILING DATE: 2002-06-12  
; NUMBER OF SEQ ID NOS: 282  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 53  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-109-349A-53

Query Match 2.4%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CTCGTTTCGCTTGCTGTAA 512  
|||  
Db 21 CTCGTTTCGCTTGCTGTAA 1

## RESULT 95

US-10-633-843-6  
; Sequence 6, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; APPLICANT: Kenneth Bennett  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSI  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Probe  
US-10-633-843-6

Query Match 2.4%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 ACGAAGCCGTGTCGTCGTG 91  
|||  
Db 1 ACGAAGCCGTGTCGTCGTG 21

## RESULT 96

US-10-672-866-6  
; Sequence 6, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 6  
; LENGTH: 21

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-672-866-6

Query Match          2.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 71 ACGAAGCCGCTGCTGCTGCTG 91
    |||||||
Db 1 ACGAAGCCGCTGCTGCTGCTG 21

RESULT 97
US-10-719-900-826010
; Sequence 826010, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 826010
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-826010

Query Match          2.4%; Score 21; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 373 TGTGATCTCACTCTCAGGAGA 393
    |||||||
Db 4 TGTGATCTCACTCTCAGGAGA 24

RESULT 98
US-10-719-900-61537
; Sequence 61537, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 61537
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-61537

Query Match          2.4%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 232 AGGCTGTACCACTGCAGTCTCTCA 255
    |||||||
Db 2 AGGCTGTACCACTGCAGTCTCTCA 25

RESULT 99
US-10-719-900-456063
; Sequence 456063, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456063
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-456063

Query Match          2.3%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.9e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 314 GACTTGGCAATGTGACTGCTG 335
    |||||||
Db 1 GACTTGGCAATGTGACTGCTG 22

RESULT 100
US-10-719-900-284833
; Sequence 284833, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 284833
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-284833

Query Match          2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 512 ATTGGGATCGCCCAATAAACATTCC 536
    |||||||
Db 1 ATTGGGATCGCCAGTAACATTCC 25

RESULT 101
US-10-719-900-458198
; Sequence 458198, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 458198
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-458198

Query Match
Best Local Similarity 2.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 0; Indels 3; Gaps 0;

Qy 341 GATGGTGGCCGATGTGCTATTG 365
||| ||||| ||||| ||||| |||||
Db 1 GACGGTGGCCCAATGTGTCATTG 25

RESULT 102
US-10-719-900-458199
; Sequence 458199, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 458199
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-458199

Query Match
Best Local Similarity 2.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 0; Indels 3; Gaps 0;

Qy 341 GATGGTGGCCGATGTGCTATTG 365
||| ||||| ||||| ||||| |||||
Db 1 GACGGTGGCCCAATGTGTCATTG 25

RESULT 103
US-10-719-900-889725
; Sequence 889725, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 889725
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-889725

Query Match
Best Local Similarity 2.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 0; Indels 3; Gaps 0;

Qy 514 TGGGATCGCCCAATAAACATTCCT 538
||| ||||| ||||| ||||| |||||
Db 1 TGGGATGGCGAGTAACATTCCT 25

RESULT 104
US-10-719-900-889726
; Sequence 889726, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 889726
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-889726

Query Match
Best Local Similarity 2.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 0; Indels 3; Gaps 0;

Qy 514 TGGGATCGCCCAATAAACATTCCT 538
||| ||||| ||||| ||||| |||||
Db 1 TGGGATGGCGAGTAACATTCCT 25

RESULT 105
US-10-719-900-893797
; Sequence 893797, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 893797
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-893797

Query Match
Best Local Similarity 2.3%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 0; Indels 3; Gaps 0;

Qy 420 TGGTCCATGAAAAAGCAGATGACTT 444
||| ||||| ||||| ||||| |||||
Db 1 TGGTCCATGAGAAACAGATGACTT 25

RESULT 106
US-10-719-900-967669/c
; Sequence 967669, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 967669
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-956-967669

Query Match      2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 315 ACTTGGCAATGTGACTGCTGACAA 339
    |||||||||||||||||||||
Db 25 ACTGGGCAATGTGACTGCTGGAAA 1

RESULT 107
US-10-719-956-119458
; Sequence 119458, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 119458
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-119458

Query Match      2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 341 GATGGTGGCGGATGCTCTATTG 365
    |||||||||||||||||||
Db 1 GACGGTGGCGCATGTGTCATTG 25

RESULT 108
US-10-719-956-324786
; Sequence 324786, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 324786
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-324786

Query Match      2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 367 AGATTCTGTGATCTCACTCTCAGGA 391
    |||||
Db 1 AGATCGTGTGATCTCACTCTCAGGA 25

RESULT 109
US-10-719-956-324787
; Sequence 324787, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 324787
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-324787

Query Match      2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 341 GATGGTGGCGGATGCTCTATTG 365
    |||||||||||||||||||
Db 1 GACGGTGGCGCATGTGTCATTG 25

RESULT 110
US-10-719-956-426002
; Sequence 426002, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 426002
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-426002

Query Match      2.3%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 341 GATGGTGGCGGATGCTCTATTG 365
    |||||||||||||||||||
Db 1 GACGGTGGCGCATGTGTCATTG 25

RESULT 111
US-10-719-956-479105
; Sequence 479105, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 479105
; LENGTH: 25
; TYPE: DNA
```

; ORGANISM: Rattus norvegicus  
US-10-719-956-479105

Query Match 2.3%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 2e+02;  
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 237 GTACCAGTCAGGTCCTCACTTAA 261  
||||| ||||| ||||| ||||| |||||  
Db 1 GTACCAGTCAGGACCTCATTTAA 25

## RESULT 112

US-10-633-843-4  
; Sequence 4, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 4  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Primer  
US-10-633-843-4

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 COTGGCCTAGCGAGTTATGG 68  
||||| ||||| ||||| ||||| |||||  
Db 1 COTGGCCTAGCGAGTTATGG 20

## RESULT 113

US-10-633-843-5/c  
; Sequence 5, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 5  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Primer  
US-10-633-843-5

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 108 TGCAGGCATCATCAATTC 127  
||||| ||||| ||||| ||||| |||||  
Db 20 TGCAGGCATCATCAATTC 1

## RESULT 114

US-10-633-843-13/c  
; Sequence 13, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 13  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-13

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 73 GAAGCCGTCGTGCTGCTGA 92  
||||| ||||| ||||| ||||| |||||  
Db 20 GAAGCCGTCGTGCTGCTGA 1

## RESULT 115

US-10-633-843-14/c  
; Sequence 14, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 14  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-14

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 78 CCGTGTGCTGCTGAAGGGC 97  
||||| ||||| ||||| ||||| |||||  
Db 20 CCGTGTGCTGCTGAAGGGC 1

## RESULT 116

US-10-633-843-15/c  
; Sequence 15, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843

; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 15  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-15

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TGTGCGTCTGAAGGCGAC 100  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 TGTGCGTCTGAAGGCGAC 1

RESULT 117  
US-10-633-843-16/c  
; Sequence 16, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 16  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-16

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 GGTTCCTGTCAGTCTCG 33  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 GGTTCCTGTCAGTCTCG 1

RESULT 118  
US-10-633-843-17/c  
; Sequence 17, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 17  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-17

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 CCGTTGCAGTCTCGGAACC 38  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 CCGTTGCAGTCTCGGAACC 1

RESULT 119  
US-10-633-843-18/c  
; Sequence 18, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 18  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-18

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 23 TGCAGTCTCGGAACGAGGA 42  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 TGCAGTCTCGGAACGAGGA 1

RESULT 120  
US-10-633-843-19/c  
; Sequence 19, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 19  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-19

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 27 GTCTCGGAACGAGCTC 46  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 GTCTCGGAACGAGCTC 1

RESULT 121

US-10-633-843-20/c  
; Sequence 20, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 20  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-20

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 38 CAGGACCTCGCGTGGCCTA 57  
|||||  
DB 20 CAGGACCTCGCGTGGCCTA 1

## RESULT 122

US-10-633-843-21/c  
; Sequence 21, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 21  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-21

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 GCCTAGCGAGTTATGGCGAC 72  
|||||  
DB 20 GCCTAGCGAGTTATGGCGAC 1

## RESULT 123

US-10-633-843-22/c  
; Sequence 22, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 22  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-22

Query Match 2.3%; Score 20; DB 1; Length 20;

; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 22  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-22

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 96 GCGACGGCCAGTGCAGGC 115  
|||||  
DB 20 GCGACGGCCAGTGCAGGC 1

## RESULT 124

US-10-633-843-23/c  
; Sequence 23, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 23  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-23

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 AGTCAGGGGCATCAATT 125  
|||||  
DB 20 AGTCAGGGGCATCAATT 1

## RESULT 125

US-10-633-843-24/c  
; Sequence 24, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 24  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-24

Query Match 2.3%; Score 20; DB 1; Length 20;

```
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-25/c
; Sequence 25, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-25

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 135 AGGAAAGTAATGGACCACTG 154
Db 20 AGGAAAGTAATGGACCACTG 1

RESULT 126
US-10-633-843-25/c
; Sequence 25, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-25

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 142 TAATGGACCACTGAAGGTGT 161
Db 20 TAATGGACCACTGAAGGTGT 1

RESULT 127
US-10-633-843-26/c
; Sequence 26, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-26

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 144 ATGGACCACTGAAGTGTGG 163
Db 20 ATGGACCACTGAAGTGTGG 1

RESULT 128
US-10-633-843-27/c
; Sequence 27, Application US/10633843
```

```
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-27

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 161 TGGGGAAGCATTAAGGACT 180
Db 20 TGGGGAAGCATTAAGGACT 1

RESULT 129
US-10-633-843-28/c
; Sequence 28, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-28

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 173 AAAGGACTGACTGAAGCCT 192
Db 20 AAAGGACTGACTGAAGCCT 1

RESULT 130
US-10-633-843-29/c
; Sequence 29, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
```



```
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-29

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 174 AAGGACTGACTGAGGCCTG 193
DB 20 AAGGACTGACTGAGGCCTG 1

RESULT 131
US-10-633-843-30/c
; Sequence 30, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-30

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 205 TGTTCATGAGTTGGAGATA 224
DB 20 TGTTCATGAGTTGGAGATA 1

RESULT 132
US-10-633-843-31/c
; Sequence 31, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-31

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 212 GAGTTTGGAGATAATACAGC 231
DB 20 GAGTTTGGAGATAATACAGC 1
```

```
RESULT 133
US-10-633-843-32/c
; Sequence 32, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-32
```

```
Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 221 GATAATACAGCAGGCTGTAC 240
DB 20 GATAATACAGCAGGCTGTAC 1
```

```
RESULT 134
US-10-633-843-33/c
; Sequence 33, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-33
```

```
Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 304 GCATGTTGGAGACTTGGGCA 323
DB 20 GCATGTTGGAGACTTGGGCA 1
```

```
RESULT 135
US-10-633-843-34/c
; Sequence 34, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
```

```
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-34

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      309 TTGAGACTTGGCAATGTG 328
Db      20 TTGAGACTTGGCAATGTG 1

RESULT 136
US-10-633-843-35/c
; Sequence 35, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-35

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      335 GACAAAGATGGTGGCCGA 354
Db      20 GACAAAGATGGTGGCCGA 1

RESULT 137
US-10-633-843-36/c
; Sequence 36, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 36
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-36

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      337 CAAAGATGGTGGCCGATG 356
Db      20 CAAAGATGGTGGCCGATG 1

RESULT 138
US-10-633-843-37/c
; Sequence 37, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-37

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      340 AGATGGTGGCCGATGTGT 359
Db      20 AGATGGTGGCCGATGTGT 1

RESULT 139
US-10-633-843-38/c
; Sequence 38, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-38

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      343 TGGTGGCCGATGTGTCTA 362
```

```

Db      20 TGGTGTGGCCGATGTGTCTA 1
|||||
RESULT 140
US-10-633-843-39/c
; Sequence 39, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-39
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      404 ATTGCCCGCACACTGGTGGT 423
|||||
Db      20 ATTGCCCGCACACTGGTGGT 1
|||||
RESULT 141
US-10-633-843-40/c
; Sequence 40, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-40
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 CCGCACACTGGTGGTCCATG 428
|||||
Db      20 CCGCACACTGGTGGTCCATG 1
|||||
RESULT 142
US-10-633-843-41/c
; Sequence 41, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie

```

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-41
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      410 CGCACACTGGTGGTCCATGA 429
|||||
Db      20 CGCACACTGGTGGTCCATGA 1
|||||
RESULT 143
US-10-633-843-42/c
; Sequence 42, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-42
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      504 GTGGTGTAAATTGGGATCGCC 523
|||||
Db      20 GTGGTGTAAATTGGGATCGCC 1
|||||
RESULT 144
US-10-633-843-43/c
; Sequence 43, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-43

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 517 GATCGCCCAATAAACATTC 536
      |||||
Db 20 GATCGCCCAATAAACATTC 1

RESULT 145
US-10-633-843-44/c
; Sequence 44, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-44

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 620 ATCTTAAAGTGTAAATTGTG 639
      |||||
Db 20 ATCTTAAAGTGTAAATTGTG 1

RESULT 148
US-10-633-843-47/c
; Sequence 47, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-47

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 625 AAAAGTGTAAATTGTGACT 644
      |||||
Db 20 AAAAGTGTAAATTGTGACT 1

RESULT 149
US-10-633-843-48/c
; Sequence 48, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
```

; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 48  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-48

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 658 TTTAAAGTACCTGTAGTGG 677  
DB 20 TTTAAAGTACCTGTAGTGG 1

## RESULT 150

US-10-633-843-49/c

; Sequence 49, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 49  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-49

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 667 CCTGTAGTGAGAACTGATT 686  
DB 20 CCTGTAGTGAGAACTGATT 1

## RESULT 151

US-10-633-843-50/c

; Sequence 50, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 50  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-633-843-50

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 670 GTAGTGAGAACTGATTAT 689  
DB 20 GTAGTGAGAACTGATTAT 1

## RESULT 152

US-10-633-843-51/c

; Sequence 51, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 51  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-51

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 TAGTGAGAACTGATTATG 690  
DB 20 TAGTGAGAACTGATTATG 1

## RESULT 153

US-10-633-843-52/c

; Sequence 52, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION

; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 52  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-52

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TTATGATCATTGGAAGATT 705  
DB 20 TTATGATCATTGGAAGATT 1

```
RESULT 154
US-10-633-843-53/c
; Sequence 53, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-53

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATCACTTGGAGATTGTAT 710
Db      20 ATCACTTGGAGATTGTAT 1
|||||

RESULT 155
US-10-633-843-54/c
; Sequence 54, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-54

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      707 GTATAGTTTATAAACTCA 726
Db      20 GTATAGTTTATAAACTCA 1
|||||

RESULT 156
US-10-633-843-55/c
; Sequence 55, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
```

```
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-55

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      710 TAGTTTATAAACTCAGTT 729
Db      20 TAGTTTATAAACTCAGTT 1
|||||

RESULT 157
US-10-633-843-56/c
; Sequence 56, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-56

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      721 AACTCAGTTAAATGCTGT 740
Db      20 AACTCAGTTAAATGCTGT 1
|||||

RESULT 158
US-10-633-843-57/c
; Sequence 57, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-57
```

```
Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 727 GTTAAATGCTGTTTCAAT 746
DB 20 GTTAAATGCTGTTTCAAT 1

RESULT 159
US-10-633-843-58/c
; Sequence 58, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-58

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 TAAATGCTGTTTCAATCA 748
DB 20 TAAATGCTGTTTCAATCA 1

RESULT 160
US-10-633-843-59/c
; Sequence 59, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-59

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 736 TCTGTTTCAATGACCTGTAT 755
DB 20 TCTGTTTCAATGACCTGTAT 1

RESULT 161
US-10-633-843-60/c
```

```
; Sequence 60, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-60

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 761 CAGACTTAAATCAGATGG 780
DB 20 CAGACTTAAATCAGATGG 1

RESULT 162
US-10-633-843-61/c
; Sequence 61, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-61

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 AATCAGATGGGTATTTAAA 788
DB 20 AATCAGATGGGTATTTAAA 1

RESULT 163
US-10-633-843-62/c
; Sequence 62, Application US/10633843
; Publication No. US20040091919A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
```

```
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-62

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 771 TCACAGATGGGTATTAACCT 790
Db 20 TCACAGATGGGTATTAACCT 1

RESULT 164
US-10-633-843-63/c
; Sequence 63, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-63

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 787 AACCTGTCAGAAATTCCTTG 806
Db 20 AACCTGTCAGAAATTCCTTG 1

RESULT 165
US-10-633-843-64/c
; Sequence 64, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-64

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
```

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 795 AGAATTTCTTTGTCAATCAA 814
Db 20 AGAATTTCTTTGTCAATCAA 1

RESULT 166
US-10-633-843-65/c
; Sequence 65, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-65

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 801 TCTTTGTCAATCAAGCCTGT 820
Db 20 TCTTTGTCAATCAAGCCTGT 1

RESULT 167
US-10-633-843-66/c
; Sequence 66, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-66

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 805 TGTCAATCAAGCCTGTGAAT 824
Db 20 TGTCAATCAAGCCTGTGAAT 1

RESULT 168
US-10-633-843-67/c
; Sequence 67, Application US/10633843
; Publication No. US2004009191A1
```



```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-67

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 812 CAAGCTGTGATAAAACC 831
DB 20 CAAGCTGTGATAAAACC 1

RESULT 169
US-10-633-843-68/c
; Sequence 68, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-68

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 AGCCTGTGATAAAACCCT 833
DB 20 AGCCTGTGATAAAACCCT 1

RESULT 170
US-10-633-843-69/c
; Sequence 69, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-69

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 TGTGAATAAAACCCTGTAT 837
DB 20 TGTGAATAAAACCCTGTAT 1

RESULT 171
US-10-633-843-70/c
; Sequence 70, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-70

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGAATAAAACCCTGTATGG 839
DB 20 TGAATAAAACCCTGTATGG 1

RESULT 172
US-10-633-843-71/c
; Sequence 71, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-71

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 825 AAAAACCTGTATGGCACTT 844  
DB 20 AAAAACCTGTATGGCACTT 1

## RESULT 173

US-10-633-843-72/c  
; Sequence 72, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 72  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-72

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 829 ACCCTGTATGGCACTTATTA 848  
DB 20 ACCCTGTATGGCACTTATTA 1

## RESULT 174

US-10-633-843-73/c  
; Sequence 73, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 73  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-73

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 832 CTGTATGGCACTTATTATGA 851  
DB 20 CTGTATGGCACTTATTATGA 1

## RESULT 175

US-10-633-843-74/c  
; Sequence 74, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett

; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 74  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-74

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 833 TGTATGGCACTTATTATGAG 852  
DB 20 TGTATGGCACTTATTATGAG 1

## RESULT 176

US-10-633-843-75/c  
; Sequence 75, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 75  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-75

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 835 TATGGCACTTATTATGAGGC 854  
DB 20 TATGGCACTTATTATGAGGC 1

## RESULT 177

US-10-633-843-76/c  
; Sequence 76, Application US/10633843  
; Publication No. US2004009191A1  
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 76  
; LENGTH: 20  
; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-76

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 843 TTATTATGAGGCTATTAAAA 862
Db 20 TTATTATGAGGCTATTAAAA 1

RESULT 178
US-10-633-843-77/c
; Sequence 77, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-77

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 TGAGGCTATTAAAGATCC 868
Db 20 TGAGGCTATTAAAGATCC 1

RESULT 179
US-10-672-866-4
; Sequence 4, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-4

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 COTGGCCTAGCGAGTTATGG 68
Db 1 COTGGCCTAGCGAGTTATGG 20

RESULT 180
US-10-672-866-5/c
; Sequence 5, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-672-866-5

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 108 TCGAGGCGCATCATCAATTC 127
Db 20 TCGAGGCGCATCATCAATTC 1

RESULT 181
US-10-672-866-13/c
; Sequence 13, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-13

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 73 GAAGCCCGTGTGCGTGCTGA 92
```

```
Db 20 GAAGGCCGTCGTGCTGCTGA 1
|||||
RESULT 182
US-10-672-866-14/c
; Sequence 14, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-14
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 78 CCGTGTGCTGCTGAAGGC 97
|||||
Db 20 CCGTGTGCTGCTGAAGGC 1

RESULT 183
US-10-672-866-15/c
; Sequence 15, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-15
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TGTGCGTCTGAAGGCGAC 100
|||||
Db 20 TGTGCGTCTGAAGGCGAC 1
```

```
RESULT 184
US-10-672-866-16/c
; Sequence 16, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-16
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 GGTTCGTTGCAGTCCTCG 33
|||||
Db 20 GGTTCGTTGCAGTCCTCG 1

RESULT 185
US-10-672-866-17/c
; Sequence 17, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-17
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 CCGTTCAGTCCTCGGAACC 38
|||||
Db 20 CCGTTCAGTCCTCGGAACC 1

RESULT 186
US-10-672-866-18/c
```

```
; Sequence 18, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-18

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 TGCAGTCTCGGAACGAGCA 42
Db 20 TGCAGTCTCGGAACGAGCA 1

RESULT 187
US-10-672-866-19/c
; Sequence 19, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-19

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GTCTCGGAACGAGGACCTC 46
Db 20 GTCTCGGAACGAGGACCTC 1

RESULT 188
US-10-672-866-20/c
; Sequence 20, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-20

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 GCCTAGCGAGTTATGGCGAC 72
Db 20 GCCTAGCGAGTTATGGCGAC 1

RESULT 189
US-10-672-866-21/c
; Sequence 21, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-21

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 38 CAGGACCTCGCGTGGCCTA 57
Db 20 CAGGACCTCGCGTGGCCTA 1

RESULT 190
US-10-672-866-22/c
; Sequence 22, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-22
```

```
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-22
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 96 GCGACGGCCCGTGCAGGCG 115
DB 20 GCGACGGCCCGTGCAGGCG 1
```

```
RESULT 191
US-10-672-866-23/c
; Sequence 23, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-23
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 106 AGTCAGGGCATCATCAATT 125
DB 20 AGTCAGGGCATCATCAATT 1
```

```
RESULT 192
US-10-672-866-24/c
; Sequence 24, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
```

```
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-24
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 135 AGGAAAGTAATGACCAAGTG 154
DB 20 AGGAAAGTAATGACCAAGTG 1
```

```
RESULT 193
US-10-672-866-25/c
; Sequence 25, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-25
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 142 TAATGGACCAAGTGAAGTGT 161
DB 20 TAATGGACCAAGTGAAGTGT 1
```

```
RESULT 194
US-10-672-866-26/c
; Sequence 26, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
```

;  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 26  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-26

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 144 ATGGACCACTGAAGGTGTGG 163  
|||  
DB 20 ATGGACCACTGAAGGTGTGG 1

## RESULT 195

US-10-672-866-27/c  
; Sequence 27, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 27  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-27

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 TGGGGAAGCATTAAAGGACT 180  
|||  
DB 20 TGGGGAAGCATTAAAGGACT 1

## RESULT 196

US-10-672-866-28/c  
; Sequence 28, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 28  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-28

;  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 28  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-28

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 173 AAAGGACTGACTGAAGGCCT 192  
|||  
DB 20 AAAGGACTGACTGAAGGCCT 1

## RESULT 197

US-10-672-866-29/c  
; Sequence 29, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 29  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-29

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 174 AAGGACTGACTGAAGGCCTG 193  
|||  
DB 20 AAGGACTGACTGAAGGCCTG 1

## RESULT 198

US-10-672-866-30/c  
; Sequence 30, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 30  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-30

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-30

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 205 TGTTCATGAGTTGGAGATA 224
Db 20 TGTTCATGAGTTGGAGATA 1

RESULT 199
US-10-672-866-31/c
; Sequence 31, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-31

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 212 GAGTTGGAGATAATACAGC 231
Db 20 GAGTTGGAGATAATACAGC 1

RESULT 200
US-10-672-866-32/c
; Sequence 32, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-32

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 304 GCATGTTGGAGACTTGGGCA 323
Db 20 GCATGTTGGAGACTTGGGCA 1

RESULT 202
US-10-672-866-34/c
; Sequence 34, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-34
```



Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 309 TTGGAGACTTGGCCCAATGTG 328  
Db 20 TTGGAGACTTGGCCCAATGTG 1

## RESULT 203

US-10-672-866-35/c  
; Sequence 35, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 35  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-35

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 335 GACAAAGATGGTGCCCGA 354  
Db 20 GACAAAGATGGTGCCCGA 1

## RESULT 204

US-10-672-866-36/c  
; Sequence 36, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 36  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-36

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 309 TTGGAGACTTGGCCCAATGTG 328  
Db 20 TTGGAGACTTGGCCCAATGTG 1

## RESULT 203

US-10-672-866-35/c  
; Sequence 35, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 35  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-35

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 335 GACAAAGATGGTGCCCGA 354  
Db 20 GACAAAGATGGTGCCCGA 1

## RESULT 204

US-10-672-866-36/c  
; Sequence 36, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 36  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-36

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 337 CAAAGATGGTGCCCGATG 356  
Db 20 CAAAGATGGTGCCCGATG 1

## RESULT 205

US-10-672-866-37/c  
; Sequence 37, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 37  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-37

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 340 AGATGGTGCCCGATGTGT 359  
Db 20 AGATGGTGCCCGATGTGT 1

## RESULT 206

US-10-672-866-38/c  
; Sequence 38, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 38  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-38

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 343 TGGTGCCCGATGTGTCTA 362  
Db 20 TGGTGCCCGATGTGTCTA 1

```
Db      20  TGGTGTGCCGATGTGTCTA 1

RESULT 207
US-10-672-866-39/c
; Sequence 39, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-39

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      404  ATTGCCCGCACACTGGTGT 423
          |||||
Db      20  ATTGCCCGCACACTGGTGT 1

RESULT 208
US-10-672-866-40/c
; Sequence 40, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-40

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      409  CCGCACACTGGTGTCATG 428
          |||||
Db      20  CCGCACACTGGTGTCATG 1

Db      20  TGGTGTGCCGATGTGTCTA 1

RESULT 209
US-10-672-866-41/c
; Sequence 41, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-41

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      410  CGCACACTGGTGTCATGA 429
          |||||
Db      20  CGCACACTGGTGTCATGA 1

RESULT 210
US-10-672-866-42/c
; Sequence 42, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-42

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      504  GTGGTGTATTGGATCGCC 523
          |||||
Db      20  GTGGTGTATTGGATCGCC 1

RESULT 211
US-10-672-866-43/c
; Sequence 43, Application US/10672866
```

```
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-43

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 GATCGCCCAATAACATTCC 536
      |||||
DB 20 GATCGCCCAATAACATTCC 1

RESULT 212
US-10-672-866-44/c
; Sequence 44, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-44

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 535 CCCTTGGATGATGCTGAGG 554
      |||||
DB 20 CCCTTGGATGATGCTGAGG 1

RESULT 213
US-10-672-866-45/c
; Sequence 45, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
```

```
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 09/888,360
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-45

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 556 CCCTTAACATCATCTGTTATC 575
      |||||
DB 20 CCCTTAACATCATCTGTTATC 1

RESULT 214
US-10-672-866-46/c
; Sequence 46, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2003-08-04
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-46

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 620 ATCTTAAAGTGTAAATTGTG 639
      |||||
DB 20 ATCTTAAAGTGTAAATTGTG 1

RESULT 215
US-10-672-866-47/c
; Sequence 47, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
```

```
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-47

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 625 AAAAGTGAATTGTGTGACT 644
Db 20 AAAAGTGAATTGTGTGACT 1

RESULT 216
US-10-672-866-48/c
; Sequence 48, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-48

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TTAAAGTACCTGTAGTGAG 677
Db 20 TTAAAGTACCTGTAGTGAG 1

RESULT 217
US-10-672-866-49/c
; Sequence 49, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
```

```
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-49

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 667 CCTGTAGTGAGAACTGATT 686
Db 20 CCTGTAGTGAGAACTGATT 1

RESULT 218
US-10-672-866-50/c
; Sequence 50, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-50

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 670 GTAGTGAGAACTGATTAT 689
Db 20 GTAGTGAGAACTGATTAT 1

RESULT 219
US-10-672-866-51/c
; Sequence 51, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
```

```
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-51

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 671 TAGTGAGAACTGATTATG 690
Db 20 TAGTGAGAACTGATTATG 1

RESULT 220
US-10-672-866-52/c
; Sequence 52, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-52

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 686 TTATGATCACTTGAAGATT 705
Db 20 TTATGATCACTTGAAGATT 1

RESULT 221
US-10-672-866-53/c
; Sequence 53, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-53

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATCACTTGAAGATTGTAT 710
Db 20 ATCACTTGAAGATTGTAT 1

RESULT 222
US-10-672-866-54/c
; Sequence 54, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-54

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 707 GTATAGTTTATAAACTCA 726
Db 20 GTATAGTTTATAAACTCA 1

RESULT 223
US-10-672-866-55/c
; Sequence 55, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-55
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-55

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 710 TAGTTTTATAAACTCAGTT 729
|||||
Db 20 TAGTTTTATAAACTCAGTT 1

RESULT 224
US-10-672-866-56/c
; Sequence 56, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-56

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 AACTCAGTTAAATGCTGT 740
|||||
Db 20 AACTCAGTTAAATGCTGT 1

RESULT 225
US-10-672-866-57/c
; Sequence 57, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-57

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 AACTCAGTTAAATGCTGT 740
|||||
Db 20 AACTCAGTTAAATGCTGT 1

RESULT 226
US-10-672-866-58/c
; Sequence 58, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-58

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 TAAATGCTGTTTCAATGA 748
|||||
Db 20 TAAATGCTGTTTCAATGA 1

RESULT 227
US-10-672-866-59/c
; Sequence 59, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-59

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 TAAATGCTGTTTCAATGA 748
|||||
Db 20 TAAATGCTGTTTCAATGA 1
```

Best Local Similarity 100.0%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;  
Matches 20; Conservative 0

Qy 736 TCTGTTTCAATGACCTGTAT 755  
Db 20 TCTGTTTCAATGACCTGTAT 1

## RESULT 228

US-10-672-866-60/c  
; Sequence 60, Application US/10672866  
; Publication No. US2005001915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 60  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-60

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 761 CAGACTTAAATCAGATGG 780  
Db 20 CAGACTTAAATCAGATGG 1

## RESULT 229

US-10-672-866-61/c  
; Sequence 61, Application US/10672866  
; Publication No. US2005001915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 61  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-61

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 769 AATCAGATGGTATTAAA 788  
Db 20 AATCAGATGGTATTAAA 1

## RESULT 230

US-10-672-866-62/c  
; Sequence 62, Application US/10672866  
; Publication No. US2005001915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 62  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-62

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 771 TCACAGATGGTATTAACT 790  
Db 20 TCACAGATGGTATTAACT 1

## RESULT 231

US-10-672-866-63/c  
; Sequence 63, Application US/10672866  
; Publication No. US2005001915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 63  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-63

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 787 AACTTGTGAGAAATTCCTTG 806  
Db 20 AACTTGTGAGAAATTCCTTG 1

```
RESULT 232
US-10-672-866-64/c
; Sequence 64, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-64

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 795 AGAATTTCTTTTCATTCAA 814
Db 20 AGAATTTCTTTTCATTCAA 1

RESULT 233
US-10-672-866-65/c
; Sequence 65, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-65

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 TCTTTGTCATTCAGCCTGT 820
Db 20 TCTTTGTCATTCAGCCTGT 1

RESULT 234
US-10-672-866-66/c
; Sequence 66, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-66

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 812 CAAGCCTGTGAATAAAACC 831
Db 20 CAAGCCTGTGAATAAAACC 1

RESULT 235
US-10-672-866-67/c
; Sequence 67, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-67

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 812 CAAGCCTGTGAATAAAACC 831
Db 20 CAAGCCTGTGAATAAAACC 1

RESULT 236
US-10-672-866-68/c
; Sequence 68, Application US/10672866
; Publication No. US20050019915A1
```



```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-68

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 ACCCTGTGAATAAAACCT 833
DB 20 AGCCTGTGAATAAAACCT 1

RESULT 237
US-10-672-866-69/c
; Sequence 69, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-69

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 TGTGAATAAAACCTGTAT 837
DB 20 TGTGAATAAAACCTGTAT 1

RESULT 238
US-10-672-866-70/c
; Sequence 70, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-70
```

```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-70

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGAATAAAACCTGTATGG 839
DB 20 TGAATAAAACCTGTATGG 1

RESULT 239
US-10-672-866-71/c
; Sequence 71, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-71

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 825 AAAAACCTGTATGGCACTT 844
DB 20 AAAAACCTGTATGGCACTT 1

RESULT 240
US-10-672-866-72/c
; Sequence 72, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-72
```

```
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-72

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 829 ACCCTGTATGGCACTTATTA 848
      |||||
Db 20 ACCCTGTATGGCACTTATTA 1

RESULT 241
US-10-672-866-73/c
; Sequence 73, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-73

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 832 CTGTATGGCACTTATTA 851
      |||||
Db 20 CTGTATGGCACTTATTA 1

RESULT 242
US-10-672-866-74/c
; Sequence 74, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-74

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 833 TGTATGGCACTTATTA 852
      |||||
Db 20 TGTATGGCACTTATTA 1

RESULT 243
US-10-672-866-75/c
; Sequence 75, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-75

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 835 TATGGCACTTATTA 854
      |||||
Db 20 TATGGCACTTATTA 1

RESULT 244
US-10-672-866-76/c
; Sequence 76, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-76
```

; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 76  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-76

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 843 TTATTATGAGCTATTAAAA 862  
|||||  
DB 20 TTATTATGAGCTATTAAAA 1

RESULT 245  
US-10-672-866-77/c  
; Sequence 77, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 77  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-77

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 TCAGGCTATTAAAGAATCC 868  
|||||  
DB 20 TCAGGCTATTAAAGAATCC 1

RESULT 246  
US-10-672-866-91/c  
; Sequence 91, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 91

; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-91

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 66 TGGCGACGAAGCCGCTGTC 85  
|||||  
DB 20 TGGCGACGAAGCCGCTGTC 1

RESULT 247  
US-10-672-866-92/c  
; Sequence 92, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 92  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-92

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 74 AAGCCGCTGCTGCTGCTGAA 93  
|||||  
DB 20 AAGCCGCTGCTGCTGCTGAA 1

RESULT 248  
US-10-672-866-93/c  
; Sequence 93, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 93  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence

```
;
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-93

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 76 GCGCGTGTGCTGCTGAAGG 95
    |||||
Db 20 GCGCGTGTGCTGCTGAAGG 1

RESULT 249
US-10-672-866-94/c
; Sequence 94, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-94

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 77 GCGGTGTGCTGCTGAAGG 96
    |||||
Db 20 GCGGTGTGCTGCTGAAGG 1

RESULT 250
US-10-672-866-95/c
; Sequence 95, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-95

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 79 CGTGTGCGTGTGCTGAAGGCG 98
    |||||
Db 20 CGTGTGCGTGTGCTGAAGGCG 1

RESULT 251
US-10-672-866-96/c
; Sequence 96, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-96

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 80 GTGTGCGTGTGCTGAAGGCGGA 99
    |||||
Db 20 GTGTGCGTGTGCTGAAGGCGGA 1

RESULT 252
US-10-672-866-97/c
; Sequence 97, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-97

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 82 GTGCTGCTGAAGGCGACG 101  
 Db 20 GTGCTGCTGAAGGCGACG 1

RESULT 253  
 US-10-672-866-98/c  
 ; Sequence 98, Application US/10672866  
 ; Publication No. US20050019915A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: C. Frank Bennett  
 ; APPLICANT: Kenneth Dobie  
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
 ; TITLE OF INVENTION: SOLUBLE  
 ; FILE REFERENCE: RTS-0242  
 ; CURRENT APPLICATION NUMBER: US/10/672,866  
 ; CURRENT FILING DATE: 2003-09-26  
 ; PRIOR FILING DATE: 2003-08-04  
 ; PRIOR APPLICATION NUMBER: 09/888,360  
 ; PRIOR FILING DATE: 2001-06-21  
 ; NUMBER OF SEQ ID NOS: 339  
 ; SEQ ID NO 98  
 ; LENGTH: 20  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Antisense Oligonucleotide  
 US-10-672-866-98

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 83 TCGCTGCTGAAGGCGACG 102  
 Db 20 TCGCTGCTGAAGGCGACG 1

RESULT 254  
 US-10-672-866-99/c  
 ; Sequence 99, Application US/10672866  
 ; Publication No. US20050019915A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: C. Frank Bennett  
 ; APPLICANT: Kenneth Dobie  
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
 ; TITLE OF INVENTION: SOLUBLE  
 ; FILE REFERENCE: RTS-0242  
 ; CURRENT APPLICATION NUMBER: US/10/672,866  
 ; CURRENT FILING DATE: 2003-09-26  
 ; PRIOR FILING DATE: 2003-08-04  
 ; PRIOR APPLICATION NUMBER: 09/888,360  
 ; PRIOR FILING DATE: 2001-06-21  
 ; NUMBER OF SEQ ID NOS: 339  
 ; SEQ ID NO 99  
 ; LENGTH: 20  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Antisense Oligonucleotide  
 US-10-672-866-99

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 292 GGATGAAGAGGCGCATGTTG 311

Db 20 GGATGAAGAGGCGCATGTTG 1

RESULT 255  
 US-10-672-866-100/c  
 ; Sequence 100, Application US/10672866  
 ; Publication No. US20050019915A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: C. Frank Bennett  
 ; APPLICANT: Kenneth Dobie  
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
 ; TITLE OF INVENTION: SOLUBLE  
 ; FILE REFERENCE: RTS-0242  
 ; CURRENT APPLICATION NUMBER: US/10/672,866  
 ; CURRENT FILING DATE: 2003-09-26  
 ; PRIOR FILING DATE: 2003-08-04  
 ; PRIOR APPLICATION NUMBER: 09/888,360  
 ; PRIOR FILING DATE: 2001-06-21  
 ; NUMBER OF SEQ ID NOS: 339  
 ; SEQ ID NO 100  
 ; LENGTH: 20  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Antisense Oligonucleotide  
 US-10-672-866-100

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 293 GATGAAGAGGCGCATGTTG 312  
 Db 20 GATGAAGAGGCGCATGTTG 1

RESULT 256  
 US-10-672-866-101/c  
 ; Sequence 101, Application US/10672866  
 ; Publication No. US20050019915A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: C. Frank Bennett  
 ; APPLICANT: Kenneth Dobie  
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
 ; TITLE OF INVENTION: SOLUBLE  
 ; FILE REFERENCE: RTS-0242  
 ; CURRENT APPLICATION NUMBER: US/10/672,866  
 ; CURRENT FILING DATE: 2003-09-26  
 ; PRIOR FILING DATE: 2003-08-04  
 ; PRIOR APPLICATION NUMBER: 09/888,360  
 ; PRIOR FILING DATE: 2001-06-21  
 ; NUMBER OF SEQ ID NOS: 339  
 ; SEQ ID NO 101  
 ; LENGTH: 20  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Antisense Oligonucleotide  
 US-10-672-866-101

Query Match 2.3%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 294 ATGAAGAGGCGCATGTTGA 313  
 Db 20 ATGAAGAGGCGCATGTTGA 1

```
RESULT 257
US-10-672-866-102/c
; Sequence 102, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-102

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 295 TGAAGAGAGCGCATGTTGGAG 314
Db 20 TGAAGAGAGCGCATGTTGGAG 1

RESULT 258
US-10-672-866-103/c
; Sequence 103, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-103

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 296 GAAGAGAGCGCATGTTGGAGA 315
Db 20 GAAGAGAGCGCATGTTGGAGA 1

RESULT 259
US-10-672-866-104/c
; Sequence 104, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-104

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 297 AAGAGAGCGCATGTTGGAGAC 316
Db 20 AAGAGAGCGCATGTTGGAGAC 1

RESULT 260
US-10-672-866-105/c
; Sequence 105, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-105

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 TGTGATCTCAGCTCTCAGGAG 392
Db 20 TGTGATCTCAGCTCTCAGGAG 1

RESULT 261
US-10-672-866-106/c
; Sequence 106, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
```

```
; Sequence 104, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-104

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 297 AAGAGAGCGCATGTTGGAGAC 316
Db 20 AAGAGAGCGCATGTTGGAGAC 1

RESULT 260
US-10-672-866-105/c
; Sequence 105, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-105

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 TGTGATCTCAGCTCTCAGGAG 392
Db 20 TGTGATCTCAGCTCTCAGGAG 1

RESULT 261
US-10-672-866-106/c
; Sequence 106, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
```

```
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-106

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 374 GTGATCTCACTCTCAGGAGA 393
DB 20 GTGATCTCACTCTCAGGAGA 1

RESULT 262
US-10-672-866-107/c
; Sequence 107, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-107

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 436 AGATGACTTGGGCAAGGTG 455
DB 20 AGATGACTTGGGCAAGGTG 1

RESULT 263
US-10-672-866-108/c
; Sequence 108, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-108

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 437 GATGACTTGGGCAAGGTG 456
DB 20 GATGACTTGGGCAAGGTG 1

RESULT 264
US-10-672-866-109/c
; Sequence 109, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-109

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 ATGACTTGGGCAAGGTGGA 457
DB 20 ATGACTTGGGCAAGGTGGA 1

RESULT 265
US-10-672-866-110/c
; Sequence 110, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-110
```

```
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-108

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 437 GATGACTTGGGCAAGGTG 456
DB 20 GATGACTTGGGCAAGGTG 1

RESULT 264
US-10-672-866-109/c
; Sequence 109, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-109

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 ATGACTTGGGCAAGGTGGA 457
DB 20 ATGACTTGGGCAAGGTGGA 1

RESULT 265
US-10-672-866-110/c
; Sequence 110, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; CURRENT APPLICATION NUMBER: 10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-110
```

```
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-110

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 439 TGACTTGGGCAAGGTGGAA 458
      |||||
Db 20 TGACTTGGGCAAGGTGGAA 1

RESULT 265
US-10-672-866-111/c
; Sequence 111, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-111

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 ACTTGGGCAAGGTGGAAAT 460
      |||||
Db 20 ACTTGGGCAAGGTGGAAAT 1

RESULT 267
US-10-672-866-112/c
; Sequence 112, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
```

```
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-112

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 442 CTTGGGCAAGGTGGAATG 461
      |||||
Db 20 CTTGGGCAAGGTGGAATG 1

RESULT 268
US-10-672-866-113/c
; Sequence 113, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-113

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 TTGGGCAAGGTGGAATGA 462
      |||||
Db 20 TTGGGCAAGGTGGAATGA 1

RESULT 269
US-10-672-866-114/c
; Sequence 114, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
```



```
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-114

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TGGCAAGGTGGAATGAAG 463
      |||||
Db 20 TGGCAAGGTGGAATGAAG 1

RESULT 270
US-10-672-866-115/c
; Sequence 115, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-115

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 445 GGGCAAGGTGGAATGAAG 464
      |||||
Db 20 GGGCAAGGTGGAATGAAG 1

RESULT 271
US-10-672-866-116/c
; Sequence 116, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-116

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 446 GCGCAAGGTGGAATGAAG 465
      |||||
Db 20 GCGCAAGGTGGAATGAAG 1

RESULT 272
US-10-672-866-117/c
; Sequence 117, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-117

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 447 GCAAAGGTGGAATGAAGAA 466
      |||||
Db 20 GCAAAGGTGGAATGAAGAA 1

RESULT 273
US-10-672-866-118/c
; Sequence 118, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-118
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-118

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 448 CAAAGGTGGAATGAAGAAA 467
    |||||
Db 20 CAAAGGTGGAATGAAGAAA 1

RESULT 274
US-10-672-866-119/c
; Sequence 119, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-119

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 AAAGGTGGAATGAAGAAAG 468
    |||||
Db 20 AAAGGTGGAATGAAGAAAG 1

RESULT 275
US-10-672-866-120/c
; Sequence 120, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-120

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 450 AAGGTGGAATGAAGAAAGT 469
    |||||
Db 20 AAGGTGGAATGAAGAAAGT 1

RESULT 276
US-10-672-866-121/c
; Sequence 121, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-121

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 AGGTGGAATGAAGAAAGTA 470
    |||||
Db 20 AGGTGGAATGAAGAAAGTA 1

RESULT 277
US-10-672-866-122/c
; Sequence 122, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-122

Query Match          2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 452 GGTGAAATGAAGAAAGTAC 471  
|||||  
Db 20 GGTGAAATGAAGAAAGTAC 1

## RESULT 278

US-10-672-866-123/c  
; Sequence 123, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 123  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-123

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 GTGGAATGAAGAAAGTACA 472  
|||||  
Db 20 GTGGAATGAAGAAAGTACA 1

## RESULT 279

US-10-672-866-124/c  
; Sequence 124, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 124  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-124

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 454 TGGAAATGAAGAAAGTACAA 473  
|||||

Db 20 TGGAAATGAAGAAAGTACAA 1

## RESULT 280

US-10-672-866-125/c  
; Sequence 125, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 125  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-125

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 GGAATGAAGAAAGTACAAA 474  
|||||  
Db 20 GGAATGAAGAAAGTACAAA 1

## RESULT 281

US-10-672-866-126/c  
; Sequence 126, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 126  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-126

Query Match 2.3%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 456 GAAATGAAGAAAGTACAAAG 475  
|||||  
Db 20 GAAATGAAGAAAGTACAAAG 1

```
RESULT 282
US-10-672-866-127/c
; Sequence 127, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-127

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 457 AATGAAGAAAGTACAAAGA 476
Db 20 AATGAAGAAAGTACAAAGA 1

RESULT 283
US-10-672-866-128/c
; Sequence 128, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-128

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 458 AATGAAGAAAGTACAAAGAC 477
Db 20 AATGAAGAAAGTACAAAGAC 1

RESULT 284
US-10-672-866-129/c
; Sequence 129, Application US/10672866
```

```
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-129

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 127 CGACGACGAGGAAAGTAATG 146
Db 20 CGACGACGAGGAAAGTAATG 1

RESULT 285
US-10-672-866-130/c
; Sequence 130, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-130

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 294 ATGACGAGGAGGCATGTTGGA 313
Db 20 ATGACGAGGAGGCATGTTGGA 1

RESULT 286
US-10-672-866-138/c
; Sequence 138, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
```

```
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-138

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 TCAGGCTATTAAAGATCC 868
      |||||
DB 20 TGAGGCTATTAAAGATCC 1

RESULT 287
US-10-672-866-168/c
; Sequence 168, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-168

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 73 GAAGCCGTCGTCGTCGA 92
      |||||
DB 20 GAAGCCGTCGTCGTCGA 1

RESULT 288
US-10-672-866-169/c
; Sequence 169, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-169
```

```
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-169

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 78 CCGTGTGCGTCTGAAGGCG 97
      |||||
DB 20 CCGTGTGCGTCTGAAGGCG 1

RESULT 289
US-10-672-866-170/c
; Sequence 170, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; FILE REFERENCE: RTS-0242
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-170

Query Match      2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 TGTGCGTCTGAAGGCGGAC 100
      |||||
DB 20 TGTGCGTCTGAAGGCGGAC 1

RESULT 290
US-10-672-866-250/c
; Sequence 250, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
```

```
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 250
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-250
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 75 AGGCCGTGTGCGTGTGAAG 94
|||||
Db 20 AGGCCGTGTGCGTGTGAAG 1
```

```
RESULT 291
US-10-672-866-314/c
; Sequence 314, Application US/10672866
; Publication No. US2005019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 314
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-314
```

```
Query Match 2.3%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 440 GACTTGGGCAAGGTGGAAA 459
|||||
Db 20 GACTTGGGCAAGGTGGAAA 1
```

```
RESULT 292
US-10-301-516-29
; Sequence 29, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown wild-type siRNA p9
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: wild-type siRNA p9
US-10-301-516-29
```

```
Query Match 2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 312 GAGACTTGGGCAATGTGACT 331
|||||
Db 1 GAGACUUGGGCAUGUGACT 20
```

```
RESULT 293
US-10-859-321-13
; Sequence 13, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; TITLE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-13
```

```
Query Match 2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 312 GAGACTTGGGCAATGTGACT 331
|||||
Db 1 GAGACUUGGGCAUGUGACT 20
```

```
RESULT 294
US-10-912-440-13
; Sequence 13, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyoergy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; TITLE OF INVENTION: SPECIFICITY OF RNAI
```

```
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-13

Query Match          2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 295
US-10-700-816-9
; Sequence 9, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuohang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-9

Query Match          2.3%; Score 20; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2.1e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 296
US-10-719-900-39194
; Sequence 39194, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1

; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-13

Query Match          2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 295
US-10-700-816-9
; Sequence 9, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuohang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-9

Query Match          2.3%; Score 20; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2.1e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 296
US-10-719-900-39194
; Sequence 39194, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1

; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-13

Query Match          2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 295
US-10-700-816-9
; Sequence 9, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuohang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-9

Query Match          2.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 335 GACAAAGATGCTGTGGCCGAT 355
      |||||:|||||:|||||
DB 1 GACAAAGATGCTGTGGCCGAT 21

RESULT 298
US-10-301-516-18/c
; Sequence 18, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 21

; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-13

Query Match          2.3%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|||||
DB 1 GAGACUUGGCAAUUGACT 20

RESULT 295
US-10-700-816-9
; Sequence 9, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuohang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; FILE REFERENCE: UMY-038
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-700-816-9

Query Match          2.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 335 GACAAAGATGCTGTGGCCGAT 355
      |||||:|||||:|||||
DB 1 GACAAAGATGCTGTGGCCGAT 21

RESULT 298
US-10-301-516-18/c
; Sequence 18, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: target sequence
US-10-301-516-18

Query Match          2.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 335 GACAAAGATGGTGTGCCCGAT 355
Db 21 GACAAAGATGCTGTGCCCGAT 1
|||||:|||||:|||||:|||||

RESULT 299
US-10-301-516-30
; Sequence 30, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown wild-type siRNA p10
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: wild-type siRNA p10
US-10-301-516-30

Query Match          2.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.9e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGGCAATGTGACT 331
Db 1 GGAGACUUGGGCAUGUGATT 21
|||||:|||||:|||||:|||||

RESULT 300
US-10-700-816-11
; Sequence 11, Application US/10700816
; Publication No. US20040192629A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Zuoshang
; APPLICANT: Xu, Zuoshang
; TITLE OF INVENTION: Allele-Specific RNA Interference
; CURRENT APPLICATION NUMBER: US/10/700,816
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: 60/423,507
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: 60/488,283
; PRIOR FILING DATE: 2003-07-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-10-700-816-11

Query Match          2.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 76.2%; Pred. No. 2.3e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGGCAATGTGACT 331
Db 1 GGAGACUUGGGCAUGUGATT 21
|||||:|||||:|||||:|||||

RESULT 301
US-10-719-900-826011
; Sequence 826011, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 826011
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-10-719-900-826011

Query Match          2.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 373 TGTGATCTCACTCTCAGGAGA 393
Db 4 TGTGATCTCTCTCTCAGGAGA 24
|||||:|||||:|||||:|||||

RESULT 302
US-10-719-956-640730
; Sequence 640730, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 640730
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
; US-10-719-956-640730

Query Match          2.2%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 243 GTGCAGGTCTCTCACTTTAATC 263
Db 3 GTGCAGGTCTCTCACTTAATC 23
|||||:|||||:|||||:|||||

RESULT 303
US-10-719-900-424623/c
; Sequence 424623, Application US/10719900
; Publication No. US20050026164A1
```



```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 424623
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-424623

Query Match      2.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 601 ATAAACATTAAACACTGTAACTT 624
Db 25 ATAAACATTAGCACTGGAACTCTT 2

RESULT 304
US-10-719-900-757938
; Sequence 757938, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 757938
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-757938

Query Match      2.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 469 TACAAAGACAGGAAACGCTGGAG 492
Db 1 TACAAAGACTGGAAATGCTGGAG 24

RESULT 305
US-10-719-956-246448
; Sequence 246448, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 246448
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-246448

Query Match      2.2%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 565 CATCTGTATCTCTGCTAGCTAG 588
Db 2 CATCTGTTTCTCTGCTTGTGTAG 25

RESULT 306
US-10-301-516-31
; Sequence 31, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown wild-type siRNA pl1
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: wild-type siRNA pl1
US-10-301-516-31

Query Match      2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328
Db 1 UGGAGACUUGGCAAAUGUG 19

RESULT 307
US-10-301-516-37/c
; Sequence 37, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown wild-type siRNA p9
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: wild-type siRNA p9
```

```

US-10-301-516-39/c
; Sequence 39, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown wild-type siRNA p11
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown

```

```

; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 75
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-75

Query Match          2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0

Qy      310 TGGAGACTTGGGCAATGTG 328
        :||||:|||||:|
Db      1 UGGAGACTUGGGCA AUGUG 19

RESULT 314
US-10-859-321-76/c
; Sequence 76, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; TITLE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: Patentin Ver. 3.3
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-76

Query Match          2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy      310 TGGAGACTTGGGCAATGTG 328
        :|||||:|||||:|
Db      19 TGGAGACTTGGGCAATGTG 1

RESULT 315
US-10-912-440-14/c
; Sequence 14, Application US/10912440

```

```
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyorgy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-14

Query Match          2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      312 GAGACTTGGGCAATGTGAC 330
Db      19 GAGACTTGGGCAATGTGAC 1

RESULT 316
US-10-912-440-18
; Sequence 18, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyorgy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 18
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-18

Query Match          2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      313 AGACTTGGGCAATGTGACT 331
Db      2 AGACUUGGGCAUUGUGACT 20

RESULT 317
US-10-912-440-19
; Sequence 19, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyorgy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 19
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: Inosine
US-10-912-440-19

Query Match          2.2%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      313 AGACTTGGGCAATGTGACT 331
Db      2 AGACUUGGGCAUUGUGACT 20

RESULT 318
US-10-912-440-75
; Sequence 75, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyorgy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
```

; TITLE OF INVENTION: SPECIFICITY OF RNAI  
 ; FILE REFERENCE: UMY-066CP  
 ; CURRENT APPLICATION NUMBER: US/10/912,440  
 ; CURRENT FILING DATE: 2004-08-04  
 ; PRIOR APPLICATION NUMBER: 10/859,321  
 ; PRIOR FILING DATE: 2004-06-02  
 ; PRIOR APPLICATION NUMBER: 60/575,268  
 ; PRIOR FILING DATE: 2004-05-28  
 ; PRIOR APPLICATION NUMBER: 60/507,928  
 ; PRIOR FILING DATE: 2003-09-30  
 ; PRIOR APPLICATION NUMBER: 60/475,331  
 ; PRIOR FILING DATE: 2003-06-02  
 ; NUMBER OF SEQ ID NOS: 164  
 ; SOFTWARE: PatentIn Ver. 3.3  
 ; SEQ ID NO 75  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
 ; OTHER INFORMATION: Synthetic oligonucleotide  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide  
 US-10-912-440-75

Query Match 2.2%; Score 19; DB 1; Length 21;  
 Best Local Similarity 73.7%; Pred. No. 2e+02;  
 Matches 14; Conservative: 5; Mismatches 0; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328  
 :|||||:|||||:|  
 Db 1 UGGAGACUUGGGCAAAUGUG 19

RESULT 319

US-10-912-440-76/c  
 ; Sequence 76, Application US/10912440  
 ; Publication No. US20050186586A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: ZAMORE, PHILLIP D.  
 ; APPLICANT: HUTVAGNER, Gyorgy  
 ; APPLICANT: SCHWARZ, Dianne  
 ; APPLICANT: SIMARD, Martin  
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND  
 ; TITLE OF INVENTION: SPECIFICITY OF RNAI  
 ; FILE REFERENCE: UMY-066CP  
 ; CURRENT APPLICATION NUMBER: US/10/912,440  
 ; CURRENT FILING DATE: 2004-08-04  
 ; PRIOR APPLICATION NUMBER: 10/859,321  
 ; PRIOR FILING DATE: 2004-06-02  
 ; PRIOR APPLICATION NUMBER: 60/575,268  
 ; PRIOR FILING DATE: 2004-05-28  
 ; PRIOR APPLICATION NUMBER: 60/507,928  
 ; PRIOR FILING DATE: 2003-09-30  
 ; PRIOR APPLICATION NUMBER: 60/475,331  
 ; PRIOR FILING DATE: 2003-06-02  
 ; NUMBER OF SEQ ID NOS: 164  
 ; SOFTWARE: PatentIn Ver. 3.3  
 ; SEQ ID NO 76  
 ; LENGTH: 21  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
 ; OTHER INFORMATION: Synthetic oligonucleotide  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide  
 US-10-912-440-76

Query Match 2.2%; Score 19; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 310 TGGAGACTTGGCAATGTG 328  
 :|||||:|||||:|  
 Db 19 TGGAGACTTGGCAATGTG 1

RESULT 320

US-10-700-816-10/c  
 ; Sequence 10, Application US/10700816  
 ; Publication No. US20040192629A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xu, Zuoshang  
 ; TITLE OF INVENTION: Allele-Specific RNA Interference  
 ; FILE REFERENCE: UMY-038  
 ; CURRENT APPLICATION NUMBER: US/10/700,816  
 ; CURRENT FILING DATE: 2003-11-04  
 ; PRIOR APPLICATION NUMBER: 60/423,507  
 ; PRIOR FILING DATE: 2002-11-04  
 ; PRIOR APPLICATION NUMBER: 60/488,283  
 ; PRIOR FILING DATE: 2003-07-18  
 ; NUMBER OF SEQ ID NOS: 19  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 10  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-10-700-816-10

Query Match 2.2%; Score 19; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGCAATGTGAC 330  
 :|||||:|||||:|  
 Db 19 GAGACTTGGCAATGTGAC 1

RESULT 321

US-10-700-816-12/c  
 ; Sequence 12, Application US/10700816  
 ; Publication No. US20040192629A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xu, Zuoshang  
 ; TITLE OF INVENTION: Allele-Specific RNA Interference  
 ; FILE REFERENCE: UMY-038  
 ; CURRENT APPLICATION NUMBER: US/10/700,816  
 ; CURRENT FILING DATE: 2003-11-04  
 ; PRIOR APPLICATION NUMBER: 60/423,507  
 ; PRIOR FILING DATE: 2002-11-04  
 ; PRIOR APPLICATION NUMBER: 60/488,283  
 ; PRIOR FILING DATE: 2003-07-18  
 ; NUMBER OF SEQ ID NOS: 19  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 12  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-10-700-816-12

Query Match 2.2%; Score 19; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGA 329  
 :|||||:|||||:|  
 Db 19 GGAGACTTGGCAATGTGA 1

RESULT 322

US-10-700-816-13  
 ; Sequence 13, Application US/10700816  
 ; Publication No. US20040192629A1

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-456062

Query Match      2.2%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 314 GACTTGGGCAATGTGACTGCTG 335
      |||||
Db 1 GACCTGGGCAATCTGACTGCTG 22
      |||||

RESULT 325
US-10-672-866-167/c
; Sequence 167, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-167

Query Match      2.1%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 65 ATGGCGAGCAAGGCGCGTGTG 84
      |||||
Db 20 ATGGCGATGAAGGCGCGTGTG 1
      |||||

RESULT 326
US-10-672-866-171/c
; Sequence 171, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

```

## US-10-672-866-171

Query Match 2.1%; Score 18.4; DB 1; Length 20;  
Best Local Similarity 95.0%; Pred. No. 2.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 86 GTGCTGAAGGCGGCGGCC 105  
DB 20 GTGCTGAAGGCGGCGGCC 1

## RESULT 327

US-10-672-866-188/c  
; Sequence 188, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 188  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-188

Query Match 2.1%; Score 18.4; DB 1; Length 20;  
Best Local Similarity 95.0%; Pred. No. 2.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 305 CATGTTGGAGACTTGGCAA 324  
DB 20 CATGTTGGAGACTTGGCAA 1

## RESULT 328

US-10-672-866-189/c  
; Sequence 189, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 189  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-189

Query Match 2.1%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 2.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 308 GTTGAGAGCTTGGGCAATGT 327  
DB 20 GTTGAGAGCTTGGGCAATGT 1

## RESULT 329

US-10-672-866-249/c  
; Sequence 249, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 249  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-249

Query Match 2.1%; Score 18.4; DB 1; Length 20;  
Best Local Similarity 95.0%; Pred. No. 2.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 70 GACGAAGCCCGTGTGCGTC 89  
DB 20 GATGAAGCCCGTGTGCGTC 1

## RESULT 330

US-10-672-866-298/c  
; Sequence 298, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 298  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-298

Query Match 2.1%; Score 18.4; DB 1; Length 20;  
Best Local Similarity 95.0%; Pred. No. 2.1e+02;  
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 512 ATTGGATCGCCCAATAAAC 531
|||||:|||||:|||||
Db 20 ATTGGATCGCCCAATAAAC 1

RESULT 331
US-10-301-516-26
; Sequence 26, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown mutant siRNA p9
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: mutant siRNA p9
US-10-301-516-26

Query Match 2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
|||||:|||||:|||||
Db 1 GAGACUUGGGCAUGUGAAT 20

RESULT 332
US-10-859-321-15
; Sequence 15, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-15

Query Match 2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
|||||:|||||:|||||
Db 1 GAGACUUGGGCAUGUGAAT 20

RESULT 333
US-10-859-321-84
; Sequence 84, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 84
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-84

Query Match 2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
|||||:|||||:|||||
Db 1 GAGACUUGGGCAUGAGACT 20

RESULT 334
US-10-859-321-85
; Sequence 85, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-15
```



```
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-85
Query Match          2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|:|:|
Db      1 GAGACUUGGGCAUGUAUAACT 20

RESULT 335
US-10-859-321-86
; Sequence 86, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 86
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-86
Query Match          2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|:|:|
Db      1 GAGACUUGGGCAUGUGUUCT 20

RESULT 336
US-10-859-321-90
; Sequence 90, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
```

```
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 90
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-859-321-90
Query Match          2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|:|:|
Db      1 GAGACUUGGGCAUGUGGCT 20

RESULT 337
US-10-912-440-15
; Sequence 15, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, GYORGY
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-912-440-15
Query Match          2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGGCAATGTGACT 331
      |||||:|||||:|:|:|
Db      1 GAGACUUGGGCAUGUGAAT 20

RESULT 338
US-10-912-440-84
; Sequence 84, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: ZAMORE, PHILLIP D.
/ APPLICANT: HUTVAGNER, Gyorgy
/ APPLICANT: SCHWARZ, Dianne
/ APPLICANT: SIMARD, Martin
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
/ FILE REFERENCE: SPECIFICITY OF RNAI
/ CURRENT APPLICATION NUMBER: US/10/912,440
/ CURRENT FILING DATE: 2004-08-04
/ PRIOR APPLICATION NUMBER: 10/859,321
/ PRIOR FILING DATE: 2004-06-02
/ PRIOR APPLICATION NUMBER: 60/575,268
/ PRIOR FILING DATE: 2004-05-28
/ PRIOR APPLICATION NUMBER: 60/507,928
/ PRIOR FILING DATE: 2003-09-30
/ PRIOR APPLICATION NUMBER: 60/475,331
/ PRIOR FILING DATE: 2003-06-02
/ NUMBER OF SEQ ID NOS: 164
/ SOFTWARE: PatentIn Ver. 3.3
/ SEQ ID NO 84
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
/ OTHER INFORMATION: Synthetic oligonucleotide
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
US-10-912-440-84

Query Match                2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity      80.0%; Pred. No. 2.3e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGCAATGTGACT 331
Db      1 GAGACUUGGCAAUAGAGACT 20

RESULT 339
US-10-912-440-85
/ Sequence 85, Application US/10912440
/ Publication No. US20050186586A1
/ GENERAL INFORMATION:
/ APPLICANT: ZAMORE, PHILLIP D.
/ APPLICANT: HUTVAGNER, Gyorgy
/ APPLICANT: SCHWARZ, Dianne
/ APPLICANT: SIMARD, Martin
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
/ FILE REFERENCE: SPECIFICITY OF RNAI
/ CURRENT APPLICATION NUMBER: US/10/912,440
/ CURRENT FILING DATE: 2004-08-04
/ PRIOR APPLICATION NUMBER: 10/859,321
/ PRIOR FILING DATE: 2004-06-02
/ PRIOR APPLICATION NUMBER: 60/575,268
/ PRIOR FILING DATE: 2004-05-28
/ PRIOR APPLICATION NUMBER: 60/507,928
/ PRIOR FILING DATE: 2003-09-30
/ PRIOR APPLICATION NUMBER: 60/475,331
/ PRIOR FILING DATE: 2003-06-02
/ NUMBER OF SEQ ID NOS: 164
/ SOFTWARE: PatentIn Ver. 3.3
/ SEQ ID NO 85
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
/ OTHER INFORMATION: Synthetic oligonucleotide
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
US-10-912-440-85
```

```
/ OTHER INFORMATION: oligonucleotide
US-10-912-440-85

Query Match                2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity      75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGCAATGTGACT 331
Db      1 GAGACUUGGCAAUAGUAACT 20

RESULT 340
US-10-912-440-86
/ Sequence 86, Application US/10912440
/ Publication No. US20050186586A1
/ GENERAL INFORMATION:
/ APPLICANT: ZAMORE, PHILLIP D.
/ APPLICANT: HUTVAGNER, Gyorgy
/ APPLICANT: SCHWARZ, Dianne
/ APPLICANT: SIMARD, Martin
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
/ FILE REFERENCE: SPECIFICITY OF RNAI
/ CURRENT APPLICATION NUMBER: US/10/912,440
/ CURRENT FILING DATE: 2004-08-04
/ PRIOR APPLICATION NUMBER: 10/859,321
/ PRIOR FILING DATE: 2004-06-02
/ PRIOR APPLICATION NUMBER: 60/575,268
/ PRIOR FILING DATE: 2004-05-28
/ PRIOR APPLICATION NUMBER: 60/507,928
/ PRIOR FILING DATE: 2003-09-30
/ PRIOR APPLICATION NUMBER: 60/475,331
/ PRIOR FILING DATE: 2003-06-02
/ NUMBER OF SEQ ID NOS: 164
/ SOFTWARE: PatentIn Ver. 3.3
/ SEQ ID NO 86
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
/ OTHER INFORMATION: Synthetic oligonucleotide
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
US-10-912-440-86

Query Match                2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity      75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      312 GAGACTTGGCAATGTGACT 331
Db      1 GAGACUUGGCAAUAGUGUCT 20

RESULT 341
US-10-912-440-90
/ Sequence 90, Application US/10912440
/ Publication No. US20050186586A1
/ GENERAL INFORMATION:
/ APPLICANT: ZAMORE, PHILLIP D.
/ APPLICANT: HUTVAGNER, Gyorgy
/ APPLICANT: SCHWARZ, Dianne
/ APPLICANT: SIMARD, Martin
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
/ FILE REFERENCE: SPECIFICITY OF RNAI
/ CURRENT APPLICATION NUMBER: US/10/912,440
/ CURRENT FILING DATE: 2004-08-04
/ PRIOR APPLICATION NUMBER: 10/859,321
/ PRIOR FILING DATE: 2004-06-02
```

```
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 90
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-90

Query Match          2.1%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGACT 331
|||||:|||||:|:|
Db 1 GAGACUUGGGCAAUUGGCT 20

RESULT 342
US-10-672-866-315/c
; Sequence 315, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 315
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-315

Query Match          2.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCCGTGTGGTCTGCTGAAG 94
|||||:|||||:|
Db 18 GCCGTGTGGTCTGCTGAAG 1

RESULT 343
US-10-859-321-16/c
; Sequence 16, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
```

```
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 16
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-16

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGA 329
|||||:|||||:|
Db 19 GAGACTTGGGCAATGTGA 2

RESULT 344
US-10-859-321-17/c
; Sequence 17, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 17
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-17

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 313 AGACTTGGGCAATGTGAC 330
|||||:|||||:|
Db 18 AGACTTGGGCAATGTGAC 1

RESULT 345
US-10-859-321-20/c
```

```
; Sequence 20, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: Inosine
; OTHER INFORMATION:
US-10-859-321-20

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGA 329
Db 19 GAGACTTGGGCAATGTGA 2

RESULT 346
US-10-859-321-77/c
; Sequence 77, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-77

; Sequence 20, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: Inosine
; OTHER INFORMATION:
US-10-859-321-20

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGA 329
Db 19 GAGACTTGGGCAATGTGA 2

RESULT 346
US-10-859-321-77/c
; Sequence 77, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066
; CURRENT APPLICATION NUMBER: US/10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 77
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-859-321-77

; Sequence 20, Application US/10859321
; Publication No. US20050181382A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 16
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-16

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGA 329
Db 19 GAGACTTGGGCAATGTGA 2

RESULT 348
US-10-912-440-17/c
; Sequence 17, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, GYORGY
; APPLICANT: SCHWARZ, DIANNE
; APPLICANT: SIMARD, MARTIN
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
```

```

; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 17
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-17

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      313 AGACTTGGGCAATGTGAC 330
Db      18 AGACTTGGGCAATGTGAC 1

RESULT 349
US-10-912-440-20/c
; Sequence 20, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, Gyorgy
; APPLICANT: SCHWARZ, Dianne
; APPLICANT: SIMARD, Martin
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; TITLE OF INVENTION: SPECIFICITY OF RNAI
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-77

Query Match          2.1%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      310 TGGAGACTTGGGCAATGT 327
Db      19 TGGAGACTTGGGCAATGT 2

RESULT 351
US-10-301-516-25
; Sequence 25, Application US/10301516
; Publication No. US20030180756A1
; GENERAL INFORMATION:
; APPLICANT: SHI, YANG
; APPLICANT: SUI, GUANGCHAO
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: HMV-084.01
; CURRENT APPLICATION NUMBER: US/10/301,516
; CURRENT FILING DATE: 2002-11-21
; PRIOR APPLICATION NUMBER: 60/366,478
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Unknown mutant siRNA p10
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Unknown
; OTHER INFORMATION: mutant siRNA p10

```

## US-10-301-516-25

Query Match 2.0%; Score 17.8; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 2.5e+02;  
Matches 15; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGACT 331  
|||||:|||||:|||||  
Db 1 GGAGACUUGCGCAAGUGATT 21

## RESULT 352

US-10-301-516-15  
; Sequence 15, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; PRIOR FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 15  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-301-516-15

Query Match 2.0%; Score 17.4; DB 1; Length 19;  
Best Local Similarity 94.7%; Pred. No. 2.4e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGA 329  
|||||:|||||:|||||  
Db 1 GGAGACTTGGCAATGTGA 19

## RESULT 353

US-10-301-516-16/c  
; Sequence 16, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 16  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-301-516-16

Query Match 2.0%; Score 17.4; DB 1; Length 19;  
Best Local Similarity 94.7%; Pred. No. 2.4e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGA 329  
|||||:|||||:|||||  
Db 19 GGAGACTTGGCAATGTGA 1

## RESULT 354

US-10-672-866-286/c  
; Sequence 286, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 286  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-286

Query Match 2.0%; Score 17.4; DB 1; Length 20;  
Best Local Similarity 94.7%; Pred. No. 2.6e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328  
|||||:|||||:|||||  
Db 20 TGGAGACTTGGCAATGTG 2

## RESULT 355

US-10-301-516-24  
; Sequence 24, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 24  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
; OTHER INFORMATION: Unknown mutant siRNA p11  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Unknown  
; OTHER INFORMATION: mutant siRNA p11  
US-10-301-516-24

Query Match 2.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 68.4%; Pred. No. 2.7e+02;  
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328  
:|||||:|:|:|:|:|  
Db 1 UGGAGACUUGCGCA AUGUG 19

RESULT 356  
US-10-301-516-34/c  
; Sequence 34, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 34  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
; OTHER INFORMATION: Unknown mutant siRNA p11  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Unknown  
; OTHER INFORMATION: mutant siRNA p11  
US-10-301-516-34

Query Match 2.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 2.7e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 310 TGGAGACTTGGCAATGTG 328  
:|||||:|:|:|:|:|  
Db 19 TGGAGACTTGGCAATGTG 1

RESULT 357  
US-10-301-516-35/c  
; Sequence 35, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 35  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
; OTHER INFORMATION: Unknown mutant siRNA p10  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Unknown  
; OTHER INFORMATION: mutant siRNA p10  
US-10-301-516-35

Query Match 2.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 2.7e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 311 GGAGACTTGGCAATGTGA 329  
:|||||:|:|:|:|:|  
Db 19 GGAGACTTGGCAATGTGA 1

RESULT 358  
US-10-301-516-36/c  
; Sequence 36, Application US/10301516  
; Publication No. US20030180756A1  
; GENERAL INFORMATION:  
; APPLICANT: SHI, YANG  
; APPLICANT: SUI, GUANGCHAO  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR SUPPRESSING EUKARYOTIC GENE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: HMV-084.01  
; CURRENT APPLICATION NUMBER: US/10/301,516  
; CURRENT FILING DATE: 2002-11-21  
; PRIOR APPLICATION NUMBER: 60/366,478  
; PRIOR FILING DATE: 2002-03-21  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 36  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
; OTHER INFORMATION: Unknown mutant siRNA p9  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Unknown  
; OTHER INFORMATION: mutant siRNA p9  
US-10-301-516-36

Query Match 2.0%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 94.7%; Pred. No. 2.7e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGCAATGTGAC 330  
:|||||:|:|:|:|:|  
Db 19 GAGACTTGGCAATGTGAC 1

RESULT 359  
US-10-859-321-87/c  
; Sequence 87, Application US/10859321  
; Publication No. US20050181382A1  
; GENERAL INFORMATION:  
; APPLICANT: ZAMORE, PHILLIP D.  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND  
; TITLE OF INVENTION: SPECIFICITY OF RNAI  
; FILE REFERENCE: UMY-066  
; CURRENT APPLICATION NUMBER: US/10/859,321  
; CURRENT FILING DATE: 2004-06-02  
; PRIOR APPLICATION NUMBER: 60/575,268  
; PRIOR FILING DATE: 2004-05-28  
; PRIOR APPLICATION NUMBER: 60/507,928  
; PRIOR FILING DATE: 2003-09-30  
; PRIOR APPLICATION NUMBER: 60/475,331  
; PRIOR FILING DATE: 2003-06-02  
; NUMBER OF SEQ ID NOS: 164  
; SOFTWARE: PatentIn Ver. 3.3  
; SEQ ID NO 87  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:  
; OTHER INFORMATION: Synthetic oligonucleotide  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: oligonucleotide  
US-10-859-321-87





```
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 87
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-912-440-87
Query Match          2.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGAC 330
DB 19 GAGCTTGGGCAATGTGAC 1

RESULT 364
US-10-912-440-88/c
; Sequence 88, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, GYORGY
; APPLICANT: SCHWARZ, DIANNE
; APPLICANT: SIMARD, MARTIN
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; PRIOR FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 88
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-912-440-89
Query Match          2.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGAC 330
DB 19 GTGACTTGGGCAATGTGAC 1

RESULT 366
US-10-912-440-91/c
; Sequence 91, Application US/10912440
; Publication No. US20050186586A1
; GENERAL INFORMATION:
; APPLICANT: ZAMORE, PHILLIP D.
; APPLICANT: HUTVAGNER, GYORGY
; APPLICANT: SCHWARZ, DIANNE
; APPLICANT: SIMARD, MARTIN
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND
; FILE REFERENCE: UMY-066CP
; CURRENT APPLICATION NUMBER: US/10/912,440
; PRIOR FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: 10/859,321
; PRIOR FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: 60/575,268
; PRIOR FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/507,928
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: 60/475,331
; PRIOR FILING DATE: 2003-06-02
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 91
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-912-440-88
Query Match          2.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 312 GAGACTTGGGCAATGTGAC 330
DB 19 GAGCTTGGGCAATGTGAC 1
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-912-440-91

```

```

Query Match          2.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 312 GAGACTGGGCAATGTGAC 330
    |||||
Db 19 GAGACTTGGCAATGTAAC 1

```

```

RESULT 367
US-09-828-366-4/c
; Sequence 4, Application US/09828366
; Patent No. US20020010137A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin L.
; APPLICANT: Klein, Robert D.
; APPLICANT: Napier, Mary
; APPLICANT: Wood, William I.
; APPLICANT: Yuan, Jean
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC
; TITLE OF INVENTION: CELL GROWTH
; FILE REFERENCE: P1694R1C1
; CURRENT APPLICATION NUMBER: US/09/828,366
; PRIOR FILING DATE: 2001-04-05
; Prior filing data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 4
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-828-366-4

```

```

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 747 GACCTGTATTTGCCAGACTTA 768
    |||||
Db 22 GACCTGTATGTGCGGACTTA 1

```

```

RESULT 368
US-09-909-320-7/c
; Sequence 7, Application US/09909320
; Patent No. US20020132240A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.

```

```

; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/909,320
; CURRENT FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-909-320-7

```

```

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 747 GACCTGTATTTGCCAGACTTA 768
    |||||
Db 22 GACCTGTATGTGCGGACTTA 1

```

```

RESULT 369
US-09-909-088B-7/c
; Sequence 7, Application US/09909088B

```

Patent No. US20020146709A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth, J.  
; APPLICANT: Kijavin, Ivar J.  
; APPLICANT: Mather, Jennie P.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Williams, P. Mickey  
; APPLICANT: Wood, William, I.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/09/909,088B  
; CURRENT FILING DATE: 2001-07-18  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US00/00219  
; PRIOR FILING DATE: 2000-01-05  
; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide probe  
US-09-909-088B-7  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGTATTTTGGCAGACTTA 768  
Db 22 GACCTGTATTTTGGCAGACTTA 1  
RESULT 370  
US-09-905-291A-7/c  
; Sequence 7, Application US/09905291A  
; Patent No. US20020160374A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth, J.  
; APPLICANT: Kijavin, Ivar J.  
; APPLICANT: Mather, Jennie P.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Williams, P. Mickey  
; APPLICANT: Wood, William, I.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/09/905,291A  
; CURRENT FILING DATE: 2001-07-12  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US99/28214  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: PCT/US99/28313  
; PRIOR FILING DATE: 1999-11-30  
; PRIOR APPLICATION NUMBER: PCT/US99/28564  
; PRIOR FILING DATE: 1999-12-02  
; PRIOR APPLICATION NUMBER: PCT/US99/28565  
; PRIOR FILING DATE: 1999-12-02

```
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-905-291A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAATGTGCCGACTTA 1

RESULT 371
US-09-902-853-7/c
; Sequence 7, Application US/09902853
; Publication No. US20020192859A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,853
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
```

```
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-853-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAATGTGCCGACTTA 1

RESULT 372
US-09-907-824-7/c
; Sequence 7, Application US/09907824
; Publication No. US20020197671A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,853
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
```

FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/907,824  
CURRENT FILING DATE: 2001-07-17  
PRIOR APPLICATION NUMBER: 09/665,350  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: 1999-12-16  
PRIOR APPLICATION NUMBER: PCT/US99/30911  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US99/30999  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US00/00219  
PRIOR FILING DATE: 2000-01-05  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-907-824-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCAGACTTA 768  
|||||  
Db 22 GACCTGTATTGGCCAGACTTA 1

RESULT 373  
US-09-907-841-7/c  
Sequence 7, Application US/09907841  
Publication No. US20020198366A1  
GENERAL INFORMATION:  
APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
TITLE OF INVENTION: Acids Encoding the Same  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/907,841  
CURRENT FILING DATE: 2001-11-20  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: oligonucleotide probe  
US-09-907-841-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCCAGACTTA 768  
|||||  
Db 22 GACCTGTATTGGCCAGACTTA 1

RESULT 374  
US-09-904-011-7/c  
Sequence 7, Application US/09904011  
Publication No. US20030003530A1  
GENERAL INFORMATION:  
APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang

```

; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,011
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-011-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTTGGCAGACTTA 768
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 376
US-09-908-093-7/c
; Sequence 7, Application US/09908093
; Publication No. US20030017498A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,640
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-640-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTTGGCAGACTTA 768
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 376
US-09-908-093-7/c
; Sequence 7, Application US/09908093
; Publication No. US20030017498A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.

```

```

; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/908,093
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-908-093-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747 GACCTGTATTTTGCACAGCTTA 768
Db      22 GACCTGTATGTGCGGACTTA 1

```

```

RESULT 377
US-906-742-7/c
; Sequence 7, Application US/09906742
; Publication No. US20030023054A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,742
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7

```

```
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-742-7
```

```
Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 747 GACCTGTATTTGGCCAGACTTA 768
Db 22 GACCTGTATGTGCGGACTTA 1
```

## RESULT 378

US-09-906-838-7/c

```
/ Sequence 7, Application US/09906838
/ Publication No. US20030027143A1
/ GENERAL INFORMATION:
/ APPLICANT: Genentech, Inc.
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, A.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth, J.
/ APPLICANT: Kijavin, Ivar J.
/ APPLICANT: Mather, Jennie P.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William, I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: 10466-14
/ CURRENT APPLICATION NUMBER: US/09/906,838
/ CURRENT FILING DATE: 2001-07-16
/ PRIOR APPLICATION NUMBER: 09/665,350
/ PRIOR FILING DATE: 2000-09-18
/ PRIOR APPLICATION NUMBER: PCT/US00/04414
/ PRIOR FILING DATE: 2000-02-22
/ PRIOR APPLICATION NUMBER: US 60/143,048
/ PRIOR FILING DATE: 1999-07-07
/ PRIOR APPLICATION NUMBER: US 60/145,698
/ PRIOR FILING DATE: 1999-07-26
/ PRIOR APPLICATION NUMBER: US 60/146,222
/ PRIOR FILING DATE: 1999-07-28
/ PRIOR APPLICATION NUMBER: PCT/US99/20594
/ PRIOR FILING DATE: 1999-09-08
/ PRIOR APPLICATION NUMBER: PCT/US99/20944
/ PRIOR FILING DATE: 1999-09-13
/ PRIOR APPLICATION NUMBER: PCT/US99/21090
/ PRIOR FILING DATE: 1999-09-15
/ PRIOR APPLICATION NUMBER: PCT/US99/21547
/ PRIOR FILING DATE: 1999-09-15
/ PRIOR APPLICATION NUMBER: PCT/US99/23089
/ PRIOR FILING DATE: 1999-10-05
/ PRIOR APPLICATION NUMBER: PCT/US99/28214
/ PRIOR FILING DATE: 1999-11-29
```

```
/ PRIOR APPLICATION NUMBER: PCT/US99/28313
/ PRIOR FILING DATE: 1999-11-30
/ PRIOR APPLICATION NUMBER: PCT/US99/28564
/ PRIOR FILING DATE: 1999-12-02
/ PRIOR APPLICATION NUMBER: PCT/US99/28565
/ PRIOR FILING DATE: 1999-12-02
/ PRIOR APPLICATION NUMBER: PCT/US99/30095
/ PRIOR FILING DATE: 1999-12-16
/ PRIOR APPLICATION NUMBER: PCT/US99/30911
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US99/30999
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US00/00219
/ PRIOR FILING DATE: 2000-01-05
/ NUMBER OF SEQ ID NOS: 423
/ SEQ ID NO 7
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-838-7
```

```
Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 747 GACCTGTATTTGGCCAGACTTA 768
Db 22 GACCTGTATGTGCGGACTTA 1
```

## RESULT 379

```
US-09-907-613-7/c
/ Sequence 7, Application US/09907613
/ Publication No. US20030027145A1
/ GENERAL INFORMATION:
/ APPLICANT: Genentech, Inc.
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, A.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth, J.
/ APPLICANT: Kijavin, Ivar J.
/ APPLICANT: Mather, Jennie P.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William, I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: 10466-14
/ CURRENT APPLICATION NUMBER: US/09/907,613
/ CURRENT FILING DATE: 2001-07-17
/ PRIOR APPLICATION NUMBER: PCT/US00/04414
/ PRIOR FILING DATE: 2000-02-22
/ PRIOR APPLICATION NUMBER: US 60/143,048
/ PRIOR FILING DATE: 1999-07-07
/ PRIOR APPLICATION NUMBER: US 60/145,698
/ PRIOR FILING DATE: 1999-07-26
```



```

; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-613-7

```

```

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      747 GACCTGTATTTGCCAGACTTA 768
      ||||| ||||| ||||| |||||
DB      22 GACCTGTATGTGCCGACTTA 1

```

```

RESULT 380
US-09-907-942-7/c
; Sequence 7, Application US/09907942
; Publication No. US20030027146A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann

```

```

; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,942
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-942-7

```

```

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      747 GACCTGTATTTGCCAGACTTA 768
      ||||| ||||| ||||| |||||
DB      22 GACCTGTATGTGCCGACTTA 1

```

```

RESULT 381
US-09-904-859-7/c
; Sequence 7, Application US/09904859
; Publication No. US20030036060A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone

```

```

; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,859
; PRIOR FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-03-904-859-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      747 GACCTGTATTTTGGCCAGACTTA 768
Db      22 GACCTGTATATGTGCGGACTTA 1

RESULT 382
US-09-909-204-7/c
; Sequence 7, Application US/09909204
; Publication No. US20030036061A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/909,204
; PRIOR FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219

```

; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence

; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe

US-09-909-204-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGGCCAGACTTA 768

Db 22 GACCTGTAATGTGCCGACTTA 1  
 ||||| ||||| |||||

RESULT 383

US-09-904-820-7/c

; Sequence 7, Application US/09904820

; Publication No. US20030036094A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 2001-07-13

; PRIOR APPLICATION NUMBER: 09/665,350

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313  
 ; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219  
 ; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe

US-09-904-820-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;

Best Local Similarity 86.4%; Pred. No. 2.9e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGGCCAGACTTA 768

Db 22 GACCTGTAATGTGCCGACTTA 1  
 ||||| ||||| |||||

RESULT 384

US-09-904-786-7/c

; Sequence 7, Application US/09904786

; Publication No. US20030039969A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/904,786

; CURRENT FILING DATE: 2001-07-12

; PRIOR APPLICATION NUMBER: 09/665,350

; PRIOR FILING DATE: 2000-09-18

; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-904-786-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
|||||  
Db 22 GACCTGTAATGTCCGGACTTA 1

## RESULT 385

US-09-906-646-7/c

; Sequence 7, Application US/09906646

; Publication No. US20030039971A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/906,646

; CURRENT FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313  
; PRIOR FILING DATE: 1999-11-30  
; PRIOR APPLICATION NUMBER: PCT/US99/28564  
; PRIOR FILING DATE: 1999-12-02  
; PRIOR APPLICATION NUMBER: PCT/US99/28565  
; PRIOR FILING DATE: 1999-12-02  
; PRIOR APPLICATION NUMBER: PCT/US99/30095  
; PRIOR FILING DATE: 1999-12-16  
; PRIOR APPLICATION NUMBER: PCT/US99/30911  
; PRIOR FILING DATE: 1999-12-20  
; PRIOR APPLICATION NUMBER: PCT/US99/30999  
; PRIOR FILING DATE: 1999-12-20  
; PRIOR APPLICATION NUMBER: PCT/US00/00219  
; PRIOR FILING DATE: 2000-01-05  
; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: Oligonucleotide probe  
US-09-906-646-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
|||||  
Db 22 GACCTGTAATGTCCGGACTTA 1

## RESULT 386

US-09-906-700-7/c

; Sequence 7, Application US/09906700

; Publication No. US20030039972A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/906,700

; CURRENT FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

;; PRIOR FILING DATE: 1999-07-26  
;; PRIOR APPLICATION NUMBER: US 60/146,222  
;; PRIOR FILING DATE: 1999-07-28  
;; PRIOR APPLICATION NUMBER: PCT/US99/20594  
;; PRIOR FILING DATE: 1999-09-08  
;; PRIOR APPLICATION NUMBER: PCT/US99/20944  
;; PRIOR FILING DATE: 1999-09-13  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/21547  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/23089  
;; PRIOR FILING DATE: 1999-10-05  
;; PRIOR APPLICATION NUMBER: PCT/US99/28214  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: 1999-11-30  
;; PRIOR APPLICATION NUMBER: PCT/US99/28564  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/28565  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: 1999-12-16  
;; PRIOR APPLICATION NUMBER: PCT/US99/30911  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US99/30999  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; PRIOR FILING DATE: 2000-01-05  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
;; OTHER INFORMATION: oligonucleotide probe  
US-09-906-700-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCAGACTTA 768  
||||| | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 387  
US-09-903-786-7/c  
;; Sequence 7, Application US/09903786  
;; Publication No. US20030044793A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Genentech, Inc.  
;; APPLICANT: Ashkenazi, David  
;; APPLICANT: Botstein, David  
;; APPLICANT: Desnoyers, Luc  
;; APPLICANT: Eaton, Dan L.  
;; APPLICANT: Ferrara, Napoleone  
;; APPLICANT: Filvaroff, Ellen  
;; APPLICANT: Fong, Sherman  
;; APPLICANT: Gao, Wei-Qiang  
;; APPLICANT: Gerber, Hanspeter  
;; APPLICANT: Gerritsen, Mary E.  
;; APPLICANT: Goddard, A.  
;; APPLICANT: Godowski, Paul J.  
;; APPLICANT: Grimaldi, Christopher J.  
;; APPLICANT: Gurney, Austin L.  
;; APPLICANT: Hillan, Kenneth J.  
;; APPLICANT: Kljavin, Ivar J.  
;; APPLICANT: Mather, Jennie P.  
;; APPLICANT: Pan, James  
;; APPLICANT: Paoni, Nicholas F.

;; APPLICANT: Roy, Margaret Ann  
;; APPLICANT: Stewart, Timothy A.  
;; APPLICANT: Tumas, Daniel  
;; APPLICANT: Williams, P. Mickey  
;; APPLICANT: Wood, William I.  
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
;; TITLE OF INVENTION: Acids Encoding the Same  
;; FILE REFERENCE: 10466-14  
;; CURRENT APPLICATION NUMBER: US/09/903,786  
;; CURRENT FILING DATE: 2001-07-11  
;; PRIOR APPLICATION NUMBER: 09/665,350  
;; PRIOR FILING DATE: 2000-09-18  
;; PRIOR APPLICATION NUMBER: PCT/US00/04414  
;; PRIOR FILING DATE: 2000-02-22  
;; PRIOR APPLICATION NUMBER: US 60/143,048  
;; PRIOR FILING DATE: 1999-07-07  
;; PRIOR APPLICATION NUMBER: US 60/145,698  
;; PRIOR FILING DATE: 1999-07-26  
;; PRIOR APPLICATION NUMBER: US 60/146,222  
;; PRIOR FILING DATE: 1999-07-28  
;; PRIOR APPLICATION NUMBER: PCT/US99/20594  
;; PRIOR FILING DATE: 1999-09-08  
;; PRIOR APPLICATION NUMBER: PCT/US99/20944  
;; PRIOR FILING DATE: 1999-09-13  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/21547  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/23089  
;; PRIOR FILING DATE: 1999-10-05  
;; PRIOR APPLICATION NUMBER: PCT/US99/28214  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: 1999-11-30  
;; PRIOR APPLICATION NUMBER: PCT/US99/28564  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/28565  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: 1999-12-16  
;; PRIOR APPLICATION NUMBER: PCT/US99/30911  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US99/30999  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; PRIOR FILING DATE: 2000-01-05  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-903-786-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGGCAGACTTA 768  
||||| | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 388  
US-09-902-903-7/c  
;; Sequence 7, Application US/09902903  
;; Publication No. US20030044839A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Genentech, Inc.  
;; APPLICANT: Ashkenazi, David  
;; APPLICANT: Botstein, David  
;; APPLICANT: Desnoyers, Luc

; APPLICANT: Baton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/09/902,903  
 ; PRIOR FILING DATE: 2001-07-10  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313  
 ; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219  
 ; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768  
 Db 22 GACCTGTAAATGTGCCGACTTA 1

RESULT 389

US-09-903-749A-7/C  
 ; Sequence 7, Application US/09903749A  
 ; Publication NO. US20030045693A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/09/903,749A  
 ; CURRENT FILING DATE: 2001-07-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313  
 ; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999  
 ; PRIOR FILING DATE: 1999-12-20

;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; PRIOR FILING DATE: 2000-01-05  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
;; OTHER INFORMATION: oligonucleotide probe  
US-09-903-749A-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
||||| | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 390

US-09-904-119-7/c  
;; Sequence 7, Application US/09904119  
;; Publication No. US20030049621A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Genentech, Inc.  
;; APPLICANT: Ashkenazi, Avi  
;; APPLICANT: Botstein, David  
;; APPLICANT: Desnoyers, Luc  
;; APPLICANT: Eaton, Dan L.  
;; APPLICANT: Ferrara, Napoleone  
;; APPLICANT: Filvaroff, Ellen  
;; APPLICANT: Fong, Sherman  
;; APPLICANT: Gao, Wei-Qiang  
;; APPLICANT: Gerber, Hanspeter  
;; APPLICANT: Gerritsen, Mary E.  
;; APPLICANT: Goddard, A.  
;; APPLICANT: Godowski, Paul J.  
;; APPLICANT: Grimaldi, Christopher J.  
;; APPLICANT: Gurney, Austin L.  
;; APPLICANT: Hillan, Kenneth, J.  
;; APPLICANT: Kljavin, Ivar J.  
;; APPLICANT: Mather, Jennie P.  
;; APPLICANT: Pan, James  
;; APPLICANT: Paoni, Nicholas F.  
;; APPLICANT: Roy, Margaret Ann  
;; APPLICANT: Stewart, Timothy A.  
;; APPLICANT: Tumas, Daniel  
;; APPLICANT: Williams, P. Mickey  
;; APPLICANT: Wood, William, I.  
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
;; FILE REFERENCE: 10466-14  
;; CURRENT APPLICATION NUMBER: US/09/904,119  
;; CURRENT FILING DATE: 2001-07-11  
;; PRIOR APPLICATION NUMBER: 09/665,350  
;; PRIOR FILING DATE: 2000-09-18  
;; PRIOR APPLICATION NUMBER: PCT/US00/04414  
;; PRIOR FILING DATE: 2000-02-22  
;; PRIOR APPLICATION NUMBER: US 60/143,048  
;; PRIOR FILING DATE: 1999-07-07  
;; PRIOR APPLICATION NUMBER: US 60/145,698  
;; PRIOR FILING DATE: 1999-07-26  
;; PRIOR APPLICATION NUMBER: US 60/146,222  
;; PRIOR FILING DATE: 1999-07-28  
;; PRIOR APPLICATION NUMBER: PCT/US99/20594  
;; PRIOR FILING DATE: 1999-09-08  
;; PRIOR APPLICATION NUMBER: PCT/US99/20944  
;; PRIOR FILING DATE: 1999-09-13  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/21547

;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/23089  
;; PRIOR FILING DATE: 1999-10-05  
;; PRIOR APPLICATION NUMBER: PCT/US99/28214  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: 1999-11-30  
;; PRIOR APPLICATION NUMBER: PCT/US99/28564  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/28565  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: 1999-12-16  
;; PRIOR APPLICATION NUMBER: PCT/US99/30911  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US99/30999  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-904-119-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
||||| | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 391

US-09-904-956-7/c  
;; Sequence 7, Application US/09904956  
;; Publication No. US20030049622A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Genentech, Inc.  
;; APPLICANT: Ashkenazi, Avi  
;; APPLICANT: Botstein, David  
;; APPLICANT: Desnoyers, Luc  
;; APPLICANT: Eaton, Dan L.  
;; APPLICANT: Ferrara, Napoleone  
;; APPLICANT: Filvaroff, Ellen  
;; APPLICANT: Fong, Sherman  
;; APPLICANT: Gao, Wei-Qiang  
;; APPLICANT: Gerber, Hanspeter  
;; APPLICANT: Gerritsen, Mary E.  
;; APPLICANT: Goddard, A.  
;; APPLICANT: Godowski, Paul J.  
;; APPLICANT: Grimaldi, Christopher J.  
;; APPLICANT: Gurney, Austin L.  
;; APPLICANT: Hillan, Kenneth, J.  
;; APPLICANT: Kljavin, Ivar J.  
;; APPLICANT: Mather, Jennie P.  
;; APPLICANT: Pan, James  
;; APPLICANT: Paoni, Nicholas F.  
;; APPLICANT: Roy, Margaret Ann  
;; APPLICANT: Stewart, Timothy A.  
;; APPLICANT: Tumas, Daniel  
;; APPLICANT: Williams, P. Mickey  
;; APPLICANT: Wood, William, I.  
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
;; FILE REFERENCE: 10466-14  
;; CURRENT APPLICATION NUMBER: US/09/904,956  
;; CURRENT FILING DATE: 2001-07-12  
;; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-904-956-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCGACTTA 768
Db 22 GACCTGTATTTCGCGACTTA 1

RESULT 392
US-09-902-736-7/c
; Sequence 7, Application US/09902736
; Publication No. US20030049676A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,736
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-736-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCGACTTA 768
Db 22 GACCTGTATTTCGCGACTTA 1

RESULT 393
US-09-907-794-7/c
; Sequence 7, Application US/09907794
; Publication No. US20030049677A1
; GENERAL INFORMATION:



APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/907,794  
CURRENT FILING DATE: 2001-07-17  
PRIOR APPLICATION NUMBER: 09/665,350  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US00/00219  
PRIOR FILING DATE: 2000-01-05  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotide Probe

US-09-907-794-7  
Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 747 GACCTGATATTTGCCAGACTTA 768  
DB 22 GACCTGTAATGTGCGGACTTA 1  
RESULT 394  
US-09-903-943-7/c  
Sequence 7, Application US/09903943  
Publication No. US20030054349A1  
GENERAL INFORMATION:  
APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/903,943  
CURRENT FILING DATE: 2001-07-11  
PRIOR APPLICATION NUMBER: 09/665,350  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565

```
/ PRIOR FILING DATE: 1999-12-02
/ PRIOR APPLICATION NUMBER: PCT/US99/30095
/ PRIOR FILING DATE: 1999-12-16
/ PRIOR APPLICATION NUMBER: PCT/US99/30911
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US99/30999
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US00/00219
/ PRIOR FILING DATE: 2000-01-05
/ NUMBER OF SEQ ID NOS: 423
/ SEQ ID NO 7
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-943-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCGACTTA 768
    ||||| ||||| ||||| |||||
Db 22 GACCTGTAAATGTCGCGACTTA 1

RESULT 395
US-09-904-462-7/c
/ Sequence 7, Application US/09904462
/ Publication No. US20030054351A1
/ GENERAL INFORMATION:
/ APPLICANT: Genentech, Inc.
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, A.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth, J.
/ APPLICANT: Kljavin, Ivar J.
/ APPLICANT: Mather, Jennie P.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William, I.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: 10466-14
/ CURRENT APPLICATION NUMBER: US/09/904,462
/ PRIOR FILING DATE: 2001-07-13
/ PRIOR APPLICATION NUMBER: 09/665,350
/ PRIOR FILING DATE: 2000-09-18
/ PRIOR APPLICATION NUMBER: PCT/US00/04414
/ PRIOR FILING DATE: 2000-02-22
/ PRIOR APPLICATION NUMBER: US 60/143,048
/ PRIOR FILING DATE: 1999-07-07
/ PRIOR APPLICATION NUMBER: US 60/145,698
/ PRIOR FILING DATE: 1999-07-26
/ PRIOR APPLICATION NUMBER: US 60/146,222
/ PRIOR FILING DATE: 1999-07-28
/ PRIOR APPLICATION NUMBER: PCT/US99/20594
```

```
/ PRIOR FILING DATE: 1999-09-08
/ PRIOR APPLICATION NUMBER: PCT/US99/20944
/ PRIOR FILING DATE: 1999-09-13
/ PRIOR APPLICATION NUMBER: PCT/US99/21090
/ PRIOR FILING DATE: 1999-09-15
/ PRIOR APPLICATION NUMBER: PCT/US99/21547
/ PRIOR FILING DATE: 1999-09-15
/ PRIOR APPLICATION NUMBER: PCT/US99/23089
/ PRIOR FILING DATE: 1999-10-05
/ PRIOR APPLICATION NUMBER: PCT/US99/28214
/ PRIOR FILING DATE: 1999-11-29
/ PRIOR APPLICATION NUMBER: PCT/US99/28313
/ PRIOR FILING DATE: 1999-11-30
/ PRIOR APPLICATION NUMBER: PCT/US99/28564
/ PRIOR FILING DATE: 1999-12-02
/ PRIOR APPLICATION NUMBER: PCT/US99/28565
/ PRIOR FILING DATE: 1999-12-02
/ PRIOR APPLICATION NUMBER: PCT/US99/30095
/ PRIOR FILING DATE: 1999-12-16
/ PRIOR APPLICATION NUMBER: PCT/US99/30911
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US99/30999
/ PRIOR FILING DATE: 1999-12-20
/ PRIOR APPLICATION NUMBER: PCT/US00/00219
/ PRIOR FILING DATE: 2000-01-05
/ NUMBER OF SEQ ID NOS: 423
/ SEQ ID NO 7
/ LENGTH: 22
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-462-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCGACTTA 768
    ||||| ||||| ||||| |||||
Db 22 GACCTGTAAATGTCGCGACTTA 1

RESULT 396
US-09-907-925-7/c
/ Sequence 7, Application US/09907925
/ Publication No. US20030054352A1
/ GENERAL INFORMATION:
/ APPLICANT: Genentech, Inc.
/ APPLICANT: Ashkenazi, Avi
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Filvaroff, Ellen
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Gerber, Hanspeter
/ APPLICANT: Gerritsen, Mary E.
/ APPLICANT: Goddard, A.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth, J.
/ APPLICANT: Kljavin, Ivar J.
/ APPLICANT: Mather, Jennie P.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ APPLICANT: Roy, Margaret Ann
/ APPLICANT: Stewart, Timothy A.
/ APPLICANT: Tumas, Daniel
/ APPLICANT: Williams, P. Mickey
/ APPLICANT: Wood, William, I.
```

```

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-07-17
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-925-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768
Db 22 GACCTGTAATGTGCCGACTTA 1

RESULT 397
US-09-902-692-7/c
; Sequence 7, Application US/09902692
; Publication NO. US20030054400A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang

```

```

; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,692
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-692-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768
Db 22 GACCTGTAATGTGCCGACTTA 1

```

## RESULT 398

US-09-903-520-7/c

; Sequence 7, Application US/09903520

; Publication No. US20030054401A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/903,520

; CURRENT FILING DATE: 2001-07-11

; PRIOR APPLICATION NUMBER: 09/665,350

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 7

; LENGTH: 22

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic Oligonucleotide Probe

US-09-903-520-7

## Query Match

Best Local Similarity 2.0%; Score 17.2; DB 1; Length 22;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768

||||||| |||||

Db 22 GACCTGTATGTGCGGACTTA 1

## RESULT 399

US-09-905-056-7/c

; Sequence 7, Application US/09905056

; Publication No. US2003005441A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/905,056

; CURRENT FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219  
 ; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe  
 US-09-905-056-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGGCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATGTGCGGACTTA 1

# RESULT 400

US-09-909-064-7/c  
 ; Sequence 7, Application US/09909064  
 ; Publication No. US20030059772A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/09/909,064  
 ; CURRENT FILING DATE: 2001-07-18  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313  
 ; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219  
 ; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe  
 US-09-909-064-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGGCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATGTGCGGACTTA 1

# RESULT 401

US-09-904-553-7/c  
 ; Sequence 7, Application US/09904553  
 ; Publication No. US20030059828A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann

```

; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,553
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-553-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGCGCAGACTTA 768
      ||||| | |||||
Db 22 GACCTGTAATGTCGCGACTTA 1

RESULT 402
US-09-905-381-7/c
; Sequence 7, Application US/09905381
; Publication No. US20030059829A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,381
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-381-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 747 GACCTGTATTTGGCAGACTTA 768  
 Db 22 GACCTGTATTTGGCAGACTTA 1

RESULT 403

US-09-904-485-7/c  
 ; Sequence 7, Application US/09904485  
 ; Publication No. US20030064367A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/09/904,485  
 ; CURRENT FILING DATE: 2001-07-13  
 ; PRIOR APPLICATION NUMBER: 09/665,350  
 ; PRIOR FILING DATE: 2000-09-18  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313  
 ; PRIOR FILING DATE: 1999-11-30  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565  
 ; PRIOR FILING DATE: 1999-12-02  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095  
 ; PRIOR FILING DATE: 1999-12-16  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911  
 ; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20  
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219  
 ; PRIOR FILING DATE: 2000-01-05  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
 US-09-904-485-7  
 Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGGCAGACTTA 768  
 Db 22 GACCTGTATTTGGCAGACTTA 1  
 RESULT 404  
 US-09-905-348-7/c  
 ; Sequence 7, Application US/09905348  
 ; Publication No. US20030064923A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/09/905,348  
 ; CURRENT FILING DATE: 2001-07-13  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089

```

; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-348-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCGACTTA 768
    ||||| ||||| |||||
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 405
US-09-905-088-7/c
; Sequence 7, Application US/09905088
; Publication No. US20030073077A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijav, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,088
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18

```

```

; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-088-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCGACTTA 768
    ||||| ||||| |||||
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 406
US-09-907-575-7/c
; Sequence 7, Application US/09907575
; Publication No. US20030073079A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.

```



```

; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US 09/907,575
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-575-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747  GACCTGTATTTGGCCAGACTTA 768
          ||||| ||||| ||||| |||||
Db      22  GACCTGTATGTGCGGACTTA 1

RESULT 408
US-09-902-759-7/c
; Sequence 7, Application US/09902759
; Publication No. US20030077654A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905.075
; CURRENT FILING DATE: 2001-07-13
; Prior application data removed. Check file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-905-075-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747  GACCTGTATTTGGCCAGACTTA 768
          ||||| ||||| ||||| |||||
Db      22  GACCTGTATGTGCGGACTTA 1

RESULT 408
US-09-902-759-7/c
; Sequence 7, Application US/09902759
; Publication No. US20030077654A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,575
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-575-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747  GACCTGTATTTGGCCAGACTTA 768
          ||||| ||||| ||||| |||||
Db      22  GACCTGTATGTGCGGACTTA 1

RESULT 407
US-09-905-075-7/c
; Sequence 7, Application US/09905075
; Publication No. US20030077583A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
```

```

; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,759
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-902-759-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768
      |||||
Db 22 GACCTGTATTTCGCCAGACTTA 1

RESULT 409
US-09-902-634-7/c
; Sequence 7, Application US/09902634
; Publication No. US20030082540A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc

```

```

; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,634
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-634-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTATTTGCCAGACTTA 1

## RESULT 410

US-09-902-713-7/c  
; Sequence 7, Application US/09902713  
; Publication No. US20030082541A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth, J.  
; APPLICANT: Kijavin, Ivar J.  
; APPLICANT: Mather, Jennie P.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Williams, P. Mickey  
; APPLICANT: Wood, William, I.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; TITLE OF INVENTION: Acids Encoding the Same  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/09/902,713  
; CURRENT FILING DATE: 2001-07-10  
; PRIOR APPLICATION NUMBER: 09/665,350  
; PRIOR FILING DATE: 2000-09-18  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US99/28214  
; PRIOR FILING DATE: 1999-11-29  
; PRIOR APPLICATION NUMBER: PCT/US99/28313  
; PRIOR FILING DATE: 1999-11-30  
; PRIOR APPLICATION NUMBER: PCT/US99/28564  
; PRIOR FILING DATE: 1999-12-02  
; PRIOR APPLICATION NUMBER: PCT/US99/28565  
; PRIOR FILING DATE: 1999-12-02  
; PRIOR APPLICATION NUMBER: PCT/US99/30095  
; PRIOR FILING DATE: 1999-12-16  
; PRIOR APPLICATION NUMBER: PCT/US99/30911  
; PRIOR FILING DATE: 1999-12-20  
; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20  
; PRIOR APPLICATION NUMBER: PCT/US00/00219  
; PRIOR FILING DATE: 2000-01-05  
; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-902-713-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTATTTGCCAGACTTA 1

## RESULT 411

US-09-907-979-7/c  
; Sequence 7, Application US/09907979  
; Publication No. US20030082542A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth, J.  
; APPLICANT: Kijavin, Ivar J.  
; APPLICANT: Mather, Jennie P.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Williams, P. Mickey  
; APPLICANT: Wood, William, I.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; TITLE OF INVENTION: Acids Encoding the Same  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/09/907,979  
; CURRENT FILING DATE: 2001-07-17  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089

```
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-979-7
```

```
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 747 GACCTGTATTTTGGCCAGACTTA 768
Db 22 GACCTGTATTTTGGCCAGACTTA 1
```

## RESULT 412

```
US-09-902-615-7/c
; Sequence 7, Application US/09902615
; Publication No. US20030092002A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,615
; CURRENT FILING DATE: 2001-12-14
; NUMBER OF SEQ ID NOS: 423
```

```
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-615-7
```

```
Query Match 2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 747 GACCTGTATTTTGGCCAGACTTA 768
Db 22 GACCTGTATTTTGGCCAGACTTA 1
```

## RESULT 413

```
US-09-903-925-7/c
; Sequence 7, Application US/09903925
; Publication No. US20030096233A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,925
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
```

```

; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-925-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747 GACCTGTATTTGCCAGACTTA 768
Db      22 GACCTGTAATGTGCCGACTTA 1

RESULT 414
US-09-906-760A-7/c
; Sequence 7, Application US/09906760A
; Publication No. US20030096340A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,760A
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 50/143,048
; PRIOR FILING DATE: 1999-07-07

```

```

; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-760A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      747 GACCTGTATTTGCCAGACTTA 768
Db      22 GACCTGTAATGTGCCGACTTA 1

RESULT 415
US-09-903-823-7/c
; Sequence 7, Application US/09903823
; Publication No. US20030104381A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James

```

```

; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,823
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-823-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTATTTCGCCAGACTTA 1

RESULT 416
US-09-907-652-7/c
; Sequence 7, Application US/09907652
; Publication No. US20030104469A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.

```

```

; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,652
; CURRENT FILING DATE: 2002-01-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-907-652-7

```

```

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```



```
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-979-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGACACTTA 768
|||||||
Db 22 GACCTGTATGTCCGACTTA 1

RESULT 419
US-09-905-125-7/c
; Sequence 7, Application US/09905125
; Publication No. US20030113719A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,125
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
```

```
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-125-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGACACTTA 768
|||||||
Db 22 GACCTGTATGTCCGACTTA 1

RESULT 420
US-09-906-815A-7/c
; Sequence 7, Application US/09906815A
; Publication No. US20030113838A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,815A
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
```



;; PRIOR FILING DATE: 2000-02-22  
;; PRIOR APPLICATION NUMBER: US 60/143,048  
;; PRIOR FILING DATE: 1999-07-07  
;; PRIOR APPLICATION NUMBER: US 60/145,698  
;; PRIOR FILING DATE: 1999-07-26  
;; PRIOR APPLICATION NUMBER: US 60/146,222  
;; PRIOR FILING DATE: 1999-07-28  
;; PRIOR APPLICATION NUMBER: PCT/US99/20594  
;; PRIOR FILING DATE: 1999-09-08  
;; PRIOR APPLICATION NUMBER: PCT/US99/20944  
;; PRIOR FILING DATE: 1999-09-13  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/21547  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/23089  
;; PRIOR FILING DATE: 1999-10-05  
;; PRIOR APPLICATION NUMBER: PCT/US99/28214  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: 1999-11-30  
;; PRIOR APPLICATION NUMBER: PCT/US99/28564  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/28565  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: 1999-12-16  
;; PRIOR APPLICATION NUMBER: PCT/US99/30911  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US99/30999  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; PRIOR FILING DATE: 2000-01-05  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
;; OTHER INFORMATION: oligonucleotide probe  
US-09-906-815A-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTATTTGCCAGACTTA 1

RESULT 421  
US-09-905-449-7/c  
; Sequence 7, Application US/09905449  
; Publication No. US20030129592A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth, J.

;; APPLICANT: Kljavin, Ivar J.  
;; APPLICANT: Mather, Jennie P.  
;; APPLICANT: Pan, James  
;; APPLICANT: Paoni, Nicholas F.  
;; APPLICANT: Roy, Margaret Ann  
;; APPLICANT: Stewart, Timothy A.  
;; APPLICANT: Tumas, Daniel  
;; APPLICANT: Williams, P. Mickey  
;; APPLICANT: Wood, William, I.  
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
;; TITLE OF INVENTION: Acids Encoding the Same  
;; FILE REFERENCE: 10466-14  
;; CURRENT APPLICATION NUMBER: US/09/905,449  
;; CURRENT FILING DATE: 2000-09-18  
;; PRIOR APPLICATION NUMBER: PCT/US00/04414  
;; PRIOR FILING DATE: 2000-02-22  
;; PRIOR APPLICATION NUMBER: US 60/143,048  
;; PRIOR FILING DATE: 1999-07-07  
;; PRIOR APPLICATION NUMBER: US 60/145,698  
;; PRIOR FILING DATE: 1999-07-26  
;; PRIOR APPLICATION NUMBER: US 60/146,222  
;; PRIOR FILING DATE: 1999-07-28  
;; PRIOR APPLICATION NUMBER: PCT/US99/20594  
;; PRIOR FILING DATE: 1999-09-08  
;; PRIOR APPLICATION NUMBER: PCT/US99/20944  
;; PRIOR FILING DATE: 1999-09-13  
;; PRIOR APPLICATION NUMBER: PCT/US99/21090  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/21547  
;; PRIOR FILING DATE: 1999-09-15  
;; PRIOR APPLICATION NUMBER: PCT/US99/23089  
;; PRIOR FILING DATE: 1999-10-05  
;; PRIOR APPLICATION NUMBER: PCT/US99/28214  
;; PRIOR FILING DATE: 1999-11-29  
;; PRIOR APPLICATION NUMBER: PCT/US99/28313  
;; PRIOR FILING DATE: 1999-11-30  
;; PRIOR APPLICATION NUMBER: PCT/US99/28564  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/28565  
;; PRIOR FILING DATE: 1999-12-02  
;; PRIOR APPLICATION NUMBER: PCT/US99/30095  
;; PRIOR FILING DATE: 1999-12-16  
;; PRIOR APPLICATION NUMBER: PCT/US99/30911  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US99/30999  
;; PRIOR FILING DATE: 1999-12-20  
;; PRIOR APPLICATION NUMBER: PCT/US00/00219  
;; PRIOR FILING DATE: 2000-01-05  
;; NUMBER OF SEQ ID NOS: 423  
;; SEQ ID NO 7  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
;; OTHER INFORMATION: oligonucleotide probe  
US-09-905-449-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTATTTGCCAGACTTA 1

RESULT 422  
US-09-903-806-7/c  
; Sequence 7, Application US/09903806  
; Publication No. US20030130489A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.

```
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,806
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-806-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCGACTTA 768
Db 22 GACCTGTATTTCGCCGACTTA 1

RESULT 423
US-09-904-992-7/c
; Sequence 7, Application US/09904992
; Publication No. US20030135025A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
```

```
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,992
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-992-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCGACTTA 768
Db 22 GACCTGTATTTCGCCGACTTA 1

RESULT 424
US-09-904-838-7/c
; Sequence 7, Application US/09904838
; Publication No. US20030148370A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
```

APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
TITLE OF INVENTION: Acids Encoding the Same  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/904,838  
CURRENT FILING DATE: 2001-09-18  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: 1999-12-16  
PRIOR APPLICATION NUMBER: PCT/US00/00219  
PRIOR FILING DATE: 2000-01-05  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: oligonucleotide probe  
US-09-904-838-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGCAGACTTA 768  
Db 22 GACCTGTATTTTGCAGACTTA 1  
RESULT 425  
US-09-906-777-7/c  
Sequence 7, Application US/09906777  
Publication No. US20030148371A1  
GENERAL INFORMATION:  
APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
TITLE OF INVENTION: Acids Encoding the Same  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/906,777  
CURRENT FILING DATE: 2001-07-16  
PRIOR APPLICATION NUMBER: 09/665,350  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: 1999-12-16  
PRIOR APPLICATION NUMBER: PCT/US99/30911  
PRIOR FILING DATE: 1999-12-20

```
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-777-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAATGTCCGACTTA 1

RESULT 426
US-09-903-603A-7/c
; Sequence 7, Application US/09903603A
; Publication No. US20030148419A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: GNE.1618P2C12
; CURRENT APPLICATION NUMBER: US/09/903,603A
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
```

```
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-903-603A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAATGTCCGACTTA 1

RESULT 427
US-09-904-532-7/c
; Sequence 7, Application US/09904532
; Publication No. US20030152922A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,532
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/665,350
```

APPLICANT: Hilan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/904,766  
PRIOR FILING DATE: 2001-07-12  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US99/30911  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US99/30999  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US00/00219  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-904-532-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 428

US-09-904-766-7/c  
Sequence 7, Application US/09904766  
Publication No. US2003015299A1  
GENERAL INFORMATION:

APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.

## Query Match

Best Local Similarity 2.0%; Score 17.2; DB 1; Length 22;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
US-09-904-766-7

QY 747 GACCTGTATTTGCCAGACTTA 768  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 429

US-09-904-920A-7/c  
Sequence 7, Application US/09904920A  
Publication No. US20030166051A1  
GENERAL INFORMATION:

```

; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,920A
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-904-920A-7

```

```

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred.No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTTGCACAGACTTA 768
      ||||| ||||| ||||| |||||
Db 22 GACCTGTATGTGCGGACTTA 1

RESULT 430
US-09-904-877A-7/c
; Sequence 7, Application US/09904877A
; Publication No. US20030186358A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,877A
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

```

OTHER INFORMATION: oligonucleotide probe  
US-09-904-877A-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGCGGACTTA 768  
||||| | | | | | | | | | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 431

US-09-903-562-7/c

Sequence 7, Application US/09903562  
Publication No. US20030187238A1

## GENERAL INFORMATION:

APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
Acids Encoding the Same  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/903,562  
PRIOR FILING DATE: 2001-07-11  
PRIOR APPLICATION NUMBER: US/09/665,350  
PRIOR FILING DATE: 2000-09-18  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13  
PRIOR APPLICATION NUMBER: PCT/US99/21090  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/21547  
PRIOR FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: PCT/US99/23089  
PRIOR FILING DATE: 1999-10-05  
PRIOR APPLICATION NUMBER: PCT/US99/28214  
PRIOR FILING DATE: 1999-11-29  
PRIOR APPLICATION NUMBER: PCT/US99/28313  
PRIOR FILING DATE: 1999-11-30  
PRIOR APPLICATION NUMBER: PCT/US99/28564  
PRIOR FILING DATE: 1999-12-02  
PRIOR APPLICATION NUMBER: PCT/US99/28565  
PRIOR FILING DATE: 1999-12-02

PRIOR APPLICATION NUMBER: PCT/US99/30095  
PRIOR FILING DATE: 1999-12-16  
PRIOR APPLICATION NUMBER: PCT/US99/30911  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US99/30999  
PRIOR FILING DATE: 1999-12-20  
PRIOR APPLICATION NUMBER: PCT/US00/00219  
PRIOR FILING DATE: 2000-01-05  
NUMBER OF SEQ ID NOS: 423  
SEQ ID NO 7  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotide Probe  
US-09-903-562-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGCGGACTTA 768  
||||| | | | | | | | | | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

## RESULT 432

US-09-906-618-7/c

Sequence 7, Application US/09906618

Publication No. US20030190610A1

## GENERAL INFORMATION:

APPLICANT: Genentech, Inc.  
APPLICANT: Ashkenazi, Avi  
APPLICANT: Botstein, David  
APPLICANT: Desnoyers, Luc  
APPLICANT: Eaton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Filvaroff, Ellen  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Gerber, Hanspeter  
APPLICANT: Gerritsen, Mary E.  
APPLICANT: Goddard, A.  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth, J.  
APPLICANT: Kljavin, Ivar J.  
APPLICANT: Mather, Jennie P.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William, I.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
Acids Encoding the Same  
FILE REFERENCE: 10466-14  
CURRENT APPLICATION NUMBER: US/09/906,618  
CURRENT FILING DATE: 2001-07-16  
PRIOR APPLICATION NUMBER: PCT/US00/04414  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: US 60/143,048  
PRIOR FILING DATE: 1999-07-07  
PRIOR APPLICATION NUMBER: US 60/145,698  
PRIOR FILING DATE: 1999-07-26  
PRIOR APPLICATION NUMBER: US 60/146,222  
PRIOR FILING DATE: 1999-07-28  
PRIOR APPLICATION NUMBER: PCT/US99/20594  
PRIOR FILING DATE: 1999-09-08  
PRIOR APPLICATION NUMBER: PCT/US99/20944  
PRIOR FILING DATE: 1999-09-13

```

; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-618-7

```

```

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAAATGTCGGGACTTA 1

```

```

RESULT 433
US-09-907-728-7/c
; Sequence 7, Application US/09907728
; Publication No. US20030190611A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

```

```

; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,728
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-728-7

```

```

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTAAATGTCGGGACTTA 1

```

```

RESULT 434
US-09-904-805-7/c
; Sequence 7, Application US/09904805
; Publication No. US20030211568A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.

```



```

; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,805
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-805-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e-02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTGTCGAGACTTA 768
Db 22 GACCTGTATTGTCGAGACTTA 1

```

```

RESULT 435
US-09-904-938A-7/c
; Sequence 7, Application US/09904938A
; Publication No. US20030211569A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,938A
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA

```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-938A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCGACACTTA 768
Db 22 GACCTGTATGTGCGGACTTA 1

RESULT 436
US-09-906-722A-7/c
; Sequence 7, Application US/09906722A
; Publication No. US20030215904A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: GNE.1618P2C61
; CURRENT APPLICATION NUMBER: US/09/906,722A
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564

```

```

; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-722A-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCGACACTTA 768
Db 22 GACCTGTATGTGCGGACTTA 1

RESULT 437
US-09-908-576-7/c
; Sequence 7, Application US/09908576
; Publication No. US20040005553A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/908,576
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: US/09/665,350B
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26

```

; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence

; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe

US-09-908-576-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATTTCGCCAGACTTA 1

#### RESULT 438

US-10-299-976-7/c  
 ; Sequence 7, Application US/10299976  
 ; Publication No. US20030180312A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: P1618P2C85  
 ; CURRENT APPLICATION NUMBER: US/10/299,976  
 ; CURRENT FILING DATE: 2002-11-18  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence

; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe

US-10-299-976-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768  
 ||||| ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATTTCGCCAGACTTA 1

#### RESULT 439

US-10-299-937-7/c  
 ; Sequence 7, Application US/10299937  
 ; Publication No. US20030185646A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: P1618P2C86  
 ; CURRENT APPLICATION NUMBER: US/10/299,937  
 ; CURRENT FILING DATE: 2002-11-18  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07

```
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-299-937-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGCGACTTA 768
Db 22 GACCTGTATTGTCGCGACTTA 1
```

```
RESULT 440
US-10-298-993-7/c
; Sequence 7, Application US/10298993
; Publication NO. US20030211576A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Goddard, A.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P16182C84
; CURRENT APPLICATION NUMBER: US/10/298,993
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
```

```
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-298-993-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTGTCGCGACTTA 768
Db 22 GACCTGTATTGTCGCGACTTA 1

RESULT 441
US-10-448-923-7/c
; Sequence 7, Application US/10448923
; Publication NO. US20030225253A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/448,923
; CURRENT FILING DATE: 2003-05-29
```

; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe  
 US-10-448-923-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGGCAGACTTA 768  
 DB 22 GACCTGTATTTGGCAGACTTA 1

RESULT 442  
 US-10-449-656-7/c  
 ; Sequence 7, Application US/10449656  
 ; Publication No. US20040005665A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnovers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/10/449,656  
 ; CURRENT FILING DATE: 2003-05-29  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe  
 US-10-449-656-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 747 GACCTGTATTTGGCAGACTTA 768  
 DB 22 GACCTGTATTTGGCAGACTTA 1

RESULT 443  
 US-10-448-713-7/c  
 ; Sequence 7, Application US/10448713  
 ; Publication No. US20040006211A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnovers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gerritsen, Mary E.  
 ; APPLICANT: Goddard, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kljavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; APPLICANT: Wood, William, I.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;  
; TITLE OF INVENTION: Acids Encoding the Same  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/10/448,713  
; CURRENT FILING DATE: 2003-05-29  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US99/28214  
; PRIOR FILING DATE: 1999-11-29  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; TYPE: DNA  
; LENGTH: 22  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-448-713-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTGTCGACACTTA 768  
||||| | | | | | | | | | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 444  
US-10-425-447-7/c  
; Sequence 7, Application US/10425447  
; Publication No. US2004002331A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Ashkenazi, Avi  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, A.  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth J.  
; APPLICANT: Kljavin, Ivar J.  
; APPLICANT: Mather, Jennie P.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Williams, P. Mickey

;  
; APPLICANT: Wood, William, I.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; FILE REFERENCE: 10466-14  
; CURRENT APPLICATION NUMBER: US/10/425,447  
; CURRENT FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: US 60/143,048  
; PRIOR FILING DATE: 1999-07-07  
; PRIOR APPLICATION NUMBER: US 60/145,698  
; PRIOR FILING DATE: 1999-07-26  
; PRIOR APPLICATION NUMBER: US 60/146,222  
; PRIOR FILING DATE: 1999-07-28  
; PRIOR APPLICATION NUMBER: PCT/US99/20594  
; PRIOR FILING DATE: 1999-09-08  
; PRIOR APPLICATION NUMBER: PCT/US99/20944  
; PRIOR FILING DATE: 1999-09-13  
; PRIOR APPLICATION NUMBER: PCT/US99/21090  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/21547  
; PRIOR FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: PCT/US99/23089  
; PRIOR FILING DATE: 1999-10-05  
; PRIOR APPLICATION NUMBER: PCT/US99/28214  
; PRIOR FILING DATE: 1999-11-29  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 423  
; SEQ ID NO 7  
; TYPE: DNA  
; LENGTH: 22  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-425-447-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 2.9e+02;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTGTCGACACTTA 768  
||||| | | | | | | | | | | | | | | | | |  
Db 22 GACCTGTAATGTGCGGACTTA 1

RESULT 445  
US-10-215-371-7/c  
; Sequence 7, Application US/10215371  
; Publication No. US20040137561A1  
; GENERAL INFORMATION:  
; APPLICANT: Genentech, Inc.  
; APPLICANT: Chen, Jian  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth  
; APPLICANT: Pennica, Diane  
; APPLICANT: Wood, William I.  
; APPLICANT: Yuan, Jean  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; FILE REFERENCE: P1618P2C83  
; CURRENT APPLICATION NUMBER: US/10/215,371  
; CURRENT FILING DATE: 2002-08-08  
; PRIOR APPLICATION NUMBER: US 09/665,350  
; PRIOR FILING DATE: 2000-09-18  
; PRIOR APPLICATION NUMBER: PCT/US00/04414  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: PCT/US98/18824  
; PRIOR FILING DATE: 1998-09-10  
; PRIOR APPLICATION NUMBER: US 60/099,803  
; PRIOR FILING DATE: 1998-09-10  
; PRIOR APPLICATION NUMBER: US 60/062,285

; PRIOR FILING DATE: 1997-10-17  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe  
 US-10-215-371-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e-02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768  
 ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATTTGCCGACTTA 1

RESULT 446  
 US-10-771-187-7/c  
 ; Sequence 7, Application US/10771187  
 ; Publication No. US20040185531A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gottstein, Mary E.  
 ; APPLICANT: Grimaldi, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kijavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Pao, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; FILE REFERENCE: 39780-1618P2C78C1  
 ; CURRENT APPLICATION NUMBER: US/10/771,187  
 ; PRIOR FILING DATE: 2004-02-02  
 ; PRIOR APPLICATION NUMBER: 09/909,064  
 ; PRIOR FILING DATE: 2001-07-18  
 ; PRIOR APPLICATION NUMBER: 09/665,350  
 ; PRIOR FILING DATE: 2000-09-18  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: PCT/US98/19437  
 ; PRIOR FILING DATE: 1998-09-17  
 ; PRIOR APPLICATION NUMBER: PCT/US98/19330  
 ; PRIOR FILING DATE: 1998-09-16  
 ; PRIOR APPLICATION NUMBER: 60/088,026  
 ; PRIOR FILING DATE: 1998-06-04  
 ; PRIOR APPLICATION NUMBER: 60/066,770  
 ; PRIOR FILING DATE: 1997-11-24  
 ; PRIOR APPLICATION NUMBER: 60/065,186  
 ; PRIOR FILING DATE: 1997-11-12  
 ; NUMBER OF SEQ ID NOS: 423  
 ; SEQ ID NO 7  
 ; LENGTH: 22

; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: oligonucleotide probe  
 US-10-771-187-7

Query Match 2.0%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 2.9e-02;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTGCCGACTTA 768  
 ||||| ||||| ||||| |||||  
 Db 22 GACCTGTATTTGCCGACTTA 1

RESULT 447  
 US-10-963-467-7/c  
 ; Sequence 7, Application US/10963467  
 ; Publication No. US20050079582A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Genentech, Inc.  
 ; APPLICANT: Ashkenazi, Avi  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Filvaroff, Ellen  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Gerber, Hanspeter  
 ; APPLICANT: Grimaldi, A.  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth, J.  
 ; APPLICANT: Kijavin, Ivar J.  
 ; APPLICANT: Mather, Jennie P.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Pao, Nicholas F.  
 ; APPLICANT: Roy, Margaret Ann  
 ; APPLICANT: Stewart, Timothy A.  
 ; APPLICANT: Tumas, Daniel  
 ; APPLICANT: Williams, P. Mickey  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; FILE REFERENCE: 10466-14  
 ; CURRENT APPLICATION NUMBER: US/10/963,467  
 ; CURRENT FILING DATE: 2004-10-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414  
 ; PRIOR FILING DATE: 2000-02-22  
 ; PRIOR APPLICATION NUMBER: US 60/143,048  
 ; PRIOR FILING DATE: 1999-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/145,698  
 ; PRIOR FILING DATE: 1999-07-26  
 ; PRIOR APPLICATION NUMBER: US 60/146,222  
 ; PRIOR FILING DATE: 1999-07-28  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594  
 ; PRIOR FILING DATE: 1999-09-08  
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944  
 ; PRIOR FILING DATE: 1999-09-13  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089  
 ; PRIOR FILING DATE: 1999-10-05  
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214  
 ; PRIOR FILING DATE: 1999-11-29  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 423

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-963-467-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTGCCAGACTTA 768
    ||||| ||||| |||||
Db 22 GACCTGTAATGTCCGCGACTTA 1

RESULT 448
US-10-978-255-7/c
; Sequence 7, Application US/10978255
; Publication No. US20050112725A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/978,255
; CURRENT FILING DATE: 2004-10-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-978-255-7

Query Match      2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 747 GACCTGTATTTGCCAGACTTA 768
    ||||| ||||| |||||
Db 22 GACCTGTAATGTCCGCGACTTA 1

RESULT 449
US-10-797-366-7/c
; Sequence 7, Application US/10797366
; Publication No. US20040147017A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/797,366
; CURRENT FILING DATE: 2004-03-09
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
```



```
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 7
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-797-366-7

Query Match          2.0%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 747 GACCTGTATTTCGCCAGACTTA 768
Db 22 GACCTGTATTTCGCCAGACTTA 1

RESULT 450
US-10-672-866-194/c
; Sequence 194, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-194

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 345 GTGTGCGCGATGTGTCTATT 364
Db 20 GTGTGCGCGAATGTGTCTATT 1

RESULT 451
US-10-672-866-195/c
; Sequence 195, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 205
```

```
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-195

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 350 GCCGATGTGTCTATTGAAGA 369
Db 20 GCCAATGTGTCCATTGAAGA 1

RESULT 452
US-10-672-866-199/c
; Sequence 199, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-199

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 GACCATTCATCATTTGCCG 411
Db 20 GAGCATTCATCATTTGCCG 1

RESULT 453
US-10-672-866-205/c
; Sequence 205, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; PRIOR FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 205
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-205

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 487 TGGAACTCGTTGGCTTGTG 506
      ||||| ||||| ||||| |||||
Db 20 TGGAGCCGCTTGGCTTGTG 1

RESULT 454
US-10-672-866-207/c
; Sequence 207, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 207
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-207

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 503 TGTGCTGAATTGGGATGCG 522
      ||||| ||||| ||||| |||||
Db 20 TGTGCTGATTTGGGATTCG 1

RESULT 455
US-10-672-866-208/c
; Sequence 208, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 208
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-208
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-208

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 GGTGTAATTGGATGCCCA 525
      ||||| ||||| ||||| |||||
Db 20 GGTGTGATTTGGATGCCCA 1

RESULT 456
US-10-672-866-209/c
; Sequence 209, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-209

Query Match          1.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 TAATTGGGATGCCCAATAA 529
      ||||| ||||| ||||| |||||
Db 20 TGATTGGGATTTGCCCAATAA 1

RESULT 457
US-10-672-866-215/c
; Sequence 215, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-215
```

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 562 ACTCATCTGTTATCTGCTA 581  
|||||  
DB 20 ACTCATCTGCTGCTCTGCTA 1

RESULT 458  
US-10-672-866-287/c  
; Sequence 287, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 287  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-287

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 312 GAGACTGGGCAATGTGACT 331  
|||||  
DB 20 GAGACTGGGCAATGTGGCT 1

RESULT 459  
US-10-672-866-291/c  
; Sequence 291, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 291  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-291

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 348 TGGCCGATGTCTATTGAA 367  
|||||  
DB 20 TGGCCAAATGTCTCATTGAA 1

RESULT 460  
US-10-672-866-296/c  
; Sequence 296, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 296  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-296

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 GAAGTCGTTTGGCTTGCTG 508  
|||||  
DB 20 GAAGCCGCTTGCTTGCTG 1

RESULT 461  
US-10-672-866-297/c  
; Sequence 297, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 297  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-297

Query Match 1.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 508 TGTAAATGGGATGCCCAAT 527

```
Db      20 TGTGATTGGGATTCGCCAAT 1
|||||
RESULT 462
US-10-190-366-126
; Sequence 126, Application US/10190366
; Publication No. US2004006031A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HMG-COA REDUCTASE EXPRESSION
; FILE REFERENCE: PTS-0023
; CURRENT APPLICATION NUMBER: US/10/190,366
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 409
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-190-366-126
Query Match      1.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      807 TCATTCAAGCCTGTGAAT 824
|||||
Db      3 TCATTCAAGCCTGTGAAT 20
|||||

RESULT 463
US-10-190-366-323/c
; Sequence 323, Application US/10190366
; Publication No. US2004006031A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HMG-COA REDUCTASE EXPRESSION
; FILE REFERENCE: PTS-0023
; CURRENT APPLICATION NUMBER: US/10/190,366
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 409
; SEQ ID NO 323
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-190-366-323
Query Match      1.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      807 TCATTCAAGCCTGTGAAT 824
|||||
Db      18 TCATTCAAGCCTGTGAAT 1
|||||

RESULT 464
US-10-786-720-19320
; Sequence 19320, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; DISEASES
```

```
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19320
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-19320
Query Match      1.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 3.3e+02;
Matches 10; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

Qy      196 TGGATTCCATGTTTCATGAGTT 216
:||:||||:||||:
Db      1 UGGCAUCCAUGUCAUAGUU 21
|||||

RESULT 465
US-10-751-736-20731
; Sequence 20731, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20731
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-20731
Query Match      1.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      435 CAGATGACTTGGGCAAGGTG 455
|||||
Db      1 CAGATGACTTGAGAGAAGGTG 21
|||||

RESULT 466
US-10-751-736-42828
; Sequence 42828, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42828
; LENGTH: 21
```

```
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-42828

Query Match      1.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 3.3e+02;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 28 TCCTCGGAACGACGACCTCGG 48
   : ||||| ||||| |||||
Db 1 UUCUCGGAACAGGAGCCUCCG 21

RESULT 467
US-10-672-866-159
; Sequence 159, Application US/10672866
; Publication No. US2005001915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 159
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-672-866-159

Query Match      1.8%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 87 TGCTGAAGGCGACGG 102
   ||||| ||||| |||||
Db 1 TGCTGAAGGCGACGG 16

RESULT 468
US-10-333-429-260/c
; Sequence 260, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-083US02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pm
; SEQ ID NO 260
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-32162 for SEQ 89,
US-10-333-429-260

Query Match      1.8%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 TGAAGGTGTGGGGAAG 168
   ||||| ||||| |||||
Db 16 TGAAGGTGTGGGGAAG 1

RESULT 469
US-10-197-280A-27
; Sequence 27, Application US/10197280A
; Publication No. US20030163837A1
; GENERAL INFORMATION:
; APPLICANT: Aldwinckle, Herbert S.
; APPLICANT: Gaitan, Alvaro L.
; TITLE OF INVENTION: CONSTITUTIVE AND INDUCIBLE PROMOTERS FROM COFFEE PLANTS
; FILE REFERENCE: 19603/3262
; CURRENT APPLICATION NUMBER: US/10/197,280A
; CURRENT FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: 60/180,934
; PRIOR FILING DATE: 2000-02-08
; PRIOR APPLICATION NUMBER: 09/545,686
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 27
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide Primer
; NAME/KEY: unsure
; LOCATION: (5)
; OTHER INFORMATION: N at any position in this sequence is either A, C,
; OTHER INFORMATION: G, or T.
US-10-197-280A-27

Query Match      1.8%; Score 16; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 195 ATGGATTCCATGTTTCATG 212
   ||||| ||||| |||||
Db 1 ATGGNTTCCATGTCATG 18

RESULT 470
US-09-909-595-79
; Sequence 79, Application US/09909595
; Publication No. US20030083278A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brenda F. Baker
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Scott E. Davis
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 LIGAND EXPRESSION
; FILE REFERENCE: RTS-0223
; CURRENT APPLICATION NUMBER: US/09/909,595
; CURRENT FILING DATE: 2001-07-18
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-909-595-79

Query Match      1.8%; Score 15.8; DB 1; Length 20;
```

Best Local Similarity 89.5%; Pred. No. 3.4e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 376 GATCTCACTCTCAGGAGAC 394  
Db 2 GATCTCACTGTCTCAGGAC 20

RESULT 471

US-10-331-907-236/c  
; Sequence 336, Application US/10331907  
; Publication No. US20030181660A1  
; GENERAL INFORMATION:  
; APPLICANT: Todd, John A  
; HESS, John W  
; Caakey, Charles T  
; Cox, Roger D  
; Gerhold, David  
; Hammond, Holly  
; Hey, Patricia  
; Kawaguchi, Yoshihiko  
; Merriman, Tony R  
; Metzger, Michael L  
; TITLE OF INVENTION: No. US20030181660A1e1 LDL-Receptor  
; NUMBER OF SEQUENCES: 455  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Nixon and Vanderhye  
; STREET: 1100 No. US20030181660A1e1 Glebe Road, Eighth Floor  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: US  
; ZIP: VA 22201-4714  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/331,907  
; FILING DATE: 31-Dec-2002  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/402,923A  
; FILING DATE: 14-Feb-2001  
; APPLICATION NUMBER: PCT/GB98/01102  
; FILING DATE: 15-Apr-1998  
; APPLICATION NUMBER: US 60/043,553  
; FILING DATE: 15-Apr-1997  
; APPLICATION NUMBER: US 60/048,740  
; FILING DATE: 05-JUN-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: B.J.Sadoff  
; REGISTRATION NUMBER: 36,663  
; REFERENCE/DOCKET NUMBER: 620-81  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (703)816-4091  
; TELEFAX: (703)816-4100  
; INFORMATION FOR SEQ ID NO: 236:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 20 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; SEQUENCE DESCRIPTION: SEQ ID NO: 236:

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 3.4e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 442 CTTGGGCAAGGTGGAAT 460  
Db 20 CTTGGGCAAGGTGGAAT 2

RESULT 472

US-10-484-007-79  
; Sequence 79, Application US/10484007  
; Publication No. US20040259824A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Brenda F. Baker  
; APPLICANT: Jacqueline Wyatt  
; APPLICANT: Scott E. Davis  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 LIGAND EXPRESSION  
; FILE REFERENCE: RTS-0397  
; CURRENT APPLICATION NUMBER: US/10/484,007  
; CURRENT FILING DATE: 2004-01-15  
; PRIOR APPLICATION NUMBER: 09/909,595  
; PRIOR FILING DATE: 2001-07-18  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 79  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
; US-10-484-007-79

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 3.4e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 376 GATCTCACTCTCAGGAGAC 394  
Db 2 GATCTCACTGTCTCAGGAC 20

RESULT 473

US-10-672-866-173/c  
; Sequence 173, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 173  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
; US-10-672-866-173

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 3.4e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 123 ATTTTCGAGCAGAGGAAG 141  
Db 19 ACTTCGAGCAGAGGCAAG 1

RESULT 474

US-10-672-866-193/c  
; Sequence 193, Application US/10672866

```

; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-193

Query Match      1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      341 GATGGTGTGGCCGATGTGT 359
DB      19 GACGGTGTGCCCAATGTGT 1

RESULT 475
US-10-672-866-206/c
; Sequence 206, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-206

Query Match      1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      494 CGTTTGGCTTGTGGTGTA 512
DB      19 CGCTTGGCTTGTGGTGTA 1

RESULT 476
US-10-672-866-285/c
; Sequence 285, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

```

```

; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 285
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-285

Query Match      1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      287 CCAAGAGTGAAGAGAGGC 305
DB      19 CCAGCGGATGAAGAGAGGC 1

RESULT 477
US-10-672-866-290/c
; Sequence 290, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 290
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-290

Query Match      1.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      342 ATGGTGTGGCCGATGTGTC 360
DB      20 ACGGTGTGGCCAATGTGTC 2

RESULT 478
US-10-672-866-292/c
; Sequence 292, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE

```

; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 292  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-292

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 3.4e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 395 CATTGCATCATTTGGCCGCA 413  
|||||  
Db 19 CATTCCATCATTTGGCCGTA 1

RESULT 479  
US-10-672-866-294/c  
; Sequence 294, Application US/10672866  
; Publication No. US2005001915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Doble  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 294  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-294

Query Match 1.8%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 3.4e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 AGACAGGAAACCTGGAAG 492  
|||||  
Db 20 AGACTGGAATGCTGGAAG 2

RESULT 480  
US-10-786-720-7376/c  
; Sequence 7376, Application US/10786720  
; Publication No. US2004019181A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: O'Toole, Margot  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
; TITLE OF INVENTION: DISEASES  
; FILE REFERENCE: 031896-023000 (AM101331L)  
; CURRENT APPLICATION NUMBER: US/10/786,720

; CURRENT FILING DATE: 2004-02-26  
; NUMBER OF SEQ ID NOS: 21135  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7376  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi-sense strand  
US-10-786-720-7376

Query Match 1.8%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 3.6e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 528 AAACATTCCTTGGATGTA 546  
|||||  
Db 21 AAACAGTGCCTTGGATGTA 3

RESULT 481  
US-10-786-720-9626/c  
; Sequence 9626, Application US/10786720  
; Publication No. US2004019181A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: O'Toole, Margot  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
; TITLE OF INVENTION: DISEASES  
; FILE REFERENCE: 031896-023000 (AM101331L)  
; CURRENT APPLICATION NUMBER: US/10/786,720  
; CURRENT FILING DATE: 2004-02-26  
; NUMBER OF SEQ ID NOS: 21135  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9626  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi-sense strand  
US-10-786-720-9626

Query Match 1.8%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 3.6e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 528 AAACATTCCTTGGATGTA 546  
|||||  
Db 21 AAACAGTGCCTTGGATGTA 3

RESULT 482  
US-10-847-918-10677/c  
; Sequence 10677, Application US/10847918  
; Publication No. US20050119210A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Be, Xiaobing  
; APPLICANT: Liu, Wei  
; APPLICANT: Slonim, Donna  
; APPLICANT: Howes, Steve  
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers  
; FILE REFERENCE: 031896-026000 (AM101264)  
; CURRENT APPLICATION NUMBER: US/10/847,918  
; CURRENT FILING DATE: 2004-05-19  
; PRIOR APPLICATION NUMBER: US 60/471,729  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 14937  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 10677  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAi-antisense strand  
US-10-847-918-10677

Query Match 1.8%; Score 15.8; DB 1; Length 21;



Best Local Similarity 89.5%; Pred. No. 3.6e+02; Indels 2; Gaps 0;  
Matches 17; Conservative 0; Mismatches 2;

QY 731 AAATGCTCTGTTTCAATGAC 749

Db 21 AAATGACTGTTTCAACGAC 3

RESULT 483

US-10-963-238-5  
; Sequence 5, Application US/10963238  
; Publication No. US20050120415A1  
; GENERAL INFORMATION:  
; APPLICANT: Aukerman, Milo  
; TITLE OF INVENTION: Gene Silencing  
; FILE REFERENCE: DD0016-US-2  
; CURRENT APPLICATION NUMBER: US/10/963,238  
; CURRENT FILING DATE: 2004-10-12  
; PRIOR APPLICATION NUMBER: 60/509,958  
; PRIOR FILING DATE: 2003-10-09  
; NUMBER OF SEQ ID NOS: 100  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: miRNA template to target At3g54340  
US-10-963-238-5

Query Match 1.8%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 3.6e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAGTA 470

Db 1 GGTGGAATGAAGACGTA 19

RESULT 484

US-10-963-394-5  
; Sequence 5, Application US/10963394  
; Publication No. US20050138689A1  
; GENERAL INFORMATION:  
; APPLICANT: Aukerman, Milo  
; TITLE OF INVENTION: Gene Silencing  
; FILE REFERENCE: DD0016  
; CURRENT APPLICATION NUMBER: US/10/963,394  
; CURRENT FILING DATE: 2004-10-12  
; PRIOR APPLICATION NUMBER: 60/509,958  
; PRIOR FILING DATE: 2003-10-09  
; NUMBER OF SEQ ID NOS: 71  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: miRNA template to target At3g54340  
US-10-963-394-5

Query Match 1.8%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 3.6e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAGTA 470

Db 1 GGTGGAATGAAGACGTA 19

RESULT 485

US-10-484-577-356  
; Sequence 356, Application US/10484577

Publication No. US20050032724A1  
; GENERAL INFORMATION:  
; APPLICANT: EPIDAUROS Biotechnologie Aktiengesellschaft  
; TITLE OF INVENTION: Means and methods for improved treatment of cancer based on UGT1A

FILE REFERENCE: F2285PCT-1  
; CURRENT APPLICATION NUMBER: US/10/484,577  
; CURRENT FILING DATE: 2004-01-22 02/08220  
; PRIOR APPLICATION NUMBER: PCT/EP 02/08220  
; PRIOR FILING DATE: 2002-07-23  
; PRIOR APPLICATION NUMBER: EP 01 11 7608.8  
; PRIOR FILING DATE: 2001-07-23  
; PRIOR APPLICATION NUMBER: EP 02011710.7  
; PRIOR FILING DATE: 2002-05-24  
; NUMBER OF SEQ ID NOS: 683  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 356  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (9)..(9)  
; OTHER INFORMATION: r=a or g  
US-10-484-577-356

Query Match 1.8%; Score 15.6; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.9e+02;  
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 321 GCAATGTCAGTCTGCA 336

Db 2 GCAATGTRACTGCTGA 17

RESULT 486

US-10-199-674-39  
; Sequence 39, Application US/10199674  
; Publication No. US20040014049A1  
; GENERAL INFORMATION:  
; APPLICANT: Lex M. Cowser  
; APPLICANT: Susan M. Freier  
; APPLICANT: Kenneth W. Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN KINASE C-10TA EXPRESSION  
; FILE REFERENCE: PTS-0030  
; CURRENT APPLICATION NUMBER: US/10/199,674  
; CURRENT FILING DATE: 2002-07-19  
; NUMBER OF SEQ ID NOS: 133  
; SEQ ID NO 39  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-199-674-39

Query Match 1.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 3.6e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 835 TATGGCACTTATATGA 851

Db 2 TATGGCACTTCTTATGA 18

RESULT 487

US-10-199-674-99/c  
; Sequence 99, Application US/10199674  
; Publication No. US20040014049A1  
; GENERAL INFORMATION:  
; APPLICANT: Lex M. Cowser  
; APPLICANT: Susan M. Freier  
; APPLICANT: Kenneth W. Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN KINASE C-10TA EXPRESSION

; FILE REFERENCE: PTS-0030  
; CURRENT APPLICATION NUMBER: US/10/199,674  
; CURRENT FILING DATE: 2002-07-19  
; NUMBER OF SEQ ID NOS: 133  
; SEQ ID NO 99  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: H. sapiens  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-199-674-99

Query Match 1.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 3.6e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 835 TATGGCACTTATTATGA 851  
Db 19 TATGGCACTTATTATGA 3

## RESULT 488

US-10-672-866-166/c  
; Sequence 166, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 166  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-166

Query Match 1.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 3.6e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 65 ATGGCGACGAGGCCGT 81  
Db 17 ATGGCGATGAGGCCGT 1

## RESULT 489

US-10-672-866-253/c  
; Sequence 253, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339

; SEQ ID NO 253  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-253

Query Match 1.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 3.6e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 125 TTCGAGCAGAGGAAG 141  
Db 19 TTCGAGCAGAGGCAAG 3

## RESULT 490

US-09-758-881-39  
; Sequence 39, Application US/09758881  
; Patent No. US20010029250A1  
; GENERAL INFORMATION:  
; APPLICANT: Karras, James G  
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3  
; TITLE OF INVENTION: Expression  
; FILE REFERENCE: ISPH-0532  
; CURRENT APPLICATION NUMBER: US/09/758,881  
; CURRENT FILING DATE: 2001-01-11  
; PRIOR APPLICATION NUMBER: PCT/US00/09054  
; PRIOR FILING DATE: 2000-04-06  
; PRIOR APPLICATION NUMBER: 09/288,461  
; PRIOR FILING DATE: 1999-04-08  
; NUMBER OF SEQ ID NOS: 152  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 39  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-09-758-881-39

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 3.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 200 TTCCATGTTTCATGAGTTTG 219  
Db 1 TTCCATGTTTCATCATTITG 20

## RESULT 491

US-10-000-213-81  
; Sequence 81, Application US/10000213  
; Publication No. US20030125271A1  
; GENERAL INFORMATION:  
; APPLICANT: Brenda P. Baker  
; APPLICANT: Mark P. Roach  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION  
; FILE REFERENCE: RTS-0327  
; CURRENT APPLICATION NUMBER: US/10/000,213  
; CURRENT FILING DATE: 2001-11-14  
; NUMBER OF SEQ ID NOS: 94  
; SEQ ID NO 81  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-000-213-81

Query Match 1.7%; Score 15.2; DB 1; Length 20;

```
Best Local Similarity 85.0%; Pred. No. 3.8e+02; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 3;

QY 215 TTGGAGATAATACAGCAGG 234
    ||||| || || |||||
Db 1 TTGGAAATCAATCAGCAGG 20

RESULT 492
US-10-006-366-68
; Sequence 68, Application US/10006366
; Publication No. US20030125273A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF MHC CLASS II TRANSCRIPTIVATOR EXPRESSION
; FILE REFERENCE: RTS-0332
; CURRENT APPLICATION NUMBER: US/10/006,366
; CURRENT FILING DATE: 2001-11-05
; NUMBER OF SEQ ID NOS: 96
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-366-68

Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 437 GATGACTTGGCAAGGTGG 456
    ||||| || |||||
Db 1 GAGGACTTGAGCCAGGTGG 20

RESULT 493
US-10-148-835-77/c
; Sequence 77, Application US/10148835
; Publication No. US20030207380A1
; GENERAL INFORMATION:
; APPLICANT: SAITO et al.
; TITLE OF INVENTION: MUTANT ER alpha AND TEST SYSTEMS FOR TRANSACTIVATION
; FILE REFERENCE: 2185-0648P
; CURRENT APPLICATION NUMBER: US/10/148,835
; CURRENT FILING DATE: 2002-10-11
; NUMBER OF SEQ ID NOS: 213
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Designed
; OTHER INFORMATION: oligonucleotide primer for PCR
US-10-148-835-77

Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 295 TGAAGAGAGCGCATGTTGGAG 314
    ||||| ||||| |||||
Db 20 TGTAGAGGGGCATGTTGGAG 1

RESULT 494
US-10-383-614-26
; Sequence 26, Application US/10383614
; Publication No. US20030225022A1
; GENERAL INFORMATION:
; APPLICANT: TAYLOR, CATHERINE
```

```
; APPLICANT: CLICHE, DOMINIC
; APPLICANT: HEIKKILA, ELIZABETH MARGARET
; APPLICANT: SENCHYNA, DIANE MICHELLE
; APPLICANT: FLANAGAN, JOHN GERARD
; APPLICANT: THOMPSON, JOHN E.
; TITLE OF INVENTION: SUPPRESSION OF e1FA 1 EXPRESSION TO PREVENT RETINAL GANGLION
; TITLE OF INVENTION: CELL DEATH IN THE GLAUCOMATOUS EYE
; FILE REFERENCE: 10799/78
; CURRENT APPLICATION NUMBER: US/10/383,614
; CURRENT FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 10/277,969
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 10/200,148
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: 10/141,647
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/909,796
; PRIOR FILING DATE: 2001-07-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic antisense
; OTHER INFORMATION: oligonucleotide
US-10-383-614-26

Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCGCTAGC 59
    ||||| ||||| |||||
Db 1 GGACCTTGGCGTGGCGGTGC 20

RESULT 495
US-10-383-614-35
; Sequence 35, Application US/10383614
; Publication No. US20030225022A1
; GENERAL INFORMATION:
; APPLICANT: TAYLOR, CATHERINE
; APPLICANT: CLICHE, DOMINIC
; APPLICANT: HEIKKILA, ELIZABETH MARGARET
; APPLICANT: SENCHYNA, DIANE MICHELLE
; APPLICANT: FLANAGAN, JOHN GERARD
; APPLICANT: THOMPSON, JOHN E.
; TITLE OF INVENTION: SUPPRESSION OF e1FA 1 EXPRESSION TO PREVENT RETINAL GANGLION
; TITLE OF INVENTION: CELL DEATH IN THE GLAUCOMATOUS EYE
; FILE REFERENCE: 10799/78
; CURRENT APPLICATION NUMBER: US/10/383,614
; CURRENT FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 10/277,969
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 10/200,148
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: 10/141,647
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/909,796
; PRIOR FILING DATE: 2001-07-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-383-614-35
```

```
Best Local Similarity   85.0%; Pred. No. 3.8e+02;
Matches    17; Conservative      0; Mismatches     3; Indels       0; Gaps        0;

QY      188 GGCTGCGATGGATTCCCATGT 207
          ||| ||||| ||||| ||||| |||||
DB       20 GGCAGCATTGGTTCCAATG  1

RESULT 498
US-10-672-866-192/c
; Sequence 192, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 192
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-192

Query Match              1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity   85.0%; Pred. No. 3.8e+02;
Matches    17; Conservative      0; Mismatches     3; Indels       0; Gaps        0;

QY      338 AAAGATGGTGCGCGCATGT 357
          ||| ||| ||||| ||||| |||||
DB       20 AAGGACGGTGTGCCCAATGT  1

RESULT 499
US-10-672-866-196/c
; Sequence 196, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-196

Query Match              1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity   85.0%; Pred. No. 3.8e+02;
Matches    17; Conservative      0; Mismatches     3; Indels       0; Gaps        0;
```

QY 355 TGTGTCTATTGAAGATTCGTG 374  
|||||  
Db 20 TGTGTCCATTGAAGATCGTG 1

## RESULT 500

US-10-672-866-197/c  
; Sequence 197, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 197  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-197

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 3.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 358 GTCATTGAAGATTCGTGA 377  
|||||  
Db 20 GTCCATTGAAGATCGTGTA 1

## RESULT 501

US-10-672-866-198/c  
; Sequence 198, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 198  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-198

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 3.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 360 CTATTGAAGATTCGTGATC 379  
|||||  
Db 20 CCATTGAAGATCGTGTGATC 1

## RESULT 502

US-10-672-866-203/c  
; Sequence 203, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 203  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-203

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 3.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 476 ACAGGAAACGCTGGAAGTCG 495  
|||||  
Db 20 ACTGGAATGCTGGAAGCCG 1

## RESULT 503

US-10-672-866-204/c  
; Sequence 204, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 204  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-204

Query Match 1.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 3.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 481 AAACCTCGAAGCTCTTTGG 500  
|||||  
Db 20 AAATGCTGGAAGCCGCTTGG 1

## RESULT 504

```
US-10-672-866-264/c
; Sequence 264, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 264
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-264

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      186 AAGGCTGCATGATTCAT 205
Db      20 AAGGCGAGCATGGTTCCAT 1
||||| ||||| ||||| ||||| |||||

RESULT 505
US-10-672-866-266/c
; Sequence 266, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 266
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-266

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      194 CATGATTCATGTTTCATGA 213
Db      20 CATGGTTCCATGTCCATCA 1
||||| ||||| ||||| ||||| |||||

RESULT 506
US-10-672-866-284/c
; Sequence 284, Application US/10672866
; Publication No. US20050019915A1
```

```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 284
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-284

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      284 GGGCCAAAGGATGAAGAGAG 303
Db      20 GGTCCAGCGGATGAAGAGAG 1
||||| ||||| ||||| ||||| |||||

RESULT 507
US-10-672-866-295/c
; Sequence 295, Application US/10672866
; Publication No. US20050019915A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
; TITLE OF INVENTION: SOLUBLE
; FILE REFERENCE: RTS-0242
; CURRENT APPLICATION NUMBER: US/10/672,866
; CURRENT FILING DATE: 2003-09-26
; PRIOR APPLICATION NUMBER: 10/633,843
; PRIOR FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 339
; SEQ ID NO 295
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-295

Query Match      1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      483 ACCTGGAAGTCGTTGGCT 502
Db      20 ATGCTGAAGCCGCTTGCT 1
||||| ||||| ||||| ||||| |||||

RESULT 508
US-10-773-678-39
; Sequence 39, Application US/10773678
; Publication No. US20050074879A1
; GENERAL INFORMATION:
; APPLICANT: Karias, James G
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
```

```
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0828
; CURRENT APPLICATION NUMBER: US/10/773,678
; CURRENT FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: 10/713,139
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 09/758,881
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 402
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-773-678-39
```

```
Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 200 TTCCATGTTTCATGAGTTTG 219
Db 1 TTCCATGTTTCATGAGTTTG 20
```

```
RESULT 509
US-10-831-901A-2219
; Sequence 2219, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-2219
```

```
Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 661 AAAGTACCTGTAGTCAGAAA 680
Db 1 AAACACCTGTATGAGAAA 20
```

```
RESULT 510
US-10-831-901A-3639
; Sequence 3639, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3639
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-3639
```

```
Query Match 1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 328 GACTGCTGACAAAGATGCTG 347
Db 1 GCCTGCTGACAAACATGCTG 20
```

```
RESULT 511
US-10-831-901A-3640
; Sequence 3640, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
```

```
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL000808)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3640
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-3640

Query Match      1.7%  Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 327 TCAGCTGCTGACAAAGATGTT 346
Db 1 TCCTGCTGACAAACATGTT 20

RESULT 512
US-10-831-901A-14406/c
; Sequence 14406, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14407
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-14407/c

Query Match      1.7%  Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 197 GGATTCATGTTTCATGAGTT 216
Db 20 GGATACCATTTTCGTGAGTT 1

RESULT 514
US-10-831-901A-14412/c
; Sequence 14412, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-14406

Query Match      1.7%  Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 196 TGGATTCATGTTTCATGAGTT 215
Db 20 TGGATACCATTTTCGTGAGTT 1

RESULT 513
US-10-831-901A-14407/c
; Sequence 14407, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14407
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-14407

Query Match      1.7%  Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 197 GGATTCATGTTTCATGAGTT 216
Db 20 GGATACCATTTTCGTGAGTT 1

RESULT 514
US-10-831-901A-14412/c
; Sequence 14412, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
```



```
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOLO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14412
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-14412

Query Match          1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 202 CCATGTTTCATGATGTTGGAG 221
Db 20 CCATTTTCGTGAGTTAGGAG 1

RESULT 515
US-10-862-440-37
; Sequence 37, Application US/10862440
; Publication No. US20050155110A1
; GENERAL INFORMATION:
; APPLICANT: SENESCO TECHNOLOGIES, INC.
; TITLE OF INVENTION: USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS
; FILE REFERENCE: 13,947-P
; CURRENT APPLICATION NUMBER: US/10/862,440
; CURRENT FILING DATE: 2004-06-08
; PRIOR APPLICATION NUMBER: 10/383,614
; PRIOR FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 10/277,969
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 10/200,148
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: 10/141,647
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/909,796
; PRIOR FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 60/451,677
; PRIOR FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/476,194
; PRIOR FILING DATE: 2003-06-06
; PRIOR APPLICATION NUMBER: 60/504,731
; PRIOR FILING DATE: 2003-09-22
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-862-440-38

Query Match          1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCCTAGC 59
Db 20 GGACCTTGGCGTGGCCGTGC 1

RESULT 517
US-10-862-440-64
; Sequence 64, Application US/10862440
; Publication No. US20050155110A1
; GENERAL INFORMATION:
; APPLICANT: SENESCO TECHNOLOGIES, INC.
; TITLE OF INVENTION: USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS
; FILE REFERENCE: 13,947-P
; CURRENT APPLICATION NUMBER: US/10/862,440
; CURRENT FILING DATE: 2004-06-08
; PRIOR APPLICATION NUMBER: 10/383,614
; PRIOR FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 10/277,969
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 10/200,148
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: 10/141,647
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/909,796
; PRIOR FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 60/451,677
; PRIOR FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/476,194
; PRIOR FILING DATE: 2003-06-06
; PRIOR APPLICATION NUMBER: 60/504,731
; PRIOR FILING DATE: 2003-09-22
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-862-440-38

Query Match          1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCCTAGC 59
Db 20 GGACCTTGGCGTGGCCGTGC 1

RESULT 516
US-10-862-440-38/c
; Sequence 38, Application US/10862440
; Publication No. US20050155110A1
; GENERAL INFORMATION:
; APPLICANT: SENESCO TECHNOLOGIES, INC.
; TITLE OF INVENTION: USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS
; FILE REFERENCE: 13,947-P
; CURRENT APPLICATION NUMBER: US/10/862,440
; CURRENT FILING DATE: 2004-06-08
; PRIOR APPLICATION NUMBER: 10/383,614
; PRIOR FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 10/277,969
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: 10/200,148
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: 10/141,647
; PRIOR FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/909,796
; PRIOR FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 60/451,677
; PRIOR FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/476,194
; PRIOR FILING DATE: 2003-06-06
; PRIOR APPLICATION NUMBER: 60/504,731
; PRIOR FILING DATE: 2003-09-22
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-862-440-38

Query Match          1.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCCTAGC 59
Db 1 GGACCTTGGCGTGGCCGTGC 20
```

```
/ PRIOR APPLICATION NUMBER: 10/277,969
/ PRIOR FILING DATE: 2002-10-23
/ PRIOR APPLICATION NUMBER: 10/200,148
/ PRIOR FILING DATE: 2002-07-23
/ PRIOR APPLICATION NUMBER: 10/141,647
/ PRIOR FILING DATE: 2002-05-07
/ PRIOR APPLICATION NUMBER: 09/909,796
/ PRIOR FILING DATE: 2001-07-23
/ PRIOR APPLICATION NUMBER: 60/451,677
/ PRIOR FILING DATE: 2003-03-05
/ PRIOR APPLICATION NUMBER: 60/476,194
/ PRIOR FILING DATE: 2003-06-06
/ PRIOR APPLICATION NUMBER: 60/504,731
/ PRIOR FILING DATE: 2003-09-22
/ NUMBER OF SEQ ID NOS: 85
/ SOFTWARE: Patentin Ver. 3.2
/ SEQ ID NO 64
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
US-10-862-440-64

Query Match
Best Local Similarity 1.7%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCCTAGC 59
Db 1 GGACCTTGGCGTGGCGGTGC 20

RESULT 518
US-10-862-440-67
/ Sequence 67, Application US/10862440
/ Publication No. US20050155110A1
/ GENERAL INFORMATION:
/ APPLICANT: SENESCO TECHNOLOGIES, INC.
/ TITLE OF INVENTION: USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS
/ TITLE OF INVENTION: EXPRESSION OF eIF-5A1
/ FILE REFERENCE: 13.947-P
/ CURRENT APPLICATION NUMBER: US/10/862,440
/ CURRENT FILING DATE: 2004-06-08
/ PRIOR APPLICATION NUMBER: 10/383,614
/ PRIOR FILING DATE: 2003-03-10
/ PRIOR APPLICATION NUMBER: 10/277,969
/ PRIOR FILING DATE: 2002-10-23
/ PRIOR APPLICATION NUMBER: 10/200,148
/ PRIOR FILING DATE: 2002-07-23
/ PRIOR APPLICATION NUMBER: 10/141,647
/ PRIOR FILING DATE: 2002-05-07
/ PRIOR APPLICATION NUMBER: 09/909,796
/ PRIOR FILING DATE: 2001-07-23
/ PRIOR APPLICATION NUMBER: 60/451,677
/ PRIOR FILING DATE: 2003-03-05
/ PRIOR APPLICATION NUMBER: 60/476,194
/ PRIOR FILING DATE: 2003-06-06
/ PRIOR APPLICATION NUMBER: 60/504,731
/ PRIOR FILING DATE: 2003-09-22
/ NUMBER OF SEQ ID NOS: 85
/ SOFTWARE: Patentin Ver. 3.2
/ SEQ ID NO 67
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: oligonucleotide
US-10-862-440-67

Query Match
Best Local Similarity 1.7%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Best Local Similarity 85.0%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 40 GGACCTCGCGTGGCCTAGC 59
Db 1 GGACCTTGGCGTGGCGGTGC 20

RESULT 519
US-10-672-866-139/c
/ Sequence 139, Application US/10672866
/ Publication No. US20050019915A1
/ GENERAL INFORMATION:
/ APPLICANT: C. Frank Bennett
/ APPLICANT: Kenneth Dobie
/ TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
/ TITLE OF INVENTION: SOLUBLE
/ TITLE OF INVENTION: EXPRESSION
/ FILE REFERENCE: RTS-0242
/ CURRENT APPLICATION NUMBER: US/10/672,866
/ CURRENT FILING DATE: 2003-09-26
/ PRIOR APPLICATION NUMBER: 10/633,843
/ PRIOR FILING DATE: 2003-08-04
/ PRIOR APPLICATION NUMBER: 09/888,360
/ PRIOR FILING DATE: 2001-06-21
/ NUMBER OF SEQ ID NOS: 339
/ SEQ ID NO 139
/ LENGTH: 15
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-139

Query Match
Best Local Similarity 1.7%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 129 AGCAGAAGAAAGTA 143
Db 15 AGCAGAAGAAAGTA 1

RESULT 520
US-10-672-866-140/c
/ Sequence 140, Application US/10672866
/ Publication No. US20050019915A1
/ GENERAL INFORMATION:
/ APPLICANT: C. Frank Bennett
/ APPLICANT: Kenneth Dobie
/ TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,
/ TITLE OF INVENTION: SOLUBLE
/ TITLE OF INVENTION: EXPRESSION
/ FILE REFERENCE: RTS-0242
/ CURRENT APPLICATION NUMBER: US/10/672,866
/ CURRENT FILING DATE: 2003-09-26
/ PRIOR APPLICATION NUMBER: 10/633,843
/ PRIOR FILING DATE: 2003-08-04
/ PRIOR APPLICATION NUMBER: 09/888,360
/ PRIOR FILING DATE: 2001-06-21
/ NUMBER OF SEQ ID NOS: 339
/ SEQ ID NO 140
/ LENGTH: 15
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-672-866-140

Query Match
Best Local Similarity 1.7%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 296 GAAGAGAGCATGTT 310  
|||||:|||||  
Db 15 GAAGAGAGCATGTT 1

RESULT 521  
US-10-672-866-148/c  
; Sequence 148, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 148  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-148

Query Match 1.7%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 AGCTATTAAAGAA 865  
|||||:|||||  
Db 15 AGCTATTAAAGAA 1

RESULT 522  
US-10-484-577-355/c  
; Sequence 355, Application US/10484577  
; Publication No. US2005032724A1  
; GENERAL INFORMATION:  
; APPLICANT: EPIDAUROS Biotechnologie Aktiengesellschaft  
; TITLE OF INVENTION: Means and methods for improved treatment of cancer based on UG1A  
; CURRENT APPLICATION NUMBER: US/10/484,577  
; CURRENT FILING DATE: 2004-01-22  
; PRIOR APPLICATION NUMBER: PCT/EP 02/08220  
; PRIOR FILING DATE: 2002-07-23  
; PRIOR APPLICATION NUMBER: EP 01 11 7608.8  
; PRIOR FILING DATE: 2001-07-23  
; PRIOR APPLICATION NUMBER: EP 02011710.7  
; PRIOR FILING DATE: 2002-05-24  
; NUMBER OF SEQ ID NOS: 683  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 355  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (8)..(8)  
; OTHER INFORMATION: y=c or t  
US-10-484-577-355

Query Match 1.7%; Score 15; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 319 GGGCAATGTGACTGTG 335

Db 17 GTGCAATGTRACTGCTG 1  
|||||:|||||

RESULT 523  
US-10-672-866-210/c  
; Sequence 210, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 210  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-210

Query Match 1.7%; Score 15; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3.9e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 524 CAATAAACATTCCT 538  
|||||:|||||  
Db 20 CAATAAACATTCCT 6

RESULT 524  
US-10-444-925-474/c  
; Sequence 474, Application US/10444925  
; Publication No. US20040009946A1  
; GENERAL INFORMATION:  
; APPLICANT: Lewis, Stephen Patrick  
; APPLICANT: Klinghoffer, Richard  
; APPLICANT: Wilson, Linda K.  
; TITLE OF INVENTION: MODULATION OF PTPIB SIGNAL TRANSDUCTION  
; TITLE OF INVENTION: BY RNA INTERFERENCE  
; FILE REFERENCE: 200125.441  
; CURRENT APPLICATION NUMBER: US/10/444,925  
; CURRENT FILING DATE: 2003-05-23  
; NUMBER OF SEQ ID NOS: 599  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 474  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Small interfering RNA  
US-10-444-925-474

Query Match 1.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 3.8e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 314 GACTGGGCAATGTGACT 331  
|||||:|||||  
Db 18 GACTGGGCAATGTGCT 1

RESULT 525  
US-10-883-218-310/c

```
/ Sequence 310, Application US/10883218
/ Publication No. US20050124567A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Haerberli, Peter
/ APPLICANT: McSwiggan, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
/ FILE REFERENCE: 400/195 (MEHB04-535)
/ CURRENT APPLICATION NUMBER: US/10/883,218
/ CURRENT FILING DATE: 2004-07-01
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2003-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2003-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 930
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 310
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-883-218-310

Query Match 1.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 765 CTTAAATCACAGATGGGT 782
Db 18 CTTTATCACAGATGGGT 1

RESULT 526
US-10-883-218-712
/ Sequence 712, Application US/10883218
/ Publication No. US20050124567A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Haerberli, Peter
/ APPLICANT: McSwiggan, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
/ FILE REFERENCE: 400/195 (MEHB04-535)
/ CURRENT APPLICATION NUMBER: US/10/883,218
/ CURRENT FILING DATE: 2004-07-01
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2003-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
```

```
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 930
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 712
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-883-218-712

Query Match 1.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 3.8e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 765 CTTAAATCACAGATGGGT 782
Db 2 CUUUUACACAGUGGU 19

RESULT 527
US-09-863-086-102/c
/ Sequence 102, Application US/09863086
/ Patent No. US20020048762A1
/ GENERAL INFORMATION:
/ APPLICANT: Roseau, Rudi
/ TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER
/ REGION BETWEEN THE 16S A
/ NUMBER OF SEQUENCES: 104
/ CORRESPONDENCE ADDRESSES:
/ ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
/ STREET: 3100 No. US20020048762A1west Center, 90 S. 7th Street
/ CITY: Minneapolis
/ STATE: MN
/ COUNTRY: U.S.A.
/ ZIP: 55402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/863,086
/ FILING DATE: 22-May-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/312,520
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: 08/412,614
/ FILING DATE: 29-MAR-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Hillson, Randall A
/ REGISTRATION NUMBER: 31,838
/ REFERENCE/DOCKET NUMBER: 8076.75USC1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 612/332-5300
/ TELEFAX: 612/332/9081
/ TELEX: <Unknown>
/ INFORMATION FOR SEQ ID NO: 102:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 102:
US-09-863-086-102

```

```

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 67 GCGCAGCAAGGCCGTG 82
    |||||
DB 16 GCGCAGCAAGGCCGTG 1

```

## RESULT 528

```

US-09-863-086-104/c
; Sequence 104, Application US/09863086
; Patent No. US20020048762A1
; GENERAL INFORMATION:
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 No. US20020048762A1west Center, 90 S. 7th Street
; CITY: Minneapolis
; STATE: MN
; COUNTRY: U.S.A.
; ZIP: 55402

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,086
; FILING DATE: 22-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/312,520
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 29-MAR-1995

```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Hillson, Randall A
; REGISTRATION NUMBER: 31,838
; REFERENCE/DOCKET NUMBER: 8076.75USC1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/332-5300
; TELEFAX: 612/332/9081
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: both

```

```

; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 104:
US-09-863-086-104

```

```

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;

```

```

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 67 GCGCAGCAAGGCCGTG 82
    |||||
DB 16 GCGCAGCAAGGCCGTG 1

```

## RESULT 529

```

US-09-780-533A-2234/c
; Sequence 2234, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2234
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2234

```

```

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 857 TTAAAGAATCCAAAT 872
    |||||
DB 17 TTAAAGAATCCAAAT 2

```

## RESULT 530

```

US-09-780-533A-2326
; Sequence 2326, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2326
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2326

```

```

Query Match      1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 822 AATAAAACCCCTGTAT 837
    |||||
DB 1 AAUAAAAAACCCUGUAU 16

```

```
RESULT 531
US-10-672-238-102/c
; Sequence 102, Application US/10672238
; Publication No. US20040053320A1
; GENERAL INFORMATION:
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER
; REGION BETWEEN THE 16S A
;
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 NO. US20040053320Alwest Center, 90 S. 7th Street
; CITY: Minneapolis
; STATE: MN
; COUNTRY: U.S.A.
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/672,238
; FILING DATE: 25-Sep-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,086
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 22-May-2001
; APPLICATION NUMBER: 09/312,520
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 29-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Hillson, Randall A
; REGISTRATION NUMBER: 31,838
; REFERENCE/DOCKET NUMBER: 8076.75USC1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/332-5300
; TELEFAX: 612/332/9081
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 102:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 102:
US-10-672-238-102
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 67 GCGGACGAAGCCGCGT 82
Db 16 GCGGACGAAGGACGCT 1

RESULT 532
US-10-672-238-104/c
; Sequence 104, Application US/10672238
; Publication No. US20040053320A1
; GENERAL INFORMATION:
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: HYBRIDIZATION PROBES DERIVED FROM THE SPACER
; REGION BETWEEN THE 16S A
```

```
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
; STREET: 3100 NO. US20040053320Alwest Center, 90 S. 7th Street
; CITY: Minneapolis
; STATE: MN
; COUNTRY: U.S.A.
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/672,238
; FILING DATE: 25-Sep-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,086
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 22-May-2001
; APPLICATION NUMBER: 09/312,520
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/412,614
; FILING DATE: 29-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Hillson, Randall A
; REGISTRATION NUMBER: 31,838
; REFERENCE/DOCKET NUMBER: 8076.75USC1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612/332-5300
; TELEFAX: 612/332/9081
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: both
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 104:
US-10-672-238-104
Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 67 GCGGACGAAGCCGCGT 82
Db 16 GCGGACGAAGGACGCT 1

RESULT 533
US-10-484-577-353/c
; Sequence 353, Application US/10484577
; Publication No. US20050032724A1
; GENERAL INFORMATION:
; APPLICANT: EPIDAUROS Biotechnologie Aktiengesellschaft
; TITLE OF INVENTION: Means and methods for improved treatment of cancer based on UGT1A
; FILE REFERENCE: F2285PCT-1
; CURRENT APPLICATION NUMBER: US/10/484,577
; CURRENT FILING DATE: 2004-01-22
; PRIOR APPLICATION NUMBER: PCT/EP 02/08220
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: EP 01 11 7608.8
; PRIOR FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: EP 02011710.7
; PRIOR FILING DATE: 2002-05-24
```

; NUMBER OF SEQ ID NOS: 693  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 353  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-484-577-353

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336  
DB 16 GCAATGTAAGTCTGA 1  
|||||

## RESULT 534

US-10-484-577-354  
; Sequence 354, Application US/10484577  
; Publication No. US20050032724A1  
; GENERAL INFORMATION:  
; APPLICANT: EPIDAUROS Biotechnologie Aktiengesellschaft  
; TITLE OF INVENTION: Means and methods for improved treatment of cancer based on UGT1A  
; FILE REFERENCE: P2285PCT-1  
; CURRENT APPLICATION NUMBER: US/10/484,577  
; PRIOR FILING DATE: 2004-01-22  
; PRIOR APPLICATION NUMBER: PCT/EP 02/08220  
; PRIOR FILING DATE: 2002-07-23  
; PRIOR APPLICATION NUMBER: EP 01 11 7608.8  
; PRIOR FILING DATE: 2001-07-23  
; PRIOR APPLICATION NUMBER: EP 02011710.7  
; PRIOR FILING DATE: 2002-05-24  
; NUMBER OF SEQ ID NOS: 683  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 354  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-484-577-354

Query Match 1.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 321 GCAATGTGACTGCTGA 336  
DB 2 GCAATGTAAGTCTGA 17  
|||||

## RESULT 535

US-09-864-785-2135  
; Sequence 2135, Application US/09864785  
; Patent No. US20020177568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: 400/022 (MEHB00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2135  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2135

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 71.4%; Pred. No. 3.9e+02;  
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 830 CCTGTATGGCACT 843  
DB 3 CCCUGAUGGCACU 16  
|||||

## RESULT 536

US-09-864-785-2949  
; Sequence 2949, Application US/09864785  
; Patent No. US20020177568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: 400/022 (MEHB00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2949  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2949

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 71.4%; Pred. No. 3.9e+02;  
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 830 CCTGTATGGCACT 843  
DB 1 CCCUGAUGGCACU 14  
|||||

## RESULT 537

US-09-780-533A-484/c  
; Sequence 484, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: Haerberli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MEHB00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 484  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-484

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.9e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 TCAGAACTGATTT 687  
|||||

Db 14 TGAGAACTGATTT 1

## RESULT 538

US-09-780-533A-1349/c  
; Sequence 1349, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: Haerberli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MBH00.878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1349  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-1349

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.9e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;

QY 674 TGAGAACTGATTT 687

Db 17 TGAGAACTGATTT 4

## RESULT 539

US-09-780-533A-1996/c  
; Sequence 1996, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: Haerberli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MBH00.878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1996  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-1996

Query Match 1.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.9e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;

QY 674 TGAGAACTGATTT 687

Db 16 TGAGAACTGATTT 3

## RESULT 540

US-10-633-843-54  
; Sequence 54, Application US/10633843  
; Publication No. US20040091919A1

; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 54  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-54

Query Match 1.6%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;

QY 711 AGTTTATAAACT 724

Db 3 AGTTTATAAACT 16

## RESULT 541

US-10-633-843-55  
; Sequence 55, Application US/10633843  
; Publication No. US20040091919A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION  
; FILE REFERENCE: ISPH-0756  
; CURRENT APPLICATION NUMBER: US/10/633,843  
; CURRENT FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: US 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 55  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-633-843-55

Query Match 1.6%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;

QY 711 AGTTTATAAACT 724

Db 6 AGTTTATAAACT 19

## RESULT 542

US-10-672-866-54  
; Sequence 54, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04



; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 54  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-54

Query Match 1.6%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AGTTTATAAACT 724  
|||||  
DB 3 AGTTTATAAACT 16

RESULT 543  
US-10-672-866-55  
; Sequence 55, Application US/10672866  
; Publication No. US20050019915A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; TITLE OF INVENTION: KENNETH DOBLE  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1,  
; TITLE OF INVENTION: SOLUBLE  
; TITLE OF INVENTION: EXPRESSION  
; FILE REFERENCE: RTS-0242  
; CURRENT APPLICATION NUMBER: US/10/672,866  
; CURRENT FILING DATE: 2003-09-26  
; PRIOR APPLICATION NUMBER: 10/633,843  
; PRIOR FILING DATE: 2003-08-04  
; PRIOR APPLICATION NUMBER: 09/888,360  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 339  
; SEQ ID NO 55  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-672-866-55

Query Match 1.6%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.6e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AGTTTATAAACT 724  
|||||  
DB 6 AGTTTATAAACT 19

RESULT 544  
US-09-866-108-8960  
; Sequence 8960, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 8960  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-8960

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 4e+02; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 183 CTGAAGCGCTGCATGGA 199  
|||||  
DB 1 CTGAAGCGCGCATGGA 17

RESULT 545  
US-09-818-875-3142  
; Sequence 3142, Application US/09818875  
; Publication No. US20030051270A1  
; GENERAL INFORMATION:  
; APPLICANT: Kmiec, Eric B.  
; APPLICANT: Gampier, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4  
; CURRENT APPLICATION NUMBER: US/09/818,875  
; CURRENT FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30  
; NUMBER OF SEQ ID NOS: 4385  
; SOFTWARE: Friedman macro Napro4  
; SEQ ID NO 3142  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-818-875-3142

Query Match	1.6%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 4e+02;	Mismatches	0;
Matches	15;	Conservative	0;	Indels
			0;	Gaps
			0;	
QY	676	AGAAACTGATTATGAT	692	
DB	1	AGATACTCATTATGAT	17	
RESULT 546				
US-09-818-875-3143/c				
; Sequence 3143, Application US/09818875				
; Publication No. US20030051270A1				
; GENERAL INFORMATION:				
; APPLICANT: Kmiec, Eric B.				
; APPLICANT: Gamper, Howard B.				
; APPLICANT: Rice, Michael C.				
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single				
; TITLE OF INVENTION: Stranded Oligonucleotides				
; FILE REFERENCE: Napro-4				
; CURRENT APPLICATION NUMBER: US/09/818,875				
; CURRENT FILING DATE: 2001-03-27				
; PRIOR APPLICATION NUMBER: US 60/192,176				
; PRIOR FILING DATE: 2000-03-27				
; PRIOR APPLICATION NUMBER: US 60/192,179				
; PRIOR FILING DATE: 2000-03-27				
; PRIOR APPLICATION NUMBER: US 60/208,538				
; PRIOR FILING DATE: 2000-06-01				
; PRIOR APPLICATION NUMBER: US 60/244,989				
; PRIOR FILING DATE: 2000-10-30				
; NUMBER OF SEQ ID NOS: 4385				
; SOFTWARE: Friedman macro Napro4				
; SEQ ID NO 3143				
; LENGTH: 17				
; TYPE: DNA				
; ORGANISM: Homo sapiens				
US-09-818-875-3143				
Query Match	1.6%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 4e+02;	Mismatches	0;
Matches	15;	Conservative	0;	Indels
			0;	Gaps
			0;	
QY	676	AGAACTGATTATGAT	692	
DB	17	AGATACTCATTATGAT	1	
RESULT 547				
US-09-780-533A-1097/c				
; Sequence 1097, Application US/09780533A				
; Publication No. US20030060611A1				
; GENERAL INFORMATION:				
; APPLICANT: Ribozyme Pharmaceuticals, Inc.				
; APPLICANT: Blatt, Larry				
; APPLICANT: McSwiggen, Jim				
; APPLICANT: Chowrira, Bharat				
; APPLICANT: Haerberli, Pete				
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene				
; FILE REFERENCE: MEH00,878-A (400/011)				
; CURRENT APPLICATION NUMBER: US/09/780,533A				
; CURRENT FILING DATE: 2001-02-09				
; PRIOR APPLICATION NUMBER: US 60/181,797				
; PRIOR FILING DATE: 2000-02-11				
; NUMBER OF SEQ ID NOS: 6679				
; SOFTWARE: PatentIn version 3.0				
; SEQ ID NO 1097				
; LENGTH: 17				
; TYPE: RNA				
; ORGANISM: Homo sapiens				
US-09-780-533A-1097				
Query Match	1.6%;	Score 13.8;	DB 1;	Length 17;

```
US-10-230-006-533/c
; Sequence 533, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 533
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-533

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      91 GAAGGCGGCGGCCGAG 107
      |||||
Db      17 GAAGGCGGAGGGCCCG 1

RESULT 551
US-10-230-006-534/c
; Sequence 534, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 534
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-534

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      87 TGCTGAAGCGGCGACGCG 103
      |||||
Db      17 TGCGGAAGGCGGAGGGC 1

RESULT 552
US-10-230-006-1258/c
; Sequence 1258, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
```

```
US-10-230-006-533/c
; Sequence 533, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 533
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1258

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      89 CTGAAGGCGGCGGCC 105
      |||||
Db      17 CGGAAGGCGGAGGGCCC 1

RESULT 553
US-10-209-787-3142
; Sequence 3142, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3142

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      676 AGAAACTGATTATGAT 692
      |||||
Db      1 AGATACTCATTTATGAT 17

RESULT 554
US-10-209-787-3143/c
; Sequence 3143, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
```



```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5100
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5100

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 ACCAGTCGAGTCCTCA 255
DB 17 ATCAGTCGAGTCCTCA 1

RESULT 559
US-10-138-674-6796
; Sequence 6796, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6796
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6796

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 4e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 642 ACTTTTCAGAGTTGCT 658
DB 1 ACGUUUCAGAGUUGU 17

RESULT 560
US-10-138-674-7893/c
; Sequence 7893, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 7893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7893

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CAGTCGAGTCCTCACT 257
DB 17 CAGTCGAGTCCTCAAT 1

RESULT 561
US-10-287-949A-2787/c
; Sequence 2787, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2787
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2787

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 TGTAGTCTGAGGCCCT 559
DB 17 TGCAGTCTGAGGTCCCT 1

RESULT 562
US-10-287-949A-5100/c
; Sequence 5100, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5100
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5100

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 239 ACCAGTGCAGGTCTCA 255  
Db 17 ATCAGTGCAGCTCTCA 1

RESULT 563

US-10-287-949A-6796  
; Sequence 6796, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6796  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-6796

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 4e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 642 ACTTTTTCAGAGTGTCT 658  
Db 1 ACGUUUUCAGAGUGGU 17

RESULT 564

US-10-287-949A-7893/c  
; Sequence 7893, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7893  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-7893

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 241 CAGTGCAGGTCTCACT 257  
Db 17 CAGTGCAGCTCTCAAT 1

RESULT 565

US-10-669-841-5350  
; Sequence 5350, Application US/10669841

Publication No. US20040127446A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: Lawrence, Blatt  
; APPLICANT: Dennis, Macejak  
; APPLICANT: James, McSwiggen  
; APPLICANT: David, Morrissey  
; APPLICANT: Pamela, Pavco  
; APPLICANT: Patrice, Lee  
; APPLICANT: Kenneth, Draper  
; APPLICANT: Elisabeth, Roberts  
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP  
; FILE REFERENCE: 400/042US (WBH02-249-E)  
; CURRENT APPLICATION NUMBER: US/10/669,841  
; CURRENT FILING DATE: 2003-09-23  
; PRIOR APPLICATION NUMBER: PCT/US02/09187  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: US 60/296,876  
; PRIOR FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/335,059  
; PRIOR FILING DATE: 2001-10-24  
; PRIOR APPLICATION NUMBER: US 60/337,055  
; PRIOR FILING DATE: 2001-12-05  
; PRIOR APPLICATION NUMBER: US 60/358,580  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: US 60/363,124  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 09/817,879  
; PRIOR FILING DATE: 2001-03-26  
; PRIOR APPLICATION NUMBER: US 09/740,332  
; PRIOR FILING DATE: 2000-12-18  
; PRIOR APPLICATION NUMBER: US 09/611,931  
; PRIOR FILING DATE: 2000-07-07  
; PRIOR APPLICATION NUMBER: US 09/504,321  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 16207  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5350  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-5350

Query Match 1.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 4e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 271 CAGAAAACACGGTGGGC 287  
Db 1 CAGAGACACGGUGGAC 17

RESULT 566

US-10-723-361-8960  
; Sequence 8960, Application US/10723361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

```

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8960

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 193 CTGAAGGCGTCATGGA 199
DB 1 CTGAAGGCGGACATGGA 17

RESULT 567
US-10-681-074-3142
; Sequence 3142, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KWIEC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NApTo-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3142
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3142

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 AGAAACTGATTATGAT 692
DB 1 AGATACTCATTTATGAT 17

RESULT 568
US-10-681-074-3143/c
; Sequence 3143, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KWIEC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NApTo-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3143
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3143

Query Match      1.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 AGAACTGATTATGAT 692
DB 17 AGATACTCATTTATGAT 1

RESULT 569
US-10-712-633-1027/c
; Sequence 1027, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1027
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1027

Query Match      1.6%; Score 13.8; DB 1; Length 17;

```

```

;
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-087 CIP21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
;
; INFORMATION FOR SEQ ID NO: 62:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; DESCRIPTION: sequence tagged-site specific PCR primer
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Human
; SEQUENCE DESCRIPTION: SEQ ID NO: 62:
US-09-736-084-62
0;

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAG 468
Db 18 GGTGGAATGTAGAATG 2
|||||
|||||

RESULT 572
US-09-969-373-2985
; Sequence 2985, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2985
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2985
0;

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 454 TCGAAATGAAGAAAGTA 470
Db 1 TCGAAATGGGAAGCA 17
|||||
|||||

RESULT 573
US-09-969-373-3559
; Sequence 3559, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373

```



; CURRENT FILING DATE: 2001-10-02  
 ; PRIOR APPLICATION NUMBER: US 09/754,853  
 ; PRIOR FILING DATE: 2001-01-05  
 ; PRIOR APPLICATION NUMBER: US 09/760,427  
 ; PRIOR FILING DATE: 2001-01-13  
 ; PRIOR APPLICATION NUMBER: US 09/855,768  
 ; PRIOR FILING DATE: 2001-05-15  
 ; NUMBER OF SEQ ID NOS: 4593  
 ; SEQ ID NO 3559  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Glycine max  
 US-09-969-373-3559

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 4.3e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 773 ACAGATGGGTATTAAAC 789  
 Db ||||| ||||| ||||| |||||  
 1 ACAGATGGGTGTGAAC 17

RESULT 574  
 US-10-376-770-121/c  
 ; Sequence 121, Application US/10376770  
 ; Publication No. US20040106102A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dhallan, Ravinder S.  
 ; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME  
 ; FILE REFERENCE: 54331200320  
 ; CURRENT APPLICATION NUMBER: US/10/376,770  
 ; CURRENT FILING DATE: 2003-02-28  
 ; PRIOR APPLICATION NUMBER: US 10/093,618  
 ; PRIOR FILING DATE: 2002-03-11  
 ; PRIOR APPLICATION NUMBER: US 60/360,232  
 ; PRIOR FILING DATE: 2002-03-01  
 ; PRIOR APPLICATION NUMBER: US 60/378,354  
 ; PRIOR FILING DATE: 2002-05-08  
 ; NUMBER OF SEQ ID NOS: 262  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 121  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; NAME/KEY: misc feature  
 ; LOCATION: 5\_6\_7\_8  
 ; OTHER INFORMATION: These nucleotides may be absent  
 US-10-376-770-121

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 4.3e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 781 GTATTAAACTTGTCTGCA 797  
 Db ||||| ||||| ||||| |||||  
 17 GTATTAAACTTGTCTGA 1

RESULT 575  
 US-10-661-165-121/c  
 ; Sequence 121, Application US/10661165  
 ; Publication No. US20040137470A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Dhallan, Ravinder S.  
 ; TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC  
 ; FILE REFERENCE: 543312000420  
 ; CURRENT APPLICATION NUMBER: US/10/661,165  
 ; CURRENT FILING DATE: 2003-09-11  
 ; PRIOR APPLICATION NUMBER: PCT/US03/06198  
 ; PRIOR FILING DATE: 2003-02-28

; PRIOR APPLICATION NUMBER: US 60/378,354  
 ; PRIOR FILING DATE: 2002-05-08  
 ; PRIOR APPLICATION NUMBER: US 10/093,618  
 ; PRIOR FILING DATE: 2002-03-11  
 ; PRIOR APPLICATION NUMBER: US 60/360,232  
 ; PRIOR FILING DATE: 2002-03-01  
 ; PRIOR APPLICATION NUMBER: PCT/US03/27308  
 ; PRIOR FILING DATE: 2003-08-29  
 ; PRIOR APPLICATION NUMBER: US 10/376,770  
 ; PRIOR FILING DATE: 2003-02-28  
 ; NUMBER OF SEQ ID NOS: 628  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 121  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; NAME/KEY: misc feature  
 ; LOCATION: (5)-(8)  
 ; OTHER INFORMATION: These nucleotides may be absent  
 US-10-661-165-121

Query Match 1.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 4.3e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 781 GTATTAAACTTGTCTGCA 797  
 Db ||||| ||||| ||||| |||||  
 17 GTATTAAACTTGTCTGA 1

RESULT 576  
 US-10-730-488-62/c  
 ; Sequence 62, Application US/10730488  
 ; Publication No. US20040213763A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: JEFFREY M. FRIEDMAN, YIYING ZHANG, RICARDO PROENCA, AND  
 ; MARGHERITA MAFFEI, JEFFREY HALAAS, KETAN GAJIWALA, AND  
 ; STEPHEN K. BURLEY  
 ; TITLE OF INVENTION: OB POLYPEPTIDE ANTIBODIES AND METHOD OF MAKING  
 ; (AS AMENDED)  
 ; NUMBER OF SEQUENCES: 102  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Klauber & Jackson  
 ; STREET: 411 Hackensack Avenue  
 ; CITY: Hackensack  
 ; STATE: New Jersey  
 ; COUNTRY: USA  
 ; ZIP: 07601  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA: US/10/730,488  
 ; FILING DATE: 08-Dec-2003  
 ; CLASSIFICATION: <Unknown>  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/736,084  
 ; FILING DATE: 13-Dec-2000  
 ; APPLICATION NUMBER: 08/438,431  
 ; FILING DATE: May 10, 1995  
 ; APPLICATION NUMBER: 08/347,563  
 ; FILING DATE: November 30, 1994  
 ; APPLICATION NUMBER: 08/292,345  
 ; FILING DATE: August 17, 1994  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Jackson Esq., David A.  
 ; REGISTRATION NUMBER: 26,742  
 ; REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2D  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 201 487-5800

```
/
/ TELEFAX: 201 343-1684
/ TELEX: 133521
/ INFORMATION FOR SEQ ID NO: 62:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (primer)
/ DESCRIPTION: sequence tagged-site specific PCR primer sWSS2588
/
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ ORIGINAL SOURCE:
/ ORGANISM: Human
/
/ SEQUENCE DESCRIPTION: SEQ ID NO: 62:
US-10-730-488-62

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 GGTGGAATGAAGAAAG 468
Db 18 GGTGGAATGTAGATG 2

RESULT 577
US-10-473-126-581
/ Sequence 581, Application US/10473126
/ Publication No. US20040234973A1
/ GENERAL INFORMATION:
/ APPLICANT: Epigenomics AG
/ TITLE OF INVENTION: Methods and nucleic acids for the analysis of hematopoietic cell
/ FILE REFERENCE: proliferative disorders
/ CURRENT APPLICATION NUMBER: US/10/473,126
/ CURRENT FILING DATE: 2003-09-26
/ NUMBER OF SEQ ID NOS: 1258
/ SEQ ID NO 581
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Detection oligonucleotide for RBI
US-10-473-126-581

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 487 TGGAAAGCTTTGGCTT 503
Db 2 TGGAAAGCTTTGGATT 18

RESULT 578
US-10-883-848-7/c
/ Sequence 7, Application US/10883848
/ Publication No. US20040235045A1
/ GENERAL INFORMATION:
/ APPLICANT: NYLAND, Harold I.
/ APPLICANT: MYHR, Kjell-Morten
/ APPLICANT: VEDELER, Christian A.
/ TITLE OF INVENTION: METHOD FOR DISEASE DIAGNOSIS BASED ON FC RECEPTOR GENOTYPING
/ FILE REFERENCE: Q59836
/ CURRENT APPLICATION NUMBER: US/10/883,848
/ CURRENT FILING DATE: 2004-07-06
/ PRIOR APPLICATION NUMBER: US/09/599,002
/ PRIOR FILING DATE: 2000-06-22
/ PRIOR APPLICATION NUMBER: PCT/GB98/03872
/ PRIOR FILING DATE: 1998-12-22
/ PRIOR APPLICATION NUMBER: GB 9727055.7
/ PRIOR FILING DATE: 1997-12-22
```

```
/
/ PRIOR APPLICATION NUMBER: GB 9802207.2
/ PRIOR FILING DATE: 1998-02-02
/ NUMBER OF SEQ ID NOS: 10
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Human
US-10-883-848-7

Query Match 1.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 229 AGCAGCTGTACCAATG 245
Db 17 AGCAGCTGTACCAATG 1

RESULT 579
US-10-641-960-157
/ Sequence 157, Application US/10641960
/ Publication No. US20050037366A1
/ GENERAL INFORMATION:
/ APPLICANT: Gut, Joseph
/ TITLE OF INVENTION: INDIVIDUAL DRUG SAFETY
/ FILE REFERENCE: DT-6622
/ CURRENT APPLICATION NUMBER: US/10/641,960
/ CURRENT FILING DATE: 2003-08-14
/ NUMBER OF SEQ ID NOS: 158
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 157
/ LENGTH: 15
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-641-960-157

Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 83 TGCCTGCTGAAGGC 97
Db 1 TGCCTGCAAGAGGC 15

RESULT 580
US-10-608-062-2
/ Sequence 2, Application US/10608062
/ Publication No. US20040014122A1
/ GENERAL INFORMATION:
/ APPLICANT: BREEN, ALEXANDER
/ APPLICANT: SINGLETON, FREDDIE
/ TITLE OF INVENTION: DETECTION OF SPORE FORMING BACTERIA
/ FILE REFERENCE: B113P
/ CURRENT APPLICATION NUMBER: US/10/608,062
/ CURRENT FILING DATE: 2003-06-27
/ PRIOR APPLICATION NUMBER: US 09/356,677
/ PRIOR FILING DATE: 1999-07-20
/ PRIOR APPLICATION NUMBER: US 09/085,359
/ PRIOR FILING DATE: 1998-05-27
/ NUMBER OF SEQ ID NOS: 52
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 2
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Bacillus cereus
US-10-608-062-2

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 429 AAAAAAGCAGTCACT 443  
 DB 2 AAAAAAGCAGTCACT 16

RESULT 581  
 US-10-138-674-5942/c  
 ; Sequence 5942, Application US/10138674  
 ; Publication No. US20040077565A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
 ; APPLICANT: Pavco, Pam  
 ; APPLICANT: McSwiggen, Jim  
 ; APPLICANT: Stinchcomb, Dan  
 ; APPLICANT: Escobedo, Jaime  
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
 ; FILE REFERENCE: MBH00-876-N (400/049)  
 ; CURRENT APPLICATION NUMBER: US/10/138,674  
 ; CURRENT FILING DATE: 2002-05-03  
 ; NUMBER OF SEQ ID NOS: 20822  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 5942  
 ; LENGTH: 16  
 ; TYPE: RNA  
 ; ORGANISM: Homo sapiens  
 US-10-138-674-5942

Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 241 CAGTCAGGCTCTCA 255  
 DB 16 CAGTCAGGCTCTCA 2

RESULT 582  
 US-10-287-949A-5942/c  
 ; Sequence 5942, Application US/10287949A  
 ; Publication No. US20040102389A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
 ; APPLICANT: Pavco, Pam  
 ; APPLICANT: McSwiggen, Jim  
 ; APPLICANT: Stinchcomb, Dan  
 ; APPLICANT: Escobedo, Jaime  
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
 ; FILE REFERENCE: MBH00-876-N (400/049)  
 ; CURRENT APPLICATION NUMBER: US/10/287,949A  
 ; CURRENT FILING DATE: 2003-04-11  
 ; NUMBER OF SEQ ID NOS: 20822  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 5942  
 ; LENGTH: 16  
 ; TYPE: RNA  
 ; ORGANISM: Homo sapiens  
 US-10-287-949A-5942

Query Match 1.5%; Score 13.4; DB 1; Length 16;  
 Best Local Similarity 93.3%; Pred. No. 4.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 241 CAGTCAGGCTCTCA 255  
 DB 16 CAGTCAGGCTCTCA 2

RESULT 583  
 US-09-818-875-3286  
 ; Sequence 3286, Application US/09818875  
 ; Publication No. US20030051270A1

GENERAL INFORMATION:  
 ; APPLICANT: Kmiec, Eric B.  
 ; APPLICANT: Gamper, Howard B.  
 ; APPLICANT: Rice, Michael C.  
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
 ; FILE REFERENCE: Napro-4  
 ; CURRENT APPLICATION NUMBER: US/09/818,875  
 ; CURRENT FILING DATE: 2001-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/192,176  
 ; PRIOR FILING DATE: 2000-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/192,179  
 ; PRIOR FILING DATE: 2000-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/208,538  
 ; PRIOR FILING DATE: 2000-06-01  
 ; PRIOR APPLICATION NUMBER: US 60/244,989  
 ; PRIOR FILING DATE: 2000-10-30  
 ; NUMBER OF SEQ ID NOS: 4385  
 ; SOFTWARE: Friedman macro Napro4  
 ; SEQ ID NO 3286  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-818-875-3286

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 TATTAAGAGATCCA 869  
 DB 1 TATTAAGAGATCCA 15

RESULT 584  
 US-09-818-875-3287/c  
 ; Sequence 3287, Application US/09818875  
 ; Publication No. US20030051270A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Kmiec, Eric B.  
 ; APPLICANT: Gamper, Howard B.  
 ; APPLICANT: Rice, Michael C.  
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
 ; FILE REFERENCE: Napro-4  
 ; CURRENT APPLICATION NUMBER: US/09/818,875  
 ; CURRENT FILING DATE: 2001-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/192,176  
 ; PRIOR FILING DATE: 2000-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/192,179  
 ; PRIOR FILING DATE: 2000-03-27  
 ; PRIOR APPLICATION NUMBER: US 60/208,538  
 ; PRIOR FILING DATE: 2000-06-01  
 ; PRIOR APPLICATION NUMBER: US 60/244,989  
 ; PRIOR FILING DATE: 2000-10-30  
 ; NUMBER OF SEQ ID NOS: 4385  
 ; SOFTWARE: Friedman macro Napro4  
 ; SEQ ID NO 3287  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-818-875-3287

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 TATTAAGAGATCCA 869  
 DB 17 TATTAAGAGATCCA 3

RESULT 585

```
US-09-780-533A-398/c
; Sequence 398, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggan, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 398
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-398

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      857 TTAAAGAAATCCAAA 871
Db      15 TTAAAGATCCAAA 1

RESULT 586
US-09-740-332-902
; Sequence 902, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-902

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      36 ACCAGGACCTGGCG 50
Db      3 ACCAGGACCCUGCG 17

RESULT 587
US-09-740-332-1799/c
; Sequence 1799, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
```

```
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1799
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1799

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      271 CAGAAACACGGTGG 285
Db      16 CAGAAGACACGGTGG 2

RESULT 588
US-09-740-332-2756
; Sequence 2756, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2756
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2756

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      271 CAGAAACACGGTGG 285
Db      3 CAGAAGACACGGUGG 17

RESULT 589
US-09-740-332-3653/c
; Sequence 3653, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3653
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
```

; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-3653

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 36 ACCAGGACCTCGGCG 50  
Db 16 ACCAGGACCTCGTGG 2

## RESULT 590

US-09-817-879-902  
; Sequence 902, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
; FILE REFERENCE: MBHB00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 902  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-902

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 86.7%; Pred. No. 4.3e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 36 ACCAGGACCTCGGCG 50  
Db 3 ACCAGGACCTCGGCG 17

## RESULT 591

US-09-817-879-1799/c  
; Sequence 1799, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
; FILE REFERENCE: MBHB00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1799  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-1799

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 271 CAGAAACACGGTGG 285  
Db 16 CAGAAACACGGTGG 2

## RESULT 592

US-09-817-879-2756  
; Sequence 2756, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
; FILE REFERENCE: MBHB00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2756  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-2756

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 86.7%; Pred. No. 4.3e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 271 CAGAAACACGGTGG 285  
Db 3 CAGAAACACGGTGG 17

## RESULT 593

US-09-817-879-3653/c  
; Sequence 3653, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
; FILE REFERENCE: MBHB00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3653  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3653

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 36 ACCAGGACCTCGGCG 50  
Db 16 ACCAGGACCTCGTGG 2

## RESULT 594

US-10-230-006-44/c  
; Sequence 44, Application US/10230006  
; Publication No. US20030191077A1

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 3678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 44
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-10-230-006-44

Query Match          1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      91 GAAGGCGGAGGCC 105
Db      16 GAAGGCGGAGGCC 2

RESULT 595
US-10-787-3286
; Sequence 3286, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3286

Query Match          1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      855 TATTAAGAATCCA 869
Db      1 TATTAAGAATCCA 15

RESULT 596
US-10-787-3287/c
; Sequence 3287, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
```

```
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3287
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3287

Query Match          1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      855 TATTAAGAATCCA 869
Db      17 TATTAAGAATCCA 3

RESULT 597
US-10-261-185-3286
; Sequence 3286, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3286

Query Match          1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      855 TATTAAGAATCCA 869
Db      1 TATTAAGAATCCA 15
```

RESULT 598  
US-10-261-185-3287/c  
; Sequence 3287, Application US/10261185  
; Publication No. US20040014057A1  
; GENERAL INFORMATION:  
; APPLICANT: Kniec, Eric B.  
; APPLICANT: Gampier, Howard B.  
; APPLICANT: Rice, Michael C.  
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single  
; TITLE OF INVENTION: Stranded Oligonucleotides  
; FILE REFERENCE: Napro-4CON  
; CURRENT APPLICATION NUMBER: US/10/261,185  
; CURRENT FILING DATE: 2002-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/09761  
; PRIOR FILING DATE: 2001-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,176  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/192,179  
; PRIOR FILING DATE: 2000-03-27  
; PRIOR APPLICATION NUMBER: US 60/208,538  
; PRIOR FILING DATE: 2000-06-01  
; PRIOR APPLICATION NUMBER: US 60/244,989  
; PRIOR FILING DATE: 2000-10-30  
; NUMBER OF SEQ ID NOS: 4385  
; SOFTWARE: Friedman macro Napro4  
; SEQ ID NO 3287  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-261-185-3287

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 855 TATTAAAGCATCCA 869  
||| ||||| |||||  
DB 17 TATTAAAGCATCCA 3

RESULT 599  
US-10-138-674-2045  
; Sequence 2045, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2045  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-2045

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 53.3%; Pred. No. 4.3e+02;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
  
QY 642 ACTTTTCAGAGTTG 656  
||| ||||| |||||  
DB 3 ACGUUCAGAGUUG 17

RESULT 600  
US-10-138-674-2046  
; Sequence 2046, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2046  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-2046

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 53.3%; Pred. No. 4.3e+02;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
  
QY 642 ACTTTTCAGAGTTG 656  
||| ||||| |||||  
DB 2 ACGUUCAGAGUUG 16

RESULT 601  
US-10-138-674-3424/c  
; Sequence 3424, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3424  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-138-674-3424

Query Match 1.5%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 252 CTCACCTTAACTCCTC 266  
||| ||||| |||||  
DB 17 CTCACCTGTAATCCTC 3

RESULT 602  
US-10-138-674-3425/c  
; Sequence 3425, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan

```

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3425
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3425

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266
Db 16 CTCACCTGTAATCCTC 2

RESULT 603
US-10-287-949A-2045
; Sequence 2045, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2045
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2045

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 4.3e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTCAGAGTTG 656
Db 3 ACGUUUCAGAGUUG 17

RESULT 604
US-10-287-949A-2046
; Sequence 2046, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2046

```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2046

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 4.3e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 642 ACTTTTCAGAGTTG 656
Db 2 ACGUUUCAGAGUUG 16

RESULT 605
US-10-287-949A-3424/C
; Sequence 3424, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3424

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 252 CTCACCTTTAATCCTC 266
Db 17 CTCACCTGTAATCCTC 3

RESULT 606
US-10-287-949A-3425/C
; Sequence 3425, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3425
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3425

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```





```
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5349
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5349

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 271 CAGAAAACACGGTGG 285
DB 3 CAGAGACACGGUGG 17
||||| ||||| |||

RESULT 610
US-10-669-841-6246/c
; Sequence 6246, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
```

```
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6246
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6246

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 36 ACCAGGACCTCGCG 50
DB 16 ACCAGGACCTCGTCG 2
||||| ||||| ||||| |||

RESULT 611
US-10-681-074-3286
; Sequence 3286, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3286

Query Match 1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 855 TATTAAGAGATCCA 869
DB 1 TATTAAGAGATCCA 15
||||| ||||| ||||| |||

RESULT 612
US-10-681-074-3287/c
```

```
; Sequence 3287, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3287
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3287

Query Match      1.5%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      855 TATTAAAGAATCCA 869
Db      17 TATTAAAGCATCCA 3

RESULT 613
US-10-257-017B-154649/c
; Sequence 154649, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 154649
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSCC0039096
US-10-257-017B-154649

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      527 TAAACATTCCTT 539
Db      13 TAAACATTCCTT 1

RESULT 614
US-10-257-017B-154650
; Sequence 154650, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
```

```
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 154650
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSCC0039096
US-10-257-017B-154650

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      527 TAAACATTCCTT 539
Db      1 TAAACATTCCTT 13

RESULT 615
US-10-257-017B-156539
; Sequence 156539, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 156539
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSCC0039466
US-10-257-017B-156539

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      706 TGTATAGTTTAT 718
Db      1 TGTATAGTTTAT 13

RESULT 616
US-10-257-017B-156540/c
; Sequence 156540, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
```

```
; SEQ ID NO 156540
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0039466
US-10-257-017B-156540

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 706 TGTATAGTTTAT 718
DB 13 TGTATAGTTTAT 1

RESULT 617
US-10-257-017B-201017
; Sequence 201017, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 201017
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0049445
US-10-257-017B-201017

Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 TTTGGAGATAATA 227
DB 1 TTTGGAGATAATA 13

RESULT 618
US-10-257-017B-201018/c
; Sequence 201018, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 201018
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0049445
US-10-257-017B-201018
```

```
Query Match      1.5%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 TTTGGAGATAATA 227
DB 13 TTTGGAGATAATA 1

RESULT 619
US-10-440-464-42/c
; Sequence 42, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
; APPLICANT: DEPRIMO, SAMUEL
; APPLICANT: O'FARRELL, ANNE-MARIE
; APPLICANT: MORIMOTO, ALYSSA
; APPLICANT: SMOLICH, BEVERLY
; APPLICANT: MANNING, WILLIAM
; APPLICANT: WALTER, SARAH
; APPLICANT: CHERRINGTON, JULIE
; APPLICANT: SCHILLING, JIM
; TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
; FILE REFERENCE: 038602/1592
; CURRENT APPLICATION NUMBER: US/10/440,464
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: 60/380,872
; PRIOR FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: 60/448,922
; PRIOR FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: 60/448,874
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 185
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-10-440-464-42

Query Match      1.5%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 ACTTGGGCAAGG 453
DB 13 ACTTGGGCAAGG 1

RESULT 620
US-10-138-674-7004
; Sequence 7004, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7004
; LENGTH: 16
; TYPE: RNA
```

; ORGANISM: Homo sapiens  
US-10-138-674-7004

Query Match 1.5%; Score 13; DB 1; Length 16;  
Best Local Similarity 84.6%; Pred. No. 4.3e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCATGAAAAA 433  
||:|:|:|:|:|:|  
Db 4 GGUCCAUGAAAAA 16

## RESULT 621

US-10-287-949A-7004  
; Sequence 7004, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Ravco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7004  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-7004

Query Match 1.5%; Score 13; DB 1; Length 16;  
Best Local Similarity 84.6%; Pred. No. 4.3e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCATGAAAAA 433  
||:|:|:|:|:|:|  
Db 4 GGUCCAUGAAAAA 16

## RESULT 622

US-09-864-785-1671  
; Sequence 1671, Application US/09864785  
; Patent No. US20020177568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: 400/022 (MBH00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1671  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-1671

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 76.9%; Pred. No. 4.6e+02;  
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 830 CCTGTATGGCAC 842

Db ||:|:|:|:|:|:|  
5 CCCUGAUGGCAC 17

## RESULT 623

US-09-864-785-1672  
; Sequence 1672, Application US/09864785  
; Patent No. US20020177568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: 400/022 (MBH00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1672  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-1672

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 69.2%; Pred. No. 4.6e+02;  
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 831 CCTGTATGGCAC 843  
||:|:|:|:|:|:|  
Db 1 CCUGAUGGCACU 13

## RESULT 624

US-09-780-533A-483/c  
; Sequence 483, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrita, Bharat  
; APPLICANT: Haeblerli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene Expression  
; FILE REFERENCE: MBH00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 483  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-483

Query Match 1.5%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 4.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 675 GAGAAACTGATT 687  
||:|:|:|:|:|:|  
Db 17 GAGAAACTGATT 5

## RESULT 625

US-09-780-533A-485/c  
; Sequence 485, Application US/09780533A

```
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowaira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 485
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-485

Query Match      1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      674 TGAGAAACTGATT 686
DB      13 TGAGAAACTGATT 1
|||||

RESULT 626
US-10-230-006-1712/c
; Sequence 1712, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fornaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1712
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1712

Query Match      1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 TGGATTCATGTT 208
DB      13 TGGATTCATGTT 1
|||||

RESULT 627
US-10-230-006-2240/c
; Sequence 2240, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fornaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
```

```
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2240
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2240

Query Match      1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 TGGATTCATGTT 208
DB      16 TGGATTCATGTT 4
|||||

RESULT 628
US-10-230-006-2241/c
; Sequence 2241, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fornaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2241
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2241

Query Match      1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 TGGATTCATGTT 208
DB      15 TGGATTCATGTT 3
|||||

RESULT 629
US-10-138-674-448
; Sequence 448, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 448
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-448
```

```
Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 4.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
DB 3 AUCACUUGGAAGA 15

RESULT 630
US-10-138-674-4718
; Sequence 4718, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4718
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4718

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 4.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
DB 4 AUCACUUGGAAGA 16

RESULT 631
US-10-138-674-6292
; Sequence 6292, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6292
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6292

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 4.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCCATGAAGAA 433
DB 5 GGUCCAUGAAGAA 17

RESULT 633
US-10-138-674-4718
; Sequence 4718, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 448
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-448

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 4.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
DB 3 AUCACUUGGAAGA 15

RESULT 634
US-10-287-949A-4718
; Sequence 4718, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
RESULT 632
US-10-138-674-6293
; Sequence 6293, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6293
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6293

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 4.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCCATGAAGAA 433
DB 4 GGUCCAUGAAGAA 16

RESULT 633
US-10-287-949A-448
; Sequence 448, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 448
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-448

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 4.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
DB 3 AUCACUUGGAAGA 15

RESULT 634
US-10-287-949A-4718
; Sequence 4718, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4718
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4718

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. NO. 4.6e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATCACTTGAAGA 703
Db 4 AUCACUUGGAAGA 16

RESULT 635
US-10-287-949A-6292
; Sequence 6292, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6292
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6292

Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. NO. 4.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 421 GGTCCATGAAAAA 433
Db 5 GGUCCAUGAAAAA 17

RESULT 636
US-10-287-949A-6293
; Sequence 6293, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6293
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6293
```

```
Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. NO. 4.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 421 GGTCCATGAAAAA 433
Db 4 GGUCCAUGAAAAA 16
```

```
RESULT 637
US-10-712-633-3698
; Sequence 3698, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3698
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-3698
```

```
Query Match 1.5%; Score 13; DB 1; Length 17;
Best Local Similarity 84.8%; Pred. NO. 4.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 421 GGTCCATGAAAAA 433
Db 4 GGUCCAUGAAAAA 16
```

```
Search completed: October 6, 2005, 10:42:52
Job time : 10 secs
```